{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "46649128",
   "metadata": {},
   "source": [
    "# Formatting data and collating it\n",
    "## Setting working directory"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "fb259f5f",
   "metadata": {},
   "outputs": [],
   "source": [
    "setwd(\"/home/jp/ICP_Responders/RawData\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "d3b694d0",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "'/home/jp/ICP_Responders/RawData'"
      ],
      "text/latex": [
       "'/home/jp/ICP\\_Responders/RawData'"
      ],
      "text/markdown": [
       "'/home/jp/ICP_Responders/RawData'"
      ],
      "text/plain": [
       "[1] \"/home/jp/ICP_Responders/RawData\""
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "getwd()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "634ef7fa",
   "metadata": {},
   "outputs": [],
   "source": [
    "library(data.table)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "9e24181a",
   "metadata": {},
   "source": [
    "## Read Transcriptome"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "cac344b5",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "35e0f5f5",
   "metadata": {},
   "source": [
    "## Read Supplementary data"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "151eee55",
   "metadata": {},
   "source": [
    "### File 1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "582c5f45",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table>\n",
       "<caption>A data.frame: 55 Ã— 15</caption>\n",
       "<thead>\n",
       "\t<tr><th scope=col>X</th><th scope=col>X.1</th><th scope=col>X.2</th><th scope=col>X.3</th><th scope=col>X.4</th><th scope=col>X.5</th><th scope=col>X.6</th><th scope=col>X.7</th><th scope=col>X.8</th><th scope=col>X.9</th><th scope=col>X.10</th><th scope=col>X.11</th><th scope=col>X.12</th><th scope=col>X.13</th><th scope=col>X.14</th></tr>\n",
       "\t<tr><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><td>Patient no.</td><td>Age (Years)</td><td>Sex</td><td>Treatment    </td><td>Best RECIST response</td><td>Progression Free Survival (Days)</td><td>Overall Survival (Days)</td><td>Site of PRE Biopsy</td><td>Days to EDT Biopsy</td><td>Site of EDT Biopsy</td><td>Progressed</td><td>Last Followup Status</td><td>RNA Sequencing</td><td>Immunofluorescence Panel 1</td><td>Immunofluorescence Panel 2</td></tr>\n",
       "\t<tr><td>1          </td><td>48         </td><td>F  </td><td>Nivolumab    </td><td>PD                  </td><td>9                               </td><td>147                    </td><td>LN                </td><td>7                 </td><td>SQ                </td><td>Yes       </td><td>Dead, melanoma      </td><td>-             </td><td>PRE                       </td><td>PRE and EDT               </td></tr>\n",
       "\t<tr><td>2          </td><td>61         </td><td>F  </td><td>Pembrolizumab</td><td>PD                  </td><td>13                              </td><td>65                     </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>Yes       </td><td>Dead, melanoma      </td><td>PRE           </td><td>-                         </td><td>-                         </td></tr>\n",
       "\t<tr><td>3          </td><td>50         </td><td>M  </td><td>Nivolumab    </td><td>PD                  </td><td>23                              </td><td>59                     </td><td>SQ                </td><td>15                </td><td>SQ                </td><td>Yes       </td><td>Dead, melanoma      </td><td>PRE           </td><td>EDT                       </td><td>EDT                       </td></tr>\n",
       "\t<tr><td>4          </td><td>84         </td><td>M  </td><td>Pembrolizumab</td><td>PD                  </td><td>23                              </td><td>22                     </td><td>SQ                </td><td>9                 </td><td>SQ                </td><td>Yes       </td><td>Dead, melanoma      </td><td>PRE           </td><td>PRE and EDT               </td><td>PRE and EDT               </td></tr>\n",
       "\t<tr><td>5          </td><td>67         </td><td>M  </td><td>Pembrolizumab</td><td>PD                  </td><td>39                              </td><td>155                    </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>Yes       </td><td>Dead, melanoma      </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>6          </td><td>68         </td><td>M  </td><td>Nivolumab    </td><td>PD                  </td><td>42                              </td><td>94                     </td><td>LN                </td><td>-                 </td><td>-                 </td><td>Yes       </td><td>Dead, melanoma      </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>7          </td><td>57         </td><td>F  </td><td>Nivolumab    </td><td>PD                  </td><td>47                              </td><td>80                     </td><td>LN                </td><td>19                </td><td>SQ                </td><td>Yes       </td><td>Dead, melanoma      </td><td>PRE           </td><td>PRE and EDT               </td><td>EDT                       </td></tr>\n",
       "\t<tr><td>8          </td><td>85         </td><td>F  </td><td>Nivolumab    </td><td>PD                  </td><td>58                              </td><td>58                     </td><td>SQ                </td><td>6                 </td><td>SQ                </td><td>Yes       </td><td>Dead, melanoma      </td><td>PRE and EDT   </td><td>PRE and EDT               </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>9          </td><td>70         </td><td>F  </td><td>Pembrolizumab</td><td>PD                  </td><td>71                              </td><td>99                     </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>Yes       </td><td>Dead, melanoma      </td><td>PRE           </td><td>-                         </td><td>-                         </td></tr>\n",
       "\t<tr><td>10         </td><td>90         </td><td>M  </td><td>Pembrolizumab</td><td>PD                  </td><td>76                              </td><td>551                    </td><td>SQ                </td><td>7                 </td><td>SQ                </td><td>Yes       </td><td>Alive               </td><td>PRE and EDT   </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>11         </td><td>66         </td><td>M  </td><td>Pembrolizumab</td><td>PD                  </td><td>78                              </td><td>166                    </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>Yes       </td><td>Dead, melanoma      </td><td>PRE           </td><td>-                         </td><td>-                         </td></tr>\n",
       "\t<tr><td>12         </td><td>52         </td><td>M  </td><td>Pembrolizumab</td><td>SD                  </td><td>80                              </td><td>199                    </td><td>SQ                </td><td>14                </td><td>SQ                </td><td>Yes       </td><td>Dead, melanoma      </td><td>PRE           </td><td>PRE and EDT               </td><td>PRE and EDT               </td></tr>\n",
       "\t<tr><td>13         </td><td>69         </td><td>M  </td><td>Pembrolizumab</td><td>PD                  </td><td>82                              </td><td>96                     </td><td>SQ                </td><td>6                 </td><td>SQ                </td><td>Yes       </td><td>Dead, melanoma      </td><td>PRE and EDT   </td><td>PRE and EDT               </td><td>PRE and EDT               </td></tr>\n",
       "\t<tr><td>14         </td><td>58         </td><td>M  </td><td>Pembrolizumab</td><td>PD                  </td><td>83                              </td><td>993                    </td><td>Mucosa            </td><td>-                 </td><td>-                 </td><td>Yes       </td><td>Dead, melanoma      </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>15         </td><td>76         </td><td>F  </td><td>Pembrolizumab</td><td>PD                  </td><td>84                              </td><td>300                    </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>Yes       </td><td>Dead                </td><td>PRE           </td><td>-                         </td><td>-                         </td></tr>\n",
       "\t<tr><td>16         </td><td>55         </td><td>M  </td><td>Pembrolizumab</td><td>PD                  </td><td>84                              </td><td>169                    </td><td>LN                </td><td>-                 </td><td>-                 </td><td>Yes       </td><td>Dead, melanoma      </td><td>PRE           </td><td>-                         </td><td>-                         </td></tr>\n",
       "\t<tr><td>17         </td><td>37         </td><td>M  </td><td>Pembrolizumab</td><td>PD                  </td><td>96                              </td><td>258                    </td><td>SQ                </td><td>9                 </td><td>Spine             </td><td>Yes       </td><td>Dead, melanoma      </td><td>PRE and EDT   </td><td>PRE and EDT               </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>18         </td><td>62         </td><td>M  </td><td>Pembrolizumab</td><td>PD                  </td><td>100                             </td><td>228                    </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>Yes       </td><td>Dead, melanoma      </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>19         </td><td>54         </td><td>M  </td><td>Pembrolizumab</td><td>SD                  </td><td>125                             </td><td>385                    </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>Yes       </td><td>Dead, melanoma      </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>20         </td><td>45         </td><td>F  </td><td>Pembrolizumab</td><td>PR                  </td><td>156                             </td><td>553                    </td><td>Brain             </td><td>-                 </td><td>-                 </td><td>Yes       </td><td>Dead, melanoma      </td><td>-             </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>21         </td><td>67         </td><td>M  </td><td>Pembrolizumab</td><td>SD                  </td><td>166                             </td><td>551                    </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>Yes       </td><td>Dead, melanoma      </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>22         </td><td>69         </td><td>F  </td><td>Pembrolizumab</td><td>SD                  </td><td>176                             </td><td>379                    </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>Yes       </td><td>Alive               </td><td>-             </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>23         </td><td>40         </td><td>M  </td><td>Nivolumab    </td><td>SD                  </td><td>191                             </td><td>191                    </td><td>SQ                </td><td>10                </td><td>SQ                </td><td>Yes       </td><td>Dead, melanoma      </td><td>PRE           </td><td>PRE and EDT               </td><td>PRE and EDT               </td></tr>\n",
       "\t<tr><td>24         </td><td>54         </td><td>F  </td><td>Pembrolizumab</td><td>SD                  </td><td>197                             </td><td>407                    </td><td>SQ                </td><td>28                </td><td>SQ                </td><td>Yes       </td><td>Dead, melanoma      </td><td>-             </td><td>PRE and EDT               </td><td>PRE and EDT               </td></tr>\n",
       "\t<tr><td>25         </td><td>49         </td><td>M  </td><td>Nivolumab    </td><td>PR                  </td><td>271                             </td><td>897                    </td><td>SQ                </td><td>43                </td><td>SQ                </td><td>Yes       </td><td>Dead, melanoma      </td><td>PRE and EDT   </td><td>PRE and EDT               </td><td>PRE and EDT               </td></tr>\n",
       "\t<tr><td>26         </td><td>89         </td><td>F  </td><td>Pembrolizumab</td><td>CR                  </td><td>275                             </td><td>275                    </td><td>SQ                </td><td>10                </td><td>SQ                </td><td>No        </td><td>Alive               </td><td>-             </td><td>PRE and EDT               </td><td>PRE and EDT               </td></tr>\n",
       "\t<tr><td>27         </td><td>76         </td><td>M  </td><td>Pembrolizumab</td><td>PR                  </td><td>314                             </td><td>1067                   </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>Yes       </td><td>Dead, melanoma      </td><td>PRE           </td><td>-                         </td><td>-                         </td></tr>\n",
       "\t<tr><td>28         </td><td>81         </td><td>M  </td><td>Pembrolizumab</td><td>PR                  </td><td>324                             </td><td>324                    </td><td>SQ                </td><td>44                </td><td>SQ                </td><td>No        </td><td>Alive               </td><td>-             </td><td>PRE and EDT               </td><td>PRE and EDT               </td></tr>\n",
       "\t<tr><td>29         </td><td>55         </td><td>M  </td><td>Pembrolizumab</td><td>SD                  </td><td>335                             </td><td>825                    </td><td>SQ                </td><td>68                </td><td>SQ                </td><td>Yes       </td><td>Dead, melanoma      </td><td>PRE and EDT   </td><td>-                         </td><td>-                         </td></tr>\n",
       "\t<tr><td>30         </td><td>86         </td><td>F  </td><td>Pembrolizumab</td><td>SD                  </td><td>358                             </td><td>581                    </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>Yes       </td><td>Alive               </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>31         </td><td>74         </td><td>F  </td><td>Nivolumab    </td><td>PR                  </td><td>365                             </td><td>365                    </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>-             </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>32         </td><td>69         </td><td>F  </td><td>Pembrolizumab</td><td>CR                  </td><td>460                             </td><td>460                    </td><td>Brain             </td><td>14                </td><td>SQ                </td><td>No        </td><td>Alive               </td><td>-             </td><td>PRE                       </td><td>EDT                       </td></tr>\n",
       "\t<tr><td>33         </td><td>76         </td><td>M  </td><td>Pembrolizumab</td><td>CR                  </td><td>477                             </td><td>477                    </td><td>LN                </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>-             </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>34         </td><td>78         </td><td>M  </td><td>Pembrolizumab</td><td>PR                  </td><td>544                             </td><td>878                    </td><td>LN                </td><td>-                 </td><td>-                 </td><td>Yes       </td><td>Dead, melanoma      </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>35         </td><td>55         </td><td>F  </td><td>Pembrolizumab</td><td>PR                  </td><td>586                             </td><td>1091                   </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>Yes       </td><td>Alive               </td><td>PRE           </td><td>-                         </td><td>-                         </td></tr>\n",
       "\t<tr><td>36         </td><td>76         </td><td>M  </td><td>Nivolumab    </td><td>PR                  </td><td>590                             </td><td>607                    </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>Yes       </td><td>Dead, melanoma      </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>37         </td><td>66         </td><td>M  </td><td>Pembrolizumab</td><td>CR                  </td><td>647                             </td><td>910                    </td><td>SQ                </td><td>7                 </td><td>SQ                </td><td>Yes       </td><td>Alive               </td><td>-             </td><td>PRE and EDT               </td><td>PRE and EDT               </td></tr>\n",
       "\t<tr><td>38         </td><td>69         </td><td>F  </td><td>Pembrolizumab</td><td>PR                  </td><td>755                             </td><td>1547                   </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>Yes       </td><td>Alive               </td><td>PRE           </td><td>-                         </td><td>-                         </td></tr>\n",
       "\t<tr><td>39         </td><td>72         </td><td>M  </td><td>Pembrolizumab</td><td>SD                  </td><td>815                             </td><td>815                    </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>-             </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>40         </td><td>78         </td><td>M  </td><td>Pembrolizumab</td><td>PR                  </td><td>845                             </td><td>845                    </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>41         </td><td>61         </td><td>F  </td><td>Pembrolizumab</td><td>PR                  </td><td>870                             </td><td>886                    </td><td>SQ                </td><td>10                </td><td>SQ                </td><td>Yes       </td><td>Alive               </td><td>PRE and EDT   </td><td>PRE and EDT               </td><td>PRE and EDT               </td></tr>\n",
       "\t<tr><td>42         </td><td>59         </td><td>F  </td><td>Pembrolizumab</td><td>CR                  </td><td>891                             </td><td>891                    </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>PRE           </td><td>-                         </td><td>-                         </td></tr>\n",
       "\t<tr><td>43         </td><td>63         </td><td>M  </td><td>Pembrolizumab</td><td>CR                  </td><td>905                             </td><td>905                    </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>-             </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>44         </td><td>45         </td><td>F  </td><td>Pembrolizumab</td><td>PR                  </td><td>1075                            </td><td>1075                   </td><td>LN                </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>PRE           </td><td>-                         </td><td>-                         </td></tr>\n",
       "\t<tr><td>45         </td><td>82         </td><td>M  </td><td>Pembrolizumab</td><td>PR                  </td><td>1085                            </td><td>1085                   </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>PRE           </td><td>-                         </td><td>-                         </td></tr>\n",
       "\t<tr><td>46         </td><td>71         </td><td>M  </td><td>Pembrolizumab</td><td>PR                  </td><td>1098                            </td><td>1098                   </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>47         </td><td>62         </td><td>M  </td><td>Pembrolizumab</td><td>PR                  </td><td>1174                            </td><td>1174                   </td><td>SQ                </td><td>7                 </td><td>SQ                </td><td>No        </td><td>Alive               </td><td>PRE and EDT   </td><td>-                         </td><td>-                         </td></tr>\n",
       "\t<tr><td>48         </td><td>40         </td><td>M  </td><td>Pembrolizumab</td><td>PR                  </td><td>1189                            </td><td>1189                   </td><td>SQ                </td><td>3                 </td><td>LN                </td><td>No        </td><td>Alive               </td><td>PRE and EDT   </td><td>-                         </td><td>-                         </td></tr>\n",
       "\t<tr><td>49         </td><td>72         </td><td>F  </td><td>Nivolumab    </td><td>CR                  </td><td>1328                            </td><td>1328                   </td><td>SQ                </td><td>2                 </td><td>SQ                </td><td>No        </td><td>Alive               </td><td>PRE           </td><td>PRE and EDT               </td><td>PRE and EDT               </td></tr>\n",
       "\t<tr><td>50         </td><td>86         </td><td>M  </td><td>Nivolumab    </td><td>CR                  </td><td>1342                            </td><td>1342                   </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>51         </td><td>64         </td><td>M  </td><td>Nivolumab    </td><td>CR                  </td><td>1397                            </td><td>1397                   </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>-             </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>52         </td><td>63         </td><td>F  </td><td>Pembrolizumab</td><td>PR                  </td><td>1553                            </td><td>1553                   </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>53         </td><td>71         </td><td>F  </td><td>Pembrolizumab</td><td>CR                  </td><td>1589                            </td><td>1589                   </td><td>LN                </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>PRE           </td><td>-                         </td><td>-                         </td></tr>\n",
       "\t<tr><td>54         </td><td>52         </td><td>F  </td><td>Pembrolizumab</td><td>PR                  </td><td>1603                            </td><td>1603                   </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A data.frame: 55 Ã— 15\n",
       "\\begin{tabular}{lllllllllllllll}\n",
       " X & X.1 & X.2 & X.3 & X.4 & X.5 & X.6 & X.7 & X.8 & X.9 & X.10 & X.11 & X.12 & X.13 & X.14\\\\\n",
       " <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct>\\\\\n",
       "\\hline\n",
       "\t Patient no. & Age (Years) & Sex & Treatment     & Best RECIST response & Progression Free Survival (Days) & Overall Survival (Days) & Site of PRE Biopsy & Days to EDT Biopsy & Site of EDT Biopsy & Progressed & Last Followup Status & RNA Sequencing & Immunofluorescence Panel 1 & Immunofluorescence Panel 2\\\\\n",
       "\t 1           & 48          & F   & Nivolumab     & PD                   & 9                                & 147                     & LN                 & 7                  & SQ                 & Yes        & Dead, melanoma       & -              & PRE                        & PRE and EDT               \\\\\n",
       "\t 2           & 61          & F   & Pembrolizumab & PD                   & 13                               & 65                      & SQ                 & -                  & -                  & Yes        & Dead, melanoma       & PRE            & -                          & -                         \\\\\n",
       "\t 3           & 50          & M   & Nivolumab     & PD                   & 23                               & 59                      & SQ                 & 15                 & SQ                 & Yes        & Dead, melanoma       & PRE            & EDT                        & EDT                       \\\\\n",
       "\t 4           & 84          & M   & Pembrolizumab & PD                   & 23                               & 22                      & SQ                 & 9                  & SQ                 & Yes        & Dead, melanoma       & PRE            & PRE and EDT                & PRE and EDT               \\\\\n",
       "\t 5           & 67          & M   & Pembrolizumab & PD                   & 39                               & 155                     & SQ                 & -                  & -                  & Yes        & Dead, melanoma       & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 6           & 68          & M   & Nivolumab     & PD                   & 42                               & 94                      & LN                 & -                  & -                  & Yes        & Dead, melanoma       & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 7           & 57          & F   & Nivolumab     & PD                   & 47                               & 80                      & LN                 & 19                 & SQ                 & Yes        & Dead, melanoma       & PRE            & PRE and EDT                & EDT                       \\\\\n",
       "\t 8           & 85          & F   & Nivolumab     & PD                   & 58                               & 58                      & SQ                 & 6                  & SQ                 & Yes        & Dead, melanoma       & PRE and EDT    & PRE and EDT                & PRE                       \\\\\n",
       "\t 9           & 70          & F   & Pembrolizumab & PD                   & 71                               & 99                      & SQ                 & -                  & -                  & Yes        & Dead, melanoma       & PRE            & -                          & -                         \\\\\n",
       "\t 10          & 90          & M   & Pembrolizumab & PD                   & 76                               & 551                     & SQ                 & 7                  & SQ                 & Yes        & Alive                & PRE and EDT    & PRE                        & PRE                       \\\\\n",
       "\t 11          & 66          & M   & Pembrolizumab & PD                   & 78                               & 166                     & SQ                 & -                  & -                  & Yes        & Dead, melanoma       & PRE            & -                          & -                         \\\\\n",
       "\t 12          & 52          & M   & Pembrolizumab & SD                   & 80                               & 199                     & SQ                 & 14                 & SQ                 & Yes        & Dead, melanoma       & PRE            & PRE and EDT                & PRE and EDT               \\\\\n",
       "\t 13          & 69          & M   & Pembrolizumab & PD                   & 82                               & 96                      & SQ                 & 6                  & SQ                 & Yes        & Dead, melanoma       & PRE and EDT    & PRE and EDT                & PRE and EDT               \\\\\n",
       "\t 14          & 58          & M   & Pembrolizumab & PD                   & 83                               & 993                     & Mucosa             & -                  & -                  & Yes        & Dead, melanoma       & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 15          & 76          & F   & Pembrolizumab & PD                   & 84                               & 300                     & SQ                 & -                  & -                  & Yes        & Dead                 & PRE            & -                          & -                         \\\\\n",
       "\t 16          & 55          & M   & Pembrolizumab & PD                   & 84                               & 169                     & LN                 & -                  & -                  & Yes        & Dead, melanoma       & PRE            & -                          & -                         \\\\\n",
       "\t 17          & 37          & M   & Pembrolizumab & PD                   & 96                               & 258                     & SQ                 & 9                  & Spine              & Yes        & Dead, melanoma       & PRE and EDT    & PRE and EDT                & PRE                       \\\\\n",
       "\t 18          & 62          & M   & Pembrolizumab & PD                   & 100                              & 228                     & SQ                 & -                  & -                  & Yes        & Dead, melanoma       & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 19          & 54          & M   & Pembrolizumab & SD                   & 125                              & 385                     & SQ                 & -                  & -                  & Yes        & Dead, melanoma       & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 20          & 45          & F   & Pembrolizumab & PR                   & 156                              & 553                     & Brain              & -                  & -                  & Yes        & Dead, melanoma       & -              & PRE                        & PRE                       \\\\\n",
       "\t 21          & 67          & M   & Pembrolizumab & SD                   & 166                              & 551                     & SQ                 & -                  & -                  & Yes        & Dead, melanoma       & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 22          & 69          & F   & Pembrolizumab & SD                   & 176                              & 379                     & SQ                 & -                  & -                  & Yes        & Alive                & -              & PRE                        & PRE                       \\\\\n",
       "\t 23          & 40          & M   & Nivolumab     & SD                   & 191                              & 191                     & SQ                 & 10                 & SQ                 & Yes        & Dead, melanoma       & PRE            & PRE and EDT                & PRE and EDT               \\\\\n",
       "\t 24          & 54          & F   & Pembrolizumab & SD                   & 197                              & 407                     & SQ                 & 28                 & SQ                 & Yes        & Dead, melanoma       & -              & PRE and EDT                & PRE and EDT               \\\\\n",
       "\t 25          & 49          & M   & Nivolumab     & PR                   & 271                              & 897                     & SQ                 & 43                 & SQ                 & Yes        & Dead, melanoma       & PRE and EDT    & PRE and EDT                & PRE and EDT               \\\\\n",
       "\t 26          & 89          & F   & Pembrolizumab & CR                   & 275                              & 275                     & SQ                 & 10                 & SQ                 & No         & Alive                & -              & PRE and EDT                & PRE and EDT               \\\\\n",
       "\t 27          & 76          & M   & Pembrolizumab & PR                   & 314                              & 1067                    & SQ                 & -                  & -                  & Yes        & Dead, melanoma       & PRE            & -                          & -                         \\\\\n",
       "\t 28          & 81          & M   & Pembrolizumab & PR                   & 324                              & 324                     & SQ                 & 44                 & SQ                 & No         & Alive                & -              & PRE and EDT                & PRE and EDT               \\\\\n",
       "\t 29          & 55          & M   & Pembrolizumab & SD                   & 335                              & 825                     & SQ                 & 68                 & SQ                 & Yes        & Dead, melanoma       & PRE and EDT    & -                          & -                         \\\\\n",
       "\t 30          & 86          & F   & Pembrolizumab & SD                   & 358                              & 581                     & SQ                 & -                  & -                  & Yes        & Alive                & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 31          & 74          & F   & Nivolumab     & PR                   & 365                              & 365                     & SQ                 & -                  & -                  & No         & Alive                & -              & PRE                        & PRE                       \\\\\n",
       "\t 32          & 69          & F   & Pembrolizumab & CR                   & 460                              & 460                     & Brain              & 14                 & SQ                 & No         & Alive                & -              & PRE                        & EDT                       \\\\\n",
       "\t 33          & 76          & M   & Pembrolizumab & CR                   & 477                              & 477                     & LN                 & -                  & -                  & No         & Alive                & -              & PRE                        & PRE                       \\\\\n",
       "\t 34          & 78          & M   & Pembrolizumab & PR                   & 544                              & 878                     & LN                 & -                  & -                  & Yes        & Dead, melanoma       & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 35          & 55          & F   & Pembrolizumab & PR                   & 586                              & 1091                    & SQ                 & -                  & -                  & Yes        & Alive                & PRE            & -                          & -                         \\\\\n",
       "\t 36          & 76          & M   & Nivolumab     & PR                   & 590                              & 607                     & SQ                 & -                  & -                  & Yes        & Dead, melanoma       & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 37          & 66          & M   & Pembrolizumab & CR                   & 647                              & 910                     & SQ                 & 7                  & SQ                 & Yes        & Alive                & -              & PRE and EDT                & PRE and EDT               \\\\\n",
       "\t 38          & 69          & F   & Pembrolizumab & PR                   & 755                              & 1547                    & SQ                 & -                  & -                  & Yes        & Alive                & PRE            & -                          & -                         \\\\\n",
       "\t 39          & 72          & M   & Pembrolizumab & SD                   & 815                              & 815                     & SQ                 & -                  & -                  & No         & Alive                & -              & PRE                        & PRE                       \\\\\n",
       "\t 40          & 78          & M   & Pembrolizumab & PR                   & 845                              & 845                     & SQ                 & -                  & -                  & No         & Alive                & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 41          & 61          & F   & Pembrolizumab & PR                   & 870                              & 886                     & SQ                 & 10                 & SQ                 & Yes        & Alive                & PRE and EDT    & PRE and EDT                & PRE and EDT               \\\\\n",
       "\t 42          & 59          & F   & Pembrolizumab & CR                   & 891                              & 891                     & SQ                 & -                  & -                  & No         & Alive                & PRE            & -                          & -                         \\\\\n",
       "\t 43          & 63          & M   & Pembrolizumab & CR                   & 905                              & 905                     & SQ                 & -                  & -                  & No         & Alive                & -              & PRE                        & PRE                       \\\\\n",
       "\t 44          & 45          & F   & Pembrolizumab & PR                   & 1075                             & 1075                    & LN                 & -                  & -                  & No         & Alive                & PRE            & -                          & -                         \\\\\n",
       "\t 45          & 82          & M   & Pembrolizumab & PR                   & 1085                             & 1085                    & SQ                 & -                  & -                  & No         & Alive                & PRE            & -                          & -                         \\\\\n",
       "\t 46          & 71          & M   & Pembrolizumab & PR                   & 1098                             & 1098                    & SQ                 & -                  & -                  & No         & Alive                & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 47          & 62          & M   & Pembrolizumab & PR                   & 1174                             & 1174                    & SQ                 & 7                  & SQ                 & No         & Alive                & PRE and EDT    & -                          & -                         \\\\\n",
       "\t 48          & 40          & M   & Pembrolizumab & PR                   & 1189                             & 1189                    & SQ                 & 3                  & LN                 & No         & Alive                & PRE and EDT    & -                          & -                         \\\\\n",
       "\t 49          & 72          & F   & Nivolumab     & CR                   & 1328                             & 1328                    & SQ                 & 2                  & SQ                 & No         & Alive                & PRE            & PRE and EDT                & PRE and EDT               \\\\\n",
       "\t 50          & 86          & M   & Nivolumab     & CR                   & 1342                             & 1342                    & SQ                 & -                  & -                  & No         & Alive                & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 51          & 64          & M   & Nivolumab     & CR                   & 1397                             & 1397                    & SQ                 & -                  & -                  & No         & Alive                & -              & PRE                        & PRE                       \\\\\n",
       "\t 52          & 63          & F   & Pembrolizumab & PR                   & 1553                             & 1553                    & SQ                 & -                  & -                  & No         & Alive                & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 53          & 71          & F   & Pembrolizumab & CR                   & 1589                             & 1589                    & LN                 & -                  & -                  & No         & Alive                & PRE            & -                          & -                         \\\\\n",
       "\t 54          & 52          & F   & Pembrolizumab & PR                   & 1603                             & 1603                    & SQ                 & -                  & -                  & No         & Alive                & PRE            & PRE                        & PRE                       \\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A data.frame: 55 Ã— 15\n",
       "\n",
       "| X &lt;fct&gt; | X.1 &lt;fct&gt; | X.2 &lt;fct&gt; | X.3 &lt;fct&gt; | X.4 &lt;fct&gt; | X.5 &lt;fct&gt; | X.6 &lt;fct&gt; | X.7 &lt;fct&gt; | X.8 &lt;fct&gt; | X.9 &lt;fct&gt; | X.10 &lt;fct&gt; | X.11 &lt;fct&gt; | X.12 &lt;fct&gt; | X.13 &lt;fct&gt; | X.14 &lt;fct&gt; |\n",
       "|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|\n",
       "| Patient no. | Age (Years) | Sex | Treatment     | Best RECIST response | Progression Free Survival (Days) | Overall Survival (Days) | Site of PRE Biopsy | Days to EDT Biopsy | Site of EDT Biopsy | Progressed | Last Followup Status | RNA Sequencing | Immunofluorescence Panel 1 | Immunofluorescence Panel 2 |\n",
       "| 1           | 48          | F   | Nivolumab     | PD                   | 9                                | 147                     | LN                 | 7                  | SQ                 | Yes        | Dead, melanoma       | -              | PRE                        | PRE and EDT                |\n",
       "| 2           | 61          | F   | Pembrolizumab | PD                   | 13                               | 65                      | SQ                 | -                  | -                  | Yes        | Dead, melanoma       | PRE            | -                          | -                          |\n",
       "| 3           | 50          | M   | Nivolumab     | PD                   | 23                               | 59                      | SQ                 | 15                 | SQ                 | Yes        | Dead, melanoma       | PRE            | EDT                        | EDT                        |\n",
       "| 4           | 84          | M   | Pembrolizumab | PD                   | 23                               | 22                      | SQ                 | 9                  | SQ                 | Yes        | Dead, melanoma       | PRE            | PRE and EDT                | PRE and EDT                |\n",
       "| 5           | 67          | M   | Pembrolizumab | PD                   | 39                               | 155                     | SQ                 | -                  | -                  | Yes        | Dead, melanoma       | PRE            | PRE                        | PRE                        |\n",
       "| 6           | 68          | M   | Nivolumab     | PD                   | 42                               | 94                      | LN                 | -                  | -                  | Yes        | Dead, melanoma       | PRE            | PRE                        | PRE                        |\n",
       "| 7           | 57          | F   | Nivolumab     | PD                   | 47                               | 80                      | LN                 | 19                 | SQ                 | Yes        | Dead, melanoma       | PRE            | PRE and EDT                | EDT                        |\n",
       "| 8           | 85          | F   | Nivolumab     | PD                   | 58                               | 58                      | SQ                 | 6                  | SQ                 | Yes        | Dead, melanoma       | PRE and EDT    | PRE and EDT                | PRE                        |\n",
       "| 9           | 70          | F   | Pembrolizumab | PD                   | 71                               | 99                      | SQ                 | -                  | -                  | Yes        | Dead, melanoma       | PRE            | -                          | -                          |\n",
       "| 10          | 90          | M   | Pembrolizumab | PD                   | 76                               | 551                     | SQ                 | 7                  | SQ                 | Yes        | Alive                | PRE and EDT    | PRE                        | PRE                        |\n",
       "| 11          | 66          | M   | Pembrolizumab | PD                   | 78                               | 166                     | SQ                 | -                  | -                  | Yes        | Dead, melanoma       | PRE            | -                          | -                          |\n",
       "| 12          | 52          | M   | Pembrolizumab | SD                   | 80                               | 199                     | SQ                 | 14                 | SQ                 | Yes        | Dead, melanoma       | PRE            | PRE and EDT                | PRE and EDT                |\n",
       "| 13          | 69          | M   | Pembrolizumab | PD                   | 82                               | 96                      | SQ                 | 6                  | SQ                 | Yes        | Dead, melanoma       | PRE and EDT    | PRE and EDT                | PRE and EDT                |\n",
       "| 14          | 58          | M   | Pembrolizumab | PD                   | 83                               | 993                     | Mucosa             | -                  | -                  | Yes        | Dead, melanoma       | PRE            | PRE                        | PRE                        |\n",
       "| 15          | 76          | F   | Pembrolizumab | PD                   | 84                               | 300                     | SQ                 | -                  | -                  | Yes        | Dead                 | PRE            | -                          | -                          |\n",
       "| 16          | 55          | M   | Pembrolizumab | PD                   | 84                               | 169                     | LN                 | -                  | -                  | Yes        | Dead, melanoma       | PRE            | -                          | -                          |\n",
       "| 17          | 37          | M   | Pembrolizumab | PD                   | 96                               | 258                     | SQ                 | 9                  | Spine              | Yes        | Dead, melanoma       | PRE and EDT    | PRE and EDT                | PRE                        |\n",
       "| 18          | 62          | M   | Pembrolizumab | PD                   | 100                              | 228                     | SQ                 | -                  | -                  | Yes        | Dead, melanoma       | PRE            | PRE                        | PRE                        |\n",
       "| 19          | 54          | M   | Pembrolizumab | SD                   | 125                              | 385                     | SQ                 | -                  | -                  | Yes        | Dead, melanoma       | PRE            | PRE                        | PRE                        |\n",
       "| 20          | 45          | F   | Pembrolizumab | PR                   | 156                              | 553                     | Brain              | -                  | -                  | Yes        | Dead, melanoma       | -              | PRE                        | PRE                        |\n",
       "| 21          | 67          | M   | Pembrolizumab | SD                   | 166                              | 551                     | SQ                 | -                  | -                  | Yes        | Dead, melanoma       | PRE            | PRE                        | PRE                        |\n",
       "| 22          | 69          | F   | Pembrolizumab | SD                   | 176                              | 379                     | SQ                 | -                  | -                  | Yes        | Alive                | -              | PRE                        | PRE                        |\n",
       "| 23          | 40          | M   | Nivolumab     | SD                   | 191                              | 191                     | SQ                 | 10                 | SQ                 | Yes        | Dead, melanoma       | PRE            | PRE and EDT                | PRE and EDT                |\n",
       "| 24          | 54          | F   | Pembrolizumab | SD                   | 197                              | 407                     | SQ                 | 28                 | SQ                 | Yes        | Dead, melanoma       | -              | PRE and EDT                | PRE and EDT                |\n",
       "| 25          | 49          | M   | Nivolumab     | PR                   | 271                              | 897                     | SQ                 | 43                 | SQ                 | Yes        | Dead, melanoma       | PRE and EDT    | PRE and EDT                | PRE and EDT                |\n",
       "| 26          | 89          | F   | Pembrolizumab | CR                   | 275                              | 275                     | SQ                 | 10                 | SQ                 | No         | Alive                | -              | PRE and EDT                | PRE and EDT                |\n",
       "| 27          | 76          | M   | Pembrolizumab | PR                   | 314                              | 1067                    | SQ                 | -                  | -                  | Yes        | Dead, melanoma       | PRE            | -                          | -                          |\n",
       "| 28          | 81          | M   | Pembrolizumab | PR                   | 324                              | 324                     | SQ                 | 44                 | SQ                 | No         | Alive                | -              | PRE and EDT                | PRE and EDT                |\n",
       "| 29          | 55          | M   | Pembrolizumab | SD                   | 335                              | 825                     | SQ                 | 68                 | SQ                 | Yes        | Dead, melanoma       | PRE and EDT    | -                          | -                          |\n",
       "| 30          | 86          | F   | Pembrolizumab | SD                   | 358                              | 581                     | SQ                 | -                  | -                  | Yes        | Alive                | PRE            | PRE                        | PRE                        |\n",
       "| 31          | 74          | F   | Nivolumab     | PR                   | 365                              | 365                     | SQ                 | -                  | -                  | No         | Alive                | -              | PRE                        | PRE                        |\n",
       "| 32          | 69          | F   | Pembrolizumab | CR                   | 460                              | 460                     | Brain              | 14                 | SQ                 | No         | Alive                | -              | PRE                        | EDT                        |\n",
       "| 33          | 76          | M   | Pembrolizumab | CR                   | 477                              | 477                     | LN                 | -                  | -                  | No         | Alive                | -              | PRE                        | PRE                        |\n",
       "| 34          | 78          | M   | Pembrolizumab | PR                   | 544                              | 878                     | LN                 | -                  | -                  | Yes        | Dead, melanoma       | PRE            | PRE                        | PRE                        |\n",
       "| 35          | 55          | F   | Pembrolizumab | PR                   | 586                              | 1091                    | SQ                 | -                  | -                  | Yes        | Alive                | PRE            | -                          | -                          |\n",
       "| 36          | 76          | M   | Nivolumab     | PR                   | 590                              | 607                     | SQ                 | -                  | -                  | Yes        | Dead, melanoma       | PRE            | PRE                        | PRE                        |\n",
       "| 37          | 66          | M   | Pembrolizumab | CR                   | 647                              | 910                     | SQ                 | 7                  | SQ                 | Yes        | Alive                | -              | PRE and EDT                | PRE and EDT                |\n",
       "| 38          | 69          | F   | Pembrolizumab | PR                   | 755                              | 1547                    | SQ                 | -                  | -                  | Yes        | Alive                | PRE            | -                          | -                          |\n",
       "| 39          | 72          | M   | Pembrolizumab | SD                   | 815                              | 815                     | SQ                 | -                  | -                  | No         | Alive                | -              | PRE                        | PRE                        |\n",
       "| 40          | 78          | M   | Pembrolizumab | PR                   | 845                              | 845                     | SQ                 | -                  | -                  | No         | Alive                | PRE            | PRE                        | PRE                        |\n",
       "| 41          | 61          | F   | Pembrolizumab | PR                   | 870                              | 886                     | SQ                 | 10                 | SQ                 | Yes        | Alive                | PRE and EDT    | PRE and EDT                | PRE and EDT                |\n",
       "| 42          | 59          | F   | Pembrolizumab | CR                   | 891                              | 891                     | SQ                 | -                  | -                  | No         | Alive                | PRE            | -                          | -                          |\n",
       "| 43          | 63          | M   | Pembrolizumab | CR                   | 905                              | 905                     | SQ                 | -                  | -                  | No         | Alive                | -              | PRE                        | PRE                        |\n",
       "| 44          | 45          | F   | Pembrolizumab | PR                   | 1075                             | 1075                    | LN                 | -                  | -                  | No         | Alive                | PRE            | -                          | -                          |\n",
       "| 45          | 82          | M   | Pembrolizumab | PR                   | 1085                             | 1085                    | SQ                 | -                  | -                  | No         | Alive                | PRE            | -                          | -                          |\n",
       "| 46          | 71          | M   | Pembrolizumab | PR                   | 1098                             | 1098                    | SQ                 | -                  | -                  | No         | Alive                | PRE            | PRE                        | PRE                        |\n",
       "| 47          | 62          | M   | Pembrolizumab | PR                   | 1174                             | 1174                    | SQ                 | 7                  | SQ                 | No         | Alive                | PRE and EDT    | -                          | -                          |\n",
       "| 48          | 40          | M   | Pembrolizumab | PR                   | 1189                             | 1189                    | SQ                 | 3                  | LN                 | No         | Alive                | PRE and EDT    | -                          | -                          |\n",
       "| 49          | 72          | F   | Nivolumab     | CR                   | 1328                             | 1328                    | SQ                 | 2                  | SQ                 | No         | Alive                | PRE            | PRE and EDT                | PRE and EDT                |\n",
       "| 50          | 86          | M   | Nivolumab     | CR                   | 1342                             | 1342                    | SQ                 | -                  | -                  | No         | Alive                | PRE            | PRE                        | PRE                        |\n",
       "| 51          | 64          | M   | Nivolumab     | CR                   | 1397                             | 1397                    | SQ                 | -                  | -                  | No         | Alive                | -              | PRE                        | PRE                        |\n",
       "| 52          | 63          | F   | Pembrolizumab | PR                   | 1553                             | 1553                    | SQ                 | -                  | -                  | No         | Alive                | PRE            | PRE                        | PRE                        |\n",
       "| 53          | 71          | F   | Pembrolizumab | CR                   | 1589                             | 1589                    | LN                 | -                  | -                  | No         | Alive                | PRE            | -                          | -                          |\n",
       "| 54          | 52          | F   | Pembrolizumab | PR                   | 1603                             | 1603                    | SQ                 | -                  | -                  | No         | Alive                | PRE            | PRE                        | PRE                        |\n",
       "\n"
      ],
      "text/plain": [
       "   X           X.1         X.2 X.3           X.4                 \n",
       "1  Patient no. Age (Years) Sex Treatment     Best RECIST response\n",
       "2  1           48          F   Nivolumab     PD                  \n",
       "3  2           61          F   Pembrolizumab PD                  \n",
       "4  3           50          M   Nivolumab     PD                  \n",
       "5  4           84          M   Pembrolizumab PD                  \n",
       "6  5           67          M   Pembrolizumab PD                  \n",
       "7  6           68          M   Nivolumab     PD                  \n",
       "8  7           57          F   Nivolumab     PD                  \n",
       "9  8           85          F   Nivolumab     PD                  \n",
       "10 9           70          F   Pembrolizumab PD                  \n",
       "11 10          90          M   Pembrolizumab PD                  \n",
       "12 11          66          M   Pembrolizumab PD                  \n",
       "13 12          52          M   Pembrolizumab SD                  \n",
       "14 13          69          M   Pembrolizumab PD                  \n",
       "15 14          58          M   Pembrolizumab PD                  \n",
       "16 15          76          F   Pembrolizumab PD                  \n",
       "17 16          55          M   Pembrolizumab PD                  \n",
       "18 17          37          M   Pembrolizumab PD                  \n",
       "19 18          62          M   Pembrolizumab PD                  \n",
       "20 19          54          M   Pembrolizumab SD                  \n",
       "21 20          45          F   Pembrolizumab PR                  \n",
       "22 21          67          M   Pembrolizumab SD                  \n",
       "23 22          69          F   Pembrolizumab SD                  \n",
       "24 23          40          M   Nivolumab     SD                  \n",
       "25 24          54          F   Pembrolizumab SD                  \n",
       "26 25          49          M   Nivolumab     PR                  \n",
       "27 26          89          F   Pembrolizumab CR                  \n",
       "28 27          76          M   Pembrolizumab PR                  \n",
       "29 28          81          M   Pembrolizumab PR                  \n",
       "30 29          55          M   Pembrolizumab SD                  \n",
       "31 30          86          F   Pembrolizumab SD                  \n",
       "32 31          74          F   Nivolumab     PR                  \n",
       "33 32          69          F   Pembrolizumab CR                  \n",
       "34 33          76          M   Pembrolizumab CR                  \n",
       "35 34          78          M   Pembrolizumab PR                  \n",
       "36 35          55          F   Pembrolizumab PR                  \n",
       "37 36          76          M   Nivolumab     PR                  \n",
       "38 37          66          M   Pembrolizumab CR                  \n",
       "39 38          69          F   Pembrolizumab PR                  \n",
       "40 39          72          M   Pembrolizumab SD                  \n",
       "41 40          78          M   Pembrolizumab PR                  \n",
       "42 41          61          F   Pembrolizumab PR                  \n",
       "43 42          59          F   Pembrolizumab CR                  \n",
       "44 43          63          M   Pembrolizumab CR                  \n",
       "45 44          45          F   Pembrolizumab PR                  \n",
       "46 45          82          M   Pembrolizumab PR                  \n",
       "47 46          71          M   Pembrolizumab PR                  \n",
       "48 47          62          M   Pembrolizumab PR                  \n",
       "49 48          40          M   Pembrolizumab PR                  \n",
       "50 49          72          F   Nivolumab     CR                  \n",
       "51 50          86          M   Nivolumab     CR                  \n",
       "52 51          64          M   Nivolumab     CR                  \n",
       "53 52          63          F   Pembrolizumab PR                  \n",
       "54 53          71          F   Pembrolizumab CR                  \n",
       "55 54          52          F   Pembrolizumab PR                  \n",
       "   X.5                              X.6                     X.7               \n",
       "1  Progression Free Survival (Days) Overall Survival (Days) Site of PRE Biopsy\n",
       "2  9                                147                     LN                \n",
       "3  13                               65                      SQ                \n",
       "4  23                               59                      SQ                \n",
       "5  23                               22                      SQ                \n",
       "6  39                               155                     SQ                \n",
       "7  42                               94                      LN                \n",
       "8  47                               80                      LN                \n",
       "9  58                               58                      SQ                \n",
       "10 71                               99                      SQ                \n",
       "11 76                               551                     SQ                \n",
       "12 78                               166                     SQ                \n",
       "13 80                               199                     SQ                \n",
       "14 82                               96                      SQ                \n",
       "15 83                               993                     Mucosa            \n",
       "16 84                               300                     SQ                \n",
       "17 84                               169                     LN                \n",
       "18 96                               258                     SQ                \n",
       "19 100                              228                     SQ                \n",
       "20 125                              385                     SQ                \n",
       "21 156                              553                     Brain             \n",
       "22 166                              551                     SQ                \n",
       "23 176                              379                     SQ                \n",
       "24 191                              191                     SQ                \n",
       "25 197                              407                     SQ                \n",
       "26 271                              897                     SQ                \n",
       "27 275                              275                     SQ                \n",
       "28 314                              1067                    SQ                \n",
       "29 324                              324                     SQ                \n",
       "30 335                              825                     SQ                \n",
       "31 358                              581                     SQ                \n",
       "32 365                              365                     SQ                \n",
       "33 460                              460                     Brain             \n",
       "34 477                              477                     LN                \n",
       "35 544                              878                     LN                \n",
       "36 586                              1091                    SQ                \n",
       "37 590                              607                     SQ                \n",
       "38 647                              910                     SQ                \n",
       "39 755                              1547                    SQ                \n",
       "40 815                              815                     SQ                \n",
       "41 845                              845                     SQ                \n",
       "42 870                              886                     SQ                \n",
       "43 891                              891                     SQ                \n",
       "44 905                              905                     SQ                \n",
       "45 1075                             1075                    LN                \n",
       "46 1085                             1085                    SQ                \n",
       "47 1098                             1098                    SQ                \n",
       "48 1174                             1174                    SQ                \n",
       "49 1189                             1189                    SQ                \n",
       "50 1328                             1328                    SQ                \n",
       "51 1342                             1342                    SQ                \n",
       "52 1397                             1397                    SQ                \n",
       "53 1553                             1553                    SQ                \n",
       "54 1589                             1589                    LN                \n",
       "55 1603                             1603                    SQ                \n",
       "   X.8                X.9                X.10       X.11                \n",
       "1  Days to EDT Biopsy Site of EDT Biopsy Progressed Last Followup Status\n",
       "2  7                  SQ                 Yes        Dead, melanoma      \n",
       "3  -                  -                  Yes        Dead, melanoma      \n",
       "4  15                 SQ                 Yes        Dead, melanoma      \n",
       "5  9                  SQ                 Yes        Dead, melanoma      \n",
       "6  -                  -                  Yes        Dead, melanoma      \n",
       "7  -                  -                  Yes        Dead, melanoma      \n",
       "8  19                 SQ                 Yes        Dead, melanoma      \n",
       "9  6                  SQ                 Yes        Dead, melanoma      \n",
       "10 -                  -                  Yes        Dead, melanoma      \n",
       "11 7                  SQ                 Yes        Alive               \n",
       "12 -                  -                  Yes        Dead, melanoma      \n",
       "13 14                 SQ                 Yes        Dead, melanoma      \n",
       "14 6                  SQ                 Yes        Dead, melanoma      \n",
       "15 -                  -                  Yes        Dead, melanoma      \n",
       "16 -                  -                  Yes        Dead                \n",
       "17 -                  -                  Yes        Dead, melanoma      \n",
       "18 9                  Spine              Yes        Dead, melanoma      \n",
       "19 -                  -                  Yes        Dead, melanoma      \n",
       "20 -                  -                  Yes        Dead, melanoma      \n",
       "21 -                  -                  Yes        Dead, melanoma      \n",
       "22 -                  -                  Yes        Dead, melanoma      \n",
       "23 -                  -                  Yes        Alive               \n",
       "24 10                 SQ                 Yes        Dead, melanoma      \n",
       "25 28                 SQ                 Yes        Dead, melanoma      \n",
       "26 43                 SQ                 Yes        Dead, melanoma      \n",
       "27 10                 SQ                 No         Alive               \n",
       "28 -                  -                  Yes        Dead, melanoma      \n",
       "29 44                 SQ                 No         Alive               \n",
       "30 68                 SQ                 Yes        Dead, melanoma      \n",
       "31 -                  -                  Yes        Alive               \n",
       "32 -                  -                  No         Alive               \n",
       "33 14                 SQ                 No         Alive               \n",
       "34 -                  -                  No         Alive               \n",
       "35 -                  -                  Yes        Dead, melanoma      \n",
       "36 -                  -                  Yes        Alive               \n",
       "37 -                  -                  Yes        Dead, melanoma      \n",
       "38 7                  SQ                 Yes        Alive               \n",
       "39 -                  -                  Yes        Alive               \n",
       "40 -                  -                  No         Alive               \n",
       "41 -                  -                  No         Alive               \n",
       "42 10                 SQ                 Yes        Alive               \n",
       "43 -                  -                  No         Alive               \n",
       "44 -                  -                  No         Alive               \n",
       "45 -                  -                  No         Alive               \n",
       "46 -                  -                  No         Alive               \n",
       "47 -                  -                  No         Alive               \n",
       "48 7                  SQ                 No         Alive               \n",
       "49 3                  LN                 No         Alive               \n",
       "50 2                  SQ                 No         Alive               \n",
       "51 -                  -                  No         Alive               \n",
       "52 -                  -                  No         Alive               \n",
       "53 -                  -                  No         Alive               \n",
       "54 -                  -                  No         Alive               \n",
       "55 -                  -                  No         Alive               \n",
       "   X.12           X.13                       X.14                      \n",
       "1  RNA Sequencing Immunofluorescence Panel 1 Immunofluorescence Panel 2\n",
       "2  -              PRE                        PRE and EDT               \n",
       "3  PRE            -                          -                         \n",
       "4  PRE            EDT                        EDT                       \n",
       "5  PRE            PRE and EDT                PRE and EDT               \n",
       "6  PRE            PRE                        PRE                       \n",
       "7  PRE            PRE                        PRE                       \n",
       "8  PRE            PRE and EDT                EDT                       \n",
       "9  PRE and EDT    PRE and EDT                PRE                       \n",
       "10 PRE            -                          -                         \n",
       "11 PRE and EDT    PRE                        PRE                       \n",
       "12 PRE            -                          -                         \n",
       "13 PRE            PRE and EDT                PRE and EDT               \n",
       "14 PRE and EDT    PRE and EDT                PRE and EDT               \n",
       "15 PRE            PRE                        PRE                       \n",
       "16 PRE            -                          -                         \n",
       "17 PRE            -                          -                         \n",
       "18 PRE and EDT    PRE and EDT                PRE                       \n",
       "19 PRE            PRE                        PRE                       \n",
       "20 PRE            PRE                        PRE                       \n",
       "21 -              PRE                        PRE                       \n",
       "22 PRE            PRE                        PRE                       \n",
       "23 -              PRE                        PRE                       \n",
       "24 PRE            PRE and EDT                PRE and EDT               \n",
       "25 -              PRE and EDT                PRE and EDT               \n",
       "26 PRE and EDT    PRE and EDT                PRE and EDT               \n",
       "27 -              PRE and EDT                PRE and EDT               \n",
       "28 PRE            -                          -                         \n",
       "29 -              PRE and EDT                PRE and EDT               \n",
       "30 PRE and EDT    -                          -                         \n",
       "31 PRE            PRE                        PRE                       \n",
       "32 -              PRE                        PRE                       \n",
       "33 -              PRE                        EDT                       \n",
       "34 -              PRE                        PRE                       \n",
       "35 PRE            PRE                        PRE                       \n",
       "36 PRE            -                          -                         \n",
       "37 PRE            PRE                        PRE                       \n",
       "38 -              PRE and EDT                PRE and EDT               \n",
       "39 PRE            -                          -                         \n",
       "40 -              PRE                        PRE                       \n",
       "41 PRE            PRE                        PRE                       \n",
       "42 PRE and EDT    PRE and EDT                PRE and EDT               \n",
       "43 PRE            -                          -                         \n",
       "44 -              PRE                        PRE                       \n",
       "45 PRE            -                          -                         \n",
       "46 PRE            -                          -                         \n",
       "47 PRE            PRE                        PRE                       \n",
       "48 PRE and EDT    -                          -                         \n",
       "49 PRE and EDT    -                          -                         \n",
       "50 PRE            PRE and EDT                PRE and EDT               \n",
       "51 PRE            PRE                        PRE                       \n",
       "52 -              PRE                        PRE                       \n",
       "53 PRE            PRE                        PRE                       \n",
       "54 PRE            -                          -                         \n",
       "55 PRE            PRE                        PRE                       "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "supp1 <- read.csv(\"Gide_supp1.csv\", skip=1)\n",
    "supp1\n",
    "# class(supp1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "1de59900",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table>\n",
       "<caption>A data.frame: 54 Ã— 14</caption>\n",
       "<thead>\n",
       "\t<tr><th></th><th scope=col>Age..Years.</th><th scope=col>Sex</th><th scope=col>Treatment</th><th scope=col>Best.RECIST.response</th><th scope=col>Progression.Free.Survival..Days.</th><th scope=col>Overall.Survival..Days.</th><th scope=col>Site.of.PRE.Biopsy</th><th scope=col>Days.to.EDT.Biopsy</th><th scope=col>Site.of.EDT.Biopsy</th><th scope=col>Progressed</th><th scope=col>Last.Followup.Status</th><th scope=col>RNA.Sequencing</th><th scope=col>Immunofluorescence.Panel.1</th><th scope=col>Immunofluorescence.Panel.2</th></tr>\n",
       "\t<tr><th></th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><th scope=row>1</th><td>48</td><td>F</td><td>Nivolumab    </td><td>PD </td><td>9   </td><td>147 </td><td>LN    </td><td>7 </td><td>SQ   </td><td>Yes</td><td>Dead, melanoma</td><td>-          </td><td>PRE        </td><td>PRE and EDT</td></tr>\n",
       "\t<tr><th scope=row>2</th><td>61</td><td>F</td><td>Pembrolizumab</td><td>PD </td><td>13  </td><td>65  </td><td>SQ    </td><td>- </td><td>-    </td><td>Yes</td><td>Dead, melanoma</td><td>PRE        </td><td>-          </td><td>-          </td></tr>\n",
       "\t<tr><th scope=row>3</th><td>50</td><td>M</td><td>Nivolumab    </td><td>PD </td><td>23  </td><td>59  </td><td>SQ    </td><td>15</td><td>SQ   </td><td>Yes</td><td>Dead, melanoma</td><td>PRE        </td><td>EDT        </td><td>EDT        </td></tr>\n",
       "\t<tr><th scope=row>4</th><td>84</td><td>M</td><td>Pembrolizumab</td><td>PD </td><td>23  </td><td>22  </td><td>SQ    </td><td>9 </td><td>SQ   </td><td>Yes</td><td>Dead, melanoma</td><td>PRE        </td><td>PRE and EDT</td><td>PRE and EDT</td></tr>\n",
       "\t<tr><th scope=row>5</th><td>67</td><td>M</td><td>Pembrolizumab</td><td>PD </td><td>39  </td><td>155 </td><td>SQ    </td><td>- </td><td>-    </td><td>Yes</td><td>Dead, melanoma</td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>6</th><td>68</td><td>M</td><td>Nivolumab    </td><td>PD </td><td>42  </td><td>94  </td><td>LN    </td><td>- </td><td>-    </td><td>Yes</td><td>Dead, melanoma</td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>7</th><td>57</td><td>F</td><td>Nivolumab    </td><td>PD </td><td>47  </td><td>80  </td><td>LN    </td><td>19</td><td>SQ   </td><td>Yes</td><td>Dead, melanoma</td><td>PRE        </td><td>PRE and EDT</td><td>EDT        </td></tr>\n",
       "\t<tr><th scope=row>8</th><td>85</td><td>F</td><td>Nivolumab    </td><td>PD </td><td>58  </td><td>58  </td><td>SQ    </td><td>6 </td><td>SQ   </td><td>Yes</td><td>Dead, melanoma</td><td>PRE and EDT</td><td>PRE and EDT</td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>9</th><td>70</td><td>F</td><td>Pembrolizumab</td><td>PD </td><td>71  </td><td>99  </td><td>SQ    </td><td>- </td><td>-    </td><td>Yes</td><td>Dead, melanoma</td><td>PRE        </td><td>-          </td><td>-          </td></tr>\n",
       "\t<tr><th scope=row>10</th><td>90</td><td>M</td><td>Pembrolizumab</td><td>PD </td><td>76  </td><td>551 </td><td>SQ    </td><td>7 </td><td>SQ   </td><td>Yes</td><td>Alive         </td><td>PRE and EDT</td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>11</th><td>66</td><td>M</td><td>Pembrolizumab</td><td>PD </td><td>78  </td><td>166 </td><td>SQ    </td><td>- </td><td>-    </td><td>Yes</td><td>Dead, melanoma</td><td>PRE        </td><td>-          </td><td>-          </td></tr>\n",
       "\t<tr><th scope=row>12</th><td>52</td><td>M</td><td>Pembrolizumab</td><td>SD </td><td>80  </td><td>199 </td><td>SQ    </td><td>14</td><td>SQ   </td><td>Yes</td><td>Dead, melanoma</td><td>PRE        </td><td>PRE and EDT</td><td>PRE and EDT</td></tr>\n",
       "\t<tr><th scope=row>13</th><td>69</td><td>M</td><td>Pembrolizumab</td><td>PD </td><td>82  </td><td>96  </td><td>SQ    </td><td>6 </td><td>SQ   </td><td>Yes</td><td>Dead, melanoma</td><td>PRE and EDT</td><td>PRE and EDT</td><td>PRE and EDT</td></tr>\n",
       "\t<tr><th scope=row>14</th><td>58</td><td>M</td><td>Pembrolizumab</td><td>PD </td><td>83  </td><td>993 </td><td>Mucosa</td><td>- </td><td>-    </td><td>Yes</td><td>Dead, melanoma</td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>15</th><td>76</td><td>F</td><td>Pembrolizumab</td><td>PD </td><td>84  </td><td>300 </td><td>SQ    </td><td>- </td><td>-    </td><td>Yes</td><td>Dead          </td><td>PRE        </td><td>-          </td><td>-          </td></tr>\n",
       "\t<tr><th scope=row>16</th><td>55</td><td>M</td><td>Pembrolizumab</td><td>PD </td><td>84  </td><td>169 </td><td>LN    </td><td>- </td><td>-    </td><td>Yes</td><td>Dead, melanoma</td><td>PRE        </td><td>-          </td><td>-          </td></tr>\n",
       "\t<tr><th scope=row>17</th><td>37</td><td>M</td><td>Pembrolizumab</td><td>PD </td><td>96  </td><td>258 </td><td>SQ    </td><td>9 </td><td>Spine</td><td>Yes</td><td>Dead, melanoma</td><td>PRE and EDT</td><td>PRE and EDT</td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>18</th><td>62</td><td>M</td><td>Pembrolizumab</td><td>PD </td><td>100 </td><td>228 </td><td>SQ    </td><td>- </td><td>-    </td><td>Yes</td><td>Dead, melanoma</td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>19</th><td>54</td><td>M</td><td>Pembrolizumab</td><td>SD </td><td>125 </td><td>385 </td><td>SQ    </td><td>- </td><td>-    </td><td>Yes</td><td>Dead, melanoma</td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>20</th><td>45</td><td>F</td><td>Pembrolizumab</td><td>PR </td><td>156 </td><td>553 </td><td>Brain </td><td>- </td><td>-    </td><td>Yes</td><td>Dead, melanoma</td><td>-          </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>21</th><td>67</td><td>M</td><td>Pembrolizumab</td><td>SD </td><td>166 </td><td>551 </td><td>SQ    </td><td>- </td><td>-    </td><td>Yes</td><td>Dead, melanoma</td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>22</th><td>69</td><td>F</td><td>Pembrolizumab</td><td>SD </td><td>176 </td><td>379 </td><td>SQ    </td><td>- </td><td>-    </td><td>Yes</td><td>Alive         </td><td>-          </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>23</th><td>40</td><td>M</td><td>Nivolumab    </td><td>SD </td><td>191 </td><td>191 </td><td>SQ    </td><td>10</td><td>SQ   </td><td>Yes</td><td>Dead, melanoma</td><td>PRE        </td><td>PRE and EDT</td><td>PRE and EDT</td></tr>\n",
       "\t<tr><th scope=row>24</th><td>54</td><td>F</td><td>Pembrolizumab</td><td>SD </td><td>197 </td><td>407 </td><td>SQ    </td><td>28</td><td>SQ   </td><td>Yes</td><td>Dead, melanoma</td><td>-          </td><td>PRE and EDT</td><td>PRE and EDT</td></tr>\n",
       "\t<tr><th scope=row>25</th><td>49</td><td>M</td><td>Nivolumab    </td><td>PR </td><td>271 </td><td>897 </td><td>SQ    </td><td>43</td><td>SQ   </td><td>Yes</td><td>Dead, melanoma</td><td>PRE and EDT</td><td>PRE and EDT</td><td>PRE and EDT</td></tr>\n",
       "\t<tr><th scope=row>26</th><td>89</td><td>F</td><td>Pembrolizumab</td><td>CR </td><td>275 </td><td>275 </td><td>SQ    </td><td>10</td><td>SQ   </td><td>No </td><td>Alive         </td><td>-          </td><td>PRE and EDT</td><td>PRE and EDT</td></tr>\n",
       "\t<tr><th scope=row>27</th><td>76</td><td>M</td><td>Pembrolizumab</td><td>PR </td><td>314 </td><td>1067</td><td>SQ    </td><td>- </td><td>-    </td><td>Yes</td><td>Dead, melanoma</td><td>PRE        </td><td>-          </td><td>-          </td></tr>\n",
       "\t<tr><th scope=row>28</th><td>81</td><td>M</td><td>Pembrolizumab</td><td>PR </td><td>324 </td><td>324 </td><td>SQ    </td><td>44</td><td>SQ   </td><td>No </td><td>Alive         </td><td>-          </td><td>PRE and EDT</td><td>PRE and EDT</td></tr>\n",
       "\t<tr><th scope=row>29</th><td>55</td><td>M</td><td>Pembrolizumab</td><td>SD </td><td>335 </td><td>825 </td><td>SQ    </td><td>68</td><td>SQ   </td><td>Yes</td><td>Dead, melanoma</td><td>PRE and EDT</td><td>-          </td><td>-          </td></tr>\n",
       "\t<tr><th scope=row>30</th><td>86</td><td>F</td><td>Pembrolizumab</td><td>SD </td><td>358 </td><td>581 </td><td>SQ    </td><td>- </td><td>-    </td><td>Yes</td><td>Alive         </td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>31</th><td>74</td><td>F</td><td>Nivolumab    </td><td>PR </td><td>365 </td><td>365 </td><td>SQ    </td><td>- </td><td>-    </td><td>No </td><td>Alive         </td><td>-          </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>32</th><td>69</td><td>F</td><td>Pembrolizumab</td><td>CR </td><td>460 </td><td>460 </td><td>Brain </td><td>14</td><td>SQ   </td><td>No </td><td>Alive         </td><td>-          </td><td>PRE        </td><td>EDT        </td></tr>\n",
       "\t<tr><th scope=row>33</th><td>76</td><td>M</td><td>Pembrolizumab</td><td>CR </td><td>477 </td><td>477 </td><td>LN    </td><td>- </td><td>-    </td><td>No </td><td>Alive         </td><td>-          </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>34</th><td>78</td><td>M</td><td>Pembrolizumab</td><td>PR </td><td>544 </td><td>878 </td><td>LN    </td><td>- </td><td>-    </td><td>Yes</td><td>Dead, melanoma</td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>35</th><td>55</td><td>F</td><td>Pembrolizumab</td><td>PR </td><td>586 </td><td>1091</td><td>SQ    </td><td>- </td><td>-    </td><td>Yes</td><td>Alive         </td><td>PRE        </td><td>-          </td><td>-          </td></tr>\n",
       "\t<tr><th scope=row>36</th><td>76</td><td>M</td><td>Nivolumab    </td><td>PR </td><td>590 </td><td>607 </td><td>SQ    </td><td>- </td><td>-    </td><td>Yes</td><td>Dead, melanoma</td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>37</th><td>66</td><td>M</td><td>Pembrolizumab</td><td>CR </td><td>647 </td><td>910 </td><td>SQ    </td><td>7 </td><td>SQ   </td><td>Yes</td><td>Alive         </td><td>-          </td><td>PRE and EDT</td><td>PRE and EDT</td></tr>\n",
       "\t<tr><th scope=row>38</th><td>69</td><td>F</td><td>Pembrolizumab</td><td>PR </td><td>755 </td><td>1547</td><td>SQ    </td><td>- </td><td>-    </td><td>Yes</td><td>Alive         </td><td>PRE        </td><td>-          </td><td>-          </td></tr>\n",
       "\t<tr><th scope=row>39</th><td>72</td><td>M</td><td>Pembrolizumab</td><td>SD </td><td>815 </td><td>815 </td><td>SQ    </td><td>- </td><td>-    </td><td>No </td><td>Alive         </td><td>-          </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>40</th><td>78</td><td>M</td><td>Pembrolizumab</td><td>PR </td><td>845 </td><td>845 </td><td>SQ    </td><td>- </td><td>-    </td><td>No </td><td>Alive         </td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>41</th><td>61</td><td>F</td><td>Pembrolizumab</td><td>PR </td><td>870 </td><td>886 </td><td>SQ    </td><td>10</td><td>SQ   </td><td>Yes</td><td>Alive         </td><td>PRE and EDT</td><td>PRE and EDT</td><td>PRE and EDT</td></tr>\n",
       "\t<tr><th scope=row>42</th><td>59</td><td>F</td><td>Pembrolizumab</td><td>CR </td><td>891 </td><td>891 </td><td>SQ    </td><td>- </td><td>-    </td><td>No </td><td>Alive         </td><td>PRE        </td><td>-          </td><td>-          </td></tr>\n",
       "\t<tr><th scope=row>43</th><td>63</td><td>M</td><td>Pembrolizumab</td><td>CR </td><td>905 </td><td>905 </td><td>SQ    </td><td>- </td><td>-    </td><td>No </td><td>Alive         </td><td>-          </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>44</th><td>45</td><td>F</td><td>Pembrolizumab</td><td>PR </td><td>1075</td><td>1075</td><td>LN    </td><td>- </td><td>-    </td><td>No </td><td>Alive         </td><td>PRE        </td><td>-          </td><td>-          </td></tr>\n",
       "\t<tr><th scope=row>45</th><td>82</td><td>M</td><td>Pembrolizumab</td><td>PR </td><td>1085</td><td>1085</td><td>SQ    </td><td>- </td><td>-    </td><td>No </td><td>Alive         </td><td>PRE        </td><td>-          </td><td>-          </td></tr>\n",
       "\t<tr><th scope=row>46</th><td>71</td><td>M</td><td>Pembrolizumab</td><td>PR </td><td>1098</td><td>1098</td><td>SQ    </td><td>- </td><td>-    </td><td>No </td><td>Alive         </td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>47</th><td>62</td><td>M</td><td>Pembrolizumab</td><td>PR </td><td>1174</td><td>1174</td><td>SQ    </td><td>7 </td><td>SQ   </td><td>No </td><td>Alive         </td><td>PRE and EDT</td><td>-          </td><td>-          </td></tr>\n",
       "\t<tr><th scope=row>48</th><td>40</td><td>M</td><td>Pembrolizumab</td><td>PR </td><td>1189</td><td>1189</td><td>SQ    </td><td>3 </td><td>LN   </td><td>No </td><td>Alive         </td><td>PRE and EDT</td><td>-          </td><td>-          </td></tr>\n",
       "\t<tr><th scope=row>49</th><td>72</td><td>F</td><td>Nivolumab    </td><td>CR </td><td>1328</td><td>1328</td><td>SQ    </td><td>2 </td><td>SQ   </td><td>No </td><td>Alive         </td><td>PRE        </td><td>PRE and EDT</td><td>PRE and EDT</td></tr>\n",
       "\t<tr><th scope=row>50</th><td>86</td><td>M</td><td>Nivolumab    </td><td>CR </td><td>1342</td><td>1342</td><td>SQ    </td><td>- </td><td>-    </td><td>No </td><td>Alive         </td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>51</th><td>64</td><td>M</td><td>Nivolumab    </td><td>CR </td><td>1397</td><td>1397</td><td>SQ    </td><td>- </td><td>-    </td><td>No </td><td>Alive         </td><td>-          </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>52</th><td>63</td><td>F</td><td>Pembrolizumab</td><td>PR </td><td>1553</td><td>1553</td><td>SQ    </td><td>- </td><td>-    </td><td>No </td><td>Alive         </td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>53</th><td>71</td><td>F</td><td>Pembrolizumab</td><td>CR </td><td>1589</td><td>1589</td><td>LN    </td><td>- </td><td>-    </td><td>No </td><td>Alive         </td><td>PRE        </td><td>-          </td><td>-          </td></tr>\n",
       "\t<tr><th scope=row>54</th><td>52</td><td>F</td><td>Pembrolizumab</td><td>PR </td><td>1603</td><td>1603</td><td>SQ    </td><td>- </td><td>-    </td><td>No </td><td>Alive         </td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A data.frame: 54 Ã— 14\n",
       "\\begin{tabular}{r|llllllllllllll}\n",
       "  & Age..Years. & Sex & Treatment & Best.RECIST.response & Progression.Free.Survival..Days. & Overall.Survival..Days. & Site.of.PRE.Biopsy & Days.to.EDT.Biopsy & Site.of.EDT.Biopsy & Progressed & Last.Followup.Status & RNA.Sequencing & Immunofluorescence.Panel.1 & Immunofluorescence.Panel.2\\\\\n",
       "  & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct>\\\\\n",
       "\\hline\n",
       "\t1 & 48 & F & Nivolumab     & PD  & 9    & 147  & LN     & 7  & SQ    & Yes & Dead, melanoma & -           & PRE         & PRE and EDT\\\\\n",
       "\t2 & 61 & F & Pembrolizumab & PD  & 13   & 65   & SQ     & -  & -     & Yes & Dead, melanoma & PRE         & -           & -          \\\\\n",
       "\t3 & 50 & M & Nivolumab     & PD  & 23   & 59   & SQ     & 15 & SQ    & Yes & Dead, melanoma & PRE         & EDT         & EDT        \\\\\n",
       "\t4 & 84 & M & Pembrolizumab & PD  & 23   & 22   & SQ     & 9  & SQ    & Yes & Dead, melanoma & PRE         & PRE and EDT & PRE and EDT\\\\\n",
       "\t5 & 67 & M & Pembrolizumab & PD  & 39   & 155  & SQ     & -  & -     & Yes & Dead, melanoma & PRE         & PRE         & PRE        \\\\\n",
       "\t6 & 68 & M & Nivolumab     & PD  & 42   & 94   & LN     & -  & -     & Yes & Dead, melanoma & PRE         & PRE         & PRE        \\\\\n",
       "\t7 & 57 & F & Nivolumab     & PD  & 47   & 80   & LN     & 19 & SQ    & Yes & Dead, melanoma & PRE         & PRE and EDT & EDT        \\\\\n",
       "\t8 & 85 & F & Nivolumab     & PD  & 58   & 58   & SQ     & 6  & SQ    & Yes & Dead, melanoma & PRE and EDT & PRE and EDT & PRE        \\\\\n",
       "\t9 & 70 & F & Pembrolizumab & PD  & 71   & 99   & SQ     & -  & -     & Yes & Dead, melanoma & PRE         & -           & -          \\\\\n",
       "\t10 & 90 & M & Pembrolizumab & PD  & 76   & 551  & SQ     & 7  & SQ    & Yes & Alive          & PRE and EDT & PRE         & PRE        \\\\\n",
       "\t11 & 66 & M & Pembrolizumab & PD  & 78   & 166  & SQ     & -  & -     & Yes & Dead, melanoma & PRE         & -           & -          \\\\\n",
       "\t12 & 52 & M & Pembrolizumab & SD  & 80   & 199  & SQ     & 14 & SQ    & Yes & Dead, melanoma & PRE         & PRE and EDT & PRE and EDT\\\\\n",
       "\t13 & 69 & M & Pembrolizumab & PD  & 82   & 96   & SQ     & 6  & SQ    & Yes & Dead, melanoma & PRE and EDT & PRE and EDT & PRE and EDT\\\\\n",
       "\t14 & 58 & M & Pembrolizumab & PD  & 83   & 993  & Mucosa & -  & -     & Yes & Dead, melanoma & PRE         & PRE         & PRE        \\\\\n",
       "\t15 & 76 & F & Pembrolizumab & PD  & 84   & 300  & SQ     & -  & -     & Yes & Dead           & PRE         & -           & -          \\\\\n",
       "\t16 & 55 & M & Pembrolizumab & PD  & 84   & 169  & LN     & -  & -     & Yes & Dead, melanoma & PRE         & -           & -          \\\\\n",
       "\t17 & 37 & M & Pembrolizumab & PD  & 96   & 258  & SQ     & 9  & Spine & Yes & Dead, melanoma & PRE and EDT & PRE and EDT & PRE        \\\\\n",
       "\t18 & 62 & M & Pembrolizumab & PD  & 100  & 228  & SQ     & -  & -     & Yes & Dead, melanoma & PRE         & PRE         & PRE        \\\\\n",
       "\t19 & 54 & M & Pembrolizumab & SD  & 125  & 385  & SQ     & -  & -     & Yes & Dead, melanoma & PRE         & PRE         & PRE        \\\\\n",
       "\t20 & 45 & F & Pembrolizumab & PR  & 156  & 553  & Brain  & -  & -     & Yes & Dead, melanoma & -           & PRE         & PRE        \\\\\n",
       "\t21 & 67 & M & Pembrolizumab & SD  & 166  & 551  & SQ     & -  & -     & Yes & Dead, melanoma & PRE         & PRE         & PRE        \\\\\n",
       "\t22 & 69 & F & Pembrolizumab & SD  & 176  & 379  & SQ     & -  & -     & Yes & Alive          & -           & PRE         & PRE        \\\\\n",
       "\t23 & 40 & M & Nivolumab     & SD  & 191  & 191  & SQ     & 10 & SQ    & Yes & Dead, melanoma & PRE         & PRE and EDT & PRE and EDT\\\\\n",
       "\t24 & 54 & F & Pembrolizumab & SD  & 197  & 407  & SQ     & 28 & SQ    & Yes & Dead, melanoma & -           & PRE and EDT & PRE and EDT\\\\\n",
       "\t25 & 49 & M & Nivolumab     & PR  & 271  & 897  & SQ     & 43 & SQ    & Yes & Dead, melanoma & PRE and EDT & PRE and EDT & PRE and EDT\\\\\n",
       "\t26 & 89 & F & Pembrolizumab & CR  & 275  & 275  & SQ     & 10 & SQ    & No  & Alive          & -           & PRE and EDT & PRE and EDT\\\\\n",
       "\t27 & 76 & M & Pembrolizumab & PR  & 314  & 1067 & SQ     & -  & -     & Yes & Dead, melanoma & PRE         & -           & -          \\\\\n",
       "\t28 & 81 & M & Pembrolizumab & PR  & 324  & 324  & SQ     & 44 & SQ    & No  & Alive          & -           & PRE and EDT & PRE and EDT\\\\\n",
       "\t29 & 55 & M & Pembrolizumab & SD  & 335  & 825  & SQ     & 68 & SQ    & Yes & Dead, melanoma & PRE and EDT & -           & -          \\\\\n",
       "\t30 & 86 & F & Pembrolizumab & SD  & 358  & 581  & SQ     & -  & -     & Yes & Alive          & PRE         & PRE         & PRE        \\\\\n",
       "\t31 & 74 & F & Nivolumab     & PR  & 365  & 365  & SQ     & -  & -     & No  & Alive          & -           & PRE         & PRE        \\\\\n",
       "\t32 & 69 & F & Pembrolizumab & CR  & 460  & 460  & Brain  & 14 & SQ    & No  & Alive          & -           & PRE         & EDT        \\\\\n",
       "\t33 & 76 & M & Pembrolizumab & CR  & 477  & 477  & LN     & -  & -     & No  & Alive          & -           & PRE         & PRE        \\\\\n",
       "\t34 & 78 & M & Pembrolizumab & PR  & 544  & 878  & LN     & -  & -     & Yes & Dead, melanoma & PRE         & PRE         & PRE        \\\\\n",
       "\t35 & 55 & F & Pembrolizumab & PR  & 586  & 1091 & SQ     & -  & -     & Yes & Alive          & PRE         & -           & -          \\\\\n",
       "\t36 & 76 & M & Nivolumab     & PR  & 590  & 607  & SQ     & -  & -     & Yes & Dead, melanoma & PRE         & PRE         & PRE        \\\\\n",
       "\t37 & 66 & M & Pembrolizumab & CR  & 647  & 910  & SQ     & 7  & SQ    & Yes & Alive          & -           & PRE and EDT & PRE and EDT\\\\\n",
       "\t38 & 69 & F & Pembrolizumab & PR  & 755  & 1547 & SQ     & -  & -     & Yes & Alive          & PRE         & -           & -          \\\\\n",
       "\t39 & 72 & M & Pembrolizumab & SD  & 815  & 815  & SQ     & -  & -     & No  & Alive          & -           & PRE         & PRE        \\\\\n",
       "\t40 & 78 & M & Pembrolizumab & PR  & 845  & 845  & SQ     & -  & -     & No  & Alive          & PRE         & PRE         & PRE        \\\\\n",
       "\t41 & 61 & F & Pembrolizumab & PR  & 870  & 886  & SQ     & 10 & SQ    & Yes & Alive          & PRE and EDT & PRE and EDT & PRE and EDT\\\\\n",
       "\t42 & 59 & F & Pembrolizumab & CR  & 891  & 891  & SQ     & -  & -     & No  & Alive          & PRE         & -           & -          \\\\\n",
       "\t43 & 63 & M & Pembrolizumab & CR  & 905  & 905  & SQ     & -  & -     & No  & Alive          & -           & PRE         & PRE        \\\\\n",
       "\t44 & 45 & F & Pembrolizumab & PR  & 1075 & 1075 & LN     & -  & -     & No  & Alive          & PRE         & -           & -          \\\\\n",
       "\t45 & 82 & M & Pembrolizumab & PR  & 1085 & 1085 & SQ     & -  & -     & No  & Alive          & PRE         & -           & -          \\\\\n",
       "\t46 & 71 & M & Pembrolizumab & PR  & 1098 & 1098 & SQ     & -  & -     & No  & Alive          & PRE         & PRE         & PRE        \\\\\n",
       "\t47 & 62 & M & Pembrolizumab & PR  & 1174 & 1174 & SQ     & 7  & SQ    & No  & Alive          & PRE and EDT & -           & -          \\\\\n",
       "\t48 & 40 & M & Pembrolizumab & PR  & 1189 & 1189 & SQ     & 3  & LN    & No  & Alive          & PRE and EDT & -           & -          \\\\\n",
       "\t49 & 72 & F & Nivolumab     & CR  & 1328 & 1328 & SQ     & 2  & SQ    & No  & Alive          & PRE         & PRE and EDT & PRE and EDT\\\\\n",
       "\t50 & 86 & M & Nivolumab     & CR  & 1342 & 1342 & SQ     & -  & -     & No  & Alive          & PRE         & PRE         & PRE        \\\\\n",
       "\t51 & 64 & M & Nivolumab     & CR  & 1397 & 1397 & SQ     & -  & -     & No  & Alive          & -           & PRE         & PRE        \\\\\n",
       "\t52 & 63 & F & Pembrolizumab & PR  & 1553 & 1553 & SQ     & -  & -     & No  & Alive          & PRE         & PRE         & PRE        \\\\\n",
       "\t53 & 71 & F & Pembrolizumab & CR  & 1589 & 1589 & LN     & -  & -     & No  & Alive          & PRE         & -           & -          \\\\\n",
       "\t54 & 52 & F & Pembrolizumab & PR  & 1603 & 1603 & SQ     & -  & -     & No  & Alive          & PRE         & PRE         & PRE        \\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A data.frame: 54 Ã— 14\n",
       "\n",
       "| <!--/--> | Age..Years. &lt;fct&gt; | Sex &lt;fct&gt; | Treatment &lt;fct&gt; | Best.RECIST.response &lt;fct&gt; | Progression.Free.Survival..Days. &lt;fct&gt; | Overall.Survival..Days. &lt;fct&gt; | Site.of.PRE.Biopsy &lt;fct&gt; | Days.to.EDT.Biopsy &lt;fct&gt; | Site.of.EDT.Biopsy &lt;fct&gt; | Progressed &lt;fct&gt; | Last.Followup.Status &lt;fct&gt; | RNA.Sequencing &lt;fct&gt; | Immunofluorescence.Panel.1 &lt;fct&gt; | Immunofluorescence.Panel.2 &lt;fct&gt; |\n",
       "|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|\n",
       "| 1 | 48 | F | Nivolumab     | PD  | 9    | 147  | LN     | 7  | SQ    | Yes | Dead, melanoma | -           | PRE         | PRE and EDT |\n",
       "| 2 | 61 | F | Pembrolizumab | PD  | 13   | 65   | SQ     | -  | -     | Yes | Dead, melanoma | PRE         | -           | -           |\n",
       "| 3 | 50 | M | Nivolumab     | PD  | 23   | 59   | SQ     | 15 | SQ    | Yes | Dead, melanoma | PRE         | EDT         | EDT         |\n",
       "| 4 | 84 | M | Pembrolizumab | PD  | 23   | 22   | SQ     | 9  | SQ    | Yes | Dead, melanoma | PRE         | PRE and EDT | PRE and EDT |\n",
       "| 5 | 67 | M | Pembrolizumab | PD  | 39   | 155  | SQ     | -  | -     | Yes | Dead, melanoma | PRE         | PRE         | PRE         |\n",
       "| 6 | 68 | M | Nivolumab     | PD  | 42   | 94   | LN     | -  | -     | Yes | Dead, melanoma | PRE         | PRE         | PRE         |\n",
       "| 7 | 57 | F | Nivolumab     | PD  | 47   | 80   | LN     | 19 | SQ    | Yes | Dead, melanoma | PRE         | PRE and EDT | EDT         |\n",
       "| 8 | 85 | F | Nivolumab     | PD  | 58   | 58   | SQ     | 6  | SQ    | Yes | Dead, melanoma | PRE and EDT | PRE and EDT | PRE         |\n",
       "| 9 | 70 | F | Pembrolizumab | PD  | 71   | 99   | SQ     | -  | -     | Yes | Dead, melanoma | PRE         | -           | -           |\n",
       "| 10 | 90 | M | Pembrolizumab | PD  | 76   | 551  | SQ     | 7  | SQ    | Yes | Alive          | PRE and EDT | PRE         | PRE         |\n",
       "| 11 | 66 | M | Pembrolizumab | PD  | 78   | 166  | SQ     | -  | -     | Yes | Dead, melanoma | PRE         | -           | -           |\n",
       "| 12 | 52 | M | Pembrolizumab | SD  | 80   | 199  | SQ     | 14 | SQ    | Yes | Dead, melanoma | PRE         | PRE and EDT | PRE and EDT |\n",
       "| 13 | 69 | M | Pembrolizumab | PD  | 82   | 96   | SQ     | 6  | SQ    | Yes | Dead, melanoma | PRE and EDT | PRE and EDT | PRE and EDT |\n",
       "| 14 | 58 | M | Pembrolizumab | PD  | 83   | 993  | Mucosa | -  | -     | Yes | Dead, melanoma | PRE         | PRE         | PRE         |\n",
       "| 15 | 76 | F | Pembrolizumab | PD  | 84   | 300  | SQ     | -  | -     | Yes | Dead           | PRE         | -           | -           |\n",
       "| 16 | 55 | M | Pembrolizumab | PD  | 84   | 169  | LN     | -  | -     | Yes | Dead, melanoma | PRE         | -           | -           |\n",
       "| 17 | 37 | M | Pembrolizumab | PD  | 96   | 258  | SQ     | 9  | Spine | Yes | Dead, melanoma | PRE and EDT | PRE and EDT | PRE         |\n",
       "| 18 | 62 | M | Pembrolizumab | PD  | 100  | 228  | SQ     | -  | -     | Yes | Dead, melanoma | PRE         | PRE         | PRE         |\n",
       "| 19 | 54 | M | Pembrolizumab | SD  | 125  | 385  | SQ     | -  | -     | Yes | Dead, melanoma | PRE         | PRE         | PRE         |\n",
       "| 20 | 45 | F | Pembrolizumab | PR  | 156  | 553  | Brain  | -  | -     | Yes | Dead, melanoma | -           | PRE         | PRE         |\n",
       "| 21 | 67 | M | Pembrolizumab | SD  | 166  | 551  | SQ     | -  | -     | Yes | Dead, melanoma | PRE         | PRE         | PRE         |\n",
       "| 22 | 69 | F | Pembrolizumab | SD  | 176  | 379  | SQ     | -  | -     | Yes | Alive          | -           | PRE         | PRE         |\n",
       "| 23 | 40 | M | Nivolumab     | SD  | 191  | 191  | SQ     | 10 | SQ    | Yes | Dead, melanoma | PRE         | PRE and EDT | PRE and EDT |\n",
       "| 24 | 54 | F | Pembrolizumab | SD  | 197  | 407  | SQ     | 28 | SQ    | Yes | Dead, melanoma | -           | PRE and EDT | PRE and EDT |\n",
       "| 25 | 49 | M | Nivolumab     | PR  | 271  | 897  | SQ     | 43 | SQ    | Yes | Dead, melanoma | PRE and EDT | PRE and EDT | PRE and EDT |\n",
       "| 26 | 89 | F | Pembrolizumab | CR  | 275  | 275  | SQ     | 10 | SQ    | No  | Alive          | -           | PRE and EDT | PRE and EDT |\n",
       "| 27 | 76 | M | Pembrolizumab | PR  | 314  | 1067 | SQ     | -  | -     | Yes | Dead, melanoma | PRE         | -           | -           |\n",
       "| 28 | 81 | M | Pembrolizumab | PR  | 324  | 324  | SQ     | 44 | SQ    | No  | Alive          | -           | PRE and EDT | PRE and EDT |\n",
       "| 29 | 55 | M | Pembrolizumab | SD  | 335  | 825  | SQ     | 68 | SQ    | Yes | Dead, melanoma | PRE and EDT | -           | -           |\n",
       "| 30 | 86 | F | Pembrolizumab | SD  | 358  | 581  | SQ     | -  | -     | Yes | Alive          | PRE         | PRE         | PRE         |\n",
       "| 31 | 74 | F | Nivolumab     | PR  | 365  | 365  | SQ     | -  | -     | No  | Alive          | -           | PRE         | PRE         |\n",
       "| 32 | 69 | F | Pembrolizumab | CR  | 460  | 460  | Brain  | 14 | SQ    | No  | Alive          | -           | PRE         | EDT         |\n",
       "| 33 | 76 | M | Pembrolizumab | CR  | 477  | 477  | LN     | -  | -     | No  | Alive          | -           | PRE         | PRE         |\n",
       "| 34 | 78 | M | Pembrolizumab | PR  | 544  | 878  | LN     | -  | -     | Yes | Dead, melanoma | PRE         | PRE         | PRE         |\n",
       "| 35 | 55 | F | Pembrolizumab | PR  | 586  | 1091 | SQ     | -  | -     | Yes | Alive          | PRE         | -           | -           |\n",
       "| 36 | 76 | M | Nivolumab     | PR  | 590  | 607  | SQ     | -  | -     | Yes | Dead, melanoma | PRE         | PRE         | PRE         |\n",
       "| 37 | 66 | M | Pembrolizumab | CR  | 647  | 910  | SQ     | 7  | SQ    | Yes | Alive          | -           | PRE and EDT | PRE and EDT |\n",
       "| 38 | 69 | F | Pembrolizumab | PR  | 755  | 1547 | SQ     | -  | -     | Yes | Alive          | PRE         | -           | -           |\n",
       "| 39 | 72 | M | Pembrolizumab | SD  | 815  | 815  | SQ     | -  | -     | No  | Alive          | -           | PRE         | PRE         |\n",
       "| 40 | 78 | M | Pembrolizumab | PR  | 845  | 845  | SQ     | -  | -     | No  | Alive          | PRE         | PRE         | PRE         |\n",
       "| 41 | 61 | F | Pembrolizumab | PR  | 870  | 886  | SQ     | 10 | SQ    | Yes | Alive          | PRE and EDT | PRE and EDT | PRE and EDT |\n",
       "| 42 | 59 | F | Pembrolizumab | CR  | 891  | 891  | SQ     | -  | -     | No  | Alive          | PRE         | -           | -           |\n",
       "| 43 | 63 | M | Pembrolizumab | CR  | 905  | 905  | SQ     | -  | -     | No  | Alive          | -           | PRE         | PRE         |\n",
       "| 44 | 45 | F | Pembrolizumab | PR  | 1075 | 1075 | LN     | -  | -     | No  | Alive          | PRE         | -           | -           |\n",
       "| 45 | 82 | M | Pembrolizumab | PR  | 1085 | 1085 | SQ     | -  | -     | No  | Alive          | PRE         | -           | -           |\n",
       "| 46 | 71 | M | Pembrolizumab | PR  | 1098 | 1098 | SQ     | -  | -     | No  | Alive          | PRE         | PRE         | PRE         |\n",
       "| 47 | 62 | M | Pembrolizumab | PR  | 1174 | 1174 | SQ     | 7  | SQ    | No  | Alive          | PRE and EDT | -           | -           |\n",
       "| 48 | 40 | M | Pembrolizumab | PR  | 1189 | 1189 | SQ     | 3  | LN    | No  | Alive          | PRE and EDT | -           | -           |\n",
       "| 49 | 72 | F | Nivolumab     | CR  | 1328 | 1328 | SQ     | 2  | SQ    | No  | Alive          | PRE         | PRE and EDT | PRE and EDT |\n",
       "| 50 | 86 | M | Nivolumab     | CR  | 1342 | 1342 | SQ     | -  | -     | No  | Alive          | PRE         | PRE         | PRE         |\n",
       "| 51 | 64 | M | Nivolumab     | CR  | 1397 | 1397 | SQ     | -  | -     | No  | Alive          | -           | PRE         | PRE         |\n",
       "| 52 | 63 | F | Pembrolizumab | PR  | 1553 | 1553 | SQ     | -  | -     | No  | Alive          | PRE         | PRE         | PRE         |\n",
       "| 53 | 71 | F | Pembrolizumab | CR  | 1589 | 1589 | LN     | -  | -     | No  | Alive          | PRE         | -           | -           |\n",
       "| 54 | 52 | F | Pembrolizumab | PR  | 1603 | 1603 | SQ     | -  | -     | No  | Alive          | PRE         | PRE         | PRE         |\n",
       "\n"
      ],
      "text/plain": [
       "   Age..Years. Sex Treatment     Best.RECIST.response\n",
       "1  48          F   Nivolumab     PD                  \n",
       "2  61          F   Pembrolizumab PD                  \n",
       "3  50          M   Nivolumab     PD                  \n",
       "4  84          M   Pembrolizumab PD                  \n",
       "5  67          M   Pembrolizumab PD                  \n",
       "6  68          M   Nivolumab     PD                  \n",
       "7  57          F   Nivolumab     PD                  \n",
       "8  85          F   Nivolumab     PD                  \n",
       "9  70          F   Pembrolizumab PD                  \n",
       "10 90          M   Pembrolizumab PD                  \n",
       "11 66          M   Pembrolizumab PD                  \n",
       "12 52          M   Pembrolizumab SD                  \n",
       "13 69          M   Pembrolizumab PD                  \n",
       "14 58          M   Pembrolizumab PD                  \n",
       "15 76          F   Pembrolizumab PD                  \n",
       "16 55          M   Pembrolizumab PD                  \n",
       "17 37          M   Pembrolizumab PD                  \n",
       "18 62          M   Pembrolizumab PD                  \n",
       "19 54          M   Pembrolizumab SD                  \n",
       "20 45          F   Pembrolizumab PR                  \n",
       "21 67          M   Pembrolizumab SD                  \n",
       "22 69          F   Pembrolizumab SD                  \n",
       "23 40          M   Nivolumab     SD                  \n",
       "24 54          F   Pembrolizumab SD                  \n",
       "25 49          M   Nivolumab     PR                  \n",
       "26 89          F   Pembrolizumab CR                  \n",
       "27 76          M   Pembrolizumab PR                  \n",
       "28 81          M   Pembrolizumab PR                  \n",
       "29 55          M   Pembrolizumab SD                  \n",
       "30 86          F   Pembrolizumab SD                  \n",
       "31 74          F   Nivolumab     PR                  \n",
       "32 69          F   Pembrolizumab CR                  \n",
       "33 76          M   Pembrolizumab CR                  \n",
       "34 78          M   Pembrolizumab PR                  \n",
       "35 55          F   Pembrolizumab PR                  \n",
       "36 76          M   Nivolumab     PR                  \n",
       "37 66          M   Pembrolizumab CR                  \n",
       "38 69          F   Pembrolizumab PR                  \n",
       "39 72          M   Pembrolizumab SD                  \n",
       "40 78          M   Pembrolizumab PR                  \n",
       "41 61          F   Pembrolizumab PR                  \n",
       "42 59          F   Pembrolizumab CR                  \n",
       "43 63          M   Pembrolizumab CR                  \n",
       "44 45          F   Pembrolizumab PR                  \n",
       "45 82          M   Pembrolizumab PR                  \n",
       "46 71          M   Pembrolizumab PR                  \n",
       "47 62          M   Pembrolizumab PR                  \n",
       "48 40          M   Pembrolizumab PR                  \n",
       "49 72          F   Nivolumab     CR                  \n",
       "50 86          M   Nivolumab     CR                  \n",
       "51 64          M   Nivolumab     CR                  \n",
       "52 63          F   Pembrolizumab PR                  \n",
       "53 71          F   Pembrolizumab CR                  \n",
       "54 52          F   Pembrolizumab PR                  \n",
       "   Progression.Free.Survival..Days. Overall.Survival..Days. Site.of.PRE.Biopsy\n",
       "1  9                                147                     LN                \n",
       "2  13                               65                      SQ                \n",
       "3  23                               59                      SQ                \n",
       "4  23                               22                      SQ                \n",
       "5  39                               155                     SQ                \n",
       "6  42                               94                      LN                \n",
       "7  47                               80                      LN                \n",
       "8  58                               58                      SQ                \n",
       "9  71                               99                      SQ                \n",
       "10 76                               551                     SQ                \n",
       "11 78                               166                     SQ                \n",
       "12 80                               199                     SQ                \n",
       "13 82                               96                      SQ                \n",
       "14 83                               993                     Mucosa            \n",
       "15 84                               300                     SQ                \n",
       "16 84                               169                     LN                \n",
       "17 96                               258                     SQ                \n",
       "18 100                              228                     SQ                \n",
       "19 125                              385                     SQ                \n",
       "20 156                              553                     Brain             \n",
       "21 166                              551                     SQ                \n",
       "22 176                              379                     SQ                \n",
       "23 191                              191                     SQ                \n",
       "24 197                              407                     SQ                \n",
       "25 271                              897                     SQ                \n",
       "26 275                              275                     SQ                \n",
       "27 314                              1067                    SQ                \n",
       "28 324                              324                     SQ                \n",
       "29 335                              825                     SQ                \n",
       "30 358                              581                     SQ                \n",
       "31 365                              365                     SQ                \n",
       "32 460                              460                     Brain             \n",
       "33 477                              477                     LN                \n",
       "34 544                              878                     LN                \n",
       "35 586                              1091                    SQ                \n",
       "36 590                              607                     SQ                \n",
       "37 647                              910                     SQ                \n",
       "38 755                              1547                    SQ                \n",
       "39 815                              815                     SQ                \n",
       "40 845                              845                     SQ                \n",
       "41 870                              886                     SQ                \n",
       "42 891                              891                     SQ                \n",
       "43 905                              905                     SQ                \n",
       "44 1075                             1075                    LN                \n",
       "45 1085                             1085                    SQ                \n",
       "46 1098                             1098                    SQ                \n",
       "47 1174                             1174                    SQ                \n",
       "48 1189                             1189                    SQ                \n",
       "49 1328                             1328                    SQ                \n",
       "50 1342                             1342                    SQ                \n",
       "51 1397                             1397                    SQ                \n",
       "52 1553                             1553                    SQ                \n",
       "53 1589                             1589                    LN                \n",
       "54 1603                             1603                    SQ                \n",
       "   Days.to.EDT.Biopsy Site.of.EDT.Biopsy Progressed Last.Followup.Status\n",
       "1  7                  SQ                 Yes        Dead, melanoma      \n",
       "2  -                  -                  Yes        Dead, melanoma      \n",
       "3  15                 SQ                 Yes        Dead, melanoma      \n",
       "4  9                  SQ                 Yes        Dead, melanoma      \n",
       "5  -                  -                  Yes        Dead, melanoma      \n",
       "6  -                  -                  Yes        Dead, melanoma      \n",
       "7  19                 SQ                 Yes        Dead, melanoma      \n",
       "8  6                  SQ                 Yes        Dead, melanoma      \n",
       "9  -                  -                  Yes        Dead, melanoma      \n",
       "10 7                  SQ                 Yes        Alive               \n",
       "11 -                  -                  Yes        Dead, melanoma      \n",
       "12 14                 SQ                 Yes        Dead, melanoma      \n",
       "13 6                  SQ                 Yes        Dead, melanoma      \n",
       "14 -                  -                  Yes        Dead, melanoma      \n",
       "15 -                  -                  Yes        Dead                \n",
       "16 -                  -                  Yes        Dead, melanoma      \n",
       "17 9                  Spine              Yes        Dead, melanoma      \n",
       "18 -                  -                  Yes        Dead, melanoma      \n",
       "19 -                  -                  Yes        Dead, melanoma      \n",
       "20 -                  -                  Yes        Dead, melanoma      \n",
       "21 -                  -                  Yes        Dead, melanoma      \n",
       "22 -                  -                  Yes        Alive               \n",
       "23 10                 SQ                 Yes        Dead, melanoma      \n",
       "24 28                 SQ                 Yes        Dead, melanoma      \n",
       "25 43                 SQ                 Yes        Dead, melanoma      \n",
       "26 10                 SQ                 No         Alive               \n",
       "27 -                  -                  Yes        Dead, melanoma      \n",
       "28 44                 SQ                 No         Alive               \n",
       "29 68                 SQ                 Yes        Dead, melanoma      \n",
       "30 -                  -                  Yes        Alive               \n",
       "31 -                  -                  No         Alive               \n",
       "32 14                 SQ                 No         Alive               \n",
       "33 -                  -                  No         Alive               \n",
       "34 -                  -                  Yes        Dead, melanoma      \n",
       "35 -                  -                  Yes        Alive               \n",
       "36 -                  -                  Yes        Dead, melanoma      \n",
       "37 7                  SQ                 Yes        Alive               \n",
       "38 -                  -                  Yes        Alive               \n",
       "39 -                  -                  No         Alive               \n",
       "40 -                  -                  No         Alive               \n",
       "41 10                 SQ                 Yes        Alive               \n",
       "42 -                  -                  No         Alive               \n",
       "43 -                  -                  No         Alive               \n",
       "44 -                  -                  No         Alive               \n",
       "45 -                  -                  No         Alive               \n",
       "46 -                  -                  No         Alive               \n",
       "47 7                  SQ                 No         Alive               \n",
       "48 3                  LN                 No         Alive               \n",
       "49 2                  SQ                 No         Alive               \n",
       "50 -                  -                  No         Alive               \n",
       "51 -                  -                  No         Alive               \n",
       "52 -                  -                  No         Alive               \n",
       "53 -                  -                  No         Alive               \n",
       "54 -                  -                  No         Alive               \n",
       "   RNA.Sequencing Immunofluorescence.Panel.1 Immunofluorescence.Panel.2\n",
       "1  -              PRE                        PRE and EDT               \n",
       "2  PRE            -                          -                         \n",
       "3  PRE            EDT                        EDT                       \n",
       "4  PRE            PRE and EDT                PRE and EDT               \n",
       "5  PRE            PRE                        PRE                       \n",
       "6  PRE            PRE                        PRE                       \n",
       "7  PRE            PRE and EDT                EDT                       \n",
       "8  PRE and EDT    PRE and EDT                PRE                       \n",
       "9  PRE            -                          -                         \n",
       "10 PRE and EDT    PRE                        PRE                       \n",
       "11 PRE            -                          -                         \n",
       "12 PRE            PRE and EDT                PRE and EDT               \n",
       "13 PRE and EDT    PRE and EDT                PRE and EDT               \n",
       "14 PRE            PRE                        PRE                       \n",
       "15 PRE            -                          -                         \n",
       "16 PRE            -                          -                         \n",
       "17 PRE and EDT    PRE and EDT                PRE                       \n",
       "18 PRE            PRE                        PRE                       \n",
       "19 PRE            PRE                        PRE                       \n",
       "20 -              PRE                        PRE                       \n",
       "21 PRE            PRE                        PRE                       \n",
       "22 -              PRE                        PRE                       \n",
       "23 PRE            PRE and EDT                PRE and EDT               \n",
       "24 -              PRE and EDT                PRE and EDT               \n",
       "25 PRE and EDT    PRE and EDT                PRE and EDT               \n",
       "26 -              PRE and EDT                PRE and EDT               \n",
       "27 PRE            -                          -                         \n",
       "28 -              PRE and EDT                PRE and EDT               \n",
       "29 PRE and EDT    -                          -                         \n",
       "30 PRE            PRE                        PRE                       \n",
       "31 -              PRE                        PRE                       \n",
       "32 -              PRE                        EDT                       \n",
       "33 -              PRE                        PRE                       \n",
       "34 PRE            PRE                        PRE                       \n",
       "35 PRE            -                          -                         \n",
       "36 PRE            PRE                        PRE                       \n",
       "37 -              PRE and EDT                PRE and EDT               \n",
       "38 PRE            -                          -                         \n",
       "39 -              PRE                        PRE                       \n",
       "40 PRE            PRE                        PRE                       \n",
       "41 PRE and EDT    PRE and EDT                PRE and EDT               \n",
       "42 PRE            -                          -                         \n",
       "43 -              PRE                        PRE                       \n",
       "44 PRE            -                          -                         \n",
       "45 PRE            -                          -                         \n",
       "46 PRE            PRE                        PRE                       \n",
       "47 PRE and EDT    -                          -                         \n",
       "48 PRE and EDT    -                          -                         \n",
       "49 PRE            PRE and EDT                PRE and EDT               \n",
       "50 PRE            PRE                        PRE                       \n",
       "51 -              PRE                        PRE                       \n",
       "52 PRE            PRE                        PRE                       \n",
       "53 PRE            -                          -                         \n",
       "54 PRE            PRE                        PRE                       "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "supp1 <- janitor::row_to_names(supp1, 1)\n",
    "supp1 <- data.frame(supp1[,-1], row.names = supp1[,1])\n",
    "supp1"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "fae91773",
   "metadata": {},
   "source": [
    "### File 2"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "52391a08",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table>\n",
       "<caption>A data.frame: 52 Ã— 15</caption>\n",
       "<thead>\n",
       "\t<tr><th scope=col>X</th><th scope=col>X.1</th><th scope=col>X.2</th><th scope=col>X.3</th><th scope=col>X.4</th><th scope=col>X.5</th><th scope=col>X.6</th><th scope=col>X.7</th><th scope=col>X.8</th><th scope=col>X.9</th><th scope=col>X.10</th><th scope=col>X.11</th><th scope=col>X.12</th><th scope=col>X.13</th><th scope=col>X.14</th></tr>\n",
       "\t<tr><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><td>Patient no.</td><td>Age (Years)</td><td>Sex</td><td>Treatment                 </td><td>Best RECIST response</td><td>Progression Free Survival (Days)</td><td>Overall Survival (Days)</td><td>Site of PRE Biopsy</td><td>Days to EDT Biopsy</td><td>Site of EDT Biopsy</td><td>Progressed</td><td>Last Followup Status</td><td>RNA Sequencing</td><td>Immunofluorescence Panel 1</td><td>Immunofluorescence Panel 2</td></tr>\n",
       "\t<tr><td>1          </td><td>42         </td><td>F  </td><td>Ipilimumab + Pembrolizumab</td><td>PD                  </td><td>15                              </td><td>689                    </td><td>SQ                </td><td>7                 </td><td>SQ                </td><td>Yes       </td><td>Alive               </td><td>PRE and EDT   </td><td>PRE and EDT               </td><td>PRE and EDT               </td></tr>\n",
       "\t<tr><td>2          </td><td>41         </td><td>M  </td><td>Ipilimumab + Pembrolizumab</td><td>PD                  </td><td>34                              </td><td>530                    </td><td>LN                </td><td>-                 </td><td>-                 </td><td>Yes       </td><td>Alive               </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>3          </td><td>58         </td><td>F  </td><td>Ipilimumab + Nivolumab    </td><td>PD                  </td><td>37                              </td><td>300                    </td><td>Lung              </td><td>-                 </td><td>-                 </td><td>Yes       </td><td>Alive               </td><td>-             </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>4          </td><td>48         </td><td>M  </td><td>Ipilimumab + Nivolumab    </td><td>PD                  </td><td>39                              </td><td>129                    </td><td>SQ                </td><td>12                </td><td>SQ                </td><td>Yes       </td><td>Alive               </td><td>EDT           </td><td>PRE and EDT               </td><td>PRE and EDT               </td></tr>\n",
       "\t<tr><td>5          </td><td>49         </td><td>F  </td><td>Ipilimumab + Pembrolizumab</td><td>PD                  </td><td>40                              </td><td>93                     </td><td>LN                </td><td>6                 </td><td>SQ                </td><td>Yes       </td><td>Dead, melanoma      </td><td>-             </td><td>PRE and EDT               </td><td>PRE and EDT               </td></tr>\n",
       "\t<tr><td>6          </td><td>75         </td><td>M  </td><td>Ipilimumab + Nivolumab    </td><td>PD                  </td><td>41                              </td><td>108                    </td><td>LN                </td><td>-                 </td><td>-                 </td><td>Yes       </td><td>Dead, melanoma      </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>7          </td><td>59         </td><td>M  </td><td>Ipilimumab + Nivolumab    </td><td>PR                  </td><td>81                              </td><td>169                    </td><td>SQ                </td><td>8                 </td><td>SQ                </td><td>Yes       </td><td>Alive               </td><td>PRE           </td><td>PRE and EDT               </td><td>PRE and EDT               </td></tr>\n",
       "\t<tr><td>8          </td><td>55         </td><td>M  </td><td>Ipilimumab + Pembrolizumab</td><td>PD                  </td><td>81                              </td><td>637                    </td><td>LN                </td><td>-                 </td><td>-                 </td><td>Yes       </td><td>Alive               </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>9          </td><td>56         </td><td>M  </td><td>Ipilimumab + Pembrolizumab</td><td>PD                  </td><td>81                              </td><td>156                    </td><td>LN                </td><td>9                 </td><td>SQ                </td><td>Yes       </td><td>Dead, melanoma      </td><td>EDT           </td><td>EDT                       </td><td>EDT                       </td></tr>\n",
       "\t<tr><td>10         </td><td>51         </td><td>M  </td><td>Ipilimumab + Pembrolizumab</td><td>PD                  </td><td>81                              </td><td>176                    </td><td>LN                </td><td>-                 </td><td>-                 </td><td>Yes       </td><td>Dead, melanoma      </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>11         </td><td>62         </td><td>M  </td><td>Ipilimumab + Nivolumab    </td><td>PD                  </td><td>82                              </td><td>221                    </td><td>LN                </td><td>-                 </td><td>-                 </td><td>Yes       </td><td>Alive               </td><td>-             </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>12         </td><td>55         </td><td>F  </td><td>Ipilimumab + Nivolumab    </td><td>PD                  </td><td>82                              </td><td>293                    </td><td>Lung              </td><td>-                 </td><td>-                 </td><td>Yes       </td><td>Alive               </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>13         </td><td>68         </td><td>F  </td><td>Ipilimumab + Nivolumab    </td><td>PR                  </td><td>108                             </td><td>357                    </td><td>SQ                </td><td>8                 </td><td>SQ                </td><td>Yes       </td><td>Dead, melanoma      </td><td>PRE and EDT   </td><td>PRE and EDT               </td><td>PRE and EDT               </td></tr>\n",
       "\t<tr><td>14         </td><td>47         </td><td>F  </td><td>Ipilimumab + Pembrolizumab</td><td>SD                  </td><td>123                             </td><td>691                    </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>Yes       </td><td>Alive               </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>15         </td><td>57         </td><td>M  </td><td>Ipilimumab + Pembrolizumab</td><td>SD                  </td><td>152                             </td><td>660                    </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>Yes       </td><td>Dead, melanoma      </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>16         </td><td>39         </td><td>F  </td><td>Ipilimumab + Pembrolizumab</td><td>PR                  </td><td>168                             </td><td>558                    </td><td>LN                </td><td>-                 </td><td>-                 </td><td>Yes       </td><td>Alive               </td><td>-             </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>17         </td><td>48         </td><td>F  </td><td>Ipilimumab + Nivolumab    </td><td>PR                  </td><td>196                             </td><td>196                    </td><td>LN                </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>18         </td><td>58         </td><td>M  </td><td>Ipilimumab + Pembrolizumab</td><td>PR                  </td><td>278                             </td><td>278                    </td><td>Lung              </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>-             </td><td>-                         </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>19         </td><td>56         </td><td>M  </td><td>Ipilimumab + Pembrolizumab</td><td>SD                  </td><td>301                             </td><td>635                    </td><td>SQ                </td><td>15                </td><td>SQ                </td><td>Yes       </td><td>Alive               </td><td>PRE and EDT   </td><td>PRE and EDT               </td><td>PRE and EDT               </td></tr>\n",
       "\t<tr><td>20         </td><td>57         </td><td>M  </td><td>Ipilimumab + Pembrolizumab</td><td>SD                  </td><td>386                             </td><td>538                    </td><td>LN                </td><td>-                 </td><td>-                 </td><td>Yes       </td><td>Alive               </td><td>PRE           </td><td>-                         </td><td>-                         </td></tr>\n",
       "\t<tr><td>21         </td><td>63         </td><td>M  </td><td>Ipilimumab + Nivolumab    </td><td>PR                  </td><td>410                             </td><td>410                    </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>22         </td><td>59         </td><td>F  </td><td>Ipilimumab + Pembrolizumab</td><td>PR                  </td><td>487                             </td><td>706                    </td><td>LN                </td><td>7                 </td><td>LN                </td><td>Yes       </td><td>Alive               </td><td>-             </td><td>PRE and EDT               </td><td>PRE and EDT               </td></tr>\n",
       "\t<tr><td>23         </td><td>51         </td><td>F  </td><td>Ipilimumab + Pembrolizumab</td><td>PR                  </td><td>506                             </td><td>506                    </td><td>Brain             </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>PRE           </td><td>PRE                       </td><td>-                         </td></tr>\n",
       "\t<tr><td>24         </td><td>34         </td><td>M  </td><td>Ipilimumab + Nivolumab    </td><td>PR                  </td><td>509                             </td><td>1203                   </td><td>LN                </td><td>-                 </td><td>-                 </td><td>Yes       </td><td>Alive               </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>25         </td><td>67         </td><td>F  </td><td>Ipilimumab + Pembrolizumab</td><td>SD                  </td><td>518                             </td><td>518                    </td><td>LN                </td><td>-                 </td><td>-                 </td><td>No        </td><td>Dead, melanoma      </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>26         </td><td>75         </td><td>M  </td><td>Ipilimumab + Pembrolizumab</td><td>CR                  </td><td>544                             </td><td>544                    </td><td>LN                </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>27         </td><td>49         </td><td>M  </td><td>Ipilimumab + Pembrolizumab</td><td>CR                  </td><td>546                             </td><td>546                    </td><td>Abdomen           </td><td>5                 </td><td>SQ                </td><td>No        </td><td>Alive               </td><td>PRE and EDT   </td><td>PRE and EDT               </td><td>PRE and EDT               </td></tr>\n",
       "\t<tr><td>28         </td><td>33         </td><td>M  </td><td>Ipilimumab + Pembrolizumab</td><td>CR                  </td><td>553                             </td><td>553                    </td><td>LN                </td><td>7                 </td><td>LN                </td><td>No        </td><td>Alive               </td><td>-             </td><td>PRE and EDT               </td><td>PRE and EDT               </td></tr>\n",
       "\t<tr><td>29         </td><td>66         </td><td>F  </td><td>Ipilimumab + Pembrolizumab</td><td>CR                  </td><td>567                             </td><td>567                    </td><td>LN                </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>-             </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>30         </td><td>56         </td><td>M  </td><td>Ipilimumab + Pembrolizumab</td><td>PR                  </td><td>573                             </td><td>573                    </td><td>Small intestine   </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>-             </td><td>-                         </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>31         </td><td>45         </td><td>M  </td><td>Ipilimumab + Pembrolizumab</td><td>CR                  </td><td>588                             </td><td>588                    </td><td>Lung              </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>-             </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>32         </td><td>71         </td><td>M  </td><td>Ipilimumab + Pembrolizumab</td><td>CR                  </td><td>597                             </td><td>597                    </td><td>LN                </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>33         </td><td>73         </td><td>M  </td><td>Ipilimumab + Pembrolizumab</td><td>PR                  </td><td>609                             </td><td>609                    </td><td>SQ                </td><td>9                 </td><td>SQ                </td><td>No        </td><td>Alive               </td><td>PRE and EDT   </td><td>PRE and EDT               </td><td>PRE and EDT               </td></tr>\n",
       "\t<tr><td>34         </td><td>51         </td><td>M  </td><td>Ipilimumab + Pembrolizumab</td><td>CR                  </td><td>623                             </td><td>623                    </td><td>Lung              </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>35         </td><td>72         </td><td>M  </td><td>Ipilimumab + Pembrolizumab</td><td>CR                  </td><td>627                             </td><td>627                    </td><td>SQ                </td><td>9                 </td><td>SQ                </td><td>No        </td><td>Alive               </td><td>PRE and EDT   </td><td>PRE and EDT               </td><td>PRE and EDT               </td></tr>\n",
       "\t<tr><td>36         </td><td>74         </td><td>F  </td><td>Ipilimumab + Pembrolizumab</td><td>CR                  </td><td>637                             </td><td>637                    </td><td>SQ                </td><td>6                 </td><td>SQ                </td><td>No        </td><td>Alive               </td><td>PRE and EDT   </td><td>PRE and EDT               </td><td>PRE and EDT               </td></tr>\n",
       "\t<tr><td>37         </td><td>76         </td><td>M  </td><td>Ipilimumab + Pembrolizumab</td><td>PR                  </td><td>637                             </td><td>637                    </td><td>LN                </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>38         </td><td>59         </td><td>F  </td><td>Ipilimumab + Pembrolizumab</td><td>CR                  </td><td>650                             </td><td>650                    </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>-             </td><td>PRE                       </td><td>-                         </td></tr>\n",
       "\t<tr><td>39         </td><td>33         </td><td>M  </td><td>Ipilimumab + Nivolumab    </td><td>CR                  </td><td>657                             </td><td>657                    </td><td>LN                </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>-             </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>40         </td><td>81         </td><td>M  </td><td>Ipilimumab + Pembrolizumab</td><td>PR                  </td><td>671                             </td><td>671                    </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>-             </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>41         </td><td>57         </td><td>F  </td><td>Ipilimumab + Pembrolizumab</td><td>PR                  </td><td>672                             </td><td>672                    </td><td>SQ                </td><td>4                 </td><td>SQ                </td><td>No        </td><td>Alive               </td><td>-             </td><td>PRE and EDT               </td><td>PRE and EDT               </td></tr>\n",
       "\t<tr><td>42         </td><td>71         </td><td>M  </td><td>Ipilimumab + Pembrolizumab</td><td>PR                  </td><td>692                             </td><td>692                    </td><td>Lung              </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>-             </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>43         </td><td>53         </td><td>F  </td><td>Ipilimumab + Pembrolizumab</td><td>CR                  </td><td>693                             </td><td>693                    </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>-             </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>44         </td><td>68         </td><td>M  </td><td>Ipilimumab + Pembrolizumab</td><td>PR                  </td><td>695                             </td><td>695                    </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>45         </td><td>70         </td><td>M  </td><td>Ipilimumab + Pembrolizumab</td><td>CR                  </td><td>721                             </td><td>721                    </td><td>Mucosa            </td><td>8                 </td><td>SQ                </td><td>No        </td><td>Alive               </td><td>PRE           </td><td>PRE and EDT               </td><td>PRE and EDT               </td></tr>\n",
       "\t<tr><td>46         </td><td>54         </td><td>F  </td><td>Ipilimumab + Pembrolizumab</td><td>CR                  </td><td>721                             </td><td>721                    </td><td>Lung              </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>47         </td><td>24         </td><td>F  </td><td>Ipilimumab + Pembrolizumab</td><td>PR                  </td><td>732                             </td><td>732                    </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>48         </td><td>72         </td><td>M  </td><td>Ipilimumab + Pembrolizumab</td><td>PR                  </td><td>737                             </td><td>737                    </td><td>SQ                </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>-             </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>49         </td><td>36         </td><td>M  </td><td>Ipilimumab + Pembrolizumab</td><td>CR                  </td><td>775                             </td><td>775                    </td><td>LN                </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>50         </td><td>68         </td><td>M  </td><td>Ipilimumab + Pembrolizumab</td><td>PR                  </td><td>904                             </td><td>904                    </td><td>LN                </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>PRE           </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "\t<tr><td>51         </td><td>64         </td><td>M  </td><td>Ipilimumab + Pembrolizumab</td><td>PR                  </td><td>1379                            </td><td>1379                   </td><td>Liver             </td><td>-                 </td><td>-                 </td><td>No        </td><td>Alive               </td><td>-             </td><td>PRE                       </td><td>PRE                       </td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A data.frame: 52 Ã— 15\n",
       "\\begin{tabular}{lllllllllllllll}\n",
       " X & X.1 & X.2 & X.3 & X.4 & X.5 & X.6 & X.7 & X.8 & X.9 & X.10 & X.11 & X.12 & X.13 & X.14\\\\\n",
       " <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct>\\\\\n",
       "\\hline\n",
       "\t Patient no. & Age (Years) & Sex & Treatment                  & Best RECIST response & Progression Free Survival (Days) & Overall Survival (Days) & Site of PRE Biopsy & Days to EDT Biopsy & Site of EDT Biopsy & Progressed & Last Followup Status & RNA Sequencing & Immunofluorescence Panel 1 & Immunofluorescence Panel 2\\\\\n",
       "\t 1           & 42          & F   & Ipilimumab + Pembrolizumab & PD                   & 15                               & 689                     & SQ                 & 7                  & SQ                 & Yes        & Alive                & PRE and EDT    & PRE and EDT                & PRE and EDT               \\\\\n",
       "\t 2           & 41          & M   & Ipilimumab + Pembrolizumab & PD                   & 34                               & 530                     & LN                 & -                  & -                  & Yes        & Alive                & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 3           & 58          & F   & Ipilimumab + Nivolumab     & PD                   & 37                               & 300                     & Lung               & -                  & -                  & Yes        & Alive                & -              & PRE                        & PRE                       \\\\\n",
       "\t 4           & 48          & M   & Ipilimumab + Nivolumab     & PD                   & 39                               & 129                     & SQ                 & 12                 & SQ                 & Yes        & Alive                & EDT            & PRE and EDT                & PRE and EDT               \\\\\n",
       "\t 5           & 49          & F   & Ipilimumab + Pembrolizumab & PD                   & 40                               & 93                      & LN                 & 6                  & SQ                 & Yes        & Dead, melanoma       & -              & PRE and EDT                & PRE and EDT               \\\\\n",
       "\t 6           & 75          & M   & Ipilimumab + Nivolumab     & PD                   & 41                               & 108                     & LN                 & -                  & -                  & Yes        & Dead, melanoma       & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 7           & 59          & M   & Ipilimumab + Nivolumab     & PR                   & 81                               & 169                     & SQ                 & 8                  & SQ                 & Yes        & Alive                & PRE            & PRE and EDT                & PRE and EDT               \\\\\n",
       "\t 8           & 55          & M   & Ipilimumab + Pembrolizumab & PD                   & 81                               & 637                     & LN                 & -                  & -                  & Yes        & Alive                & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 9           & 56          & M   & Ipilimumab + Pembrolizumab & PD                   & 81                               & 156                     & LN                 & 9                  & SQ                 & Yes        & Dead, melanoma       & EDT            & EDT                        & EDT                       \\\\\n",
       "\t 10          & 51          & M   & Ipilimumab + Pembrolizumab & PD                   & 81                               & 176                     & LN                 & -                  & -                  & Yes        & Dead, melanoma       & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 11          & 62          & M   & Ipilimumab + Nivolumab     & PD                   & 82                               & 221                     & LN                 & -                  & -                  & Yes        & Alive                & -              & PRE                        & PRE                       \\\\\n",
       "\t 12          & 55          & F   & Ipilimumab + Nivolumab     & PD                   & 82                               & 293                     & Lung               & -                  & -                  & Yes        & Alive                & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 13          & 68          & F   & Ipilimumab + Nivolumab     & PR                   & 108                              & 357                     & SQ                 & 8                  & SQ                 & Yes        & Dead, melanoma       & PRE and EDT    & PRE and EDT                & PRE and EDT               \\\\\n",
       "\t 14          & 47          & F   & Ipilimumab + Pembrolizumab & SD                   & 123                              & 691                     & SQ                 & -                  & -                  & Yes        & Alive                & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 15          & 57          & M   & Ipilimumab + Pembrolizumab & SD                   & 152                              & 660                     & SQ                 & -                  & -                  & Yes        & Dead, melanoma       & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 16          & 39          & F   & Ipilimumab + Pembrolizumab & PR                   & 168                              & 558                     & LN                 & -                  & -                  & Yes        & Alive                & -              & PRE                        & PRE                       \\\\\n",
       "\t 17          & 48          & F   & Ipilimumab + Nivolumab     & PR                   & 196                              & 196                     & LN                 & -                  & -                  & No         & Alive                & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 18          & 58          & M   & Ipilimumab + Pembrolizumab & PR                   & 278                              & 278                     & Lung               & -                  & -                  & No         & Alive                & -              & -                          & PRE                       \\\\\n",
       "\t 19          & 56          & M   & Ipilimumab + Pembrolizumab & SD                   & 301                              & 635                     & SQ                 & 15                 & SQ                 & Yes        & Alive                & PRE and EDT    & PRE and EDT                & PRE and EDT               \\\\\n",
       "\t 20          & 57          & M   & Ipilimumab + Pembrolizumab & SD                   & 386                              & 538                     & LN                 & -                  & -                  & Yes        & Alive                & PRE            & -                          & -                         \\\\\n",
       "\t 21          & 63          & M   & Ipilimumab + Nivolumab     & PR                   & 410                              & 410                     & SQ                 & -                  & -                  & No         & Alive                & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 22          & 59          & F   & Ipilimumab + Pembrolizumab & PR                   & 487                              & 706                     & LN                 & 7                  & LN                 & Yes        & Alive                & -              & PRE and EDT                & PRE and EDT               \\\\\n",
       "\t 23          & 51          & F   & Ipilimumab + Pembrolizumab & PR                   & 506                              & 506                     & Brain              & -                  & -                  & No         & Alive                & PRE            & PRE                        & -                         \\\\\n",
       "\t 24          & 34          & M   & Ipilimumab + Nivolumab     & PR                   & 509                              & 1203                    & LN                 & -                  & -                  & Yes        & Alive                & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 25          & 67          & F   & Ipilimumab + Pembrolizumab & SD                   & 518                              & 518                     & LN                 & -                  & -                  & No         & Dead, melanoma       & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 26          & 75          & M   & Ipilimumab + Pembrolizumab & CR                   & 544                              & 544                     & LN                 & -                  & -                  & No         & Alive                & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 27          & 49          & M   & Ipilimumab + Pembrolizumab & CR                   & 546                              & 546                     & Abdomen            & 5                  & SQ                 & No         & Alive                & PRE and EDT    & PRE and EDT                & PRE and EDT               \\\\\n",
       "\t 28          & 33          & M   & Ipilimumab + Pembrolizumab & CR                   & 553                              & 553                     & LN                 & 7                  & LN                 & No         & Alive                & -              & PRE and EDT                & PRE and EDT               \\\\\n",
       "\t 29          & 66          & F   & Ipilimumab + Pembrolizumab & CR                   & 567                              & 567                     & LN                 & -                  & -                  & No         & Alive                & -              & PRE                        & PRE                       \\\\\n",
       "\t 30          & 56          & M   & Ipilimumab + Pembrolizumab & PR                   & 573                              & 573                     & Small intestine    & -                  & -                  & No         & Alive                & -              & -                          & PRE                       \\\\\n",
       "\t 31          & 45          & M   & Ipilimumab + Pembrolizumab & CR                   & 588                              & 588                     & Lung               & -                  & -                  & No         & Alive                & -              & PRE                        & PRE                       \\\\\n",
       "\t 32          & 71          & M   & Ipilimumab + Pembrolizumab & CR                   & 597                              & 597                     & LN                 & -                  & -                  & No         & Alive                & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 33          & 73          & M   & Ipilimumab + Pembrolizumab & PR                   & 609                              & 609                     & SQ                 & 9                  & SQ                 & No         & Alive                & PRE and EDT    & PRE and EDT                & PRE and EDT               \\\\\n",
       "\t 34          & 51          & M   & Ipilimumab + Pembrolizumab & CR                   & 623                              & 623                     & Lung               & -                  & -                  & No         & Alive                & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 35          & 72          & M   & Ipilimumab + Pembrolizumab & CR                   & 627                              & 627                     & SQ                 & 9                  & SQ                 & No         & Alive                & PRE and EDT    & PRE and EDT                & PRE and EDT               \\\\\n",
       "\t 36          & 74          & F   & Ipilimumab + Pembrolizumab & CR                   & 637                              & 637                     & SQ                 & 6                  & SQ                 & No         & Alive                & PRE and EDT    & PRE and EDT                & PRE and EDT               \\\\\n",
       "\t 37          & 76          & M   & Ipilimumab + Pembrolizumab & PR                   & 637                              & 637                     & LN                 & -                  & -                  & No         & Alive                & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 38          & 59          & F   & Ipilimumab + Pembrolizumab & CR                   & 650                              & 650                     & SQ                 & -                  & -                  & No         & Alive                & -              & PRE                        & -                         \\\\\n",
       "\t 39          & 33          & M   & Ipilimumab + Nivolumab     & CR                   & 657                              & 657                     & LN                 & -                  & -                  & No         & Alive                & -              & PRE                        & PRE                       \\\\\n",
       "\t 40          & 81          & M   & Ipilimumab + Pembrolizumab & PR                   & 671                              & 671                     & SQ                 & -                  & -                  & No         & Alive                & -              & PRE                        & PRE                       \\\\\n",
       "\t 41          & 57          & F   & Ipilimumab + Pembrolizumab & PR                   & 672                              & 672                     & SQ                 & 4                  & SQ                 & No         & Alive                & -              & PRE and EDT                & PRE and EDT               \\\\\n",
       "\t 42          & 71          & M   & Ipilimumab + Pembrolizumab & PR                   & 692                              & 692                     & Lung               & -                  & -                  & No         & Alive                & -              & PRE                        & PRE                       \\\\\n",
       "\t 43          & 53          & F   & Ipilimumab + Pembrolizumab & CR                   & 693                              & 693                     & SQ                 & -                  & -                  & No         & Alive                & -              & PRE                        & PRE                       \\\\\n",
       "\t 44          & 68          & M   & Ipilimumab + Pembrolizumab & PR                   & 695                              & 695                     & SQ                 & -                  & -                  & No         & Alive                & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 45          & 70          & M   & Ipilimumab + Pembrolizumab & CR                   & 721                              & 721                     & Mucosa             & 8                  & SQ                 & No         & Alive                & PRE            & PRE and EDT                & PRE and EDT               \\\\\n",
       "\t 46          & 54          & F   & Ipilimumab + Pembrolizumab & CR                   & 721                              & 721                     & Lung               & -                  & -                  & No         & Alive                & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 47          & 24          & F   & Ipilimumab + Pembrolizumab & PR                   & 732                              & 732                     & SQ                 & -                  & -                  & No         & Alive                & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 48          & 72          & M   & Ipilimumab + Pembrolizumab & PR                   & 737                              & 737                     & SQ                 & -                  & -                  & No         & Alive                & -              & PRE                        & PRE                       \\\\\n",
       "\t 49          & 36          & M   & Ipilimumab + Pembrolizumab & CR                   & 775                              & 775                     & LN                 & -                  & -                  & No         & Alive                & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 50          & 68          & M   & Ipilimumab + Pembrolizumab & PR                   & 904                              & 904                     & LN                 & -                  & -                  & No         & Alive                & PRE            & PRE                        & PRE                       \\\\\n",
       "\t 51          & 64          & M   & Ipilimumab + Pembrolizumab & PR                   & 1379                             & 1379                    & Liver              & -                  & -                  & No         & Alive                & -              & PRE                        & PRE                       \\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A data.frame: 52 Ã— 15\n",
       "\n",
       "| X &lt;fct&gt; | X.1 &lt;fct&gt; | X.2 &lt;fct&gt; | X.3 &lt;fct&gt; | X.4 &lt;fct&gt; | X.5 &lt;fct&gt; | X.6 &lt;fct&gt; | X.7 &lt;fct&gt; | X.8 &lt;fct&gt; | X.9 &lt;fct&gt; | X.10 &lt;fct&gt; | X.11 &lt;fct&gt; | X.12 &lt;fct&gt; | X.13 &lt;fct&gt; | X.14 &lt;fct&gt; |\n",
       "|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|\n",
       "| Patient no. | Age (Years) | Sex | Treatment                  | Best RECIST response | Progression Free Survival (Days) | Overall Survival (Days) | Site of PRE Biopsy | Days to EDT Biopsy | Site of EDT Biopsy | Progressed | Last Followup Status | RNA Sequencing | Immunofluorescence Panel 1 | Immunofluorescence Panel 2 |\n",
       "| 1           | 42          | F   | Ipilimumab + Pembrolizumab | PD                   | 15                               | 689                     | SQ                 | 7                  | SQ                 | Yes        | Alive                | PRE and EDT    | PRE and EDT                | PRE and EDT                |\n",
       "| 2           | 41          | M   | Ipilimumab + Pembrolizumab | PD                   | 34                               | 530                     | LN                 | -                  | -                  | Yes        | Alive                | PRE            | PRE                        | PRE                        |\n",
       "| 3           | 58          | F   | Ipilimumab + Nivolumab     | PD                   | 37                               | 300                     | Lung               | -                  | -                  | Yes        | Alive                | -              | PRE                        | PRE                        |\n",
       "| 4           | 48          | M   | Ipilimumab + Nivolumab     | PD                   | 39                               | 129                     | SQ                 | 12                 | SQ                 | Yes        | Alive                | EDT            | PRE and EDT                | PRE and EDT                |\n",
       "| 5           | 49          | F   | Ipilimumab + Pembrolizumab | PD                   | 40                               | 93                      | LN                 | 6                  | SQ                 | Yes        | Dead, melanoma       | -              | PRE and EDT                | PRE and EDT                |\n",
       "| 6           | 75          | M   | Ipilimumab + Nivolumab     | PD                   | 41                               | 108                     | LN                 | -                  | -                  | Yes        | Dead, melanoma       | PRE            | PRE                        | PRE                        |\n",
       "| 7           | 59          | M   | Ipilimumab + Nivolumab     | PR                   | 81                               | 169                     | SQ                 | 8                  | SQ                 | Yes        | Alive                | PRE            | PRE and EDT                | PRE and EDT                |\n",
       "| 8           | 55          | M   | Ipilimumab + Pembrolizumab | PD                   | 81                               | 637                     | LN                 | -                  | -                  | Yes        | Alive                | PRE            | PRE                        | PRE                        |\n",
       "| 9           | 56          | M   | Ipilimumab + Pembrolizumab | PD                   | 81                               | 156                     | LN                 | 9                  | SQ                 | Yes        | Dead, melanoma       | EDT            | EDT                        | EDT                        |\n",
       "| 10          | 51          | M   | Ipilimumab + Pembrolizumab | PD                   | 81                               | 176                     | LN                 | -                  | -                  | Yes        | Dead, melanoma       | PRE            | PRE                        | PRE                        |\n",
       "| 11          | 62          | M   | Ipilimumab + Nivolumab     | PD                   | 82                               | 221                     | LN                 | -                  | -                  | Yes        | Alive                | -              | PRE                        | PRE                        |\n",
       "| 12          | 55          | F   | Ipilimumab + Nivolumab     | PD                   | 82                               | 293                     | Lung               | -                  | -                  | Yes        | Alive                | PRE            | PRE                        | PRE                        |\n",
       "| 13          | 68          | F   | Ipilimumab + Nivolumab     | PR                   | 108                              | 357                     | SQ                 | 8                  | SQ                 | Yes        | Dead, melanoma       | PRE and EDT    | PRE and EDT                | PRE and EDT                |\n",
       "| 14          | 47          | F   | Ipilimumab + Pembrolizumab | SD                   | 123                              | 691                     | SQ                 | -                  | -                  | Yes        | Alive                | PRE            | PRE                        | PRE                        |\n",
       "| 15          | 57          | M   | Ipilimumab + Pembrolizumab | SD                   | 152                              | 660                     | SQ                 | -                  | -                  | Yes        | Dead, melanoma       | PRE            | PRE                        | PRE                        |\n",
       "| 16          | 39          | F   | Ipilimumab + Pembrolizumab | PR                   | 168                              | 558                     | LN                 | -                  | -                  | Yes        | Alive                | -              | PRE                        | PRE                        |\n",
       "| 17          | 48          | F   | Ipilimumab + Nivolumab     | PR                   | 196                              | 196                     | LN                 | -                  | -                  | No         | Alive                | PRE            | PRE                        | PRE                        |\n",
       "| 18          | 58          | M   | Ipilimumab + Pembrolizumab | PR                   | 278                              | 278                     | Lung               | -                  | -                  | No         | Alive                | -              | -                          | PRE                        |\n",
       "| 19          | 56          | M   | Ipilimumab + Pembrolizumab | SD                   | 301                              | 635                     | SQ                 | 15                 | SQ                 | Yes        | Alive                | PRE and EDT    | PRE and EDT                | PRE and EDT                |\n",
       "| 20          | 57          | M   | Ipilimumab + Pembrolizumab | SD                   | 386                              | 538                     | LN                 | -                  | -                  | Yes        | Alive                | PRE            | -                          | -                          |\n",
       "| 21          | 63          | M   | Ipilimumab + Nivolumab     | PR                   | 410                              | 410                     | SQ                 | -                  | -                  | No         | Alive                | PRE            | PRE                        | PRE                        |\n",
       "| 22          | 59          | F   | Ipilimumab + Pembrolizumab | PR                   | 487                              | 706                     | LN                 | 7                  | LN                 | Yes        | Alive                | -              | PRE and EDT                | PRE and EDT                |\n",
       "| 23          | 51          | F   | Ipilimumab + Pembrolizumab | PR                   | 506                              | 506                     | Brain              | -                  | -                  | No         | Alive                | PRE            | PRE                        | -                          |\n",
       "| 24          | 34          | M   | Ipilimumab + Nivolumab     | PR                   | 509                              | 1203                    | LN                 | -                  | -                  | Yes        | Alive                | PRE            | PRE                        | PRE                        |\n",
       "| 25          | 67          | F   | Ipilimumab + Pembrolizumab | SD                   | 518                              | 518                     | LN                 | -                  | -                  | No         | Dead, melanoma       | PRE            | PRE                        | PRE                        |\n",
       "| 26          | 75          | M   | Ipilimumab + Pembrolizumab | CR                   | 544                              | 544                     | LN                 | -                  | -                  | No         | Alive                | PRE            | PRE                        | PRE                        |\n",
       "| 27          | 49          | M   | Ipilimumab + Pembrolizumab | CR                   | 546                              | 546                     | Abdomen            | 5                  | SQ                 | No         | Alive                | PRE and EDT    | PRE and EDT                | PRE and EDT                |\n",
       "| 28          | 33          | M   | Ipilimumab + Pembrolizumab | CR                   | 553                              | 553                     | LN                 | 7                  | LN                 | No         | Alive                | -              | PRE and EDT                | PRE and EDT                |\n",
       "| 29          | 66          | F   | Ipilimumab + Pembrolizumab | CR                   | 567                              | 567                     | LN                 | -                  | -                  | No         | Alive                | -              | PRE                        | PRE                        |\n",
       "| 30          | 56          | M   | Ipilimumab + Pembrolizumab | PR                   | 573                              | 573                     | Small intestine    | -                  | -                  | No         | Alive                | -              | -                          | PRE                        |\n",
       "| 31          | 45          | M   | Ipilimumab + Pembrolizumab | CR                   | 588                              | 588                     | Lung               | -                  | -                  | No         | Alive                | -              | PRE                        | PRE                        |\n",
       "| 32          | 71          | M   | Ipilimumab + Pembrolizumab | CR                   | 597                              | 597                     | LN                 | -                  | -                  | No         | Alive                | PRE            | PRE                        | PRE                        |\n",
       "| 33          | 73          | M   | Ipilimumab + Pembrolizumab | PR                   | 609                              | 609                     | SQ                 | 9                  | SQ                 | No         | Alive                | PRE and EDT    | PRE and EDT                | PRE and EDT                |\n",
       "| 34          | 51          | M   | Ipilimumab + Pembrolizumab | CR                   | 623                              | 623                     | Lung               | -                  | -                  | No         | Alive                | PRE            | PRE                        | PRE                        |\n",
       "| 35          | 72          | M   | Ipilimumab + Pembrolizumab | CR                   | 627                              | 627                     | SQ                 | 9                  | SQ                 | No         | Alive                | PRE and EDT    | PRE and EDT                | PRE and EDT                |\n",
       "| 36          | 74          | F   | Ipilimumab + Pembrolizumab | CR                   | 637                              | 637                     | SQ                 | 6                  | SQ                 | No         | Alive                | PRE and EDT    | PRE and EDT                | PRE and EDT                |\n",
       "| 37          | 76          | M   | Ipilimumab + Pembrolizumab | PR                   | 637                              | 637                     | LN                 | -                  | -                  | No         | Alive                | PRE            | PRE                        | PRE                        |\n",
       "| 38          | 59          | F   | Ipilimumab + Pembrolizumab | CR                   | 650                              | 650                     | SQ                 | -                  | -                  | No         | Alive                | -              | PRE                        | -                          |\n",
       "| 39          | 33          | M   | Ipilimumab + Nivolumab     | CR                   | 657                              | 657                     | LN                 | -                  | -                  | No         | Alive                | -              | PRE                        | PRE                        |\n",
       "| 40          | 81          | M   | Ipilimumab + Pembrolizumab | PR                   | 671                              | 671                     | SQ                 | -                  | -                  | No         | Alive                | -              | PRE                        | PRE                        |\n",
       "| 41          | 57          | F   | Ipilimumab + Pembrolizumab | PR                   | 672                              | 672                     | SQ                 | 4                  | SQ                 | No         | Alive                | -              | PRE and EDT                | PRE and EDT                |\n",
       "| 42          | 71          | M   | Ipilimumab + Pembrolizumab | PR                   | 692                              | 692                     | Lung               | -                  | -                  | No         | Alive                | -              | PRE                        | PRE                        |\n",
       "| 43          | 53          | F   | Ipilimumab + Pembrolizumab | CR                   | 693                              | 693                     | SQ                 | -                  | -                  | No         | Alive                | -              | PRE                        | PRE                        |\n",
       "| 44          | 68          | M   | Ipilimumab + Pembrolizumab | PR                   | 695                              | 695                     | SQ                 | -                  | -                  | No         | Alive                | PRE            | PRE                        | PRE                        |\n",
       "| 45          | 70          | M   | Ipilimumab + Pembrolizumab | CR                   | 721                              | 721                     | Mucosa             | 8                  | SQ                 | No         | Alive                | PRE            | PRE and EDT                | PRE and EDT                |\n",
       "| 46          | 54          | F   | Ipilimumab + Pembrolizumab | CR                   | 721                              | 721                     | Lung               | -                  | -                  | No         | Alive                | PRE            | PRE                        | PRE                        |\n",
       "| 47          | 24          | F   | Ipilimumab + Pembrolizumab | PR                   | 732                              | 732                     | SQ                 | -                  | -                  | No         | Alive                | PRE            | PRE                        | PRE                        |\n",
       "| 48          | 72          | M   | Ipilimumab + Pembrolizumab | PR                   | 737                              | 737                     | SQ                 | -                  | -                  | No         | Alive                | -              | PRE                        | PRE                        |\n",
       "| 49          | 36          | M   | Ipilimumab + Pembrolizumab | CR                   | 775                              | 775                     | LN                 | -                  | -                  | No         | Alive                | PRE            | PRE                        | PRE                        |\n",
       "| 50          | 68          | M   | Ipilimumab + Pembrolizumab | PR                   | 904                              | 904                     | LN                 | -                  | -                  | No         | Alive                | PRE            | PRE                        | PRE                        |\n",
       "| 51          | 64          | M   | Ipilimumab + Pembrolizumab | PR                   | 1379                             | 1379                    | Liver              | -                  | -                  | No         | Alive                | -              | PRE                        | PRE                        |\n",
       "\n"
      ],
      "text/plain": [
       "   X           X.1         X.2 X.3                        X.4                 \n",
       "1  Patient no. Age (Years) Sex Treatment                  Best RECIST response\n",
       "2  1           42          F   Ipilimumab + Pembrolizumab PD                  \n",
       "3  2           41          M   Ipilimumab + Pembrolizumab PD                  \n",
       "4  3           58          F   Ipilimumab + Nivolumab     PD                  \n",
       "5  4           48          M   Ipilimumab + Nivolumab     PD                  \n",
       "6  5           49          F   Ipilimumab + Pembrolizumab PD                  \n",
       "7  6           75          M   Ipilimumab + Nivolumab     PD                  \n",
       "8  7           59          M   Ipilimumab + Nivolumab     PR                  \n",
       "9  8           55          M   Ipilimumab + Pembrolizumab PD                  \n",
       "10 9           56          M   Ipilimumab + Pembrolizumab PD                  \n",
       "11 10          51          M   Ipilimumab + Pembrolizumab PD                  \n",
       "12 11          62          M   Ipilimumab + Nivolumab     PD                  \n",
       "13 12          55          F   Ipilimumab + Nivolumab     PD                  \n",
       "14 13          68          F   Ipilimumab + Nivolumab     PR                  \n",
       "15 14          47          F   Ipilimumab + Pembrolizumab SD                  \n",
       "16 15          57          M   Ipilimumab + Pembrolizumab SD                  \n",
       "17 16          39          F   Ipilimumab + Pembrolizumab PR                  \n",
       "18 17          48          F   Ipilimumab + Nivolumab     PR                  \n",
       "19 18          58          M   Ipilimumab + Pembrolizumab PR                  \n",
       "20 19          56          M   Ipilimumab + Pembrolizumab SD                  \n",
       "21 20          57          M   Ipilimumab + Pembrolizumab SD                  \n",
       "22 21          63          M   Ipilimumab + Nivolumab     PR                  \n",
       "23 22          59          F   Ipilimumab + Pembrolizumab PR                  \n",
       "24 23          51          F   Ipilimumab + Pembrolizumab PR                  \n",
       "25 24          34          M   Ipilimumab + Nivolumab     PR                  \n",
       "26 25          67          F   Ipilimumab + Pembrolizumab SD                  \n",
       "27 26          75          M   Ipilimumab + Pembrolizumab CR                  \n",
       "28 27          49          M   Ipilimumab + Pembrolizumab CR                  \n",
       "29 28          33          M   Ipilimumab + Pembrolizumab CR                  \n",
       "30 29          66          F   Ipilimumab + Pembrolizumab CR                  \n",
       "31 30          56          M   Ipilimumab + Pembrolizumab PR                  \n",
       "32 31          45          M   Ipilimumab + Pembrolizumab CR                  \n",
       "33 32          71          M   Ipilimumab + Pembrolizumab CR                  \n",
       "34 33          73          M   Ipilimumab + Pembrolizumab PR                  \n",
       "35 34          51          M   Ipilimumab + Pembrolizumab CR                  \n",
       "36 35          72          M   Ipilimumab + Pembrolizumab CR                  \n",
       "37 36          74          F   Ipilimumab + Pembrolizumab CR                  \n",
       "38 37          76          M   Ipilimumab + Pembrolizumab PR                  \n",
       "39 38          59          F   Ipilimumab + Pembrolizumab CR                  \n",
       "40 39          33          M   Ipilimumab + Nivolumab     CR                  \n",
       "41 40          81          M   Ipilimumab + Pembrolizumab PR                  \n",
       "42 41          57          F   Ipilimumab + Pembrolizumab PR                  \n",
       "43 42          71          M   Ipilimumab + Pembrolizumab PR                  \n",
       "44 43          53          F   Ipilimumab + Pembrolizumab CR                  \n",
       "45 44          68          M   Ipilimumab + Pembrolizumab PR                  \n",
       "46 45          70          M   Ipilimumab + Pembrolizumab CR                  \n",
       "47 46          54          F   Ipilimumab + Pembrolizumab CR                  \n",
       "48 47          24          F   Ipilimumab + Pembrolizumab PR                  \n",
       "49 48          72          M   Ipilimumab + Pembrolizumab PR                  \n",
       "50 49          36          M   Ipilimumab + Pembrolizumab CR                  \n",
       "51 50          68          M   Ipilimumab + Pembrolizumab PR                  \n",
       "52 51          64          M   Ipilimumab + Pembrolizumab PR                  \n",
       "   X.5                              X.6                     X.7               \n",
       "1  Progression Free Survival (Days) Overall Survival (Days) Site of PRE Biopsy\n",
       "2  15                               689                     SQ                \n",
       "3  34                               530                     LN                \n",
       "4  37                               300                     Lung              \n",
       "5  39                               129                     SQ                \n",
       "6  40                               93                      LN                \n",
       "7  41                               108                     LN                \n",
       "8  81                               169                     SQ                \n",
       "9  81                               637                     LN                \n",
       "10 81                               156                     LN                \n",
       "11 81                               176                     LN                \n",
       "12 82                               221                     LN                \n",
       "13 82                               293                     Lung              \n",
       "14 108                              357                     SQ                \n",
       "15 123                              691                     SQ                \n",
       "16 152                              660                     SQ                \n",
       "17 168                              558                     LN                \n",
       "18 196                              196                     LN                \n",
       "19 278                              278                     Lung              \n",
       "20 301                              635                     SQ                \n",
       "21 386                              538                     LN                \n",
       "22 410                              410                     SQ                \n",
       "23 487                              706                     LN                \n",
       "24 506                              506                     Brain             \n",
       "25 509                              1203                    LN                \n",
       "26 518                              518                     LN                \n",
       "27 544                              544                     LN                \n",
       "28 546                              546                     Abdomen           \n",
       "29 553                              553                     LN                \n",
       "30 567                              567                     LN                \n",
       "31 573                              573                     Small intestine   \n",
       "32 588                              588                     Lung              \n",
       "33 597                              597                     LN                \n",
       "34 609                              609                     SQ                \n",
       "35 623                              623                     Lung              \n",
       "36 627                              627                     SQ                \n",
       "37 637                              637                     SQ                \n",
       "38 637                              637                     LN                \n",
       "39 650                              650                     SQ                \n",
       "40 657                              657                     LN                \n",
       "41 671                              671                     SQ                \n",
       "42 672                              672                     SQ                \n",
       "43 692                              692                     Lung              \n",
       "44 693                              693                     SQ                \n",
       "45 695                              695                     SQ                \n",
       "46 721                              721                     Mucosa            \n",
       "47 721                              721                     Lung              \n",
       "48 732                              732                     SQ                \n",
       "49 737                              737                     SQ                \n",
       "50 775                              775                     LN                \n",
       "51 904                              904                     LN                \n",
       "52 1379                             1379                    Liver             \n",
       "   X.8                X.9                X.10       X.11                \n",
       "1  Days to EDT Biopsy Site of EDT Biopsy Progressed Last Followup Status\n",
       "2  7                  SQ                 Yes        Alive               \n",
       "3  -                  -                  Yes        Alive               \n",
       "4  -                  -                  Yes        Alive               \n",
       "5  12                 SQ                 Yes        Alive               \n",
       "6  6                  SQ                 Yes        Dead, melanoma      \n",
       "7  -                  -                  Yes        Dead, melanoma      \n",
       "8  8                  SQ                 Yes        Alive               \n",
       "9  -                  -                  Yes        Alive               \n",
       "10 9                  SQ                 Yes        Dead, melanoma      \n",
       "11 -                  -                  Yes        Dead, melanoma      \n",
       "12 -                  -                  Yes        Alive               \n",
       "13 -                  -                  Yes        Alive               \n",
       "14 8                  SQ                 Yes        Dead, melanoma      \n",
       "15 -                  -                  Yes        Alive               \n",
       "16 -                  -                  Yes        Dead, melanoma      \n",
       "17 -                  -                  Yes        Alive               \n",
       "18 -                  -                  No         Alive               \n",
       "19 -                  -                  No         Alive               \n",
       "20 15                 SQ                 Yes        Alive               \n",
       "21 -                  -                  Yes        Alive               \n",
       "22 -                  -                  No         Alive               \n",
       "23 7                  LN                 Yes        Alive               \n",
       "24 -                  -                  No         Alive               \n",
       "25 -                  -                  Yes        Alive               \n",
       "26 -                  -                  No         Dead, melanoma      \n",
       "27 -                  -                  No         Alive               \n",
       "28 5                  SQ                 No         Alive               \n",
       "29 7                  LN                 No         Alive               \n",
       "30 -                  -                  No         Alive               \n",
       "31 -                  -                  No         Alive               \n",
       "32 -                  -                  No         Alive               \n",
       "33 -                  -                  No         Alive               \n",
       "34 9                  SQ                 No         Alive               \n",
       "35 -                  -                  No         Alive               \n",
       "36 9                  SQ                 No         Alive               \n",
       "37 6                  SQ                 No         Alive               \n",
       "38 -                  -                  No         Alive               \n",
       "39 -                  -                  No         Alive               \n",
       "40 -                  -                  No         Alive               \n",
       "41 -                  -                  No         Alive               \n",
       "42 4                  SQ                 No         Alive               \n",
       "43 -                  -                  No         Alive               \n",
       "44 -                  -                  No         Alive               \n",
       "45 -                  -                  No         Alive               \n",
       "46 8                  SQ                 No         Alive               \n",
       "47 -                  -                  No         Alive               \n",
       "48 -                  -                  No         Alive               \n",
       "49 -                  -                  No         Alive               \n",
       "50 -                  -                  No         Alive               \n",
       "51 -                  -                  No         Alive               \n",
       "52 -                  -                  No         Alive               \n",
       "   X.12           X.13                       X.14                      \n",
       "1  RNA Sequencing Immunofluorescence Panel 1 Immunofluorescence Panel 2\n",
       "2  PRE and EDT    PRE and EDT                PRE and EDT               \n",
       "3  PRE            PRE                        PRE                       \n",
       "4  -              PRE                        PRE                       \n",
       "5  EDT            PRE and EDT                PRE and EDT               \n",
       "6  -              PRE and EDT                PRE and EDT               \n",
       "7  PRE            PRE                        PRE                       \n",
       "8  PRE            PRE and EDT                PRE and EDT               \n",
       "9  PRE            PRE                        PRE                       \n",
       "10 EDT            EDT                        EDT                       \n",
       "11 PRE            PRE                        PRE                       \n",
       "12 -              PRE                        PRE                       \n",
       "13 PRE            PRE                        PRE                       \n",
       "14 PRE and EDT    PRE and EDT                PRE and EDT               \n",
       "15 PRE            PRE                        PRE                       \n",
       "16 PRE            PRE                        PRE                       \n",
       "17 -              PRE                        PRE                       \n",
       "18 PRE            PRE                        PRE                       \n",
       "19 -              -                          PRE                       \n",
       "20 PRE and EDT    PRE and EDT                PRE and EDT               \n",
       "21 PRE            -                          -                         \n",
       "22 PRE            PRE                        PRE                       \n",
       "23 -              PRE and EDT                PRE and EDT               \n",
       "24 PRE            PRE                        -                         \n",
       "25 PRE            PRE                        PRE                       \n",
       "26 PRE            PRE                        PRE                       \n",
       "27 PRE            PRE                        PRE                       \n",
       "28 PRE and EDT    PRE and EDT                PRE and EDT               \n",
       "29 -              PRE and EDT                PRE and EDT               \n",
       "30 -              PRE                        PRE                       \n",
       "31 -              -                          PRE                       \n",
       "32 -              PRE                        PRE                       \n",
       "33 PRE            PRE                        PRE                       \n",
       "34 PRE and EDT    PRE and EDT                PRE and EDT               \n",
       "35 PRE            PRE                        PRE                       \n",
       "36 PRE and EDT    PRE and EDT                PRE and EDT               \n",
       "37 PRE and EDT    PRE and EDT                PRE and EDT               \n",
       "38 PRE            PRE                        PRE                       \n",
       "39 -              PRE                        -                         \n",
       "40 -              PRE                        PRE                       \n",
       "41 -              PRE                        PRE                       \n",
       "42 -              PRE and EDT                PRE and EDT               \n",
       "43 -              PRE                        PRE                       \n",
       "44 -              PRE                        PRE                       \n",
       "45 PRE            PRE                        PRE                       \n",
       "46 PRE            PRE and EDT                PRE and EDT               \n",
       "47 PRE            PRE                        PRE                       \n",
       "48 PRE            PRE                        PRE                       \n",
       "49 -              PRE                        PRE                       \n",
       "50 PRE            PRE                        PRE                       \n",
       "51 PRE            PRE                        PRE                       \n",
       "52 -              PRE                        PRE                       "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "supp2 <- read.csv(\"Gide_supp2.csv\", skip=1)\n",
    "supp2"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "5ec3039e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table>\n",
       "<caption>A data.frame: 51 Ã— 14</caption>\n",
       "<thead>\n",
       "\t<tr><th></th><th scope=col>Age..Years.</th><th scope=col>Sex</th><th scope=col>Treatment</th><th scope=col>Best.RECIST.response</th><th scope=col>Progression.Free.Survival..Days.</th><th scope=col>Overall.Survival..Days.</th><th scope=col>Site.of.PRE.Biopsy</th><th scope=col>Days.to.EDT.Biopsy</th><th scope=col>Site.of.EDT.Biopsy</th><th scope=col>Progressed</th><th scope=col>Last.Followup.Status</th><th scope=col>RNA.Sequencing</th><th scope=col>Immunofluorescence.Panel.1</th><th scope=col>Immunofluorescence.Panel.2</th></tr>\n",
       "\t<tr><th></th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><th scope=row>1</th><td>42</td><td>F</td><td>Ipilimumab + Pembrolizumab</td><td>PD</td><td>15  </td><td>689 </td><td>SQ             </td><td>7 </td><td>SQ</td><td>Yes</td><td>Alive         </td><td>PRE and EDT</td><td>PRE and EDT</td><td>PRE and EDT</td></tr>\n",
       "\t<tr><th scope=row>2</th><td>41</td><td>M</td><td>Ipilimumab + Pembrolizumab</td><td>PD</td><td>34  </td><td>530 </td><td>LN             </td><td>- </td><td>- </td><td>Yes</td><td>Alive         </td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>3</th><td>58</td><td>F</td><td>Ipilimumab + Nivolumab    </td><td>PD</td><td>37  </td><td>300 </td><td>Lung           </td><td>- </td><td>- </td><td>Yes</td><td>Alive         </td><td>-          </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>4</th><td>48</td><td>M</td><td>Ipilimumab + Nivolumab    </td><td>PD</td><td>39  </td><td>129 </td><td>SQ             </td><td>12</td><td>SQ</td><td>Yes</td><td>Alive         </td><td>EDT        </td><td>PRE and EDT</td><td>PRE and EDT</td></tr>\n",
       "\t<tr><th scope=row>5</th><td>49</td><td>F</td><td>Ipilimumab + Pembrolizumab</td><td>PD</td><td>40  </td><td>93  </td><td>LN             </td><td>6 </td><td>SQ</td><td>Yes</td><td>Dead, melanoma</td><td>-          </td><td>PRE and EDT</td><td>PRE and EDT</td></tr>\n",
       "\t<tr><th scope=row>6</th><td>75</td><td>M</td><td>Ipilimumab + Nivolumab    </td><td>PD</td><td>41  </td><td>108 </td><td>LN             </td><td>- </td><td>- </td><td>Yes</td><td>Dead, melanoma</td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>7</th><td>59</td><td>M</td><td>Ipilimumab + Nivolumab    </td><td>PR</td><td>81  </td><td>169 </td><td>SQ             </td><td>8 </td><td>SQ</td><td>Yes</td><td>Alive         </td><td>PRE        </td><td>PRE and EDT</td><td>PRE and EDT</td></tr>\n",
       "\t<tr><th scope=row>8</th><td>55</td><td>M</td><td>Ipilimumab + Pembrolizumab</td><td>PD</td><td>81  </td><td>637 </td><td>LN             </td><td>- </td><td>- </td><td>Yes</td><td>Alive         </td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>9</th><td>56</td><td>M</td><td>Ipilimumab + Pembrolizumab</td><td>PD</td><td>81  </td><td>156 </td><td>LN             </td><td>9 </td><td>SQ</td><td>Yes</td><td>Dead, melanoma</td><td>EDT        </td><td>EDT        </td><td>EDT        </td></tr>\n",
       "\t<tr><th scope=row>10</th><td>51</td><td>M</td><td>Ipilimumab + Pembrolizumab</td><td>PD</td><td>81  </td><td>176 </td><td>LN             </td><td>- </td><td>- </td><td>Yes</td><td>Dead, melanoma</td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>11</th><td>62</td><td>M</td><td>Ipilimumab + Nivolumab    </td><td>PD</td><td>82  </td><td>221 </td><td>LN             </td><td>- </td><td>- </td><td>Yes</td><td>Alive         </td><td>-          </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>12</th><td>55</td><td>F</td><td>Ipilimumab + Nivolumab    </td><td>PD</td><td>82  </td><td>293 </td><td>Lung           </td><td>- </td><td>- </td><td>Yes</td><td>Alive         </td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>13</th><td>68</td><td>F</td><td>Ipilimumab + Nivolumab    </td><td>PR</td><td>108 </td><td>357 </td><td>SQ             </td><td>8 </td><td>SQ</td><td>Yes</td><td>Dead, melanoma</td><td>PRE and EDT</td><td>PRE and EDT</td><td>PRE and EDT</td></tr>\n",
       "\t<tr><th scope=row>14</th><td>47</td><td>F</td><td>Ipilimumab + Pembrolizumab</td><td>SD</td><td>123 </td><td>691 </td><td>SQ             </td><td>- </td><td>- </td><td>Yes</td><td>Alive         </td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>15</th><td>57</td><td>M</td><td>Ipilimumab + Pembrolizumab</td><td>SD</td><td>152 </td><td>660 </td><td>SQ             </td><td>- </td><td>- </td><td>Yes</td><td>Dead, melanoma</td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>16</th><td>39</td><td>F</td><td>Ipilimumab + Pembrolizumab</td><td>PR</td><td>168 </td><td>558 </td><td>LN             </td><td>- </td><td>- </td><td>Yes</td><td>Alive         </td><td>-          </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>17</th><td>48</td><td>F</td><td>Ipilimumab + Nivolumab    </td><td>PR</td><td>196 </td><td>196 </td><td>LN             </td><td>- </td><td>- </td><td>No </td><td>Alive         </td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>18</th><td>58</td><td>M</td><td>Ipilimumab + Pembrolizumab</td><td>PR</td><td>278 </td><td>278 </td><td>Lung           </td><td>- </td><td>- </td><td>No </td><td>Alive         </td><td>-          </td><td>-          </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>19</th><td>56</td><td>M</td><td>Ipilimumab + Pembrolizumab</td><td>SD</td><td>301 </td><td>635 </td><td>SQ             </td><td>15</td><td>SQ</td><td>Yes</td><td>Alive         </td><td>PRE and EDT</td><td>PRE and EDT</td><td>PRE and EDT</td></tr>\n",
       "\t<tr><th scope=row>20</th><td>57</td><td>M</td><td>Ipilimumab + Pembrolizumab</td><td>SD</td><td>386 </td><td>538 </td><td>LN             </td><td>- </td><td>- </td><td>Yes</td><td>Alive         </td><td>PRE        </td><td>-          </td><td>-          </td></tr>\n",
       "\t<tr><th scope=row>21</th><td>63</td><td>M</td><td>Ipilimumab + Nivolumab    </td><td>PR</td><td>410 </td><td>410 </td><td>SQ             </td><td>- </td><td>- </td><td>No </td><td>Alive         </td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>22</th><td>59</td><td>F</td><td>Ipilimumab + Pembrolizumab</td><td>PR</td><td>487 </td><td>706 </td><td>LN             </td><td>7 </td><td>LN</td><td>Yes</td><td>Alive         </td><td>-          </td><td>PRE and EDT</td><td>PRE and EDT</td></tr>\n",
       "\t<tr><th scope=row>23</th><td>51</td><td>F</td><td>Ipilimumab + Pembrolizumab</td><td>PR</td><td>506 </td><td>506 </td><td>Brain          </td><td>- </td><td>- </td><td>No </td><td>Alive         </td><td>PRE        </td><td>PRE        </td><td>-          </td></tr>\n",
       "\t<tr><th scope=row>24</th><td>34</td><td>M</td><td>Ipilimumab + Nivolumab    </td><td>PR</td><td>509 </td><td>1203</td><td>LN             </td><td>- </td><td>- </td><td>Yes</td><td>Alive         </td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>25</th><td>67</td><td>F</td><td>Ipilimumab + Pembrolizumab</td><td>SD</td><td>518 </td><td>518 </td><td>LN             </td><td>- </td><td>- </td><td>No </td><td>Dead, melanoma</td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>26</th><td>75</td><td>M</td><td>Ipilimumab + Pembrolizumab</td><td>CR</td><td>544 </td><td>544 </td><td>LN             </td><td>- </td><td>- </td><td>No </td><td>Alive         </td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>27</th><td>49</td><td>M</td><td>Ipilimumab + Pembrolizumab</td><td>CR</td><td>546 </td><td>546 </td><td>Abdomen        </td><td>5 </td><td>SQ</td><td>No </td><td>Alive         </td><td>PRE and EDT</td><td>PRE and EDT</td><td>PRE and EDT</td></tr>\n",
       "\t<tr><th scope=row>28</th><td>33</td><td>M</td><td>Ipilimumab + Pembrolizumab</td><td>CR</td><td>553 </td><td>553 </td><td>LN             </td><td>7 </td><td>LN</td><td>No </td><td>Alive         </td><td>-          </td><td>PRE and EDT</td><td>PRE and EDT</td></tr>\n",
       "\t<tr><th scope=row>29</th><td>66</td><td>F</td><td>Ipilimumab + Pembrolizumab</td><td>CR</td><td>567 </td><td>567 </td><td>LN             </td><td>- </td><td>- </td><td>No </td><td>Alive         </td><td>-          </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>30</th><td>56</td><td>M</td><td>Ipilimumab + Pembrolizumab</td><td>PR</td><td>573 </td><td>573 </td><td>Small intestine</td><td>- </td><td>- </td><td>No </td><td>Alive         </td><td>-          </td><td>-          </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>31</th><td>45</td><td>M</td><td>Ipilimumab + Pembrolizumab</td><td>CR</td><td>588 </td><td>588 </td><td>Lung           </td><td>- </td><td>- </td><td>No </td><td>Alive         </td><td>-          </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>32</th><td>71</td><td>M</td><td>Ipilimumab + Pembrolizumab</td><td>CR</td><td>597 </td><td>597 </td><td>LN             </td><td>- </td><td>- </td><td>No </td><td>Alive         </td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>33</th><td>73</td><td>M</td><td>Ipilimumab + Pembrolizumab</td><td>PR</td><td>609 </td><td>609 </td><td>SQ             </td><td>9 </td><td>SQ</td><td>No </td><td>Alive         </td><td>PRE and EDT</td><td>PRE and EDT</td><td>PRE and EDT</td></tr>\n",
       "\t<tr><th scope=row>34</th><td>51</td><td>M</td><td>Ipilimumab + Pembrolizumab</td><td>CR</td><td>623 </td><td>623 </td><td>Lung           </td><td>- </td><td>- </td><td>No </td><td>Alive         </td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>35</th><td>72</td><td>M</td><td>Ipilimumab + Pembrolizumab</td><td>CR</td><td>627 </td><td>627 </td><td>SQ             </td><td>9 </td><td>SQ</td><td>No </td><td>Alive         </td><td>PRE and EDT</td><td>PRE and EDT</td><td>PRE and EDT</td></tr>\n",
       "\t<tr><th scope=row>36</th><td>74</td><td>F</td><td>Ipilimumab + Pembrolizumab</td><td>CR</td><td>637 </td><td>637 </td><td>SQ             </td><td>6 </td><td>SQ</td><td>No </td><td>Alive         </td><td>PRE and EDT</td><td>PRE and EDT</td><td>PRE and EDT</td></tr>\n",
       "\t<tr><th scope=row>37</th><td>76</td><td>M</td><td>Ipilimumab + Pembrolizumab</td><td>PR</td><td>637 </td><td>637 </td><td>LN             </td><td>- </td><td>- </td><td>No </td><td>Alive         </td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>38</th><td>59</td><td>F</td><td>Ipilimumab + Pembrolizumab</td><td>CR</td><td>650 </td><td>650 </td><td>SQ             </td><td>- </td><td>- </td><td>No </td><td>Alive         </td><td>-          </td><td>PRE        </td><td>-          </td></tr>\n",
       "\t<tr><th scope=row>39</th><td>33</td><td>M</td><td>Ipilimumab + Nivolumab    </td><td>CR</td><td>657 </td><td>657 </td><td>LN             </td><td>- </td><td>- </td><td>No </td><td>Alive         </td><td>-          </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>40</th><td>81</td><td>M</td><td>Ipilimumab + Pembrolizumab</td><td>PR</td><td>671 </td><td>671 </td><td>SQ             </td><td>- </td><td>- </td><td>No </td><td>Alive         </td><td>-          </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>41</th><td>57</td><td>F</td><td>Ipilimumab + Pembrolizumab</td><td>PR</td><td>672 </td><td>672 </td><td>SQ             </td><td>4 </td><td>SQ</td><td>No </td><td>Alive         </td><td>-          </td><td>PRE and EDT</td><td>PRE and EDT</td></tr>\n",
       "\t<tr><th scope=row>42</th><td>71</td><td>M</td><td>Ipilimumab + Pembrolizumab</td><td>PR</td><td>692 </td><td>692 </td><td>Lung           </td><td>- </td><td>- </td><td>No </td><td>Alive         </td><td>-          </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>43</th><td>53</td><td>F</td><td>Ipilimumab + Pembrolizumab</td><td>CR</td><td>693 </td><td>693 </td><td>SQ             </td><td>- </td><td>- </td><td>No </td><td>Alive         </td><td>-          </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>44</th><td>68</td><td>M</td><td>Ipilimumab + Pembrolizumab</td><td>PR</td><td>695 </td><td>695 </td><td>SQ             </td><td>- </td><td>- </td><td>No </td><td>Alive         </td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>45</th><td>70</td><td>M</td><td>Ipilimumab + Pembrolizumab</td><td>CR</td><td>721 </td><td>721 </td><td>Mucosa         </td><td>8 </td><td>SQ</td><td>No </td><td>Alive         </td><td>PRE        </td><td>PRE and EDT</td><td>PRE and EDT</td></tr>\n",
       "\t<tr><th scope=row>46</th><td>54</td><td>F</td><td>Ipilimumab + Pembrolizumab</td><td>CR</td><td>721 </td><td>721 </td><td>Lung           </td><td>- </td><td>- </td><td>No </td><td>Alive         </td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>47</th><td>24</td><td>F</td><td>Ipilimumab + Pembrolizumab</td><td>PR</td><td>732 </td><td>732 </td><td>SQ             </td><td>- </td><td>- </td><td>No </td><td>Alive         </td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>48</th><td>72</td><td>M</td><td>Ipilimumab + Pembrolizumab</td><td>PR</td><td>737 </td><td>737 </td><td>SQ             </td><td>- </td><td>- </td><td>No </td><td>Alive         </td><td>-          </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>49</th><td>36</td><td>M</td><td>Ipilimumab + Pembrolizumab</td><td>CR</td><td>775 </td><td>775 </td><td>LN             </td><td>- </td><td>- </td><td>No </td><td>Alive         </td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>50</th><td>68</td><td>M</td><td>Ipilimumab + Pembrolizumab</td><td>PR</td><td>904 </td><td>904 </td><td>LN             </td><td>- </td><td>- </td><td>No </td><td>Alive         </td><td>PRE        </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "\t<tr><th scope=row>51</th><td>64</td><td>M</td><td>Ipilimumab + Pembrolizumab</td><td>PR</td><td>1379</td><td>1379</td><td>Liver          </td><td>- </td><td>- </td><td>No </td><td>Alive         </td><td>-          </td><td>PRE        </td><td>PRE        </td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A data.frame: 51 Ã— 14\n",
       "\\begin{tabular}{r|llllllllllllll}\n",
       "  & Age..Years. & Sex & Treatment & Best.RECIST.response & Progression.Free.Survival..Days. & Overall.Survival..Days. & Site.of.PRE.Biopsy & Days.to.EDT.Biopsy & Site.of.EDT.Biopsy & Progressed & Last.Followup.Status & RNA.Sequencing & Immunofluorescence.Panel.1 & Immunofluorescence.Panel.2\\\\\n",
       "  & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct> & <fct>\\\\\n",
       "\\hline\n",
       "\t1 & 42 & F & Ipilimumab + Pembrolizumab & PD & 15   & 689  & SQ              & 7  & SQ & Yes & Alive          & PRE and EDT & PRE and EDT & PRE and EDT\\\\\n",
       "\t2 & 41 & M & Ipilimumab + Pembrolizumab & PD & 34   & 530  & LN              & -  & -  & Yes & Alive          & PRE         & PRE         & PRE        \\\\\n",
       "\t3 & 58 & F & Ipilimumab + Nivolumab     & PD & 37   & 300  & Lung            & -  & -  & Yes & Alive          & -           & PRE         & PRE        \\\\\n",
       "\t4 & 48 & M & Ipilimumab + Nivolumab     & PD & 39   & 129  & SQ              & 12 & SQ & Yes & Alive          & EDT         & PRE and EDT & PRE and EDT\\\\\n",
       "\t5 & 49 & F & Ipilimumab + Pembrolizumab & PD & 40   & 93   & LN              & 6  & SQ & Yes & Dead, melanoma & -           & PRE and EDT & PRE and EDT\\\\\n",
       "\t6 & 75 & M & Ipilimumab + Nivolumab     & PD & 41   & 108  & LN              & -  & -  & Yes & Dead, melanoma & PRE         & PRE         & PRE        \\\\\n",
       "\t7 & 59 & M & Ipilimumab + Nivolumab     & PR & 81   & 169  & SQ              & 8  & SQ & Yes & Alive          & PRE         & PRE and EDT & PRE and EDT\\\\\n",
       "\t8 & 55 & M & Ipilimumab + Pembrolizumab & PD & 81   & 637  & LN              & -  & -  & Yes & Alive          & PRE         & PRE         & PRE        \\\\\n",
       "\t9 & 56 & M & Ipilimumab + Pembrolizumab & PD & 81   & 156  & LN              & 9  & SQ & Yes & Dead, melanoma & EDT         & EDT         & EDT        \\\\\n",
       "\t10 & 51 & M & Ipilimumab + Pembrolizumab & PD & 81   & 176  & LN              & -  & -  & Yes & Dead, melanoma & PRE         & PRE         & PRE        \\\\\n",
       "\t11 & 62 & M & Ipilimumab + Nivolumab     & PD & 82   & 221  & LN              & -  & -  & Yes & Alive          & -           & PRE         & PRE        \\\\\n",
       "\t12 & 55 & F & Ipilimumab + Nivolumab     & PD & 82   & 293  & Lung            & -  & -  & Yes & Alive          & PRE         & PRE         & PRE        \\\\\n",
       "\t13 & 68 & F & Ipilimumab + Nivolumab     & PR & 108  & 357  & SQ              & 8  & SQ & Yes & Dead, melanoma & PRE and EDT & PRE and EDT & PRE and EDT\\\\\n",
       "\t14 & 47 & F & Ipilimumab + Pembrolizumab & SD & 123  & 691  & SQ              & -  & -  & Yes & Alive          & PRE         & PRE         & PRE        \\\\\n",
       "\t15 & 57 & M & Ipilimumab + Pembrolizumab & SD & 152  & 660  & SQ              & -  & -  & Yes & Dead, melanoma & PRE         & PRE         & PRE        \\\\\n",
       "\t16 & 39 & F & Ipilimumab + Pembrolizumab & PR & 168  & 558  & LN              & -  & -  & Yes & Alive          & -           & PRE         & PRE        \\\\\n",
       "\t17 & 48 & F & Ipilimumab + Nivolumab     & PR & 196  & 196  & LN              & -  & -  & No  & Alive          & PRE         & PRE         & PRE        \\\\\n",
       "\t18 & 58 & M & Ipilimumab + Pembrolizumab & PR & 278  & 278  & Lung            & -  & -  & No  & Alive          & -           & -           & PRE        \\\\\n",
       "\t19 & 56 & M & Ipilimumab + Pembrolizumab & SD & 301  & 635  & SQ              & 15 & SQ & Yes & Alive          & PRE and EDT & PRE and EDT & PRE and EDT\\\\\n",
       "\t20 & 57 & M & Ipilimumab + Pembrolizumab & SD & 386  & 538  & LN              & -  & -  & Yes & Alive          & PRE         & -           & -          \\\\\n",
       "\t21 & 63 & M & Ipilimumab + Nivolumab     & PR & 410  & 410  & SQ              & -  & -  & No  & Alive          & PRE         & PRE         & PRE        \\\\\n",
       "\t22 & 59 & F & Ipilimumab + Pembrolizumab & PR & 487  & 706  & LN              & 7  & LN & Yes & Alive          & -           & PRE and EDT & PRE and EDT\\\\\n",
       "\t23 & 51 & F & Ipilimumab + Pembrolizumab & PR & 506  & 506  & Brain           & -  & -  & No  & Alive          & PRE         & PRE         & -          \\\\\n",
       "\t24 & 34 & M & Ipilimumab + Nivolumab     & PR & 509  & 1203 & LN              & -  & -  & Yes & Alive          & PRE         & PRE         & PRE        \\\\\n",
       "\t25 & 67 & F & Ipilimumab + Pembrolizumab & SD & 518  & 518  & LN              & -  & -  & No  & Dead, melanoma & PRE         & PRE         & PRE        \\\\\n",
       "\t26 & 75 & M & Ipilimumab + Pembrolizumab & CR & 544  & 544  & LN              & -  & -  & No  & Alive          & PRE         & PRE         & PRE        \\\\\n",
       "\t27 & 49 & M & Ipilimumab + Pembrolizumab & CR & 546  & 546  & Abdomen         & 5  & SQ & No  & Alive          & PRE and EDT & PRE and EDT & PRE and EDT\\\\\n",
       "\t28 & 33 & M & Ipilimumab + Pembrolizumab & CR & 553  & 553  & LN              & 7  & LN & No  & Alive          & -           & PRE and EDT & PRE and EDT\\\\\n",
       "\t29 & 66 & F & Ipilimumab + Pembrolizumab & CR & 567  & 567  & LN              & -  & -  & No  & Alive          & -           & PRE         & PRE        \\\\\n",
       "\t30 & 56 & M & Ipilimumab + Pembrolizumab & PR & 573  & 573  & Small intestine & -  & -  & No  & Alive          & -           & -           & PRE        \\\\\n",
       "\t31 & 45 & M & Ipilimumab + Pembrolizumab & CR & 588  & 588  & Lung            & -  & -  & No  & Alive          & -           & PRE         & PRE        \\\\\n",
       "\t32 & 71 & M & Ipilimumab + Pembrolizumab & CR & 597  & 597  & LN              & -  & -  & No  & Alive          & PRE         & PRE         & PRE        \\\\\n",
       "\t33 & 73 & M & Ipilimumab + Pembrolizumab & PR & 609  & 609  & SQ              & 9  & SQ & No  & Alive          & PRE and EDT & PRE and EDT & PRE and EDT\\\\\n",
       "\t34 & 51 & M & Ipilimumab + Pembrolizumab & CR & 623  & 623  & Lung            & -  & -  & No  & Alive          & PRE         & PRE         & PRE        \\\\\n",
       "\t35 & 72 & M & Ipilimumab + Pembrolizumab & CR & 627  & 627  & SQ              & 9  & SQ & No  & Alive          & PRE and EDT & PRE and EDT & PRE and EDT\\\\\n",
       "\t36 & 74 & F & Ipilimumab + Pembrolizumab & CR & 637  & 637  & SQ              & 6  & SQ & No  & Alive          & PRE and EDT & PRE and EDT & PRE and EDT\\\\\n",
       "\t37 & 76 & M & Ipilimumab + Pembrolizumab & PR & 637  & 637  & LN              & -  & -  & No  & Alive          & PRE         & PRE         & PRE        \\\\\n",
       "\t38 & 59 & F & Ipilimumab + Pembrolizumab & CR & 650  & 650  & SQ              & -  & -  & No  & Alive          & -           & PRE         & -          \\\\\n",
       "\t39 & 33 & M & Ipilimumab + Nivolumab     & CR & 657  & 657  & LN              & -  & -  & No  & Alive          & -           & PRE         & PRE        \\\\\n",
       "\t40 & 81 & M & Ipilimumab + Pembrolizumab & PR & 671  & 671  & SQ              & -  & -  & No  & Alive          & -           & PRE         & PRE        \\\\\n",
       "\t41 & 57 & F & Ipilimumab + Pembrolizumab & PR & 672  & 672  & SQ              & 4  & SQ & No  & Alive          & -           & PRE and EDT & PRE and EDT\\\\\n",
       "\t42 & 71 & M & Ipilimumab + Pembrolizumab & PR & 692  & 692  & Lung            & -  & -  & No  & Alive          & -           & PRE         & PRE        \\\\\n",
       "\t43 & 53 & F & Ipilimumab + Pembrolizumab & CR & 693  & 693  & SQ              & -  & -  & No  & Alive          & -           & PRE         & PRE        \\\\\n",
       "\t44 & 68 & M & Ipilimumab + Pembrolizumab & PR & 695  & 695  & SQ              & -  & -  & No  & Alive          & PRE         & PRE         & PRE        \\\\\n",
       "\t45 & 70 & M & Ipilimumab + Pembrolizumab & CR & 721  & 721  & Mucosa          & 8  & SQ & No  & Alive          & PRE         & PRE and EDT & PRE and EDT\\\\\n",
       "\t46 & 54 & F & Ipilimumab + Pembrolizumab & CR & 721  & 721  & Lung            & -  & -  & No  & Alive          & PRE         & PRE         & PRE        \\\\\n",
       "\t47 & 24 & F & Ipilimumab + Pembrolizumab & PR & 732  & 732  & SQ              & -  & -  & No  & Alive          & PRE         & PRE         & PRE        \\\\\n",
       "\t48 & 72 & M & Ipilimumab + Pembrolizumab & PR & 737  & 737  & SQ              & -  & -  & No  & Alive          & -           & PRE         & PRE        \\\\\n",
       "\t49 & 36 & M & Ipilimumab + Pembrolizumab & CR & 775  & 775  & LN              & -  & -  & No  & Alive          & PRE         & PRE         & PRE        \\\\\n",
       "\t50 & 68 & M & Ipilimumab + Pembrolizumab & PR & 904  & 904  & LN              & -  & -  & No  & Alive          & PRE         & PRE         & PRE        \\\\\n",
       "\t51 & 64 & M & Ipilimumab + Pembrolizumab & PR & 1379 & 1379 & Liver           & -  & -  & No  & Alive          & -           & PRE         & PRE        \\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A data.frame: 51 Ã— 14\n",
       "\n",
       "| <!--/--> | Age..Years. &lt;fct&gt; | Sex &lt;fct&gt; | Treatment &lt;fct&gt; | Best.RECIST.response &lt;fct&gt; | Progression.Free.Survival..Days. &lt;fct&gt; | Overall.Survival..Days. &lt;fct&gt; | Site.of.PRE.Biopsy &lt;fct&gt; | Days.to.EDT.Biopsy &lt;fct&gt; | Site.of.EDT.Biopsy &lt;fct&gt; | Progressed &lt;fct&gt; | Last.Followup.Status &lt;fct&gt; | RNA.Sequencing &lt;fct&gt; | Immunofluorescence.Panel.1 &lt;fct&gt; | Immunofluorescence.Panel.2 &lt;fct&gt; |\n",
       "|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|\n",
       "| 1 | 42 | F | Ipilimumab + Pembrolizumab | PD | 15   | 689  | SQ              | 7  | SQ | Yes | Alive          | PRE and EDT | PRE and EDT | PRE and EDT |\n",
       "| 2 | 41 | M | Ipilimumab + Pembrolizumab | PD | 34   | 530  | LN              | -  | -  | Yes | Alive          | PRE         | PRE         | PRE         |\n",
       "| 3 | 58 | F | Ipilimumab + Nivolumab     | PD | 37   | 300  | Lung            | -  | -  | Yes | Alive          | -           | PRE         | PRE         |\n",
       "| 4 | 48 | M | Ipilimumab + Nivolumab     | PD | 39   | 129  | SQ              | 12 | SQ | Yes | Alive          | EDT         | PRE and EDT | PRE and EDT |\n",
       "| 5 | 49 | F | Ipilimumab + Pembrolizumab | PD | 40   | 93   | LN              | 6  | SQ | Yes | Dead, melanoma | -           | PRE and EDT | PRE and EDT |\n",
       "| 6 | 75 | M | Ipilimumab + Nivolumab     | PD | 41   | 108  | LN              | -  | -  | Yes | Dead, melanoma | PRE         | PRE         | PRE         |\n",
       "| 7 | 59 | M | Ipilimumab + Nivolumab     | PR | 81   | 169  | SQ              | 8  | SQ | Yes | Alive          | PRE         | PRE and EDT | PRE and EDT |\n",
       "| 8 | 55 | M | Ipilimumab + Pembrolizumab | PD | 81   | 637  | LN              | -  | -  | Yes | Alive          | PRE         | PRE         | PRE         |\n",
       "| 9 | 56 | M | Ipilimumab + Pembrolizumab | PD | 81   | 156  | LN              | 9  | SQ | Yes | Dead, melanoma | EDT         | EDT         | EDT         |\n",
       "| 10 | 51 | M | Ipilimumab + Pembrolizumab | PD | 81   | 176  | LN              | -  | -  | Yes | Dead, melanoma | PRE         | PRE         | PRE         |\n",
       "| 11 | 62 | M | Ipilimumab + Nivolumab     | PD | 82   | 221  | LN              | -  | -  | Yes | Alive          | -           | PRE         | PRE         |\n",
       "| 12 | 55 | F | Ipilimumab + Nivolumab     | PD | 82   | 293  | Lung            | -  | -  | Yes | Alive          | PRE         | PRE         | PRE         |\n",
       "| 13 | 68 | F | Ipilimumab + Nivolumab     | PR | 108  | 357  | SQ              | 8  | SQ | Yes | Dead, melanoma | PRE and EDT | PRE and EDT | PRE and EDT |\n",
       "| 14 | 47 | F | Ipilimumab + Pembrolizumab | SD | 123  | 691  | SQ              | -  | -  | Yes | Alive          | PRE         | PRE         | PRE         |\n",
       "| 15 | 57 | M | Ipilimumab + Pembrolizumab | SD | 152  | 660  | SQ              | -  | -  | Yes | Dead, melanoma | PRE         | PRE         | PRE         |\n",
       "| 16 | 39 | F | Ipilimumab + Pembrolizumab | PR | 168  | 558  | LN              | -  | -  | Yes | Alive          | -           | PRE         | PRE         |\n",
       "| 17 | 48 | F | Ipilimumab + Nivolumab     | PR | 196  | 196  | LN              | -  | -  | No  | Alive          | PRE         | PRE         | PRE         |\n",
       "| 18 | 58 | M | Ipilimumab + Pembrolizumab | PR | 278  | 278  | Lung            | -  | -  | No  | Alive          | -           | -           | PRE         |\n",
       "| 19 | 56 | M | Ipilimumab + Pembrolizumab | SD | 301  | 635  | SQ              | 15 | SQ | Yes | Alive          | PRE and EDT | PRE and EDT | PRE and EDT |\n",
       "| 20 | 57 | M | Ipilimumab + Pembrolizumab | SD | 386  | 538  | LN              | -  | -  | Yes | Alive          | PRE         | -           | -           |\n",
       "| 21 | 63 | M | Ipilimumab + Nivolumab     | PR | 410  | 410  | SQ              | -  | -  | No  | Alive          | PRE         | PRE         | PRE         |\n",
       "| 22 | 59 | F | Ipilimumab + Pembrolizumab | PR | 487  | 706  | LN              | 7  | LN | Yes | Alive          | -           | PRE and EDT | PRE and EDT |\n",
       "| 23 | 51 | F | Ipilimumab + Pembrolizumab | PR | 506  | 506  | Brain           | -  | -  | No  | Alive          | PRE         | PRE         | -           |\n",
       "| 24 | 34 | M | Ipilimumab + Nivolumab     | PR | 509  | 1203 | LN              | -  | -  | Yes | Alive          | PRE         | PRE         | PRE         |\n",
       "| 25 | 67 | F | Ipilimumab + Pembrolizumab | SD | 518  | 518  | LN              | -  | -  | No  | Dead, melanoma | PRE         | PRE         | PRE         |\n",
       "| 26 | 75 | M | Ipilimumab + Pembrolizumab | CR | 544  | 544  | LN              | -  | -  | No  | Alive          | PRE         | PRE         | PRE         |\n",
       "| 27 | 49 | M | Ipilimumab + Pembrolizumab | CR | 546  | 546  | Abdomen         | 5  | SQ | No  | Alive          | PRE and EDT | PRE and EDT | PRE and EDT |\n",
       "| 28 | 33 | M | Ipilimumab + Pembrolizumab | CR | 553  | 553  | LN              | 7  | LN | No  | Alive          | -           | PRE and EDT | PRE and EDT |\n",
       "| 29 | 66 | F | Ipilimumab + Pembrolizumab | CR | 567  | 567  | LN              | -  | -  | No  | Alive          | -           | PRE         | PRE         |\n",
       "| 30 | 56 | M | Ipilimumab + Pembrolizumab | PR | 573  | 573  | Small intestine | -  | -  | No  | Alive          | -           | -           | PRE         |\n",
       "| 31 | 45 | M | Ipilimumab + Pembrolizumab | CR | 588  | 588  | Lung            | -  | -  | No  | Alive          | -           | PRE         | PRE         |\n",
       "| 32 | 71 | M | Ipilimumab + Pembrolizumab | CR | 597  | 597  | LN              | -  | -  | No  | Alive          | PRE         | PRE         | PRE         |\n",
       "| 33 | 73 | M | Ipilimumab + Pembrolizumab | PR | 609  | 609  | SQ              | 9  | SQ | No  | Alive          | PRE and EDT | PRE and EDT | PRE and EDT |\n",
       "| 34 | 51 | M | Ipilimumab + Pembrolizumab | CR | 623  | 623  | Lung            | -  | -  | No  | Alive          | PRE         | PRE         | PRE         |\n",
       "| 35 | 72 | M | Ipilimumab + Pembrolizumab | CR | 627  | 627  | SQ              | 9  | SQ | No  | Alive          | PRE and EDT | PRE and EDT | PRE and EDT |\n",
       "| 36 | 74 | F | Ipilimumab + Pembrolizumab | CR | 637  | 637  | SQ              | 6  | SQ | No  | Alive          | PRE and EDT | PRE and EDT | PRE and EDT |\n",
       "| 37 | 76 | M | Ipilimumab + Pembrolizumab | PR | 637  | 637  | LN              | -  | -  | No  | Alive          | PRE         | PRE         | PRE         |\n",
       "| 38 | 59 | F | Ipilimumab + Pembrolizumab | CR | 650  | 650  | SQ              | -  | -  | No  | Alive          | -           | PRE         | -           |\n",
       "| 39 | 33 | M | Ipilimumab + Nivolumab     | CR | 657  | 657  | LN              | -  | -  | No  | Alive          | -           | PRE         | PRE         |\n",
       "| 40 | 81 | M | Ipilimumab + Pembrolizumab | PR | 671  | 671  | SQ              | -  | -  | No  | Alive          | -           | PRE         | PRE         |\n",
       "| 41 | 57 | F | Ipilimumab + Pembrolizumab | PR | 672  | 672  | SQ              | 4  | SQ | No  | Alive          | -           | PRE and EDT | PRE and EDT |\n",
       "| 42 | 71 | M | Ipilimumab + Pembrolizumab | PR | 692  | 692  | Lung            | -  | -  | No  | Alive          | -           | PRE         | PRE         |\n",
       "| 43 | 53 | F | Ipilimumab + Pembrolizumab | CR | 693  | 693  | SQ              | -  | -  | No  | Alive          | -           | PRE         | PRE         |\n",
       "| 44 | 68 | M | Ipilimumab + Pembrolizumab | PR | 695  | 695  | SQ              | -  | -  | No  | Alive          | PRE         | PRE         | PRE         |\n",
       "| 45 | 70 | M | Ipilimumab + Pembrolizumab | CR | 721  | 721  | Mucosa          | 8  | SQ | No  | Alive          | PRE         | PRE and EDT | PRE and EDT |\n",
       "| 46 | 54 | F | Ipilimumab + Pembrolizumab | CR | 721  | 721  | Lung            | -  | -  | No  | Alive          | PRE         | PRE         | PRE         |\n",
       "| 47 | 24 | F | Ipilimumab + Pembrolizumab | PR | 732  | 732  | SQ              | -  | -  | No  | Alive          | PRE         | PRE         | PRE         |\n",
       "| 48 | 72 | M | Ipilimumab + Pembrolizumab | PR | 737  | 737  | SQ              | -  | -  | No  | Alive          | -           | PRE         | PRE         |\n",
       "| 49 | 36 | M | Ipilimumab + Pembrolizumab | CR | 775  | 775  | LN              | -  | -  | No  | Alive          | PRE         | PRE         | PRE         |\n",
       "| 50 | 68 | M | Ipilimumab + Pembrolizumab | PR | 904  | 904  | LN              | -  | -  | No  | Alive          | PRE         | PRE         | PRE         |\n",
       "| 51 | 64 | M | Ipilimumab + Pembrolizumab | PR | 1379 | 1379 | Liver           | -  | -  | No  | Alive          | -           | PRE         | PRE         |\n",
       "\n"
      ],
      "text/plain": [
       "   Age..Years. Sex Treatment                  Best.RECIST.response\n",
       "1  42          F   Ipilimumab + Pembrolizumab PD                  \n",
       "2  41          M   Ipilimumab + Pembrolizumab PD                  \n",
       "3  58          F   Ipilimumab + Nivolumab     PD                  \n",
       "4  48          M   Ipilimumab + Nivolumab     PD                  \n",
       "5  49          F   Ipilimumab + Pembrolizumab PD                  \n",
       "6  75          M   Ipilimumab + Nivolumab     PD                  \n",
       "7  59          M   Ipilimumab + Nivolumab     PR                  \n",
       "8  55          M   Ipilimumab + Pembrolizumab PD                  \n",
       "9  56          M   Ipilimumab + Pembrolizumab PD                  \n",
       "10 51          M   Ipilimumab + Pembrolizumab PD                  \n",
       "11 62          M   Ipilimumab + Nivolumab     PD                  \n",
       "12 55          F   Ipilimumab + Nivolumab     PD                  \n",
       "13 68          F   Ipilimumab + Nivolumab     PR                  \n",
       "14 47          F   Ipilimumab + Pembrolizumab SD                  \n",
       "15 57          M   Ipilimumab + Pembrolizumab SD                  \n",
       "16 39          F   Ipilimumab + Pembrolizumab PR                  \n",
       "17 48          F   Ipilimumab + Nivolumab     PR                  \n",
       "18 58          M   Ipilimumab + Pembrolizumab PR                  \n",
       "19 56          M   Ipilimumab + Pembrolizumab SD                  \n",
       "20 57          M   Ipilimumab + Pembrolizumab SD                  \n",
       "21 63          M   Ipilimumab + Nivolumab     PR                  \n",
       "22 59          F   Ipilimumab + Pembrolizumab PR                  \n",
       "23 51          F   Ipilimumab + Pembrolizumab PR                  \n",
       "24 34          M   Ipilimumab + Nivolumab     PR                  \n",
       "25 67          F   Ipilimumab + Pembrolizumab SD                  \n",
       "26 75          M   Ipilimumab + Pembrolizumab CR                  \n",
       "27 49          M   Ipilimumab + Pembrolizumab CR                  \n",
       "28 33          M   Ipilimumab + Pembrolizumab CR                  \n",
       "29 66          F   Ipilimumab + Pembrolizumab CR                  \n",
       "30 56          M   Ipilimumab + Pembrolizumab PR                  \n",
       "31 45          M   Ipilimumab + Pembrolizumab CR                  \n",
       "32 71          M   Ipilimumab + Pembrolizumab CR                  \n",
       "33 73          M   Ipilimumab + Pembrolizumab PR                  \n",
       "34 51          M   Ipilimumab + Pembrolizumab CR                  \n",
       "35 72          M   Ipilimumab + Pembrolizumab CR                  \n",
       "36 74          F   Ipilimumab + Pembrolizumab CR                  \n",
       "37 76          M   Ipilimumab + Pembrolizumab PR                  \n",
       "38 59          F   Ipilimumab + Pembrolizumab CR                  \n",
       "39 33          M   Ipilimumab + Nivolumab     CR                  \n",
       "40 81          M   Ipilimumab + Pembrolizumab PR                  \n",
       "41 57          F   Ipilimumab + Pembrolizumab PR                  \n",
       "42 71          M   Ipilimumab + Pembrolizumab PR                  \n",
       "43 53          F   Ipilimumab + Pembrolizumab CR                  \n",
       "44 68          M   Ipilimumab + Pembrolizumab PR                  \n",
       "45 70          M   Ipilimumab + Pembrolizumab CR                  \n",
       "46 54          F   Ipilimumab + Pembrolizumab CR                  \n",
       "47 24          F   Ipilimumab + Pembrolizumab PR                  \n",
       "48 72          M   Ipilimumab + Pembrolizumab PR                  \n",
       "49 36          M   Ipilimumab + Pembrolizumab CR                  \n",
       "50 68          M   Ipilimumab + Pembrolizumab PR                  \n",
       "51 64          M   Ipilimumab + Pembrolizumab PR                  \n",
       "   Progression.Free.Survival..Days. Overall.Survival..Days. Site.of.PRE.Biopsy\n",
       "1  15                               689                     SQ                \n",
       "2  34                               530                     LN                \n",
       "3  37                               300                     Lung              \n",
       "4  39                               129                     SQ                \n",
       "5  40                               93                      LN                \n",
       "6  41                               108                     LN                \n",
       "7  81                               169                     SQ                \n",
       "8  81                               637                     LN                \n",
       "9  81                               156                     LN                \n",
       "10 81                               176                     LN                \n",
       "11 82                               221                     LN                \n",
       "12 82                               293                     Lung              \n",
       "13 108                              357                     SQ                \n",
       "14 123                              691                     SQ                \n",
       "15 152                              660                     SQ                \n",
       "16 168                              558                     LN                \n",
       "17 196                              196                     LN                \n",
       "18 278                              278                     Lung              \n",
       "19 301                              635                     SQ                \n",
       "20 386                              538                     LN                \n",
       "21 410                              410                     SQ                \n",
       "22 487                              706                     LN                \n",
       "23 506                              506                     Brain             \n",
       "24 509                              1203                    LN                \n",
       "25 518                              518                     LN                \n",
       "26 544                              544                     LN                \n",
       "27 546                              546                     Abdomen           \n",
       "28 553                              553                     LN                \n",
       "29 567                              567                     LN                \n",
       "30 573                              573                     Small intestine   \n",
       "31 588                              588                     Lung              \n",
       "32 597                              597                     LN                \n",
       "33 609                              609                     SQ                \n",
       "34 623                              623                     Lung              \n",
       "35 627                              627                     SQ                \n",
       "36 637                              637                     SQ                \n",
       "37 637                              637                     LN                \n",
       "38 650                              650                     SQ                \n",
       "39 657                              657                     LN                \n",
       "40 671                              671                     SQ                \n",
       "41 672                              672                     SQ                \n",
       "42 692                              692                     Lung              \n",
       "43 693                              693                     SQ                \n",
       "44 695                              695                     SQ                \n",
       "45 721                              721                     Mucosa            \n",
       "46 721                              721                     Lung              \n",
       "47 732                              732                     SQ                \n",
       "48 737                              737                     SQ                \n",
       "49 775                              775                     LN                \n",
       "50 904                              904                     LN                \n",
       "51 1379                             1379                    Liver             \n",
       "   Days.to.EDT.Biopsy Site.of.EDT.Biopsy Progressed Last.Followup.Status\n",
       "1  7                  SQ                 Yes        Alive               \n",
       "2  -                  -                  Yes        Alive               \n",
       "3  -                  -                  Yes        Alive               \n",
       "4  12                 SQ                 Yes        Alive               \n",
       "5  6                  SQ                 Yes        Dead, melanoma      \n",
       "6  -                  -                  Yes        Dead, melanoma      \n",
       "7  8                  SQ                 Yes        Alive               \n",
       "8  -                  -                  Yes        Alive               \n",
       "9  9                  SQ                 Yes        Dead, melanoma      \n",
       "10 -                  -                  Yes        Dead, melanoma      \n",
       "11 -                  -                  Yes        Alive               \n",
       "12 -                  -                  Yes        Alive               \n",
       "13 8                  SQ                 Yes        Dead, melanoma      \n",
       "14 -                  -                  Yes        Alive               \n",
       "15 -                  -                  Yes        Dead, melanoma      \n",
       "16 -                  -                  Yes        Alive               \n",
       "17 -                  -                  No         Alive               \n",
       "18 -                  -                  No         Alive               \n",
       "19 15                 SQ                 Yes        Alive               \n",
       "20 -                  -                  Yes        Alive               \n",
       "21 -                  -                  No         Alive               \n",
       "22 7                  LN                 Yes        Alive               \n",
       "23 -                  -                  No         Alive               \n",
       "24 -                  -                  Yes        Alive               \n",
       "25 -                  -                  No         Dead, melanoma      \n",
       "26 -                  -                  No         Alive               \n",
       "27 5                  SQ                 No         Alive               \n",
       "28 7                  LN                 No         Alive               \n",
       "29 -                  -                  No         Alive               \n",
       "30 -                  -                  No         Alive               \n",
       "31 -                  -                  No         Alive               \n",
       "32 -                  -                  No         Alive               \n",
       "33 9                  SQ                 No         Alive               \n",
       "34 -                  -                  No         Alive               \n",
       "35 9                  SQ                 No         Alive               \n",
       "36 6                  SQ                 No         Alive               \n",
       "37 -                  -                  No         Alive               \n",
       "38 -                  -                  No         Alive               \n",
       "39 -                  -                  No         Alive               \n",
       "40 -                  -                  No         Alive               \n",
       "41 4                  SQ                 No         Alive               \n",
       "42 -                  -                  No         Alive               \n",
       "43 -                  -                  No         Alive               \n",
       "44 -                  -                  No         Alive               \n",
       "45 8                  SQ                 No         Alive               \n",
       "46 -                  -                  No         Alive               \n",
       "47 -                  -                  No         Alive               \n",
       "48 -                  -                  No         Alive               \n",
       "49 -                  -                  No         Alive               \n",
       "50 -                  -                  No         Alive               \n",
       "51 -                  -                  No         Alive               \n",
       "   RNA.Sequencing Immunofluorescence.Panel.1 Immunofluorescence.Panel.2\n",
       "1  PRE and EDT    PRE and EDT                PRE and EDT               \n",
       "2  PRE            PRE                        PRE                       \n",
       "3  -              PRE                        PRE                       \n",
       "4  EDT            PRE and EDT                PRE and EDT               \n",
       "5  -              PRE and EDT                PRE and EDT               \n",
       "6  PRE            PRE                        PRE                       \n",
       "7  PRE            PRE and EDT                PRE and EDT               \n",
       "8  PRE            PRE                        PRE                       \n",
       "9  EDT            EDT                        EDT                       \n",
       "10 PRE            PRE                        PRE                       \n",
       "11 -              PRE                        PRE                       \n",
       "12 PRE            PRE                        PRE                       \n",
       "13 PRE and EDT    PRE and EDT                PRE and EDT               \n",
       "14 PRE            PRE                        PRE                       \n",
       "15 PRE            PRE                        PRE                       \n",
       "16 -              PRE                        PRE                       \n",
       "17 PRE            PRE                        PRE                       \n",
       "18 -              -                          PRE                       \n",
       "19 PRE and EDT    PRE and EDT                PRE and EDT               \n",
       "20 PRE            -                          -                         \n",
       "21 PRE            PRE                        PRE                       \n",
       "22 -              PRE and EDT                PRE and EDT               \n",
       "23 PRE            PRE                        -                         \n",
       "24 PRE            PRE                        PRE                       \n",
       "25 PRE            PRE                        PRE                       \n",
       "26 PRE            PRE                        PRE                       \n",
       "27 PRE and EDT    PRE and EDT                PRE and EDT               \n",
       "28 -              PRE and EDT                PRE and EDT               \n",
       "29 -              PRE                        PRE                       \n",
       "30 -              -                          PRE                       \n",
       "31 -              PRE                        PRE                       \n",
       "32 PRE            PRE                        PRE                       \n",
       "33 PRE and EDT    PRE and EDT                PRE and EDT               \n",
       "34 PRE            PRE                        PRE                       \n",
       "35 PRE and EDT    PRE and EDT                PRE and EDT               \n",
       "36 PRE and EDT    PRE and EDT                PRE and EDT               \n",
       "37 PRE            PRE                        PRE                       \n",
       "38 -              PRE                        -                         \n",
       "39 -              PRE                        PRE                       \n",
       "40 -              PRE                        PRE                       \n",
       "41 -              PRE and EDT                PRE and EDT               \n",
       "42 -              PRE                        PRE                       \n",
       "43 -              PRE                        PRE                       \n",
       "44 PRE            PRE                        PRE                       \n",
       "45 PRE            PRE and EDT                PRE and EDT               \n",
       "46 PRE            PRE                        PRE                       \n",
       "47 PRE            PRE                        PRE                       \n",
       "48 -              PRE                        PRE                       \n",
       "49 PRE            PRE                        PRE                       \n",
       "50 PRE            PRE                        PRE                       \n",
       "51 -              PRE                        PRE                       "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "supp2 <- janitor::row_to_names(supp2, 1)\n",
    "supp2 <- data.frame(supp2[,-1], row.names = supp2[,1])\n",
    "supp2"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "c056872b",
   "metadata": {},
   "source": [
    "## Read Pembrolizumab-Nivolumab+Ipilimumab\n",
    "### Clinical"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "540384ab",
   "metadata": {},
   "outputs": [],
   "source": [
    "pni_clinical <- read.csv(\"Gide2019_PD1+CTLA4_Melanoma_RNASeq/ICB.Gide2019_Pembrolizumab-Nivolumab+Ipilimumab_Melanoma.clinical\", sep=\"\\t\" )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "eaddc919",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table>\n",
       "<caption>A data.frame: 51 Ã— 12</caption>\n",
       "<thead>\n",
       "\t<tr><th scope=col>X</th><th scope=col>OS</th><th scope=col>OS.Event</th><th scope=col>PFS</th><th scope=col>PFS.Event</th><th scope=col>RECIST</th><th scope=col>Age</th><th scope=col>Gender</th><th scope=col>Treatment</th><th scope=col>Site</th><th scope=col>Best.RECIST.response</th><th scope=col>Response</th></tr>\n",
       "\t<tr><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;int&gt;</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><td> 1</td><td> 689</td><td>0</td><td>  15</td><td>1</td><td>0</td><td>42</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><td> 2</td><td> 530</td><td>0</td><td>  34</td><td>1</td><td>0</td><td>41</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><td> 3</td><td> 300</td><td>0</td><td>  37</td><td>1</td><td>0</td><td>58</td><td>1</td><td>Ipilimumab + Nivolumab    </td><td>Lung           </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><td> 4</td><td> 129</td><td>0</td><td>  39</td><td>1</td><td>0</td><td>48</td><td>0</td><td>Ipilimumab + Nivolumab    </td><td>SQ             </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><td> 5</td><td>  93</td><td>1</td><td>  40</td><td>1</td><td>0</td><td>49</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><td> 6</td><td> 108</td><td>1</td><td>  41</td><td>1</td><td>0</td><td>75</td><td>0</td><td>Ipilimumab + Nivolumab    </td><td>LN             </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><td> 7</td><td> 169</td><td>0</td><td>  81</td><td>1</td><td>2</td><td>59</td><td>0</td><td>Ipilimumab + Nivolumab    </td><td>SQ             </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td> 8</td><td> 637</td><td>0</td><td>  81</td><td>1</td><td>0</td><td>55</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><td> 9</td><td> 156</td><td>1</td><td>  81</td><td>1</td><td>0</td><td>56</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><td>10</td><td> 176</td><td>1</td><td>  81</td><td>1</td><td>0</td><td>51</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><td>11</td><td> 221</td><td>0</td><td>  82</td><td>1</td><td>0</td><td>62</td><td>0</td><td>Ipilimumab + Nivolumab    </td><td>LN             </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><td>12</td><td> 293</td><td>0</td><td>  82</td><td>1</td><td>0</td><td>55</td><td>1</td><td>Ipilimumab + Nivolumab    </td><td>Lung           </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><td>13</td><td> 357</td><td>1</td><td> 108</td><td>1</td><td>2</td><td>68</td><td>1</td><td>Ipilimumab + Nivolumab    </td><td>SQ             </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>14</td><td> 691</td><td>0</td><td> 123</td><td>1</td><td>1</td><td>47</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>SD</td><td>0</td></tr>\n",
       "\t<tr><td>15</td><td> 660</td><td>1</td><td> 152</td><td>1</td><td>1</td><td>57</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>SD</td><td>0</td></tr>\n",
       "\t<tr><td>16</td><td> 558</td><td>0</td><td> 168</td><td>1</td><td>2</td><td>39</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>17</td><td> 196</td><td>0</td><td> 196</td><td>0</td><td>2</td><td>48</td><td>1</td><td>Ipilimumab + Nivolumab    </td><td>LN             </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>18</td><td> 278</td><td>0</td><td> 278</td><td>0</td><td>2</td><td>58</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Lung           </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>19</td><td> 635</td><td>0</td><td> 301</td><td>1</td><td>1</td><td>56</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>SD</td><td>0</td></tr>\n",
       "\t<tr><td>20</td><td> 538</td><td>0</td><td> 386</td><td>1</td><td>1</td><td>57</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>SD</td><td>0</td></tr>\n",
       "\t<tr><td>21</td><td> 410</td><td>0</td><td> 410</td><td>0</td><td>2</td><td>63</td><td>0</td><td>Ipilimumab + Nivolumab    </td><td>SQ             </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>22</td><td> 706</td><td>0</td><td> 487</td><td>1</td><td>2</td><td>59</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>23</td><td> 506</td><td>0</td><td> 506</td><td>0</td><td>2</td><td>51</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>Brain          </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>24</td><td>1203</td><td>0</td><td> 509</td><td>1</td><td>2</td><td>34</td><td>0</td><td>Ipilimumab + Nivolumab    </td><td>LN             </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>25</td><td> 518</td><td>1</td><td> 518</td><td>0</td><td>1</td><td>67</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>SD</td><td>0</td></tr>\n",
       "\t<tr><td>26</td><td> 544</td><td>0</td><td> 544</td><td>0</td><td>3</td><td>75</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><td>27</td><td> 546</td><td>0</td><td> 546</td><td>0</td><td>3</td><td>49</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Abdomen        </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><td>28</td><td> 553</td><td>0</td><td> 553</td><td>0</td><td>3</td><td>33</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><td>29</td><td> 567</td><td>0</td><td> 567</td><td>0</td><td>3</td><td>66</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><td>30</td><td> 573</td><td>0</td><td> 573</td><td>0</td><td>2</td><td>56</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Small intestine</td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>31</td><td> 588</td><td>0</td><td> 588</td><td>0</td><td>3</td><td>45</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Lung           </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><td>32</td><td> 597</td><td>0</td><td> 597</td><td>0</td><td>3</td><td>71</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><td>33</td><td> 609</td><td>0</td><td> 609</td><td>0</td><td>2</td><td>73</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>34</td><td> 623</td><td>0</td><td> 623</td><td>0</td><td>3</td><td>51</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Lung           </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><td>35</td><td> 627</td><td>0</td><td> 627</td><td>0</td><td>3</td><td>72</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><td>36</td><td> 637</td><td>0</td><td> 637</td><td>0</td><td>3</td><td>74</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><td>37</td><td> 637</td><td>0</td><td> 637</td><td>0</td><td>2</td><td>76</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>38</td><td> 650</td><td>0</td><td> 650</td><td>0</td><td>3</td><td>59</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><td>39</td><td> 657</td><td>0</td><td> 657</td><td>0</td><td>3</td><td>33</td><td>0</td><td>Ipilimumab + Nivolumab    </td><td>LN             </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><td>40</td><td> 671</td><td>0</td><td> 671</td><td>0</td><td>2</td><td>81</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>41</td><td> 672</td><td>0</td><td> 672</td><td>0</td><td>2</td><td>57</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>42</td><td> 692</td><td>0</td><td> 692</td><td>0</td><td>2</td><td>71</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Lung           </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>43</td><td> 693</td><td>0</td><td> 693</td><td>0</td><td>3</td><td>53</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><td>44</td><td> 695</td><td>0</td><td> 695</td><td>0</td><td>2</td><td>68</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>45</td><td> 721</td><td>0</td><td> 721</td><td>0</td><td>3</td><td>70</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Mucosa         </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><td>46</td><td> 721</td><td>0</td><td> 721</td><td>0</td><td>3</td><td>54</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>Lung           </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><td>47</td><td> 732</td><td>0</td><td> 732</td><td>0</td><td>2</td><td>24</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>48</td><td> 737</td><td>0</td><td> 737</td><td>0</td><td>2</td><td>72</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>49</td><td> 775</td><td>0</td><td> 775</td><td>0</td><td>3</td><td>36</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><td>50</td><td> 904</td><td>0</td><td> 904</td><td>0</td><td>2</td><td>68</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>51</td><td>1379</td><td>0</td><td>1379</td><td>0</td><td>2</td><td>64</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Liver          </td><td>PR</td><td>1</td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A data.frame: 51 Ã— 12\n",
       "\\begin{tabular}{llllllllllll}\n",
       " X & OS & OS.Event & PFS & PFS.Event & RECIST & Age & Gender & Treatment & Site & Best.RECIST.response & Response\\\\\n",
       " <int> & <int> & <int> & <int> & <int> & <int> & <int> & <int> & <fct> & <fct> & <fct> & <int>\\\\\n",
       "\\hline\n",
       "\t  1 &  689 & 0 &   15 & 1 & 0 & 42 & 1 & Ipilimumab + Pembrolizumab & SQ              & PD & 0\\\\\n",
       "\t  2 &  530 & 0 &   34 & 1 & 0 & 41 & 0 & Ipilimumab + Pembrolizumab & LN              & PD & 0\\\\\n",
       "\t  3 &  300 & 0 &   37 & 1 & 0 & 58 & 1 & Ipilimumab + Nivolumab     & Lung            & PD & 0\\\\\n",
       "\t  4 &  129 & 0 &   39 & 1 & 0 & 48 & 0 & Ipilimumab + Nivolumab     & SQ              & PD & 0\\\\\n",
       "\t  5 &   93 & 1 &   40 & 1 & 0 & 49 & 1 & Ipilimumab + Pembrolizumab & LN              & PD & 0\\\\\n",
       "\t  6 &  108 & 1 &   41 & 1 & 0 & 75 & 0 & Ipilimumab + Nivolumab     & LN              & PD & 0\\\\\n",
       "\t  7 &  169 & 0 &   81 & 1 & 2 & 59 & 0 & Ipilimumab + Nivolumab     & SQ              & PR & 1\\\\\n",
       "\t  8 &  637 & 0 &   81 & 1 & 0 & 55 & 0 & Ipilimumab + Pembrolizumab & LN              & PD & 0\\\\\n",
       "\t  9 &  156 & 1 &   81 & 1 & 0 & 56 & 0 & Ipilimumab + Pembrolizumab & LN              & PD & 0\\\\\n",
       "\t 10 &  176 & 1 &   81 & 1 & 0 & 51 & 0 & Ipilimumab + Pembrolizumab & LN              & PD & 0\\\\\n",
       "\t 11 &  221 & 0 &   82 & 1 & 0 & 62 & 0 & Ipilimumab + Nivolumab     & LN              & PD & 0\\\\\n",
       "\t 12 &  293 & 0 &   82 & 1 & 0 & 55 & 1 & Ipilimumab + Nivolumab     & Lung            & PD & 0\\\\\n",
       "\t 13 &  357 & 1 &  108 & 1 & 2 & 68 & 1 & Ipilimumab + Nivolumab     & SQ              & PR & 1\\\\\n",
       "\t 14 &  691 & 0 &  123 & 1 & 1 & 47 & 1 & Ipilimumab + Pembrolizumab & SQ              & SD & 0\\\\\n",
       "\t 15 &  660 & 1 &  152 & 1 & 1 & 57 & 0 & Ipilimumab + Pembrolizumab & SQ              & SD & 0\\\\\n",
       "\t 16 &  558 & 0 &  168 & 1 & 2 & 39 & 1 & Ipilimumab + Pembrolizumab & LN              & PR & 1\\\\\n",
       "\t 17 &  196 & 0 &  196 & 0 & 2 & 48 & 1 & Ipilimumab + Nivolumab     & LN              & PR & 1\\\\\n",
       "\t 18 &  278 & 0 &  278 & 0 & 2 & 58 & 0 & Ipilimumab + Pembrolizumab & Lung            & PR & 1\\\\\n",
       "\t 19 &  635 & 0 &  301 & 1 & 1 & 56 & 0 & Ipilimumab + Pembrolizumab & SQ              & SD & 0\\\\\n",
       "\t 20 &  538 & 0 &  386 & 1 & 1 & 57 & 0 & Ipilimumab + Pembrolizumab & LN              & SD & 0\\\\\n",
       "\t 21 &  410 & 0 &  410 & 0 & 2 & 63 & 0 & Ipilimumab + Nivolumab     & SQ              & PR & 1\\\\\n",
       "\t 22 &  706 & 0 &  487 & 1 & 2 & 59 & 1 & Ipilimumab + Pembrolizumab & LN              & PR & 1\\\\\n",
       "\t 23 &  506 & 0 &  506 & 0 & 2 & 51 & 1 & Ipilimumab + Pembrolizumab & Brain           & PR & 1\\\\\n",
       "\t 24 & 1203 & 0 &  509 & 1 & 2 & 34 & 0 & Ipilimumab + Nivolumab     & LN              & PR & 1\\\\\n",
       "\t 25 &  518 & 1 &  518 & 0 & 1 & 67 & 1 & Ipilimumab + Pembrolizumab & LN              & SD & 0\\\\\n",
       "\t 26 &  544 & 0 &  544 & 0 & 3 & 75 & 0 & Ipilimumab + Pembrolizumab & LN              & CR & 1\\\\\n",
       "\t 27 &  546 & 0 &  546 & 0 & 3 & 49 & 0 & Ipilimumab + Pembrolizumab & Abdomen         & CR & 1\\\\\n",
       "\t 28 &  553 & 0 &  553 & 0 & 3 & 33 & 0 & Ipilimumab + Pembrolizumab & LN              & CR & 1\\\\\n",
       "\t 29 &  567 & 0 &  567 & 0 & 3 & 66 & 1 & Ipilimumab + Pembrolizumab & LN              & CR & 1\\\\\n",
       "\t 30 &  573 & 0 &  573 & 0 & 2 & 56 & 0 & Ipilimumab + Pembrolizumab & Small intestine & PR & 1\\\\\n",
       "\t 31 &  588 & 0 &  588 & 0 & 3 & 45 & 0 & Ipilimumab + Pembrolizumab & Lung            & CR & 1\\\\\n",
       "\t 32 &  597 & 0 &  597 & 0 & 3 & 71 & 0 & Ipilimumab + Pembrolizumab & LN              & CR & 1\\\\\n",
       "\t 33 &  609 & 0 &  609 & 0 & 2 & 73 & 0 & Ipilimumab + Pembrolizumab & SQ              & PR & 1\\\\\n",
       "\t 34 &  623 & 0 &  623 & 0 & 3 & 51 & 0 & Ipilimumab + Pembrolizumab & Lung            & CR & 1\\\\\n",
       "\t 35 &  627 & 0 &  627 & 0 & 3 & 72 & 0 & Ipilimumab + Pembrolizumab & SQ              & CR & 1\\\\\n",
       "\t 36 &  637 & 0 &  637 & 0 & 3 & 74 & 1 & Ipilimumab + Pembrolizumab & SQ              & CR & 1\\\\\n",
       "\t 37 &  637 & 0 &  637 & 0 & 2 & 76 & 0 & Ipilimumab + Pembrolizumab & LN              & PR & 1\\\\\n",
       "\t 38 &  650 & 0 &  650 & 0 & 3 & 59 & 1 & Ipilimumab + Pembrolizumab & SQ              & CR & 1\\\\\n",
       "\t 39 &  657 & 0 &  657 & 0 & 3 & 33 & 0 & Ipilimumab + Nivolumab     & LN              & CR & 1\\\\\n",
       "\t 40 &  671 & 0 &  671 & 0 & 2 & 81 & 0 & Ipilimumab + Pembrolizumab & SQ              & PR & 1\\\\\n",
       "\t 41 &  672 & 0 &  672 & 0 & 2 & 57 & 1 & Ipilimumab + Pembrolizumab & SQ              & PR & 1\\\\\n",
       "\t 42 &  692 & 0 &  692 & 0 & 2 & 71 & 0 & Ipilimumab + Pembrolizumab & Lung            & PR & 1\\\\\n",
       "\t 43 &  693 & 0 &  693 & 0 & 3 & 53 & 1 & Ipilimumab + Pembrolizumab & SQ              & CR & 1\\\\\n",
       "\t 44 &  695 & 0 &  695 & 0 & 2 & 68 & 0 & Ipilimumab + Pembrolizumab & SQ              & PR & 1\\\\\n",
       "\t 45 &  721 & 0 &  721 & 0 & 3 & 70 & 0 & Ipilimumab + Pembrolizumab & Mucosa          & CR & 1\\\\\n",
       "\t 46 &  721 & 0 &  721 & 0 & 3 & 54 & 1 & Ipilimumab + Pembrolizumab & Lung            & CR & 1\\\\\n",
       "\t 47 &  732 & 0 &  732 & 0 & 2 & 24 & 1 & Ipilimumab + Pembrolizumab & SQ              & PR & 1\\\\\n",
       "\t 48 &  737 & 0 &  737 & 0 & 2 & 72 & 0 & Ipilimumab + Pembrolizumab & SQ              & PR & 1\\\\\n",
       "\t 49 &  775 & 0 &  775 & 0 & 3 & 36 & 0 & Ipilimumab + Pembrolizumab & LN              & CR & 1\\\\\n",
       "\t 50 &  904 & 0 &  904 & 0 & 2 & 68 & 0 & Ipilimumab + Pembrolizumab & LN              & PR & 1\\\\\n",
       "\t 51 & 1379 & 0 & 1379 & 0 & 2 & 64 & 0 & Ipilimumab + Pembrolizumab & Liver           & PR & 1\\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A data.frame: 51 Ã— 12\n",
       "\n",
       "| X &lt;int&gt; | OS &lt;int&gt; | OS.Event &lt;int&gt; | PFS &lt;int&gt; | PFS.Event &lt;int&gt; | RECIST &lt;int&gt; | Age &lt;int&gt; | Gender &lt;int&gt; | Treatment &lt;fct&gt; | Site &lt;fct&gt; | Best.RECIST.response &lt;fct&gt; | Response &lt;int&gt; |\n",
       "|---|---|---|---|---|---|---|---|---|---|---|---|\n",
       "|  1 |  689 | 0 |   15 | 1 | 0 | 42 | 1 | Ipilimumab + Pembrolizumab | SQ              | PD | 0 |\n",
       "|  2 |  530 | 0 |   34 | 1 | 0 | 41 | 0 | Ipilimumab + Pembrolizumab | LN              | PD | 0 |\n",
       "|  3 |  300 | 0 |   37 | 1 | 0 | 58 | 1 | Ipilimumab + Nivolumab     | Lung            | PD | 0 |\n",
       "|  4 |  129 | 0 |   39 | 1 | 0 | 48 | 0 | Ipilimumab + Nivolumab     | SQ              | PD | 0 |\n",
       "|  5 |   93 | 1 |   40 | 1 | 0 | 49 | 1 | Ipilimumab + Pembrolizumab | LN              | PD | 0 |\n",
       "|  6 |  108 | 1 |   41 | 1 | 0 | 75 | 0 | Ipilimumab + Nivolumab     | LN              | PD | 0 |\n",
       "|  7 |  169 | 0 |   81 | 1 | 2 | 59 | 0 | Ipilimumab + Nivolumab     | SQ              | PR | 1 |\n",
       "|  8 |  637 | 0 |   81 | 1 | 0 | 55 | 0 | Ipilimumab + Pembrolizumab | LN              | PD | 0 |\n",
       "|  9 |  156 | 1 |   81 | 1 | 0 | 56 | 0 | Ipilimumab + Pembrolizumab | LN              | PD | 0 |\n",
       "| 10 |  176 | 1 |   81 | 1 | 0 | 51 | 0 | Ipilimumab + Pembrolizumab | LN              | PD | 0 |\n",
       "| 11 |  221 | 0 |   82 | 1 | 0 | 62 | 0 | Ipilimumab + Nivolumab     | LN              | PD | 0 |\n",
       "| 12 |  293 | 0 |   82 | 1 | 0 | 55 | 1 | Ipilimumab + Nivolumab     | Lung            | PD | 0 |\n",
       "| 13 |  357 | 1 |  108 | 1 | 2 | 68 | 1 | Ipilimumab + Nivolumab     | SQ              | PR | 1 |\n",
       "| 14 |  691 | 0 |  123 | 1 | 1 | 47 | 1 | Ipilimumab + Pembrolizumab | SQ              | SD | 0 |\n",
       "| 15 |  660 | 1 |  152 | 1 | 1 | 57 | 0 | Ipilimumab + Pembrolizumab | SQ              | SD | 0 |\n",
       "| 16 |  558 | 0 |  168 | 1 | 2 | 39 | 1 | Ipilimumab + Pembrolizumab | LN              | PR | 1 |\n",
       "| 17 |  196 | 0 |  196 | 0 | 2 | 48 | 1 | Ipilimumab + Nivolumab     | LN              | PR | 1 |\n",
       "| 18 |  278 | 0 |  278 | 0 | 2 | 58 | 0 | Ipilimumab + Pembrolizumab | Lung            | PR | 1 |\n",
       "| 19 |  635 | 0 |  301 | 1 | 1 | 56 | 0 | Ipilimumab + Pembrolizumab | SQ              | SD | 0 |\n",
       "| 20 |  538 | 0 |  386 | 1 | 1 | 57 | 0 | Ipilimumab + Pembrolizumab | LN              | SD | 0 |\n",
       "| 21 |  410 | 0 |  410 | 0 | 2 | 63 | 0 | Ipilimumab + Nivolumab     | SQ              | PR | 1 |\n",
       "| 22 |  706 | 0 |  487 | 1 | 2 | 59 | 1 | Ipilimumab + Pembrolizumab | LN              | PR | 1 |\n",
       "| 23 |  506 | 0 |  506 | 0 | 2 | 51 | 1 | Ipilimumab + Pembrolizumab | Brain           | PR | 1 |\n",
       "| 24 | 1203 | 0 |  509 | 1 | 2 | 34 | 0 | Ipilimumab + Nivolumab     | LN              | PR | 1 |\n",
       "| 25 |  518 | 1 |  518 | 0 | 1 | 67 | 1 | Ipilimumab + Pembrolizumab | LN              | SD | 0 |\n",
       "| 26 |  544 | 0 |  544 | 0 | 3 | 75 | 0 | Ipilimumab + Pembrolizumab | LN              | CR | 1 |\n",
       "| 27 |  546 | 0 |  546 | 0 | 3 | 49 | 0 | Ipilimumab + Pembrolizumab | Abdomen         | CR | 1 |\n",
       "| 28 |  553 | 0 |  553 | 0 | 3 | 33 | 0 | Ipilimumab + Pembrolizumab | LN              | CR | 1 |\n",
       "| 29 |  567 | 0 |  567 | 0 | 3 | 66 | 1 | Ipilimumab + Pembrolizumab | LN              | CR | 1 |\n",
       "| 30 |  573 | 0 |  573 | 0 | 2 | 56 | 0 | Ipilimumab + Pembrolizumab | Small intestine | PR | 1 |\n",
       "| 31 |  588 | 0 |  588 | 0 | 3 | 45 | 0 | Ipilimumab + Pembrolizumab | Lung            | CR | 1 |\n",
       "| 32 |  597 | 0 |  597 | 0 | 3 | 71 | 0 | Ipilimumab + Pembrolizumab | LN              | CR | 1 |\n",
       "| 33 |  609 | 0 |  609 | 0 | 2 | 73 | 0 | Ipilimumab + Pembrolizumab | SQ              | PR | 1 |\n",
       "| 34 |  623 | 0 |  623 | 0 | 3 | 51 | 0 | Ipilimumab + Pembrolizumab | Lung            | CR | 1 |\n",
       "| 35 |  627 | 0 |  627 | 0 | 3 | 72 | 0 | Ipilimumab + Pembrolizumab | SQ              | CR | 1 |\n",
       "| 36 |  637 | 0 |  637 | 0 | 3 | 74 | 1 | Ipilimumab + Pembrolizumab | SQ              | CR | 1 |\n",
       "| 37 |  637 | 0 |  637 | 0 | 2 | 76 | 0 | Ipilimumab + Pembrolizumab | LN              | PR | 1 |\n",
       "| 38 |  650 | 0 |  650 | 0 | 3 | 59 | 1 | Ipilimumab + Pembrolizumab | SQ              | CR | 1 |\n",
       "| 39 |  657 | 0 |  657 | 0 | 3 | 33 | 0 | Ipilimumab + Nivolumab     | LN              | CR | 1 |\n",
       "| 40 |  671 | 0 |  671 | 0 | 2 | 81 | 0 | Ipilimumab + Pembrolizumab | SQ              | PR | 1 |\n",
       "| 41 |  672 | 0 |  672 | 0 | 2 | 57 | 1 | Ipilimumab + Pembrolizumab | SQ              | PR | 1 |\n",
       "| 42 |  692 | 0 |  692 | 0 | 2 | 71 | 0 | Ipilimumab + Pembrolizumab | Lung            | PR | 1 |\n",
       "| 43 |  693 | 0 |  693 | 0 | 3 | 53 | 1 | Ipilimumab + Pembrolizumab | SQ              | CR | 1 |\n",
       "| 44 |  695 | 0 |  695 | 0 | 2 | 68 | 0 | Ipilimumab + Pembrolizumab | SQ              | PR | 1 |\n",
       "| 45 |  721 | 0 |  721 | 0 | 3 | 70 | 0 | Ipilimumab + Pembrolizumab | Mucosa          | CR | 1 |\n",
       "| 46 |  721 | 0 |  721 | 0 | 3 | 54 | 1 | Ipilimumab + Pembrolizumab | Lung            | CR | 1 |\n",
       "| 47 |  732 | 0 |  732 | 0 | 2 | 24 | 1 | Ipilimumab + Pembrolizumab | SQ              | PR | 1 |\n",
       "| 48 |  737 | 0 |  737 | 0 | 2 | 72 | 0 | Ipilimumab + Pembrolizumab | SQ              | PR | 1 |\n",
       "| 49 |  775 | 0 |  775 | 0 | 3 | 36 | 0 | Ipilimumab + Pembrolizumab | LN              | CR | 1 |\n",
       "| 50 |  904 | 0 |  904 | 0 | 2 | 68 | 0 | Ipilimumab + Pembrolizumab | LN              | PR | 1 |\n",
       "| 51 | 1379 | 0 | 1379 | 0 | 2 | 64 | 0 | Ipilimumab + Pembrolizumab | Liver           | PR | 1 |\n",
       "\n"
      ],
      "text/plain": [
       "   X  OS   OS.Event PFS  PFS.Event RECIST Age Gender Treatment                 \n",
       "1   1  689 0          15 1         0      42  1      Ipilimumab + Pembrolizumab\n",
       "2   2  530 0          34 1         0      41  0      Ipilimumab + Pembrolizumab\n",
       "3   3  300 0          37 1         0      58  1      Ipilimumab + Nivolumab    \n",
       "4   4  129 0          39 1         0      48  0      Ipilimumab + Nivolumab    \n",
       "5   5   93 1          40 1         0      49  1      Ipilimumab + Pembrolizumab\n",
       "6   6  108 1          41 1         0      75  0      Ipilimumab + Nivolumab    \n",
       "7   7  169 0          81 1         2      59  0      Ipilimumab + Nivolumab    \n",
       "8   8  637 0          81 1         0      55  0      Ipilimumab + Pembrolizumab\n",
       "9   9  156 1          81 1         0      56  0      Ipilimumab + Pembrolizumab\n",
       "10 10  176 1          81 1         0      51  0      Ipilimumab + Pembrolizumab\n",
       "11 11  221 0          82 1         0      62  0      Ipilimumab + Nivolumab    \n",
       "12 12  293 0          82 1         0      55  1      Ipilimumab + Nivolumab    \n",
       "13 13  357 1         108 1         2      68  1      Ipilimumab + Nivolumab    \n",
       "14 14  691 0         123 1         1      47  1      Ipilimumab + Pembrolizumab\n",
       "15 15  660 1         152 1         1      57  0      Ipilimumab + Pembrolizumab\n",
       "16 16  558 0         168 1         2      39  1      Ipilimumab + Pembrolizumab\n",
       "17 17  196 0         196 0         2      48  1      Ipilimumab + Nivolumab    \n",
       "18 18  278 0         278 0         2      58  0      Ipilimumab + Pembrolizumab\n",
       "19 19  635 0         301 1         1      56  0      Ipilimumab + Pembrolizumab\n",
       "20 20  538 0         386 1         1      57  0      Ipilimumab + Pembrolizumab\n",
       "21 21  410 0         410 0         2      63  0      Ipilimumab + Nivolumab    \n",
       "22 22  706 0         487 1         2      59  1      Ipilimumab + Pembrolizumab\n",
       "23 23  506 0         506 0         2      51  1      Ipilimumab + Pembrolizumab\n",
       "24 24 1203 0         509 1         2      34  0      Ipilimumab + Nivolumab    \n",
       "25 25  518 1         518 0         1      67  1      Ipilimumab + Pembrolizumab\n",
       "26 26  544 0         544 0         3      75  0      Ipilimumab + Pembrolizumab\n",
       "27 27  546 0         546 0         3      49  0      Ipilimumab + Pembrolizumab\n",
       "28 28  553 0         553 0         3      33  0      Ipilimumab + Pembrolizumab\n",
       "29 29  567 0         567 0         3      66  1      Ipilimumab + Pembrolizumab\n",
       "30 30  573 0         573 0         2      56  0      Ipilimumab + Pembrolizumab\n",
       "31 31  588 0         588 0         3      45  0      Ipilimumab + Pembrolizumab\n",
       "32 32  597 0         597 0         3      71  0      Ipilimumab + Pembrolizumab\n",
       "33 33  609 0         609 0         2      73  0      Ipilimumab + Pembrolizumab\n",
       "34 34  623 0         623 0         3      51  0      Ipilimumab + Pembrolizumab\n",
       "35 35  627 0         627 0         3      72  0      Ipilimumab + Pembrolizumab\n",
       "36 36  637 0         637 0         3      74  1      Ipilimumab + Pembrolizumab\n",
       "37 37  637 0         637 0         2      76  0      Ipilimumab + Pembrolizumab\n",
       "38 38  650 0         650 0         3      59  1      Ipilimumab + Pembrolizumab\n",
       "39 39  657 0         657 0         3      33  0      Ipilimumab + Nivolumab    \n",
       "40 40  671 0         671 0         2      81  0      Ipilimumab + Pembrolizumab\n",
       "41 41  672 0         672 0         2      57  1      Ipilimumab + Pembrolizumab\n",
       "42 42  692 0         692 0         2      71  0      Ipilimumab + Pembrolizumab\n",
       "43 43  693 0         693 0         3      53  1      Ipilimumab + Pembrolizumab\n",
       "44 44  695 0         695 0         2      68  0      Ipilimumab + Pembrolizumab\n",
       "45 45  721 0         721 0         3      70  0      Ipilimumab + Pembrolizumab\n",
       "46 46  721 0         721 0         3      54  1      Ipilimumab + Pembrolizumab\n",
       "47 47  732 0         732 0         2      24  1      Ipilimumab + Pembrolizumab\n",
       "48 48  737 0         737 0         2      72  0      Ipilimumab + Pembrolizumab\n",
       "49 49  775 0         775 0         3      36  0      Ipilimumab + Pembrolizumab\n",
       "50 50  904 0         904 0         2      68  0      Ipilimumab + Pembrolizumab\n",
       "51 51 1379 0        1379 0         2      64  0      Ipilimumab + Pembrolizumab\n",
       "   Site            Best.RECIST.response Response\n",
       "1  SQ              PD                   0       \n",
       "2  LN              PD                   0       \n",
       "3  Lung            PD                   0       \n",
       "4  SQ              PD                   0       \n",
       "5  LN              PD                   0       \n",
       "6  LN              PD                   0       \n",
       "7  SQ              PR                   1       \n",
       "8  LN              PD                   0       \n",
       "9  LN              PD                   0       \n",
       "10 LN              PD                   0       \n",
       "11 LN              PD                   0       \n",
       "12 Lung            PD                   0       \n",
       "13 SQ              PR                   1       \n",
       "14 SQ              SD                   0       \n",
       "15 SQ              SD                   0       \n",
       "16 LN              PR                   1       \n",
       "17 LN              PR                   1       \n",
       "18 Lung            PR                   1       \n",
       "19 SQ              SD                   0       \n",
       "20 LN              SD                   0       \n",
       "21 SQ              PR                   1       \n",
       "22 LN              PR                   1       \n",
       "23 Brain           PR                   1       \n",
       "24 LN              PR                   1       \n",
       "25 LN              SD                   0       \n",
       "26 LN              CR                   1       \n",
       "27 Abdomen         CR                   1       \n",
       "28 LN              CR                   1       \n",
       "29 LN              CR                   1       \n",
       "30 Small intestine PR                   1       \n",
       "31 Lung            CR                   1       \n",
       "32 LN              CR                   1       \n",
       "33 SQ              PR                   1       \n",
       "34 Lung            CR                   1       \n",
       "35 SQ              CR                   1       \n",
       "36 SQ              CR                   1       \n",
       "37 LN              PR                   1       \n",
       "38 SQ              CR                   1       \n",
       "39 LN              CR                   1       \n",
       "40 SQ              PR                   1       \n",
       "41 SQ              PR                   1       \n",
       "42 Lung            PR                   1       \n",
       "43 SQ              CR                   1       \n",
       "44 SQ              PR                   1       \n",
       "45 Mucosa          CR                   1       \n",
       "46 Lung            CR                   1       \n",
       "47 SQ              PR                   1       \n",
       "48 SQ              PR                   1       \n",
       "49 LN              CR                   1       \n",
       "50 LN              PR                   1       \n",
       "51 Liver           PR                   1       "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "pni_clinical"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "4a92588c",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table>\n",
       "<caption>A data.frame: 51 Ã— 11</caption>\n",
       "<thead>\n",
       "\t<tr><th></th><th scope=col>OS</th><th scope=col>OS.Event</th><th scope=col>PFS</th><th scope=col>PFS.Event</th><th scope=col>RECIST</th><th scope=col>Age</th><th scope=col>Gender</th><th scope=col>Treatment</th><th scope=col>Site</th><th scope=col>Best.RECIST.response</th><th scope=col>Response</th></tr>\n",
       "\t<tr><th></th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;int&gt;</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><th scope=row>1</th><td> 689</td><td>0</td><td>  15</td><td>1</td><td>0</td><td>42</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>2</th><td> 530</td><td>0</td><td>  34</td><td>1</td><td>0</td><td>41</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>3</th><td> 300</td><td>0</td><td>  37</td><td>1</td><td>0</td><td>58</td><td>1</td><td>Ipilimumab + Nivolumab    </td><td>Lung           </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>4</th><td> 129</td><td>0</td><td>  39</td><td>1</td><td>0</td><td>48</td><td>0</td><td>Ipilimumab + Nivolumab    </td><td>SQ             </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>5</th><td>  93</td><td>1</td><td>  40</td><td>1</td><td>0</td><td>49</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>6</th><td> 108</td><td>1</td><td>  41</td><td>1</td><td>0</td><td>75</td><td>0</td><td>Ipilimumab + Nivolumab    </td><td>LN             </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>7</th><td> 169</td><td>0</td><td>  81</td><td>1</td><td>2</td><td>59</td><td>0</td><td>Ipilimumab + Nivolumab    </td><td>SQ             </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>8</th><td> 637</td><td>0</td><td>  81</td><td>1</td><td>0</td><td>55</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>9</th><td> 156</td><td>1</td><td>  81</td><td>1</td><td>0</td><td>56</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>10</th><td> 176</td><td>1</td><td>  81</td><td>1</td><td>0</td><td>51</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>11</th><td> 221</td><td>0</td><td>  82</td><td>1</td><td>0</td><td>62</td><td>0</td><td>Ipilimumab + Nivolumab    </td><td>LN             </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>12</th><td> 293</td><td>0</td><td>  82</td><td>1</td><td>0</td><td>55</td><td>1</td><td>Ipilimumab + Nivolumab    </td><td>Lung           </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>13</th><td> 357</td><td>1</td><td> 108</td><td>1</td><td>2</td><td>68</td><td>1</td><td>Ipilimumab + Nivolumab    </td><td>SQ             </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>14</th><td> 691</td><td>0</td><td> 123</td><td>1</td><td>1</td><td>47</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>SD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>15</th><td> 660</td><td>1</td><td> 152</td><td>1</td><td>1</td><td>57</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>SD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>16</th><td> 558</td><td>0</td><td> 168</td><td>1</td><td>2</td><td>39</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>17</th><td> 196</td><td>0</td><td> 196</td><td>0</td><td>2</td><td>48</td><td>1</td><td>Ipilimumab + Nivolumab    </td><td>LN             </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>18</th><td> 278</td><td>0</td><td> 278</td><td>0</td><td>2</td><td>58</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Lung           </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>19</th><td> 635</td><td>0</td><td> 301</td><td>1</td><td>1</td><td>56</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>SD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>20</th><td> 538</td><td>0</td><td> 386</td><td>1</td><td>1</td><td>57</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>SD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>21</th><td> 410</td><td>0</td><td> 410</td><td>0</td><td>2</td><td>63</td><td>0</td><td>Ipilimumab + Nivolumab    </td><td>SQ             </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>22</th><td> 706</td><td>0</td><td> 487</td><td>1</td><td>2</td><td>59</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>23</th><td> 506</td><td>0</td><td> 506</td><td>0</td><td>2</td><td>51</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>Brain          </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>24</th><td>1203</td><td>0</td><td> 509</td><td>1</td><td>2</td><td>34</td><td>0</td><td>Ipilimumab + Nivolumab    </td><td>LN             </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>25</th><td> 518</td><td>1</td><td> 518</td><td>0</td><td>1</td><td>67</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>SD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>26</th><td> 544</td><td>0</td><td> 544</td><td>0</td><td>3</td><td>75</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>27</th><td> 546</td><td>0</td><td> 546</td><td>0</td><td>3</td><td>49</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Abdomen        </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>28</th><td> 553</td><td>0</td><td> 553</td><td>0</td><td>3</td><td>33</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>29</th><td> 567</td><td>0</td><td> 567</td><td>0</td><td>3</td><td>66</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>30</th><td> 573</td><td>0</td><td> 573</td><td>0</td><td>2</td><td>56</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Small intestine</td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>31</th><td> 588</td><td>0</td><td> 588</td><td>0</td><td>3</td><td>45</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Lung           </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>32</th><td> 597</td><td>0</td><td> 597</td><td>0</td><td>3</td><td>71</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>33</th><td> 609</td><td>0</td><td> 609</td><td>0</td><td>2</td><td>73</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>34</th><td> 623</td><td>0</td><td> 623</td><td>0</td><td>3</td><td>51</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Lung           </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>35</th><td> 627</td><td>0</td><td> 627</td><td>0</td><td>3</td><td>72</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>36</th><td> 637</td><td>0</td><td> 637</td><td>0</td><td>3</td><td>74</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>37</th><td> 637</td><td>0</td><td> 637</td><td>0</td><td>2</td><td>76</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>38</th><td> 650</td><td>0</td><td> 650</td><td>0</td><td>3</td><td>59</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>39</th><td> 657</td><td>0</td><td> 657</td><td>0</td><td>3</td><td>33</td><td>0</td><td>Ipilimumab + Nivolumab    </td><td>LN             </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>40</th><td> 671</td><td>0</td><td> 671</td><td>0</td><td>2</td><td>81</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>41</th><td> 672</td><td>0</td><td> 672</td><td>0</td><td>2</td><td>57</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>42</th><td> 692</td><td>0</td><td> 692</td><td>0</td><td>2</td><td>71</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Lung           </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>43</th><td> 693</td><td>0</td><td> 693</td><td>0</td><td>3</td><td>53</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>44</th><td> 695</td><td>0</td><td> 695</td><td>0</td><td>2</td><td>68</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>45</th><td> 721</td><td>0</td><td> 721</td><td>0</td><td>3</td><td>70</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Mucosa         </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>46</th><td> 721</td><td>0</td><td> 721</td><td>0</td><td>3</td><td>54</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>Lung           </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>47</th><td> 732</td><td>0</td><td> 732</td><td>0</td><td>2</td><td>24</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>48</th><td> 737</td><td>0</td><td> 737</td><td>0</td><td>2</td><td>72</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>49</th><td> 775</td><td>0</td><td> 775</td><td>0</td><td>3</td><td>36</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>50</th><td> 904</td><td>0</td><td> 904</td><td>0</td><td>2</td><td>68</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>51</th><td>1379</td><td>0</td><td>1379</td><td>0</td><td>2</td><td>64</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Liver          </td><td>PR</td><td>1</td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A data.frame: 51 Ã— 11\n",
       "\\begin{tabular}{r|lllllllllll}\n",
       "  & OS & OS.Event & PFS & PFS.Event & RECIST & Age & Gender & Treatment & Site & Best.RECIST.response & Response\\\\\n",
       "  & <int> & <int> & <int> & <int> & <int> & <int> & <int> & <fct> & <fct> & <fct> & <int>\\\\\n",
       "\\hline\n",
       "\t1 &  689 & 0 &   15 & 1 & 0 & 42 & 1 & Ipilimumab + Pembrolizumab & SQ              & PD & 0\\\\\n",
       "\t2 &  530 & 0 &   34 & 1 & 0 & 41 & 0 & Ipilimumab + Pembrolizumab & LN              & PD & 0\\\\\n",
       "\t3 &  300 & 0 &   37 & 1 & 0 & 58 & 1 & Ipilimumab + Nivolumab     & Lung            & PD & 0\\\\\n",
       "\t4 &  129 & 0 &   39 & 1 & 0 & 48 & 0 & Ipilimumab + Nivolumab     & SQ              & PD & 0\\\\\n",
       "\t5 &   93 & 1 &   40 & 1 & 0 & 49 & 1 & Ipilimumab + Pembrolizumab & LN              & PD & 0\\\\\n",
       "\t6 &  108 & 1 &   41 & 1 & 0 & 75 & 0 & Ipilimumab + Nivolumab     & LN              & PD & 0\\\\\n",
       "\t7 &  169 & 0 &   81 & 1 & 2 & 59 & 0 & Ipilimumab + Nivolumab     & SQ              & PR & 1\\\\\n",
       "\t8 &  637 & 0 &   81 & 1 & 0 & 55 & 0 & Ipilimumab + Pembrolizumab & LN              & PD & 0\\\\\n",
       "\t9 &  156 & 1 &   81 & 1 & 0 & 56 & 0 & Ipilimumab + Pembrolizumab & LN              & PD & 0\\\\\n",
       "\t10 &  176 & 1 &   81 & 1 & 0 & 51 & 0 & Ipilimumab + Pembrolizumab & LN              & PD & 0\\\\\n",
       "\t11 &  221 & 0 &   82 & 1 & 0 & 62 & 0 & Ipilimumab + Nivolumab     & LN              & PD & 0\\\\\n",
       "\t12 &  293 & 0 &   82 & 1 & 0 & 55 & 1 & Ipilimumab + Nivolumab     & Lung            & PD & 0\\\\\n",
       "\t13 &  357 & 1 &  108 & 1 & 2 & 68 & 1 & Ipilimumab + Nivolumab     & SQ              & PR & 1\\\\\n",
       "\t14 &  691 & 0 &  123 & 1 & 1 & 47 & 1 & Ipilimumab + Pembrolizumab & SQ              & SD & 0\\\\\n",
       "\t15 &  660 & 1 &  152 & 1 & 1 & 57 & 0 & Ipilimumab + Pembrolizumab & SQ              & SD & 0\\\\\n",
       "\t16 &  558 & 0 &  168 & 1 & 2 & 39 & 1 & Ipilimumab + Pembrolizumab & LN              & PR & 1\\\\\n",
       "\t17 &  196 & 0 &  196 & 0 & 2 & 48 & 1 & Ipilimumab + Nivolumab     & LN              & PR & 1\\\\\n",
       "\t18 &  278 & 0 &  278 & 0 & 2 & 58 & 0 & Ipilimumab + Pembrolizumab & Lung            & PR & 1\\\\\n",
       "\t19 &  635 & 0 &  301 & 1 & 1 & 56 & 0 & Ipilimumab + Pembrolizumab & SQ              & SD & 0\\\\\n",
       "\t20 &  538 & 0 &  386 & 1 & 1 & 57 & 0 & Ipilimumab + Pembrolizumab & LN              & SD & 0\\\\\n",
       "\t21 &  410 & 0 &  410 & 0 & 2 & 63 & 0 & Ipilimumab + Nivolumab     & SQ              & PR & 1\\\\\n",
       "\t22 &  706 & 0 &  487 & 1 & 2 & 59 & 1 & Ipilimumab + Pembrolizumab & LN              & PR & 1\\\\\n",
       "\t23 &  506 & 0 &  506 & 0 & 2 & 51 & 1 & Ipilimumab + Pembrolizumab & Brain           & PR & 1\\\\\n",
       "\t24 & 1203 & 0 &  509 & 1 & 2 & 34 & 0 & Ipilimumab + Nivolumab     & LN              & PR & 1\\\\\n",
       "\t25 &  518 & 1 &  518 & 0 & 1 & 67 & 1 & Ipilimumab + Pembrolizumab & LN              & SD & 0\\\\\n",
       "\t26 &  544 & 0 &  544 & 0 & 3 & 75 & 0 & Ipilimumab + Pembrolizumab & LN              & CR & 1\\\\\n",
       "\t27 &  546 & 0 &  546 & 0 & 3 & 49 & 0 & Ipilimumab + Pembrolizumab & Abdomen         & CR & 1\\\\\n",
       "\t28 &  553 & 0 &  553 & 0 & 3 & 33 & 0 & Ipilimumab + Pembrolizumab & LN              & CR & 1\\\\\n",
       "\t29 &  567 & 0 &  567 & 0 & 3 & 66 & 1 & Ipilimumab + Pembrolizumab & LN              & CR & 1\\\\\n",
       "\t30 &  573 & 0 &  573 & 0 & 2 & 56 & 0 & Ipilimumab + Pembrolizumab & Small intestine & PR & 1\\\\\n",
       "\t31 &  588 & 0 &  588 & 0 & 3 & 45 & 0 & Ipilimumab + Pembrolizumab & Lung            & CR & 1\\\\\n",
       "\t32 &  597 & 0 &  597 & 0 & 3 & 71 & 0 & Ipilimumab + Pembrolizumab & LN              & CR & 1\\\\\n",
       "\t33 &  609 & 0 &  609 & 0 & 2 & 73 & 0 & Ipilimumab + Pembrolizumab & SQ              & PR & 1\\\\\n",
       "\t34 &  623 & 0 &  623 & 0 & 3 & 51 & 0 & Ipilimumab + Pembrolizumab & Lung            & CR & 1\\\\\n",
       "\t35 &  627 & 0 &  627 & 0 & 3 & 72 & 0 & Ipilimumab + Pembrolizumab & SQ              & CR & 1\\\\\n",
       "\t36 &  637 & 0 &  637 & 0 & 3 & 74 & 1 & Ipilimumab + Pembrolizumab & SQ              & CR & 1\\\\\n",
       "\t37 &  637 & 0 &  637 & 0 & 2 & 76 & 0 & Ipilimumab + Pembrolizumab & LN              & PR & 1\\\\\n",
       "\t38 &  650 & 0 &  650 & 0 & 3 & 59 & 1 & Ipilimumab + Pembrolizumab & SQ              & CR & 1\\\\\n",
       "\t39 &  657 & 0 &  657 & 0 & 3 & 33 & 0 & Ipilimumab + Nivolumab     & LN              & CR & 1\\\\\n",
       "\t40 &  671 & 0 &  671 & 0 & 2 & 81 & 0 & Ipilimumab + Pembrolizumab & SQ              & PR & 1\\\\\n",
       "\t41 &  672 & 0 &  672 & 0 & 2 & 57 & 1 & Ipilimumab + Pembrolizumab & SQ              & PR & 1\\\\\n",
       "\t42 &  692 & 0 &  692 & 0 & 2 & 71 & 0 & Ipilimumab + Pembrolizumab & Lung            & PR & 1\\\\\n",
       "\t43 &  693 & 0 &  693 & 0 & 3 & 53 & 1 & Ipilimumab + Pembrolizumab & SQ              & CR & 1\\\\\n",
       "\t44 &  695 & 0 &  695 & 0 & 2 & 68 & 0 & Ipilimumab + Pembrolizumab & SQ              & PR & 1\\\\\n",
       "\t45 &  721 & 0 &  721 & 0 & 3 & 70 & 0 & Ipilimumab + Pembrolizumab & Mucosa          & CR & 1\\\\\n",
       "\t46 &  721 & 0 &  721 & 0 & 3 & 54 & 1 & Ipilimumab + Pembrolizumab & Lung            & CR & 1\\\\\n",
       "\t47 &  732 & 0 &  732 & 0 & 2 & 24 & 1 & Ipilimumab + Pembrolizumab & SQ              & PR & 1\\\\\n",
       "\t48 &  737 & 0 &  737 & 0 & 2 & 72 & 0 & Ipilimumab + Pembrolizumab & SQ              & PR & 1\\\\\n",
       "\t49 &  775 & 0 &  775 & 0 & 3 & 36 & 0 & Ipilimumab + Pembrolizumab & LN              & CR & 1\\\\\n",
       "\t50 &  904 & 0 &  904 & 0 & 2 & 68 & 0 & Ipilimumab + Pembrolizumab & LN              & PR & 1\\\\\n",
       "\t51 & 1379 & 0 & 1379 & 0 & 2 & 64 & 0 & Ipilimumab + Pembrolizumab & Liver           & PR & 1\\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A data.frame: 51 Ã— 11\n",
       "\n",
       "| <!--/--> | OS &lt;int&gt; | OS.Event &lt;int&gt; | PFS &lt;int&gt; | PFS.Event &lt;int&gt; | RECIST &lt;int&gt; | Age &lt;int&gt; | Gender &lt;int&gt; | Treatment &lt;fct&gt; | Site &lt;fct&gt; | Best.RECIST.response &lt;fct&gt; | Response &lt;int&gt; |\n",
       "|---|---|---|---|---|---|---|---|---|---|---|---|\n",
       "| 1 |  689 | 0 |   15 | 1 | 0 | 42 | 1 | Ipilimumab + Pembrolizumab | SQ              | PD | 0 |\n",
       "| 2 |  530 | 0 |   34 | 1 | 0 | 41 | 0 | Ipilimumab + Pembrolizumab | LN              | PD | 0 |\n",
       "| 3 |  300 | 0 |   37 | 1 | 0 | 58 | 1 | Ipilimumab + Nivolumab     | Lung            | PD | 0 |\n",
       "| 4 |  129 | 0 |   39 | 1 | 0 | 48 | 0 | Ipilimumab + Nivolumab     | SQ              | PD | 0 |\n",
       "| 5 |   93 | 1 |   40 | 1 | 0 | 49 | 1 | Ipilimumab + Pembrolizumab | LN              | PD | 0 |\n",
       "| 6 |  108 | 1 |   41 | 1 | 0 | 75 | 0 | Ipilimumab + Nivolumab     | LN              | PD | 0 |\n",
       "| 7 |  169 | 0 |   81 | 1 | 2 | 59 | 0 | Ipilimumab + Nivolumab     | SQ              | PR | 1 |\n",
       "| 8 |  637 | 0 |   81 | 1 | 0 | 55 | 0 | Ipilimumab + Pembrolizumab | LN              | PD | 0 |\n",
       "| 9 |  156 | 1 |   81 | 1 | 0 | 56 | 0 | Ipilimumab + Pembrolizumab | LN              | PD | 0 |\n",
       "| 10 |  176 | 1 |   81 | 1 | 0 | 51 | 0 | Ipilimumab + Pembrolizumab | LN              | PD | 0 |\n",
       "| 11 |  221 | 0 |   82 | 1 | 0 | 62 | 0 | Ipilimumab + Nivolumab     | LN              | PD | 0 |\n",
       "| 12 |  293 | 0 |   82 | 1 | 0 | 55 | 1 | Ipilimumab + Nivolumab     | Lung            | PD | 0 |\n",
       "| 13 |  357 | 1 |  108 | 1 | 2 | 68 | 1 | Ipilimumab + Nivolumab     | SQ              | PR | 1 |\n",
       "| 14 |  691 | 0 |  123 | 1 | 1 | 47 | 1 | Ipilimumab + Pembrolizumab | SQ              | SD | 0 |\n",
       "| 15 |  660 | 1 |  152 | 1 | 1 | 57 | 0 | Ipilimumab + Pembrolizumab | SQ              | SD | 0 |\n",
       "| 16 |  558 | 0 |  168 | 1 | 2 | 39 | 1 | Ipilimumab + Pembrolizumab | LN              | PR | 1 |\n",
       "| 17 |  196 | 0 |  196 | 0 | 2 | 48 | 1 | Ipilimumab + Nivolumab     | LN              | PR | 1 |\n",
       "| 18 |  278 | 0 |  278 | 0 | 2 | 58 | 0 | Ipilimumab + Pembrolizumab | Lung            | PR | 1 |\n",
       "| 19 |  635 | 0 |  301 | 1 | 1 | 56 | 0 | Ipilimumab + Pembrolizumab | SQ              | SD | 0 |\n",
       "| 20 |  538 | 0 |  386 | 1 | 1 | 57 | 0 | Ipilimumab + Pembrolizumab | LN              | SD | 0 |\n",
       "| 21 |  410 | 0 |  410 | 0 | 2 | 63 | 0 | Ipilimumab + Nivolumab     | SQ              | PR | 1 |\n",
       "| 22 |  706 | 0 |  487 | 1 | 2 | 59 | 1 | Ipilimumab + Pembrolizumab | LN              | PR | 1 |\n",
       "| 23 |  506 | 0 |  506 | 0 | 2 | 51 | 1 | Ipilimumab + Pembrolizumab | Brain           | PR | 1 |\n",
       "| 24 | 1203 | 0 |  509 | 1 | 2 | 34 | 0 | Ipilimumab + Nivolumab     | LN              | PR | 1 |\n",
       "| 25 |  518 | 1 |  518 | 0 | 1 | 67 | 1 | Ipilimumab + Pembrolizumab | LN              | SD | 0 |\n",
       "| 26 |  544 | 0 |  544 | 0 | 3 | 75 | 0 | Ipilimumab + Pembrolizumab | LN              | CR | 1 |\n",
       "| 27 |  546 | 0 |  546 | 0 | 3 | 49 | 0 | Ipilimumab + Pembrolizumab | Abdomen         | CR | 1 |\n",
       "| 28 |  553 | 0 |  553 | 0 | 3 | 33 | 0 | Ipilimumab + Pembrolizumab | LN              | CR | 1 |\n",
       "| 29 |  567 | 0 |  567 | 0 | 3 | 66 | 1 | Ipilimumab + Pembrolizumab | LN              | CR | 1 |\n",
       "| 30 |  573 | 0 |  573 | 0 | 2 | 56 | 0 | Ipilimumab + Pembrolizumab | Small intestine | PR | 1 |\n",
       "| 31 |  588 | 0 |  588 | 0 | 3 | 45 | 0 | Ipilimumab + Pembrolizumab | Lung            | CR | 1 |\n",
       "| 32 |  597 | 0 |  597 | 0 | 3 | 71 | 0 | Ipilimumab + Pembrolizumab | LN              | CR | 1 |\n",
       "| 33 |  609 | 0 |  609 | 0 | 2 | 73 | 0 | Ipilimumab + Pembrolizumab | SQ              | PR | 1 |\n",
       "| 34 |  623 | 0 |  623 | 0 | 3 | 51 | 0 | Ipilimumab + Pembrolizumab | Lung            | CR | 1 |\n",
       "| 35 |  627 | 0 |  627 | 0 | 3 | 72 | 0 | Ipilimumab + Pembrolizumab | SQ              | CR | 1 |\n",
       "| 36 |  637 | 0 |  637 | 0 | 3 | 74 | 1 | Ipilimumab + Pembrolizumab | SQ              | CR | 1 |\n",
       "| 37 |  637 | 0 |  637 | 0 | 2 | 76 | 0 | Ipilimumab + Pembrolizumab | LN              | PR | 1 |\n",
       "| 38 |  650 | 0 |  650 | 0 | 3 | 59 | 1 | Ipilimumab + Pembrolizumab | SQ              | CR | 1 |\n",
       "| 39 |  657 | 0 |  657 | 0 | 3 | 33 | 0 | Ipilimumab + Nivolumab     | LN              | CR | 1 |\n",
       "| 40 |  671 | 0 |  671 | 0 | 2 | 81 | 0 | Ipilimumab + Pembrolizumab | SQ              | PR | 1 |\n",
       "| 41 |  672 | 0 |  672 | 0 | 2 | 57 | 1 | Ipilimumab + Pembrolizumab | SQ              | PR | 1 |\n",
       "| 42 |  692 | 0 |  692 | 0 | 2 | 71 | 0 | Ipilimumab + Pembrolizumab | Lung            | PR | 1 |\n",
       "| 43 |  693 | 0 |  693 | 0 | 3 | 53 | 1 | Ipilimumab + Pembrolizumab | SQ              | CR | 1 |\n",
       "| 44 |  695 | 0 |  695 | 0 | 2 | 68 | 0 | Ipilimumab + Pembrolizumab | SQ              | PR | 1 |\n",
       "| 45 |  721 | 0 |  721 | 0 | 3 | 70 | 0 | Ipilimumab + Pembrolizumab | Mucosa          | CR | 1 |\n",
       "| 46 |  721 | 0 |  721 | 0 | 3 | 54 | 1 | Ipilimumab + Pembrolizumab | Lung            | CR | 1 |\n",
       "| 47 |  732 | 0 |  732 | 0 | 2 | 24 | 1 | Ipilimumab + Pembrolizumab | SQ              | PR | 1 |\n",
       "| 48 |  737 | 0 |  737 | 0 | 2 | 72 | 0 | Ipilimumab + Pembrolizumab | SQ              | PR | 1 |\n",
       "| 49 |  775 | 0 |  775 | 0 | 3 | 36 | 0 | Ipilimumab + Pembrolizumab | LN              | CR | 1 |\n",
       "| 50 |  904 | 0 |  904 | 0 | 2 | 68 | 0 | Ipilimumab + Pembrolizumab | LN              | PR | 1 |\n",
       "| 51 | 1379 | 0 | 1379 | 0 | 2 | 64 | 0 | Ipilimumab + Pembrolizumab | Liver           | PR | 1 |\n",
       "\n"
      ],
      "text/plain": [
       "   OS   OS.Event PFS  PFS.Event RECIST Age Gender Treatment                 \n",
       "1   689 0          15 1         0      42  1      Ipilimumab + Pembrolizumab\n",
       "2   530 0          34 1         0      41  0      Ipilimumab + Pembrolizumab\n",
       "3   300 0          37 1         0      58  1      Ipilimumab + Nivolumab    \n",
       "4   129 0          39 1         0      48  0      Ipilimumab + Nivolumab    \n",
       "5    93 1          40 1         0      49  1      Ipilimumab + Pembrolizumab\n",
       "6   108 1          41 1         0      75  0      Ipilimumab + Nivolumab    \n",
       "7   169 0          81 1         2      59  0      Ipilimumab + Nivolumab    \n",
       "8   637 0          81 1         0      55  0      Ipilimumab + Pembrolizumab\n",
       "9   156 1          81 1         0      56  0      Ipilimumab + Pembrolizumab\n",
       "10  176 1          81 1         0      51  0      Ipilimumab + Pembrolizumab\n",
       "11  221 0          82 1         0      62  0      Ipilimumab + Nivolumab    \n",
       "12  293 0          82 1         0      55  1      Ipilimumab + Nivolumab    \n",
       "13  357 1         108 1         2      68  1      Ipilimumab + Nivolumab    \n",
       "14  691 0         123 1         1      47  1      Ipilimumab + Pembrolizumab\n",
       "15  660 1         152 1         1      57  0      Ipilimumab + Pembrolizumab\n",
       "16  558 0         168 1         2      39  1      Ipilimumab + Pembrolizumab\n",
       "17  196 0         196 0         2      48  1      Ipilimumab + Nivolumab    \n",
       "18  278 0         278 0         2      58  0      Ipilimumab + Pembrolizumab\n",
       "19  635 0         301 1         1      56  0      Ipilimumab + Pembrolizumab\n",
       "20  538 0         386 1         1      57  0      Ipilimumab + Pembrolizumab\n",
       "21  410 0         410 0         2      63  0      Ipilimumab + Nivolumab    \n",
       "22  706 0         487 1         2      59  1      Ipilimumab + Pembrolizumab\n",
       "23  506 0         506 0         2      51  1      Ipilimumab + Pembrolizumab\n",
       "24 1203 0         509 1         2      34  0      Ipilimumab + Nivolumab    \n",
       "25  518 1         518 0         1      67  1      Ipilimumab + Pembrolizumab\n",
       "26  544 0         544 0         3      75  0      Ipilimumab + Pembrolizumab\n",
       "27  546 0         546 0         3      49  0      Ipilimumab + Pembrolizumab\n",
       "28  553 0         553 0         3      33  0      Ipilimumab + Pembrolizumab\n",
       "29  567 0         567 0         3      66  1      Ipilimumab + Pembrolizumab\n",
       "30  573 0         573 0         2      56  0      Ipilimumab + Pembrolizumab\n",
       "31  588 0         588 0         3      45  0      Ipilimumab + Pembrolizumab\n",
       "32  597 0         597 0         3      71  0      Ipilimumab + Pembrolizumab\n",
       "33  609 0         609 0         2      73  0      Ipilimumab + Pembrolizumab\n",
       "34  623 0         623 0         3      51  0      Ipilimumab + Pembrolizumab\n",
       "35  627 0         627 0         3      72  0      Ipilimumab + Pembrolizumab\n",
       "36  637 0         637 0         3      74  1      Ipilimumab + Pembrolizumab\n",
       "37  637 0         637 0         2      76  0      Ipilimumab + Pembrolizumab\n",
       "38  650 0         650 0         3      59  1      Ipilimumab + Pembrolizumab\n",
       "39  657 0         657 0         3      33  0      Ipilimumab + Nivolumab    \n",
       "40  671 0         671 0         2      81  0      Ipilimumab + Pembrolizumab\n",
       "41  672 0         672 0         2      57  1      Ipilimumab + Pembrolizumab\n",
       "42  692 0         692 0         2      71  0      Ipilimumab + Pembrolizumab\n",
       "43  693 0         693 0         3      53  1      Ipilimumab + Pembrolizumab\n",
       "44  695 0         695 0         2      68  0      Ipilimumab + Pembrolizumab\n",
       "45  721 0         721 0         3      70  0      Ipilimumab + Pembrolizumab\n",
       "46  721 0         721 0         3      54  1      Ipilimumab + Pembrolizumab\n",
       "47  732 0         732 0         2      24  1      Ipilimumab + Pembrolizumab\n",
       "48  737 0         737 0         2      72  0      Ipilimumab + Pembrolizumab\n",
       "49  775 0         775 0         3      36  0      Ipilimumab + Pembrolizumab\n",
       "50  904 0         904 0         2      68  0      Ipilimumab + Pembrolizumab\n",
       "51 1379 0        1379 0         2      64  0      Ipilimumab + Pembrolizumab\n",
       "   Site            Best.RECIST.response Response\n",
       "1  SQ              PD                   0       \n",
       "2  LN              PD                   0       \n",
       "3  Lung            PD                   0       \n",
       "4  SQ              PD                   0       \n",
       "5  LN              PD                   0       \n",
       "6  LN              PD                   0       \n",
       "7  SQ              PR                   1       \n",
       "8  LN              PD                   0       \n",
       "9  LN              PD                   0       \n",
       "10 LN              PD                   0       \n",
       "11 LN              PD                   0       \n",
       "12 Lung            PD                   0       \n",
       "13 SQ              PR                   1       \n",
       "14 SQ              SD                   0       \n",
       "15 SQ              SD                   0       \n",
       "16 LN              PR                   1       \n",
       "17 LN              PR                   1       \n",
       "18 Lung            PR                   1       \n",
       "19 SQ              SD                   0       \n",
       "20 LN              SD                   0       \n",
       "21 SQ              PR                   1       \n",
       "22 LN              PR                   1       \n",
       "23 Brain           PR                   1       \n",
       "24 LN              PR                   1       \n",
       "25 LN              SD                   0       \n",
       "26 LN              CR                   1       \n",
       "27 Abdomen         CR                   1       \n",
       "28 LN              CR                   1       \n",
       "29 LN              CR                   1       \n",
       "30 Small intestine PR                   1       \n",
       "31 Lung            CR                   1       \n",
       "32 LN              CR                   1       \n",
       "33 SQ              PR                   1       \n",
       "34 Lung            CR                   1       \n",
       "35 SQ              CR                   1       \n",
       "36 SQ              CR                   1       \n",
       "37 LN              PR                   1       \n",
       "38 SQ              CR                   1       \n",
       "39 LN              CR                   1       \n",
       "40 SQ              PR                   1       \n",
       "41 SQ              PR                   1       \n",
       "42 Lung            PR                   1       \n",
       "43 SQ              CR                   1       \n",
       "44 SQ              PR                   1       \n",
       "45 Mucosa          CR                   1       \n",
       "46 Lung            CR                   1       \n",
       "47 SQ              PR                   1       \n",
       "48 SQ              PR                   1       \n",
       "49 LN              CR                   1       \n",
       "50 LN              PR                   1       \n",
       "51 Liver           PR                   1       "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "row.names(pni_clinical) <- pni_clinical$X\n",
    "pni_clinical <- pni_clinical[, -1]\n",
    "pni_clinical"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "1f512ae2",
   "metadata": {},
   "source": [
    "### Self Subtract"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "ea964f4a",
   "metadata": {},
   "outputs": [],
   "source": [
    "pni_self_subtract <- read.csv(\"Gide2019_PD1+CTLA4_Melanoma_RNASeq/ICB.Gide2019_Pembrolizumab-Nivolumab+Ipilimumab_Melanoma.self_subtract\", sep=\"\\t\", check.names = FALSE, row.names = 1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "d5c8e1ff",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table>\n",
       "<caption>A data.frame: 18780 Ã— 32</caption>\n",
       "<thead>\n",
       "\t<tr><th></th><th scope=col>36</th><th scope=col>26</th><th scope=col>19</th><th scope=col>7</th><th scope=col>44</th><th scope=col>12</th><th scope=col>49</th><th scope=col>35</th><th scope=col>13</th><th scope=col>10</th><th scope=col>â‹¯</th><th scope=col>27</th><th scope=col>45</th><th scope=col>37</th><th scope=col>50</th><th scope=col>21</th><th scope=col>17</th><th scope=col>15</th><th scope=col>23</th><th scope=col>34</th><th scope=col>32</th></tr>\n",
       "\t<tr><th></th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>â‹¯</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><th scope=row>1</th><td> 0.02207971</td><td> 0.36939855</td><td> 0.01444574</td><td> 0.316403660</td><td>-0.9679687344</td><td>-1.07111293</td><td> 1.121695219</td><td> 0.475150825</td><td>-1.209204816</td><td>-0.61833240</td><td>â‹¯</td><td> 0.41001548</td><td> 0.56281081</td><td>-0.404080959</td><td>-0.09683531</td><td> 0.07795682</td><td> 0.53014756</td><td> 0.844647025</td><td>-0.134897783</td><td> 0.50874883</td><td>-0.15193508</td></tr>\n",
       "\t<tr><th scope=row>503538</th><td>-0.39934403</td><td> 0.49379652</td><td> 0.30317249</td><td>-0.235838135</td><td>-0.3717351375</td><td>-0.44326685</td><td> 0.006291004</td><td> 0.339123809</td><td>-0.541433333</td><td> 0.01471473</td><td>â‹¯</td><td> 0.52472946</td><td> 0.20896041</td><td>-0.078336393</td><td> 0.28806367</td><td>-0.19962044</td><td>-0.65357875</td><td> 0.408755426</td><td>-0.916067934</td><td>-0.15391097</td><td>-0.10178292</td></tr>\n",
       "\t<tr><th scope=row>2</th><td> 1.31004461</td><td>-2.05553544</td><td>-0.68074489</td><td>-0.030216264</td><td> 0.5225906718</td><td> 2.31713808</td><td> 1.456297873</td><td>-0.665860393</td><td>-0.019892875</td><td>-0.70065194</td><td>â‹¯</td><td> 1.21509583</td><td>-0.44592739</td><td> 0.053971450</td><td>-1.33779511</td><td> 0.91527044</td><td> 0.50604193</td><td>-0.245655206</td><td>-0.687799180</td><td> 1.39761539</td><td>-2.91035093</td></tr>\n",
       "\t<tr><th scope=row>144571</th><td> 0.28266209</td><td>-0.13408502</td><td> 0.09653197</td><td>-0.395291281</td><td> 0.2905811363</td><td> 0.10786869</td><td> 1.013609213</td><td>-0.093081711</td><td> 0.654085858</td><td>-0.36349872</td><td>â‹¯</td><td> 0.34009902</td><td>-0.13785662</td><td> 0.298329396</td><td>-0.31798891</td><td> 0.21741237</td><td>-0.12240057</td><td>-0.581928186</td><td>-0.648592702</td><td>-0.88460073</td><td> 2.14689483</td></tr>\n",
       "\t<tr><th scope=row>144568</th><td>-0.21165347</td><td>-0.23288261</td><td>-0.22800050</td><td>-0.237359796</td><td> 1.3954592948</td><td>-0.23199857</td><td> 0.002645532</td><td> 1.333911644</td><td>-0.225330893</td><td>-0.23735980</td><td>â‹¯</td><td>-0.21934878</td><td>-0.21692891</td><td>-0.237359796</td><td>-0.23735980</td><td>-0.23735980</td><td>-0.13673470</td><td> 1.177814024</td><td>-0.005646842</td><td>-0.06694260</td><td>-0.23735980</td></tr>\n",
       "\t<tr><th scope=row>53947</th><td>-0.20174329</td><td>-0.17725880</td><td>-0.12162473</td><td>-0.417878450</td><td> 1.2496034714</td><td> 0.63256619</td><td> 0.948400783</td><td> 0.015965002</td><td>-0.876077033</td><td> 0.49662548</td><td>â‹¯</td><td>-0.17836320</td><td> 0.51738358</td><td>-0.443095914</td><td> 0.17021327</td><td>-0.33249362</td><td>-0.10290469</td><td>-0.426662879</td><td>-0.778098432</td><td> 0.36754271</td><td>-0.50179098</td></tr>\n",
       "\t<tr><th scope=row>8086</th><td> 0.27101637</td><td> 0.12710253</td><td>-0.03935541</td><td>-0.957904849</td><td>-0.0984823825</td><td>-0.06593464</td><td>-0.201537844</td><td>-0.019883185</td><td>-0.346078741</td><td>-0.49421422</td><td>â‹¯</td><td>-0.24621711</td><td> 0.06665660</td><td> 0.046360254</td><td>-0.14301866</td><td>-0.57249323</td><td> 0.50947306</td><td> 0.577894297</td><td> 0.127102527</td><td> 0.37857683</td><td>-0.29167394</td></tr>\n",
       "\t<tr><th scope=row>65985</th><td> 0.35830600</td><td>-0.56364047</td><td>-0.27866488</td><td>-0.269379893</td><td> 0.4585162860</td><td>-0.69375733</td><td> 0.833486730</td><td> 0.391613692</td><td> 0.000386568</td><td> 1.18470918</td><td>â‹¯</td><td>-0.61963981</td><td>-0.40027635</td><td>-0.512799468</td><td>-0.07653565</td><td>-0.82674049</td><td> 0.59438443</td><td> 0.196602903</td><td>-0.371793764</td><td>-0.46038391</td><td>-0.70080812</td></tr>\n",
       "\t<tr><th scope=row>13</th><td>-0.17851692</td><td>-0.27782151</td><td>-0.24476760</td><td> 0.255566934</td><td>-0.2028786308</td><td> 0.95305094</td><td> 0.984990581</td><td> 0.007535656</td><td>-0.049628185</td><td>-0.30266465</td><td>â‹¯</td><td>-0.30266465</td><td>-0.29286117</td><td>-0.302664653</td><td>-0.21290145</td><td>-0.30221605</td><td> 0.17466136</td><td>-0.086528609</td><td> 0.233683066</td><td> 0.06160048</td><td>-0.27430590</td></tr>\n",
       "\t<tr><th scope=row>51166</th><td>-0.27117599</td><td> 0.54745043</td><td>-1.29409560</td><td> 0.365705763</td><td>-0.0845393945</td><td>-0.26277554</td><td>-0.176682218</td><td>-0.687497427</td><td>-0.983992317</td><td> 1.68367428</td><td>â‹¯</td><td>-0.73347481</td><td>-0.08721195</td><td> 0.153937049</td><td>-0.10080308</td><td> 0.94718541</td><td> 0.45424333</td><td>-0.080781519</td><td>-0.460277938</td><td>-1.57796916</td><td>-0.57448733</td></tr>\n",
       "\t<tr><th scope=row>195827</th><td>-0.77985660</td><td> 0.59333069</td><td>-0.28273074</td><td> 0.738627592</td><td>-0.0710368206</td><td> 0.32201075</td><td> 0.018074438</td><td>-0.209719976</td><td>-0.116849439</td><td>-1.66551214</td><td>â‹¯</td><td>-0.38340551</td><td> 0.01999654</td><td>-0.215550749</td><td>-0.05664716</td><td> 1.00056670</td><td> 1.65211601</td><td> 0.604318857</td><td>-0.445781787</td><td>-0.64032807</td><td> 0.97142098</td></tr>\n",
       "\t<tr><th scope=row>79719</th><td> 0.49797932</td><td>-0.31433680</td><td> 0.43068710</td><td>-0.200661492</td><td> 0.0689009864</td><td>-0.60521081</td><td> 0.400089008</td><td>-0.194474967</td><td> 0.426915663</td><td> 0.40963274</td><td>â‹¯</td><td> 0.13297377</td><td>-0.40617561</td><td> 0.222397759</td><td> 0.25820075</td><td>-0.22124877</td><td>-0.42028947</td><td> 0.771840637</td><td>-0.548539669</td><td>-0.44464181</td><td>-0.81239457</td></tr>\n",
       "\t<tr><th scope=row>22848</th><td> 0.11786066</td><td> 0.07461847</td><td>-0.75284884</td><td>-0.400474857</td><td> 0.1571324522</td><td> 0.37060547</td><td> 0.252537149</td><td>-0.348677409</td><td>-0.131050801</td><td>-0.46394573</td><td>â‹¯</td><td>-0.24071918</td><td> 0.55907181</td><td> 0.169113091</td><td> 0.39831088</td><td> 0.48747341</td><td>-0.28194137</td><td>-0.139581325</td><td>-0.632987209</td><td>-0.61763596</td><td> 0.13236627</td></tr>\n",
       "\t<tr><th scope=row>28971</th><td>-0.80783791</td><td> 0.16487612</td><td> 0.05425462</td><td>-0.007148987</td><td>-1.2280832996</td><td> 0.19117423</td><td> 0.330179227</td><td> 0.656983940</td><td>-0.048596345</td><td> 0.30912117</td><td>â‹¯</td><td>-0.13406401</td><td> 0.03353913</td><td> 0.121743688</td><td> 0.26792034</td><td>-0.45384589</td><td>-0.04184918</td><td> 1.045931122</td><td>-0.125502782</td><td>-0.10081843</td><td>-0.65537677</td></tr>\n",
       "\t<tr><th scope=row>14</th><td> 0.56155991</td><td> 0.40625931</td><td>-0.25463777</td><td>-0.668279321</td><td>-0.0003211111</td><td>-0.68856750</td><td> 0.301076053</td><td>-0.019939882</td><td> 0.362935613</td><td>-0.22390700</td><td>â‹¯</td><td> 0.66149884</td><td> 0.25990243</td><td> 0.239565954</td><td> 0.40472396</td><td>-0.57777526</td><td>-0.04119417</td><td> 0.326728387</td><td> 0.202824053</td><td> 0.17986536</td><td>-1.27793190</td></tr>\n",
       "\t<tr><th scope=row>25980</th><td> 0.46062340</td><td>-0.34842853</td><td> 0.75909384</td><td> 0.114309879</td><td>-0.1262416145</td><td>-0.87175674</td><td> 0.477847801</td><td>-0.101035416</td><td> 0.468756091</td><td> 0.91878426</td><td>â‹¯</td><td> 0.89911132</td><td> 0.01760844</td><td> 0.002114438</td><td> 0.06208155</td><td>-0.88950808</td><td>-0.60202869</td><td> 0.869248872</td><td>-0.248164679</td><td>-0.51028527</td><td>-1.24746975</td></tr>\n",
       "\t<tr><th scope=row>441376</th><td>-0.08761253</td><td>-0.42379401</td><td>-0.37623194</td><td>-0.298795461</td><td>-0.4237940130</td><td> 0.18142316</td><td>-0.423794013</td><td>-0.048902719</td><td>-0.139289427</td><td>-0.42379401</td><td>â‹¯</td><td>-0.42379401</td><td>-0.36806678</td><td>-0.423794013</td><td> 0.31468868</td><td> 0.15504126</td><td> 2.19837135</td><td>-0.423794013</td><td>-0.423794013</td><td>-0.29551276</td><td>-0.08484930</td></tr>\n",
       "\t<tr><th scope=row>16</th><td>-0.26041291</td><td>-0.73418685</td><td> 0.53675093</td><td>-0.731130153</td><td> 0.2515506241</td><td>-0.42970774</td><td>-0.314009220</td><td> 0.239018534</td><td>-0.566988783</td><td>-0.61392828</td><td>â‹¯</td><td> 0.01239516</td><td> 0.13642365</td><td> 0.582612286</td><td> 0.71406991</td><td>-0.22469959</td><td>-0.70040197</td><td> 0.629494689</td><td> 0.959250726</td><td>-0.55692466</td><td>-0.88930128</td></tr>\n",
       "\t<tr><th scope=row>57505</th><td>-0.67989773</td><td> 0.71788009</td><td> 1.44109571</td><td>-0.080880257</td><td>-1.1704450955</td><td>-1.12052878</td><td> 0.304528505</td><td> 0.290185364</td><td>-0.178302553</td><td> 0.23058904</td><td>â‹¯</td><td>-0.46620276</td><td> 0.07045982</td><td>-0.268643908</td><td>-0.31731923</td><td>-0.38380968</td><td>-0.72578157</td><td> 0.275779920</td><td> 0.007205364</td><td> 1.42682008</td><td>-0.45322791</td></tr>\n",
       "\t<tr><th scope=row>80755</th><td> 0.56662472</td><td> 0.20456306</td><td> 0.52982798</td><td>-0.948498986</td><td>-0.2328836172</td><td>-1.01593797</td><td> 0.676331199</td><td> 0.025929684</td><td>-0.015551511</td><td>-0.48190870</td><td>â‹¯</td><td> 0.38620060</td><td>-0.17520963</td><td>-0.034471880</td><td> 0.20682546</td><td> 0.22783938</td><td>-0.63131328</td><td> 0.101147324</td><td>-0.175523506</td><td>-0.35160431</td><td>-0.16351672</td></tr>\n",
       "\t<tr><th scope=row>132949</th><td> 0.04666709</td><td>-0.51685028</td><td> 0.57314858</td><td> 0.252866918</td><td> 0.9219149045</td><td>-0.14750111</td><td> 0.008273773</td><td>-0.354295910</td><td>-0.468248650</td><td> 1.12450233</td><td>â‹¯</td><td> 0.46125608</td><td>-1.16516003</td><td>-0.122944663</td><td>-0.22843993</td><td>-0.93798320</td><td>-0.94662104</td><td> 2.960583846</td><td>-0.415552259</td><td>-0.18049176</td><td>-0.11060645</td></tr>\n",
       "\t<tr><th scope=row>60496</th><td>-1.04384916</td><td> 0.47830669</td><td>-0.10781073</td><td> 0.627294430</td><td>-0.9443698151</td><td>-0.20656249</td><td>-1.447627430</td><td>-0.635972151</td><td>-0.813942587</td><td>-0.30351542</td><td>â‹¯</td><td>-0.15001615</td><td>-0.48741332</td><td>-0.764905026</td><td>-0.94913318</td><td> 0.23441955</td><td> 0.50415037</td><td>-0.024640740</td><td> 0.867782801</td><td> 1.01564139</td><td>-0.50311937</td></tr>\n",
       "\t<tr><th scope=row>10157</th><td> 0.22673049</td><td> 0.02039899</td><td>-0.03313650</td><td>-1.611559104</td><td>-0.4222279431</td><td> 0.06619184</td><td>-1.073017967</td><td> 0.360057858</td><td> 0.088183064</td><td> 0.10562297</td><td>â‹¯</td><td>-0.04040087</td><td> 0.09155972</td><td>-0.725416873</td><td> 0.09209233</td><td>-0.38325458</td><td> 0.92546584</td><td>-0.356148312</td><td>-1.032546605</td><td> 0.28288690</td><td> 0.95538032</td></tr>\n",
       "\t<tr><th scope=row>26574</th><td> 0.32513626</td><td>-0.71064628</td><td> 0.57474138</td><td>-0.307859096</td><td>-0.1157644599</td><td>-0.90696552</td><td> 0.741722227</td><td> 0.115525095</td><td> 0.525127204</td><td>-0.02269603</td><td>â‹¯</td><td> 0.20510758</td><td>-0.14944834</td><td> 0.170449658</td><td> 0.42970776</td><td>-0.42352100</td><td>-0.35025961</td><td> 0.202482977</td><td>-0.208935643</td><td>-0.19650144</td><td>-0.88508592</td></tr>\n",
       "\t<tr><th scope=row>9625</th><td> 3.60898132</td><td>-0.84524935</td><td> 0.31257703</td><td> 1.691484290</td><td> 0.0125097794</td><td> 0.40020503</td><td> 0.846322791</td><td>-0.563722812</td><td>-0.421367303</td><td>-0.37741081</td><td>â‹¯</td><td> 0.02403999</td><td>-0.22568269</td><td>-0.643619983</td><td> 1.88205421</td><td>-0.80027603</td><td>-0.79644491</td><td> 1.298371192</td><td>-0.476999606</td><td> 0.13362286</td><td>-0.91172718</td></tr>\n",
       "\t<tr><th scope=row>18</th><td> 0.47449052</td><td>-0.51482861</td><td>-0.08855294</td><td>-0.963038667</td><td> 0.2553193875</td><td> 0.37397031</td><td>-0.694774261</td><td> 0.863512974</td><td> 0.599104197</td><td> 2.67146770</td><td>â‹¯</td><td>-0.11896869</td><td>-0.92173298</td><td> 0.648023325</td><td> 0.74306569</td><td> 0.06889974</td><td> 0.33279060</td><td>-1.103800435</td><td>-0.381884336</td><td>-1.16396909</td><td>-1.06332196</td></tr>\n",
       "\t<tr><th scope=row>19</th><td> 0.41546373</td><td> 0.08109892</td><td> 0.08602522</td><td>-0.004840843</td><td> 0.7078058559</td><td> 1.26404969</td><td>-0.427511343</td><td>-1.482748285</td><td>-0.696181189</td><td>-0.06458417</td><td>â‹¯</td><td> 0.22976258</td><td>-0.03133024</td><td> 0.632936139</td><td> 0.57053063</td><td>-0.08189527</td><td> 0.25661952</td><td>-0.524177121</td><td>-1.848173543</td><td> 0.71687019</td><td> 0.58731357</td></tr>\n",
       "\t<tr><th scope=row>10349</th><td>-0.50742249</td><td> 0.04290351</td><td> 0.60138091</td><td>-0.927208930</td><td>-0.6668527568</td><td> 1.61967255</td><td>-0.032507461</td><td> 0.914324720</td><td>-1.342999228</td><td>-0.17663893</td><td>â‹¯</td><td>-0.62589869</td><td>-0.81863690</td><td>-0.766357479</td><td>-0.28938889</td><td>-0.04469534</td><td>-0.57412553</td><td>-0.405181147</td><td>-1.755711771</td><td>-0.46663115</td><td>-0.09948639</td></tr>\n",
       "\t<tr><th scope=row>79963</th><td>-1.09871946</td><td> 0.48615484</td><td>-0.22090270</td><td>-0.228321221</td><td>-0.4222808996</td><td> 0.41920735</td><td>-0.400974687</td><td> 0.645256758</td><td>-1.092692381</td><td> 0.66469135</td><td>â‹¯</td><td>-0.15225939</td><td>-0.22946814</td><td>-0.008558539</td><td>-0.15615992</td><td> 0.52627577</td><td>-0.28912370</td><td> 0.008149144</td><td> 0.039477559</td><td> 0.45518284</td><td> 0.95346227</td></tr>\n",
       "\t<tr><th scope=row>26154</th><td>-0.36804763</td><td>-0.37874390</td><td>-0.29320773</td><td>-0.378743901</td><td> 1.2951447378</td><td>-0.37161444</td><td>-0.028227463</td><td> 2.638924429</td><td>-0.164492476</td><td> 0.10278166</td><td>â‹¯</td><td>-0.15810368</td><td>-0.37516392</td><td>-0.378743901</td><td>-0.23750015</td><td>-0.37650973</td><td>-0.37072166</td><td> 1.668581091</td><td>-0.218187538</td><td>-0.37606112</td><td>-0.37874390</td></tr>\n",
       "\t<tr><th scope=row>â‹®</th><td>â‹®</td><td>â‹®</td><td>â‹®</td><td>â‹®</td><td>â‹®</td><td>â‹®</td><td>â‹®</td><td>â‹®</td><td>â‹®</td><td>â‹®</td><td>â‹±</td><td>â‹®</td><td>â‹®</td><td>â‹®</td><td>â‹®</td><td>â‹®</td><td>â‹®</td><td>â‹®</td><td>â‹®</td><td>â‹®</td><td>â‹®</td></tr>\n",
       "\t<tr><th scope=row>342945</th><td>-0.06738728</td><td> 0.22307312</td><td> 0.056812029</td><td>-0.32551551</td><td>-0.11756152</td><td>-0.39842900</td><td>-0.06185009</td><td> 0.295370553</td><td>-0.034573759</td><td>-0.09391874</td><td>â‹¯</td><td>-0.104833874</td><td> 0.0789830727</td><td>-0.19024034</td><td> 0.06554628</td><td> 0.042405031</td><td>-0.03541245</td><td> 0.73451363</td><td> 0.28303949</td><td> 0.074671159</td><td>-0.262986827</td></tr>\n",
       "\t<tr><th scope=row>222696</th><td>-0.64881799</td><td>-0.78227877</td><td> 0.873485822</td><td>-1.07304830</td><td> 0.02625283</td><td>-0.01449303</td><td> 0.75284400</td><td> 0.289436376</td><td>-1.085860282</td><td>-1.05721611</td><td>â‹¯</td><td>-0.684481588</td><td>-0.2293771875</td><td>-0.72426880</td><td> 0.61944225</td><td> 1.329224079</td><td> 1.18560242</td><td> 0.13528489</td><td>-1.19121746</td><td> 0.416159043</td><td>-0.825154290</td></tr>\n",
       "\t<tr><th scope=row>221785</th><td> 0.29078478</td><td>-0.31493083</td><td> 0.599902756</td><td>-0.78878690</td><td>-0.90867364</td><td>-0.51898336</td><td> 0.13570131</td><td> 0.409446288</td><td>-0.637340889</td><td>-1.37948687</td><td>â‹¯</td><td> 0.165301677</td><td>-0.1770653416</td><td>-0.11729290</td><td>-0.17972412</td><td> 0.066222843</td><td> 0.62846703</td><td> 0.02671665</td><td> 0.48032970</td><td> 1.568978142</td><td>-0.467369389</td></tr>\n",
       "\t<tr><th scope=row>7741</th><td>-1.35500422</td><td> 0.73987162</td><td> 0.727950091</td><td> 0.44338877</td><td>-0.96928065</td><td> 0.01065774</td><td>-0.63283478</td><td> 0.058726096</td><td>-0.577334677</td><td> 0.86416063</td><td>â‹¯</td><td>-0.260105972</td><td> 0.0669740558</td><td>-0.28622020</td><td>-0.15996478</td><td> 0.523249135</td><td>-0.60984859</td><td>-0.22257846</td><td> 0.51790614</td><td> 1.199042844</td><td> 0.528596755</td></tr>\n",
       "\t<tr><th scope=row>146050</th><td>-0.18952771</td><td> 0.15541497</td><td> 0.468589177</td><td>-0.48089053</td><td>-0.40048375</td><td>-0.32627016</td><td>-0.17288547</td><td>-0.005024687</td><td>-0.002828181</td><td> 1.00703927</td><td>â‹¯</td><td> 0.037084696</td><td>-0.5998269449</td><td> 0.10593199</td><td>-0.26650265</td><td> 0.151094573</td><td>-0.39833543</td><td> 0.14627413</td><td>-0.08036012</td><td>-0.183474542</td><td>-0.287613243</td></tr>\n",
       "\t<tr><th scope=row>100101467</th><td>-1.23392320</td><td>-0.31396794</td><td>-0.406738489</td><td>-0.70732650</td><td>-0.42237568</td><td> 0.67420610</td><td>-1.89818737</td><td> 0.119016022</td><td>-1.131928408</td><td>-0.67472947</td><td>â‹¯</td><td>-1.041502131</td><td> 0.3057801131</td><td>-1.05158559</td><td> 0.12320090</td><td> 0.776823791</td><td> 1.12900218</td><td>-0.84748896</td><td> 0.76690701</td><td> 0.857210539</td><td> 0.688969184</td></tr>\n",
       "\t<tr><th scope=row>64288</th><td>-0.63391608</td><td>-0.79938418</td><td> 0.701345493</td><td>-0.17769917</td><td>-0.36281240</td><td> 1.09726680</td><td> 0.04967595</td><td> 0.632491905</td><td>-0.667296562</td><td> 1.18707021</td><td>â‹¯</td><td> 0.438984502</td><td> 0.5274614781</td><td> 0.32051797</td><td>-0.02793021</td><td>-0.747579020</td><td>-0.56504221</td><td> 0.41067112</td><td> 0.86166539</td><td> 1.305194452</td><td>-0.406043240</td></tr>\n",
       "\t<tr><th scope=row>54925</th><td>-0.17731612</td><td>-0.35204130</td><td> 0.102240822</td><td>-0.52758045</td><td>-0.40278098</td><td>-0.14868130</td><td> 0.09693914</td><td> 0.076161039</td><td>-0.171999152</td><td> 0.59047047</td><td>â‹¯</td><td>-0.008358507</td><td>-0.4524072714</td><td>-0.16986475</td><td>-0.14406371</td><td>-0.350141136</td><td> 0.24989487</td><td> 0.10502969</td><td> 0.84371340</td><td>-0.257445582</td><td>-0.231349766</td></tr>\n",
       "\t<tr><th scope=row>79149</th><td>-0.09341219</td><td>-0.23361444</td><td>-0.012420629</td><td>-0.17611090</td><td>-0.40303035</td><td>-0.08029009</td><td>-0.30285166</td><td>-0.248634781</td><td> 0.177474305</td><td> 0.60403101</td><td>â‹¯</td><td>-0.104324744</td><td> 0.4320254326</td><td> 0.64677035</td><td> 0.26582626</td><td>-0.381941568</td><td>-0.36031561</td><td> 0.44353157</td><td>-0.07201303</td><td>-0.341529079</td><td>-0.303601981</td></tr>\n",
       "\t<tr><th scope=row>7746</th><td>-0.82911884</td><td> 0.25724378</td><td> 0.611044299</td><td>-0.37846353</td><td>-0.78120710</td><td>-0.45949079</td><td> 0.10044855</td><td> 0.432152688</td><td>-0.690101255</td><td> 1.64129037</td><td>â‹¯</td><td> 0.313789705</td><td> 0.0642196942</td><td>-0.31365218</td><td> 0.11595008</td><td> 0.295624118</td><td>-0.02733395</td><td>-0.02991003</td><td>-0.12986269</td><td> 0.141537709</td><td> 0.289072689</td></tr>\n",
       "\t<tr><th scope=row>90204</th><td>-0.57628329</td><td> 0.29424788</td><td>-0.080423689</td><td> 0.48981582</td><td>-0.82961441</td><td>-0.41047321</td><td> 0.16082499</td><td>-0.319394868</td><td>-0.088091568</td><td> 0.70775603</td><td>â‹¯</td><td> 0.207165527</td><td>-0.3161638070</td><td>-0.09191130</td><td> 0.04321212</td><td> 0.234567670</td><td>-0.10930172</td><td> 0.31839563</td><td> 0.52723083</td><td>-0.250318350</td><td>-0.058405510</td></tr>\n",
       "\t<tr><th scope=row>140831</th><td>-0.10865092</td><td>-0.04968098</td><td>-0.228834966</td><td>-0.27989994</td><td>-0.31119849</td><td>-0.09417891</td><td>-0.05364741</td><td>-0.117780642</td><td>-0.130384785</td><td> 0.21099894</td><td>â‹¯</td><td>-0.082798713</td><td>-0.0250849141</td><td>-0.08791917</td><td> 0.09762790</td><td> 0.150667063</td><td> 0.01352765</td><td> 0.17423614</td><td> 0.63538207</td><td> 0.130425590</td><td> 0.057133464</td></tr>\n",
       "\t<tr><th scope=row>65249</th><td>-0.31093770</td><td>-0.10462758</td><td>-0.071795268</td><td> 0.47046613</td><td> 0.48132730</td><td>-0.41079358</td><td>-0.65455483</td><td>-0.242563205</td><td>-0.746319797</td><td> 0.51845273</td><td>â‹¯</td><td> 0.040745861</td><td>-0.3207680305</td><td>-0.20890297</td><td> 0.29902682</td><td> 0.043011201</td><td> 0.63356178</td><td> 0.12632883</td><td> 0.22340880</td><td> 1.186349306</td><td>-0.460522686</td></tr>\n",
       "\t<tr><th scope=row>57643</th><td> 0.08906239</td><td>-0.33661134</td><td>-0.285473003</td><td>-0.51184333</td><td> 0.73010598</td><td> 0.06687714</td><td>-0.05579481</td><td>-0.114751841</td><td> 1.162620098</td><td>-0.04053377</td><td>â‹¯</td><td> 0.646442700</td><td>-0.4041607330</td><td>-0.42057300</td><td>-0.43117742</td><td>-0.587895416</td><td>-0.09822088</td><td>-0.68013720</td><td>-0.42665048</td><td> 0.480719433</td><td>-0.534976999</td></tr>\n",
       "\t<tr><th scope=row>57688</th><td> 0.25097250</td><td>-0.19576322</td><td>-0.051295448</td><td>-0.45963970</td><td> 0.78423338</td><td>-0.53290552</td><td>-0.12483556</td><td> 0.759970760</td><td> 0.793365263</td><td> 0.57702926</td><td>â‹¯</td><td> 0.508247388</td><td>-0.3163794667</td><td> 0.13041877</td><td> 0.61104754</td><td> 0.067794381</td><td>-0.43397318</td><td> 0.03590784</td><td> 0.02205099</td><td>-0.700488597</td><td>-0.465451820</td></tr>\n",
       "\t<tr><th scope=row>125150</th><td>-0.71034766</td><td>-0.04673484</td><td>-0.008407714</td><td> 0.23523953</td><td>-0.50263675</td><td>-0.22642199</td><td>-0.71603039</td><td> 0.392523766</td><td> 0.282615580</td><td>-0.53713084</td><td>â‹¯</td><td> 0.293565902</td><td>-0.4012750092</td><td>-0.49602970</td><td>-0.62909866</td><td>-0.349480025</td><td> 1.27328563</td><td> 1.53141429</td><td>-0.14398185</td><td>-0.001833785</td><td>-0.325687813</td></tr>\n",
       "\t<tr><th scope=row>23053</th><td>-0.24836838</td><td> 0.69448423</td><td>-0.363755100</td><td> 0.10966341</td><td>-0.11320148</td><td> 0.41428274</td><td>-0.51550697</td><td>-0.080894641</td><td> 0.082133502</td><td>-0.76319584</td><td>â‹¯</td><td>-0.292052772</td><td> 1.0704226931</td><td>-0.03271785</td><td> 0.45097641</td><td>-0.086864206</td><td> 0.38212822</td><td>-0.57909518</td><td>-1.10373494</td><td> 0.094320651</td><td> 0.080271987</td></tr>\n",
       "\t<tr><th scope=row>100507331</th><td>-0.11936992</td><td> 0.14567118</td><td> 0.038331165</td><td>-0.11936992</td><td> 0.48221246</td><td>-0.11400870</td><td>-0.11936992</td><td> 0.159699991</td><td>-0.006716149</td><td>-0.11936992</td><td>â‹¯</td><td>-0.025406186</td><td>-0.0989390329</td><td>-0.03258464</td><td> 0.18147031</td><td>-0.119369924</td><td>-0.11936992</td><td> 0.07702330</td><td> 0.09514177</td><td>-0.119369924</td><td>-0.119369924</td></tr>\n",
       "\t<tr><th scope=row>221302</th><td> 0.23716312</td><td>-0.22049439</td><td> 0.164318863</td><td>-0.28415268</td><td> 0.20568352</td><td>-0.72205206</td><td>-0.14894922</td><td> 0.394013252</td><td> 0.460304807</td><td>-0.42601126</td><td>â‹¯</td><td> 0.167630424</td><td>-0.4062481772</td><td> 0.22824109</td><td> 0.70563831</td><td>-0.090649064</td><td>-0.85519296</td><td> 0.16246605</td><td> 0.96827871</td><td>-1.022146067</td><td> 0.670878172</td></tr>\n",
       "\t<tr><th scope=row>9183</th><td>-0.32887167</td><td>-0.20082769</td><td> 0.455712201</td><td>-0.57247184</td><td>-0.08610647</td><td>-0.48571814</td><td>-0.06369578</td><td> 0.504081784</td><td> 0.136045250</td><td> 0.91063613</td><td>â‹¯</td><td> 0.243505506</td><td>-0.4439087932</td><td> 0.03013266</td><td> 0.08423296</td><td>-0.018914051</td><td>-0.13432189</td><td> 0.53900488</td><td>-0.21405222</td><td>-0.538250246</td><td>-0.015166293</td></tr>\n",
       "\t<tr><th scope=row>55055</th><td>-0.23155487</td><td> 0.46212792</td><td>-0.990153661</td><td> 0.71531472</td><td> 0.20677370</td><td>-1.11556081</td><td> 0.38706633</td><td>-0.468675161</td><td>-0.209928304</td><td> 0.46482463</td><td>â‹¯</td><td>-0.605366439</td><td>-0.4412846494</td><td> 0.25503931</td><td> 0.31496113</td><td> 0.262799951</td><td> 0.39724886</td><td>-0.03329266</td><td> 0.41080232</td><td>-0.766047908</td><td> 0.008691614</td></tr>\n",
       "\t<tr><th scope=row>11130</th><td> 0.42826173</td><td> 0.57497284</td><td>-0.668849952</td><td> 0.32665483</td><td>-0.42747899</td><td>-2.62608070</td><td> 0.80556102</td><td> 0.381913246</td><td> 0.812508915</td><td> 0.30872910</td><td>â‹¯</td><td> 0.351439294</td><td>-0.9000318013</td><td> 0.97348718</td><td> 1.37143617</td><td> 0.640111663</td><td>-0.54785782</td><td> 1.11436707</td><td>-0.35400995</td><td>-1.695316744</td><td>-0.394695493</td></tr>\n",
       "\t<tr><th scope=row>7789</th><td> 0.17136963</td><td>-0.59890304</td><td> 0.755074459</td><td> 0.27464873</td><td>-0.06521667</td><td> 0.33662516</td><td>-0.04602627</td><td>-0.133536302</td><td> 0.044225248</td><td>-0.66759771</td><td>â‹¯</td><td> 0.328510667</td><td>-0.5599443165</td><td> 0.37727755</td><td> 0.08818719</td><td> 0.240113319</td><td>-0.22319036</td><td> 0.13554354</td><td>-0.38289902</td><td>-0.143425114</td><td>-0.734985177</td></tr>\n",
       "\t<tr><th scope=row>158586</th><td> 0.43681965</td><td>-0.44415190</td><td> 0.457020340</td><td>-0.37869573</td><td>-0.31779465</td><td>-0.09917793</td><td> 0.15027246</td><td> 0.446774536</td><td> 0.069298676</td><td> 0.56592965</td><td>â‹¯</td><td> 0.357462377</td><td>-0.5646742600</td><td> 0.11511414</td><td> 0.27088915</td><td>-0.111782930</td><td>-0.51547930</td><td> 0.25877652</td><td> 0.26529255</td><td>-0.171242002</td><td>-0.431495671</td></tr>\n",
       "\t<tr><th scope=row>79364</th><td>-0.04349335</td><td> 0.74411930</td><td>-0.097860826</td><td>-0.20007843</td><td>-0.63084343</td><td> 0.56529909</td><td>-0.67849788</td><td>-0.190789794</td><td>-0.329499666</td><td>-0.46066913</td><td>â‹¯</td><td>-0.140778229</td><td>-0.0005595549</td><td>-0.50095875</td><td>-0.28793686</td><td> 0.160131815</td><td> 0.13651835</td><td>-0.26315230</td><td> 0.06811924</td><td> 0.564314391</td><td> 0.553030834</td></tr>\n",
       "\t<tr><th scope=row>440590</th><td>-0.07010125</td><td> 0.06946522</td><td>-0.037910521</td><td>-0.09580757</td><td>-0.01279774</td><td>-0.06131873</td><td> 0.03818382</td><td>-0.014894504</td><td>-0.095807574</td><td> 0.55426201</td><td>â‹¯</td><td>-0.077796562</td><td>-0.0958075738</td><td>-0.05913173</td><td> 0.04543618</td><td> 0.001045315</td><td>-0.02594056</td><td>-0.05478135</td><td>-0.04695407</td><td>-0.068337272</td><td> 0.567570255</td></tr>\n",
       "\t<tr><th scope=row>79699</th><td>-0.77012086</td><td>-0.38604727</td><td>-0.196414999</td><td> 0.13778226</td><td> 0.16718252</td><td> 0.01378568</td><td> 0.16128751</td><td>-0.060919007</td><td>-0.019271522</td><td> 0.69282995</td><td>â‹¯</td><td> 0.071425738</td><td>-0.4277571728</td><td> 0.17357627</td><td> 0.33126353</td><td>-0.027790606</td><td> 0.18921212</td><td> 0.14859193</td><td>-0.03533289</td><td>-0.191640998</td><td>-0.170930205</td></tr>\n",
       "\t<tr><th scope=row>7791</th><td> 0.02624200</td><td>-0.89931187</td><td>-0.002663966</td><td> 0.70494792</td><td> 1.34419206</td><td> 0.63244321</td><td>-0.23837056</td><td>-0.292491200</td><td> 0.254432485</td><td> 0.53947147</td><td>â‹¯</td><td> 0.107125170</td><td> 0.0735204548</td><td> 0.33610451</td><td> 0.21013737</td><td>-0.079428025</td><td> 0.42419145</td><td>-0.33001021</td><td>-0.55516310</td><td> 0.736564406</td><td>-0.578044742</td></tr>\n",
       "\t<tr><th scope=row>23140</th><td>-0.29389081</td><td> 0.37238568</td><td> 0.142429270</td><td>-0.55133851</td><td>-0.03809493</td><td> 0.78257787</td><td>-0.13963415</td><td> 0.064831497</td><td>-0.036326222</td><td>-0.33190657</td><td>â‹¯</td><td>-0.014908065</td><td> 0.3206683458</td><td>-0.43932309</td><td>-0.54818555</td><td> 0.241345309</td><td> 0.10411358</td><td>-0.70105036</td><td>-0.54986056</td><td> 0.066472443</td><td> 1.003023165</td></tr>\n",
       "\t<tr><th scope=row>26009</th><td>-1.04418568</td><td>-0.43646272</td><td>-0.536034138</td><td> 0.40732392</td><td>-0.45864802</td><td>-0.20470475</td><td>-0.21243155</td><td> 0.367259701</td><td> 0.108939675</td><td> 0.11705793</td><td>â‹¯</td><td>-0.755442532</td><td>-0.2027674488</td><td>-0.15576478</td><td>-0.23738481</td><td> 0.227673130</td><td>-0.16324147</td><td> 1.23636907</td><td> 1.10751447</td><td>-0.166047613</td><td> 0.725873295</td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A data.frame: 18780 Ã— 32\n",
       "\\begin{tabular}{r|lllllllllllllllllllll}\n",
       "  & 36 & 26 & 19 & 7 & 44 & 12 & 49 & 35 & 13 & 10 & â‹¯ & 27 & 45 & 37 & 50 & 21 & 17 & 15 & 23 & 34 & 32\\\\\n",
       "  & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & â‹¯ & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl>\\\\\n",
       "\\hline\n",
       "\t1 &  0.02207971 &  0.36939855 &  0.01444574 &  0.316403660 & -0.9679687344 & -1.07111293 &  1.121695219 &  0.475150825 & -1.209204816 & -0.61833240 & â‹¯ &  0.41001548 &  0.56281081 & -0.404080959 & -0.09683531 &  0.07795682 &  0.53014756 &  0.844647025 & -0.134897783 &  0.50874883 & -0.15193508\\\\\n",
       "\t503538 & -0.39934403 &  0.49379652 &  0.30317249 & -0.235838135 & -0.3717351375 & -0.44326685 &  0.006291004 &  0.339123809 & -0.541433333 &  0.01471473 & â‹¯ &  0.52472946 &  0.20896041 & -0.078336393 &  0.28806367 & -0.19962044 & -0.65357875 &  0.408755426 & -0.916067934 & -0.15391097 & -0.10178292\\\\\n",
       "\t2 &  1.31004461 & -2.05553544 & -0.68074489 & -0.030216264 &  0.5225906718 &  2.31713808 &  1.456297873 & -0.665860393 & -0.019892875 & -0.70065194 & â‹¯ &  1.21509583 & -0.44592739 &  0.053971450 & -1.33779511 &  0.91527044 &  0.50604193 & -0.245655206 & -0.687799180 &  1.39761539 & -2.91035093\\\\\n",
       "\t144571 &  0.28266209 & -0.13408502 &  0.09653197 & -0.395291281 &  0.2905811363 &  0.10786869 &  1.013609213 & -0.093081711 &  0.654085858 & -0.36349872 & â‹¯ &  0.34009902 & -0.13785662 &  0.298329396 & -0.31798891 &  0.21741237 & -0.12240057 & -0.581928186 & -0.648592702 & -0.88460073 &  2.14689483\\\\\n",
       "\t144568 & -0.21165347 & -0.23288261 & -0.22800050 & -0.237359796 &  1.3954592948 & -0.23199857 &  0.002645532 &  1.333911644 & -0.225330893 & -0.23735980 & â‹¯ & -0.21934878 & -0.21692891 & -0.237359796 & -0.23735980 & -0.23735980 & -0.13673470 &  1.177814024 & -0.005646842 & -0.06694260 & -0.23735980\\\\\n",
       "\t53947 & -0.20174329 & -0.17725880 & -0.12162473 & -0.417878450 &  1.2496034714 &  0.63256619 &  0.948400783 &  0.015965002 & -0.876077033 &  0.49662548 & â‹¯ & -0.17836320 &  0.51738358 & -0.443095914 &  0.17021327 & -0.33249362 & -0.10290469 & -0.426662879 & -0.778098432 &  0.36754271 & -0.50179098\\\\\n",
       "\t8086 &  0.27101637 &  0.12710253 & -0.03935541 & -0.957904849 & -0.0984823825 & -0.06593464 & -0.201537844 & -0.019883185 & -0.346078741 & -0.49421422 & â‹¯ & -0.24621711 &  0.06665660 &  0.046360254 & -0.14301866 & -0.57249323 &  0.50947306 &  0.577894297 &  0.127102527 &  0.37857683 & -0.29167394\\\\\n",
       "\t65985 &  0.35830600 & -0.56364047 & -0.27866488 & -0.269379893 &  0.4585162860 & -0.69375733 &  0.833486730 &  0.391613692 &  0.000386568 &  1.18470918 & â‹¯ & -0.61963981 & -0.40027635 & -0.512799468 & -0.07653565 & -0.82674049 &  0.59438443 &  0.196602903 & -0.371793764 & -0.46038391 & -0.70080812\\\\\n",
       "\t13 & -0.17851692 & -0.27782151 & -0.24476760 &  0.255566934 & -0.2028786308 &  0.95305094 &  0.984990581 &  0.007535656 & -0.049628185 & -0.30266465 & â‹¯ & -0.30266465 & -0.29286117 & -0.302664653 & -0.21290145 & -0.30221605 &  0.17466136 & -0.086528609 &  0.233683066 &  0.06160048 & -0.27430590\\\\\n",
       "\t51166 & -0.27117599 &  0.54745043 & -1.29409560 &  0.365705763 & -0.0845393945 & -0.26277554 & -0.176682218 & -0.687497427 & -0.983992317 &  1.68367428 & â‹¯ & -0.73347481 & -0.08721195 &  0.153937049 & -0.10080308 &  0.94718541 &  0.45424333 & -0.080781519 & -0.460277938 & -1.57796916 & -0.57448733\\\\\n",
       "\t195827 & -0.77985660 &  0.59333069 & -0.28273074 &  0.738627592 & -0.0710368206 &  0.32201075 &  0.018074438 & -0.209719976 & -0.116849439 & -1.66551214 & â‹¯ & -0.38340551 &  0.01999654 & -0.215550749 & -0.05664716 &  1.00056670 &  1.65211601 &  0.604318857 & -0.445781787 & -0.64032807 &  0.97142098\\\\\n",
       "\t79719 &  0.49797932 & -0.31433680 &  0.43068710 & -0.200661492 &  0.0689009864 & -0.60521081 &  0.400089008 & -0.194474967 &  0.426915663 &  0.40963274 & â‹¯ &  0.13297377 & -0.40617561 &  0.222397759 &  0.25820075 & -0.22124877 & -0.42028947 &  0.771840637 & -0.548539669 & -0.44464181 & -0.81239457\\\\\n",
       "\t22848 &  0.11786066 &  0.07461847 & -0.75284884 & -0.400474857 &  0.1571324522 &  0.37060547 &  0.252537149 & -0.348677409 & -0.131050801 & -0.46394573 & â‹¯ & -0.24071918 &  0.55907181 &  0.169113091 &  0.39831088 &  0.48747341 & -0.28194137 & -0.139581325 & -0.632987209 & -0.61763596 &  0.13236627\\\\\n",
       "\t28971 & -0.80783791 &  0.16487612 &  0.05425462 & -0.007148987 & -1.2280832996 &  0.19117423 &  0.330179227 &  0.656983940 & -0.048596345 &  0.30912117 & â‹¯ & -0.13406401 &  0.03353913 &  0.121743688 &  0.26792034 & -0.45384589 & -0.04184918 &  1.045931122 & -0.125502782 & -0.10081843 & -0.65537677\\\\\n",
       "\t14 &  0.56155991 &  0.40625931 & -0.25463777 & -0.668279321 & -0.0003211111 & -0.68856750 &  0.301076053 & -0.019939882 &  0.362935613 & -0.22390700 & â‹¯ &  0.66149884 &  0.25990243 &  0.239565954 &  0.40472396 & -0.57777526 & -0.04119417 &  0.326728387 &  0.202824053 &  0.17986536 & -1.27793190\\\\\n",
       "\t25980 &  0.46062340 & -0.34842853 &  0.75909384 &  0.114309879 & -0.1262416145 & -0.87175674 &  0.477847801 & -0.101035416 &  0.468756091 &  0.91878426 & â‹¯ &  0.89911132 &  0.01760844 &  0.002114438 &  0.06208155 & -0.88950808 & -0.60202869 &  0.869248872 & -0.248164679 & -0.51028527 & -1.24746975\\\\\n",
       "\t441376 & -0.08761253 & -0.42379401 & -0.37623194 & -0.298795461 & -0.4237940130 &  0.18142316 & -0.423794013 & -0.048902719 & -0.139289427 & -0.42379401 & â‹¯ & -0.42379401 & -0.36806678 & -0.423794013 &  0.31468868 &  0.15504126 &  2.19837135 & -0.423794013 & -0.423794013 & -0.29551276 & -0.08484930\\\\\n",
       "\t16 & -0.26041291 & -0.73418685 &  0.53675093 & -0.731130153 &  0.2515506241 & -0.42970774 & -0.314009220 &  0.239018534 & -0.566988783 & -0.61392828 & â‹¯ &  0.01239516 &  0.13642365 &  0.582612286 &  0.71406991 & -0.22469959 & -0.70040197 &  0.629494689 &  0.959250726 & -0.55692466 & -0.88930128\\\\\n",
       "\t57505 & -0.67989773 &  0.71788009 &  1.44109571 & -0.080880257 & -1.1704450955 & -1.12052878 &  0.304528505 &  0.290185364 & -0.178302553 &  0.23058904 & â‹¯ & -0.46620276 &  0.07045982 & -0.268643908 & -0.31731923 & -0.38380968 & -0.72578157 &  0.275779920 &  0.007205364 &  1.42682008 & -0.45322791\\\\\n",
       "\t80755 &  0.56662472 &  0.20456306 &  0.52982798 & -0.948498986 & -0.2328836172 & -1.01593797 &  0.676331199 &  0.025929684 & -0.015551511 & -0.48190870 & â‹¯ &  0.38620060 & -0.17520963 & -0.034471880 &  0.20682546 &  0.22783938 & -0.63131328 &  0.101147324 & -0.175523506 & -0.35160431 & -0.16351672\\\\\n",
       "\t132949 &  0.04666709 & -0.51685028 &  0.57314858 &  0.252866918 &  0.9219149045 & -0.14750111 &  0.008273773 & -0.354295910 & -0.468248650 &  1.12450233 & â‹¯ &  0.46125608 & -1.16516003 & -0.122944663 & -0.22843993 & -0.93798320 & -0.94662104 &  2.960583846 & -0.415552259 & -0.18049176 & -0.11060645\\\\\n",
       "\t60496 & -1.04384916 &  0.47830669 & -0.10781073 &  0.627294430 & -0.9443698151 & -0.20656249 & -1.447627430 & -0.635972151 & -0.813942587 & -0.30351542 & â‹¯ & -0.15001615 & -0.48741332 & -0.764905026 & -0.94913318 &  0.23441955 &  0.50415037 & -0.024640740 &  0.867782801 &  1.01564139 & -0.50311937\\\\\n",
       "\t10157 &  0.22673049 &  0.02039899 & -0.03313650 & -1.611559104 & -0.4222279431 &  0.06619184 & -1.073017967 &  0.360057858 &  0.088183064 &  0.10562297 & â‹¯ & -0.04040087 &  0.09155972 & -0.725416873 &  0.09209233 & -0.38325458 &  0.92546584 & -0.356148312 & -1.032546605 &  0.28288690 &  0.95538032\\\\\n",
       "\t26574 &  0.32513626 & -0.71064628 &  0.57474138 & -0.307859096 & -0.1157644599 & -0.90696552 &  0.741722227 &  0.115525095 &  0.525127204 & -0.02269603 & â‹¯ &  0.20510758 & -0.14944834 &  0.170449658 &  0.42970776 & -0.42352100 & -0.35025961 &  0.202482977 & -0.208935643 & -0.19650144 & -0.88508592\\\\\n",
       "\t9625 &  3.60898132 & -0.84524935 &  0.31257703 &  1.691484290 &  0.0125097794 &  0.40020503 &  0.846322791 & -0.563722812 & -0.421367303 & -0.37741081 & â‹¯ &  0.02403999 & -0.22568269 & -0.643619983 &  1.88205421 & -0.80027603 & -0.79644491 &  1.298371192 & -0.476999606 &  0.13362286 & -0.91172718\\\\\n",
       "\t18 &  0.47449052 & -0.51482861 & -0.08855294 & -0.963038667 &  0.2553193875 &  0.37397031 & -0.694774261 &  0.863512974 &  0.599104197 &  2.67146770 & â‹¯ & -0.11896869 & -0.92173298 &  0.648023325 &  0.74306569 &  0.06889974 &  0.33279060 & -1.103800435 & -0.381884336 & -1.16396909 & -1.06332196\\\\\n",
       "\t19 &  0.41546373 &  0.08109892 &  0.08602522 & -0.004840843 &  0.7078058559 &  1.26404969 & -0.427511343 & -1.482748285 & -0.696181189 & -0.06458417 & â‹¯ &  0.22976258 & -0.03133024 &  0.632936139 &  0.57053063 & -0.08189527 &  0.25661952 & -0.524177121 & -1.848173543 &  0.71687019 &  0.58731357\\\\\n",
       "\t10349 & -0.50742249 &  0.04290351 &  0.60138091 & -0.927208930 & -0.6668527568 &  1.61967255 & -0.032507461 &  0.914324720 & -1.342999228 & -0.17663893 & â‹¯ & -0.62589869 & -0.81863690 & -0.766357479 & -0.28938889 & -0.04469534 & -0.57412553 & -0.405181147 & -1.755711771 & -0.46663115 & -0.09948639\\\\\n",
       "\t79963 & -1.09871946 &  0.48615484 & -0.22090270 & -0.228321221 & -0.4222808996 &  0.41920735 & -0.400974687 &  0.645256758 & -1.092692381 &  0.66469135 & â‹¯ & -0.15225939 & -0.22946814 & -0.008558539 & -0.15615992 &  0.52627577 & -0.28912370 &  0.008149144 &  0.039477559 &  0.45518284 &  0.95346227\\\\\n",
       "\t26154 & -0.36804763 & -0.37874390 & -0.29320773 & -0.378743901 &  1.2951447378 & -0.37161444 & -0.028227463 &  2.638924429 & -0.164492476 &  0.10278166 & â‹¯ & -0.15810368 & -0.37516392 & -0.378743901 & -0.23750015 & -0.37650973 & -0.37072166 &  1.668581091 & -0.218187538 & -0.37606112 & -0.37874390\\\\\n",
       "\tâ‹® & â‹® & â‹® & â‹® & â‹® & â‹® & â‹® & â‹® & â‹® & â‹® & â‹® & â‹± & â‹® & â‹® & â‹® & â‹® & â‹® & â‹® & â‹® & â‹® & â‹® & â‹®\\\\\n",
       "\t342945 & -0.06738728 &  0.22307312 &  0.056812029 & -0.32551551 & -0.11756152 & -0.39842900 & -0.06185009 &  0.295370553 & -0.034573759 & -0.09391874 & â‹¯ & -0.104833874 &  0.0789830727 & -0.19024034 &  0.06554628 &  0.042405031 & -0.03541245 &  0.73451363 &  0.28303949 &  0.074671159 & -0.262986827\\\\\n",
       "\t222696 & -0.64881799 & -0.78227877 &  0.873485822 & -1.07304830 &  0.02625283 & -0.01449303 &  0.75284400 &  0.289436376 & -1.085860282 & -1.05721611 & â‹¯ & -0.684481588 & -0.2293771875 & -0.72426880 &  0.61944225 &  1.329224079 &  1.18560242 &  0.13528489 & -1.19121746 &  0.416159043 & -0.825154290\\\\\n",
       "\t221785 &  0.29078478 & -0.31493083 &  0.599902756 & -0.78878690 & -0.90867364 & -0.51898336 &  0.13570131 &  0.409446288 & -0.637340889 & -1.37948687 & â‹¯ &  0.165301677 & -0.1770653416 & -0.11729290 & -0.17972412 &  0.066222843 &  0.62846703 &  0.02671665 &  0.48032970 &  1.568978142 & -0.467369389\\\\\n",
       "\t7741 & -1.35500422 &  0.73987162 &  0.727950091 &  0.44338877 & -0.96928065 &  0.01065774 & -0.63283478 &  0.058726096 & -0.577334677 &  0.86416063 & â‹¯ & -0.260105972 &  0.0669740558 & -0.28622020 & -0.15996478 &  0.523249135 & -0.60984859 & -0.22257846 &  0.51790614 &  1.199042844 &  0.528596755\\\\\n",
       "\t146050 & -0.18952771 &  0.15541497 &  0.468589177 & -0.48089053 & -0.40048375 & -0.32627016 & -0.17288547 & -0.005024687 & -0.002828181 &  1.00703927 & â‹¯ &  0.037084696 & -0.5998269449 &  0.10593199 & -0.26650265 &  0.151094573 & -0.39833543 &  0.14627413 & -0.08036012 & -0.183474542 & -0.287613243\\\\\n",
       "\t100101467 & -1.23392320 & -0.31396794 & -0.406738489 & -0.70732650 & -0.42237568 &  0.67420610 & -1.89818737 &  0.119016022 & -1.131928408 & -0.67472947 & â‹¯ & -1.041502131 &  0.3057801131 & -1.05158559 &  0.12320090 &  0.776823791 &  1.12900218 & -0.84748896 &  0.76690701 &  0.857210539 &  0.688969184\\\\\n",
       "\t64288 & -0.63391608 & -0.79938418 &  0.701345493 & -0.17769917 & -0.36281240 &  1.09726680 &  0.04967595 &  0.632491905 & -0.667296562 &  1.18707021 & â‹¯ &  0.438984502 &  0.5274614781 &  0.32051797 & -0.02793021 & -0.747579020 & -0.56504221 &  0.41067112 &  0.86166539 &  1.305194452 & -0.406043240\\\\\n",
       "\t54925 & -0.17731612 & -0.35204130 &  0.102240822 & -0.52758045 & -0.40278098 & -0.14868130 &  0.09693914 &  0.076161039 & -0.171999152 &  0.59047047 & â‹¯ & -0.008358507 & -0.4524072714 & -0.16986475 & -0.14406371 & -0.350141136 &  0.24989487 &  0.10502969 &  0.84371340 & -0.257445582 & -0.231349766\\\\\n",
       "\t79149 & -0.09341219 & -0.23361444 & -0.012420629 & -0.17611090 & -0.40303035 & -0.08029009 & -0.30285166 & -0.248634781 &  0.177474305 &  0.60403101 & â‹¯ & -0.104324744 &  0.4320254326 &  0.64677035 &  0.26582626 & -0.381941568 & -0.36031561 &  0.44353157 & -0.07201303 & -0.341529079 & -0.303601981\\\\\n",
       "\t7746 & -0.82911884 &  0.25724378 &  0.611044299 & -0.37846353 & -0.78120710 & -0.45949079 &  0.10044855 &  0.432152688 & -0.690101255 &  1.64129037 & â‹¯ &  0.313789705 &  0.0642196942 & -0.31365218 &  0.11595008 &  0.295624118 & -0.02733395 & -0.02991003 & -0.12986269 &  0.141537709 &  0.289072689\\\\\n",
       "\t90204 & -0.57628329 &  0.29424788 & -0.080423689 &  0.48981582 & -0.82961441 & -0.41047321 &  0.16082499 & -0.319394868 & -0.088091568 &  0.70775603 & â‹¯ &  0.207165527 & -0.3161638070 & -0.09191130 &  0.04321212 &  0.234567670 & -0.10930172 &  0.31839563 &  0.52723083 & -0.250318350 & -0.058405510\\\\\n",
       "\t140831 & -0.10865092 & -0.04968098 & -0.228834966 & -0.27989994 & -0.31119849 & -0.09417891 & -0.05364741 & -0.117780642 & -0.130384785 &  0.21099894 & â‹¯ & -0.082798713 & -0.0250849141 & -0.08791917 &  0.09762790 &  0.150667063 &  0.01352765 &  0.17423614 &  0.63538207 &  0.130425590 &  0.057133464\\\\\n",
       "\t65249 & -0.31093770 & -0.10462758 & -0.071795268 &  0.47046613 &  0.48132730 & -0.41079358 & -0.65455483 & -0.242563205 & -0.746319797 &  0.51845273 & â‹¯ &  0.040745861 & -0.3207680305 & -0.20890297 &  0.29902682 &  0.043011201 &  0.63356178 &  0.12632883 &  0.22340880 &  1.186349306 & -0.460522686\\\\\n",
       "\t57643 &  0.08906239 & -0.33661134 & -0.285473003 & -0.51184333 &  0.73010598 &  0.06687714 & -0.05579481 & -0.114751841 &  1.162620098 & -0.04053377 & â‹¯ &  0.646442700 & -0.4041607330 & -0.42057300 & -0.43117742 & -0.587895416 & -0.09822088 & -0.68013720 & -0.42665048 &  0.480719433 & -0.534976999\\\\\n",
       "\t57688 &  0.25097250 & -0.19576322 & -0.051295448 & -0.45963970 &  0.78423338 & -0.53290552 & -0.12483556 &  0.759970760 &  0.793365263 &  0.57702926 & â‹¯ &  0.508247388 & -0.3163794667 &  0.13041877 &  0.61104754 &  0.067794381 & -0.43397318 &  0.03590784 &  0.02205099 & -0.700488597 & -0.465451820\\\\\n",
       "\t125150 & -0.71034766 & -0.04673484 & -0.008407714 &  0.23523953 & -0.50263675 & -0.22642199 & -0.71603039 &  0.392523766 &  0.282615580 & -0.53713084 & â‹¯ &  0.293565902 & -0.4012750092 & -0.49602970 & -0.62909866 & -0.349480025 &  1.27328563 &  1.53141429 & -0.14398185 & -0.001833785 & -0.325687813\\\\\n",
       "\t23053 & -0.24836838 &  0.69448423 & -0.363755100 &  0.10966341 & -0.11320148 &  0.41428274 & -0.51550697 & -0.080894641 &  0.082133502 & -0.76319584 & â‹¯ & -0.292052772 &  1.0704226931 & -0.03271785 &  0.45097641 & -0.086864206 &  0.38212822 & -0.57909518 & -1.10373494 &  0.094320651 &  0.080271987\\\\\n",
       "\t100507331 & -0.11936992 &  0.14567118 &  0.038331165 & -0.11936992 &  0.48221246 & -0.11400870 & -0.11936992 &  0.159699991 & -0.006716149 & -0.11936992 & â‹¯ & -0.025406186 & -0.0989390329 & -0.03258464 &  0.18147031 & -0.119369924 & -0.11936992 &  0.07702330 &  0.09514177 & -0.119369924 & -0.119369924\\\\\n",
       "\t221302 &  0.23716312 & -0.22049439 &  0.164318863 & -0.28415268 &  0.20568352 & -0.72205206 & -0.14894922 &  0.394013252 &  0.460304807 & -0.42601126 & â‹¯ &  0.167630424 & -0.4062481772 &  0.22824109 &  0.70563831 & -0.090649064 & -0.85519296 &  0.16246605 &  0.96827871 & -1.022146067 &  0.670878172\\\\\n",
       "\t9183 & -0.32887167 & -0.20082769 &  0.455712201 & -0.57247184 & -0.08610647 & -0.48571814 & -0.06369578 &  0.504081784 &  0.136045250 &  0.91063613 & â‹¯ &  0.243505506 & -0.4439087932 &  0.03013266 &  0.08423296 & -0.018914051 & -0.13432189 &  0.53900488 & -0.21405222 & -0.538250246 & -0.015166293\\\\\n",
       "\t55055 & -0.23155487 &  0.46212792 & -0.990153661 &  0.71531472 &  0.20677370 & -1.11556081 &  0.38706633 & -0.468675161 & -0.209928304 &  0.46482463 & â‹¯ & -0.605366439 & -0.4412846494 &  0.25503931 &  0.31496113 &  0.262799951 &  0.39724886 & -0.03329266 &  0.41080232 & -0.766047908 &  0.008691614\\\\\n",
       "\t11130 &  0.42826173 &  0.57497284 & -0.668849952 &  0.32665483 & -0.42747899 & -2.62608070 &  0.80556102 &  0.381913246 &  0.812508915 &  0.30872910 & â‹¯ &  0.351439294 & -0.9000318013 &  0.97348718 &  1.37143617 &  0.640111663 & -0.54785782 &  1.11436707 & -0.35400995 & -1.695316744 & -0.394695493\\\\\n",
       "\t7789 &  0.17136963 & -0.59890304 &  0.755074459 &  0.27464873 & -0.06521667 &  0.33662516 & -0.04602627 & -0.133536302 &  0.044225248 & -0.66759771 & â‹¯ &  0.328510667 & -0.5599443165 &  0.37727755 &  0.08818719 &  0.240113319 & -0.22319036 &  0.13554354 & -0.38289902 & -0.143425114 & -0.734985177\\\\\n",
       "\t158586 &  0.43681965 & -0.44415190 &  0.457020340 & -0.37869573 & -0.31779465 & -0.09917793 &  0.15027246 &  0.446774536 &  0.069298676 &  0.56592965 & â‹¯ &  0.357462377 & -0.5646742600 &  0.11511414 &  0.27088915 & -0.111782930 & -0.51547930 &  0.25877652 &  0.26529255 & -0.171242002 & -0.431495671\\\\\n",
       "\t79364 & -0.04349335 &  0.74411930 & -0.097860826 & -0.20007843 & -0.63084343 &  0.56529909 & -0.67849788 & -0.190789794 & -0.329499666 & -0.46066913 & â‹¯ & -0.140778229 & -0.0005595549 & -0.50095875 & -0.28793686 &  0.160131815 &  0.13651835 & -0.26315230 &  0.06811924 &  0.564314391 &  0.553030834\\\\\n",
       "\t440590 & -0.07010125 &  0.06946522 & -0.037910521 & -0.09580757 & -0.01279774 & -0.06131873 &  0.03818382 & -0.014894504 & -0.095807574 &  0.55426201 & â‹¯ & -0.077796562 & -0.0958075738 & -0.05913173 &  0.04543618 &  0.001045315 & -0.02594056 & -0.05478135 & -0.04695407 & -0.068337272 &  0.567570255\\\\\n",
       "\t79699 & -0.77012086 & -0.38604727 & -0.196414999 &  0.13778226 &  0.16718252 &  0.01378568 &  0.16128751 & -0.060919007 & -0.019271522 &  0.69282995 & â‹¯ &  0.071425738 & -0.4277571728 &  0.17357627 &  0.33126353 & -0.027790606 &  0.18921212 &  0.14859193 & -0.03533289 & -0.191640998 & -0.170930205\\\\\n",
       "\t7791 &  0.02624200 & -0.89931187 & -0.002663966 &  0.70494792 &  1.34419206 &  0.63244321 & -0.23837056 & -0.292491200 &  0.254432485 &  0.53947147 & â‹¯ &  0.107125170 &  0.0735204548 &  0.33610451 &  0.21013737 & -0.079428025 &  0.42419145 & -0.33001021 & -0.55516310 &  0.736564406 & -0.578044742\\\\\n",
       "\t23140 & -0.29389081 &  0.37238568 &  0.142429270 & -0.55133851 & -0.03809493 &  0.78257787 & -0.13963415 &  0.064831497 & -0.036326222 & -0.33190657 & â‹¯ & -0.014908065 &  0.3206683458 & -0.43932309 & -0.54818555 &  0.241345309 &  0.10411358 & -0.70105036 & -0.54986056 &  0.066472443 &  1.003023165\\\\\n",
       "\t26009 & -1.04418568 & -0.43646272 & -0.536034138 &  0.40732392 & -0.45864802 & -0.20470475 & -0.21243155 &  0.367259701 &  0.108939675 &  0.11705793 & â‹¯ & -0.755442532 & -0.2027674488 & -0.15576478 & -0.23738481 &  0.227673130 & -0.16324147 &  1.23636907 &  1.10751447 & -0.166047613 &  0.725873295\\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A data.frame: 18780 Ã— 32\n",
       "\n",
       "| <!--/--> | 36 &lt;dbl&gt; | 26 &lt;dbl&gt; | 19 &lt;dbl&gt; | 7 &lt;dbl&gt; | 44 &lt;dbl&gt; | 12 &lt;dbl&gt; | 49 &lt;dbl&gt; | 35 &lt;dbl&gt; | 13 &lt;dbl&gt; | 10 &lt;dbl&gt; | â‹¯ â‹¯ | 27 &lt;dbl&gt; | 45 &lt;dbl&gt; | 37 &lt;dbl&gt; | 50 &lt;dbl&gt; | 21 &lt;dbl&gt; | 17 &lt;dbl&gt; | 15 &lt;dbl&gt; | 23 &lt;dbl&gt; | 34 &lt;dbl&gt; | 32 &lt;dbl&gt; |\n",
       "|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|\n",
       "| 1 |  0.02207971 |  0.36939855 |  0.01444574 |  0.316403660 | -0.9679687344 | -1.07111293 |  1.121695219 |  0.475150825 | -1.209204816 | -0.61833240 | â‹¯ |  0.41001548 |  0.56281081 | -0.404080959 | -0.09683531 |  0.07795682 |  0.53014756 |  0.844647025 | -0.134897783 |  0.50874883 | -0.15193508 |\n",
       "| 503538 | -0.39934403 |  0.49379652 |  0.30317249 | -0.235838135 | -0.3717351375 | -0.44326685 |  0.006291004 |  0.339123809 | -0.541433333 |  0.01471473 | â‹¯ |  0.52472946 |  0.20896041 | -0.078336393 |  0.28806367 | -0.19962044 | -0.65357875 |  0.408755426 | -0.916067934 | -0.15391097 | -0.10178292 |\n",
       "| 2 |  1.31004461 | -2.05553544 | -0.68074489 | -0.030216264 |  0.5225906718 |  2.31713808 |  1.456297873 | -0.665860393 | -0.019892875 | -0.70065194 | â‹¯ |  1.21509583 | -0.44592739 |  0.053971450 | -1.33779511 |  0.91527044 |  0.50604193 | -0.245655206 | -0.687799180 |  1.39761539 | -2.91035093 |\n",
       "| 144571 |  0.28266209 | -0.13408502 |  0.09653197 | -0.395291281 |  0.2905811363 |  0.10786869 |  1.013609213 | -0.093081711 |  0.654085858 | -0.36349872 | â‹¯ |  0.34009902 | -0.13785662 |  0.298329396 | -0.31798891 |  0.21741237 | -0.12240057 | -0.581928186 | -0.648592702 | -0.88460073 |  2.14689483 |\n",
       "| 144568 | -0.21165347 | -0.23288261 | -0.22800050 | -0.237359796 |  1.3954592948 | -0.23199857 |  0.002645532 |  1.333911644 | -0.225330893 | -0.23735980 | â‹¯ | -0.21934878 | -0.21692891 | -0.237359796 | -0.23735980 | -0.23735980 | -0.13673470 |  1.177814024 | -0.005646842 | -0.06694260 | -0.23735980 |\n",
       "| 53947 | -0.20174329 | -0.17725880 | -0.12162473 | -0.417878450 |  1.2496034714 |  0.63256619 |  0.948400783 |  0.015965002 | -0.876077033 |  0.49662548 | â‹¯ | -0.17836320 |  0.51738358 | -0.443095914 |  0.17021327 | -0.33249362 | -0.10290469 | -0.426662879 | -0.778098432 |  0.36754271 | -0.50179098 |\n",
       "| 8086 |  0.27101637 |  0.12710253 | -0.03935541 | -0.957904849 | -0.0984823825 | -0.06593464 | -0.201537844 | -0.019883185 | -0.346078741 | -0.49421422 | â‹¯ | -0.24621711 |  0.06665660 |  0.046360254 | -0.14301866 | -0.57249323 |  0.50947306 |  0.577894297 |  0.127102527 |  0.37857683 | -0.29167394 |\n",
       "| 65985 |  0.35830600 | -0.56364047 | -0.27866488 | -0.269379893 |  0.4585162860 | -0.69375733 |  0.833486730 |  0.391613692 |  0.000386568 |  1.18470918 | â‹¯ | -0.61963981 | -0.40027635 | -0.512799468 | -0.07653565 | -0.82674049 |  0.59438443 |  0.196602903 | -0.371793764 | -0.46038391 | -0.70080812 |\n",
       "| 13 | -0.17851692 | -0.27782151 | -0.24476760 |  0.255566934 | -0.2028786308 |  0.95305094 |  0.984990581 |  0.007535656 | -0.049628185 | -0.30266465 | â‹¯ | -0.30266465 | -0.29286117 | -0.302664653 | -0.21290145 | -0.30221605 |  0.17466136 | -0.086528609 |  0.233683066 |  0.06160048 | -0.27430590 |\n",
       "| 51166 | -0.27117599 |  0.54745043 | -1.29409560 |  0.365705763 | -0.0845393945 | -0.26277554 | -0.176682218 | -0.687497427 | -0.983992317 |  1.68367428 | â‹¯ | -0.73347481 | -0.08721195 |  0.153937049 | -0.10080308 |  0.94718541 |  0.45424333 | -0.080781519 | -0.460277938 | -1.57796916 | -0.57448733 |\n",
       "| 195827 | -0.77985660 |  0.59333069 | -0.28273074 |  0.738627592 | -0.0710368206 |  0.32201075 |  0.018074438 | -0.209719976 | -0.116849439 | -1.66551214 | â‹¯ | -0.38340551 |  0.01999654 | -0.215550749 | -0.05664716 |  1.00056670 |  1.65211601 |  0.604318857 | -0.445781787 | -0.64032807 |  0.97142098 |\n",
       "| 79719 |  0.49797932 | -0.31433680 |  0.43068710 | -0.200661492 |  0.0689009864 | -0.60521081 |  0.400089008 | -0.194474967 |  0.426915663 |  0.40963274 | â‹¯ |  0.13297377 | -0.40617561 |  0.222397759 |  0.25820075 | -0.22124877 | -0.42028947 |  0.771840637 | -0.548539669 | -0.44464181 | -0.81239457 |\n",
       "| 22848 |  0.11786066 |  0.07461847 | -0.75284884 | -0.400474857 |  0.1571324522 |  0.37060547 |  0.252537149 | -0.348677409 | -0.131050801 | -0.46394573 | â‹¯ | -0.24071918 |  0.55907181 |  0.169113091 |  0.39831088 |  0.48747341 | -0.28194137 | -0.139581325 | -0.632987209 | -0.61763596 |  0.13236627 |\n",
       "| 28971 | -0.80783791 |  0.16487612 |  0.05425462 | -0.007148987 | -1.2280832996 |  0.19117423 |  0.330179227 |  0.656983940 | -0.048596345 |  0.30912117 | â‹¯ | -0.13406401 |  0.03353913 |  0.121743688 |  0.26792034 | -0.45384589 | -0.04184918 |  1.045931122 | -0.125502782 | -0.10081843 | -0.65537677 |\n",
       "| 14 |  0.56155991 |  0.40625931 | -0.25463777 | -0.668279321 | -0.0003211111 | -0.68856750 |  0.301076053 | -0.019939882 |  0.362935613 | -0.22390700 | â‹¯ |  0.66149884 |  0.25990243 |  0.239565954 |  0.40472396 | -0.57777526 | -0.04119417 |  0.326728387 |  0.202824053 |  0.17986536 | -1.27793190 |\n",
       "| 25980 |  0.46062340 | -0.34842853 |  0.75909384 |  0.114309879 | -0.1262416145 | -0.87175674 |  0.477847801 | -0.101035416 |  0.468756091 |  0.91878426 | â‹¯ |  0.89911132 |  0.01760844 |  0.002114438 |  0.06208155 | -0.88950808 | -0.60202869 |  0.869248872 | -0.248164679 | -0.51028527 | -1.24746975 |\n",
       "| 441376 | -0.08761253 | -0.42379401 | -0.37623194 | -0.298795461 | -0.4237940130 |  0.18142316 | -0.423794013 | -0.048902719 | -0.139289427 | -0.42379401 | â‹¯ | -0.42379401 | -0.36806678 | -0.423794013 |  0.31468868 |  0.15504126 |  2.19837135 | -0.423794013 | -0.423794013 | -0.29551276 | -0.08484930 |\n",
       "| 16 | -0.26041291 | -0.73418685 |  0.53675093 | -0.731130153 |  0.2515506241 | -0.42970774 | -0.314009220 |  0.239018534 | -0.566988783 | -0.61392828 | â‹¯ |  0.01239516 |  0.13642365 |  0.582612286 |  0.71406991 | -0.22469959 | -0.70040197 |  0.629494689 |  0.959250726 | -0.55692466 | -0.88930128 |\n",
       "| 57505 | -0.67989773 |  0.71788009 |  1.44109571 | -0.080880257 | -1.1704450955 | -1.12052878 |  0.304528505 |  0.290185364 | -0.178302553 |  0.23058904 | â‹¯ | -0.46620276 |  0.07045982 | -0.268643908 | -0.31731923 | -0.38380968 | -0.72578157 |  0.275779920 |  0.007205364 |  1.42682008 | -0.45322791 |\n",
       "| 80755 |  0.56662472 |  0.20456306 |  0.52982798 | -0.948498986 | -0.2328836172 | -1.01593797 |  0.676331199 |  0.025929684 | -0.015551511 | -0.48190870 | â‹¯ |  0.38620060 | -0.17520963 | -0.034471880 |  0.20682546 |  0.22783938 | -0.63131328 |  0.101147324 | -0.175523506 | -0.35160431 | -0.16351672 |\n",
       "| 132949 |  0.04666709 | -0.51685028 |  0.57314858 |  0.252866918 |  0.9219149045 | -0.14750111 |  0.008273773 | -0.354295910 | -0.468248650 |  1.12450233 | â‹¯ |  0.46125608 | -1.16516003 | -0.122944663 | -0.22843993 | -0.93798320 | -0.94662104 |  2.960583846 | -0.415552259 | -0.18049176 | -0.11060645 |\n",
       "| 60496 | -1.04384916 |  0.47830669 | -0.10781073 |  0.627294430 | -0.9443698151 | -0.20656249 | -1.447627430 | -0.635972151 | -0.813942587 | -0.30351542 | â‹¯ | -0.15001615 | -0.48741332 | -0.764905026 | -0.94913318 |  0.23441955 |  0.50415037 | -0.024640740 |  0.867782801 |  1.01564139 | -0.50311937 |\n",
       "| 10157 |  0.22673049 |  0.02039899 | -0.03313650 | -1.611559104 | -0.4222279431 |  0.06619184 | -1.073017967 |  0.360057858 |  0.088183064 |  0.10562297 | â‹¯ | -0.04040087 |  0.09155972 | -0.725416873 |  0.09209233 | -0.38325458 |  0.92546584 | -0.356148312 | -1.032546605 |  0.28288690 |  0.95538032 |\n",
       "| 26574 |  0.32513626 | -0.71064628 |  0.57474138 | -0.307859096 | -0.1157644599 | -0.90696552 |  0.741722227 |  0.115525095 |  0.525127204 | -0.02269603 | â‹¯ |  0.20510758 | -0.14944834 |  0.170449658 |  0.42970776 | -0.42352100 | -0.35025961 |  0.202482977 | -0.208935643 | -0.19650144 | -0.88508592 |\n",
       "| 9625 |  3.60898132 | -0.84524935 |  0.31257703 |  1.691484290 |  0.0125097794 |  0.40020503 |  0.846322791 | -0.563722812 | -0.421367303 | -0.37741081 | â‹¯ |  0.02403999 | -0.22568269 | -0.643619983 |  1.88205421 | -0.80027603 | -0.79644491 |  1.298371192 | -0.476999606 |  0.13362286 | -0.91172718 |\n",
       "| 18 |  0.47449052 | -0.51482861 | -0.08855294 | -0.963038667 |  0.2553193875 |  0.37397031 | -0.694774261 |  0.863512974 |  0.599104197 |  2.67146770 | â‹¯ | -0.11896869 | -0.92173298 |  0.648023325 |  0.74306569 |  0.06889974 |  0.33279060 | -1.103800435 | -0.381884336 | -1.16396909 | -1.06332196 |\n",
       "| 19 |  0.41546373 |  0.08109892 |  0.08602522 | -0.004840843 |  0.7078058559 |  1.26404969 | -0.427511343 | -1.482748285 | -0.696181189 | -0.06458417 | â‹¯ |  0.22976258 | -0.03133024 |  0.632936139 |  0.57053063 | -0.08189527 |  0.25661952 | -0.524177121 | -1.848173543 |  0.71687019 |  0.58731357 |\n",
       "| 10349 | -0.50742249 |  0.04290351 |  0.60138091 | -0.927208930 | -0.6668527568 |  1.61967255 | -0.032507461 |  0.914324720 | -1.342999228 | -0.17663893 | â‹¯ | -0.62589869 | -0.81863690 | -0.766357479 | -0.28938889 | -0.04469534 | -0.57412553 | -0.405181147 | -1.755711771 | -0.46663115 | -0.09948639 |\n",
       "| 79963 | -1.09871946 |  0.48615484 | -0.22090270 | -0.228321221 | -0.4222808996 |  0.41920735 | -0.400974687 |  0.645256758 | -1.092692381 |  0.66469135 | â‹¯ | -0.15225939 | -0.22946814 | -0.008558539 | -0.15615992 |  0.52627577 | -0.28912370 |  0.008149144 |  0.039477559 |  0.45518284 |  0.95346227 |\n",
       "| 26154 | -0.36804763 | -0.37874390 | -0.29320773 | -0.378743901 |  1.2951447378 | -0.37161444 | -0.028227463 |  2.638924429 | -0.164492476 |  0.10278166 | â‹¯ | -0.15810368 | -0.37516392 | -0.378743901 | -0.23750015 | -0.37650973 | -0.37072166 |  1.668581091 | -0.218187538 | -0.37606112 | -0.37874390 |\n",
       "| â‹® | â‹® | â‹® | â‹® | â‹® | â‹® | â‹® | â‹® | â‹® | â‹® | â‹® | â‹± | â‹® | â‹® | â‹® | â‹® | â‹® | â‹® | â‹® | â‹® | â‹® | â‹® |\n",
       "| 342945 | -0.06738728 |  0.22307312 |  0.056812029 | -0.32551551 | -0.11756152 | -0.39842900 | -0.06185009 |  0.295370553 | -0.034573759 | -0.09391874 | â‹¯ | -0.104833874 |  0.0789830727 | -0.19024034 |  0.06554628 |  0.042405031 | -0.03541245 |  0.73451363 |  0.28303949 |  0.074671159 | -0.262986827 |\n",
       "| 222696 | -0.64881799 | -0.78227877 |  0.873485822 | -1.07304830 |  0.02625283 | -0.01449303 |  0.75284400 |  0.289436376 | -1.085860282 | -1.05721611 | â‹¯ | -0.684481588 | -0.2293771875 | -0.72426880 |  0.61944225 |  1.329224079 |  1.18560242 |  0.13528489 | -1.19121746 |  0.416159043 | -0.825154290 |\n",
       "| 221785 |  0.29078478 | -0.31493083 |  0.599902756 | -0.78878690 | -0.90867364 | -0.51898336 |  0.13570131 |  0.409446288 | -0.637340889 | -1.37948687 | â‹¯ |  0.165301677 | -0.1770653416 | -0.11729290 | -0.17972412 |  0.066222843 |  0.62846703 |  0.02671665 |  0.48032970 |  1.568978142 | -0.467369389 |\n",
       "| 7741 | -1.35500422 |  0.73987162 |  0.727950091 |  0.44338877 | -0.96928065 |  0.01065774 | -0.63283478 |  0.058726096 | -0.577334677 |  0.86416063 | â‹¯ | -0.260105972 |  0.0669740558 | -0.28622020 | -0.15996478 |  0.523249135 | -0.60984859 | -0.22257846 |  0.51790614 |  1.199042844 |  0.528596755 |\n",
       "| 146050 | -0.18952771 |  0.15541497 |  0.468589177 | -0.48089053 | -0.40048375 | -0.32627016 | -0.17288547 | -0.005024687 | -0.002828181 |  1.00703927 | â‹¯ |  0.037084696 | -0.5998269449 |  0.10593199 | -0.26650265 |  0.151094573 | -0.39833543 |  0.14627413 | -0.08036012 | -0.183474542 | -0.287613243 |\n",
       "| 100101467 | -1.23392320 | -0.31396794 | -0.406738489 | -0.70732650 | -0.42237568 |  0.67420610 | -1.89818737 |  0.119016022 | -1.131928408 | -0.67472947 | â‹¯ | -1.041502131 |  0.3057801131 | -1.05158559 |  0.12320090 |  0.776823791 |  1.12900218 | -0.84748896 |  0.76690701 |  0.857210539 |  0.688969184 |\n",
       "| 64288 | -0.63391608 | -0.79938418 |  0.701345493 | -0.17769917 | -0.36281240 |  1.09726680 |  0.04967595 |  0.632491905 | -0.667296562 |  1.18707021 | â‹¯ |  0.438984502 |  0.5274614781 |  0.32051797 | -0.02793021 | -0.747579020 | -0.56504221 |  0.41067112 |  0.86166539 |  1.305194452 | -0.406043240 |\n",
       "| 54925 | -0.17731612 | -0.35204130 |  0.102240822 | -0.52758045 | -0.40278098 | -0.14868130 |  0.09693914 |  0.076161039 | -0.171999152 |  0.59047047 | â‹¯ | -0.008358507 | -0.4524072714 | -0.16986475 | -0.14406371 | -0.350141136 |  0.24989487 |  0.10502969 |  0.84371340 | -0.257445582 | -0.231349766 |\n",
       "| 79149 | -0.09341219 | -0.23361444 | -0.012420629 | -0.17611090 | -0.40303035 | -0.08029009 | -0.30285166 | -0.248634781 |  0.177474305 |  0.60403101 | â‹¯ | -0.104324744 |  0.4320254326 |  0.64677035 |  0.26582626 | -0.381941568 | -0.36031561 |  0.44353157 | -0.07201303 | -0.341529079 | -0.303601981 |\n",
       "| 7746 | -0.82911884 |  0.25724378 |  0.611044299 | -0.37846353 | -0.78120710 | -0.45949079 |  0.10044855 |  0.432152688 | -0.690101255 |  1.64129037 | â‹¯ |  0.313789705 |  0.0642196942 | -0.31365218 |  0.11595008 |  0.295624118 | -0.02733395 | -0.02991003 | -0.12986269 |  0.141537709 |  0.289072689 |\n",
       "| 90204 | -0.57628329 |  0.29424788 | -0.080423689 |  0.48981582 | -0.82961441 | -0.41047321 |  0.16082499 | -0.319394868 | -0.088091568 |  0.70775603 | â‹¯ |  0.207165527 | -0.3161638070 | -0.09191130 |  0.04321212 |  0.234567670 | -0.10930172 |  0.31839563 |  0.52723083 | -0.250318350 | -0.058405510 |\n",
       "| 140831 | -0.10865092 | -0.04968098 | -0.228834966 | -0.27989994 | -0.31119849 | -0.09417891 | -0.05364741 | -0.117780642 | -0.130384785 |  0.21099894 | â‹¯ | -0.082798713 | -0.0250849141 | -0.08791917 |  0.09762790 |  0.150667063 |  0.01352765 |  0.17423614 |  0.63538207 |  0.130425590 |  0.057133464 |\n",
       "| 65249 | -0.31093770 | -0.10462758 | -0.071795268 |  0.47046613 |  0.48132730 | -0.41079358 | -0.65455483 | -0.242563205 | -0.746319797 |  0.51845273 | â‹¯ |  0.040745861 | -0.3207680305 | -0.20890297 |  0.29902682 |  0.043011201 |  0.63356178 |  0.12632883 |  0.22340880 |  1.186349306 | -0.460522686 |\n",
       "| 57643 |  0.08906239 | -0.33661134 | -0.285473003 | -0.51184333 |  0.73010598 |  0.06687714 | -0.05579481 | -0.114751841 |  1.162620098 | -0.04053377 | â‹¯ |  0.646442700 | -0.4041607330 | -0.42057300 | -0.43117742 | -0.587895416 | -0.09822088 | -0.68013720 | -0.42665048 |  0.480719433 | -0.534976999 |\n",
       "| 57688 |  0.25097250 | -0.19576322 | -0.051295448 | -0.45963970 |  0.78423338 | -0.53290552 | -0.12483556 |  0.759970760 |  0.793365263 |  0.57702926 | â‹¯ |  0.508247388 | -0.3163794667 |  0.13041877 |  0.61104754 |  0.067794381 | -0.43397318 |  0.03590784 |  0.02205099 | -0.700488597 | -0.465451820 |\n",
       "| 125150 | -0.71034766 | -0.04673484 | -0.008407714 |  0.23523953 | -0.50263675 | -0.22642199 | -0.71603039 |  0.392523766 |  0.282615580 | -0.53713084 | â‹¯ |  0.293565902 | -0.4012750092 | -0.49602970 | -0.62909866 | -0.349480025 |  1.27328563 |  1.53141429 | -0.14398185 | -0.001833785 | -0.325687813 |\n",
       "| 23053 | -0.24836838 |  0.69448423 | -0.363755100 |  0.10966341 | -0.11320148 |  0.41428274 | -0.51550697 | -0.080894641 |  0.082133502 | -0.76319584 | â‹¯ | -0.292052772 |  1.0704226931 | -0.03271785 |  0.45097641 | -0.086864206 |  0.38212822 | -0.57909518 | -1.10373494 |  0.094320651 |  0.080271987 |\n",
       "| 100507331 | -0.11936992 |  0.14567118 |  0.038331165 | -0.11936992 |  0.48221246 | -0.11400870 | -0.11936992 |  0.159699991 | -0.006716149 | -0.11936992 | â‹¯ | -0.025406186 | -0.0989390329 | -0.03258464 |  0.18147031 | -0.119369924 | -0.11936992 |  0.07702330 |  0.09514177 | -0.119369924 | -0.119369924 |\n",
       "| 221302 |  0.23716312 | -0.22049439 |  0.164318863 | -0.28415268 |  0.20568352 | -0.72205206 | -0.14894922 |  0.394013252 |  0.460304807 | -0.42601126 | â‹¯ |  0.167630424 | -0.4062481772 |  0.22824109 |  0.70563831 | -0.090649064 | -0.85519296 |  0.16246605 |  0.96827871 | -1.022146067 |  0.670878172 |\n",
       "| 9183 | -0.32887167 | -0.20082769 |  0.455712201 | -0.57247184 | -0.08610647 | -0.48571814 | -0.06369578 |  0.504081784 |  0.136045250 |  0.91063613 | â‹¯ |  0.243505506 | -0.4439087932 |  0.03013266 |  0.08423296 | -0.018914051 | -0.13432189 |  0.53900488 | -0.21405222 | -0.538250246 | -0.015166293 |\n",
       "| 55055 | -0.23155487 |  0.46212792 | -0.990153661 |  0.71531472 |  0.20677370 | -1.11556081 |  0.38706633 | -0.468675161 | -0.209928304 |  0.46482463 | â‹¯ | -0.605366439 | -0.4412846494 |  0.25503931 |  0.31496113 |  0.262799951 |  0.39724886 | -0.03329266 |  0.41080232 | -0.766047908 |  0.008691614 |\n",
       "| 11130 |  0.42826173 |  0.57497284 | -0.668849952 |  0.32665483 | -0.42747899 | -2.62608070 |  0.80556102 |  0.381913246 |  0.812508915 |  0.30872910 | â‹¯ |  0.351439294 | -0.9000318013 |  0.97348718 |  1.37143617 |  0.640111663 | -0.54785782 |  1.11436707 | -0.35400995 | -1.695316744 | -0.394695493 |\n",
       "| 7789 |  0.17136963 | -0.59890304 |  0.755074459 |  0.27464873 | -0.06521667 |  0.33662516 | -0.04602627 | -0.133536302 |  0.044225248 | -0.66759771 | â‹¯ |  0.328510667 | -0.5599443165 |  0.37727755 |  0.08818719 |  0.240113319 | -0.22319036 |  0.13554354 | -0.38289902 | -0.143425114 | -0.734985177 |\n",
       "| 158586 |  0.43681965 | -0.44415190 |  0.457020340 | -0.37869573 | -0.31779465 | -0.09917793 |  0.15027246 |  0.446774536 |  0.069298676 |  0.56592965 | â‹¯ |  0.357462377 | -0.5646742600 |  0.11511414 |  0.27088915 | -0.111782930 | -0.51547930 |  0.25877652 |  0.26529255 | -0.171242002 | -0.431495671 |\n",
       "| 79364 | -0.04349335 |  0.74411930 | -0.097860826 | -0.20007843 | -0.63084343 |  0.56529909 | -0.67849788 | -0.190789794 | -0.329499666 | -0.46066913 | â‹¯ | -0.140778229 | -0.0005595549 | -0.50095875 | -0.28793686 |  0.160131815 |  0.13651835 | -0.26315230 |  0.06811924 |  0.564314391 |  0.553030834 |\n",
       "| 440590 | -0.07010125 |  0.06946522 | -0.037910521 | -0.09580757 | -0.01279774 | -0.06131873 |  0.03818382 | -0.014894504 | -0.095807574 |  0.55426201 | â‹¯ | -0.077796562 | -0.0958075738 | -0.05913173 |  0.04543618 |  0.001045315 | -0.02594056 | -0.05478135 | -0.04695407 | -0.068337272 |  0.567570255 |\n",
       "| 79699 | -0.77012086 | -0.38604727 | -0.196414999 |  0.13778226 |  0.16718252 |  0.01378568 |  0.16128751 | -0.060919007 | -0.019271522 |  0.69282995 | â‹¯ |  0.071425738 | -0.4277571728 |  0.17357627 |  0.33126353 | -0.027790606 |  0.18921212 |  0.14859193 | -0.03533289 | -0.191640998 | -0.170930205 |\n",
       "| 7791 |  0.02624200 | -0.89931187 | -0.002663966 |  0.70494792 |  1.34419206 |  0.63244321 | -0.23837056 | -0.292491200 |  0.254432485 |  0.53947147 | â‹¯ |  0.107125170 |  0.0735204548 |  0.33610451 |  0.21013737 | -0.079428025 |  0.42419145 | -0.33001021 | -0.55516310 |  0.736564406 | -0.578044742 |\n",
       "| 23140 | -0.29389081 |  0.37238568 |  0.142429270 | -0.55133851 | -0.03809493 |  0.78257787 | -0.13963415 |  0.064831497 | -0.036326222 | -0.33190657 | â‹¯ | -0.014908065 |  0.3206683458 | -0.43932309 | -0.54818555 |  0.241345309 |  0.10411358 | -0.70105036 | -0.54986056 |  0.066472443 |  1.003023165 |\n",
       "| 26009 | -1.04418568 | -0.43646272 | -0.536034138 |  0.40732392 | -0.45864802 | -0.20470475 | -0.21243155 |  0.367259701 |  0.108939675 |  0.11705793 | â‹¯ | -0.755442532 | -0.2027674488 | -0.15576478 | -0.23738481 |  0.227673130 | -0.16324147 |  1.23636907 |  1.10751447 | -0.166047613 |  0.725873295 |\n",
       "\n"
      ],
      "text/plain": [
       "          36          26          19           7            44           \n",
       "1          0.02207971  0.36939855  0.01444574   0.316403660 -0.9679687344\n",
       "503538    -0.39934403  0.49379652  0.30317249  -0.235838135 -0.3717351375\n",
       "2          1.31004461 -2.05553544 -0.68074489  -0.030216264  0.5225906718\n",
       "144571     0.28266209 -0.13408502  0.09653197  -0.395291281  0.2905811363\n",
       "144568    -0.21165347 -0.23288261 -0.22800050  -0.237359796  1.3954592948\n",
       "53947     -0.20174329 -0.17725880 -0.12162473  -0.417878450  1.2496034714\n",
       "8086       0.27101637  0.12710253 -0.03935541  -0.957904849 -0.0984823825\n",
       "65985      0.35830600 -0.56364047 -0.27866488  -0.269379893  0.4585162860\n",
       "13        -0.17851692 -0.27782151 -0.24476760   0.255566934 -0.2028786308\n",
       "51166     -0.27117599  0.54745043 -1.29409560   0.365705763 -0.0845393945\n",
       "195827    -0.77985660  0.59333069 -0.28273074   0.738627592 -0.0710368206\n",
       "79719      0.49797932 -0.31433680  0.43068710  -0.200661492  0.0689009864\n",
       "22848      0.11786066  0.07461847 -0.75284884  -0.400474857  0.1571324522\n",
       "28971     -0.80783791  0.16487612  0.05425462  -0.007148987 -1.2280832996\n",
       "14         0.56155991  0.40625931 -0.25463777  -0.668279321 -0.0003211111\n",
       "25980      0.46062340 -0.34842853  0.75909384   0.114309879 -0.1262416145\n",
       "441376    -0.08761253 -0.42379401 -0.37623194  -0.298795461 -0.4237940130\n",
       "16        -0.26041291 -0.73418685  0.53675093  -0.731130153  0.2515506241\n",
       "57505     -0.67989773  0.71788009  1.44109571  -0.080880257 -1.1704450955\n",
       "80755      0.56662472  0.20456306  0.52982798  -0.948498986 -0.2328836172\n",
       "132949     0.04666709 -0.51685028  0.57314858   0.252866918  0.9219149045\n",
       "60496     -1.04384916  0.47830669 -0.10781073   0.627294430 -0.9443698151\n",
       "10157      0.22673049  0.02039899 -0.03313650  -1.611559104 -0.4222279431\n",
       "26574      0.32513626 -0.71064628  0.57474138  -0.307859096 -0.1157644599\n",
       "9625       3.60898132 -0.84524935  0.31257703   1.691484290  0.0125097794\n",
       "18         0.47449052 -0.51482861 -0.08855294  -0.963038667  0.2553193875\n",
       "19         0.41546373  0.08109892  0.08602522  -0.004840843  0.7078058559\n",
       "10349     -0.50742249  0.04290351  0.60138091  -0.927208930 -0.6668527568\n",
       "79963     -1.09871946  0.48615484 -0.22090270  -0.228321221 -0.4222808996\n",
       "26154     -0.36804763 -0.37874390 -0.29320773  -0.378743901  1.2951447378\n",
       "â‹®         â‹®           â‹®           â‹®            â‹®            â‹®            \n",
       "342945    -0.06738728  0.22307312  0.056812029 -0.32551551  -0.11756152  \n",
       "222696    -0.64881799 -0.78227877  0.873485822 -1.07304830   0.02625283  \n",
       "221785     0.29078478 -0.31493083  0.599902756 -0.78878690  -0.90867364  \n",
       "7741      -1.35500422  0.73987162  0.727950091  0.44338877  -0.96928065  \n",
       "146050    -0.18952771  0.15541497  0.468589177 -0.48089053  -0.40048375  \n",
       "100101467 -1.23392320 -0.31396794 -0.406738489 -0.70732650  -0.42237568  \n",
       "64288     -0.63391608 -0.79938418  0.701345493 -0.17769917  -0.36281240  \n",
       "54925     -0.17731612 -0.35204130  0.102240822 -0.52758045  -0.40278098  \n",
       "79149     -0.09341219 -0.23361444 -0.012420629 -0.17611090  -0.40303035  \n",
       "7746      -0.82911884  0.25724378  0.611044299 -0.37846353  -0.78120710  \n",
       "90204     -0.57628329  0.29424788 -0.080423689  0.48981582  -0.82961441  \n",
       "140831    -0.10865092 -0.04968098 -0.228834966 -0.27989994  -0.31119849  \n",
       "65249     -0.31093770 -0.10462758 -0.071795268  0.47046613   0.48132730  \n",
       "57643      0.08906239 -0.33661134 -0.285473003 -0.51184333   0.73010598  \n",
       "57688      0.25097250 -0.19576322 -0.051295448 -0.45963970   0.78423338  \n",
       "125150    -0.71034766 -0.04673484 -0.008407714  0.23523953  -0.50263675  \n",
       "23053     -0.24836838  0.69448423 -0.363755100  0.10966341  -0.11320148  \n",
       "100507331 -0.11936992  0.14567118  0.038331165 -0.11936992   0.48221246  \n",
       "221302     0.23716312 -0.22049439  0.164318863 -0.28415268   0.20568352  \n",
       "9183      -0.32887167 -0.20082769  0.455712201 -0.57247184  -0.08610647  \n",
       "55055     -0.23155487  0.46212792 -0.990153661  0.71531472   0.20677370  \n",
       "11130      0.42826173  0.57497284 -0.668849952  0.32665483  -0.42747899  \n",
       "7789       0.17136963 -0.59890304  0.755074459  0.27464873  -0.06521667  \n",
       "158586     0.43681965 -0.44415190  0.457020340 -0.37869573  -0.31779465  \n",
       "79364     -0.04349335  0.74411930 -0.097860826 -0.20007843  -0.63084343  \n",
       "440590    -0.07010125  0.06946522 -0.037910521 -0.09580757  -0.01279774  \n",
       "79699     -0.77012086 -0.38604727 -0.196414999  0.13778226   0.16718252  \n",
       "7791       0.02624200 -0.89931187 -0.002663966  0.70494792   1.34419206  \n",
       "23140     -0.29389081  0.37238568  0.142429270 -0.55133851  -0.03809493  \n",
       "26009     -1.04418568 -0.43646272 -0.536034138  0.40732392  -0.45864802  \n",
       "          12          49           35           13           10          â‹¯\n",
       "1         -1.07111293  1.121695219  0.475150825 -1.209204816 -0.61833240 â‹¯\n",
       "503538    -0.44326685  0.006291004  0.339123809 -0.541433333  0.01471473 â‹¯\n",
       "2          2.31713808  1.456297873 -0.665860393 -0.019892875 -0.70065194 â‹¯\n",
       "144571     0.10786869  1.013609213 -0.093081711  0.654085858 -0.36349872 â‹¯\n",
       "144568    -0.23199857  0.002645532  1.333911644 -0.225330893 -0.23735980 â‹¯\n",
       "53947      0.63256619  0.948400783  0.015965002 -0.876077033  0.49662548 â‹¯\n",
       "8086      -0.06593464 -0.201537844 -0.019883185 -0.346078741 -0.49421422 â‹¯\n",
       "65985     -0.69375733  0.833486730  0.391613692  0.000386568  1.18470918 â‹¯\n",
       "13         0.95305094  0.984990581  0.007535656 -0.049628185 -0.30266465 â‹¯\n",
       "51166     -0.26277554 -0.176682218 -0.687497427 -0.983992317  1.68367428 â‹¯\n",
       "195827     0.32201075  0.018074438 -0.209719976 -0.116849439 -1.66551214 â‹¯\n",
       "79719     -0.60521081  0.400089008 -0.194474967  0.426915663  0.40963274 â‹¯\n",
       "22848      0.37060547  0.252537149 -0.348677409 -0.131050801 -0.46394573 â‹¯\n",
       "28971      0.19117423  0.330179227  0.656983940 -0.048596345  0.30912117 â‹¯\n",
       "14        -0.68856750  0.301076053 -0.019939882  0.362935613 -0.22390700 â‹¯\n",
       "25980     -0.87175674  0.477847801 -0.101035416  0.468756091  0.91878426 â‹¯\n",
       "441376     0.18142316 -0.423794013 -0.048902719 -0.139289427 -0.42379401 â‹¯\n",
       "16        -0.42970774 -0.314009220  0.239018534 -0.566988783 -0.61392828 â‹¯\n",
       "57505     -1.12052878  0.304528505  0.290185364 -0.178302553  0.23058904 â‹¯\n",
       "80755     -1.01593797  0.676331199  0.025929684 -0.015551511 -0.48190870 â‹¯\n",
       "132949    -0.14750111  0.008273773 -0.354295910 -0.468248650  1.12450233 â‹¯\n",
       "60496     -0.20656249 -1.447627430 -0.635972151 -0.813942587 -0.30351542 â‹¯\n",
       "10157      0.06619184 -1.073017967  0.360057858  0.088183064  0.10562297 â‹¯\n",
       "26574     -0.90696552  0.741722227  0.115525095  0.525127204 -0.02269603 â‹¯\n",
       "9625       0.40020503  0.846322791 -0.563722812 -0.421367303 -0.37741081 â‹¯\n",
       "18         0.37397031 -0.694774261  0.863512974  0.599104197  2.67146770 â‹¯\n",
       "19         1.26404969 -0.427511343 -1.482748285 -0.696181189 -0.06458417 â‹¯\n",
       "10349      1.61967255 -0.032507461  0.914324720 -1.342999228 -0.17663893 â‹¯\n",
       "79963      0.41920735 -0.400974687  0.645256758 -1.092692381  0.66469135 â‹¯\n",
       "26154     -0.37161444 -0.028227463  2.638924429 -0.164492476  0.10278166 â‹¯\n",
       "â‹®         â‹®           â‹®            â‹®            â‹®            â‹®           â‹±\n",
       "342945    -0.39842900 -0.06185009   0.295370553 -0.034573759 -0.09391874 â‹¯\n",
       "222696    -0.01449303  0.75284400   0.289436376 -1.085860282 -1.05721611 â‹¯\n",
       "221785    -0.51898336  0.13570131   0.409446288 -0.637340889 -1.37948687 â‹¯\n",
       "7741       0.01065774 -0.63283478   0.058726096 -0.577334677  0.86416063 â‹¯\n",
       "146050    -0.32627016 -0.17288547  -0.005024687 -0.002828181  1.00703927 â‹¯\n",
       "100101467  0.67420610 -1.89818737   0.119016022 -1.131928408 -0.67472947 â‹¯\n",
       "64288      1.09726680  0.04967595   0.632491905 -0.667296562  1.18707021 â‹¯\n",
       "54925     -0.14868130  0.09693914   0.076161039 -0.171999152  0.59047047 â‹¯\n",
       "79149     -0.08029009 -0.30285166  -0.248634781  0.177474305  0.60403101 â‹¯\n",
       "7746      -0.45949079  0.10044855   0.432152688 -0.690101255  1.64129037 â‹¯\n",
       "90204     -0.41047321  0.16082499  -0.319394868 -0.088091568  0.70775603 â‹¯\n",
       "140831    -0.09417891 -0.05364741  -0.117780642 -0.130384785  0.21099894 â‹¯\n",
       "65249     -0.41079358 -0.65455483  -0.242563205 -0.746319797  0.51845273 â‹¯\n",
       "57643      0.06687714 -0.05579481  -0.114751841  1.162620098 -0.04053377 â‹¯\n",
       "57688     -0.53290552 -0.12483556   0.759970760  0.793365263  0.57702926 â‹¯\n",
       "125150    -0.22642199 -0.71603039   0.392523766  0.282615580 -0.53713084 â‹¯\n",
       "23053      0.41428274 -0.51550697  -0.080894641  0.082133502 -0.76319584 â‹¯\n",
       "100507331 -0.11400870 -0.11936992   0.159699991 -0.006716149 -0.11936992 â‹¯\n",
       "221302    -0.72205206 -0.14894922   0.394013252  0.460304807 -0.42601126 â‹¯\n",
       "9183      -0.48571814 -0.06369578   0.504081784  0.136045250  0.91063613 â‹¯\n",
       "55055     -1.11556081  0.38706633  -0.468675161 -0.209928304  0.46482463 â‹¯\n",
       "11130     -2.62608070  0.80556102   0.381913246  0.812508915  0.30872910 â‹¯\n",
       "7789       0.33662516 -0.04602627  -0.133536302  0.044225248 -0.66759771 â‹¯\n",
       "158586    -0.09917793  0.15027246   0.446774536  0.069298676  0.56592965 â‹¯\n",
       "79364      0.56529909 -0.67849788  -0.190789794 -0.329499666 -0.46066913 â‹¯\n",
       "440590    -0.06131873  0.03818382  -0.014894504 -0.095807574  0.55426201 â‹¯\n",
       "79699      0.01378568  0.16128751  -0.060919007 -0.019271522  0.69282995 â‹¯\n",
       "7791       0.63244321 -0.23837056  -0.292491200  0.254432485  0.53947147 â‹¯\n",
       "23140      0.78257787 -0.13963415   0.064831497 -0.036326222 -0.33190657 â‹¯\n",
       "26009     -0.20470475 -0.21243155   0.367259701  0.108939675  0.11705793 â‹¯\n",
       "          27           45            37           50          21          \n",
       "1          0.41001548   0.56281081   -0.404080959 -0.09683531  0.07795682 \n",
       "503538     0.52472946   0.20896041   -0.078336393  0.28806367 -0.19962044 \n",
       "2          1.21509583  -0.44592739    0.053971450 -1.33779511  0.91527044 \n",
       "144571     0.34009902  -0.13785662    0.298329396 -0.31798891  0.21741237 \n",
       "144568    -0.21934878  -0.21692891   -0.237359796 -0.23735980 -0.23735980 \n",
       "53947     -0.17836320   0.51738358   -0.443095914  0.17021327 -0.33249362 \n",
       "8086      -0.24621711   0.06665660    0.046360254 -0.14301866 -0.57249323 \n",
       "65985     -0.61963981  -0.40027635   -0.512799468 -0.07653565 -0.82674049 \n",
       "13        -0.30266465  -0.29286117   -0.302664653 -0.21290145 -0.30221605 \n",
       "51166     -0.73347481  -0.08721195    0.153937049 -0.10080308  0.94718541 \n",
       "195827    -0.38340551   0.01999654   -0.215550749 -0.05664716  1.00056670 \n",
       "79719      0.13297377  -0.40617561    0.222397759  0.25820075 -0.22124877 \n",
       "22848     -0.24071918   0.55907181    0.169113091  0.39831088  0.48747341 \n",
       "28971     -0.13406401   0.03353913    0.121743688  0.26792034 -0.45384589 \n",
       "14         0.66149884   0.25990243    0.239565954  0.40472396 -0.57777526 \n",
       "25980      0.89911132   0.01760844    0.002114438  0.06208155 -0.88950808 \n",
       "441376    -0.42379401  -0.36806678   -0.423794013  0.31468868  0.15504126 \n",
       "16         0.01239516   0.13642365    0.582612286  0.71406991 -0.22469959 \n",
       "57505     -0.46620276   0.07045982   -0.268643908 -0.31731923 -0.38380968 \n",
       "80755      0.38620060  -0.17520963   -0.034471880  0.20682546  0.22783938 \n",
       "132949     0.46125608  -1.16516003   -0.122944663 -0.22843993 -0.93798320 \n",
       "60496     -0.15001615  -0.48741332   -0.764905026 -0.94913318  0.23441955 \n",
       "10157     -0.04040087   0.09155972   -0.725416873  0.09209233 -0.38325458 \n",
       "26574      0.20510758  -0.14944834    0.170449658  0.42970776 -0.42352100 \n",
       "9625       0.02403999  -0.22568269   -0.643619983  1.88205421 -0.80027603 \n",
       "18        -0.11896869  -0.92173298    0.648023325  0.74306569  0.06889974 \n",
       "19         0.22976258  -0.03133024    0.632936139  0.57053063 -0.08189527 \n",
       "10349     -0.62589869  -0.81863690   -0.766357479 -0.28938889 -0.04469534 \n",
       "79963     -0.15225939  -0.22946814   -0.008558539 -0.15615992  0.52627577 \n",
       "26154     -0.15810368  -0.37516392   -0.378743901 -0.23750015 -0.37650973 \n",
       "â‹®         â‹®            â‹®             â‹®            â‹®           â‹®           \n",
       "342945    -0.104833874  0.0789830727 -0.19024034   0.06554628  0.042405031\n",
       "222696    -0.684481588 -0.2293771875 -0.72426880   0.61944225  1.329224079\n",
       "221785     0.165301677 -0.1770653416 -0.11729290  -0.17972412  0.066222843\n",
       "7741      -0.260105972  0.0669740558 -0.28622020  -0.15996478  0.523249135\n",
       "146050     0.037084696 -0.5998269449  0.10593199  -0.26650265  0.151094573\n",
       "100101467 -1.041502131  0.3057801131 -1.05158559   0.12320090  0.776823791\n",
       "64288      0.438984502  0.5274614781  0.32051797  -0.02793021 -0.747579020\n",
       "54925     -0.008358507 -0.4524072714 -0.16986475  -0.14406371 -0.350141136\n",
       "79149     -0.104324744  0.4320254326  0.64677035   0.26582626 -0.381941568\n",
       "7746       0.313789705  0.0642196942 -0.31365218   0.11595008  0.295624118\n",
       "90204      0.207165527 -0.3161638070 -0.09191130   0.04321212  0.234567670\n",
       "140831    -0.082798713 -0.0250849141 -0.08791917   0.09762790  0.150667063\n",
       "65249      0.040745861 -0.3207680305 -0.20890297   0.29902682  0.043011201\n",
       "57643      0.646442700 -0.4041607330 -0.42057300  -0.43117742 -0.587895416\n",
       "57688      0.508247388 -0.3163794667  0.13041877   0.61104754  0.067794381\n",
       "125150     0.293565902 -0.4012750092 -0.49602970  -0.62909866 -0.349480025\n",
       "23053     -0.292052772  1.0704226931 -0.03271785   0.45097641 -0.086864206\n",
       "100507331 -0.025406186 -0.0989390329 -0.03258464   0.18147031 -0.119369924\n",
       "221302     0.167630424 -0.4062481772  0.22824109   0.70563831 -0.090649064\n",
       "9183       0.243505506 -0.4439087932  0.03013266   0.08423296 -0.018914051\n",
       "55055     -0.605366439 -0.4412846494  0.25503931   0.31496113  0.262799951\n",
       "11130      0.351439294 -0.9000318013  0.97348718   1.37143617  0.640111663\n",
       "7789       0.328510667 -0.5599443165  0.37727755   0.08818719  0.240113319\n",
       "158586     0.357462377 -0.5646742600  0.11511414   0.27088915 -0.111782930\n",
       "79364     -0.140778229 -0.0005595549 -0.50095875  -0.28793686  0.160131815\n",
       "440590    -0.077796562 -0.0958075738 -0.05913173   0.04543618  0.001045315\n",
       "79699      0.071425738 -0.4277571728  0.17357627   0.33126353 -0.027790606\n",
       "7791       0.107125170  0.0735204548  0.33610451   0.21013737 -0.079428025\n",
       "23140     -0.014908065  0.3206683458 -0.43932309  -0.54818555  0.241345309\n",
       "26009     -0.755442532 -0.2027674488 -0.15576478  -0.23738481  0.227673130\n",
       "          17          15           23           34           32          \n",
       "1          0.53014756  0.844647025 -0.134897783  0.50874883  -0.15193508 \n",
       "503538    -0.65357875  0.408755426 -0.916067934 -0.15391097  -0.10178292 \n",
       "2          0.50604193 -0.245655206 -0.687799180  1.39761539  -2.91035093 \n",
       "144571    -0.12240057 -0.581928186 -0.648592702 -0.88460073   2.14689483 \n",
       "144568    -0.13673470  1.177814024 -0.005646842 -0.06694260  -0.23735980 \n",
       "53947     -0.10290469 -0.426662879 -0.778098432  0.36754271  -0.50179098 \n",
       "8086       0.50947306  0.577894297  0.127102527  0.37857683  -0.29167394 \n",
       "65985      0.59438443  0.196602903 -0.371793764 -0.46038391  -0.70080812 \n",
       "13         0.17466136 -0.086528609  0.233683066  0.06160048  -0.27430590 \n",
       "51166      0.45424333 -0.080781519 -0.460277938 -1.57796916  -0.57448733 \n",
       "195827     1.65211601  0.604318857 -0.445781787 -0.64032807   0.97142098 \n",
       "79719     -0.42028947  0.771840637 -0.548539669 -0.44464181  -0.81239457 \n",
       "22848     -0.28194137 -0.139581325 -0.632987209 -0.61763596   0.13236627 \n",
       "28971     -0.04184918  1.045931122 -0.125502782 -0.10081843  -0.65537677 \n",
       "14        -0.04119417  0.326728387  0.202824053  0.17986536  -1.27793190 \n",
       "25980     -0.60202869  0.869248872 -0.248164679 -0.51028527  -1.24746975 \n",
       "441376     2.19837135 -0.423794013 -0.423794013 -0.29551276  -0.08484930 \n",
       "16        -0.70040197  0.629494689  0.959250726 -0.55692466  -0.88930128 \n",
       "57505     -0.72578157  0.275779920  0.007205364  1.42682008  -0.45322791 \n",
       "80755     -0.63131328  0.101147324 -0.175523506 -0.35160431  -0.16351672 \n",
       "132949    -0.94662104  2.960583846 -0.415552259 -0.18049176  -0.11060645 \n",
       "60496      0.50415037 -0.024640740  0.867782801  1.01564139  -0.50311937 \n",
       "10157      0.92546584 -0.356148312 -1.032546605  0.28288690   0.95538032 \n",
       "26574     -0.35025961  0.202482977 -0.208935643 -0.19650144  -0.88508592 \n",
       "9625      -0.79644491  1.298371192 -0.476999606  0.13362286  -0.91172718 \n",
       "18         0.33279060 -1.103800435 -0.381884336 -1.16396909  -1.06332196 \n",
       "19         0.25661952 -0.524177121 -1.848173543  0.71687019   0.58731357 \n",
       "10349     -0.57412553 -0.405181147 -1.755711771 -0.46663115  -0.09948639 \n",
       "79963     -0.28912370  0.008149144  0.039477559  0.45518284   0.95346227 \n",
       "26154     -0.37072166  1.668581091 -0.218187538 -0.37606112  -0.37874390 \n",
       "â‹®         â‹®           â‹®            â‹®            â‹®            â‹®           \n",
       "342945    -0.03541245  0.73451363   0.28303949   0.074671159 -0.262986827\n",
       "222696     1.18560242  0.13528489  -1.19121746   0.416159043 -0.825154290\n",
       "221785     0.62846703  0.02671665   0.48032970   1.568978142 -0.467369389\n",
       "7741      -0.60984859 -0.22257846   0.51790614   1.199042844  0.528596755\n",
       "146050    -0.39833543  0.14627413  -0.08036012  -0.183474542 -0.287613243\n",
       "100101467  1.12900218 -0.84748896   0.76690701   0.857210539  0.688969184\n",
       "64288     -0.56504221  0.41067112   0.86166539   1.305194452 -0.406043240\n",
       "54925      0.24989487  0.10502969   0.84371340  -0.257445582 -0.231349766\n",
       "79149     -0.36031561  0.44353157  -0.07201303  -0.341529079 -0.303601981\n",
       "7746      -0.02733395 -0.02991003  -0.12986269   0.141537709  0.289072689\n",
       "90204     -0.10930172  0.31839563   0.52723083  -0.250318350 -0.058405510\n",
       "140831     0.01352765  0.17423614   0.63538207   0.130425590  0.057133464\n",
       "65249      0.63356178  0.12632883   0.22340880   1.186349306 -0.460522686\n",
       "57643     -0.09822088 -0.68013720  -0.42665048   0.480719433 -0.534976999\n",
       "57688     -0.43397318  0.03590784   0.02205099  -0.700488597 -0.465451820\n",
       "125150     1.27328563  1.53141429  -0.14398185  -0.001833785 -0.325687813\n",
       "23053      0.38212822 -0.57909518  -1.10373494   0.094320651  0.080271987\n",
       "100507331 -0.11936992  0.07702330   0.09514177  -0.119369924 -0.119369924\n",
       "221302    -0.85519296  0.16246605   0.96827871  -1.022146067  0.670878172\n",
       "9183      -0.13432189  0.53900488  -0.21405222  -0.538250246 -0.015166293\n",
       "55055      0.39724886 -0.03329266   0.41080232  -0.766047908  0.008691614\n",
       "11130     -0.54785782  1.11436707  -0.35400995  -1.695316744 -0.394695493\n",
       "7789      -0.22319036  0.13554354  -0.38289902  -0.143425114 -0.734985177\n",
       "158586    -0.51547930  0.25877652   0.26529255  -0.171242002 -0.431495671\n",
       "79364      0.13651835 -0.26315230   0.06811924   0.564314391  0.553030834\n",
       "440590    -0.02594056 -0.05478135  -0.04695407  -0.068337272  0.567570255\n",
       "79699      0.18921212  0.14859193  -0.03533289  -0.191640998 -0.170930205\n",
       "7791       0.42419145 -0.33001021  -0.55516310   0.736564406 -0.578044742\n",
       "23140      0.10411358 -0.70105036  -0.54986056   0.066472443  1.003023165\n",
       "26009     -0.16324147  1.23636907   1.10751447  -0.166047613  0.725873295"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "pni_self_subtract"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "23f8d36f",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table>\n",
       "<caption>A data.frame: 32 Ã— 18780</caption>\n",
       "<thead>\n",
       "\t<tr><th></th><th scope=col>1</th><th scope=col>503538</th><th scope=col>2</th><th scope=col>144571</th><th scope=col>144568</th><th scope=col>53947</th><th scope=col>8086</th><th scope=col>65985</th><th scope=col>13</th><th scope=col>51166</th><th scope=col>â‹¯</th><th scope=col>55055</th><th scope=col>11130</th><th scope=col>7789</th><th scope=col>158586</th><th scope=col>79364</th><th scope=col>440590</th><th scope=col>79699</th><th scope=col>7791</th><th scope=col>23140</th><th scope=col>26009</th></tr>\n",
       "\t<tr><th></th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>â‹¯</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><th scope=row>36</th><td> 0.02207971</td><td>-0.399344035</td><td> 1.31004461</td><td> 0.28266209</td><td>-0.211653475</td><td>-0.20174329</td><td> 0.27101637</td><td> 0.358306002</td><td>-0.178516924</td><td>-0.27117599</td><td>â‹¯</td><td>-0.231554875</td><td> 0.42826173</td><td> 0.17136963</td><td> 0.43681965</td><td>-0.0434933523</td><td>-0.070101252</td><td>-0.77012086</td><td> 0.026242002</td><td>-0.29389081</td><td>-1.04418568</td></tr>\n",
       "\t<tr><th scope=row>26</th><td> 0.36939855</td><td> 0.493796520</td><td>-2.05553544</td><td>-0.13408502</td><td>-0.232882607</td><td>-0.17725880</td><td> 0.12710253</td><td>-0.563640470</td><td>-0.277821510</td><td> 0.54745043</td><td>â‹¯</td><td> 0.462127921</td><td> 0.57497284</td><td>-0.59890304</td><td>-0.44415190</td><td> 0.7441192974</td><td> 0.069465219</td><td>-0.38604727</td><td>-0.899311870</td><td> 0.37238568</td><td>-0.43646272</td></tr>\n",
       "\t<tr><th scope=row>19</th><td> 0.01444574</td><td> 0.303172491</td><td>-0.68074489</td><td> 0.09653197</td><td>-0.228000498</td><td>-0.12162473</td><td>-0.03935541</td><td>-0.278664880</td><td>-0.244767600</td><td>-1.29409560</td><td>â‹¯</td><td>-0.990153661</td><td>-0.66884995</td><td> 0.75507446</td><td> 0.45702034</td><td>-0.0978608256</td><td>-0.037910521</td><td>-0.19641500</td><td>-0.002663966</td><td> 0.14242927</td><td>-0.53603414</td></tr>\n",
       "\t<tr><th scope=row>7</th><td> 0.31640366</td><td>-0.235838135</td><td>-0.03021626</td><td>-0.39529128</td><td>-0.237359796</td><td>-0.41787845</td><td>-0.95790485</td><td>-0.269379893</td><td> 0.255566934</td><td> 0.36570576</td><td>â‹¯</td><td> 0.715314720</td><td> 0.32665483</td><td> 0.27464873</td><td>-0.37869573</td><td>-0.2000784318</td><td>-0.095807574</td><td> 0.13778226</td><td> 0.704947921</td><td>-0.55133851</td><td> 0.40732392</td></tr>\n",
       "\t<tr><th scope=row>44</th><td>-0.96796873</td><td>-0.371735137</td><td> 0.52259067</td><td> 0.29058114</td><td> 1.395459295</td><td> 1.24960347</td><td>-0.09848238</td><td> 0.458516286</td><td>-0.202878631</td><td>-0.08453939</td><td>â‹¯</td><td> 0.206773696</td><td>-0.42747899</td><td>-0.06521667</td><td>-0.31779465</td><td>-0.6308434283</td><td>-0.012797742</td><td> 0.16718252</td><td> 1.344192060</td><td>-0.03809493</td><td>-0.45864802</td></tr>\n",
       "\t<tr><th scope=row>12</th><td>-1.07111293</td><td>-0.443266849</td><td> 2.31713808</td><td> 0.10786869</td><td>-0.231998574</td><td> 0.63256619</td><td>-0.06593464</td><td>-0.693757330</td><td> 0.953050943</td><td>-0.26277554</td><td>â‹¯</td><td>-1.115560810</td><td>-2.62608070</td><td> 0.33662516</td><td>-0.09917793</td><td> 0.5652990871</td><td>-0.061318728</td><td> 0.01378568</td><td> 0.632443208</td><td> 0.78257787</td><td>-0.20470475</td></tr>\n",
       "\t<tr><th scope=row>49</th><td> 1.12169522</td><td> 0.006291004</td><td> 1.45629787</td><td> 1.01360921</td><td> 0.002645532</td><td> 0.94840078</td><td>-0.20153784</td><td> 0.833486730</td><td> 0.984990581</td><td>-0.17668222</td><td>â‹¯</td><td> 0.387066334</td><td> 0.80556102</td><td>-0.04602627</td><td> 0.15027246</td><td>-0.6784978765</td><td> 0.038183825</td><td> 0.16128751</td><td>-0.238370565</td><td>-0.13963415</td><td>-0.21243155</td></tr>\n",
       "\t<tr><th scope=row>35</th><td> 0.47515082</td><td> 0.339123809</td><td>-0.66586039</td><td>-0.09308171</td><td> 1.333911644</td><td> 0.01596500</td><td>-0.01988318</td><td> 0.391613692</td><td> 0.007535656</td><td>-0.68749743</td><td>â‹¯</td><td>-0.468675161</td><td> 0.38191325</td><td>-0.13353630</td><td> 0.44677454</td><td>-0.1907897938</td><td>-0.014894504</td><td>-0.06091901</td><td>-0.292491200</td><td> 0.06483150</td><td> 0.36725970</td></tr>\n",
       "\t<tr><th scope=row>13</th><td>-1.20920482</td><td>-0.541433333</td><td>-0.01989287</td><td> 0.65408586</td><td>-0.225330893</td><td>-0.87607703</td><td>-0.34607874</td><td> 0.000386568</td><td>-0.049628185</td><td>-0.98399232</td><td>â‹¯</td><td>-0.209928304</td><td> 0.81250891</td><td> 0.04422525</td><td> 0.06929868</td><td>-0.3294996664</td><td>-0.095807574</td><td>-0.01927152</td><td> 0.254432485</td><td>-0.03632622</td><td> 0.10893968</td></tr>\n",
       "\t<tr><th scope=row>10</th><td>-0.61833240</td><td> 0.014714726</td><td>-0.70065194</td><td>-0.36349872</td><td>-0.237359796</td><td> 0.49662548</td><td>-0.49421422</td><td> 1.184709176</td><td>-0.302664653</td><td> 1.68367428</td><td>â‹¯</td><td> 0.464824631</td><td> 0.30872910</td><td>-0.66759771</td><td> 0.56592965</td><td>-0.4606691302</td><td> 0.554262011</td><td> 0.69282995</td><td> 0.539471466</td><td>-0.33190657</td><td> 0.11705793</td></tr>\n",
       "\t<tr><th scope=row>20</th><td>-0.65328955</td><td>-0.009017929</td><td>-2.61089336</td><td> 1.56201705</td><td>-0.237359796</td><td>-0.02991692</td><td>-0.33408666</td><td>-0.470624511</td><td>-0.302664653</td><td>-1.67812454</td><td>â‹¯</td><td>-0.399369346</td><td>-1.27744820</td><td> 1.16563917</td><td> 0.44796852</td><td> 0.9177473835</td><td>-0.044360443</td><td>-0.21307855</td><td>-0.099479074</td><td> 1.54256398</td><td> 0.60783149</td></tr>\n",
       "\t<tr><th scope=row>47</th><td> 0.11378060</td><td>-0.021088798</td><td> 2.53003058</td><td>-0.22085073</td><td>-0.237359796</td><td>-0.38662798</td><td>-0.08049887</td><td> 0.084577558</td><td>-0.111384349</td><td> 1.85279854</td><td>â‹¯</td><td>-0.570139294</td><td>-0.38900084</td><td> 0.20432131</td><td> 0.13540615</td><td>-0.4530921630</td><td>-0.018278153</td><td> 0.07228018</td><td> 0.273916435</td><td>-0.32552466</td><td>-0.16369490</td></tr>\n",
       "\t<tr><th scope=row>6</th><td> 0.62167117</td><td> 0.091416345</td><td> 0.62158990</td><td>-0.03477088</td><td>-0.175185870</td><td>-0.08569925</td><td> 0.47304122</td><td> 0.092149856</td><td>-0.302664653</td><td>-1.47604319</td><td>â‹¯</td><td> 0.230476038</td><td>-0.34597308</td><td>-0.02931501</td><td> 0.33392762</td><td> 0.1422300068</td><td>-0.006887237</td><td>-0.09623038</td><td>-1.180614170</td><td> 0.44382387</td><td> 0.03539586</td></tr>\n",
       "\t<tr><th scope=row>8</th><td>-0.54902719</td><td> 0.341409675</td><td>-2.46492428</td><td> 0.44848632</td><td>-0.237359796</td><td>-0.31377513</td><td>-0.03090046</td><td> 0.023858648</td><td>-0.302664653</td><td> 0.28155117</td><td>â‹¯</td><td> 0.445047608</td><td> 0.80762933</td><td>-0.38707532</td><td> 0.08435613</td><td>-0.3666242486</td><td>-0.043040810</td><td> 0.32211429</td><td>-0.606676792</td><td>-1.13187658</td><td> 0.65424050</td></tr>\n",
       "\t<tr><th scope=row>25</th><td>-0.07396639</td><td> 0.401290758</td><td> 0.55684035</td><td>-0.39839382</td><td>-0.237359796</td><td>-0.58350184</td><td>-0.02299018</td><td>-0.174699076</td><td>-0.220938440</td><td> 2.56189614</td><td>â‹¯</td><td> 0.323958497</td><td>-0.28877420</td><td>-0.34308412</td><td>-0.42472156</td><td> 0.7366265926</td><td>-0.095807574</td><td> 0.41074512</td><td>-0.507792891</td><td> 0.20384346</td><td> 0.47588991</td></tr>\n",
       "\t<tr><th scope=row>38</th><td>-0.78473411</td><td>-0.007786946</td><td> 0.12535732</td><td> 0.17412395</td><td> 1.627082607</td><td> 1.06191207</td><td>-0.42805163</td><td> 1.255571317</td><td> 0.863890733</td><td> 0.82273223</td><td>â‹¯</td><td>-0.253086816</td><td>-1.03622267</td><td> 0.74340903</td><td>-0.44263081</td><td>-0.7088331041</td><td> 0.021772744</td><td> 0.30909709</td><td> 0.001373924</td><td> 0.42681432</td><td>-0.13050942</td></tr>\n",
       "\t<tr><th scope=row>33</th><td> 0.07099564</td><td> 0.126628269</td><td>-1.06228132</td><td>-1.02816088</td><td>-0.237359796</td><td>-0.05546289</td><td>-0.16485930</td><td> 0.057565285</td><td> 0.476762432</td><td> 0.26284499</td><td>â‹¯</td><td> 0.543191258</td><td> 0.96220905</td><td> 0.08654803</td><td> 0.29531747</td><td>-0.0733442796</td><td>-0.071404280</td><td> 0.04744246</td><td> 0.311459770</td><td>-0.45692695</td><td>-0.22853974</td></tr>\n",
       "\t<tr><th scope=row>24</th><td> 0.37516263</td><td> 0.426870012</td><td> 2.01021002</td><td>-0.34082043</td><td>-0.237359796</td><td> 0.48781240</td><td> 0.81495642</td><td> 0.719710922</td><td> 0.116441049</td><td>-0.44445564</td><td>â‹¯</td><td>-0.772687949</td><td>-0.17954929</td><td> 0.15757350</td><td>-0.04612901</td><td> 0.1787330668</td><td>-0.049971772</td><td> 0.06365311</td><td>-0.651993693</td><td> 0.41805088</td><td>-0.40544793</td></tr>\n",
       "\t<tr><th scope=row>46</th><td>-0.60460995</td><td>-0.633224248</td><td> 0.35203165</td><td> 0.02142486</td><td>-0.160261807</td><td> 0.52801138</td><td> 0.40059380</td><td>-0.407841262</td><td>-0.036193900</td><td>-0.14603845</td><td>â‹¯</td><td>-0.235865821</td><td>-0.80103916</td><td> 0.22053955</td><td>-0.19983454</td><td> 0.2138286755</td><td>-0.086896878</td><td>-0.09116498</td><td> 0.038010253</td><td> 0.27755322</td><td> 0.04282373</td></tr>\n",
       "\t<tr><th scope=row>2</th><td> 0.26308695</td><td>-0.198786053</td><td> 2.61522967</td><td>-0.87343823</td><td>-0.237359796</td><td>-0.43357541</td><td> 0.58687354</td><td>-0.931199668</td><td>-0.250773339</td><td> 0.90035292</td><td>â‹¯</td><td> 1.079653224</td><td> 0.62934788</td><td>-1.23471534</td><td>-0.96470192</td><td> 0.5255918237</td><td>-0.095807574</td><td>-0.52099920</td><td> 0.825633802</td><td> 0.08874634</td><td> 0.01569202</td></tr>\n",
       "\t<tr><th scope=row>1</th><td> 0.30924051</td><td> 0.175282282</td><td>-1.30334835</td><td>-0.07670974</td><td>-0.102960393</td><td>-0.09473420</td><td> 0.27427407</td><td> 0.427291541</td><td>-0.182195396</td><td> 0.10514388</td><td>â‹¯</td><td> 0.814559991</td><td> 0.09616738</td><td>-0.27965633</td><td> 0.31559451</td><td>-0.0626374123</td><td> 0.055108447</td><td>-0.56911380</td><td>-0.380607347</td><td>-0.52103880</td><td>-0.46877980</td></tr>\n",
       "\t<tr><th scope=row>14</th><td> 0.31255748</td><td> 0.814314007</td><td>-1.28347883</td><td>-1.00165760</td><td>-0.237359796</td><td> 0.06524928</td><td>-0.11574019</td><td> 1.080053742</td><td> 0.611716136</td><td> 0.18090993</td><td>â‹¯</td><td>-0.229523423</td><td> 1.34753221</td><td> 0.49996400</td><td> 0.10629174</td><td>-0.0166411617</td><td>-0.023002256</td><td> 0.46454270</td><td>-0.437119044</td><td>-0.41935743</td><td>-0.15979738</td></tr>\n",
       "\t<tr><th scope=row>27</th><td> 0.41001548</td><td> 0.524729460</td><td> 1.21509583</td><td> 0.34009902</td><td>-0.219348784</td><td>-0.17836320</td><td>-0.24621711</td><td>-0.619639812</td><td>-0.302664653</td><td>-0.73347481</td><td>â‹¯</td><td>-0.605366439</td><td> 0.35143929</td><td> 0.32851067</td><td> 0.35746238</td><td>-0.1407782292</td><td>-0.077796562</td><td> 0.07142574</td><td> 0.107125170</td><td>-0.01490806</td><td>-0.75544253</td></tr>\n",
       "\t<tr><th scope=row>45</th><td> 0.56281081</td><td> 0.208960409</td><td>-0.44592739</td><td>-0.13785662</td><td>-0.216928906</td><td> 0.51738358</td><td> 0.06665660</td><td>-0.400276352</td><td>-0.292861171</td><td>-0.08721195</td><td>â‹¯</td><td>-0.441284649</td><td>-0.90003180</td><td>-0.55994432</td><td>-0.56467426</td><td>-0.0005595549</td><td>-0.095807574</td><td>-0.42775717</td><td> 0.073520455</td><td> 0.32066835</td><td>-0.20276745</td></tr>\n",
       "\t<tr><th scope=row>37</th><td>-0.40408096</td><td>-0.078336393</td><td> 0.05397145</td><td> 0.29832940</td><td>-0.237359796</td><td>-0.44309591</td><td> 0.04636025</td><td>-0.512799468</td><td>-0.302664653</td><td> 0.15393705</td><td>â‹¯</td><td> 0.255039312</td><td> 0.97348718</td><td> 0.37727755</td><td> 0.11511414</td><td>-0.5009587486</td><td>-0.059131734</td><td> 0.17357627</td><td> 0.336104507</td><td>-0.43932309</td><td>-0.15576478</td></tr>\n",
       "\t<tr><th scope=row>50</th><td>-0.09683531</td><td> 0.288063672</td><td>-1.33779511</td><td>-0.31798891</td><td>-0.237359796</td><td> 0.17021327</td><td>-0.14301866</td><td>-0.076535653</td><td>-0.212901448</td><td>-0.10080308</td><td>â‹¯</td><td> 0.314961134</td><td> 1.37143617</td><td> 0.08818719</td><td> 0.27088915</td><td>-0.2879368575</td><td> 0.045436179</td><td> 0.33126353</td><td> 0.210137373</td><td>-0.54818555</td><td>-0.23738481</td></tr>\n",
       "\t<tr><th scope=row>21</th><td> 0.07795682</td><td>-0.199620442</td><td> 0.91527044</td><td> 0.21741237</td><td>-0.237359796</td><td>-0.33249362</td><td>-0.57249323</td><td>-0.826740488</td><td>-0.302216050</td><td> 0.94718541</td><td>â‹¯</td><td> 0.262799951</td><td> 0.64011166</td><td> 0.24011332</td><td>-0.11178293</td><td> 0.1601318153</td><td> 0.001045315</td><td>-0.02779061</td><td>-0.079428025</td><td> 0.24134531</td><td> 0.22767313</td></tr>\n",
       "\t<tr><th scope=row>17</th><td> 0.53014756</td><td>-0.653578751</td><td> 0.50604193</td><td>-0.12240057</td><td>-0.136734702</td><td>-0.10290469</td><td> 0.50947306</td><td> 0.594384435</td><td> 0.174661357</td><td> 0.45424333</td><td>â‹¯</td><td> 0.397248856</td><td>-0.54785782</td><td>-0.22319036</td><td>-0.51547930</td><td> 0.1365183514</td><td>-0.025940561</td><td> 0.18921212</td><td> 0.424191448</td><td> 0.10411358</td><td>-0.16324147</td></tr>\n",
       "\t<tr><th scope=row>15</th><td> 0.84464702</td><td> 0.408755426</td><td>-0.24565521</td><td>-0.58192819</td><td> 1.177814024</td><td>-0.42666288</td><td> 0.57789430</td><td> 0.196602903</td><td>-0.086528609</td><td>-0.08078152</td><td>â‹¯</td><td>-0.033292657</td><td> 1.11436707</td><td> 0.13554354</td><td> 0.25877652</td><td>-0.2631522968</td><td>-0.054781348</td><td> 0.14859193</td><td>-0.330010210</td><td>-0.70105036</td><td> 1.23636907</td></tr>\n",
       "\t<tr><th scope=row>23</th><td>-0.13489778</td><td>-0.916067934</td><td>-0.68779918</td><td>-0.64859270</td><td>-0.005646842</td><td>-0.77809843</td><td> 0.12710253</td><td>-0.371793764</td><td> 0.233683066</td><td>-0.46027794</td><td>â‹¯</td><td> 0.410802324</td><td>-0.35400995</td><td>-0.38289902</td><td> 0.26529255</td><td> 0.0681192357</td><td>-0.046954071</td><td>-0.03533289</td><td>-0.555163096</td><td>-0.54986056</td><td> 1.10751447</td></tr>\n",
       "\t<tr><th scope=row>34</th><td> 0.50874883</td><td>-0.153910966</td><td> 1.39761539</td><td>-0.88460073</td><td>-0.066942602</td><td> 0.36754271</td><td> 0.37857683</td><td>-0.460383913</td><td> 0.061600482</td><td>-1.57796916</td><td>â‹¯</td><td>-0.766047908</td><td>-1.69531674</td><td>-0.14342511</td><td>-0.17124200</td><td> 0.5643143914</td><td>-0.068337272</td><td>-0.19164100</td><td> 0.736564406</td><td> 0.06647244</td><td>-0.16604761</td></tr>\n",
       "\t<tr><th scope=row>32</th><td>-0.15193508</td><td>-0.101782915</td><td>-2.91035093</td><td> 2.14689483</td><td>-0.237359796</td><td>-0.50179098</td><td>-0.29167394</td><td>-0.700808119</td><td>-0.274305898</td><td>-0.57448733</td><td>â‹¯</td><td> 0.008691614</td><td>-0.39469549</td><td>-0.73498518</td><td>-0.43149567</td><td> 0.5530308342</td><td> 0.567570255</td><td>-0.17093020</td><td>-0.578044742</td><td> 1.00302316</td><td> 0.72587330</td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A data.frame: 32 Ã— 18780\n",
       "\\begin{tabular}{r|lllllllllllllllllllll}\n",
       "  & 1 & 503538 & 2 & 144571 & 144568 & 53947 & 8086 & 65985 & 13 & 51166 & â‹¯ & 55055 & 11130 & 7789 & 158586 & 79364 & 440590 & 79699 & 7791 & 23140 & 26009\\\\\n",
       "  & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & â‹¯ & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl>\\\\\n",
       "\\hline\n",
       "\t36 &  0.02207971 & -0.399344035 &  1.31004461 &  0.28266209 & -0.211653475 & -0.20174329 &  0.27101637 &  0.358306002 & -0.178516924 & -0.27117599 & â‹¯ & -0.231554875 &  0.42826173 &  0.17136963 &  0.43681965 & -0.0434933523 & -0.070101252 & -0.77012086 &  0.026242002 & -0.29389081 & -1.04418568\\\\\n",
       "\t26 &  0.36939855 &  0.493796520 & -2.05553544 & -0.13408502 & -0.232882607 & -0.17725880 &  0.12710253 & -0.563640470 & -0.277821510 &  0.54745043 & â‹¯ &  0.462127921 &  0.57497284 & -0.59890304 & -0.44415190 &  0.7441192974 &  0.069465219 & -0.38604727 & -0.899311870 &  0.37238568 & -0.43646272\\\\\n",
       "\t19 &  0.01444574 &  0.303172491 & -0.68074489 &  0.09653197 & -0.228000498 & -0.12162473 & -0.03935541 & -0.278664880 & -0.244767600 & -1.29409560 & â‹¯ & -0.990153661 & -0.66884995 &  0.75507446 &  0.45702034 & -0.0978608256 & -0.037910521 & -0.19641500 & -0.002663966 &  0.14242927 & -0.53603414\\\\\n",
       "\t7 &  0.31640366 & -0.235838135 & -0.03021626 & -0.39529128 & -0.237359796 & -0.41787845 & -0.95790485 & -0.269379893 &  0.255566934 &  0.36570576 & â‹¯ &  0.715314720 &  0.32665483 &  0.27464873 & -0.37869573 & -0.2000784318 & -0.095807574 &  0.13778226 &  0.704947921 & -0.55133851 &  0.40732392\\\\\n",
       "\t44 & -0.96796873 & -0.371735137 &  0.52259067 &  0.29058114 &  1.395459295 &  1.24960347 & -0.09848238 &  0.458516286 & -0.202878631 & -0.08453939 & â‹¯ &  0.206773696 & -0.42747899 & -0.06521667 & -0.31779465 & -0.6308434283 & -0.012797742 &  0.16718252 &  1.344192060 & -0.03809493 & -0.45864802\\\\\n",
       "\t12 & -1.07111293 & -0.443266849 &  2.31713808 &  0.10786869 & -0.231998574 &  0.63256619 & -0.06593464 & -0.693757330 &  0.953050943 & -0.26277554 & â‹¯ & -1.115560810 & -2.62608070 &  0.33662516 & -0.09917793 &  0.5652990871 & -0.061318728 &  0.01378568 &  0.632443208 &  0.78257787 & -0.20470475\\\\\n",
       "\t49 &  1.12169522 &  0.006291004 &  1.45629787 &  1.01360921 &  0.002645532 &  0.94840078 & -0.20153784 &  0.833486730 &  0.984990581 & -0.17668222 & â‹¯ &  0.387066334 &  0.80556102 & -0.04602627 &  0.15027246 & -0.6784978765 &  0.038183825 &  0.16128751 & -0.238370565 & -0.13963415 & -0.21243155\\\\\n",
       "\t35 &  0.47515082 &  0.339123809 & -0.66586039 & -0.09308171 &  1.333911644 &  0.01596500 & -0.01988318 &  0.391613692 &  0.007535656 & -0.68749743 & â‹¯ & -0.468675161 &  0.38191325 & -0.13353630 &  0.44677454 & -0.1907897938 & -0.014894504 & -0.06091901 & -0.292491200 &  0.06483150 &  0.36725970\\\\\n",
       "\t13 & -1.20920482 & -0.541433333 & -0.01989287 &  0.65408586 & -0.225330893 & -0.87607703 & -0.34607874 &  0.000386568 & -0.049628185 & -0.98399232 & â‹¯ & -0.209928304 &  0.81250891 &  0.04422525 &  0.06929868 & -0.3294996664 & -0.095807574 & -0.01927152 &  0.254432485 & -0.03632622 &  0.10893968\\\\\n",
       "\t10 & -0.61833240 &  0.014714726 & -0.70065194 & -0.36349872 & -0.237359796 &  0.49662548 & -0.49421422 &  1.184709176 & -0.302664653 &  1.68367428 & â‹¯ &  0.464824631 &  0.30872910 & -0.66759771 &  0.56592965 & -0.4606691302 &  0.554262011 &  0.69282995 &  0.539471466 & -0.33190657 &  0.11705793\\\\\n",
       "\t20 & -0.65328955 & -0.009017929 & -2.61089336 &  1.56201705 & -0.237359796 & -0.02991692 & -0.33408666 & -0.470624511 & -0.302664653 & -1.67812454 & â‹¯ & -0.399369346 & -1.27744820 &  1.16563917 &  0.44796852 &  0.9177473835 & -0.044360443 & -0.21307855 & -0.099479074 &  1.54256398 &  0.60783149\\\\\n",
       "\t47 &  0.11378060 & -0.021088798 &  2.53003058 & -0.22085073 & -0.237359796 & -0.38662798 & -0.08049887 &  0.084577558 & -0.111384349 &  1.85279854 & â‹¯ & -0.570139294 & -0.38900084 &  0.20432131 &  0.13540615 & -0.4530921630 & -0.018278153 &  0.07228018 &  0.273916435 & -0.32552466 & -0.16369490\\\\\n",
       "\t6 &  0.62167117 &  0.091416345 &  0.62158990 & -0.03477088 & -0.175185870 & -0.08569925 &  0.47304122 &  0.092149856 & -0.302664653 & -1.47604319 & â‹¯ &  0.230476038 & -0.34597308 & -0.02931501 &  0.33392762 &  0.1422300068 & -0.006887237 & -0.09623038 & -1.180614170 &  0.44382387 &  0.03539586\\\\\n",
       "\t8 & -0.54902719 &  0.341409675 & -2.46492428 &  0.44848632 & -0.237359796 & -0.31377513 & -0.03090046 &  0.023858648 & -0.302664653 &  0.28155117 & â‹¯ &  0.445047608 &  0.80762933 & -0.38707532 &  0.08435613 & -0.3666242486 & -0.043040810 &  0.32211429 & -0.606676792 & -1.13187658 &  0.65424050\\\\\n",
       "\t25 & -0.07396639 &  0.401290758 &  0.55684035 & -0.39839382 & -0.237359796 & -0.58350184 & -0.02299018 & -0.174699076 & -0.220938440 &  2.56189614 & â‹¯ &  0.323958497 & -0.28877420 & -0.34308412 & -0.42472156 &  0.7366265926 & -0.095807574 &  0.41074512 & -0.507792891 &  0.20384346 &  0.47588991\\\\\n",
       "\t38 & -0.78473411 & -0.007786946 &  0.12535732 &  0.17412395 &  1.627082607 &  1.06191207 & -0.42805163 &  1.255571317 &  0.863890733 &  0.82273223 & â‹¯ & -0.253086816 & -1.03622267 &  0.74340903 & -0.44263081 & -0.7088331041 &  0.021772744 &  0.30909709 &  0.001373924 &  0.42681432 & -0.13050942\\\\\n",
       "\t33 &  0.07099564 &  0.126628269 & -1.06228132 & -1.02816088 & -0.237359796 & -0.05546289 & -0.16485930 &  0.057565285 &  0.476762432 &  0.26284499 & â‹¯ &  0.543191258 &  0.96220905 &  0.08654803 &  0.29531747 & -0.0733442796 & -0.071404280 &  0.04744246 &  0.311459770 & -0.45692695 & -0.22853974\\\\\n",
       "\t24 &  0.37516263 &  0.426870012 &  2.01021002 & -0.34082043 & -0.237359796 &  0.48781240 &  0.81495642 &  0.719710922 &  0.116441049 & -0.44445564 & â‹¯ & -0.772687949 & -0.17954929 &  0.15757350 & -0.04612901 &  0.1787330668 & -0.049971772 &  0.06365311 & -0.651993693 &  0.41805088 & -0.40544793\\\\\n",
       "\t46 & -0.60460995 & -0.633224248 &  0.35203165 &  0.02142486 & -0.160261807 &  0.52801138 &  0.40059380 & -0.407841262 & -0.036193900 & -0.14603845 & â‹¯ & -0.235865821 & -0.80103916 &  0.22053955 & -0.19983454 &  0.2138286755 & -0.086896878 & -0.09116498 &  0.038010253 &  0.27755322 &  0.04282373\\\\\n",
       "\t2 &  0.26308695 & -0.198786053 &  2.61522967 & -0.87343823 & -0.237359796 & -0.43357541 &  0.58687354 & -0.931199668 & -0.250773339 &  0.90035292 & â‹¯ &  1.079653224 &  0.62934788 & -1.23471534 & -0.96470192 &  0.5255918237 & -0.095807574 & -0.52099920 &  0.825633802 &  0.08874634 &  0.01569202\\\\\n",
       "\t1 &  0.30924051 &  0.175282282 & -1.30334835 & -0.07670974 & -0.102960393 & -0.09473420 &  0.27427407 &  0.427291541 & -0.182195396 &  0.10514388 & â‹¯ &  0.814559991 &  0.09616738 & -0.27965633 &  0.31559451 & -0.0626374123 &  0.055108447 & -0.56911380 & -0.380607347 & -0.52103880 & -0.46877980\\\\\n",
       "\t14 &  0.31255748 &  0.814314007 & -1.28347883 & -1.00165760 & -0.237359796 &  0.06524928 & -0.11574019 &  1.080053742 &  0.611716136 &  0.18090993 & â‹¯ & -0.229523423 &  1.34753221 &  0.49996400 &  0.10629174 & -0.0166411617 & -0.023002256 &  0.46454270 & -0.437119044 & -0.41935743 & -0.15979738\\\\\n",
       "\t27 &  0.41001548 &  0.524729460 &  1.21509583 &  0.34009902 & -0.219348784 & -0.17836320 & -0.24621711 & -0.619639812 & -0.302664653 & -0.73347481 & â‹¯ & -0.605366439 &  0.35143929 &  0.32851067 &  0.35746238 & -0.1407782292 & -0.077796562 &  0.07142574 &  0.107125170 & -0.01490806 & -0.75544253\\\\\n",
       "\t45 &  0.56281081 &  0.208960409 & -0.44592739 & -0.13785662 & -0.216928906 &  0.51738358 &  0.06665660 & -0.400276352 & -0.292861171 & -0.08721195 & â‹¯ & -0.441284649 & -0.90003180 & -0.55994432 & -0.56467426 & -0.0005595549 & -0.095807574 & -0.42775717 &  0.073520455 &  0.32066835 & -0.20276745\\\\\n",
       "\t37 & -0.40408096 & -0.078336393 &  0.05397145 &  0.29832940 & -0.237359796 & -0.44309591 &  0.04636025 & -0.512799468 & -0.302664653 &  0.15393705 & â‹¯ &  0.255039312 &  0.97348718 &  0.37727755 &  0.11511414 & -0.5009587486 & -0.059131734 &  0.17357627 &  0.336104507 & -0.43932309 & -0.15576478\\\\\n",
       "\t50 & -0.09683531 &  0.288063672 & -1.33779511 & -0.31798891 & -0.237359796 &  0.17021327 & -0.14301866 & -0.076535653 & -0.212901448 & -0.10080308 & â‹¯ &  0.314961134 &  1.37143617 &  0.08818719 &  0.27088915 & -0.2879368575 &  0.045436179 &  0.33126353 &  0.210137373 & -0.54818555 & -0.23738481\\\\\n",
       "\t21 &  0.07795682 & -0.199620442 &  0.91527044 &  0.21741237 & -0.237359796 & -0.33249362 & -0.57249323 & -0.826740488 & -0.302216050 &  0.94718541 & â‹¯ &  0.262799951 &  0.64011166 &  0.24011332 & -0.11178293 &  0.1601318153 &  0.001045315 & -0.02779061 & -0.079428025 &  0.24134531 &  0.22767313\\\\\n",
       "\t17 &  0.53014756 & -0.653578751 &  0.50604193 & -0.12240057 & -0.136734702 & -0.10290469 &  0.50947306 &  0.594384435 &  0.174661357 &  0.45424333 & â‹¯ &  0.397248856 & -0.54785782 & -0.22319036 & -0.51547930 &  0.1365183514 & -0.025940561 &  0.18921212 &  0.424191448 &  0.10411358 & -0.16324147\\\\\n",
       "\t15 &  0.84464702 &  0.408755426 & -0.24565521 & -0.58192819 &  1.177814024 & -0.42666288 &  0.57789430 &  0.196602903 & -0.086528609 & -0.08078152 & â‹¯ & -0.033292657 &  1.11436707 &  0.13554354 &  0.25877652 & -0.2631522968 & -0.054781348 &  0.14859193 & -0.330010210 & -0.70105036 &  1.23636907\\\\\n",
       "\t23 & -0.13489778 & -0.916067934 & -0.68779918 & -0.64859270 & -0.005646842 & -0.77809843 &  0.12710253 & -0.371793764 &  0.233683066 & -0.46027794 & â‹¯ &  0.410802324 & -0.35400995 & -0.38289902 &  0.26529255 &  0.0681192357 & -0.046954071 & -0.03533289 & -0.555163096 & -0.54986056 &  1.10751447\\\\\n",
       "\t34 &  0.50874883 & -0.153910966 &  1.39761539 & -0.88460073 & -0.066942602 &  0.36754271 &  0.37857683 & -0.460383913 &  0.061600482 & -1.57796916 & â‹¯ & -0.766047908 & -1.69531674 & -0.14342511 & -0.17124200 &  0.5643143914 & -0.068337272 & -0.19164100 &  0.736564406 &  0.06647244 & -0.16604761\\\\\n",
       "\t32 & -0.15193508 & -0.101782915 & -2.91035093 &  2.14689483 & -0.237359796 & -0.50179098 & -0.29167394 & -0.700808119 & -0.274305898 & -0.57448733 & â‹¯ &  0.008691614 & -0.39469549 & -0.73498518 & -0.43149567 &  0.5530308342 &  0.567570255 & -0.17093020 & -0.578044742 &  1.00302316 &  0.72587330\\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A data.frame: 32 Ã— 18780\n",
       "\n",
       "| <!--/--> | 1 &lt;dbl&gt; | 503538 &lt;dbl&gt; | 2 &lt;dbl&gt; | 144571 &lt;dbl&gt; | 144568 &lt;dbl&gt; | 53947 &lt;dbl&gt; | 8086 &lt;dbl&gt; | 65985 &lt;dbl&gt; | 13 &lt;dbl&gt; | 51166 &lt;dbl&gt; | â‹¯ â‹¯ | 55055 &lt;dbl&gt; | 11130 &lt;dbl&gt; | 7789 &lt;dbl&gt; | 158586 &lt;dbl&gt; | 79364 &lt;dbl&gt; | 440590 &lt;dbl&gt; | 79699 &lt;dbl&gt; | 7791 &lt;dbl&gt; | 23140 &lt;dbl&gt; | 26009 &lt;dbl&gt; |\n",
       "|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|\n",
       "| 36 |  0.02207971 | -0.399344035 |  1.31004461 |  0.28266209 | -0.211653475 | -0.20174329 |  0.27101637 |  0.358306002 | -0.178516924 | -0.27117599 | â‹¯ | -0.231554875 |  0.42826173 |  0.17136963 |  0.43681965 | -0.0434933523 | -0.070101252 | -0.77012086 |  0.026242002 | -0.29389081 | -1.04418568 |\n",
       "| 26 |  0.36939855 |  0.493796520 | -2.05553544 | -0.13408502 | -0.232882607 | -0.17725880 |  0.12710253 | -0.563640470 | -0.277821510 |  0.54745043 | â‹¯ |  0.462127921 |  0.57497284 | -0.59890304 | -0.44415190 |  0.7441192974 |  0.069465219 | -0.38604727 | -0.899311870 |  0.37238568 | -0.43646272 |\n",
       "| 19 |  0.01444574 |  0.303172491 | -0.68074489 |  0.09653197 | -0.228000498 | -0.12162473 | -0.03935541 | -0.278664880 | -0.244767600 | -1.29409560 | â‹¯ | -0.990153661 | -0.66884995 |  0.75507446 |  0.45702034 | -0.0978608256 | -0.037910521 | -0.19641500 | -0.002663966 |  0.14242927 | -0.53603414 |\n",
       "| 7 |  0.31640366 | -0.235838135 | -0.03021626 | -0.39529128 | -0.237359796 | -0.41787845 | -0.95790485 | -0.269379893 |  0.255566934 |  0.36570576 | â‹¯ |  0.715314720 |  0.32665483 |  0.27464873 | -0.37869573 | -0.2000784318 | -0.095807574 |  0.13778226 |  0.704947921 | -0.55133851 |  0.40732392 |\n",
       "| 44 | -0.96796873 | -0.371735137 |  0.52259067 |  0.29058114 |  1.395459295 |  1.24960347 | -0.09848238 |  0.458516286 | -0.202878631 | -0.08453939 | â‹¯ |  0.206773696 | -0.42747899 | -0.06521667 | -0.31779465 | -0.6308434283 | -0.012797742 |  0.16718252 |  1.344192060 | -0.03809493 | -0.45864802 |\n",
       "| 12 | -1.07111293 | -0.443266849 |  2.31713808 |  0.10786869 | -0.231998574 |  0.63256619 | -0.06593464 | -0.693757330 |  0.953050943 | -0.26277554 | â‹¯ | -1.115560810 | -2.62608070 |  0.33662516 | -0.09917793 |  0.5652990871 | -0.061318728 |  0.01378568 |  0.632443208 |  0.78257787 | -0.20470475 |\n",
       "| 49 |  1.12169522 |  0.006291004 |  1.45629787 |  1.01360921 |  0.002645532 |  0.94840078 | -0.20153784 |  0.833486730 |  0.984990581 | -0.17668222 | â‹¯ |  0.387066334 |  0.80556102 | -0.04602627 |  0.15027246 | -0.6784978765 |  0.038183825 |  0.16128751 | -0.238370565 | -0.13963415 | -0.21243155 |\n",
       "| 35 |  0.47515082 |  0.339123809 | -0.66586039 | -0.09308171 |  1.333911644 |  0.01596500 | -0.01988318 |  0.391613692 |  0.007535656 | -0.68749743 | â‹¯ | -0.468675161 |  0.38191325 | -0.13353630 |  0.44677454 | -0.1907897938 | -0.014894504 | -0.06091901 | -0.292491200 |  0.06483150 |  0.36725970 |\n",
       "| 13 | -1.20920482 | -0.541433333 | -0.01989287 |  0.65408586 | -0.225330893 | -0.87607703 | -0.34607874 |  0.000386568 | -0.049628185 | -0.98399232 | â‹¯ | -0.209928304 |  0.81250891 |  0.04422525 |  0.06929868 | -0.3294996664 | -0.095807574 | -0.01927152 |  0.254432485 | -0.03632622 |  0.10893968 |\n",
       "| 10 | -0.61833240 |  0.014714726 | -0.70065194 | -0.36349872 | -0.237359796 |  0.49662548 | -0.49421422 |  1.184709176 | -0.302664653 |  1.68367428 | â‹¯ |  0.464824631 |  0.30872910 | -0.66759771 |  0.56592965 | -0.4606691302 |  0.554262011 |  0.69282995 |  0.539471466 | -0.33190657 |  0.11705793 |\n",
       "| 20 | -0.65328955 | -0.009017929 | -2.61089336 |  1.56201705 | -0.237359796 | -0.02991692 | -0.33408666 | -0.470624511 | -0.302664653 | -1.67812454 | â‹¯ | -0.399369346 | -1.27744820 |  1.16563917 |  0.44796852 |  0.9177473835 | -0.044360443 | -0.21307855 | -0.099479074 |  1.54256398 |  0.60783149 |\n",
       "| 47 |  0.11378060 | -0.021088798 |  2.53003058 | -0.22085073 | -0.237359796 | -0.38662798 | -0.08049887 |  0.084577558 | -0.111384349 |  1.85279854 | â‹¯ | -0.570139294 | -0.38900084 |  0.20432131 |  0.13540615 | -0.4530921630 | -0.018278153 |  0.07228018 |  0.273916435 | -0.32552466 | -0.16369490 |\n",
       "| 6 |  0.62167117 |  0.091416345 |  0.62158990 | -0.03477088 | -0.175185870 | -0.08569925 |  0.47304122 |  0.092149856 | -0.302664653 | -1.47604319 | â‹¯ |  0.230476038 | -0.34597308 | -0.02931501 |  0.33392762 |  0.1422300068 | -0.006887237 | -0.09623038 | -1.180614170 |  0.44382387 |  0.03539586 |\n",
       "| 8 | -0.54902719 |  0.341409675 | -2.46492428 |  0.44848632 | -0.237359796 | -0.31377513 | -0.03090046 |  0.023858648 | -0.302664653 |  0.28155117 | â‹¯ |  0.445047608 |  0.80762933 | -0.38707532 |  0.08435613 | -0.3666242486 | -0.043040810 |  0.32211429 | -0.606676792 | -1.13187658 |  0.65424050 |\n",
       "| 25 | -0.07396639 |  0.401290758 |  0.55684035 | -0.39839382 | -0.237359796 | -0.58350184 | -0.02299018 | -0.174699076 | -0.220938440 |  2.56189614 | â‹¯ |  0.323958497 | -0.28877420 | -0.34308412 | -0.42472156 |  0.7366265926 | -0.095807574 |  0.41074512 | -0.507792891 |  0.20384346 |  0.47588991 |\n",
       "| 38 | -0.78473411 | -0.007786946 |  0.12535732 |  0.17412395 |  1.627082607 |  1.06191207 | -0.42805163 |  1.255571317 |  0.863890733 |  0.82273223 | â‹¯ | -0.253086816 | -1.03622267 |  0.74340903 | -0.44263081 | -0.7088331041 |  0.021772744 |  0.30909709 |  0.001373924 |  0.42681432 | -0.13050942 |\n",
       "| 33 |  0.07099564 |  0.126628269 | -1.06228132 | -1.02816088 | -0.237359796 | -0.05546289 | -0.16485930 |  0.057565285 |  0.476762432 |  0.26284499 | â‹¯ |  0.543191258 |  0.96220905 |  0.08654803 |  0.29531747 | -0.0733442796 | -0.071404280 |  0.04744246 |  0.311459770 | -0.45692695 | -0.22853974 |\n",
       "| 24 |  0.37516263 |  0.426870012 |  2.01021002 | -0.34082043 | -0.237359796 |  0.48781240 |  0.81495642 |  0.719710922 |  0.116441049 | -0.44445564 | â‹¯ | -0.772687949 | -0.17954929 |  0.15757350 | -0.04612901 |  0.1787330668 | -0.049971772 |  0.06365311 | -0.651993693 |  0.41805088 | -0.40544793 |\n",
       "| 46 | -0.60460995 | -0.633224248 |  0.35203165 |  0.02142486 | -0.160261807 |  0.52801138 |  0.40059380 | -0.407841262 | -0.036193900 | -0.14603845 | â‹¯ | -0.235865821 | -0.80103916 |  0.22053955 | -0.19983454 |  0.2138286755 | -0.086896878 | -0.09116498 |  0.038010253 |  0.27755322 |  0.04282373 |\n",
       "| 2 |  0.26308695 | -0.198786053 |  2.61522967 | -0.87343823 | -0.237359796 | -0.43357541 |  0.58687354 | -0.931199668 | -0.250773339 |  0.90035292 | â‹¯ |  1.079653224 |  0.62934788 | -1.23471534 | -0.96470192 |  0.5255918237 | -0.095807574 | -0.52099920 |  0.825633802 |  0.08874634 |  0.01569202 |\n",
       "| 1 |  0.30924051 |  0.175282282 | -1.30334835 | -0.07670974 | -0.102960393 | -0.09473420 |  0.27427407 |  0.427291541 | -0.182195396 |  0.10514388 | â‹¯ |  0.814559991 |  0.09616738 | -0.27965633 |  0.31559451 | -0.0626374123 |  0.055108447 | -0.56911380 | -0.380607347 | -0.52103880 | -0.46877980 |\n",
       "| 14 |  0.31255748 |  0.814314007 | -1.28347883 | -1.00165760 | -0.237359796 |  0.06524928 | -0.11574019 |  1.080053742 |  0.611716136 |  0.18090993 | â‹¯ | -0.229523423 |  1.34753221 |  0.49996400 |  0.10629174 | -0.0166411617 | -0.023002256 |  0.46454270 | -0.437119044 | -0.41935743 | -0.15979738 |\n",
       "| 27 |  0.41001548 |  0.524729460 |  1.21509583 |  0.34009902 | -0.219348784 | -0.17836320 | -0.24621711 | -0.619639812 | -0.302664653 | -0.73347481 | â‹¯ | -0.605366439 |  0.35143929 |  0.32851067 |  0.35746238 | -0.1407782292 | -0.077796562 |  0.07142574 |  0.107125170 | -0.01490806 | -0.75544253 |\n",
       "| 45 |  0.56281081 |  0.208960409 | -0.44592739 | -0.13785662 | -0.216928906 |  0.51738358 |  0.06665660 | -0.400276352 | -0.292861171 | -0.08721195 | â‹¯ | -0.441284649 | -0.90003180 | -0.55994432 | -0.56467426 | -0.0005595549 | -0.095807574 | -0.42775717 |  0.073520455 |  0.32066835 | -0.20276745 |\n",
       "| 37 | -0.40408096 | -0.078336393 |  0.05397145 |  0.29832940 | -0.237359796 | -0.44309591 |  0.04636025 | -0.512799468 | -0.302664653 |  0.15393705 | â‹¯ |  0.255039312 |  0.97348718 |  0.37727755 |  0.11511414 | -0.5009587486 | -0.059131734 |  0.17357627 |  0.336104507 | -0.43932309 | -0.15576478 |\n",
       "| 50 | -0.09683531 |  0.288063672 | -1.33779511 | -0.31798891 | -0.237359796 |  0.17021327 | -0.14301866 | -0.076535653 | -0.212901448 | -0.10080308 | â‹¯ |  0.314961134 |  1.37143617 |  0.08818719 |  0.27088915 | -0.2879368575 |  0.045436179 |  0.33126353 |  0.210137373 | -0.54818555 | -0.23738481 |\n",
       "| 21 |  0.07795682 | -0.199620442 |  0.91527044 |  0.21741237 | -0.237359796 | -0.33249362 | -0.57249323 | -0.826740488 | -0.302216050 |  0.94718541 | â‹¯ |  0.262799951 |  0.64011166 |  0.24011332 | -0.11178293 |  0.1601318153 |  0.001045315 | -0.02779061 | -0.079428025 |  0.24134531 |  0.22767313 |\n",
       "| 17 |  0.53014756 | -0.653578751 |  0.50604193 | -0.12240057 | -0.136734702 | -0.10290469 |  0.50947306 |  0.594384435 |  0.174661357 |  0.45424333 | â‹¯ |  0.397248856 | -0.54785782 | -0.22319036 | -0.51547930 |  0.1365183514 | -0.025940561 |  0.18921212 |  0.424191448 |  0.10411358 | -0.16324147 |\n",
       "| 15 |  0.84464702 |  0.408755426 | -0.24565521 | -0.58192819 |  1.177814024 | -0.42666288 |  0.57789430 |  0.196602903 | -0.086528609 | -0.08078152 | â‹¯ | -0.033292657 |  1.11436707 |  0.13554354 |  0.25877652 | -0.2631522968 | -0.054781348 |  0.14859193 | -0.330010210 | -0.70105036 |  1.23636907 |\n",
       "| 23 | -0.13489778 | -0.916067934 | -0.68779918 | -0.64859270 | -0.005646842 | -0.77809843 |  0.12710253 | -0.371793764 |  0.233683066 | -0.46027794 | â‹¯ |  0.410802324 | -0.35400995 | -0.38289902 |  0.26529255 |  0.0681192357 | -0.046954071 | -0.03533289 | -0.555163096 | -0.54986056 |  1.10751447 |\n",
       "| 34 |  0.50874883 | -0.153910966 |  1.39761539 | -0.88460073 | -0.066942602 |  0.36754271 |  0.37857683 | -0.460383913 |  0.061600482 | -1.57796916 | â‹¯ | -0.766047908 | -1.69531674 | -0.14342511 | -0.17124200 |  0.5643143914 | -0.068337272 | -0.19164100 |  0.736564406 |  0.06647244 | -0.16604761 |\n",
       "| 32 | -0.15193508 | -0.101782915 | -2.91035093 |  2.14689483 | -0.237359796 | -0.50179098 | -0.29167394 | -0.700808119 | -0.274305898 | -0.57448733 | â‹¯ |  0.008691614 | -0.39469549 | -0.73498518 | -0.43149567 |  0.5530308342 |  0.567570255 | -0.17093020 | -0.578044742 |  1.00302316 |  0.72587330 |\n",
       "\n"
      ],
      "text/plain": [
       "   1           503538       2           144571      144568       53947      \n",
       "36  0.02207971 -0.399344035  1.31004461  0.28266209 -0.211653475 -0.20174329\n",
       "26  0.36939855  0.493796520 -2.05553544 -0.13408502 -0.232882607 -0.17725880\n",
       "19  0.01444574  0.303172491 -0.68074489  0.09653197 -0.228000498 -0.12162473\n",
       "7   0.31640366 -0.235838135 -0.03021626 -0.39529128 -0.237359796 -0.41787845\n",
       "44 -0.96796873 -0.371735137  0.52259067  0.29058114  1.395459295  1.24960347\n",
       "12 -1.07111293 -0.443266849  2.31713808  0.10786869 -0.231998574  0.63256619\n",
       "49  1.12169522  0.006291004  1.45629787  1.01360921  0.002645532  0.94840078\n",
       "35  0.47515082  0.339123809 -0.66586039 -0.09308171  1.333911644  0.01596500\n",
       "13 -1.20920482 -0.541433333 -0.01989287  0.65408586 -0.225330893 -0.87607703\n",
       "10 -0.61833240  0.014714726 -0.70065194 -0.36349872 -0.237359796  0.49662548\n",
       "20 -0.65328955 -0.009017929 -2.61089336  1.56201705 -0.237359796 -0.02991692\n",
       "47  0.11378060 -0.021088798  2.53003058 -0.22085073 -0.237359796 -0.38662798\n",
       "6   0.62167117  0.091416345  0.62158990 -0.03477088 -0.175185870 -0.08569925\n",
       "8  -0.54902719  0.341409675 -2.46492428  0.44848632 -0.237359796 -0.31377513\n",
       "25 -0.07396639  0.401290758  0.55684035 -0.39839382 -0.237359796 -0.58350184\n",
       "38 -0.78473411 -0.007786946  0.12535732  0.17412395  1.627082607  1.06191207\n",
       "33  0.07099564  0.126628269 -1.06228132 -1.02816088 -0.237359796 -0.05546289\n",
       "24  0.37516263  0.426870012  2.01021002 -0.34082043 -0.237359796  0.48781240\n",
       "46 -0.60460995 -0.633224248  0.35203165  0.02142486 -0.160261807  0.52801138\n",
       "2   0.26308695 -0.198786053  2.61522967 -0.87343823 -0.237359796 -0.43357541\n",
       "1   0.30924051  0.175282282 -1.30334835 -0.07670974 -0.102960393 -0.09473420\n",
       "14  0.31255748  0.814314007 -1.28347883 -1.00165760 -0.237359796  0.06524928\n",
       "27  0.41001548  0.524729460  1.21509583  0.34009902 -0.219348784 -0.17836320\n",
       "45  0.56281081  0.208960409 -0.44592739 -0.13785662 -0.216928906  0.51738358\n",
       "37 -0.40408096 -0.078336393  0.05397145  0.29832940 -0.237359796 -0.44309591\n",
       "50 -0.09683531  0.288063672 -1.33779511 -0.31798891 -0.237359796  0.17021327\n",
       "21  0.07795682 -0.199620442  0.91527044  0.21741237 -0.237359796 -0.33249362\n",
       "17  0.53014756 -0.653578751  0.50604193 -0.12240057 -0.136734702 -0.10290469\n",
       "15  0.84464702  0.408755426 -0.24565521 -0.58192819  1.177814024 -0.42666288\n",
       "23 -0.13489778 -0.916067934 -0.68779918 -0.64859270 -0.005646842 -0.77809843\n",
       "34  0.50874883 -0.153910966  1.39761539 -0.88460073 -0.066942602  0.36754271\n",
       "32 -0.15193508 -0.101782915 -2.91035093  2.14689483 -0.237359796 -0.50179098\n",
       "   8086        65985        13           51166       â‹¯ 55055        11130      \n",
       "36  0.27101637  0.358306002 -0.178516924 -0.27117599 â‹¯ -0.231554875  0.42826173\n",
       "26  0.12710253 -0.563640470 -0.277821510  0.54745043 â‹¯  0.462127921  0.57497284\n",
       "19 -0.03935541 -0.278664880 -0.244767600 -1.29409560 â‹¯ -0.990153661 -0.66884995\n",
       "7  -0.95790485 -0.269379893  0.255566934  0.36570576 â‹¯  0.715314720  0.32665483\n",
       "44 -0.09848238  0.458516286 -0.202878631 -0.08453939 â‹¯  0.206773696 -0.42747899\n",
       "12 -0.06593464 -0.693757330  0.953050943 -0.26277554 â‹¯ -1.115560810 -2.62608070\n",
       "49 -0.20153784  0.833486730  0.984990581 -0.17668222 â‹¯  0.387066334  0.80556102\n",
       "35 -0.01988318  0.391613692  0.007535656 -0.68749743 â‹¯ -0.468675161  0.38191325\n",
       "13 -0.34607874  0.000386568 -0.049628185 -0.98399232 â‹¯ -0.209928304  0.81250891\n",
       "10 -0.49421422  1.184709176 -0.302664653  1.68367428 â‹¯  0.464824631  0.30872910\n",
       "20 -0.33408666 -0.470624511 -0.302664653 -1.67812454 â‹¯ -0.399369346 -1.27744820\n",
       "47 -0.08049887  0.084577558 -0.111384349  1.85279854 â‹¯ -0.570139294 -0.38900084\n",
       "6   0.47304122  0.092149856 -0.302664653 -1.47604319 â‹¯  0.230476038 -0.34597308\n",
       "8  -0.03090046  0.023858648 -0.302664653  0.28155117 â‹¯  0.445047608  0.80762933\n",
       "25 -0.02299018 -0.174699076 -0.220938440  2.56189614 â‹¯  0.323958497 -0.28877420\n",
       "38 -0.42805163  1.255571317  0.863890733  0.82273223 â‹¯ -0.253086816 -1.03622267\n",
       "33 -0.16485930  0.057565285  0.476762432  0.26284499 â‹¯  0.543191258  0.96220905\n",
       "24  0.81495642  0.719710922  0.116441049 -0.44445564 â‹¯ -0.772687949 -0.17954929\n",
       "46  0.40059380 -0.407841262 -0.036193900 -0.14603845 â‹¯ -0.235865821 -0.80103916\n",
       "2   0.58687354 -0.931199668 -0.250773339  0.90035292 â‹¯  1.079653224  0.62934788\n",
       "1   0.27427407  0.427291541 -0.182195396  0.10514388 â‹¯  0.814559991  0.09616738\n",
       "14 -0.11574019  1.080053742  0.611716136  0.18090993 â‹¯ -0.229523423  1.34753221\n",
       "27 -0.24621711 -0.619639812 -0.302664653 -0.73347481 â‹¯ -0.605366439  0.35143929\n",
       "45  0.06665660 -0.400276352 -0.292861171 -0.08721195 â‹¯ -0.441284649 -0.90003180\n",
       "37  0.04636025 -0.512799468 -0.302664653  0.15393705 â‹¯  0.255039312  0.97348718\n",
       "50 -0.14301866 -0.076535653 -0.212901448 -0.10080308 â‹¯  0.314961134  1.37143617\n",
       "21 -0.57249323 -0.826740488 -0.302216050  0.94718541 â‹¯  0.262799951  0.64011166\n",
       "17  0.50947306  0.594384435  0.174661357  0.45424333 â‹¯  0.397248856 -0.54785782\n",
       "15  0.57789430  0.196602903 -0.086528609 -0.08078152 â‹¯ -0.033292657  1.11436707\n",
       "23  0.12710253 -0.371793764  0.233683066 -0.46027794 â‹¯  0.410802324 -0.35400995\n",
       "34  0.37857683 -0.460383913  0.061600482 -1.57796916 â‹¯ -0.766047908 -1.69531674\n",
       "32 -0.29167394 -0.700808119 -0.274305898 -0.57448733 â‹¯  0.008691614 -0.39469549\n",
       "   7789        158586      79364         440590       79699       7791        \n",
       "36  0.17136963  0.43681965 -0.0434933523 -0.070101252 -0.77012086  0.026242002\n",
       "26 -0.59890304 -0.44415190  0.7441192974  0.069465219 -0.38604727 -0.899311870\n",
       "19  0.75507446  0.45702034 -0.0978608256 -0.037910521 -0.19641500 -0.002663966\n",
       "7   0.27464873 -0.37869573 -0.2000784318 -0.095807574  0.13778226  0.704947921\n",
       "44 -0.06521667 -0.31779465 -0.6308434283 -0.012797742  0.16718252  1.344192060\n",
       "12  0.33662516 -0.09917793  0.5652990871 -0.061318728  0.01378568  0.632443208\n",
       "49 -0.04602627  0.15027246 -0.6784978765  0.038183825  0.16128751 -0.238370565\n",
       "35 -0.13353630  0.44677454 -0.1907897938 -0.014894504 -0.06091901 -0.292491200\n",
       "13  0.04422525  0.06929868 -0.3294996664 -0.095807574 -0.01927152  0.254432485\n",
       "10 -0.66759771  0.56592965 -0.4606691302  0.554262011  0.69282995  0.539471466\n",
       "20  1.16563917  0.44796852  0.9177473835 -0.044360443 -0.21307855 -0.099479074\n",
       "47  0.20432131  0.13540615 -0.4530921630 -0.018278153  0.07228018  0.273916435\n",
       "6  -0.02931501  0.33392762  0.1422300068 -0.006887237 -0.09623038 -1.180614170\n",
       "8  -0.38707532  0.08435613 -0.3666242486 -0.043040810  0.32211429 -0.606676792\n",
       "25 -0.34308412 -0.42472156  0.7366265926 -0.095807574  0.41074512 -0.507792891\n",
       "38  0.74340903 -0.44263081 -0.7088331041  0.021772744  0.30909709  0.001373924\n",
       "33  0.08654803  0.29531747 -0.0733442796 -0.071404280  0.04744246  0.311459770\n",
       "24  0.15757350 -0.04612901  0.1787330668 -0.049971772  0.06365311 -0.651993693\n",
       "46  0.22053955 -0.19983454  0.2138286755 -0.086896878 -0.09116498  0.038010253\n",
       "2  -1.23471534 -0.96470192  0.5255918237 -0.095807574 -0.52099920  0.825633802\n",
       "1  -0.27965633  0.31559451 -0.0626374123  0.055108447 -0.56911380 -0.380607347\n",
       "14  0.49996400  0.10629174 -0.0166411617 -0.023002256  0.46454270 -0.437119044\n",
       "27  0.32851067  0.35746238 -0.1407782292 -0.077796562  0.07142574  0.107125170\n",
       "45 -0.55994432 -0.56467426 -0.0005595549 -0.095807574 -0.42775717  0.073520455\n",
       "37  0.37727755  0.11511414 -0.5009587486 -0.059131734  0.17357627  0.336104507\n",
       "50  0.08818719  0.27088915 -0.2879368575  0.045436179  0.33126353  0.210137373\n",
       "21  0.24011332 -0.11178293  0.1601318153  0.001045315 -0.02779061 -0.079428025\n",
       "17 -0.22319036 -0.51547930  0.1365183514 -0.025940561  0.18921212  0.424191448\n",
       "15  0.13554354  0.25877652 -0.2631522968 -0.054781348  0.14859193 -0.330010210\n",
       "23 -0.38289902  0.26529255  0.0681192357 -0.046954071 -0.03533289 -0.555163096\n",
       "34 -0.14342511 -0.17124200  0.5643143914 -0.068337272 -0.19164100  0.736564406\n",
       "32 -0.73498518 -0.43149567  0.5530308342  0.567570255 -0.17093020 -0.578044742\n",
       "   23140       26009      \n",
       "36 -0.29389081 -1.04418568\n",
       "26  0.37238568 -0.43646272\n",
       "19  0.14242927 -0.53603414\n",
       "7  -0.55133851  0.40732392\n",
       "44 -0.03809493 -0.45864802\n",
       "12  0.78257787 -0.20470475\n",
       "49 -0.13963415 -0.21243155\n",
       "35  0.06483150  0.36725970\n",
       "13 -0.03632622  0.10893968\n",
       "10 -0.33190657  0.11705793\n",
       "20  1.54256398  0.60783149\n",
       "47 -0.32552466 -0.16369490\n",
       "6   0.44382387  0.03539586\n",
       "8  -1.13187658  0.65424050\n",
       "25  0.20384346  0.47588991\n",
       "38  0.42681432 -0.13050942\n",
       "33 -0.45692695 -0.22853974\n",
       "24  0.41805088 -0.40544793\n",
       "46  0.27755322  0.04282373\n",
       "2   0.08874634  0.01569202\n",
       "1  -0.52103880 -0.46877980\n",
       "14 -0.41935743 -0.15979738\n",
       "27 -0.01490806 -0.75544253\n",
       "45  0.32066835 -0.20276745\n",
       "37 -0.43932309 -0.15576478\n",
       "50 -0.54818555 -0.23738481\n",
       "21  0.24134531  0.22767313\n",
       "17  0.10411358 -0.16324147\n",
       "15 -0.70105036  1.23636907\n",
       "23 -0.54986056  1.10751447\n",
       "34  0.06647244 -0.16604761\n",
       "32  1.00302316  0.72587330"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "pni_self_subtract <- as.data.frame(t(pni_self_subtract))  # transpose\n",
    "pni_self_subtract"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "26c8d50f",
   "metadata": {},
   "source": [
    "### Merge"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "22d8fa95",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table>\n",
       "<caption>A data.frame: 51 Ã— 18792</caption>\n",
       "<thead>\n",
       "\t<tr><th scope=col>Patient</th><th scope=col>OS</th><th scope=col>OS.Event</th><th scope=col>PFS</th><th scope=col>PFS.Event</th><th scope=col>RECIST</th><th scope=col>Age</th><th scope=col>Gender</th><th scope=col>Treatment</th><th scope=col>Site</th><th scope=col>â‹¯</th><th scope=col>55055</th><th scope=col>11130</th><th scope=col>7789</th><th scope=col>158586</th><th scope=col>79364</th><th scope=col>440590</th><th scope=col>79699</th><th scope=col>7791</th><th scope=col>23140</th><th scope=col>26009</th></tr>\n",
       "\t<tr><th scope=col>&lt;I&lt;chr&gt;&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>â‹¯</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><td>1 </td><td> 689</td><td>0</td><td>  15</td><td>1</td><td>0</td><td>42</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>â‹¯</td><td> 0.814559991</td><td> 0.09616738</td><td>-0.27965633</td><td> 0.31559451</td><td>-0.0626374123</td><td> 0.055108447</td><td>-0.56911380</td><td>-0.380607347</td><td>-0.52103880</td><td>-0.46877980</td></tr>\n",
       "\t<tr><td>10</td><td> 176</td><td>1</td><td>  81</td><td>1</td><td>0</td><td>51</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td> 0.464824631</td><td> 0.30872910</td><td>-0.66759771</td><td> 0.56592965</td><td>-0.4606691302</td><td> 0.554262011</td><td> 0.69282995</td><td> 0.539471466</td><td>-0.33190657</td><td> 0.11705793</td></tr>\n",
       "\t<tr><td>11</td><td> 221</td><td>0</td><td>  82</td><td>1</td><td>0</td><td>62</td><td>0</td><td>Ipilimumab + Nivolumab    </td><td>LN             </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>12</td><td> 293</td><td>0</td><td>  82</td><td>1</td><td>0</td><td>55</td><td>1</td><td>Ipilimumab + Nivolumab    </td><td>Lung           </td><td>â‹¯</td><td>-1.115560810</td><td>-2.62608070</td><td> 0.33662516</td><td>-0.09917793</td><td> 0.5652990871</td><td>-0.061318728</td><td> 0.01378568</td><td> 0.632443208</td><td> 0.78257787</td><td>-0.20470475</td></tr>\n",
       "\t<tr><td>13</td><td> 357</td><td>1</td><td> 108</td><td>1</td><td>2</td><td>68</td><td>1</td><td>Ipilimumab + Nivolumab    </td><td>SQ             </td><td>â‹¯</td><td>-0.209928304</td><td> 0.81250891</td><td> 0.04422525</td><td> 0.06929868</td><td>-0.3294996664</td><td>-0.095807574</td><td>-0.01927152</td><td> 0.254432485</td><td>-0.03632622</td><td> 0.10893968</td></tr>\n",
       "\t<tr><td>14</td><td> 691</td><td>0</td><td> 123</td><td>1</td><td>1</td><td>47</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>â‹¯</td><td>-0.229523423</td><td> 1.34753221</td><td> 0.49996400</td><td> 0.10629174</td><td>-0.0166411617</td><td>-0.023002256</td><td> 0.46454270</td><td>-0.437119044</td><td>-0.41935743</td><td>-0.15979738</td></tr>\n",
       "\t<tr><td>15</td><td> 660</td><td>1</td><td> 152</td><td>1</td><td>1</td><td>57</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>â‹¯</td><td>-0.033292657</td><td> 1.11436707</td><td> 0.13554354</td><td> 0.25877652</td><td>-0.2631522968</td><td>-0.054781348</td><td> 0.14859193</td><td>-0.330010210</td><td>-0.70105036</td><td> 1.23636907</td></tr>\n",
       "\t<tr><td>16</td><td> 558</td><td>0</td><td> 168</td><td>1</td><td>2</td><td>39</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>17</td><td> 196</td><td>0</td><td> 196</td><td>0</td><td>2</td><td>48</td><td>1</td><td>Ipilimumab + Nivolumab    </td><td>LN             </td><td>â‹¯</td><td> 0.397248856</td><td>-0.54785782</td><td>-0.22319036</td><td>-0.51547930</td><td> 0.1365183514</td><td>-0.025940561</td><td> 0.18921212</td><td> 0.424191448</td><td> 0.10411358</td><td>-0.16324147</td></tr>\n",
       "\t<tr><td>18</td><td> 278</td><td>0</td><td> 278</td><td>0</td><td>2</td><td>58</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Lung           </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>19</td><td> 635</td><td>0</td><td> 301</td><td>1</td><td>1</td><td>56</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>â‹¯</td><td>-0.990153661</td><td>-0.66884995</td><td> 0.75507446</td><td> 0.45702034</td><td>-0.0978608256</td><td>-0.037910521</td><td>-0.19641500</td><td>-0.002663966</td><td> 0.14242927</td><td>-0.53603414</td></tr>\n",
       "\t<tr><td>2 </td><td> 530</td><td>0</td><td>  34</td><td>1</td><td>0</td><td>41</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td> 1.079653224</td><td> 0.62934788</td><td>-1.23471534</td><td>-0.96470192</td><td> 0.5255918237</td><td>-0.095807574</td><td>-0.52099920</td><td> 0.825633802</td><td> 0.08874634</td><td> 0.01569202</td></tr>\n",
       "\t<tr><td>20</td><td> 538</td><td>0</td><td> 386</td><td>1</td><td>1</td><td>57</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td>-0.399369346</td><td>-1.27744820</td><td> 1.16563917</td><td> 0.44796852</td><td> 0.9177473835</td><td>-0.044360443</td><td>-0.21307855</td><td>-0.099479074</td><td> 1.54256398</td><td> 0.60783149</td></tr>\n",
       "\t<tr><td>21</td><td> 410</td><td>0</td><td> 410</td><td>0</td><td>2</td><td>63</td><td>0</td><td>Ipilimumab + Nivolumab    </td><td>SQ             </td><td>â‹¯</td><td> 0.262799951</td><td> 0.64011166</td><td> 0.24011332</td><td>-0.11178293</td><td> 0.1601318153</td><td> 0.001045315</td><td>-0.02779061</td><td>-0.079428025</td><td> 0.24134531</td><td> 0.22767313</td></tr>\n",
       "\t<tr><td>22</td><td> 706</td><td>0</td><td> 487</td><td>1</td><td>2</td><td>59</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>23</td><td> 506</td><td>0</td><td> 506</td><td>0</td><td>2</td><td>51</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>Brain          </td><td>â‹¯</td><td> 0.410802324</td><td>-0.35400995</td><td>-0.38289902</td><td> 0.26529255</td><td> 0.0681192357</td><td>-0.046954071</td><td>-0.03533289</td><td>-0.555163096</td><td>-0.54986056</td><td> 1.10751447</td></tr>\n",
       "\t<tr><td>24</td><td>1203</td><td>0</td><td> 509</td><td>1</td><td>2</td><td>34</td><td>0</td><td>Ipilimumab + Nivolumab    </td><td>LN             </td><td>â‹¯</td><td>-0.772687949</td><td>-0.17954929</td><td> 0.15757350</td><td>-0.04612901</td><td> 0.1787330668</td><td>-0.049971772</td><td> 0.06365311</td><td>-0.651993693</td><td> 0.41805088</td><td>-0.40544793</td></tr>\n",
       "\t<tr><td>25</td><td> 518</td><td>1</td><td> 518</td><td>0</td><td>1</td><td>67</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td> 0.323958497</td><td>-0.28877420</td><td>-0.34308412</td><td>-0.42472156</td><td> 0.7366265926</td><td>-0.095807574</td><td> 0.41074512</td><td>-0.507792891</td><td> 0.20384346</td><td> 0.47588991</td></tr>\n",
       "\t<tr><td>26</td><td> 544</td><td>0</td><td> 544</td><td>0</td><td>3</td><td>75</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td> 0.462127921</td><td> 0.57497284</td><td>-0.59890304</td><td>-0.44415190</td><td> 0.7441192974</td><td> 0.069465219</td><td>-0.38604727</td><td>-0.899311870</td><td> 0.37238568</td><td>-0.43646272</td></tr>\n",
       "\t<tr><td>27</td><td> 546</td><td>0</td><td> 546</td><td>0</td><td>3</td><td>49</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Abdomen        </td><td>â‹¯</td><td>-0.605366439</td><td> 0.35143929</td><td> 0.32851067</td><td> 0.35746238</td><td>-0.1407782292</td><td>-0.077796562</td><td> 0.07142574</td><td> 0.107125170</td><td>-0.01490806</td><td>-0.75544253</td></tr>\n",
       "\t<tr><td>28</td><td> 553</td><td>0</td><td> 553</td><td>0</td><td>3</td><td>33</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>29</td><td> 567</td><td>0</td><td> 567</td><td>0</td><td>3</td><td>66</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>3 </td><td> 300</td><td>0</td><td>  37</td><td>1</td><td>0</td><td>58</td><td>1</td><td>Ipilimumab + Nivolumab    </td><td>Lung           </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>30</td><td> 573</td><td>0</td><td> 573</td><td>0</td><td>2</td><td>56</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Small intestine</td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>31</td><td> 588</td><td>0</td><td> 588</td><td>0</td><td>3</td><td>45</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Lung           </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>32</td><td> 597</td><td>0</td><td> 597</td><td>0</td><td>3</td><td>71</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td> 0.008691614</td><td>-0.39469549</td><td>-0.73498518</td><td>-0.43149567</td><td> 0.5530308342</td><td> 0.567570255</td><td>-0.17093020</td><td>-0.578044742</td><td> 1.00302316</td><td> 0.72587330</td></tr>\n",
       "\t<tr><td>33</td><td> 609</td><td>0</td><td> 609</td><td>0</td><td>2</td><td>73</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>â‹¯</td><td> 0.543191258</td><td> 0.96220905</td><td> 0.08654803</td><td> 0.29531747</td><td>-0.0733442796</td><td>-0.071404280</td><td> 0.04744246</td><td> 0.311459770</td><td>-0.45692695</td><td>-0.22853974</td></tr>\n",
       "\t<tr><td>34</td><td> 623</td><td>0</td><td> 623</td><td>0</td><td>3</td><td>51</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Lung           </td><td>â‹¯</td><td>-0.766047908</td><td>-1.69531674</td><td>-0.14342511</td><td>-0.17124200</td><td> 0.5643143914</td><td>-0.068337272</td><td>-0.19164100</td><td> 0.736564406</td><td> 0.06647244</td><td>-0.16604761</td></tr>\n",
       "\t<tr><td>35</td><td> 627</td><td>0</td><td> 627</td><td>0</td><td>3</td><td>72</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>â‹¯</td><td>-0.468675161</td><td> 0.38191325</td><td>-0.13353630</td><td> 0.44677454</td><td>-0.1907897938</td><td>-0.014894504</td><td>-0.06091901</td><td>-0.292491200</td><td> 0.06483150</td><td> 0.36725970</td></tr>\n",
       "\t<tr><td>36</td><td> 637</td><td>0</td><td> 637</td><td>0</td><td>3</td><td>74</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>â‹¯</td><td>-0.231554875</td><td> 0.42826173</td><td> 0.17136963</td><td> 0.43681965</td><td>-0.0434933523</td><td>-0.070101252</td><td>-0.77012086</td><td> 0.026242002</td><td>-0.29389081</td><td>-1.04418568</td></tr>\n",
       "\t<tr><td>37</td><td> 637</td><td>0</td><td> 637</td><td>0</td><td>2</td><td>76</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td> 0.255039312</td><td> 0.97348718</td><td> 0.37727755</td><td> 0.11511414</td><td>-0.5009587486</td><td>-0.059131734</td><td> 0.17357627</td><td> 0.336104507</td><td>-0.43932309</td><td>-0.15576478</td></tr>\n",
       "\t<tr><td>38</td><td> 650</td><td>0</td><td> 650</td><td>0</td><td>3</td><td>59</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>â‹¯</td><td>-0.253086816</td><td>-1.03622267</td><td> 0.74340903</td><td>-0.44263081</td><td>-0.7088331041</td><td> 0.021772744</td><td> 0.30909709</td><td> 0.001373924</td><td> 0.42681432</td><td>-0.13050942</td></tr>\n",
       "\t<tr><td>39</td><td> 657</td><td>0</td><td> 657</td><td>0</td><td>3</td><td>33</td><td>0</td><td>Ipilimumab + Nivolumab    </td><td>LN             </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>4 </td><td> 129</td><td>0</td><td>  39</td><td>1</td><td>0</td><td>48</td><td>0</td><td>Ipilimumab + Nivolumab    </td><td>SQ             </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>40</td><td> 671</td><td>0</td><td> 671</td><td>0</td><td>2</td><td>81</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>41</td><td> 672</td><td>0</td><td> 672</td><td>0</td><td>2</td><td>57</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>42</td><td> 692</td><td>0</td><td> 692</td><td>0</td><td>2</td><td>71</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Lung           </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>43</td><td> 693</td><td>0</td><td> 693</td><td>0</td><td>3</td><td>53</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>44</td><td> 695</td><td>0</td><td> 695</td><td>0</td><td>2</td><td>68</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>â‹¯</td><td> 0.206773696</td><td>-0.42747899</td><td>-0.06521667</td><td>-0.31779465</td><td>-0.6308434283</td><td>-0.012797742</td><td> 0.16718252</td><td> 1.344192060</td><td>-0.03809493</td><td>-0.45864802</td></tr>\n",
       "\t<tr><td>45</td><td> 721</td><td>0</td><td> 721</td><td>0</td><td>3</td><td>70</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Mucosa         </td><td>â‹¯</td><td>-0.441284649</td><td>-0.90003180</td><td>-0.55994432</td><td>-0.56467426</td><td>-0.0005595549</td><td>-0.095807574</td><td>-0.42775717</td><td> 0.073520455</td><td> 0.32066835</td><td>-0.20276745</td></tr>\n",
       "\t<tr><td>46</td><td> 721</td><td>0</td><td> 721</td><td>0</td><td>3</td><td>54</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>Lung           </td><td>â‹¯</td><td>-0.235865821</td><td>-0.80103916</td><td> 0.22053955</td><td>-0.19983454</td><td> 0.2138286755</td><td>-0.086896878</td><td>-0.09116498</td><td> 0.038010253</td><td> 0.27755322</td><td> 0.04282373</td></tr>\n",
       "\t<tr><td>47</td><td> 732</td><td>0</td><td> 732</td><td>0</td><td>2</td><td>24</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>â‹¯</td><td>-0.570139294</td><td>-0.38900084</td><td> 0.20432131</td><td> 0.13540615</td><td>-0.4530921630</td><td>-0.018278153</td><td> 0.07228018</td><td> 0.273916435</td><td>-0.32552466</td><td>-0.16369490</td></tr>\n",
       "\t<tr><td>48</td><td> 737</td><td>0</td><td> 737</td><td>0</td><td>2</td><td>72</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>49</td><td> 775</td><td>0</td><td> 775</td><td>0</td><td>3</td><td>36</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td> 0.387066334</td><td> 0.80556102</td><td>-0.04602627</td><td> 0.15027246</td><td>-0.6784978765</td><td> 0.038183825</td><td> 0.16128751</td><td>-0.238370565</td><td>-0.13963415</td><td>-0.21243155</td></tr>\n",
       "\t<tr><td>5 </td><td>  93</td><td>1</td><td>  40</td><td>1</td><td>0</td><td>49</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>50</td><td> 904</td><td>0</td><td> 904</td><td>0</td><td>2</td><td>68</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td> 0.314961134</td><td> 1.37143617</td><td> 0.08818719</td><td> 0.27088915</td><td>-0.2879368575</td><td> 0.045436179</td><td> 0.33126353</td><td> 0.210137373</td><td>-0.54818555</td><td>-0.23738481</td></tr>\n",
       "\t<tr><td>51</td><td>1379</td><td>0</td><td>1379</td><td>0</td><td>2</td><td>64</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Liver          </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>6 </td><td> 108</td><td>1</td><td>  41</td><td>1</td><td>0</td><td>75</td><td>0</td><td>Ipilimumab + Nivolumab    </td><td>LN             </td><td>â‹¯</td><td> 0.230476038</td><td>-0.34597308</td><td>-0.02931501</td><td> 0.33392762</td><td> 0.1422300068</td><td>-0.006887237</td><td>-0.09623038</td><td>-1.180614170</td><td> 0.44382387</td><td> 0.03539586</td></tr>\n",
       "\t<tr><td>7 </td><td> 169</td><td>0</td><td>  81</td><td>1</td><td>2</td><td>59</td><td>0</td><td>Ipilimumab + Nivolumab    </td><td>SQ             </td><td>â‹¯</td><td> 0.715314720</td><td> 0.32665483</td><td> 0.27464873</td><td>-0.37869573</td><td>-0.2000784318</td><td>-0.095807574</td><td> 0.13778226</td><td> 0.704947921</td><td>-0.55133851</td><td> 0.40732392</td></tr>\n",
       "\t<tr><td>8 </td><td> 637</td><td>0</td><td>  81</td><td>1</td><td>0</td><td>55</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td> 0.445047608</td><td> 0.80762933</td><td>-0.38707532</td><td> 0.08435613</td><td>-0.3666242486</td><td>-0.043040810</td><td> 0.32211429</td><td>-0.606676792</td><td>-1.13187658</td><td> 0.65424050</td></tr>\n",
       "\t<tr><td>9 </td><td> 156</td><td>1</td><td>  81</td><td>1</td><td>0</td><td>56</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A data.frame: 51 Ã— 18792\n",
       "\\begin{tabular}{lllllllllllllllllllll}\n",
       " Patient & OS & OS.Event & PFS & PFS.Event & RECIST & Age & Gender & Treatment & Site & â‹¯ & 55055 & 11130 & 7789 & 158586 & 79364 & 440590 & 79699 & 7791 & 23140 & 26009\\\\\n",
       " <I<chr>> & <int> & <int> & <int> & <int> & <int> & <int> & <int> & <fct> & <fct> & â‹¯ & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl>\\\\\n",
       "\\hline\n",
       "\t 1  &  689 & 0 &   15 & 1 & 0 & 42 & 1 & Ipilimumab + Pembrolizumab & SQ              & â‹¯ &  0.814559991 &  0.09616738 & -0.27965633 &  0.31559451 & -0.0626374123 &  0.055108447 & -0.56911380 & -0.380607347 & -0.52103880 & -0.46877980\\\\\n",
       "\t 10 &  176 & 1 &   81 & 1 & 0 & 51 & 0 & Ipilimumab + Pembrolizumab & LN              & â‹¯ &  0.464824631 &  0.30872910 & -0.66759771 &  0.56592965 & -0.4606691302 &  0.554262011 &  0.69282995 &  0.539471466 & -0.33190657 &  0.11705793\\\\\n",
       "\t 11 &  221 & 0 &   82 & 1 & 0 & 62 & 0 & Ipilimumab + Nivolumab     & LN              & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 12 &  293 & 0 &   82 & 1 & 0 & 55 & 1 & Ipilimumab + Nivolumab     & Lung            & â‹¯ & -1.115560810 & -2.62608070 &  0.33662516 & -0.09917793 &  0.5652990871 & -0.061318728 &  0.01378568 &  0.632443208 &  0.78257787 & -0.20470475\\\\\n",
       "\t 13 &  357 & 1 &  108 & 1 & 2 & 68 & 1 & Ipilimumab + Nivolumab     & SQ              & â‹¯ & -0.209928304 &  0.81250891 &  0.04422525 &  0.06929868 & -0.3294996664 & -0.095807574 & -0.01927152 &  0.254432485 & -0.03632622 &  0.10893968\\\\\n",
       "\t 14 &  691 & 0 &  123 & 1 & 1 & 47 & 1 & Ipilimumab + Pembrolizumab & SQ              & â‹¯ & -0.229523423 &  1.34753221 &  0.49996400 &  0.10629174 & -0.0166411617 & -0.023002256 &  0.46454270 & -0.437119044 & -0.41935743 & -0.15979738\\\\\n",
       "\t 15 &  660 & 1 &  152 & 1 & 1 & 57 & 0 & Ipilimumab + Pembrolizumab & SQ              & â‹¯ & -0.033292657 &  1.11436707 &  0.13554354 &  0.25877652 & -0.2631522968 & -0.054781348 &  0.14859193 & -0.330010210 & -0.70105036 &  1.23636907\\\\\n",
       "\t 16 &  558 & 0 &  168 & 1 & 2 & 39 & 1 & Ipilimumab + Pembrolizumab & LN              & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 17 &  196 & 0 &  196 & 0 & 2 & 48 & 1 & Ipilimumab + Nivolumab     & LN              & â‹¯ &  0.397248856 & -0.54785782 & -0.22319036 & -0.51547930 &  0.1365183514 & -0.025940561 &  0.18921212 &  0.424191448 &  0.10411358 & -0.16324147\\\\\n",
       "\t 18 &  278 & 0 &  278 & 0 & 2 & 58 & 0 & Ipilimumab + Pembrolizumab & Lung            & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 19 &  635 & 0 &  301 & 1 & 1 & 56 & 0 & Ipilimumab + Pembrolizumab & SQ              & â‹¯ & -0.990153661 & -0.66884995 &  0.75507446 &  0.45702034 & -0.0978608256 & -0.037910521 & -0.19641500 & -0.002663966 &  0.14242927 & -0.53603414\\\\\n",
       "\t 2  &  530 & 0 &   34 & 1 & 0 & 41 & 0 & Ipilimumab + Pembrolizumab & LN              & â‹¯ &  1.079653224 &  0.62934788 & -1.23471534 & -0.96470192 &  0.5255918237 & -0.095807574 & -0.52099920 &  0.825633802 &  0.08874634 &  0.01569202\\\\\n",
       "\t 20 &  538 & 0 &  386 & 1 & 1 & 57 & 0 & Ipilimumab + Pembrolizumab & LN              & â‹¯ & -0.399369346 & -1.27744820 &  1.16563917 &  0.44796852 &  0.9177473835 & -0.044360443 & -0.21307855 & -0.099479074 &  1.54256398 &  0.60783149\\\\\n",
       "\t 21 &  410 & 0 &  410 & 0 & 2 & 63 & 0 & Ipilimumab + Nivolumab     & SQ              & â‹¯ &  0.262799951 &  0.64011166 &  0.24011332 & -0.11178293 &  0.1601318153 &  0.001045315 & -0.02779061 & -0.079428025 &  0.24134531 &  0.22767313\\\\\n",
       "\t 22 &  706 & 0 &  487 & 1 & 2 & 59 & 1 & Ipilimumab + Pembrolizumab & LN              & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 23 &  506 & 0 &  506 & 0 & 2 & 51 & 1 & Ipilimumab + Pembrolizumab & Brain           & â‹¯ &  0.410802324 & -0.35400995 & -0.38289902 &  0.26529255 &  0.0681192357 & -0.046954071 & -0.03533289 & -0.555163096 & -0.54986056 &  1.10751447\\\\\n",
       "\t 24 & 1203 & 0 &  509 & 1 & 2 & 34 & 0 & Ipilimumab + Nivolumab     & LN              & â‹¯ & -0.772687949 & -0.17954929 &  0.15757350 & -0.04612901 &  0.1787330668 & -0.049971772 &  0.06365311 & -0.651993693 &  0.41805088 & -0.40544793\\\\\n",
       "\t 25 &  518 & 1 &  518 & 0 & 1 & 67 & 1 & Ipilimumab + Pembrolizumab & LN              & â‹¯ &  0.323958497 & -0.28877420 & -0.34308412 & -0.42472156 &  0.7366265926 & -0.095807574 &  0.41074512 & -0.507792891 &  0.20384346 &  0.47588991\\\\\n",
       "\t 26 &  544 & 0 &  544 & 0 & 3 & 75 & 0 & Ipilimumab + Pembrolizumab & LN              & â‹¯ &  0.462127921 &  0.57497284 & -0.59890304 & -0.44415190 &  0.7441192974 &  0.069465219 & -0.38604727 & -0.899311870 &  0.37238568 & -0.43646272\\\\\n",
       "\t 27 &  546 & 0 &  546 & 0 & 3 & 49 & 0 & Ipilimumab + Pembrolizumab & Abdomen         & â‹¯ & -0.605366439 &  0.35143929 &  0.32851067 &  0.35746238 & -0.1407782292 & -0.077796562 &  0.07142574 &  0.107125170 & -0.01490806 & -0.75544253\\\\\n",
       "\t 28 &  553 & 0 &  553 & 0 & 3 & 33 & 0 & Ipilimumab + Pembrolizumab & LN              & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 29 &  567 & 0 &  567 & 0 & 3 & 66 & 1 & Ipilimumab + Pembrolizumab & LN              & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 3  &  300 & 0 &   37 & 1 & 0 & 58 & 1 & Ipilimumab + Nivolumab     & Lung            & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 30 &  573 & 0 &  573 & 0 & 2 & 56 & 0 & Ipilimumab + Pembrolizumab & Small intestine & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 31 &  588 & 0 &  588 & 0 & 3 & 45 & 0 & Ipilimumab + Pembrolizumab & Lung            & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 32 &  597 & 0 &  597 & 0 & 3 & 71 & 0 & Ipilimumab + Pembrolizumab & LN              & â‹¯ &  0.008691614 & -0.39469549 & -0.73498518 & -0.43149567 &  0.5530308342 &  0.567570255 & -0.17093020 & -0.578044742 &  1.00302316 &  0.72587330\\\\\n",
       "\t 33 &  609 & 0 &  609 & 0 & 2 & 73 & 0 & Ipilimumab + Pembrolizumab & SQ              & â‹¯ &  0.543191258 &  0.96220905 &  0.08654803 &  0.29531747 & -0.0733442796 & -0.071404280 &  0.04744246 &  0.311459770 & -0.45692695 & -0.22853974\\\\\n",
       "\t 34 &  623 & 0 &  623 & 0 & 3 & 51 & 0 & Ipilimumab + Pembrolizumab & Lung            & â‹¯ & -0.766047908 & -1.69531674 & -0.14342511 & -0.17124200 &  0.5643143914 & -0.068337272 & -0.19164100 &  0.736564406 &  0.06647244 & -0.16604761\\\\\n",
       "\t 35 &  627 & 0 &  627 & 0 & 3 & 72 & 0 & Ipilimumab + Pembrolizumab & SQ              & â‹¯ & -0.468675161 &  0.38191325 & -0.13353630 &  0.44677454 & -0.1907897938 & -0.014894504 & -0.06091901 & -0.292491200 &  0.06483150 &  0.36725970\\\\\n",
       "\t 36 &  637 & 0 &  637 & 0 & 3 & 74 & 1 & Ipilimumab + Pembrolizumab & SQ              & â‹¯ & -0.231554875 &  0.42826173 &  0.17136963 &  0.43681965 & -0.0434933523 & -0.070101252 & -0.77012086 &  0.026242002 & -0.29389081 & -1.04418568\\\\\n",
       "\t 37 &  637 & 0 &  637 & 0 & 2 & 76 & 0 & Ipilimumab + Pembrolizumab & LN              & â‹¯ &  0.255039312 &  0.97348718 &  0.37727755 &  0.11511414 & -0.5009587486 & -0.059131734 &  0.17357627 &  0.336104507 & -0.43932309 & -0.15576478\\\\\n",
       "\t 38 &  650 & 0 &  650 & 0 & 3 & 59 & 1 & Ipilimumab + Pembrolizumab & SQ              & â‹¯ & -0.253086816 & -1.03622267 &  0.74340903 & -0.44263081 & -0.7088331041 &  0.021772744 &  0.30909709 &  0.001373924 &  0.42681432 & -0.13050942\\\\\n",
       "\t 39 &  657 & 0 &  657 & 0 & 3 & 33 & 0 & Ipilimumab + Nivolumab     & LN              & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 4  &  129 & 0 &   39 & 1 & 0 & 48 & 0 & Ipilimumab + Nivolumab     & SQ              & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 40 &  671 & 0 &  671 & 0 & 2 & 81 & 0 & Ipilimumab + Pembrolizumab & SQ              & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 41 &  672 & 0 &  672 & 0 & 2 & 57 & 1 & Ipilimumab + Pembrolizumab & SQ              & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 42 &  692 & 0 &  692 & 0 & 2 & 71 & 0 & Ipilimumab + Pembrolizumab & Lung            & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 43 &  693 & 0 &  693 & 0 & 3 & 53 & 1 & Ipilimumab + Pembrolizumab & SQ              & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 44 &  695 & 0 &  695 & 0 & 2 & 68 & 0 & Ipilimumab + Pembrolizumab & SQ              & â‹¯ &  0.206773696 & -0.42747899 & -0.06521667 & -0.31779465 & -0.6308434283 & -0.012797742 &  0.16718252 &  1.344192060 & -0.03809493 & -0.45864802\\\\\n",
       "\t 45 &  721 & 0 &  721 & 0 & 3 & 70 & 0 & Ipilimumab + Pembrolizumab & Mucosa          & â‹¯ & -0.441284649 & -0.90003180 & -0.55994432 & -0.56467426 & -0.0005595549 & -0.095807574 & -0.42775717 &  0.073520455 &  0.32066835 & -0.20276745\\\\\n",
       "\t 46 &  721 & 0 &  721 & 0 & 3 & 54 & 1 & Ipilimumab + Pembrolizumab & Lung            & â‹¯ & -0.235865821 & -0.80103916 &  0.22053955 & -0.19983454 &  0.2138286755 & -0.086896878 & -0.09116498 &  0.038010253 &  0.27755322 &  0.04282373\\\\\n",
       "\t 47 &  732 & 0 &  732 & 0 & 2 & 24 & 1 & Ipilimumab + Pembrolizumab & SQ              & â‹¯ & -0.570139294 & -0.38900084 &  0.20432131 &  0.13540615 & -0.4530921630 & -0.018278153 &  0.07228018 &  0.273916435 & -0.32552466 & -0.16369490\\\\\n",
       "\t 48 &  737 & 0 &  737 & 0 & 2 & 72 & 0 & Ipilimumab + Pembrolizumab & SQ              & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 49 &  775 & 0 &  775 & 0 & 3 & 36 & 0 & Ipilimumab + Pembrolizumab & LN              & â‹¯ &  0.387066334 &  0.80556102 & -0.04602627 &  0.15027246 & -0.6784978765 &  0.038183825 &  0.16128751 & -0.238370565 & -0.13963415 & -0.21243155\\\\\n",
       "\t 5  &   93 & 1 &   40 & 1 & 0 & 49 & 1 & Ipilimumab + Pembrolizumab & LN              & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 50 &  904 & 0 &  904 & 0 & 2 & 68 & 0 & Ipilimumab + Pembrolizumab & LN              & â‹¯ &  0.314961134 &  1.37143617 &  0.08818719 &  0.27088915 & -0.2879368575 &  0.045436179 &  0.33126353 &  0.210137373 & -0.54818555 & -0.23738481\\\\\n",
       "\t 51 & 1379 & 0 & 1379 & 0 & 2 & 64 & 0 & Ipilimumab + Pembrolizumab & Liver           & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 6  &  108 & 1 &   41 & 1 & 0 & 75 & 0 & Ipilimumab + Nivolumab     & LN              & â‹¯ &  0.230476038 & -0.34597308 & -0.02931501 &  0.33392762 &  0.1422300068 & -0.006887237 & -0.09623038 & -1.180614170 &  0.44382387 &  0.03539586\\\\\n",
       "\t 7  &  169 & 0 &   81 & 1 & 2 & 59 & 0 & Ipilimumab + Nivolumab     & SQ              & â‹¯ &  0.715314720 &  0.32665483 &  0.27464873 & -0.37869573 & -0.2000784318 & -0.095807574 &  0.13778226 &  0.704947921 & -0.55133851 &  0.40732392\\\\\n",
       "\t 8  &  637 & 0 &   81 & 1 & 0 & 55 & 0 & Ipilimumab + Pembrolizumab & LN              & â‹¯ &  0.445047608 &  0.80762933 & -0.38707532 &  0.08435613 & -0.3666242486 & -0.043040810 &  0.32211429 & -0.606676792 & -1.13187658 &  0.65424050\\\\\n",
       "\t 9  &  156 & 1 &   81 & 1 & 0 & 56 & 0 & Ipilimumab + Pembrolizumab & LN              & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A data.frame: 51 Ã— 18792\n",
       "\n",
       "| Patient &lt;I&lt;chr&gt;&gt; | OS &lt;int&gt; | OS.Event &lt;int&gt; | PFS &lt;int&gt; | PFS.Event &lt;int&gt; | RECIST &lt;int&gt; | Age &lt;int&gt; | Gender &lt;int&gt; | Treatment &lt;fct&gt; | Site &lt;fct&gt; | â‹¯ â‹¯ | 55055 &lt;dbl&gt; | 11130 &lt;dbl&gt; | 7789 &lt;dbl&gt; | 158586 &lt;dbl&gt; | 79364 &lt;dbl&gt; | 440590 &lt;dbl&gt; | 79699 &lt;dbl&gt; | 7791 &lt;dbl&gt; | 23140 &lt;dbl&gt; | 26009 &lt;dbl&gt; |\n",
       "|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|\n",
       "| 1  |  689 | 0 |   15 | 1 | 0 | 42 | 1 | Ipilimumab + Pembrolizumab | SQ              | â‹¯ |  0.814559991 |  0.09616738 | -0.27965633 |  0.31559451 | -0.0626374123 |  0.055108447 | -0.56911380 | -0.380607347 | -0.52103880 | -0.46877980 |\n",
       "| 10 |  176 | 1 |   81 | 1 | 0 | 51 | 0 | Ipilimumab + Pembrolizumab | LN              | â‹¯ |  0.464824631 |  0.30872910 | -0.66759771 |  0.56592965 | -0.4606691302 |  0.554262011 |  0.69282995 |  0.539471466 | -0.33190657 |  0.11705793 |\n",
       "| 11 |  221 | 0 |   82 | 1 | 0 | 62 | 0 | Ipilimumab + Nivolumab     | LN              | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 12 |  293 | 0 |   82 | 1 | 0 | 55 | 1 | Ipilimumab + Nivolumab     | Lung            | â‹¯ | -1.115560810 | -2.62608070 |  0.33662516 | -0.09917793 |  0.5652990871 | -0.061318728 |  0.01378568 |  0.632443208 |  0.78257787 | -0.20470475 |\n",
       "| 13 |  357 | 1 |  108 | 1 | 2 | 68 | 1 | Ipilimumab + Nivolumab     | SQ              | â‹¯ | -0.209928304 |  0.81250891 |  0.04422525 |  0.06929868 | -0.3294996664 | -0.095807574 | -0.01927152 |  0.254432485 | -0.03632622 |  0.10893968 |\n",
       "| 14 |  691 | 0 |  123 | 1 | 1 | 47 | 1 | Ipilimumab + Pembrolizumab | SQ              | â‹¯ | -0.229523423 |  1.34753221 |  0.49996400 |  0.10629174 | -0.0166411617 | -0.023002256 |  0.46454270 | -0.437119044 | -0.41935743 | -0.15979738 |\n",
       "| 15 |  660 | 1 |  152 | 1 | 1 | 57 | 0 | Ipilimumab + Pembrolizumab | SQ              | â‹¯ | -0.033292657 |  1.11436707 |  0.13554354 |  0.25877652 | -0.2631522968 | -0.054781348 |  0.14859193 | -0.330010210 | -0.70105036 |  1.23636907 |\n",
       "| 16 |  558 | 0 |  168 | 1 | 2 | 39 | 1 | Ipilimumab + Pembrolizumab | LN              | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 17 |  196 | 0 |  196 | 0 | 2 | 48 | 1 | Ipilimumab + Nivolumab     | LN              | â‹¯ |  0.397248856 | -0.54785782 | -0.22319036 | -0.51547930 |  0.1365183514 | -0.025940561 |  0.18921212 |  0.424191448 |  0.10411358 | -0.16324147 |\n",
       "| 18 |  278 | 0 |  278 | 0 | 2 | 58 | 0 | Ipilimumab + Pembrolizumab | Lung            | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 19 |  635 | 0 |  301 | 1 | 1 | 56 | 0 | Ipilimumab + Pembrolizumab | SQ              | â‹¯ | -0.990153661 | -0.66884995 |  0.75507446 |  0.45702034 | -0.0978608256 | -0.037910521 | -0.19641500 | -0.002663966 |  0.14242927 | -0.53603414 |\n",
       "| 2  |  530 | 0 |   34 | 1 | 0 | 41 | 0 | Ipilimumab + Pembrolizumab | LN              | â‹¯ |  1.079653224 |  0.62934788 | -1.23471534 | -0.96470192 |  0.5255918237 | -0.095807574 | -0.52099920 |  0.825633802 |  0.08874634 |  0.01569202 |\n",
       "| 20 |  538 | 0 |  386 | 1 | 1 | 57 | 0 | Ipilimumab + Pembrolizumab | LN              | â‹¯ | -0.399369346 | -1.27744820 |  1.16563917 |  0.44796852 |  0.9177473835 | -0.044360443 | -0.21307855 | -0.099479074 |  1.54256398 |  0.60783149 |\n",
       "| 21 |  410 | 0 |  410 | 0 | 2 | 63 | 0 | Ipilimumab + Nivolumab     | SQ              | â‹¯ |  0.262799951 |  0.64011166 |  0.24011332 | -0.11178293 |  0.1601318153 |  0.001045315 | -0.02779061 | -0.079428025 |  0.24134531 |  0.22767313 |\n",
       "| 22 |  706 | 0 |  487 | 1 | 2 | 59 | 1 | Ipilimumab + Pembrolizumab | LN              | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 23 |  506 | 0 |  506 | 0 | 2 | 51 | 1 | Ipilimumab + Pembrolizumab | Brain           | â‹¯ |  0.410802324 | -0.35400995 | -0.38289902 |  0.26529255 |  0.0681192357 | -0.046954071 | -0.03533289 | -0.555163096 | -0.54986056 |  1.10751447 |\n",
       "| 24 | 1203 | 0 |  509 | 1 | 2 | 34 | 0 | Ipilimumab + Nivolumab     | LN              | â‹¯ | -0.772687949 | -0.17954929 |  0.15757350 | -0.04612901 |  0.1787330668 | -0.049971772 |  0.06365311 | -0.651993693 |  0.41805088 | -0.40544793 |\n",
       "| 25 |  518 | 1 |  518 | 0 | 1 | 67 | 1 | Ipilimumab + Pembrolizumab | LN              | â‹¯ |  0.323958497 | -0.28877420 | -0.34308412 | -0.42472156 |  0.7366265926 | -0.095807574 |  0.41074512 | -0.507792891 |  0.20384346 |  0.47588991 |\n",
       "| 26 |  544 | 0 |  544 | 0 | 3 | 75 | 0 | Ipilimumab + Pembrolizumab | LN              | â‹¯ |  0.462127921 |  0.57497284 | -0.59890304 | -0.44415190 |  0.7441192974 |  0.069465219 | -0.38604727 | -0.899311870 |  0.37238568 | -0.43646272 |\n",
       "| 27 |  546 | 0 |  546 | 0 | 3 | 49 | 0 | Ipilimumab + Pembrolizumab | Abdomen         | â‹¯ | -0.605366439 |  0.35143929 |  0.32851067 |  0.35746238 | -0.1407782292 | -0.077796562 |  0.07142574 |  0.107125170 | -0.01490806 | -0.75544253 |\n",
       "| 28 |  553 | 0 |  553 | 0 | 3 | 33 | 0 | Ipilimumab + Pembrolizumab | LN              | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 29 |  567 | 0 |  567 | 0 | 3 | 66 | 1 | Ipilimumab + Pembrolizumab | LN              | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 3  |  300 | 0 |   37 | 1 | 0 | 58 | 1 | Ipilimumab + Nivolumab     | Lung            | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 30 |  573 | 0 |  573 | 0 | 2 | 56 | 0 | Ipilimumab + Pembrolizumab | Small intestine | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 31 |  588 | 0 |  588 | 0 | 3 | 45 | 0 | Ipilimumab + Pembrolizumab | Lung            | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 32 |  597 | 0 |  597 | 0 | 3 | 71 | 0 | Ipilimumab + Pembrolizumab | LN              | â‹¯ |  0.008691614 | -0.39469549 | -0.73498518 | -0.43149567 |  0.5530308342 |  0.567570255 | -0.17093020 | -0.578044742 |  1.00302316 |  0.72587330 |\n",
       "| 33 |  609 | 0 |  609 | 0 | 2 | 73 | 0 | Ipilimumab + Pembrolizumab | SQ              | â‹¯ |  0.543191258 |  0.96220905 |  0.08654803 |  0.29531747 | -0.0733442796 | -0.071404280 |  0.04744246 |  0.311459770 | -0.45692695 | -0.22853974 |\n",
       "| 34 |  623 | 0 |  623 | 0 | 3 | 51 | 0 | Ipilimumab + Pembrolizumab | Lung            | â‹¯ | -0.766047908 | -1.69531674 | -0.14342511 | -0.17124200 |  0.5643143914 | -0.068337272 | -0.19164100 |  0.736564406 |  0.06647244 | -0.16604761 |\n",
       "| 35 |  627 | 0 |  627 | 0 | 3 | 72 | 0 | Ipilimumab + Pembrolizumab | SQ              | â‹¯ | -0.468675161 |  0.38191325 | -0.13353630 |  0.44677454 | -0.1907897938 | -0.014894504 | -0.06091901 | -0.292491200 |  0.06483150 |  0.36725970 |\n",
       "| 36 |  637 | 0 |  637 | 0 | 3 | 74 | 1 | Ipilimumab + Pembrolizumab | SQ              | â‹¯ | -0.231554875 |  0.42826173 |  0.17136963 |  0.43681965 | -0.0434933523 | -0.070101252 | -0.77012086 |  0.026242002 | -0.29389081 | -1.04418568 |\n",
       "| 37 |  637 | 0 |  637 | 0 | 2 | 76 | 0 | Ipilimumab + Pembrolizumab | LN              | â‹¯ |  0.255039312 |  0.97348718 |  0.37727755 |  0.11511414 | -0.5009587486 | -0.059131734 |  0.17357627 |  0.336104507 | -0.43932309 | -0.15576478 |\n",
       "| 38 |  650 | 0 |  650 | 0 | 3 | 59 | 1 | Ipilimumab + Pembrolizumab | SQ              | â‹¯ | -0.253086816 | -1.03622267 |  0.74340903 | -0.44263081 | -0.7088331041 |  0.021772744 |  0.30909709 |  0.001373924 |  0.42681432 | -0.13050942 |\n",
       "| 39 |  657 | 0 |  657 | 0 | 3 | 33 | 0 | Ipilimumab + Nivolumab     | LN              | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 4  |  129 | 0 |   39 | 1 | 0 | 48 | 0 | Ipilimumab + Nivolumab     | SQ              | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 40 |  671 | 0 |  671 | 0 | 2 | 81 | 0 | Ipilimumab + Pembrolizumab | SQ              | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 41 |  672 | 0 |  672 | 0 | 2 | 57 | 1 | Ipilimumab + Pembrolizumab | SQ              | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 42 |  692 | 0 |  692 | 0 | 2 | 71 | 0 | Ipilimumab + Pembrolizumab | Lung            | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 43 |  693 | 0 |  693 | 0 | 3 | 53 | 1 | Ipilimumab + Pembrolizumab | SQ              | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 44 |  695 | 0 |  695 | 0 | 2 | 68 | 0 | Ipilimumab + Pembrolizumab | SQ              | â‹¯ |  0.206773696 | -0.42747899 | -0.06521667 | -0.31779465 | -0.6308434283 | -0.012797742 |  0.16718252 |  1.344192060 | -0.03809493 | -0.45864802 |\n",
       "| 45 |  721 | 0 |  721 | 0 | 3 | 70 | 0 | Ipilimumab + Pembrolizumab | Mucosa          | â‹¯ | -0.441284649 | -0.90003180 | -0.55994432 | -0.56467426 | -0.0005595549 | -0.095807574 | -0.42775717 |  0.073520455 |  0.32066835 | -0.20276745 |\n",
       "| 46 |  721 | 0 |  721 | 0 | 3 | 54 | 1 | Ipilimumab + Pembrolizumab | Lung            | â‹¯ | -0.235865821 | -0.80103916 |  0.22053955 | -0.19983454 |  0.2138286755 | -0.086896878 | -0.09116498 |  0.038010253 |  0.27755322 |  0.04282373 |\n",
       "| 47 |  732 | 0 |  732 | 0 | 2 | 24 | 1 | Ipilimumab + Pembrolizumab | SQ              | â‹¯ | -0.570139294 | -0.38900084 |  0.20432131 |  0.13540615 | -0.4530921630 | -0.018278153 |  0.07228018 |  0.273916435 | -0.32552466 | -0.16369490 |\n",
       "| 48 |  737 | 0 |  737 | 0 | 2 | 72 | 0 | Ipilimumab + Pembrolizumab | SQ              | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 49 |  775 | 0 |  775 | 0 | 3 | 36 | 0 | Ipilimumab + Pembrolizumab | LN              | â‹¯ |  0.387066334 |  0.80556102 | -0.04602627 |  0.15027246 | -0.6784978765 |  0.038183825 |  0.16128751 | -0.238370565 | -0.13963415 | -0.21243155 |\n",
       "| 5  |   93 | 1 |   40 | 1 | 0 | 49 | 1 | Ipilimumab + Pembrolizumab | LN              | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 50 |  904 | 0 |  904 | 0 | 2 | 68 | 0 | Ipilimumab + Pembrolizumab | LN              | â‹¯ |  0.314961134 |  1.37143617 |  0.08818719 |  0.27088915 | -0.2879368575 |  0.045436179 |  0.33126353 |  0.210137373 | -0.54818555 | -0.23738481 |\n",
       "| 51 | 1379 | 0 | 1379 | 0 | 2 | 64 | 0 | Ipilimumab + Pembrolizumab | Liver           | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 6  |  108 | 1 |   41 | 1 | 0 | 75 | 0 | Ipilimumab + Nivolumab     | LN              | â‹¯ |  0.230476038 | -0.34597308 | -0.02931501 |  0.33392762 |  0.1422300068 | -0.006887237 | -0.09623038 | -1.180614170 |  0.44382387 |  0.03539586 |\n",
       "| 7  |  169 | 0 |   81 | 1 | 2 | 59 | 0 | Ipilimumab + Nivolumab     | SQ              | â‹¯ |  0.715314720 |  0.32665483 |  0.27464873 | -0.37869573 | -0.2000784318 | -0.095807574 |  0.13778226 |  0.704947921 | -0.55133851 |  0.40732392 |\n",
       "| 8  |  637 | 0 |   81 | 1 | 0 | 55 | 0 | Ipilimumab + Pembrolizumab | LN              | â‹¯ |  0.445047608 |  0.80762933 | -0.38707532 |  0.08435613 | -0.3666242486 | -0.043040810 |  0.32211429 | -0.606676792 | -1.13187658 |  0.65424050 |\n",
       "| 9  |  156 | 1 |   81 | 1 | 0 | 56 | 0 | Ipilimumab + Pembrolizumab | LN              | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "\n"
      ],
      "text/plain": [
       "   Patient OS   OS.Event PFS  PFS.Event RECIST Age Gender\n",
       "1  1        689 0          15 1         0      42  1     \n",
       "2  10       176 1          81 1         0      51  0     \n",
       "3  11       221 0          82 1         0      62  0     \n",
       "4  12       293 0          82 1         0      55  1     \n",
       "5  13       357 1         108 1         2      68  1     \n",
       "6  14       691 0         123 1         1      47  1     \n",
       "7  15       660 1         152 1         1      57  0     \n",
       "8  16       558 0         168 1         2      39  1     \n",
       "9  17       196 0         196 0         2      48  1     \n",
       "10 18       278 0         278 0         2      58  0     \n",
       "11 19       635 0         301 1         1      56  0     \n",
       "12 2        530 0          34 1         0      41  0     \n",
       "13 20       538 0         386 1         1      57  0     \n",
       "14 21       410 0         410 0         2      63  0     \n",
       "15 22       706 0         487 1         2      59  1     \n",
       "16 23       506 0         506 0         2      51  1     \n",
       "17 24      1203 0         509 1         2      34  0     \n",
       "18 25       518 1         518 0         1      67  1     \n",
       "19 26       544 0         544 0         3      75  0     \n",
       "20 27       546 0         546 0         3      49  0     \n",
       "21 28       553 0         553 0         3      33  0     \n",
       "22 29       567 0         567 0         3      66  1     \n",
       "23 3        300 0          37 1         0      58  1     \n",
       "24 30       573 0         573 0         2      56  0     \n",
       "25 31       588 0         588 0         3      45  0     \n",
       "26 32       597 0         597 0         3      71  0     \n",
       "27 33       609 0         609 0         2      73  0     \n",
       "28 34       623 0         623 0         3      51  0     \n",
       "29 35       627 0         627 0         3      72  0     \n",
       "30 36       637 0         637 0         3      74  1     \n",
       "31 37       637 0         637 0         2      76  0     \n",
       "32 38       650 0         650 0         3      59  1     \n",
       "33 39       657 0         657 0         3      33  0     \n",
       "34 4        129 0          39 1         0      48  0     \n",
       "35 40       671 0         671 0         2      81  0     \n",
       "36 41       672 0         672 0         2      57  1     \n",
       "37 42       692 0         692 0         2      71  0     \n",
       "38 43       693 0         693 0         3      53  1     \n",
       "39 44       695 0         695 0         2      68  0     \n",
       "40 45       721 0         721 0         3      70  0     \n",
       "41 46       721 0         721 0         3      54  1     \n",
       "42 47       732 0         732 0         2      24  1     \n",
       "43 48       737 0         737 0         2      72  0     \n",
       "44 49       775 0         775 0         3      36  0     \n",
       "45 5         93 1          40 1         0      49  1     \n",
       "46 50       904 0         904 0         2      68  0     \n",
       "47 51      1379 0        1379 0         2      64  0     \n",
       "48 6        108 1          41 1         0      75  0     \n",
       "49 7        169 0          81 1         2      59  0     \n",
       "50 8        637 0          81 1         0      55  0     \n",
       "51 9        156 1          81 1         0      56  0     \n",
       "   Treatment                  Site            â‹¯ 55055        11130      \n",
       "1  Ipilimumab + Pembrolizumab SQ              â‹¯  0.814559991  0.09616738\n",
       "2  Ipilimumab + Pembrolizumab LN              â‹¯  0.464824631  0.30872910\n",
       "3  Ipilimumab + Nivolumab     LN              â‹¯           NA          NA\n",
       "4  Ipilimumab + Nivolumab     Lung            â‹¯ -1.115560810 -2.62608070\n",
       "5  Ipilimumab + Nivolumab     SQ              â‹¯ -0.209928304  0.81250891\n",
       "6  Ipilimumab + Pembrolizumab SQ              â‹¯ -0.229523423  1.34753221\n",
       "7  Ipilimumab + Pembrolizumab SQ              â‹¯ -0.033292657  1.11436707\n",
       "8  Ipilimumab + Pembrolizumab LN              â‹¯           NA          NA\n",
       "9  Ipilimumab + Nivolumab     LN              â‹¯  0.397248856 -0.54785782\n",
       "10 Ipilimumab + Pembrolizumab Lung            â‹¯           NA          NA\n",
       "11 Ipilimumab + Pembrolizumab SQ              â‹¯ -0.990153661 -0.66884995\n",
       "12 Ipilimumab + Pembrolizumab LN              â‹¯  1.079653224  0.62934788\n",
       "13 Ipilimumab + Pembrolizumab LN              â‹¯ -0.399369346 -1.27744820\n",
       "14 Ipilimumab + Nivolumab     SQ              â‹¯  0.262799951  0.64011166\n",
       "15 Ipilimumab + Pembrolizumab LN              â‹¯           NA          NA\n",
       "16 Ipilimumab + Pembrolizumab Brain           â‹¯  0.410802324 -0.35400995\n",
       "17 Ipilimumab + Nivolumab     LN              â‹¯ -0.772687949 -0.17954929\n",
       "18 Ipilimumab + Pembrolizumab LN              â‹¯  0.323958497 -0.28877420\n",
       "19 Ipilimumab + Pembrolizumab LN              â‹¯  0.462127921  0.57497284\n",
       "20 Ipilimumab + Pembrolizumab Abdomen         â‹¯ -0.605366439  0.35143929\n",
       "21 Ipilimumab + Pembrolizumab LN              â‹¯           NA          NA\n",
       "22 Ipilimumab + Pembrolizumab LN              â‹¯           NA          NA\n",
       "23 Ipilimumab + Nivolumab     Lung            â‹¯           NA          NA\n",
       "24 Ipilimumab + Pembrolizumab Small intestine â‹¯           NA          NA\n",
       "25 Ipilimumab + Pembrolizumab Lung            â‹¯           NA          NA\n",
       "26 Ipilimumab + Pembrolizumab LN              â‹¯  0.008691614 -0.39469549\n",
       "27 Ipilimumab + Pembrolizumab SQ              â‹¯  0.543191258  0.96220905\n",
       "28 Ipilimumab + Pembrolizumab Lung            â‹¯ -0.766047908 -1.69531674\n",
       "29 Ipilimumab + Pembrolizumab SQ              â‹¯ -0.468675161  0.38191325\n",
       "30 Ipilimumab + Pembrolizumab SQ              â‹¯ -0.231554875  0.42826173\n",
       "31 Ipilimumab + Pembrolizumab LN              â‹¯  0.255039312  0.97348718\n",
       "32 Ipilimumab + Pembrolizumab SQ              â‹¯ -0.253086816 -1.03622267\n",
       "33 Ipilimumab + Nivolumab     LN              â‹¯           NA          NA\n",
       "34 Ipilimumab + Nivolumab     SQ              â‹¯           NA          NA\n",
       "35 Ipilimumab + Pembrolizumab SQ              â‹¯           NA          NA\n",
       "36 Ipilimumab + Pembrolizumab SQ              â‹¯           NA          NA\n",
       "37 Ipilimumab + Pembrolizumab Lung            â‹¯           NA          NA\n",
       "38 Ipilimumab + Pembrolizumab SQ              â‹¯           NA          NA\n",
       "39 Ipilimumab + Pembrolizumab SQ              â‹¯  0.206773696 -0.42747899\n",
       "40 Ipilimumab + Pembrolizumab Mucosa          â‹¯ -0.441284649 -0.90003180\n",
       "41 Ipilimumab + Pembrolizumab Lung            â‹¯ -0.235865821 -0.80103916\n",
       "42 Ipilimumab + Pembrolizumab SQ              â‹¯ -0.570139294 -0.38900084\n",
       "43 Ipilimumab + Pembrolizumab SQ              â‹¯           NA          NA\n",
       "44 Ipilimumab + Pembrolizumab LN              â‹¯  0.387066334  0.80556102\n",
       "45 Ipilimumab + Pembrolizumab LN              â‹¯           NA          NA\n",
       "46 Ipilimumab + Pembrolizumab LN              â‹¯  0.314961134  1.37143617\n",
       "47 Ipilimumab + Pembrolizumab Liver           â‹¯           NA          NA\n",
       "48 Ipilimumab + Nivolumab     LN              â‹¯  0.230476038 -0.34597308\n",
       "49 Ipilimumab + Nivolumab     SQ              â‹¯  0.715314720  0.32665483\n",
       "50 Ipilimumab + Pembrolizumab LN              â‹¯  0.445047608  0.80762933\n",
       "51 Ipilimumab + Pembrolizumab LN              â‹¯           NA          NA\n",
       "   7789        158586      79364         440590       79699       7791        \n",
       "1  -0.27965633  0.31559451 -0.0626374123  0.055108447 -0.56911380 -0.380607347\n",
       "2  -0.66759771  0.56592965 -0.4606691302  0.554262011  0.69282995  0.539471466\n",
       "3           NA          NA            NA           NA          NA           NA\n",
       "4   0.33662516 -0.09917793  0.5652990871 -0.061318728  0.01378568  0.632443208\n",
       "5   0.04422525  0.06929868 -0.3294996664 -0.095807574 -0.01927152  0.254432485\n",
       "6   0.49996400  0.10629174 -0.0166411617 -0.023002256  0.46454270 -0.437119044\n",
       "7   0.13554354  0.25877652 -0.2631522968 -0.054781348  0.14859193 -0.330010210\n",
       "8           NA          NA            NA           NA          NA           NA\n",
       "9  -0.22319036 -0.51547930  0.1365183514 -0.025940561  0.18921212  0.424191448\n",
       "10          NA          NA            NA           NA          NA           NA\n",
       "11  0.75507446  0.45702034 -0.0978608256 -0.037910521 -0.19641500 -0.002663966\n",
       "12 -1.23471534 -0.96470192  0.5255918237 -0.095807574 -0.52099920  0.825633802\n",
       "13  1.16563917  0.44796852  0.9177473835 -0.044360443 -0.21307855 -0.099479074\n",
       "14  0.24011332 -0.11178293  0.1601318153  0.001045315 -0.02779061 -0.079428025\n",
       "15          NA          NA            NA           NA          NA           NA\n",
       "16 -0.38289902  0.26529255  0.0681192357 -0.046954071 -0.03533289 -0.555163096\n",
       "17  0.15757350 -0.04612901  0.1787330668 -0.049971772  0.06365311 -0.651993693\n",
       "18 -0.34308412 -0.42472156  0.7366265926 -0.095807574  0.41074512 -0.507792891\n",
       "19 -0.59890304 -0.44415190  0.7441192974  0.069465219 -0.38604727 -0.899311870\n",
       "20  0.32851067  0.35746238 -0.1407782292 -0.077796562  0.07142574  0.107125170\n",
       "21          NA          NA            NA           NA          NA           NA\n",
       "22          NA          NA            NA           NA          NA           NA\n",
       "23          NA          NA            NA           NA          NA           NA\n",
       "24          NA          NA            NA           NA          NA           NA\n",
       "25          NA          NA            NA           NA          NA           NA\n",
       "26 -0.73498518 -0.43149567  0.5530308342  0.567570255 -0.17093020 -0.578044742\n",
       "27  0.08654803  0.29531747 -0.0733442796 -0.071404280  0.04744246  0.311459770\n",
       "28 -0.14342511 -0.17124200  0.5643143914 -0.068337272 -0.19164100  0.736564406\n",
       "29 -0.13353630  0.44677454 -0.1907897938 -0.014894504 -0.06091901 -0.292491200\n",
       "30  0.17136963  0.43681965 -0.0434933523 -0.070101252 -0.77012086  0.026242002\n",
       "31  0.37727755  0.11511414 -0.5009587486 -0.059131734  0.17357627  0.336104507\n",
       "32  0.74340903 -0.44263081 -0.7088331041  0.021772744  0.30909709  0.001373924\n",
       "33          NA          NA            NA           NA          NA           NA\n",
       "34          NA          NA            NA           NA          NA           NA\n",
       "35          NA          NA            NA           NA          NA           NA\n",
       "36          NA          NA            NA           NA          NA           NA\n",
       "37          NA          NA            NA           NA          NA           NA\n",
       "38          NA          NA            NA           NA          NA           NA\n",
       "39 -0.06521667 -0.31779465 -0.6308434283 -0.012797742  0.16718252  1.344192060\n",
       "40 -0.55994432 -0.56467426 -0.0005595549 -0.095807574 -0.42775717  0.073520455\n",
       "41  0.22053955 -0.19983454  0.2138286755 -0.086896878 -0.09116498  0.038010253\n",
       "42  0.20432131  0.13540615 -0.4530921630 -0.018278153  0.07228018  0.273916435\n",
       "43          NA          NA            NA           NA          NA           NA\n",
       "44 -0.04602627  0.15027246 -0.6784978765  0.038183825  0.16128751 -0.238370565\n",
       "45          NA          NA            NA           NA          NA           NA\n",
       "46  0.08818719  0.27088915 -0.2879368575  0.045436179  0.33126353  0.210137373\n",
       "47          NA          NA            NA           NA          NA           NA\n",
       "48 -0.02931501  0.33392762  0.1422300068 -0.006887237 -0.09623038 -1.180614170\n",
       "49  0.27464873 -0.37869573 -0.2000784318 -0.095807574  0.13778226  0.704947921\n",
       "50 -0.38707532  0.08435613 -0.3666242486 -0.043040810  0.32211429 -0.606676792\n",
       "51          NA          NA            NA           NA          NA           NA\n",
       "   23140       26009      \n",
       "1  -0.52103880 -0.46877980\n",
       "2  -0.33190657  0.11705793\n",
       "3           NA          NA\n",
       "4   0.78257787 -0.20470475\n",
       "5  -0.03632622  0.10893968\n",
       "6  -0.41935743 -0.15979738\n",
       "7  -0.70105036  1.23636907\n",
       "8           NA          NA\n",
       "9   0.10411358 -0.16324147\n",
       "10          NA          NA\n",
       "11  0.14242927 -0.53603414\n",
       "12  0.08874634  0.01569202\n",
       "13  1.54256398  0.60783149\n",
       "14  0.24134531  0.22767313\n",
       "15          NA          NA\n",
       "16 -0.54986056  1.10751447\n",
       "17  0.41805088 -0.40544793\n",
       "18  0.20384346  0.47588991\n",
       "19  0.37238568 -0.43646272\n",
       "20 -0.01490806 -0.75544253\n",
       "21          NA          NA\n",
       "22          NA          NA\n",
       "23          NA          NA\n",
       "24          NA          NA\n",
       "25          NA          NA\n",
       "26  1.00302316  0.72587330\n",
       "27 -0.45692695 -0.22853974\n",
       "28  0.06647244 -0.16604761\n",
       "29  0.06483150  0.36725970\n",
       "30 -0.29389081 -1.04418568\n",
       "31 -0.43932309 -0.15576478\n",
       "32  0.42681432 -0.13050942\n",
       "33          NA          NA\n",
       "34          NA          NA\n",
       "35          NA          NA\n",
       "36          NA          NA\n",
       "37          NA          NA\n",
       "38          NA          NA\n",
       "39 -0.03809493 -0.45864802\n",
       "40  0.32066835 -0.20276745\n",
       "41  0.27755322  0.04282373\n",
       "42 -0.32552466 -0.16369490\n",
       "43          NA          NA\n",
       "44 -0.13963415 -0.21243155\n",
       "45          NA          NA\n",
       "46 -0.54818555 -0.23738481\n",
       "47          NA          NA\n",
       "48  0.44382387  0.03539586\n",
       "49 -0.55133851  0.40732392\n",
       "50 -1.13187658  0.65424050\n",
       "51          NA          NA"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "pni_combined <- merge(pni_clinical,pni_self_subtract,by='row.names',all=TRUE)\n",
    "colnames(pni_combined)[colnames(pni_combined) == \"Row.names\"] <- \"Patient\"\n",
    "pni_combined"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "9a197ef2",
   "metadata": {},
   "source": [
    "## Read Pembrolizumab-Nivolumab"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "ef700119",
   "metadata": {},
   "source": [
    "### Clinical"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "c2f8763c",
   "metadata": {},
   "outputs": [],
   "source": [
    "pn_clinical <- read.csv(\"Gide2019_PD1_Melanoma_RNASeq/ICB.Gide2019_Pembrolizumab-Nivolumab_Melanoma.clinical\", sep=\"\\t\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "5762cef7",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table>\n",
       "<caption>A data.frame: 54 Ã— 12</caption>\n",
       "<thead>\n",
       "\t<tr><th scope=col>X</th><th scope=col>OS</th><th scope=col>OS.Event</th><th scope=col>PFS</th><th scope=col>PFS.Event</th><th scope=col>RECIST</th><th scope=col>Age</th><th scope=col>Gender</th><th scope=col>Treatment</th><th scope=col>Site</th><th scope=col>Best.RECIST.response</th><th scope=col>Response</th></tr>\n",
       "\t<tr><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;int&gt;</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><td> 1</td><td> 147</td><td>1</td><td>   9</td><td>1</td><td>0</td><td>48</td><td>1</td><td>Nivolumab    </td><td>LN    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><td> 2</td><td>  65</td><td>1</td><td>  13</td><td>1</td><td>0</td><td>61</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><td> 3</td><td>  59</td><td>1</td><td>  23</td><td>1</td><td>0</td><td>50</td><td>0</td><td>Nivolumab    </td><td>SQ    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><td> 4</td><td>  22</td><td>1</td><td>  23</td><td>1</td><td>0</td><td>84</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><td> 5</td><td> 155</td><td>1</td><td>  39</td><td>1</td><td>0</td><td>67</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><td> 6</td><td>  94</td><td>1</td><td>  42</td><td>1</td><td>0</td><td>68</td><td>0</td><td>Nivolumab    </td><td>LN    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><td> 7</td><td>  80</td><td>1</td><td>  47</td><td>1</td><td>0</td><td>57</td><td>1</td><td>Nivolumab    </td><td>LN    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><td> 8</td><td>  58</td><td>1</td><td>  58</td><td>1</td><td>0</td><td>85</td><td>1</td><td>Nivolumab    </td><td>SQ    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><td> 9</td><td>  99</td><td>1</td><td>  71</td><td>1</td><td>0</td><td>70</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><td>10</td><td> 551</td><td>0</td><td>  76</td><td>1</td><td>0</td><td>90</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><td>11</td><td> 166</td><td>1</td><td>  78</td><td>1</td><td>0</td><td>66</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><td>12</td><td> 199</td><td>1</td><td>  80</td><td>1</td><td>1</td><td>52</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>SD</td><td>0</td></tr>\n",
       "\t<tr><td>13</td><td>  96</td><td>1</td><td>  82</td><td>1</td><td>0</td><td>69</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><td>14</td><td> 993</td><td>1</td><td>  83</td><td>1</td><td>0</td><td>58</td><td>0</td><td>Pembrolizumab</td><td>Mucosa</td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><td>15</td><td> 300</td><td>0</td><td>  84</td><td>1</td><td>0</td><td>76</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><td>16</td><td> 169</td><td>1</td><td>  84</td><td>1</td><td>0</td><td>55</td><td>0</td><td>Pembrolizumab</td><td>LN    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><td>17</td><td> 258</td><td>1</td><td>  96</td><td>1</td><td>0</td><td>37</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><td>18</td><td> 228</td><td>1</td><td> 100</td><td>1</td><td>0</td><td>62</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><td>19</td><td> 385</td><td>1</td><td> 125</td><td>1</td><td>1</td><td>54</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>SD</td><td>0</td></tr>\n",
       "\t<tr><td>20</td><td> 553</td><td>1</td><td> 156</td><td>1</td><td>2</td><td>45</td><td>1</td><td>Pembrolizumab</td><td>Brain </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>21</td><td> 551</td><td>1</td><td> 166</td><td>1</td><td>1</td><td>67</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>SD</td><td>0</td></tr>\n",
       "\t<tr><td>22</td><td> 379</td><td>0</td><td> 176</td><td>1</td><td>1</td><td>69</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>SD</td><td>0</td></tr>\n",
       "\t<tr><td>23</td><td> 191</td><td>1</td><td> 191</td><td>1</td><td>1</td><td>40</td><td>0</td><td>Nivolumab    </td><td>SQ    </td><td>SD</td><td>0</td></tr>\n",
       "\t<tr><td>24</td><td> 407</td><td>1</td><td> 197</td><td>1</td><td>1</td><td>54</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>SD</td><td>0</td></tr>\n",
       "\t<tr><td>25</td><td> 897</td><td>1</td><td> 271</td><td>1</td><td>2</td><td>49</td><td>0</td><td>Nivolumab    </td><td>SQ    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>26</td><td> 275</td><td>0</td><td> 275</td><td>0</td><td>3</td><td>89</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><td>27</td><td>1067</td><td>1</td><td> 314</td><td>1</td><td>2</td><td>76</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>28</td><td> 324</td><td>0</td><td> 324</td><td>0</td><td>2</td><td>81</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>29</td><td> 825</td><td>1</td><td> 335</td><td>1</td><td>1</td><td>55</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>SD</td><td>0</td></tr>\n",
       "\t<tr><td>30</td><td> 581</td><td>0</td><td> 358</td><td>1</td><td>1</td><td>86</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>SD</td><td>0</td></tr>\n",
       "\t<tr><td>31</td><td> 365</td><td>0</td><td> 365</td><td>0</td><td>2</td><td>74</td><td>1</td><td>Nivolumab    </td><td>SQ    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>32</td><td> 460</td><td>0</td><td> 460</td><td>0</td><td>3</td><td>69</td><td>1</td><td>Pembrolizumab</td><td>Brain </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><td>33</td><td> 477</td><td>0</td><td> 477</td><td>0</td><td>3</td><td>76</td><td>0</td><td>Pembrolizumab</td><td>LN    </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><td>34</td><td> 878</td><td>1</td><td> 544</td><td>1</td><td>2</td><td>78</td><td>0</td><td>Pembrolizumab</td><td>LN    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>35</td><td>1091</td><td>0</td><td> 586</td><td>1</td><td>2</td><td>55</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>36</td><td> 607</td><td>1</td><td> 590</td><td>1</td><td>2</td><td>76</td><td>0</td><td>Nivolumab    </td><td>SQ    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>37</td><td> 910</td><td>0</td><td> 647</td><td>1</td><td>3</td><td>66</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><td>38</td><td>1547</td><td>0</td><td> 755</td><td>1</td><td>2</td><td>69</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>39</td><td> 815</td><td>0</td><td> 815</td><td>0</td><td>1</td><td>72</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>SD</td><td>0</td></tr>\n",
       "\t<tr><td>40</td><td> 845</td><td>0</td><td> 845</td><td>0</td><td>2</td><td>78</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>41</td><td> 886</td><td>0</td><td> 870</td><td>1</td><td>2</td><td>61</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>42</td><td> 891</td><td>0</td><td> 891</td><td>0</td><td>3</td><td>59</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><td>43</td><td> 905</td><td>0</td><td> 905</td><td>0</td><td>3</td><td>63</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><td>44</td><td>1075</td><td>0</td><td>1075</td><td>0</td><td>2</td><td>45</td><td>1</td><td>Pembrolizumab</td><td>LN    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>45</td><td>1085</td><td>0</td><td>1085</td><td>0</td><td>2</td><td>82</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>46</td><td>1098</td><td>0</td><td>1098</td><td>0</td><td>2</td><td>71</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>47</td><td>1174</td><td>0</td><td>1174</td><td>0</td><td>2</td><td>62</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>48</td><td>1189</td><td>0</td><td>1189</td><td>0</td><td>2</td><td>40</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>49</td><td>1328</td><td>0</td><td>1328</td><td>0</td><td>3</td><td>72</td><td>1</td><td>Nivolumab    </td><td>SQ    </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><td>50</td><td>1342</td><td>0</td><td>1342</td><td>0</td><td>3</td><td>86</td><td>0</td><td>Nivolumab    </td><td>SQ    </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><td>51</td><td>1397</td><td>0</td><td>1397</td><td>0</td><td>3</td><td>64</td><td>0</td><td>Nivolumab    </td><td>SQ    </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><td>52</td><td>1553</td><td>0</td><td>1553</td><td>0</td><td>2</td><td>63</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><td>53</td><td>1589</td><td>0</td><td>1589</td><td>0</td><td>3</td><td>71</td><td>1</td><td>Pembrolizumab</td><td>LN    </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><td>54</td><td>1603</td><td>0</td><td>1603</td><td>0</td><td>2</td><td>52</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>PR</td><td>1</td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A data.frame: 54 Ã— 12\n",
       "\\begin{tabular}{llllllllllll}\n",
       " X & OS & OS.Event & PFS & PFS.Event & RECIST & Age & Gender & Treatment & Site & Best.RECIST.response & Response\\\\\n",
       " <int> & <int> & <int> & <int> & <int> & <int> & <int> & <int> & <fct> & <fct> & <fct> & <int>\\\\\n",
       "\\hline\n",
       "\t  1 &  147 & 1 &    9 & 1 & 0 & 48 & 1 & Nivolumab     & LN     & PD & 0\\\\\n",
       "\t  2 &   65 & 1 &   13 & 1 & 0 & 61 & 1 & Pembrolizumab & SQ     & PD & 0\\\\\n",
       "\t  3 &   59 & 1 &   23 & 1 & 0 & 50 & 0 & Nivolumab     & SQ     & PD & 0\\\\\n",
       "\t  4 &   22 & 1 &   23 & 1 & 0 & 84 & 0 & Pembrolizumab & SQ     & PD & 0\\\\\n",
       "\t  5 &  155 & 1 &   39 & 1 & 0 & 67 & 0 & Pembrolizumab & SQ     & PD & 0\\\\\n",
       "\t  6 &   94 & 1 &   42 & 1 & 0 & 68 & 0 & Nivolumab     & LN     & PD & 0\\\\\n",
       "\t  7 &   80 & 1 &   47 & 1 & 0 & 57 & 1 & Nivolumab     & LN     & PD & 0\\\\\n",
       "\t  8 &   58 & 1 &   58 & 1 & 0 & 85 & 1 & Nivolumab     & SQ     & PD & 0\\\\\n",
       "\t  9 &   99 & 1 &   71 & 1 & 0 & 70 & 1 & Pembrolizumab & SQ     & PD & 0\\\\\n",
       "\t 10 &  551 & 0 &   76 & 1 & 0 & 90 & 0 & Pembrolizumab & SQ     & PD & 0\\\\\n",
       "\t 11 &  166 & 1 &   78 & 1 & 0 & 66 & 0 & Pembrolizumab & SQ     & PD & 0\\\\\n",
       "\t 12 &  199 & 1 &   80 & 1 & 1 & 52 & 0 & Pembrolizumab & SQ     & SD & 0\\\\\n",
       "\t 13 &   96 & 1 &   82 & 1 & 0 & 69 & 0 & Pembrolizumab & SQ     & PD & 0\\\\\n",
       "\t 14 &  993 & 1 &   83 & 1 & 0 & 58 & 0 & Pembrolizumab & Mucosa & PD & 0\\\\\n",
       "\t 15 &  300 & 0 &   84 & 1 & 0 & 76 & 1 & Pembrolizumab & SQ     & PD & 0\\\\\n",
       "\t 16 &  169 & 1 &   84 & 1 & 0 & 55 & 0 & Pembrolizumab & LN     & PD & 0\\\\\n",
       "\t 17 &  258 & 1 &   96 & 1 & 0 & 37 & 0 & Pembrolizumab & SQ     & PD & 0\\\\\n",
       "\t 18 &  228 & 1 &  100 & 1 & 0 & 62 & 0 & Pembrolizumab & SQ     & PD & 0\\\\\n",
       "\t 19 &  385 & 1 &  125 & 1 & 1 & 54 & 0 & Pembrolizumab & SQ     & SD & 0\\\\\n",
       "\t 20 &  553 & 1 &  156 & 1 & 2 & 45 & 1 & Pembrolizumab & Brain  & PR & 1\\\\\n",
       "\t 21 &  551 & 1 &  166 & 1 & 1 & 67 & 0 & Pembrolizumab & SQ     & SD & 0\\\\\n",
       "\t 22 &  379 & 0 &  176 & 1 & 1 & 69 & 1 & Pembrolizumab & SQ     & SD & 0\\\\\n",
       "\t 23 &  191 & 1 &  191 & 1 & 1 & 40 & 0 & Nivolumab     & SQ     & SD & 0\\\\\n",
       "\t 24 &  407 & 1 &  197 & 1 & 1 & 54 & 1 & Pembrolizumab & SQ     & SD & 0\\\\\n",
       "\t 25 &  897 & 1 &  271 & 1 & 2 & 49 & 0 & Nivolumab     & SQ     & PR & 1\\\\\n",
       "\t 26 &  275 & 0 &  275 & 0 & 3 & 89 & 1 & Pembrolizumab & SQ     & CR & 1\\\\\n",
       "\t 27 & 1067 & 1 &  314 & 1 & 2 & 76 & 0 & Pembrolizumab & SQ     & PR & 1\\\\\n",
       "\t 28 &  324 & 0 &  324 & 0 & 2 & 81 & 0 & Pembrolizumab & SQ     & PR & 1\\\\\n",
       "\t 29 &  825 & 1 &  335 & 1 & 1 & 55 & 0 & Pembrolizumab & SQ     & SD & 0\\\\\n",
       "\t 30 &  581 & 0 &  358 & 1 & 1 & 86 & 1 & Pembrolizumab & SQ     & SD & 0\\\\\n",
       "\t 31 &  365 & 0 &  365 & 0 & 2 & 74 & 1 & Nivolumab     & SQ     & PR & 1\\\\\n",
       "\t 32 &  460 & 0 &  460 & 0 & 3 & 69 & 1 & Pembrolizumab & Brain  & CR & 1\\\\\n",
       "\t 33 &  477 & 0 &  477 & 0 & 3 & 76 & 0 & Pembrolizumab & LN     & CR & 1\\\\\n",
       "\t 34 &  878 & 1 &  544 & 1 & 2 & 78 & 0 & Pembrolizumab & LN     & PR & 1\\\\\n",
       "\t 35 & 1091 & 0 &  586 & 1 & 2 & 55 & 1 & Pembrolizumab & SQ     & PR & 1\\\\\n",
       "\t 36 &  607 & 1 &  590 & 1 & 2 & 76 & 0 & Nivolumab     & SQ     & PR & 1\\\\\n",
       "\t 37 &  910 & 0 &  647 & 1 & 3 & 66 & 0 & Pembrolizumab & SQ     & CR & 1\\\\\n",
       "\t 38 & 1547 & 0 &  755 & 1 & 2 & 69 & 1 & Pembrolizumab & SQ     & PR & 1\\\\\n",
       "\t 39 &  815 & 0 &  815 & 0 & 1 & 72 & 0 & Pembrolizumab & SQ     & SD & 0\\\\\n",
       "\t 40 &  845 & 0 &  845 & 0 & 2 & 78 & 0 & Pembrolizumab & SQ     & PR & 1\\\\\n",
       "\t 41 &  886 & 0 &  870 & 1 & 2 & 61 & 1 & Pembrolizumab & SQ     & PR & 1\\\\\n",
       "\t 42 &  891 & 0 &  891 & 0 & 3 & 59 & 1 & Pembrolizumab & SQ     & CR & 1\\\\\n",
       "\t 43 &  905 & 0 &  905 & 0 & 3 & 63 & 0 & Pembrolizumab & SQ     & CR & 1\\\\\n",
       "\t 44 & 1075 & 0 & 1075 & 0 & 2 & 45 & 1 & Pembrolizumab & LN     & PR & 1\\\\\n",
       "\t 45 & 1085 & 0 & 1085 & 0 & 2 & 82 & 0 & Pembrolizumab & SQ     & PR & 1\\\\\n",
       "\t 46 & 1098 & 0 & 1098 & 0 & 2 & 71 & 0 & Pembrolizumab & SQ     & PR & 1\\\\\n",
       "\t 47 & 1174 & 0 & 1174 & 0 & 2 & 62 & 0 & Pembrolizumab & SQ     & PR & 1\\\\\n",
       "\t 48 & 1189 & 0 & 1189 & 0 & 2 & 40 & 0 & Pembrolizumab & SQ     & PR & 1\\\\\n",
       "\t 49 & 1328 & 0 & 1328 & 0 & 3 & 72 & 1 & Nivolumab     & SQ     & CR & 1\\\\\n",
       "\t 50 & 1342 & 0 & 1342 & 0 & 3 & 86 & 0 & Nivolumab     & SQ     & CR & 1\\\\\n",
       "\t 51 & 1397 & 0 & 1397 & 0 & 3 & 64 & 0 & Nivolumab     & SQ     & CR & 1\\\\\n",
       "\t 52 & 1553 & 0 & 1553 & 0 & 2 & 63 & 1 & Pembrolizumab & SQ     & PR & 1\\\\\n",
       "\t 53 & 1589 & 0 & 1589 & 0 & 3 & 71 & 1 & Pembrolizumab & LN     & CR & 1\\\\\n",
       "\t 54 & 1603 & 0 & 1603 & 0 & 2 & 52 & 1 & Pembrolizumab & SQ     & PR & 1\\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A data.frame: 54 Ã— 12\n",
       "\n",
       "| X &lt;int&gt; | OS &lt;int&gt; | OS.Event &lt;int&gt; | PFS &lt;int&gt; | PFS.Event &lt;int&gt; | RECIST &lt;int&gt; | Age &lt;int&gt; | Gender &lt;int&gt; | Treatment &lt;fct&gt; | Site &lt;fct&gt; | Best.RECIST.response &lt;fct&gt; | Response &lt;int&gt; |\n",
       "|---|---|---|---|---|---|---|---|---|---|---|---|\n",
       "|  1 |  147 | 1 |    9 | 1 | 0 | 48 | 1 | Nivolumab     | LN     | PD | 0 |\n",
       "|  2 |   65 | 1 |   13 | 1 | 0 | 61 | 1 | Pembrolizumab | SQ     | PD | 0 |\n",
       "|  3 |   59 | 1 |   23 | 1 | 0 | 50 | 0 | Nivolumab     | SQ     | PD | 0 |\n",
       "|  4 |   22 | 1 |   23 | 1 | 0 | 84 | 0 | Pembrolizumab | SQ     | PD | 0 |\n",
       "|  5 |  155 | 1 |   39 | 1 | 0 | 67 | 0 | Pembrolizumab | SQ     | PD | 0 |\n",
       "|  6 |   94 | 1 |   42 | 1 | 0 | 68 | 0 | Nivolumab     | LN     | PD | 0 |\n",
       "|  7 |   80 | 1 |   47 | 1 | 0 | 57 | 1 | Nivolumab     | LN     | PD | 0 |\n",
       "|  8 |   58 | 1 |   58 | 1 | 0 | 85 | 1 | Nivolumab     | SQ     | PD | 0 |\n",
       "|  9 |   99 | 1 |   71 | 1 | 0 | 70 | 1 | Pembrolizumab | SQ     | PD | 0 |\n",
       "| 10 |  551 | 0 |   76 | 1 | 0 | 90 | 0 | Pembrolizumab | SQ     | PD | 0 |\n",
       "| 11 |  166 | 1 |   78 | 1 | 0 | 66 | 0 | Pembrolizumab | SQ     | PD | 0 |\n",
       "| 12 |  199 | 1 |   80 | 1 | 1 | 52 | 0 | Pembrolizumab | SQ     | SD | 0 |\n",
       "| 13 |   96 | 1 |   82 | 1 | 0 | 69 | 0 | Pembrolizumab | SQ     | PD | 0 |\n",
       "| 14 |  993 | 1 |   83 | 1 | 0 | 58 | 0 | Pembrolizumab | Mucosa | PD | 0 |\n",
       "| 15 |  300 | 0 |   84 | 1 | 0 | 76 | 1 | Pembrolizumab | SQ     | PD | 0 |\n",
       "| 16 |  169 | 1 |   84 | 1 | 0 | 55 | 0 | Pembrolizumab | LN     | PD | 0 |\n",
       "| 17 |  258 | 1 |   96 | 1 | 0 | 37 | 0 | Pembrolizumab | SQ     | PD | 0 |\n",
       "| 18 |  228 | 1 |  100 | 1 | 0 | 62 | 0 | Pembrolizumab | SQ     | PD | 0 |\n",
       "| 19 |  385 | 1 |  125 | 1 | 1 | 54 | 0 | Pembrolizumab | SQ     | SD | 0 |\n",
       "| 20 |  553 | 1 |  156 | 1 | 2 | 45 | 1 | Pembrolizumab | Brain  | PR | 1 |\n",
       "| 21 |  551 | 1 |  166 | 1 | 1 | 67 | 0 | Pembrolizumab | SQ     | SD | 0 |\n",
       "| 22 |  379 | 0 |  176 | 1 | 1 | 69 | 1 | Pembrolizumab | SQ     | SD | 0 |\n",
       "| 23 |  191 | 1 |  191 | 1 | 1 | 40 | 0 | Nivolumab     | SQ     | SD | 0 |\n",
       "| 24 |  407 | 1 |  197 | 1 | 1 | 54 | 1 | Pembrolizumab | SQ     | SD | 0 |\n",
       "| 25 |  897 | 1 |  271 | 1 | 2 | 49 | 0 | Nivolumab     | SQ     | PR | 1 |\n",
       "| 26 |  275 | 0 |  275 | 0 | 3 | 89 | 1 | Pembrolizumab | SQ     | CR | 1 |\n",
       "| 27 | 1067 | 1 |  314 | 1 | 2 | 76 | 0 | Pembrolizumab | SQ     | PR | 1 |\n",
       "| 28 |  324 | 0 |  324 | 0 | 2 | 81 | 0 | Pembrolizumab | SQ     | PR | 1 |\n",
       "| 29 |  825 | 1 |  335 | 1 | 1 | 55 | 0 | Pembrolizumab | SQ     | SD | 0 |\n",
       "| 30 |  581 | 0 |  358 | 1 | 1 | 86 | 1 | Pembrolizumab | SQ     | SD | 0 |\n",
       "| 31 |  365 | 0 |  365 | 0 | 2 | 74 | 1 | Nivolumab     | SQ     | PR | 1 |\n",
       "| 32 |  460 | 0 |  460 | 0 | 3 | 69 | 1 | Pembrolizumab | Brain  | CR | 1 |\n",
       "| 33 |  477 | 0 |  477 | 0 | 3 | 76 | 0 | Pembrolizumab | LN     | CR | 1 |\n",
       "| 34 |  878 | 1 |  544 | 1 | 2 | 78 | 0 | Pembrolizumab | LN     | PR | 1 |\n",
       "| 35 | 1091 | 0 |  586 | 1 | 2 | 55 | 1 | Pembrolizumab | SQ     | PR | 1 |\n",
       "| 36 |  607 | 1 |  590 | 1 | 2 | 76 | 0 | Nivolumab     | SQ     | PR | 1 |\n",
       "| 37 |  910 | 0 |  647 | 1 | 3 | 66 | 0 | Pembrolizumab | SQ     | CR | 1 |\n",
       "| 38 | 1547 | 0 |  755 | 1 | 2 | 69 | 1 | Pembrolizumab | SQ     | PR | 1 |\n",
       "| 39 |  815 | 0 |  815 | 0 | 1 | 72 | 0 | Pembrolizumab | SQ     | SD | 0 |\n",
       "| 40 |  845 | 0 |  845 | 0 | 2 | 78 | 0 | Pembrolizumab | SQ     | PR | 1 |\n",
       "| 41 |  886 | 0 |  870 | 1 | 2 | 61 | 1 | Pembrolizumab | SQ     | PR | 1 |\n",
       "| 42 |  891 | 0 |  891 | 0 | 3 | 59 | 1 | Pembrolizumab | SQ     | CR | 1 |\n",
       "| 43 |  905 | 0 |  905 | 0 | 3 | 63 | 0 | Pembrolizumab | SQ     | CR | 1 |\n",
       "| 44 | 1075 | 0 | 1075 | 0 | 2 | 45 | 1 | Pembrolizumab | LN     | PR | 1 |\n",
       "| 45 | 1085 | 0 | 1085 | 0 | 2 | 82 | 0 | Pembrolizumab | SQ     | PR | 1 |\n",
       "| 46 | 1098 | 0 | 1098 | 0 | 2 | 71 | 0 | Pembrolizumab | SQ     | PR | 1 |\n",
       "| 47 | 1174 | 0 | 1174 | 0 | 2 | 62 | 0 | Pembrolizumab | SQ     | PR | 1 |\n",
       "| 48 | 1189 | 0 | 1189 | 0 | 2 | 40 | 0 | Pembrolizumab | SQ     | PR | 1 |\n",
       "| 49 | 1328 | 0 | 1328 | 0 | 3 | 72 | 1 | Nivolumab     | SQ     | CR | 1 |\n",
       "| 50 | 1342 | 0 | 1342 | 0 | 3 | 86 | 0 | Nivolumab     | SQ     | CR | 1 |\n",
       "| 51 | 1397 | 0 | 1397 | 0 | 3 | 64 | 0 | Nivolumab     | SQ     | CR | 1 |\n",
       "| 52 | 1553 | 0 | 1553 | 0 | 2 | 63 | 1 | Pembrolizumab | SQ     | PR | 1 |\n",
       "| 53 | 1589 | 0 | 1589 | 0 | 3 | 71 | 1 | Pembrolizumab | LN     | CR | 1 |\n",
       "| 54 | 1603 | 0 | 1603 | 0 | 2 | 52 | 1 | Pembrolizumab | SQ     | PR | 1 |\n",
       "\n"
      ],
      "text/plain": [
       "   X  OS   OS.Event PFS  PFS.Event RECIST Age Gender Treatment     Site  \n",
       "1   1  147 1           9 1         0      48  1      Nivolumab     LN    \n",
       "2   2   65 1          13 1         0      61  1      Pembrolizumab SQ    \n",
       "3   3   59 1          23 1         0      50  0      Nivolumab     SQ    \n",
       "4   4   22 1          23 1         0      84  0      Pembrolizumab SQ    \n",
       "5   5  155 1          39 1         0      67  0      Pembrolizumab SQ    \n",
       "6   6   94 1          42 1         0      68  0      Nivolumab     LN    \n",
       "7   7   80 1          47 1         0      57  1      Nivolumab     LN    \n",
       "8   8   58 1          58 1         0      85  1      Nivolumab     SQ    \n",
       "9   9   99 1          71 1         0      70  1      Pembrolizumab SQ    \n",
       "10 10  551 0          76 1         0      90  0      Pembrolizumab SQ    \n",
       "11 11  166 1          78 1         0      66  0      Pembrolizumab SQ    \n",
       "12 12  199 1          80 1         1      52  0      Pembrolizumab SQ    \n",
       "13 13   96 1          82 1         0      69  0      Pembrolizumab SQ    \n",
       "14 14  993 1          83 1         0      58  0      Pembrolizumab Mucosa\n",
       "15 15  300 0          84 1         0      76  1      Pembrolizumab SQ    \n",
       "16 16  169 1          84 1         0      55  0      Pembrolizumab LN    \n",
       "17 17  258 1          96 1         0      37  0      Pembrolizumab SQ    \n",
       "18 18  228 1         100 1         0      62  0      Pembrolizumab SQ    \n",
       "19 19  385 1         125 1         1      54  0      Pembrolizumab SQ    \n",
       "20 20  553 1         156 1         2      45  1      Pembrolizumab Brain \n",
       "21 21  551 1         166 1         1      67  0      Pembrolizumab SQ    \n",
       "22 22  379 0         176 1         1      69  1      Pembrolizumab SQ    \n",
       "23 23  191 1         191 1         1      40  0      Nivolumab     SQ    \n",
       "24 24  407 1         197 1         1      54  1      Pembrolizumab SQ    \n",
       "25 25  897 1         271 1         2      49  0      Nivolumab     SQ    \n",
       "26 26  275 0         275 0         3      89  1      Pembrolizumab SQ    \n",
       "27 27 1067 1         314 1         2      76  0      Pembrolizumab SQ    \n",
       "28 28  324 0         324 0         2      81  0      Pembrolizumab SQ    \n",
       "29 29  825 1         335 1         1      55  0      Pembrolizumab SQ    \n",
       "30 30  581 0         358 1         1      86  1      Pembrolizumab SQ    \n",
       "31 31  365 0         365 0         2      74  1      Nivolumab     SQ    \n",
       "32 32  460 0         460 0         3      69  1      Pembrolizumab Brain \n",
       "33 33  477 0         477 0         3      76  0      Pembrolizumab LN    \n",
       "34 34  878 1         544 1         2      78  0      Pembrolizumab LN    \n",
       "35 35 1091 0         586 1         2      55  1      Pembrolizumab SQ    \n",
       "36 36  607 1         590 1         2      76  0      Nivolumab     SQ    \n",
       "37 37  910 0         647 1         3      66  0      Pembrolizumab SQ    \n",
       "38 38 1547 0         755 1         2      69  1      Pembrolizumab SQ    \n",
       "39 39  815 0         815 0         1      72  0      Pembrolizumab SQ    \n",
       "40 40  845 0         845 0         2      78  0      Pembrolizumab SQ    \n",
       "41 41  886 0         870 1         2      61  1      Pembrolizumab SQ    \n",
       "42 42  891 0         891 0         3      59  1      Pembrolizumab SQ    \n",
       "43 43  905 0         905 0         3      63  0      Pembrolizumab SQ    \n",
       "44 44 1075 0        1075 0         2      45  1      Pembrolizumab LN    \n",
       "45 45 1085 0        1085 0         2      82  0      Pembrolizumab SQ    \n",
       "46 46 1098 0        1098 0         2      71  0      Pembrolizumab SQ    \n",
       "47 47 1174 0        1174 0         2      62  0      Pembrolizumab SQ    \n",
       "48 48 1189 0        1189 0         2      40  0      Pembrolizumab SQ    \n",
       "49 49 1328 0        1328 0         3      72  1      Nivolumab     SQ    \n",
       "50 50 1342 0        1342 0         3      86  0      Nivolumab     SQ    \n",
       "51 51 1397 0        1397 0         3      64  0      Nivolumab     SQ    \n",
       "52 52 1553 0        1553 0         2      63  1      Pembrolizumab SQ    \n",
       "53 53 1589 0        1589 0         3      71  1      Pembrolizumab LN    \n",
       "54 54 1603 0        1603 0         2      52  1      Pembrolizumab SQ    \n",
       "   Best.RECIST.response Response\n",
       "1  PD                   0       \n",
       "2  PD                   0       \n",
       "3  PD                   0       \n",
       "4  PD                   0       \n",
       "5  PD                   0       \n",
       "6  PD                   0       \n",
       "7  PD                   0       \n",
       "8  PD                   0       \n",
       "9  PD                   0       \n",
       "10 PD                   0       \n",
       "11 PD                   0       \n",
       "12 SD                   0       \n",
       "13 PD                   0       \n",
       "14 PD                   0       \n",
       "15 PD                   0       \n",
       "16 PD                   0       \n",
       "17 PD                   0       \n",
       "18 PD                   0       \n",
       "19 SD                   0       \n",
       "20 PR                   1       \n",
       "21 SD                   0       \n",
       "22 SD                   0       \n",
       "23 SD                   0       \n",
       "24 SD                   0       \n",
       "25 PR                   1       \n",
       "26 CR                   1       \n",
       "27 PR                   1       \n",
       "28 PR                   1       \n",
       "29 SD                   0       \n",
       "30 SD                   0       \n",
       "31 PR                   1       \n",
       "32 CR                   1       \n",
       "33 CR                   1       \n",
       "34 PR                   1       \n",
       "35 PR                   1       \n",
       "36 PR                   1       \n",
       "37 CR                   1       \n",
       "38 PR                   1       \n",
       "39 SD                   0       \n",
       "40 PR                   1       \n",
       "41 PR                   1       \n",
       "42 CR                   1       \n",
       "43 CR                   1       \n",
       "44 PR                   1       \n",
       "45 PR                   1       \n",
       "46 PR                   1       \n",
       "47 PR                   1       \n",
       "48 PR                   1       \n",
       "49 CR                   1       \n",
       "50 CR                   1       \n",
       "51 CR                   1       \n",
       "52 PR                   1       \n",
       "53 CR                   1       \n",
       "54 PR                   1       "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "pn_clinical"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "58b113d7",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table>\n",
       "<caption>A data.frame: 54 Ã— 11</caption>\n",
       "<thead>\n",
       "\t<tr><th></th><th scope=col>OS</th><th scope=col>OS.Event</th><th scope=col>PFS</th><th scope=col>PFS.Event</th><th scope=col>RECIST</th><th scope=col>Age</th><th scope=col>Gender</th><th scope=col>Treatment</th><th scope=col>Site</th><th scope=col>Best.RECIST.response</th><th scope=col>Response</th></tr>\n",
       "\t<tr><th></th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;int&gt;</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><th scope=row>1</th><td> 147</td><td>1</td><td>   9</td><td>1</td><td>0</td><td>48</td><td>1</td><td>Nivolumab    </td><td>LN    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>2</th><td>  65</td><td>1</td><td>  13</td><td>1</td><td>0</td><td>61</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>3</th><td>  59</td><td>1</td><td>  23</td><td>1</td><td>0</td><td>50</td><td>0</td><td>Nivolumab    </td><td>SQ    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>4</th><td>  22</td><td>1</td><td>  23</td><td>1</td><td>0</td><td>84</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>5</th><td> 155</td><td>1</td><td>  39</td><td>1</td><td>0</td><td>67</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>6</th><td>  94</td><td>1</td><td>  42</td><td>1</td><td>0</td><td>68</td><td>0</td><td>Nivolumab    </td><td>LN    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>7</th><td>  80</td><td>1</td><td>  47</td><td>1</td><td>0</td><td>57</td><td>1</td><td>Nivolumab    </td><td>LN    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>8</th><td>  58</td><td>1</td><td>  58</td><td>1</td><td>0</td><td>85</td><td>1</td><td>Nivolumab    </td><td>SQ    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>9</th><td>  99</td><td>1</td><td>  71</td><td>1</td><td>0</td><td>70</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>10</th><td> 551</td><td>0</td><td>  76</td><td>1</td><td>0</td><td>90</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>11</th><td> 166</td><td>1</td><td>  78</td><td>1</td><td>0</td><td>66</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>12</th><td> 199</td><td>1</td><td>  80</td><td>1</td><td>1</td><td>52</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>SD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>13</th><td>  96</td><td>1</td><td>  82</td><td>1</td><td>0</td><td>69</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>14</th><td> 993</td><td>1</td><td>  83</td><td>1</td><td>0</td><td>58</td><td>0</td><td>Pembrolizumab</td><td>Mucosa</td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>15</th><td> 300</td><td>0</td><td>  84</td><td>1</td><td>0</td><td>76</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>16</th><td> 169</td><td>1</td><td>  84</td><td>1</td><td>0</td><td>55</td><td>0</td><td>Pembrolizumab</td><td>LN    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>17</th><td> 258</td><td>1</td><td>  96</td><td>1</td><td>0</td><td>37</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>18</th><td> 228</td><td>1</td><td> 100</td><td>1</td><td>0</td><td>62</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>PD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>19</th><td> 385</td><td>1</td><td> 125</td><td>1</td><td>1</td><td>54</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>SD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>20</th><td> 553</td><td>1</td><td> 156</td><td>1</td><td>2</td><td>45</td><td>1</td><td>Pembrolizumab</td><td>Brain </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>21</th><td> 551</td><td>1</td><td> 166</td><td>1</td><td>1</td><td>67</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>SD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>22</th><td> 379</td><td>0</td><td> 176</td><td>1</td><td>1</td><td>69</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>SD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>23</th><td> 191</td><td>1</td><td> 191</td><td>1</td><td>1</td><td>40</td><td>0</td><td>Nivolumab    </td><td>SQ    </td><td>SD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>24</th><td> 407</td><td>1</td><td> 197</td><td>1</td><td>1</td><td>54</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>SD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>25</th><td> 897</td><td>1</td><td> 271</td><td>1</td><td>2</td><td>49</td><td>0</td><td>Nivolumab    </td><td>SQ    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>26</th><td> 275</td><td>0</td><td> 275</td><td>0</td><td>3</td><td>89</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>27</th><td>1067</td><td>1</td><td> 314</td><td>1</td><td>2</td><td>76</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>28</th><td> 324</td><td>0</td><td> 324</td><td>0</td><td>2</td><td>81</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>29</th><td> 825</td><td>1</td><td> 335</td><td>1</td><td>1</td><td>55</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>SD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>30</th><td> 581</td><td>0</td><td> 358</td><td>1</td><td>1</td><td>86</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>SD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>31</th><td> 365</td><td>0</td><td> 365</td><td>0</td><td>2</td><td>74</td><td>1</td><td>Nivolumab    </td><td>SQ    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>32</th><td> 460</td><td>0</td><td> 460</td><td>0</td><td>3</td><td>69</td><td>1</td><td>Pembrolizumab</td><td>Brain </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>33</th><td> 477</td><td>0</td><td> 477</td><td>0</td><td>3</td><td>76</td><td>0</td><td>Pembrolizumab</td><td>LN    </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>34</th><td> 878</td><td>1</td><td> 544</td><td>1</td><td>2</td><td>78</td><td>0</td><td>Pembrolizumab</td><td>LN    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>35</th><td>1091</td><td>0</td><td> 586</td><td>1</td><td>2</td><td>55</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>36</th><td> 607</td><td>1</td><td> 590</td><td>1</td><td>2</td><td>76</td><td>0</td><td>Nivolumab    </td><td>SQ    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>37</th><td> 910</td><td>0</td><td> 647</td><td>1</td><td>3</td><td>66</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>38</th><td>1547</td><td>0</td><td> 755</td><td>1</td><td>2</td><td>69</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>39</th><td> 815</td><td>0</td><td> 815</td><td>0</td><td>1</td><td>72</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>SD</td><td>0</td></tr>\n",
       "\t<tr><th scope=row>40</th><td> 845</td><td>0</td><td> 845</td><td>0</td><td>2</td><td>78</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>41</th><td> 886</td><td>0</td><td> 870</td><td>1</td><td>2</td><td>61</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>42</th><td> 891</td><td>0</td><td> 891</td><td>0</td><td>3</td><td>59</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>43</th><td> 905</td><td>0</td><td> 905</td><td>0</td><td>3</td><td>63</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>44</th><td>1075</td><td>0</td><td>1075</td><td>0</td><td>2</td><td>45</td><td>1</td><td>Pembrolizumab</td><td>LN    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>45</th><td>1085</td><td>0</td><td>1085</td><td>0</td><td>2</td><td>82</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>46</th><td>1098</td><td>0</td><td>1098</td><td>0</td><td>2</td><td>71</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>47</th><td>1174</td><td>0</td><td>1174</td><td>0</td><td>2</td><td>62</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>48</th><td>1189</td><td>0</td><td>1189</td><td>0</td><td>2</td><td>40</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>49</th><td>1328</td><td>0</td><td>1328</td><td>0</td><td>3</td><td>72</td><td>1</td><td>Nivolumab    </td><td>SQ    </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>50</th><td>1342</td><td>0</td><td>1342</td><td>0</td><td>3</td><td>86</td><td>0</td><td>Nivolumab    </td><td>SQ    </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>51</th><td>1397</td><td>0</td><td>1397</td><td>0</td><td>3</td><td>64</td><td>0</td><td>Nivolumab    </td><td>SQ    </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>52</th><td>1553</td><td>0</td><td>1553</td><td>0</td><td>2</td><td>63</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>PR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>53</th><td>1589</td><td>0</td><td>1589</td><td>0</td><td>3</td><td>71</td><td>1</td><td>Pembrolizumab</td><td>LN    </td><td>CR</td><td>1</td></tr>\n",
       "\t<tr><th scope=row>54</th><td>1603</td><td>0</td><td>1603</td><td>0</td><td>2</td><td>52</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>PR</td><td>1</td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A data.frame: 54 Ã— 11\n",
       "\\begin{tabular}{r|lllllllllll}\n",
       "  & OS & OS.Event & PFS & PFS.Event & RECIST & Age & Gender & Treatment & Site & Best.RECIST.response & Response\\\\\n",
       "  & <int> & <int> & <int> & <int> & <int> & <int> & <int> & <fct> & <fct> & <fct> & <int>\\\\\n",
       "\\hline\n",
       "\t1 &  147 & 1 &    9 & 1 & 0 & 48 & 1 & Nivolumab     & LN     & PD & 0\\\\\n",
       "\t2 &   65 & 1 &   13 & 1 & 0 & 61 & 1 & Pembrolizumab & SQ     & PD & 0\\\\\n",
       "\t3 &   59 & 1 &   23 & 1 & 0 & 50 & 0 & Nivolumab     & SQ     & PD & 0\\\\\n",
       "\t4 &   22 & 1 &   23 & 1 & 0 & 84 & 0 & Pembrolizumab & SQ     & PD & 0\\\\\n",
       "\t5 &  155 & 1 &   39 & 1 & 0 & 67 & 0 & Pembrolizumab & SQ     & PD & 0\\\\\n",
       "\t6 &   94 & 1 &   42 & 1 & 0 & 68 & 0 & Nivolumab     & LN     & PD & 0\\\\\n",
       "\t7 &   80 & 1 &   47 & 1 & 0 & 57 & 1 & Nivolumab     & LN     & PD & 0\\\\\n",
       "\t8 &   58 & 1 &   58 & 1 & 0 & 85 & 1 & Nivolumab     & SQ     & PD & 0\\\\\n",
       "\t9 &   99 & 1 &   71 & 1 & 0 & 70 & 1 & Pembrolizumab & SQ     & PD & 0\\\\\n",
       "\t10 &  551 & 0 &   76 & 1 & 0 & 90 & 0 & Pembrolizumab & SQ     & PD & 0\\\\\n",
       "\t11 &  166 & 1 &   78 & 1 & 0 & 66 & 0 & Pembrolizumab & SQ     & PD & 0\\\\\n",
       "\t12 &  199 & 1 &   80 & 1 & 1 & 52 & 0 & Pembrolizumab & SQ     & SD & 0\\\\\n",
       "\t13 &   96 & 1 &   82 & 1 & 0 & 69 & 0 & Pembrolizumab & SQ     & PD & 0\\\\\n",
       "\t14 &  993 & 1 &   83 & 1 & 0 & 58 & 0 & Pembrolizumab & Mucosa & PD & 0\\\\\n",
       "\t15 &  300 & 0 &   84 & 1 & 0 & 76 & 1 & Pembrolizumab & SQ     & PD & 0\\\\\n",
       "\t16 &  169 & 1 &   84 & 1 & 0 & 55 & 0 & Pembrolizumab & LN     & PD & 0\\\\\n",
       "\t17 &  258 & 1 &   96 & 1 & 0 & 37 & 0 & Pembrolizumab & SQ     & PD & 0\\\\\n",
       "\t18 &  228 & 1 &  100 & 1 & 0 & 62 & 0 & Pembrolizumab & SQ     & PD & 0\\\\\n",
       "\t19 &  385 & 1 &  125 & 1 & 1 & 54 & 0 & Pembrolizumab & SQ     & SD & 0\\\\\n",
       "\t20 &  553 & 1 &  156 & 1 & 2 & 45 & 1 & Pembrolizumab & Brain  & PR & 1\\\\\n",
       "\t21 &  551 & 1 &  166 & 1 & 1 & 67 & 0 & Pembrolizumab & SQ     & SD & 0\\\\\n",
       "\t22 &  379 & 0 &  176 & 1 & 1 & 69 & 1 & Pembrolizumab & SQ     & SD & 0\\\\\n",
       "\t23 &  191 & 1 &  191 & 1 & 1 & 40 & 0 & Nivolumab     & SQ     & SD & 0\\\\\n",
       "\t24 &  407 & 1 &  197 & 1 & 1 & 54 & 1 & Pembrolizumab & SQ     & SD & 0\\\\\n",
       "\t25 &  897 & 1 &  271 & 1 & 2 & 49 & 0 & Nivolumab     & SQ     & PR & 1\\\\\n",
       "\t26 &  275 & 0 &  275 & 0 & 3 & 89 & 1 & Pembrolizumab & SQ     & CR & 1\\\\\n",
       "\t27 & 1067 & 1 &  314 & 1 & 2 & 76 & 0 & Pembrolizumab & SQ     & PR & 1\\\\\n",
       "\t28 &  324 & 0 &  324 & 0 & 2 & 81 & 0 & Pembrolizumab & SQ     & PR & 1\\\\\n",
       "\t29 &  825 & 1 &  335 & 1 & 1 & 55 & 0 & Pembrolizumab & SQ     & SD & 0\\\\\n",
       "\t30 &  581 & 0 &  358 & 1 & 1 & 86 & 1 & Pembrolizumab & SQ     & SD & 0\\\\\n",
       "\t31 &  365 & 0 &  365 & 0 & 2 & 74 & 1 & Nivolumab     & SQ     & PR & 1\\\\\n",
       "\t32 &  460 & 0 &  460 & 0 & 3 & 69 & 1 & Pembrolizumab & Brain  & CR & 1\\\\\n",
       "\t33 &  477 & 0 &  477 & 0 & 3 & 76 & 0 & Pembrolizumab & LN     & CR & 1\\\\\n",
       "\t34 &  878 & 1 &  544 & 1 & 2 & 78 & 0 & Pembrolizumab & LN     & PR & 1\\\\\n",
       "\t35 & 1091 & 0 &  586 & 1 & 2 & 55 & 1 & Pembrolizumab & SQ     & PR & 1\\\\\n",
       "\t36 &  607 & 1 &  590 & 1 & 2 & 76 & 0 & Nivolumab     & SQ     & PR & 1\\\\\n",
       "\t37 &  910 & 0 &  647 & 1 & 3 & 66 & 0 & Pembrolizumab & SQ     & CR & 1\\\\\n",
       "\t38 & 1547 & 0 &  755 & 1 & 2 & 69 & 1 & Pembrolizumab & SQ     & PR & 1\\\\\n",
       "\t39 &  815 & 0 &  815 & 0 & 1 & 72 & 0 & Pembrolizumab & SQ     & SD & 0\\\\\n",
       "\t40 &  845 & 0 &  845 & 0 & 2 & 78 & 0 & Pembrolizumab & SQ     & PR & 1\\\\\n",
       "\t41 &  886 & 0 &  870 & 1 & 2 & 61 & 1 & Pembrolizumab & SQ     & PR & 1\\\\\n",
       "\t42 &  891 & 0 &  891 & 0 & 3 & 59 & 1 & Pembrolizumab & SQ     & CR & 1\\\\\n",
       "\t43 &  905 & 0 &  905 & 0 & 3 & 63 & 0 & Pembrolizumab & SQ     & CR & 1\\\\\n",
       "\t44 & 1075 & 0 & 1075 & 0 & 2 & 45 & 1 & Pembrolizumab & LN     & PR & 1\\\\\n",
       "\t45 & 1085 & 0 & 1085 & 0 & 2 & 82 & 0 & Pembrolizumab & SQ     & PR & 1\\\\\n",
       "\t46 & 1098 & 0 & 1098 & 0 & 2 & 71 & 0 & Pembrolizumab & SQ     & PR & 1\\\\\n",
       "\t47 & 1174 & 0 & 1174 & 0 & 2 & 62 & 0 & Pembrolizumab & SQ     & PR & 1\\\\\n",
       "\t48 & 1189 & 0 & 1189 & 0 & 2 & 40 & 0 & Pembrolizumab & SQ     & PR & 1\\\\\n",
       "\t49 & 1328 & 0 & 1328 & 0 & 3 & 72 & 1 & Nivolumab     & SQ     & CR & 1\\\\\n",
       "\t50 & 1342 & 0 & 1342 & 0 & 3 & 86 & 0 & Nivolumab     & SQ     & CR & 1\\\\\n",
       "\t51 & 1397 & 0 & 1397 & 0 & 3 & 64 & 0 & Nivolumab     & SQ     & CR & 1\\\\\n",
       "\t52 & 1553 & 0 & 1553 & 0 & 2 & 63 & 1 & Pembrolizumab & SQ     & PR & 1\\\\\n",
       "\t53 & 1589 & 0 & 1589 & 0 & 3 & 71 & 1 & Pembrolizumab & LN     & CR & 1\\\\\n",
       "\t54 & 1603 & 0 & 1603 & 0 & 2 & 52 & 1 & Pembrolizumab & SQ     & PR & 1\\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A data.frame: 54 Ã— 11\n",
       "\n",
       "| <!--/--> | OS &lt;int&gt; | OS.Event &lt;int&gt; | PFS &lt;int&gt; | PFS.Event &lt;int&gt; | RECIST &lt;int&gt; | Age &lt;int&gt; | Gender &lt;int&gt; | Treatment &lt;fct&gt; | Site &lt;fct&gt; | Best.RECIST.response &lt;fct&gt; | Response &lt;int&gt; |\n",
       "|---|---|---|---|---|---|---|---|---|---|---|---|\n",
       "| 1 |  147 | 1 |    9 | 1 | 0 | 48 | 1 | Nivolumab     | LN     | PD | 0 |\n",
       "| 2 |   65 | 1 |   13 | 1 | 0 | 61 | 1 | Pembrolizumab | SQ     | PD | 0 |\n",
       "| 3 |   59 | 1 |   23 | 1 | 0 | 50 | 0 | Nivolumab     | SQ     | PD | 0 |\n",
       "| 4 |   22 | 1 |   23 | 1 | 0 | 84 | 0 | Pembrolizumab | SQ     | PD | 0 |\n",
       "| 5 |  155 | 1 |   39 | 1 | 0 | 67 | 0 | Pembrolizumab | SQ     | PD | 0 |\n",
       "| 6 |   94 | 1 |   42 | 1 | 0 | 68 | 0 | Nivolumab     | LN     | PD | 0 |\n",
       "| 7 |   80 | 1 |   47 | 1 | 0 | 57 | 1 | Nivolumab     | LN     | PD | 0 |\n",
       "| 8 |   58 | 1 |   58 | 1 | 0 | 85 | 1 | Nivolumab     | SQ     | PD | 0 |\n",
       "| 9 |   99 | 1 |   71 | 1 | 0 | 70 | 1 | Pembrolizumab | SQ     | PD | 0 |\n",
       "| 10 |  551 | 0 |   76 | 1 | 0 | 90 | 0 | Pembrolizumab | SQ     | PD | 0 |\n",
       "| 11 |  166 | 1 |   78 | 1 | 0 | 66 | 0 | Pembrolizumab | SQ     | PD | 0 |\n",
       "| 12 |  199 | 1 |   80 | 1 | 1 | 52 | 0 | Pembrolizumab | SQ     | SD | 0 |\n",
       "| 13 |   96 | 1 |   82 | 1 | 0 | 69 | 0 | Pembrolizumab | SQ     | PD | 0 |\n",
       "| 14 |  993 | 1 |   83 | 1 | 0 | 58 | 0 | Pembrolizumab | Mucosa | PD | 0 |\n",
       "| 15 |  300 | 0 |   84 | 1 | 0 | 76 | 1 | Pembrolizumab | SQ     | PD | 0 |\n",
       "| 16 |  169 | 1 |   84 | 1 | 0 | 55 | 0 | Pembrolizumab | LN     | PD | 0 |\n",
       "| 17 |  258 | 1 |   96 | 1 | 0 | 37 | 0 | Pembrolizumab | SQ     | PD | 0 |\n",
       "| 18 |  228 | 1 |  100 | 1 | 0 | 62 | 0 | Pembrolizumab | SQ     | PD | 0 |\n",
       "| 19 |  385 | 1 |  125 | 1 | 1 | 54 | 0 | Pembrolizumab | SQ     | SD | 0 |\n",
       "| 20 |  553 | 1 |  156 | 1 | 2 | 45 | 1 | Pembrolizumab | Brain  | PR | 1 |\n",
       "| 21 |  551 | 1 |  166 | 1 | 1 | 67 | 0 | Pembrolizumab | SQ     | SD | 0 |\n",
       "| 22 |  379 | 0 |  176 | 1 | 1 | 69 | 1 | Pembrolizumab | SQ     | SD | 0 |\n",
       "| 23 |  191 | 1 |  191 | 1 | 1 | 40 | 0 | Nivolumab     | SQ     | SD | 0 |\n",
       "| 24 |  407 | 1 |  197 | 1 | 1 | 54 | 1 | Pembrolizumab | SQ     | SD | 0 |\n",
       "| 25 |  897 | 1 |  271 | 1 | 2 | 49 | 0 | Nivolumab     | SQ     | PR | 1 |\n",
       "| 26 |  275 | 0 |  275 | 0 | 3 | 89 | 1 | Pembrolizumab | SQ     | CR | 1 |\n",
       "| 27 | 1067 | 1 |  314 | 1 | 2 | 76 | 0 | Pembrolizumab | SQ     | PR | 1 |\n",
       "| 28 |  324 | 0 |  324 | 0 | 2 | 81 | 0 | Pembrolizumab | SQ     | PR | 1 |\n",
       "| 29 |  825 | 1 |  335 | 1 | 1 | 55 | 0 | Pembrolizumab | SQ     | SD | 0 |\n",
       "| 30 |  581 | 0 |  358 | 1 | 1 | 86 | 1 | Pembrolizumab | SQ     | SD | 0 |\n",
       "| 31 |  365 | 0 |  365 | 0 | 2 | 74 | 1 | Nivolumab     | SQ     | PR | 1 |\n",
       "| 32 |  460 | 0 |  460 | 0 | 3 | 69 | 1 | Pembrolizumab | Brain  | CR | 1 |\n",
       "| 33 |  477 | 0 |  477 | 0 | 3 | 76 | 0 | Pembrolizumab | LN     | CR | 1 |\n",
       "| 34 |  878 | 1 |  544 | 1 | 2 | 78 | 0 | Pembrolizumab | LN     | PR | 1 |\n",
       "| 35 | 1091 | 0 |  586 | 1 | 2 | 55 | 1 | Pembrolizumab | SQ     | PR | 1 |\n",
       "| 36 |  607 | 1 |  590 | 1 | 2 | 76 | 0 | Nivolumab     | SQ     | PR | 1 |\n",
       "| 37 |  910 | 0 |  647 | 1 | 3 | 66 | 0 | Pembrolizumab | SQ     | CR | 1 |\n",
       "| 38 | 1547 | 0 |  755 | 1 | 2 | 69 | 1 | Pembrolizumab | SQ     | PR | 1 |\n",
       "| 39 |  815 | 0 |  815 | 0 | 1 | 72 | 0 | Pembrolizumab | SQ     | SD | 0 |\n",
       "| 40 |  845 | 0 |  845 | 0 | 2 | 78 | 0 | Pembrolizumab | SQ     | PR | 1 |\n",
       "| 41 |  886 | 0 |  870 | 1 | 2 | 61 | 1 | Pembrolizumab | SQ     | PR | 1 |\n",
       "| 42 |  891 | 0 |  891 | 0 | 3 | 59 | 1 | Pembrolizumab | SQ     | CR | 1 |\n",
       "| 43 |  905 | 0 |  905 | 0 | 3 | 63 | 0 | Pembrolizumab | SQ     | CR | 1 |\n",
       "| 44 | 1075 | 0 | 1075 | 0 | 2 | 45 | 1 | Pembrolizumab | LN     | PR | 1 |\n",
       "| 45 | 1085 | 0 | 1085 | 0 | 2 | 82 | 0 | Pembrolizumab | SQ     | PR | 1 |\n",
       "| 46 | 1098 | 0 | 1098 | 0 | 2 | 71 | 0 | Pembrolizumab | SQ     | PR | 1 |\n",
       "| 47 | 1174 | 0 | 1174 | 0 | 2 | 62 | 0 | Pembrolizumab | SQ     | PR | 1 |\n",
       "| 48 | 1189 | 0 | 1189 | 0 | 2 | 40 | 0 | Pembrolizumab | SQ     | PR | 1 |\n",
       "| 49 | 1328 | 0 | 1328 | 0 | 3 | 72 | 1 | Nivolumab     | SQ     | CR | 1 |\n",
       "| 50 | 1342 | 0 | 1342 | 0 | 3 | 86 | 0 | Nivolumab     | SQ     | CR | 1 |\n",
       "| 51 | 1397 | 0 | 1397 | 0 | 3 | 64 | 0 | Nivolumab     | SQ     | CR | 1 |\n",
       "| 52 | 1553 | 0 | 1553 | 0 | 2 | 63 | 1 | Pembrolizumab | SQ     | PR | 1 |\n",
       "| 53 | 1589 | 0 | 1589 | 0 | 3 | 71 | 1 | Pembrolizumab | LN     | CR | 1 |\n",
       "| 54 | 1603 | 0 | 1603 | 0 | 2 | 52 | 1 | Pembrolizumab | SQ     | PR | 1 |\n",
       "\n"
      ],
      "text/plain": [
       "   OS   OS.Event PFS  PFS.Event RECIST Age Gender Treatment     Site  \n",
       "1   147 1           9 1         0      48  1      Nivolumab     LN    \n",
       "2    65 1          13 1         0      61  1      Pembrolizumab SQ    \n",
       "3    59 1          23 1         0      50  0      Nivolumab     SQ    \n",
       "4    22 1          23 1         0      84  0      Pembrolizumab SQ    \n",
       "5   155 1          39 1         0      67  0      Pembrolizumab SQ    \n",
       "6    94 1          42 1         0      68  0      Nivolumab     LN    \n",
       "7    80 1          47 1         0      57  1      Nivolumab     LN    \n",
       "8    58 1          58 1         0      85  1      Nivolumab     SQ    \n",
       "9    99 1          71 1         0      70  1      Pembrolizumab SQ    \n",
       "10  551 0          76 1         0      90  0      Pembrolizumab SQ    \n",
       "11  166 1          78 1         0      66  0      Pembrolizumab SQ    \n",
       "12  199 1          80 1         1      52  0      Pembrolizumab SQ    \n",
       "13   96 1          82 1         0      69  0      Pembrolizumab SQ    \n",
       "14  993 1          83 1         0      58  0      Pembrolizumab Mucosa\n",
       "15  300 0          84 1         0      76  1      Pembrolizumab SQ    \n",
       "16  169 1          84 1         0      55  0      Pembrolizumab LN    \n",
       "17  258 1          96 1         0      37  0      Pembrolizumab SQ    \n",
       "18  228 1         100 1         0      62  0      Pembrolizumab SQ    \n",
       "19  385 1         125 1         1      54  0      Pembrolizumab SQ    \n",
       "20  553 1         156 1         2      45  1      Pembrolizumab Brain \n",
       "21  551 1         166 1         1      67  0      Pembrolizumab SQ    \n",
       "22  379 0         176 1         1      69  1      Pembrolizumab SQ    \n",
       "23  191 1         191 1         1      40  0      Nivolumab     SQ    \n",
       "24  407 1         197 1         1      54  1      Pembrolizumab SQ    \n",
       "25  897 1         271 1         2      49  0      Nivolumab     SQ    \n",
       "26  275 0         275 0         3      89  1      Pembrolizumab SQ    \n",
       "27 1067 1         314 1         2      76  0      Pembrolizumab SQ    \n",
       "28  324 0         324 0         2      81  0      Pembrolizumab SQ    \n",
       "29  825 1         335 1         1      55  0      Pembrolizumab SQ    \n",
       "30  581 0         358 1         1      86  1      Pembrolizumab SQ    \n",
       "31  365 0         365 0         2      74  1      Nivolumab     SQ    \n",
       "32  460 0         460 0         3      69  1      Pembrolizumab Brain \n",
       "33  477 0         477 0         3      76  0      Pembrolizumab LN    \n",
       "34  878 1         544 1         2      78  0      Pembrolizumab LN    \n",
       "35 1091 0         586 1         2      55  1      Pembrolizumab SQ    \n",
       "36  607 1         590 1         2      76  0      Nivolumab     SQ    \n",
       "37  910 0         647 1         3      66  0      Pembrolizumab SQ    \n",
       "38 1547 0         755 1         2      69  1      Pembrolizumab SQ    \n",
       "39  815 0         815 0         1      72  0      Pembrolizumab SQ    \n",
       "40  845 0         845 0         2      78  0      Pembrolizumab SQ    \n",
       "41  886 0         870 1         2      61  1      Pembrolizumab SQ    \n",
       "42  891 0         891 0         3      59  1      Pembrolizumab SQ    \n",
       "43  905 0         905 0         3      63  0      Pembrolizumab SQ    \n",
       "44 1075 0        1075 0         2      45  1      Pembrolizumab LN    \n",
       "45 1085 0        1085 0         2      82  0      Pembrolizumab SQ    \n",
       "46 1098 0        1098 0         2      71  0      Pembrolizumab SQ    \n",
       "47 1174 0        1174 0         2      62  0      Pembrolizumab SQ    \n",
       "48 1189 0        1189 0         2      40  0      Pembrolizumab SQ    \n",
       "49 1328 0        1328 0         3      72  1      Nivolumab     SQ    \n",
       "50 1342 0        1342 0         3      86  0      Nivolumab     SQ    \n",
       "51 1397 0        1397 0         3      64  0      Nivolumab     SQ    \n",
       "52 1553 0        1553 0         2      63  1      Pembrolizumab SQ    \n",
       "53 1589 0        1589 0         3      71  1      Pembrolizumab LN    \n",
       "54 1603 0        1603 0         2      52  1      Pembrolizumab SQ    \n",
       "   Best.RECIST.response Response\n",
       "1  PD                   0       \n",
       "2  PD                   0       \n",
       "3  PD                   0       \n",
       "4  PD                   0       \n",
       "5  PD                   0       \n",
       "6  PD                   0       \n",
       "7  PD                   0       \n",
       "8  PD                   0       \n",
       "9  PD                   0       \n",
       "10 PD                   0       \n",
       "11 PD                   0       \n",
       "12 SD                   0       \n",
       "13 PD                   0       \n",
       "14 PD                   0       \n",
       "15 PD                   0       \n",
       "16 PD                   0       \n",
       "17 PD                   0       \n",
       "18 PD                   0       \n",
       "19 SD                   0       \n",
       "20 PR                   1       \n",
       "21 SD                   0       \n",
       "22 SD                   0       \n",
       "23 SD                   0       \n",
       "24 SD                   0       \n",
       "25 PR                   1       \n",
       "26 CR                   1       \n",
       "27 PR                   1       \n",
       "28 PR                   1       \n",
       "29 SD                   0       \n",
       "30 SD                   0       \n",
       "31 PR                   1       \n",
       "32 CR                   1       \n",
       "33 CR                   1       \n",
       "34 PR                   1       \n",
       "35 PR                   1       \n",
       "36 PR                   1       \n",
       "37 CR                   1       \n",
       "38 PR                   1       \n",
       "39 SD                   0       \n",
       "40 PR                   1       \n",
       "41 PR                   1       \n",
       "42 CR                   1       \n",
       "43 CR                   1       \n",
       "44 PR                   1       \n",
       "45 PR                   1       \n",
       "46 PR                   1       \n",
       "47 PR                   1       \n",
       "48 PR                   1       \n",
       "49 CR                   1       \n",
       "50 CR                   1       \n",
       "51 CR                   1       \n",
       "52 PR                   1       \n",
       "53 CR                   1       \n",
       "54 PR                   1       "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "row.names(pn_clinical) <- pn_clinical$X\n",
    "pn_clinical <- pn_clinical[, -1]\n",
    "pn_clinical"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "45ab3899",
   "metadata": {},
   "source": [
    "### Self Subtract"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "a5584517",
   "metadata": {},
   "outputs": [],
   "source": [
    "pn_self_subtract <- read.csv(\"Gide2019_PD1_Melanoma_RNASeq/ICB.Gide2019_Pembrolizumab-Nivolumab_Melanoma.self_subtract\", sep=\"\\t\", check.names = FALSE, row.names = 1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "72dd848d",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table>\n",
       "<caption>A data.frame: 18570 Ã— 41</caption>\n",
       "<thead>\n",
       "\t<tr><th></th><th scope=col>9</th><th scope=col>3</th><th scope=col>35</th><th scope=col>18</th><th scope=col>7</th><th scope=col>48</th><th scope=col>30</th><th scope=col>14</th><th scope=col>13</th><th scope=col>46</th><th scope=col>â‹¯</th><th scope=col>50</th><th scope=col>4</th><th scope=col>40</th><th scope=col>25</th><th scope=col>52</th><th scope=col>19</th><th scope=col>41</th><th scope=col>34</th><th scope=col>23</th><th scope=col>54</th></tr>\n",
       "\t<tr><th></th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>â‹¯</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><th scope=row>1</th><td>-1.58231886</td><td> 0.41362108</td><td>-1.22017300</td><td> 0.075095675</td><td> 0.05888384</td><td>-0.662010151</td><td> 0.42966948</td><td>-0.11535008</td><td> 0.67577556</td><td> 0.513876358</td><td>â‹¯</td><td>-0.92372234</td><td>-0.91234682</td><td>-0.19708134</td><td> 0.718437503</td><td> 0.25690495</td><td> 0.83904346</td><td>-0.40860109</td><td> 1.44645031</td><td> 0.04754928</td><td> 0.473103225</td></tr>\n",
       "\t<tr><th scope=row>503538</th><td> 0.22612657</td><td> 0.02686424</td><td>-0.46544478</td><td>-0.176204605</td><td>-0.70208641</td><td>-0.458452942</td><td>-0.84484596</td><td>-0.18471088</td><td>-0.48203131</td><td> 0.005365473</td><td>â‹¯</td><td>-0.02059807</td><td>-1.08931032</td><td> 0.28315354</td><td>-0.047598322</td><td> 0.19613082</td><td> 0.40829813</td><td>-0.04866972</td><td> 0.32854358</td><td>-0.66091660</td><td>-0.195425198</td></tr>\n",
       "\t<tr><th scope=row>2</th><td> 1.66568079</td><td>-0.63666687</td><td>-0.17419729</td><td>-0.326858659</td><td> 0.47458381</td><td>-1.241568243</td><td>-0.98130509</td><td>-0.45533603</td><td>-1.63309646</td><td>-0.610543313</td><td>â‹¯</td><td>-1.26427983</td><td> 0.23970161</td><td> 1.18647523</td><td> 0.737057442</td><td>-1.81640023</td><td>-0.25034316</td><td> 2.96944712</td><td> 0.32667241</td><td> 2.03186221</td><td>-0.355766075</td></tr>\n",
       "\t<tr><th scope=row>144571</th><td> 0.41620526</td><td>-0.52085278</td><td>-0.15142775</td><td>-0.301583681</td><td> 0.11572232</td><td> 0.546215021</td><td>-0.55657029</td><td> 0.11802313</td><td> 0.49090024</td><td> 0.145104377</td><td>â‹¯</td><td>-0.11756944</td><td> 0.20399209</td><td> 0.39210061</td><td> 0.253308910</td><td>-0.43541291</td><td>-0.58517654</td><td>-0.89701142</td><td>-0.30074905</td><td>-0.50093196</td><td>-0.515324225</td></tr>\n",
       "\t<tr><th scope=row>144568</th><td>-0.81472165</td><td> 3.15369407</td><td> 2.88161537</td><td>-1.017703568</td><td>-1.01770357</td><td>-0.988625504</td><td>-1.01770357</td><td> 3.30190882</td><td> 2.39125358</td><td> 0.024950337</td><td>â‹¯</td><td>-0.96750137</td><td> 0.53103697</td><td>-1.01770357</td><td> 0.481178167</td><td>-1.01770357</td><td> 1.40950498</td><td>-1.01770357</td><td>-1.01770357</td><td>-1.01770357</td><td>-1.017703568</td></tr>\n",
       "\t<tr><th scope=row>53947</th><td> 0.75217226</td><td>-0.35293797</td><td>-0.39829659</td><td>-0.457284541</td><td>-0.81206319</td><td>-0.235179430</td><td> 0.20997399</td><td>-0.45430870</td><td>-0.79193292</td><td>-0.032976780</td><td>â‹¯</td><td> 1.09366423</td><td> 0.76756632</td><td> 0.17559646</td><td>-0.011900328</td><td>-0.59484600</td><td>-0.81832864</td><td>-0.70901232</td><td>-0.77721338</td><td> 0.29027153</td><td>-1.092249883</td></tr>\n",
       "\t<tr><th scope=row>8086</th><td> 0.48742979</td><td> 0.21737047</td><td> 0.11733274</td><td> 0.244340206</td><td>-0.52053759</td><td>-0.209526830</td><td>-1.27586077</td><td> 0.24283611</td><td>-0.07076524</td><td> 0.042689150</td><td>â‹¯</td><td>-0.36088541</td><td>-0.15312547</td><td>-0.28569714</td><td> 0.121104364</td><td> 0.55932299</td><td> 0.28172048</td><td>-0.66782403</td><td>-0.76282357</td><td> 0.12643972</td><td>-0.171057793</td></tr>\n",
       "\t<tr><th scope=row>65985</th><td>-0.11137395</td><td> 0.94451945</td><td> 0.86124177</td><td> 0.374050600</td><td>-0.83866229</td><td> 0.739460281</td><td>-0.63456805</td><td> 0.10825169</td><td> 0.60201350</td><td> 0.292313400</td><td>â‹¯</td><td>-1.32322790</td><td>-0.21753685</td><td>-0.05100234</td><td> 0.273182689</td><td>-0.45761784</td><td>-0.03626696</td><td> 0.41864303</td><td> 0.19990466</td><td> 0.75946942</td><td>-0.252467977</td></tr>\n",
       "\t<tr><th scope=row>13</th><td> 2.28027252</td><td> 1.21879050</td><td>-0.15999967</td><td>-0.387926308</td><td>-0.15818095</td><td>-0.387926308</td><td>-0.38792631</td><td>-0.38792631</td><td> 0.49829857</td><td> 0.279778470</td><td>â‹¯</td><td> 1.36663079</td><td> 0.38520734</td><td>-0.38792631</td><td>-0.082744787</td><td>-0.17048984</td><td>-0.29837480</td><td>-0.38792631</td><td>-0.36056831</td><td>-0.33097686</td><td>-0.204260693</td></tr>\n",
       "\t<tr><th scope=row>51166</th><td> 0.07411433</td><td> 0.40828556</td><td>-0.42778929</td><td> 0.498749883</td><td> 0.25237782</td><td> 0.483951204</td><td>-0.36446250</td><td>-0.77588290</td><td> 0.51513916</td><td>-0.567818972</td><td>â‹¯</td><td> 0.22049161</td><td>-0.64948469</td><td>-0.02668299</td><td>-0.063968115</td><td>-1.37391267</td><td> 0.22347496</td><td> 0.04092749</td><td>-0.14311666</td><td>-0.05786118</td><td>-0.416186634</td></tr>\n",
       "\t<tr><th scope=row>195827</th><td>-0.15622431</td><td>-0.78312785</td><td>-0.59006520</td><td> 0.551936365</td><td> 0.67649007</td><td> 0.002704479</td><td> 2.07968485</td><td>-0.98986906</td><td> 0.23131085</td><td> 0.234997541</td><td>â‹¯</td><td> 0.23435838</td><td> 0.61337288</td><td> 0.07559452</td><td>-0.041484582</td><td>-1.08635043</td><td> 0.45579427</td><td>-0.53358223</td><td>-0.01506003</td><td>-0.25253726</td><td>-0.197310382</td></tr>\n",
       "\t<tr><th scope=row>79719</th><td>-0.16976131</td><td>-0.22447172</td><td>-0.22749895</td><td> 0.534682617</td><td> 0.12373455</td><td>-0.110848158</td><td>-0.23184604</td><td>-0.01083574</td><td> 0.27340130</td><td> 0.243176297</td><td>â‹¯</td><td> 0.56435072</td><td>-0.12728530</td><td> 0.01733162</td><td>-0.251213399</td><td> 0.53918913</td><td> 0.28851319</td><td>-0.22284338</td><td>-0.03750106</td><td> 0.45867577</td><td> 0.200807668</td></tr>\n",
       "\t<tr><th scope=row>22848</th><td>-0.46017301</td><td>-0.29121717</td><td> 0.21594748</td><td> 0.326251447</td><td> 0.25445216</td><td>-0.026024129</td><td> 0.30164170</td><td>-0.05457508</td><td>-0.85703852</td><td>-0.327565362</td><td>â‹¯</td><td> 0.41537062</td><td> 0.20026864</td><td> 0.39486466</td><td>-0.064217165</td><td>-0.14424554</td><td>-0.79530881</td><td> 0.05579869</td><td> 0.28014132</td><td> 0.09369848</td><td>-0.301176142</td></tr>\n",
       "\t<tr><th scope=row>28971</th><td>-0.48638879</td><td>-0.21824053</td><td>-1.17608636</td><td>-0.231041671</td><td> 0.09737793</td><td>-0.208717060</td><td>-0.03902958</td><td>-1.54787646</td><td>-0.26017828</td><td>-0.081992985</td><td>â‹¯</td><td>-0.31408441</td><td> 0.02798369</td><td>-0.96179339</td><td>-0.002690759</td><td>-0.07200012</td><td> 0.03923363</td><td> 0.58644076</td><td>-0.86111829</td><td> 0.24225485</td><td> 1.931549639</td></tr>\n",
       "\t<tr><th scope=row>14</th><td>-0.65785204</td><td> 0.71096814</td><td>-0.33834631</td><td> 0.854973969</td><td> 0.16286874</td><td> 0.252956602</td><td>-0.70442039</td><td>-0.11893037</td><td> 0.19064217</td><td> 0.504712351</td><td>â‹¯</td><td> 0.12815124</td><td>-0.48746042</td><td>-0.33896029</td><td> 0.555516426</td><td> 0.45480429</td><td> 0.32689198</td><td> 0.33728202</td><td>-0.31787005</td><td> 0.66394344</td><td> 0.488121780</td></tr>\n",
       "\t<tr><th scope=row>25980</th><td>-0.78707497</td><td>-0.32964982</td><td>-0.95395678</td><td> 0.045168229</td><td>-0.40703090</td><td> 0.743494230</td><td>-0.97246165</td><td> 0.08247697</td><td>-0.13492104</td><td> 0.155322460</td><td>â‹¯</td><td> 0.39814979</td><td>-1.12073787</td><td>-0.77615949</td><td> 0.287138265</td><td> 0.28906247</td><td> 0.44357998</td><td> 0.03860262</td><td> 0.79306882</td><td> 0.24078442</td><td> 0.018539172</td></tr>\n",
       "\t<tr><th scope=row>441376</th><td> 0.17069129</td><td>-0.39929260</td><td>-0.39929260</td><td>-0.275296321</td><td>-0.04612832</td><td>-0.399292598</td><td> 0.32547599</td><td>-0.39929260</td><td> 0.08184085</td><td>-0.302149654</td><td>â‹¯</td><td> 0.25473658</td><td>-0.28207724</td><td>-0.39929260</td><td>-0.197240187</td><td>-0.15507086</td><td> 1.22369793</td><td>-0.39929260</td><td>-0.39929260</td><td> 0.79279905</td><td>-0.366114299</td></tr>\n",
       "\t<tr><th scope=row>16</th><td>-0.29852934</td><td>-0.25603742</td><td>-0.32059161</td><td> 0.794134979</td><td>-0.05356968</td><td>-0.090494599</td><td> 1.13564450</td><td> 0.68170751</td><td>-0.40844636</td><td> 0.250835705</td><td>â‹¯</td><td> 0.59019100</td><td>-0.86965064</td><td> 0.56005477</td><td>-0.288958537</td><td> 0.98258352</td><td>-0.03887593</td><td> 0.22293528</td><td> 0.31553218</td><td>-0.65155946</td><td>-0.009516557</td></tr>\n",
       "\t<tr><th scope=row>57505</th><td>-0.96633877</td><td> 0.05055959</td><td>-0.27581646</td><td>-1.116953635</td><td>-0.11914141</td><td> 0.339404995</td><td>-0.58047375</td><td> 0.73854765</td><td>-0.19135946</td><td> 0.190814401</td><td>â‹¯</td><td>-0.38099883</td><td>-0.31885272</td><td>-0.35588020</td><td> 0.117412713</td><td> 0.42701335</td><td> 0.66773792</td><td>-0.11955801</td><td> 0.01002852</td><td>-0.38868035</td><td> 0.460412600</td></tr>\n",
       "\t<tr><th scope=row>80755</th><td> 0.48769170</td><td> 0.03067254</td><td>-0.75952377</td><td>-0.108241457</td><td>-0.55017112</td><td> 0.027737771</td><td>-0.27220937</td><td>-0.04731449</td><td> 0.03021470</td><td> 0.245068451</td><td>â‹¯</td><td> 0.66515244</td><td>-0.99256546</td><td> 0.06394071</td><td> 0.322414374</td><td> 0.78806025</td><td> 0.32029527</td><td>-0.35662562</td><td>-0.59348610</td><td>-0.05527100</td><td> 0.382764203</td></tr>\n",
       "\t<tr><th scope=row>132949</th><td> 0.86332423</td><td>-0.06173112</td><td> 0.44876646</td><td>-0.946300713</td><td>-0.33610057</td><td> 0.350492560</td><td>-1.67205617</td><td>-0.15645411</td><td> 0.14392756</td><td>-0.468626608</td><td>â‹¯</td><td>-0.60969240</td><td>-0.77181384</td><td> 0.76987189</td><td>-0.125153194</td><td>-0.04695216</td><td>-0.50405529</td><td> 0.24828407</td><td> 0.32803017</td><td>-0.46622640</td><td>-0.150818256</td></tr>\n",
       "\t<tr><th scope=row>60496</th><td>-0.52066005</td><td>-0.83259409</td><td>-0.90452187</td><td> 0.007721265</td><td> 0.34966399</td><td> 0.072953185</td><td> 1.08434100</td><td> 0.49852088</td><td>-0.47817360</td><td> 0.035106906</td><td>â‹¯</td><td>-0.26016705</td><td> 0.94000318</td><td>-0.59660687</td><td> 0.239252511</td><td> 0.66599271</td><td> 0.31312698</td><td> 0.61389364</td><td>-0.02754601</td><td> 0.07727379</td><td> 0.050452719</td></tr>\n",
       "\t<tr><th scope=row>10157</th><td>-0.28107565</td><td>-0.11313725</td><td>-0.19382979</td><td> 0.138589209</td><td>-1.27446539</td><td> 0.040623811</td><td>-0.90281200</td><td> 1.08500532</td><td> 0.54223586</td><td> 0.373594229</td><td>â‹¯</td><td>-0.43716549</td><td>-0.56186282</td><td>-0.40903938</td><td> 0.694874411</td><td> 0.48684804</td><td> 0.28716461</td><td>-0.25439021</td><td>-0.79120250</td><td> 0.08412152</td><td>-0.151727888</td></tr>\n",
       "\t<tr><th scope=row>26574</th><td>-0.36949241</td><td> 0.09586981</td><td>-0.08007427</td><td> 0.305067084</td><td> 0.31037075</td><td> 0.219291256</td><td>-0.38057925</td><td> 0.21194798</td><td>-0.02866318</td><td> 0.340586441</td><td>â‹¯</td><td> 1.05987638</td><td>-0.95376429</td><td>-0.07585459</td><td> 0.367789073</td><td> 0.08194599</td><td> 0.70871374</td><td> 0.31888482</td><td>-0.63148827</td><td>-0.69475016</td><td> 0.637940467</td></tr>\n",
       "\t<tr><th scope=row>9625</th><td> 1.33596224</td><td>-0.64153963</td><td>-0.76434337</td><td> 2.813354136</td><td> 0.36940161</td><td>-0.359284895</td><td>-0.61628550</td><td>-0.22869959</td><td>-0.11397219</td><td> 0.024823023</td><td>â‹¯</td><td> 2.36858681</td><td>-0.93226101</td><td>-0.02532996</td><td>-0.552781114</td><td> 0.02734172</td><td>-1.16950265</td><td>-1.04696869</td><td>-0.36775984</td><td>-0.17492891</td><td> 1.134896901</td></tr>\n",
       "\t<tr><th scope=row>18</th><td>-1.34884806</td><td>-1.22335298</td><td> 0.19324014</td><td> 0.749346603</td><td> 0.05016278</td><td>-0.081464081</td><td>-1.46347567</td><td> 1.15016654</td><td> 1.44516632</td><td>-0.394611391</td><td>â‹¯</td><td> 0.23292362</td><td>-0.34922853</td><td> 1.15692495</td><td> 0.338521821</td><td> 0.25730823</td><td>-1.01733786</td><td>-0.81613792</td><td>-0.77483279</td><td>-0.16228471</td><td>-0.616790030</td></tr>\n",
       "\t<tr><th scope=row>19</th><td> 0.57062632</td><td>-0.62202917</td><td> 0.06079913</td><td> 0.053167363</td><td> 0.84822211</td><td> 0.109128273</td><td> 0.28281056</td><td>-0.62430545</td><td>-1.30694301</td><td>-0.179727567</td><td>â‹¯</td><td>-0.10482467</td><td> 0.90796692</td><td> 1.04065385</td><td>-0.275747047</td><td> 0.18227452</td><td>-0.99483322</td><td>-0.34180255</td><td> 0.02461895</td><td> 0.13689279</td><td>-0.486670325</td></tr>\n",
       "\t<tr><th scope=row>10349</th><td> 0.76894096</td><td>-0.28041801</td><td> 0.18591823</td><td>-1.140640744</td><td>-0.57503604</td><td>-1.121317065</td><td>-1.25531169</td><td>-1.07364413</td><td>-0.98652452</td><td>-0.059129827</td><td>â‹¯</td><td>-0.05785176</td><td> 1.25167870</td><td> 0.34050201</td><td>-1.098587752</td><td>-0.65226049</td><td>-1.79959384</td><td>-0.79578118</td><td>-1.39103008</td><td>-1.00275071</td><td> 1.047646825</td></tr>\n",
       "\t<tr><th scope=row>79963</th><td>-0.09047424</td><td> 0.07728631</td><td> 0.31389312</td><td>-0.736425825</td><td> 0.45394367</td><td>-0.177660722</td><td>-0.23023263</td><td>-0.39486568</td><td> 0.17138151</td><td> 0.300319076</td><td>â‹¯</td><td>-0.27733364</td><td> 0.54842656</td><td> 0.14685390</td><td>-0.320077364</td><td>-0.15694583</td><td> 0.13253828</td><td>-0.90280482</td><td>-0.54179962</td><td>-0.51918678</td><td>-0.870386578</td></tr>\n",
       "\t<tr><th scope=row>26154</th><td>-1.16538393</td><td> 3.15509099</td><td> 4.98314606</td><td>-1.353532409</td><td>-1.37951032</td><td>-1.170400887</td><td> 0.15566811</td><td> 0.44696954</td><td> 1.74485005</td><td> 1.937359390</td><td>â‹¯</td><td>-1.36386728</td><td> 1.51554187</td><td>-1.18750135</td><td> 0.911097223</td><td>-0.71180554</td><td> 0.88865516</td><td>-1.26938294</td><td>-1.24849157</td><td>-1.29689731</td><td>-1.057288203</td></tr>\n",
       "\t<tr><th scope=row>â‹®</th><td>â‹®</td><td>â‹®</td><td>â‹®</td><td>â‹®</td><td>â‹®</td><td>â‹®</td><td>â‹®</td><td>â‹®</td><td>â‹®</td><td>â‹®</td><td>â‹±</td><td>â‹®</td><td>â‹®</td><td>â‹®</td><td>â‹®</td><td>â‹®</td><td>â‹®</td><td>â‹®</td><td>â‹®</td><td>â‹®</td><td>â‹®</td></tr>\n",
       "\t<tr><th scope=row>342945</th><td>-0.39294577</td><td> 0.096308836</td><td>-0.26777865</td><td>-0.003399216</td><td>-0.041148565</td><td> 0.08257988</td><td> 0.08671578</td><td>-0.22094886</td><td>-0.22588735</td><td>-0.28616068</td><td>â‹¯</td><td>-0.178795354</td><td>-0.20914143</td><td>-0.1646908853</td><td>-0.01495588</td><td>-0.029144403</td><td> 0.690412486</td><td> 0.09128651</td><td> 0.013489043</td><td>-0.134634221</td><td> 0.119221310</td></tr>\n",
       "\t<tr><th scope=row>222696</th><td>-0.07896764</td><td> 0.256559940</td><td> 0.53548393</td><td>-1.077633334</td><td>-0.347763031</td><td> 0.06051791</td><td>-0.08824179</td><td> 0.96799885</td><td>-1.20323474</td><td>-0.78240965</td><td>â‹¯</td><td> 0.187451703</td><td>-0.20500992</td><td>-0.3409709978</td><td> 0.56968717</td><td>-0.262422582</td><td>-1.157966151</td><td> 0.92961187</td><td>-0.175632238</td><td> 0.592542651</td><td>-1.305869998</td></tr>\n",
       "\t<tr><th scope=row>221785</th><td>-0.07410275</td><td> 0.310468830</td><td>-0.52020067</td><td> 0.147978885</td><td>-0.249543264</td><td> 0.27914555</td><td>-0.15915279</td><td> 0.44407197</td><td>-0.32460787</td><td> 0.67977028</td><td>â‹¯</td><td> 0.039696162</td><td>-0.38818506</td><td>-0.3768563963</td><td>-0.02315919</td><td> 0.388894491</td><td> 0.057598233</td><td>-0.22957282</td><td>-0.555731094</td><td>-0.160710100</td><td>-0.427696151</td></tr>\n",
       "\t<tr><th scope=row>7741</th><td> 0.16242310</td><td>-0.208648160</td><td>-0.86760850</td><td>-0.326618305</td><td>-0.049824697</td><td>-0.56721658</td><td> 0.46012375</td><td>-0.53993221</td><td>-0.03964494</td><td>-0.73673124</td><td>â‹¯</td><td>-0.174276131</td><td> 0.26534046</td><td>-1.2589476332</td><td>-0.01356772</td><td> 0.165900039</td><td>-0.191272435</td><td> 0.07697543</td><td> 0.077322733</td><td>-0.523910072</td><td> 0.351234287</td></tr>\n",
       "\t<tr><th scope=row>146050</th><td>-0.27147497</td><td>-0.302664855</td><td> 0.06591467</td><td>-0.152672835</td><td>-0.160049443</td><td>-0.10847992</td><td>-0.04025381</td><td> 0.46024624</td><td>-0.20124888</td><td> 0.07894973</td><td>â‹¯</td><td>-0.095310917</td><td>-0.43302860</td><td>-0.6724953769</td><td> 0.17577914</td><td>-0.417197835</td><td> 0.048865450</td><td>-0.42079745</td><td> 0.180282284</td><td>-0.193613714</td><td>-1.044585072</td></tr>\n",
       "\t<tr><th scope=row>100101467</th><td> 0.12910724</td><td>-0.166620561</td><td> 0.28927637</td><td> 0.073944360</td><td>-0.490339352</td><td>-0.60852126</td><td> 1.33012799</td><td> 0.12608064</td><td> 0.38993901</td><td>-0.27890109</td><td>â‹¯</td><td> 0.265599008</td><td> 0.49555501</td><td>-0.6722087756</td><td>-0.26699014</td><td>-0.123679235</td><td>-0.475728154</td><td>-0.19272112</td><td>-1.073103044</td><td> 0.242644181</td><td>-0.794825133</td></tr>\n",
       "\t<tr><th scope=row>64288</th><td>-1.02840200</td><td> 0.359290820</td><td> 1.85331112</td><td> 0.818719068</td><td>-1.023331801</td><td>-0.67226726</td><td> 0.54029218</td><td> 0.59971663</td><td>-0.12614354</td><td>-0.48486218</td><td>â‹¯</td><td>-0.007849682</td><td>-1.22117992</td><td>-0.8857645827</td><td> 0.09952779</td><td>-0.068071370</td><td> 0.217354160</td><td> 0.05392430</td><td> 0.079637817</td><td>-0.204035242</td><td>-0.009157544</td></tr>\n",
       "\t<tr><th scope=row>54925</th><td>-0.83947128</td><td>-0.004984449</td><td> 0.04287005</td><td> 0.170293562</td><td>-0.144611436</td><td> 0.05666641</td><td> 0.02912597</td><td> 0.77800716</td><td>-0.15610934</td><td>-0.29030552</td><td>â‹¯</td><td> 0.083809267</td><td> 0.21760002</td><td>-0.8257328974</td><td>-0.08204672</td><td> 0.004640902</td><td> 0.126605086</td><td> 0.03212684</td><td>-0.429831001</td><td>-0.010845006</td><td>-0.434026241</td></tr>\n",
       "\t<tr><th scope=row>79149</th><td>-0.36451498</td><td>-0.282897107</td><td> 0.22024346</td><td> 0.240838354</td><td>-0.022385447</td><td>-0.03440686</td><td> 0.02211164</td><td> 0.76406537</td><td>-0.75989309</td><td>-0.06453149</td><td>â‹¯</td><td> 0.294939368</td><td> 0.27671880</td><td>-0.1937818421</td><td>-0.35622686</td><td> 0.481398402</td><td> 0.599227666</td><td> 0.27045953</td><td> 0.309293515</td><td>-0.132427098</td><td>-0.222590252</td></tr>\n",
       "\t<tr><th scope=row>7746</th><td>-0.00206872</td><td>-0.520789273</td><td>-0.56790558</td><td>-0.164572233</td><td>-0.252870332</td><td>-0.53017798</td><td>-0.02311678</td><td>-0.67609253</td><td> 0.12835082</td><td>-0.40101131</td><td>â‹¯</td><td>-0.384008553</td><td>-0.35158415</td><td>-0.5736452159</td><td>-0.52383119</td><td> 0.153667005</td><td> 0.603364808</td><td>-0.03279160</td><td> 0.228336635</td><td>-0.243975627</td><td> 0.469857667</td></tr>\n",
       "\t<tr><th scope=row>90204</th><td>-1.14964320</td><td>-0.147744435</td><td>-0.09304375</td><td>-0.369502811</td><td>-0.215164625</td><td> 0.42634586</td><td> 0.43448683</td><td>-0.23477435</td><td> 0.01957181</td><td>-0.51313923</td><td>â‹¯</td><td>-0.343985279</td><td> 0.04973041</td><td>-0.3105190487</td><td> 0.04228306</td><td>-0.111616776</td><td> 0.379118126</td><td> 0.14163935</td><td> 0.384902809</td><td>-0.087591757</td><td>-0.044880902</td></tr>\n",
       "\t<tr><th scope=row>140831</th><td>-0.00666463</td><td>-0.162000037</td><td>-0.34872188</td><td>-0.038364962</td><td> 0.031084124</td><td>-0.03009380</td><td> 0.53934447</td><td> 0.03553720</td><td>-0.10423836</td><td>-0.34545282</td><td>â‹¯</td><td>-0.242998865</td><td>-0.07201809</td><td>-0.0007784702</td><td> 0.32665021</td><td> 0.169246474</td><td>-0.026439721</td><td> 0.12896315</td><td> 0.145807970</td><td>-0.119736675</td><td>-0.054596189</td></tr>\n",
       "\t<tr><th scope=row>65249</th><td>-0.38720323</td><td>-0.093166377</td><td>-0.23694355</td><td> 0.100231654</td><td> 0.165662988</td><td>-0.06423251</td><td> 0.97493166</td><td> 0.03873013</td><td>-0.20637817</td><td>-0.21953342</td><td>â‹¯</td><td> 0.583283002</td><td>-0.83624952</td><td> 0.0492035308</td><td>-0.16030035</td><td>-0.761126445</td><td> 0.098385831</td><td> 0.23489732</td><td>-0.560842467</td><td> 0.421292358</td><td> 0.561837969</td></tr>\n",
       "\t<tr><th scope=row>57643</th><td>-0.01064160</td><td>-0.465813717</td><td> 0.20079688</td><td>-0.085240817</td><td>-0.002401227</td><td>-0.39307241</td><td>-0.27559524</td><td>-0.57942548</td><td> 0.53107017</td><td>-0.20389400</td><td>â‹¯</td><td> 0.463350109</td><td>-0.37742257</td><td>-0.0131313227</td><td> 0.15980244</td><td>-0.330078675</td><td>-0.721802712</td><td>-0.61027707</td><td>-0.433239676</td><td> 0.297839050</td><td>-0.253985786</td></tr>\n",
       "\t<tr><th scope=row>57688</th><td> 0.19444757</td><td>-0.277799290</td><td>-0.18015048</td><td> 0.667250124</td><td> 0.548716996</td><td>-0.29490229</td><td>-0.11153040</td><td>-0.20611479</td><td>-0.40036983</td><td>-0.57255898</td><td>â‹¯</td><td> 0.329921606</td><td>-0.96986065</td><td> 0.3099456389</td><td>-0.21927048</td><td>-0.016714678</td><td>-0.027766105</td><td> 0.40985529</td><td>-0.006746855</td><td> 0.041948886</td><td> 0.091440517</td></tr>\n",
       "\t<tr><th scope=row>125150</th><td> 0.95979664</td><td> 0.097384370</td><td>-0.25316554</td><td>-0.238988700</td><td> 0.304486775</td><td> 0.03438547</td><td>-2.04427608</td><td>-0.71663732</td><td> 0.50273247</td><td> 0.45390129</td><td>â‹¯</td><td>-0.958073429</td><td>-0.27029898</td><td> 0.1194006800</td><td>-0.06238310</td><td>-0.683516498</td><td> 1.016254289</td><td> 0.35361223</td><td>-0.088079050</td><td> 0.691974840</td><td>-0.638923716</td></tr>\n",
       "\t<tr><th scope=row>23053</th><td>-0.13607023</td><td> 0.171724976</td><td> 0.04046160</td><td>-0.194183921</td><td>-0.207473320</td><td> 0.25460964</td><td>-0.44015119</td><td> 0.61839382</td><td> 0.12357510</td><td>-0.28101915</td><td>â‹¯</td><td>-0.861787937</td><td>-0.34138932</td><td>-0.2637888566</td><td> 0.07440251</td><td>-0.392845775</td><td>-0.420510190</td><td>-0.38840345</td><td> 0.194476008</td><td>-0.633980586</td><td>-0.661179112</td></tr>\n",
       "\t<tr><th scope=row>100507331</th><td>-0.24203460</td><td>-0.124494934</td><td>-0.24203460</td><td>-0.242034603</td><td>-0.242034603</td><td> 0.11690554</td><td>-0.24203460</td><td> 0.28866537</td><td> 0.21692086</td><td>-0.24203460</td><td>â‹¯</td><td>-0.242034603</td><td>-0.24203460</td><td> 0.2670646726</td><td>-0.24203460</td><td> 0.014790405</td><td>-0.002485746</td><td>-0.07627356</td><td> 0.196455240</td><td>-0.242034603</td><td> 0.010426021</td></tr>\n",
       "\t<tr><th scope=row>221302</th><td> 0.69326584</td><td>-0.071362313</td><td>-0.19068943</td><td>-0.427521968</td><td> 0.550458540</td><td> 0.37559772</td><td>-0.07026790</td><td>-0.03371417</td><td>-0.23804433</td><td>-0.05715200</td><td>â‹¯</td><td> 0.462491077</td><td>-0.07180390</td><td>-0.1259258508</td><td>-0.24241293</td><td> 0.430207997</td><td>-0.084899135</td><td> 0.38791226</td><td>-0.519062960</td><td> 0.002186549</td><td> 0.306981441</td></tr>\n",
       "\t<tr><th scope=row>9183</th><td>-0.50392570</td><td>-0.258998258</td><td> 0.11535521</td><td>-0.185181954</td><td> 0.396080431</td><td>-0.09233644</td><td>-0.19261525</td><td> 0.02280537</td><td>-0.39436320</td><td>-0.29743124</td><td>â‹¯</td><td> 0.467873073</td><td>-0.50126227</td><td> 0.1511000508</td><td>-0.12861326</td><td> 0.301007503</td><td> 0.042471843</td><td> 0.42301333</td><td> 0.069997069</td><td>-0.208229171</td><td>-0.155087675</td></tr>\n",
       "\t<tr><th scope=row>55055</th><td>-0.51800739</td><td>-0.777894079</td><td>-0.32027729</td><td> 0.565210576</td><td> 0.334335123</td><td>-0.23997050</td><td> 1.41658928</td><td> 0.33614144</td><td>-0.43369412</td><td> 0.63079954</td><td>â‹¯</td><td> 0.492820836</td><td> 0.45022427</td><td>-0.3112274005</td><td> 0.21330995</td><td>-0.513242871</td><td> 0.466551049</td><td>-0.13648162</td><td>-0.338087624</td><td> 0.249057137</td><td> 0.867817473</td></tr>\n",
       "\t<tr><th scope=row>11130</th><td>-0.62215237</td><td> 0.478047773</td><td>-0.86643923</td><td> 0.374102143</td><td> 0.873875033</td><td> 0.20676718</td><td> 0.06242660</td><td>-0.17613154</td><td> 1.13091160</td><td> 1.03166565</td><td>â‹¯</td><td> 0.097252152</td><td>-0.65085397</td><td> 0.3316220752</td><td> 0.53110123</td><td>-0.118791410</td><td> 0.548726697</td><td> 0.38776064</td><td> 0.164356651</td><td> 0.069003376</td><td> 1.328808019</td></tr>\n",
       "\t<tr><th scope=row>7789</th><td> 0.22747089</td><td> 0.323184074</td><td> 0.15631043</td><td>-0.117003751</td><td> 0.359357971</td><td>-0.17908868</td><td>-1.42470143</td><td>-0.36559417</td><td>-0.27771088</td><td> 0.01034329</td><td>â‹¯</td><td>-0.091538589</td><td> 0.04578399</td><td>-0.6211025988</td><td>-0.64730355</td><td>-0.589203198</td><td>-0.340982084</td><td>-0.77864076</td><td>-0.394253124</td><td>-0.403180937</td><td> 0.228809433</td></tr>\n",
       "\t<tr><th scope=row>158586</th><td>-0.22274651</td><td> 0.077719635</td><td>-0.18119199</td><td> 0.323917763</td><td> 0.612691509</td><td>-0.14261207</td><td>-0.24798209</td><td>-0.75921926</td><td>-0.12975976</td><td> 0.13307078</td><td>â‹¯</td><td>-0.234891836</td><td>-0.24236341</td><td>-0.0978002512</td><td>-0.54270486</td><td>-0.171341938</td><td> 0.132527627</td><td>-0.07954015</td><td> 0.011956714</td><td> 0.088811412</td><td> 0.189385304</td></tr>\n",
       "\t<tr><th scope=row>79364</th><td>-0.31517698</td><td>-0.135534837</td><td> 0.11321388</td><td>-0.140344557</td><td>-0.445200566</td><td>-0.10593877</td><td>-0.11521950</td><td> 0.41185003</td><td>-0.06003260</td><td>-0.06398976</td><td>â‹¯</td><td>-0.386671757</td><td> 0.44765703</td><td>-0.2266679192</td><td> 0.10962948</td><td>-0.082831527</td><td>-0.530266017</td><td>-0.27904401</td><td>-0.173219621</td><td> 0.504679141</td><td>-0.040919069</td></tr>\n",
       "\t<tr><th scope=row>440590</th><td> 0.02419371</td><td>-0.149946066</td><td> 0.25268109</td><td>-0.189932683</td><td>-0.125614127</td><td>-0.10368129</td><td> 1.03268700</td><td>-0.11559656</td><td>-0.12662805</td><td>-0.11879850</td><td>â‹¯</td><td>-0.174289645</td><td>-0.18958255</td><td> 0.2600903669</td><td>-0.16842562</td><td>-0.111939726</td><td>-0.189932683</td><td>-0.18993268</td><td>-0.136040572</td><td>-0.186795252</td><td> 0.705853569</td></tr>\n",
       "\t<tr><th scope=row>79699</th><td>-0.35364727</td><td> 0.251256278</td><td>-0.40650049</td><td> 0.402207088</td><td> 0.150676605</td><td>-0.42023214</td><td> 0.46235717</td><td>-0.05134074</td><td>-0.13856663</td><td> 0.13974445</td><td>â‹¯</td><td> 0.101051639</td><td>-0.28079830</td><td>-0.0513407417</td><td> 0.34721238</td><td>-0.863812255</td><td>-0.088285115</td><td> 0.35310596</td><td>-0.363313462</td><td> 0.279728853</td><td> 0.197300128</td></tr>\n",
       "\t<tr><th scope=row>7791</th><td> 0.91660440</td><td> 0.468444252</td><td>-0.12853882</td><td> 0.768776526</td><td> 0.563966735</td><td> 0.48732913</td><td> 0.57172041</td><td>-0.26650284</td><td>-1.21787913</td><td> 0.05403603</td><td>â‹¯</td><td> 0.216502940</td><td>-0.26692534</td><td> 0.5937474997</td><td> 0.10479040</td><td> 0.167516338</td><td>-0.150368204</td><td> 0.09664086</td><td>-0.469149675</td><td> 1.324224649</td><td>-0.433947225</td></tr>\n",
       "\t<tr><th scope=row>23140</th><td>-0.36565228</td><td> 0.202778225</td><td> 0.79860248</td><td>-0.193560502</td><td> 0.006282023</td><td> 0.18718332</td><td>-0.68741730</td><td>-0.30519406</td><td>-0.20991515</td><td>-0.10143972</td><td>â‹¯</td><td>-0.434137380</td><td> 0.41458369</td><td>-0.1535201829</td><td>-0.49286569</td><td>-0.493717489</td><td>-0.062418433</td><td>-0.49286569</td><td> 0.105545635</td><td> 0.624400137</td><td>-0.979660281</td></tr>\n",
       "\t<tr><th scope=row>26009</th><td>-0.28997347</td><td> 0.125021499</td><td>-0.02921499</td><td> 0.201748892</td><td>-0.239514994</td><td>-0.19190377</td><td> 1.00008741</td><td>-0.84401986</td><td> 0.08612588</td><td>-0.25613537</td><td>â‹¯</td><td> 0.888723568</td><td> 0.49895492</td><td> 0.2160336185</td><td> 0.14336281</td><td>-0.041202772</td><td> 0.022793456</td><td>-0.31798122</td><td>-0.365189237</td><td>-0.229886863</td><td>-0.328878046</td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A data.frame: 18570 Ã— 41\n",
       "\\begin{tabular}{r|lllllllllllllllllllll}\n",
       "  & 9 & 3 & 35 & 18 & 7 & 48 & 30 & 14 & 13 & 46 & â‹¯ & 50 & 4 & 40 & 25 & 52 & 19 & 41 & 34 & 23 & 54\\\\\n",
       "  & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & â‹¯ & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl>\\\\\n",
       "\\hline\n",
       "\t1 & -1.58231886 &  0.41362108 & -1.22017300 &  0.075095675 &  0.05888384 & -0.662010151 &  0.42966948 & -0.11535008 &  0.67577556 &  0.513876358 & â‹¯ & -0.92372234 & -0.91234682 & -0.19708134 &  0.718437503 &  0.25690495 &  0.83904346 & -0.40860109 &  1.44645031 &  0.04754928 &  0.473103225\\\\\n",
       "\t503538 &  0.22612657 &  0.02686424 & -0.46544478 & -0.176204605 & -0.70208641 & -0.458452942 & -0.84484596 & -0.18471088 & -0.48203131 &  0.005365473 & â‹¯ & -0.02059807 & -1.08931032 &  0.28315354 & -0.047598322 &  0.19613082 &  0.40829813 & -0.04866972 &  0.32854358 & -0.66091660 & -0.195425198\\\\\n",
       "\t2 &  1.66568079 & -0.63666687 & -0.17419729 & -0.326858659 &  0.47458381 & -1.241568243 & -0.98130509 & -0.45533603 & -1.63309646 & -0.610543313 & â‹¯ & -1.26427983 &  0.23970161 &  1.18647523 &  0.737057442 & -1.81640023 & -0.25034316 &  2.96944712 &  0.32667241 &  2.03186221 & -0.355766075\\\\\n",
       "\t144571 &  0.41620526 & -0.52085278 & -0.15142775 & -0.301583681 &  0.11572232 &  0.546215021 & -0.55657029 &  0.11802313 &  0.49090024 &  0.145104377 & â‹¯ & -0.11756944 &  0.20399209 &  0.39210061 &  0.253308910 & -0.43541291 & -0.58517654 & -0.89701142 & -0.30074905 & -0.50093196 & -0.515324225\\\\\n",
       "\t144568 & -0.81472165 &  3.15369407 &  2.88161537 & -1.017703568 & -1.01770357 & -0.988625504 & -1.01770357 &  3.30190882 &  2.39125358 &  0.024950337 & â‹¯ & -0.96750137 &  0.53103697 & -1.01770357 &  0.481178167 & -1.01770357 &  1.40950498 & -1.01770357 & -1.01770357 & -1.01770357 & -1.017703568\\\\\n",
       "\t53947 &  0.75217226 & -0.35293797 & -0.39829659 & -0.457284541 & -0.81206319 & -0.235179430 &  0.20997399 & -0.45430870 & -0.79193292 & -0.032976780 & â‹¯ &  1.09366423 &  0.76756632 &  0.17559646 & -0.011900328 & -0.59484600 & -0.81832864 & -0.70901232 & -0.77721338 &  0.29027153 & -1.092249883\\\\\n",
       "\t8086 &  0.48742979 &  0.21737047 &  0.11733274 &  0.244340206 & -0.52053759 & -0.209526830 & -1.27586077 &  0.24283611 & -0.07076524 &  0.042689150 & â‹¯ & -0.36088541 & -0.15312547 & -0.28569714 &  0.121104364 &  0.55932299 &  0.28172048 & -0.66782403 & -0.76282357 &  0.12643972 & -0.171057793\\\\\n",
       "\t65985 & -0.11137395 &  0.94451945 &  0.86124177 &  0.374050600 & -0.83866229 &  0.739460281 & -0.63456805 &  0.10825169 &  0.60201350 &  0.292313400 & â‹¯ & -1.32322790 & -0.21753685 & -0.05100234 &  0.273182689 & -0.45761784 & -0.03626696 &  0.41864303 &  0.19990466 &  0.75946942 & -0.252467977\\\\\n",
       "\t13 &  2.28027252 &  1.21879050 & -0.15999967 & -0.387926308 & -0.15818095 & -0.387926308 & -0.38792631 & -0.38792631 &  0.49829857 &  0.279778470 & â‹¯ &  1.36663079 &  0.38520734 & -0.38792631 & -0.082744787 & -0.17048984 & -0.29837480 & -0.38792631 & -0.36056831 & -0.33097686 & -0.204260693\\\\\n",
       "\t51166 &  0.07411433 &  0.40828556 & -0.42778929 &  0.498749883 &  0.25237782 &  0.483951204 & -0.36446250 & -0.77588290 &  0.51513916 & -0.567818972 & â‹¯ &  0.22049161 & -0.64948469 & -0.02668299 & -0.063968115 & -1.37391267 &  0.22347496 &  0.04092749 & -0.14311666 & -0.05786118 & -0.416186634\\\\\n",
       "\t195827 & -0.15622431 & -0.78312785 & -0.59006520 &  0.551936365 &  0.67649007 &  0.002704479 &  2.07968485 & -0.98986906 &  0.23131085 &  0.234997541 & â‹¯ &  0.23435838 &  0.61337288 &  0.07559452 & -0.041484582 & -1.08635043 &  0.45579427 & -0.53358223 & -0.01506003 & -0.25253726 & -0.197310382\\\\\n",
       "\t79719 & -0.16976131 & -0.22447172 & -0.22749895 &  0.534682617 &  0.12373455 & -0.110848158 & -0.23184604 & -0.01083574 &  0.27340130 &  0.243176297 & â‹¯ &  0.56435072 & -0.12728530 &  0.01733162 & -0.251213399 &  0.53918913 &  0.28851319 & -0.22284338 & -0.03750106 &  0.45867577 &  0.200807668\\\\\n",
       "\t22848 & -0.46017301 & -0.29121717 &  0.21594748 &  0.326251447 &  0.25445216 & -0.026024129 &  0.30164170 & -0.05457508 & -0.85703852 & -0.327565362 & â‹¯ &  0.41537062 &  0.20026864 &  0.39486466 & -0.064217165 & -0.14424554 & -0.79530881 &  0.05579869 &  0.28014132 &  0.09369848 & -0.301176142\\\\\n",
       "\t28971 & -0.48638879 & -0.21824053 & -1.17608636 & -0.231041671 &  0.09737793 & -0.208717060 & -0.03902958 & -1.54787646 & -0.26017828 & -0.081992985 & â‹¯ & -0.31408441 &  0.02798369 & -0.96179339 & -0.002690759 & -0.07200012 &  0.03923363 &  0.58644076 & -0.86111829 &  0.24225485 &  1.931549639\\\\\n",
       "\t14 & -0.65785204 &  0.71096814 & -0.33834631 &  0.854973969 &  0.16286874 &  0.252956602 & -0.70442039 & -0.11893037 &  0.19064217 &  0.504712351 & â‹¯ &  0.12815124 & -0.48746042 & -0.33896029 &  0.555516426 &  0.45480429 &  0.32689198 &  0.33728202 & -0.31787005 &  0.66394344 &  0.488121780\\\\\n",
       "\t25980 & -0.78707497 & -0.32964982 & -0.95395678 &  0.045168229 & -0.40703090 &  0.743494230 & -0.97246165 &  0.08247697 & -0.13492104 &  0.155322460 & â‹¯ &  0.39814979 & -1.12073787 & -0.77615949 &  0.287138265 &  0.28906247 &  0.44357998 &  0.03860262 &  0.79306882 &  0.24078442 &  0.018539172\\\\\n",
       "\t441376 &  0.17069129 & -0.39929260 & -0.39929260 & -0.275296321 & -0.04612832 & -0.399292598 &  0.32547599 & -0.39929260 &  0.08184085 & -0.302149654 & â‹¯ &  0.25473658 & -0.28207724 & -0.39929260 & -0.197240187 & -0.15507086 &  1.22369793 & -0.39929260 & -0.39929260 &  0.79279905 & -0.366114299\\\\\n",
       "\t16 & -0.29852934 & -0.25603742 & -0.32059161 &  0.794134979 & -0.05356968 & -0.090494599 &  1.13564450 &  0.68170751 & -0.40844636 &  0.250835705 & â‹¯ &  0.59019100 & -0.86965064 &  0.56005477 & -0.288958537 &  0.98258352 & -0.03887593 &  0.22293528 &  0.31553218 & -0.65155946 & -0.009516557\\\\\n",
       "\t57505 & -0.96633877 &  0.05055959 & -0.27581646 & -1.116953635 & -0.11914141 &  0.339404995 & -0.58047375 &  0.73854765 & -0.19135946 &  0.190814401 & â‹¯ & -0.38099883 & -0.31885272 & -0.35588020 &  0.117412713 &  0.42701335 &  0.66773792 & -0.11955801 &  0.01002852 & -0.38868035 &  0.460412600\\\\\n",
       "\t80755 &  0.48769170 &  0.03067254 & -0.75952377 & -0.108241457 & -0.55017112 &  0.027737771 & -0.27220937 & -0.04731449 &  0.03021470 &  0.245068451 & â‹¯ &  0.66515244 & -0.99256546 &  0.06394071 &  0.322414374 &  0.78806025 &  0.32029527 & -0.35662562 & -0.59348610 & -0.05527100 &  0.382764203\\\\\n",
       "\t132949 &  0.86332423 & -0.06173112 &  0.44876646 & -0.946300713 & -0.33610057 &  0.350492560 & -1.67205617 & -0.15645411 &  0.14392756 & -0.468626608 & â‹¯ & -0.60969240 & -0.77181384 &  0.76987189 & -0.125153194 & -0.04695216 & -0.50405529 &  0.24828407 &  0.32803017 & -0.46622640 & -0.150818256\\\\\n",
       "\t60496 & -0.52066005 & -0.83259409 & -0.90452187 &  0.007721265 &  0.34966399 &  0.072953185 &  1.08434100 &  0.49852088 & -0.47817360 &  0.035106906 & â‹¯ & -0.26016705 &  0.94000318 & -0.59660687 &  0.239252511 &  0.66599271 &  0.31312698 &  0.61389364 & -0.02754601 &  0.07727379 &  0.050452719\\\\\n",
       "\t10157 & -0.28107565 & -0.11313725 & -0.19382979 &  0.138589209 & -1.27446539 &  0.040623811 & -0.90281200 &  1.08500532 &  0.54223586 &  0.373594229 & â‹¯ & -0.43716549 & -0.56186282 & -0.40903938 &  0.694874411 &  0.48684804 &  0.28716461 & -0.25439021 & -0.79120250 &  0.08412152 & -0.151727888\\\\\n",
       "\t26574 & -0.36949241 &  0.09586981 & -0.08007427 &  0.305067084 &  0.31037075 &  0.219291256 & -0.38057925 &  0.21194798 & -0.02866318 &  0.340586441 & â‹¯ &  1.05987638 & -0.95376429 & -0.07585459 &  0.367789073 &  0.08194599 &  0.70871374 &  0.31888482 & -0.63148827 & -0.69475016 &  0.637940467\\\\\n",
       "\t9625 &  1.33596224 & -0.64153963 & -0.76434337 &  2.813354136 &  0.36940161 & -0.359284895 & -0.61628550 & -0.22869959 & -0.11397219 &  0.024823023 & â‹¯ &  2.36858681 & -0.93226101 & -0.02532996 & -0.552781114 &  0.02734172 & -1.16950265 & -1.04696869 & -0.36775984 & -0.17492891 &  1.134896901\\\\\n",
       "\t18 & -1.34884806 & -1.22335298 &  0.19324014 &  0.749346603 &  0.05016278 & -0.081464081 & -1.46347567 &  1.15016654 &  1.44516632 & -0.394611391 & â‹¯ &  0.23292362 & -0.34922853 &  1.15692495 &  0.338521821 &  0.25730823 & -1.01733786 & -0.81613792 & -0.77483279 & -0.16228471 & -0.616790030\\\\\n",
       "\t19 &  0.57062632 & -0.62202917 &  0.06079913 &  0.053167363 &  0.84822211 &  0.109128273 &  0.28281056 & -0.62430545 & -1.30694301 & -0.179727567 & â‹¯ & -0.10482467 &  0.90796692 &  1.04065385 & -0.275747047 &  0.18227452 & -0.99483322 & -0.34180255 &  0.02461895 &  0.13689279 & -0.486670325\\\\\n",
       "\t10349 &  0.76894096 & -0.28041801 &  0.18591823 & -1.140640744 & -0.57503604 & -1.121317065 & -1.25531169 & -1.07364413 & -0.98652452 & -0.059129827 & â‹¯ & -0.05785176 &  1.25167870 &  0.34050201 & -1.098587752 & -0.65226049 & -1.79959384 & -0.79578118 & -1.39103008 & -1.00275071 &  1.047646825\\\\\n",
       "\t79963 & -0.09047424 &  0.07728631 &  0.31389312 & -0.736425825 &  0.45394367 & -0.177660722 & -0.23023263 & -0.39486568 &  0.17138151 &  0.300319076 & â‹¯ & -0.27733364 &  0.54842656 &  0.14685390 & -0.320077364 & -0.15694583 &  0.13253828 & -0.90280482 & -0.54179962 & -0.51918678 & -0.870386578\\\\\n",
       "\t26154 & -1.16538393 &  3.15509099 &  4.98314606 & -1.353532409 & -1.37951032 & -1.170400887 &  0.15566811 &  0.44696954 &  1.74485005 &  1.937359390 & â‹¯ & -1.36386728 &  1.51554187 & -1.18750135 &  0.911097223 & -0.71180554 &  0.88865516 & -1.26938294 & -1.24849157 & -1.29689731 & -1.057288203\\\\\n",
       "\tâ‹® & â‹® & â‹® & â‹® & â‹® & â‹® & â‹® & â‹® & â‹® & â‹® & â‹® & â‹± & â‹® & â‹® & â‹® & â‹® & â‹® & â‹® & â‹® & â‹® & â‹® & â‹®\\\\\n",
       "\t342945 & -0.39294577 &  0.096308836 & -0.26777865 & -0.003399216 & -0.041148565 &  0.08257988 &  0.08671578 & -0.22094886 & -0.22588735 & -0.28616068 & â‹¯ & -0.178795354 & -0.20914143 & -0.1646908853 & -0.01495588 & -0.029144403 &  0.690412486 &  0.09128651 &  0.013489043 & -0.134634221 &  0.119221310\\\\\n",
       "\t222696 & -0.07896764 &  0.256559940 &  0.53548393 & -1.077633334 & -0.347763031 &  0.06051791 & -0.08824179 &  0.96799885 & -1.20323474 & -0.78240965 & â‹¯ &  0.187451703 & -0.20500992 & -0.3409709978 &  0.56968717 & -0.262422582 & -1.157966151 &  0.92961187 & -0.175632238 &  0.592542651 & -1.305869998\\\\\n",
       "\t221785 & -0.07410275 &  0.310468830 & -0.52020067 &  0.147978885 & -0.249543264 &  0.27914555 & -0.15915279 &  0.44407197 & -0.32460787 &  0.67977028 & â‹¯ &  0.039696162 & -0.38818506 & -0.3768563963 & -0.02315919 &  0.388894491 &  0.057598233 & -0.22957282 & -0.555731094 & -0.160710100 & -0.427696151\\\\\n",
       "\t7741 &  0.16242310 & -0.208648160 & -0.86760850 & -0.326618305 & -0.049824697 & -0.56721658 &  0.46012375 & -0.53993221 & -0.03964494 & -0.73673124 & â‹¯ & -0.174276131 &  0.26534046 & -1.2589476332 & -0.01356772 &  0.165900039 & -0.191272435 &  0.07697543 &  0.077322733 & -0.523910072 &  0.351234287\\\\\n",
       "\t146050 & -0.27147497 & -0.302664855 &  0.06591467 & -0.152672835 & -0.160049443 & -0.10847992 & -0.04025381 &  0.46024624 & -0.20124888 &  0.07894973 & â‹¯ & -0.095310917 & -0.43302860 & -0.6724953769 &  0.17577914 & -0.417197835 &  0.048865450 & -0.42079745 &  0.180282284 & -0.193613714 & -1.044585072\\\\\n",
       "\t100101467 &  0.12910724 & -0.166620561 &  0.28927637 &  0.073944360 & -0.490339352 & -0.60852126 &  1.33012799 &  0.12608064 &  0.38993901 & -0.27890109 & â‹¯ &  0.265599008 &  0.49555501 & -0.6722087756 & -0.26699014 & -0.123679235 & -0.475728154 & -0.19272112 & -1.073103044 &  0.242644181 & -0.794825133\\\\\n",
       "\t64288 & -1.02840200 &  0.359290820 &  1.85331112 &  0.818719068 & -1.023331801 & -0.67226726 &  0.54029218 &  0.59971663 & -0.12614354 & -0.48486218 & â‹¯ & -0.007849682 & -1.22117992 & -0.8857645827 &  0.09952779 & -0.068071370 &  0.217354160 &  0.05392430 &  0.079637817 & -0.204035242 & -0.009157544\\\\\n",
       "\t54925 & -0.83947128 & -0.004984449 &  0.04287005 &  0.170293562 & -0.144611436 &  0.05666641 &  0.02912597 &  0.77800716 & -0.15610934 & -0.29030552 & â‹¯ &  0.083809267 &  0.21760002 & -0.8257328974 & -0.08204672 &  0.004640902 &  0.126605086 &  0.03212684 & -0.429831001 & -0.010845006 & -0.434026241\\\\\n",
       "\t79149 & -0.36451498 & -0.282897107 &  0.22024346 &  0.240838354 & -0.022385447 & -0.03440686 &  0.02211164 &  0.76406537 & -0.75989309 & -0.06453149 & â‹¯ &  0.294939368 &  0.27671880 & -0.1937818421 & -0.35622686 &  0.481398402 &  0.599227666 &  0.27045953 &  0.309293515 & -0.132427098 & -0.222590252\\\\\n",
       "\t7746 & -0.00206872 & -0.520789273 & -0.56790558 & -0.164572233 & -0.252870332 & -0.53017798 & -0.02311678 & -0.67609253 &  0.12835082 & -0.40101131 & â‹¯ & -0.384008553 & -0.35158415 & -0.5736452159 & -0.52383119 &  0.153667005 &  0.603364808 & -0.03279160 &  0.228336635 & -0.243975627 &  0.469857667\\\\\n",
       "\t90204 & -1.14964320 & -0.147744435 & -0.09304375 & -0.369502811 & -0.215164625 &  0.42634586 &  0.43448683 & -0.23477435 &  0.01957181 & -0.51313923 & â‹¯ & -0.343985279 &  0.04973041 & -0.3105190487 &  0.04228306 & -0.111616776 &  0.379118126 &  0.14163935 &  0.384902809 & -0.087591757 & -0.044880902\\\\\n",
       "\t140831 & -0.00666463 & -0.162000037 & -0.34872188 & -0.038364962 &  0.031084124 & -0.03009380 &  0.53934447 &  0.03553720 & -0.10423836 & -0.34545282 & â‹¯ & -0.242998865 & -0.07201809 & -0.0007784702 &  0.32665021 &  0.169246474 & -0.026439721 &  0.12896315 &  0.145807970 & -0.119736675 & -0.054596189\\\\\n",
       "\t65249 & -0.38720323 & -0.093166377 & -0.23694355 &  0.100231654 &  0.165662988 & -0.06423251 &  0.97493166 &  0.03873013 & -0.20637817 & -0.21953342 & â‹¯ &  0.583283002 & -0.83624952 &  0.0492035308 & -0.16030035 & -0.761126445 &  0.098385831 &  0.23489732 & -0.560842467 &  0.421292358 &  0.561837969\\\\\n",
       "\t57643 & -0.01064160 & -0.465813717 &  0.20079688 & -0.085240817 & -0.002401227 & -0.39307241 & -0.27559524 & -0.57942548 &  0.53107017 & -0.20389400 & â‹¯ &  0.463350109 & -0.37742257 & -0.0131313227 &  0.15980244 & -0.330078675 & -0.721802712 & -0.61027707 & -0.433239676 &  0.297839050 & -0.253985786\\\\\n",
       "\t57688 &  0.19444757 & -0.277799290 & -0.18015048 &  0.667250124 &  0.548716996 & -0.29490229 & -0.11153040 & -0.20611479 & -0.40036983 & -0.57255898 & â‹¯ &  0.329921606 & -0.96986065 &  0.3099456389 & -0.21927048 & -0.016714678 & -0.027766105 &  0.40985529 & -0.006746855 &  0.041948886 &  0.091440517\\\\\n",
       "\t125150 &  0.95979664 &  0.097384370 & -0.25316554 & -0.238988700 &  0.304486775 &  0.03438547 & -2.04427608 & -0.71663732 &  0.50273247 &  0.45390129 & â‹¯ & -0.958073429 & -0.27029898 &  0.1194006800 & -0.06238310 & -0.683516498 &  1.016254289 &  0.35361223 & -0.088079050 &  0.691974840 & -0.638923716\\\\\n",
       "\t23053 & -0.13607023 &  0.171724976 &  0.04046160 & -0.194183921 & -0.207473320 &  0.25460964 & -0.44015119 &  0.61839382 &  0.12357510 & -0.28101915 & â‹¯ & -0.861787937 & -0.34138932 & -0.2637888566 &  0.07440251 & -0.392845775 & -0.420510190 & -0.38840345 &  0.194476008 & -0.633980586 & -0.661179112\\\\\n",
       "\t100507331 & -0.24203460 & -0.124494934 & -0.24203460 & -0.242034603 & -0.242034603 &  0.11690554 & -0.24203460 &  0.28866537 &  0.21692086 & -0.24203460 & â‹¯ & -0.242034603 & -0.24203460 &  0.2670646726 & -0.24203460 &  0.014790405 & -0.002485746 & -0.07627356 &  0.196455240 & -0.242034603 &  0.010426021\\\\\n",
       "\t221302 &  0.69326584 & -0.071362313 & -0.19068943 & -0.427521968 &  0.550458540 &  0.37559772 & -0.07026790 & -0.03371417 & -0.23804433 & -0.05715200 & â‹¯ &  0.462491077 & -0.07180390 & -0.1259258508 & -0.24241293 &  0.430207997 & -0.084899135 &  0.38791226 & -0.519062960 &  0.002186549 &  0.306981441\\\\\n",
       "\t9183 & -0.50392570 & -0.258998258 &  0.11535521 & -0.185181954 &  0.396080431 & -0.09233644 & -0.19261525 &  0.02280537 & -0.39436320 & -0.29743124 & â‹¯ &  0.467873073 & -0.50126227 &  0.1511000508 & -0.12861326 &  0.301007503 &  0.042471843 &  0.42301333 &  0.069997069 & -0.208229171 & -0.155087675\\\\\n",
       "\t55055 & -0.51800739 & -0.777894079 & -0.32027729 &  0.565210576 &  0.334335123 & -0.23997050 &  1.41658928 &  0.33614144 & -0.43369412 &  0.63079954 & â‹¯ &  0.492820836 &  0.45022427 & -0.3112274005 &  0.21330995 & -0.513242871 &  0.466551049 & -0.13648162 & -0.338087624 &  0.249057137 &  0.867817473\\\\\n",
       "\t11130 & -0.62215237 &  0.478047773 & -0.86643923 &  0.374102143 &  0.873875033 &  0.20676718 &  0.06242660 & -0.17613154 &  1.13091160 &  1.03166565 & â‹¯ &  0.097252152 & -0.65085397 &  0.3316220752 &  0.53110123 & -0.118791410 &  0.548726697 &  0.38776064 &  0.164356651 &  0.069003376 &  1.328808019\\\\\n",
       "\t7789 &  0.22747089 &  0.323184074 &  0.15631043 & -0.117003751 &  0.359357971 & -0.17908868 & -1.42470143 & -0.36559417 & -0.27771088 &  0.01034329 & â‹¯ & -0.091538589 &  0.04578399 & -0.6211025988 & -0.64730355 & -0.589203198 & -0.340982084 & -0.77864076 & -0.394253124 & -0.403180937 &  0.228809433\\\\\n",
       "\t158586 & -0.22274651 &  0.077719635 & -0.18119199 &  0.323917763 &  0.612691509 & -0.14261207 & -0.24798209 & -0.75921926 & -0.12975976 &  0.13307078 & â‹¯ & -0.234891836 & -0.24236341 & -0.0978002512 & -0.54270486 & -0.171341938 &  0.132527627 & -0.07954015 &  0.011956714 &  0.088811412 &  0.189385304\\\\\n",
       "\t79364 & -0.31517698 & -0.135534837 &  0.11321388 & -0.140344557 & -0.445200566 & -0.10593877 & -0.11521950 &  0.41185003 & -0.06003260 & -0.06398976 & â‹¯ & -0.386671757 &  0.44765703 & -0.2266679192 &  0.10962948 & -0.082831527 & -0.530266017 & -0.27904401 & -0.173219621 &  0.504679141 & -0.040919069\\\\\n",
       "\t440590 &  0.02419371 & -0.149946066 &  0.25268109 & -0.189932683 & -0.125614127 & -0.10368129 &  1.03268700 & -0.11559656 & -0.12662805 & -0.11879850 & â‹¯ & -0.174289645 & -0.18958255 &  0.2600903669 & -0.16842562 & -0.111939726 & -0.189932683 & -0.18993268 & -0.136040572 & -0.186795252 &  0.705853569\\\\\n",
       "\t79699 & -0.35364727 &  0.251256278 & -0.40650049 &  0.402207088 &  0.150676605 & -0.42023214 &  0.46235717 & -0.05134074 & -0.13856663 &  0.13974445 & â‹¯ &  0.101051639 & -0.28079830 & -0.0513407417 &  0.34721238 & -0.863812255 & -0.088285115 &  0.35310596 & -0.363313462 &  0.279728853 &  0.197300128\\\\\n",
       "\t7791 &  0.91660440 &  0.468444252 & -0.12853882 &  0.768776526 &  0.563966735 &  0.48732913 &  0.57172041 & -0.26650284 & -1.21787913 &  0.05403603 & â‹¯ &  0.216502940 & -0.26692534 &  0.5937474997 &  0.10479040 &  0.167516338 & -0.150368204 &  0.09664086 & -0.469149675 &  1.324224649 & -0.433947225\\\\\n",
       "\t23140 & -0.36565228 &  0.202778225 &  0.79860248 & -0.193560502 &  0.006282023 &  0.18718332 & -0.68741730 & -0.30519406 & -0.20991515 & -0.10143972 & â‹¯ & -0.434137380 &  0.41458369 & -0.1535201829 & -0.49286569 & -0.493717489 & -0.062418433 & -0.49286569 &  0.105545635 &  0.624400137 & -0.979660281\\\\\n",
       "\t26009 & -0.28997347 &  0.125021499 & -0.02921499 &  0.201748892 & -0.239514994 & -0.19190377 &  1.00008741 & -0.84401986 &  0.08612588 & -0.25613537 & â‹¯ &  0.888723568 &  0.49895492 &  0.2160336185 &  0.14336281 & -0.041202772 &  0.022793456 & -0.31798122 & -0.365189237 & -0.229886863 & -0.328878046\\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A data.frame: 18570 Ã— 41\n",
       "\n",
       "| <!--/--> | 9 &lt;dbl&gt; | 3 &lt;dbl&gt; | 35 &lt;dbl&gt; | 18 &lt;dbl&gt; | 7 &lt;dbl&gt; | 48 &lt;dbl&gt; | 30 &lt;dbl&gt; | 14 &lt;dbl&gt; | 13 &lt;dbl&gt; | 46 &lt;dbl&gt; | â‹¯ â‹¯ | 50 &lt;dbl&gt; | 4 &lt;dbl&gt; | 40 &lt;dbl&gt; | 25 &lt;dbl&gt; | 52 &lt;dbl&gt; | 19 &lt;dbl&gt; | 41 &lt;dbl&gt; | 34 &lt;dbl&gt; | 23 &lt;dbl&gt; | 54 &lt;dbl&gt; |\n",
       "|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|\n",
       "| 1 | -1.58231886 |  0.41362108 | -1.22017300 |  0.075095675 |  0.05888384 | -0.662010151 |  0.42966948 | -0.11535008 |  0.67577556 |  0.513876358 | â‹¯ | -0.92372234 | -0.91234682 | -0.19708134 |  0.718437503 |  0.25690495 |  0.83904346 | -0.40860109 |  1.44645031 |  0.04754928 |  0.473103225 |\n",
       "| 503538 |  0.22612657 |  0.02686424 | -0.46544478 | -0.176204605 | -0.70208641 | -0.458452942 | -0.84484596 | -0.18471088 | -0.48203131 |  0.005365473 | â‹¯ | -0.02059807 | -1.08931032 |  0.28315354 | -0.047598322 |  0.19613082 |  0.40829813 | -0.04866972 |  0.32854358 | -0.66091660 | -0.195425198 |\n",
       "| 2 |  1.66568079 | -0.63666687 | -0.17419729 | -0.326858659 |  0.47458381 | -1.241568243 | -0.98130509 | -0.45533603 | -1.63309646 | -0.610543313 | â‹¯ | -1.26427983 |  0.23970161 |  1.18647523 |  0.737057442 | -1.81640023 | -0.25034316 |  2.96944712 |  0.32667241 |  2.03186221 | -0.355766075 |\n",
       "| 144571 |  0.41620526 | -0.52085278 | -0.15142775 | -0.301583681 |  0.11572232 |  0.546215021 | -0.55657029 |  0.11802313 |  0.49090024 |  0.145104377 | â‹¯ | -0.11756944 |  0.20399209 |  0.39210061 |  0.253308910 | -0.43541291 | -0.58517654 | -0.89701142 | -0.30074905 | -0.50093196 | -0.515324225 |\n",
       "| 144568 | -0.81472165 |  3.15369407 |  2.88161537 | -1.017703568 | -1.01770357 | -0.988625504 | -1.01770357 |  3.30190882 |  2.39125358 |  0.024950337 | â‹¯ | -0.96750137 |  0.53103697 | -1.01770357 |  0.481178167 | -1.01770357 |  1.40950498 | -1.01770357 | -1.01770357 | -1.01770357 | -1.017703568 |\n",
       "| 53947 |  0.75217226 | -0.35293797 | -0.39829659 | -0.457284541 | -0.81206319 | -0.235179430 |  0.20997399 | -0.45430870 | -0.79193292 | -0.032976780 | â‹¯ |  1.09366423 |  0.76756632 |  0.17559646 | -0.011900328 | -0.59484600 | -0.81832864 | -0.70901232 | -0.77721338 |  0.29027153 | -1.092249883 |\n",
       "| 8086 |  0.48742979 |  0.21737047 |  0.11733274 |  0.244340206 | -0.52053759 | -0.209526830 | -1.27586077 |  0.24283611 | -0.07076524 |  0.042689150 | â‹¯ | -0.36088541 | -0.15312547 | -0.28569714 |  0.121104364 |  0.55932299 |  0.28172048 | -0.66782403 | -0.76282357 |  0.12643972 | -0.171057793 |\n",
       "| 65985 | -0.11137395 |  0.94451945 |  0.86124177 |  0.374050600 | -0.83866229 |  0.739460281 | -0.63456805 |  0.10825169 |  0.60201350 |  0.292313400 | â‹¯ | -1.32322790 | -0.21753685 | -0.05100234 |  0.273182689 | -0.45761784 | -0.03626696 |  0.41864303 |  0.19990466 |  0.75946942 | -0.252467977 |\n",
       "| 13 |  2.28027252 |  1.21879050 | -0.15999967 | -0.387926308 | -0.15818095 | -0.387926308 | -0.38792631 | -0.38792631 |  0.49829857 |  0.279778470 | â‹¯ |  1.36663079 |  0.38520734 | -0.38792631 | -0.082744787 | -0.17048984 | -0.29837480 | -0.38792631 | -0.36056831 | -0.33097686 | -0.204260693 |\n",
       "| 51166 |  0.07411433 |  0.40828556 | -0.42778929 |  0.498749883 |  0.25237782 |  0.483951204 | -0.36446250 | -0.77588290 |  0.51513916 | -0.567818972 | â‹¯ |  0.22049161 | -0.64948469 | -0.02668299 | -0.063968115 | -1.37391267 |  0.22347496 |  0.04092749 | -0.14311666 | -0.05786118 | -0.416186634 |\n",
       "| 195827 | -0.15622431 | -0.78312785 | -0.59006520 |  0.551936365 |  0.67649007 |  0.002704479 |  2.07968485 | -0.98986906 |  0.23131085 |  0.234997541 | â‹¯ |  0.23435838 |  0.61337288 |  0.07559452 | -0.041484582 | -1.08635043 |  0.45579427 | -0.53358223 | -0.01506003 | -0.25253726 | -0.197310382 |\n",
       "| 79719 | -0.16976131 | -0.22447172 | -0.22749895 |  0.534682617 |  0.12373455 | -0.110848158 | -0.23184604 | -0.01083574 |  0.27340130 |  0.243176297 | â‹¯ |  0.56435072 | -0.12728530 |  0.01733162 | -0.251213399 |  0.53918913 |  0.28851319 | -0.22284338 | -0.03750106 |  0.45867577 |  0.200807668 |\n",
       "| 22848 | -0.46017301 | -0.29121717 |  0.21594748 |  0.326251447 |  0.25445216 | -0.026024129 |  0.30164170 | -0.05457508 | -0.85703852 | -0.327565362 | â‹¯ |  0.41537062 |  0.20026864 |  0.39486466 | -0.064217165 | -0.14424554 | -0.79530881 |  0.05579869 |  0.28014132 |  0.09369848 | -0.301176142 |\n",
       "| 28971 | -0.48638879 | -0.21824053 | -1.17608636 | -0.231041671 |  0.09737793 | -0.208717060 | -0.03902958 | -1.54787646 | -0.26017828 | -0.081992985 | â‹¯ | -0.31408441 |  0.02798369 | -0.96179339 | -0.002690759 | -0.07200012 |  0.03923363 |  0.58644076 | -0.86111829 |  0.24225485 |  1.931549639 |\n",
       "| 14 | -0.65785204 |  0.71096814 | -0.33834631 |  0.854973969 |  0.16286874 |  0.252956602 | -0.70442039 | -0.11893037 |  0.19064217 |  0.504712351 | â‹¯ |  0.12815124 | -0.48746042 | -0.33896029 |  0.555516426 |  0.45480429 |  0.32689198 |  0.33728202 | -0.31787005 |  0.66394344 |  0.488121780 |\n",
       "| 25980 | -0.78707497 | -0.32964982 | -0.95395678 |  0.045168229 | -0.40703090 |  0.743494230 | -0.97246165 |  0.08247697 | -0.13492104 |  0.155322460 | â‹¯ |  0.39814979 | -1.12073787 | -0.77615949 |  0.287138265 |  0.28906247 |  0.44357998 |  0.03860262 |  0.79306882 |  0.24078442 |  0.018539172 |\n",
       "| 441376 |  0.17069129 | -0.39929260 | -0.39929260 | -0.275296321 | -0.04612832 | -0.399292598 |  0.32547599 | -0.39929260 |  0.08184085 | -0.302149654 | â‹¯ |  0.25473658 | -0.28207724 | -0.39929260 | -0.197240187 | -0.15507086 |  1.22369793 | -0.39929260 | -0.39929260 |  0.79279905 | -0.366114299 |\n",
       "| 16 | -0.29852934 | -0.25603742 | -0.32059161 |  0.794134979 | -0.05356968 | -0.090494599 |  1.13564450 |  0.68170751 | -0.40844636 |  0.250835705 | â‹¯ |  0.59019100 | -0.86965064 |  0.56005477 | -0.288958537 |  0.98258352 | -0.03887593 |  0.22293528 |  0.31553218 | -0.65155946 | -0.009516557 |\n",
       "| 57505 | -0.96633877 |  0.05055959 | -0.27581646 | -1.116953635 | -0.11914141 |  0.339404995 | -0.58047375 |  0.73854765 | -0.19135946 |  0.190814401 | â‹¯ | -0.38099883 | -0.31885272 | -0.35588020 |  0.117412713 |  0.42701335 |  0.66773792 | -0.11955801 |  0.01002852 | -0.38868035 |  0.460412600 |\n",
       "| 80755 |  0.48769170 |  0.03067254 | -0.75952377 | -0.108241457 | -0.55017112 |  0.027737771 | -0.27220937 | -0.04731449 |  0.03021470 |  0.245068451 | â‹¯ |  0.66515244 | -0.99256546 |  0.06394071 |  0.322414374 |  0.78806025 |  0.32029527 | -0.35662562 | -0.59348610 | -0.05527100 |  0.382764203 |\n",
       "| 132949 |  0.86332423 | -0.06173112 |  0.44876646 | -0.946300713 | -0.33610057 |  0.350492560 | -1.67205617 | -0.15645411 |  0.14392756 | -0.468626608 | â‹¯ | -0.60969240 | -0.77181384 |  0.76987189 | -0.125153194 | -0.04695216 | -0.50405529 |  0.24828407 |  0.32803017 | -0.46622640 | -0.150818256 |\n",
       "| 60496 | -0.52066005 | -0.83259409 | -0.90452187 |  0.007721265 |  0.34966399 |  0.072953185 |  1.08434100 |  0.49852088 | -0.47817360 |  0.035106906 | â‹¯ | -0.26016705 |  0.94000318 | -0.59660687 |  0.239252511 |  0.66599271 |  0.31312698 |  0.61389364 | -0.02754601 |  0.07727379 |  0.050452719 |\n",
       "| 10157 | -0.28107565 | -0.11313725 | -0.19382979 |  0.138589209 | -1.27446539 |  0.040623811 | -0.90281200 |  1.08500532 |  0.54223586 |  0.373594229 | â‹¯ | -0.43716549 | -0.56186282 | -0.40903938 |  0.694874411 |  0.48684804 |  0.28716461 | -0.25439021 | -0.79120250 |  0.08412152 | -0.151727888 |\n",
       "| 26574 | -0.36949241 |  0.09586981 | -0.08007427 |  0.305067084 |  0.31037075 |  0.219291256 | -0.38057925 |  0.21194798 | -0.02866318 |  0.340586441 | â‹¯ |  1.05987638 | -0.95376429 | -0.07585459 |  0.367789073 |  0.08194599 |  0.70871374 |  0.31888482 | -0.63148827 | -0.69475016 |  0.637940467 |\n",
       "| 9625 |  1.33596224 | -0.64153963 | -0.76434337 |  2.813354136 |  0.36940161 | -0.359284895 | -0.61628550 | -0.22869959 | -0.11397219 |  0.024823023 | â‹¯ |  2.36858681 | -0.93226101 | -0.02532996 | -0.552781114 |  0.02734172 | -1.16950265 | -1.04696869 | -0.36775984 | -0.17492891 |  1.134896901 |\n",
       "| 18 | -1.34884806 | -1.22335298 |  0.19324014 |  0.749346603 |  0.05016278 | -0.081464081 | -1.46347567 |  1.15016654 |  1.44516632 | -0.394611391 | â‹¯ |  0.23292362 | -0.34922853 |  1.15692495 |  0.338521821 |  0.25730823 | -1.01733786 | -0.81613792 | -0.77483279 | -0.16228471 | -0.616790030 |\n",
       "| 19 |  0.57062632 | -0.62202917 |  0.06079913 |  0.053167363 |  0.84822211 |  0.109128273 |  0.28281056 | -0.62430545 | -1.30694301 | -0.179727567 | â‹¯ | -0.10482467 |  0.90796692 |  1.04065385 | -0.275747047 |  0.18227452 | -0.99483322 | -0.34180255 |  0.02461895 |  0.13689279 | -0.486670325 |\n",
       "| 10349 |  0.76894096 | -0.28041801 |  0.18591823 | -1.140640744 | -0.57503604 | -1.121317065 | -1.25531169 | -1.07364413 | -0.98652452 | -0.059129827 | â‹¯ | -0.05785176 |  1.25167870 |  0.34050201 | -1.098587752 | -0.65226049 | -1.79959384 | -0.79578118 | -1.39103008 | -1.00275071 |  1.047646825 |\n",
       "| 79963 | -0.09047424 |  0.07728631 |  0.31389312 | -0.736425825 |  0.45394367 | -0.177660722 | -0.23023263 | -0.39486568 |  0.17138151 |  0.300319076 | â‹¯ | -0.27733364 |  0.54842656 |  0.14685390 | -0.320077364 | -0.15694583 |  0.13253828 | -0.90280482 | -0.54179962 | -0.51918678 | -0.870386578 |\n",
       "| 26154 | -1.16538393 |  3.15509099 |  4.98314606 | -1.353532409 | -1.37951032 | -1.170400887 |  0.15566811 |  0.44696954 |  1.74485005 |  1.937359390 | â‹¯ | -1.36386728 |  1.51554187 | -1.18750135 |  0.911097223 | -0.71180554 |  0.88865516 | -1.26938294 | -1.24849157 | -1.29689731 | -1.057288203 |\n",
       "| â‹® | â‹® | â‹® | â‹® | â‹® | â‹® | â‹® | â‹® | â‹® | â‹® | â‹® | â‹± | â‹® | â‹® | â‹® | â‹® | â‹® | â‹® | â‹® | â‹® | â‹® | â‹® |\n",
       "| 342945 | -0.39294577 |  0.096308836 | -0.26777865 | -0.003399216 | -0.041148565 |  0.08257988 |  0.08671578 | -0.22094886 | -0.22588735 | -0.28616068 | â‹¯ | -0.178795354 | -0.20914143 | -0.1646908853 | -0.01495588 | -0.029144403 |  0.690412486 |  0.09128651 |  0.013489043 | -0.134634221 |  0.119221310 |\n",
       "| 222696 | -0.07896764 |  0.256559940 |  0.53548393 | -1.077633334 | -0.347763031 |  0.06051791 | -0.08824179 |  0.96799885 | -1.20323474 | -0.78240965 | â‹¯ |  0.187451703 | -0.20500992 | -0.3409709978 |  0.56968717 | -0.262422582 | -1.157966151 |  0.92961187 | -0.175632238 |  0.592542651 | -1.305869998 |\n",
       "| 221785 | -0.07410275 |  0.310468830 | -0.52020067 |  0.147978885 | -0.249543264 |  0.27914555 | -0.15915279 |  0.44407197 | -0.32460787 |  0.67977028 | â‹¯ |  0.039696162 | -0.38818506 | -0.3768563963 | -0.02315919 |  0.388894491 |  0.057598233 | -0.22957282 | -0.555731094 | -0.160710100 | -0.427696151 |\n",
       "| 7741 |  0.16242310 | -0.208648160 | -0.86760850 | -0.326618305 | -0.049824697 | -0.56721658 |  0.46012375 | -0.53993221 | -0.03964494 | -0.73673124 | â‹¯ | -0.174276131 |  0.26534046 | -1.2589476332 | -0.01356772 |  0.165900039 | -0.191272435 |  0.07697543 |  0.077322733 | -0.523910072 |  0.351234287 |\n",
       "| 146050 | -0.27147497 | -0.302664855 |  0.06591467 | -0.152672835 | -0.160049443 | -0.10847992 | -0.04025381 |  0.46024624 | -0.20124888 |  0.07894973 | â‹¯ | -0.095310917 | -0.43302860 | -0.6724953769 |  0.17577914 | -0.417197835 |  0.048865450 | -0.42079745 |  0.180282284 | -0.193613714 | -1.044585072 |\n",
       "| 100101467 |  0.12910724 | -0.166620561 |  0.28927637 |  0.073944360 | -0.490339352 | -0.60852126 |  1.33012799 |  0.12608064 |  0.38993901 | -0.27890109 | â‹¯ |  0.265599008 |  0.49555501 | -0.6722087756 | -0.26699014 | -0.123679235 | -0.475728154 | -0.19272112 | -1.073103044 |  0.242644181 | -0.794825133 |\n",
       "| 64288 | -1.02840200 |  0.359290820 |  1.85331112 |  0.818719068 | -1.023331801 | -0.67226726 |  0.54029218 |  0.59971663 | -0.12614354 | -0.48486218 | â‹¯ | -0.007849682 | -1.22117992 | -0.8857645827 |  0.09952779 | -0.068071370 |  0.217354160 |  0.05392430 |  0.079637817 | -0.204035242 | -0.009157544 |\n",
       "| 54925 | -0.83947128 | -0.004984449 |  0.04287005 |  0.170293562 | -0.144611436 |  0.05666641 |  0.02912597 |  0.77800716 | -0.15610934 | -0.29030552 | â‹¯ |  0.083809267 |  0.21760002 | -0.8257328974 | -0.08204672 |  0.004640902 |  0.126605086 |  0.03212684 | -0.429831001 | -0.010845006 | -0.434026241 |\n",
       "| 79149 | -0.36451498 | -0.282897107 |  0.22024346 |  0.240838354 | -0.022385447 | -0.03440686 |  0.02211164 |  0.76406537 | -0.75989309 | -0.06453149 | â‹¯ |  0.294939368 |  0.27671880 | -0.1937818421 | -0.35622686 |  0.481398402 |  0.599227666 |  0.27045953 |  0.309293515 | -0.132427098 | -0.222590252 |\n",
       "| 7746 | -0.00206872 | -0.520789273 | -0.56790558 | -0.164572233 | -0.252870332 | -0.53017798 | -0.02311678 | -0.67609253 |  0.12835082 | -0.40101131 | â‹¯ | -0.384008553 | -0.35158415 | -0.5736452159 | -0.52383119 |  0.153667005 |  0.603364808 | -0.03279160 |  0.228336635 | -0.243975627 |  0.469857667 |\n",
       "| 90204 | -1.14964320 | -0.147744435 | -0.09304375 | -0.369502811 | -0.215164625 |  0.42634586 |  0.43448683 | -0.23477435 |  0.01957181 | -0.51313923 | â‹¯ | -0.343985279 |  0.04973041 | -0.3105190487 |  0.04228306 | -0.111616776 |  0.379118126 |  0.14163935 |  0.384902809 | -0.087591757 | -0.044880902 |\n",
       "| 140831 | -0.00666463 | -0.162000037 | -0.34872188 | -0.038364962 |  0.031084124 | -0.03009380 |  0.53934447 |  0.03553720 | -0.10423836 | -0.34545282 | â‹¯ | -0.242998865 | -0.07201809 | -0.0007784702 |  0.32665021 |  0.169246474 | -0.026439721 |  0.12896315 |  0.145807970 | -0.119736675 | -0.054596189 |\n",
       "| 65249 | -0.38720323 | -0.093166377 | -0.23694355 |  0.100231654 |  0.165662988 | -0.06423251 |  0.97493166 |  0.03873013 | -0.20637817 | -0.21953342 | â‹¯ |  0.583283002 | -0.83624952 |  0.0492035308 | -0.16030035 | -0.761126445 |  0.098385831 |  0.23489732 | -0.560842467 |  0.421292358 |  0.561837969 |\n",
       "| 57643 | -0.01064160 | -0.465813717 |  0.20079688 | -0.085240817 | -0.002401227 | -0.39307241 | -0.27559524 | -0.57942548 |  0.53107017 | -0.20389400 | â‹¯ |  0.463350109 | -0.37742257 | -0.0131313227 |  0.15980244 | -0.330078675 | -0.721802712 | -0.61027707 | -0.433239676 |  0.297839050 | -0.253985786 |\n",
       "| 57688 |  0.19444757 | -0.277799290 | -0.18015048 |  0.667250124 |  0.548716996 | -0.29490229 | -0.11153040 | -0.20611479 | -0.40036983 | -0.57255898 | â‹¯ |  0.329921606 | -0.96986065 |  0.3099456389 | -0.21927048 | -0.016714678 | -0.027766105 |  0.40985529 | -0.006746855 |  0.041948886 |  0.091440517 |\n",
       "| 125150 |  0.95979664 |  0.097384370 | -0.25316554 | -0.238988700 |  0.304486775 |  0.03438547 | -2.04427608 | -0.71663732 |  0.50273247 |  0.45390129 | â‹¯ | -0.958073429 | -0.27029898 |  0.1194006800 | -0.06238310 | -0.683516498 |  1.016254289 |  0.35361223 | -0.088079050 |  0.691974840 | -0.638923716 |\n",
       "| 23053 | -0.13607023 |  0.171724976 |  0.04046160 | -0.194183921 | -0.207473320 |  0.25460964 | -0.44015119 |  0.61839382 |  0.12357510 | -0.28101915 | â‹¯ | -0.861787937 | -0.34138932 | -0.2637888566 |  0.07440251 | -0.392845775 | -0.420510190 | -0.38840345 |  0.194476008 | -0.633980586 | -0.661179112 |\n",
       "| 100507331 | -0.24203460 | -0.124494934 | -0.24203460 | -0.242034603 | -0.242034603 |  0.11690554 | -0.24203460 |  0.28866537 |  0.21692086 | -0.24203460 | â‹¯ | -0.242034603 | -0.24203460 |  0.2670646726 | -0.24203460 |  0.014790405 | -0.002485746 | -0.07627356 |  0.196455240 | -0.242034603 |  0.010426021 |\n",
       "| 221302 |  0.69326584 | -0.071362313 | -0.19068943 | -0.427521968 |  0.550458540 |  0.37559772 | -0.07026790 | -0.03371417 | -0.23804433 | -0.05715200 | â‹¯ |  0.462491077 | -0.07180390 | -0.1259258508 | -0.24241293 |  0.430207997 | -0.084899135 |  0.38791226 | -0.519062960 |  0.002186549 |  0.306981441 |\n",
       "| 9183 | -0.50392570 | -0.258998258 |  0.11535521 | -0.185181954 |  0.396080431 | -0.09233644 | -0.19261525 |  0.02280537 | -0.39436320 | -0.29743124 | â‹¯ |  0.467873073 | -0.50126227 |  0.1511000508 | -0.12861326 |  0.301007503 |  0.042471843 |  0.42301333 |  0.069997069 | -0.208229171 | -0.155087675 |\n",
       "| 55055 | -0.51800739 | -0.777894079 | -0.32027729 |  0.565210576 |  0.334335123 | -0.23997050 |  1.41658928 |  0.33614144 | -0.43369412 |  0.63079954 | â‹¯ |  0.492820836 |  0.45022427 | -0.3112274005 |  0.21330995 | -0.513242871 |  0.466551049 | -0.13648162 | -0.338087624 |  0.249057137 |  0.867817473 |\n",
       "| 11130 | -0.62215237 |  0.478047773 | -0.86643923 |  0.374102143 |  0.873875033 |  0.20676718 |  0.06242660 | -0.17613154 |  1.13091160 |  1.03166565 | â‹¯ |  0.097252152 | -0.65085397 |  0.3316220752 |  0.53110123 | -0.118791410 |  0.548726697 |  0.38776064 |  0.164356651 |  0.069003376 |  1.328808019 |\n",
       "| 7789 |  0.22747089 |  0.323184074 |  0.15631043 | -0.117003751 |  0.359357971 | -0.17908868 | -1.42470143 | -0.36559417 | -0.27771088 |  0.01034329 | â‹¯ | -0.091538589 |  0.04578399 | -0.6211025988 | -0.64730355 | -0.589203198 | -0.340982084 | -0.77864076 | -0.394253124 | -0.403180937 |  0.228809433 |\n",
       "| 158586 | -0.22274651 |  0.077719635 | -0.18119199 |  0.323917763 |  0.612691509 | -0.14261207 | -0.24798209 | -0.75921926 | -0.12975976 |  0.13307078 | â‹¯ | -0.234891836 | -0.24236341 | -0.0978002512 | -0.54270486 | -0.171341938 |  0.132527627 | -0.07954015 |  0.011956714 |  0.088811412 |  0.189385304 |\n",
       "| 79364 | -0.31517698 | -0.135534837 |  0.11321388 | -0.140344557 | -0.445200566 | -0.10593877 | -0.11521950 |  0.41185003 | -0.06003260 | -0.06398976 | â‹¯ | -0.386671757 |  0.44765703 | -0.2266679192 |  0.10962948 | -0.082831527 | -0.530266017 | -0.27904401 | -0.173219621 |  0.504679141 | -0.040919069 |\n",
       "| 440590 |  0.02419371 | -0.149946066 |  0.25268109 | -0.189932683 | -0.125614127 | -0.10368129 |  1.03268700 | -0.11559656 | -0.12662805 | -0.11879850 | â‹¯ | -0.174289645 | -0.18958255 |  0.2600903669 | -0.16842562 | -0.111939726 | -0.189932683 | -0.18993268 | -0.136040572 | -0.186795252 |  0.705853569 |\n",
       "| 79699 | -0.35364727 |  0.251256278 | -0.40650049 |  0.402207088 |  0.150676605 | -0.42023214 |  0.46235717 | -0.05134074 | -0.13856663 |  0.13974445 | â‹¯ |  0.101051639 | -0.28079830 | -0.0513407417 |  0.34721238 | -0.863812255 | -0.088285115 |  0.35310596 | -0.363313462 |  0.279728853 |  0.197300128 |\n",
       "| 7791 |  0.91660440 |  0.468444252 | -0.12853882 |  0.768776526 |  0.563966735 |  0.48732913 |  0.57172041 | -0.26650284 | -1.21787913 |  0.05403603 | â‹¯ |  0.216502940 | -0.26692534 |  0.5937474997 |  0.10479040 |  0.167516338 | -0.150368204 |  0.09664086 | -0.469149675 |  1.324224649 | -0.433947225 |\n",
       "| 23140 | -0.36565228 |  0.202778225 |  0.79860248 | -0.193560502 |  0.006282023 |  0.18718332 | -0.68741730 | -0.30519406 | -0.20991515 | -0.10143972 | â‹¯ | -0.434137380 |  0.41458369 | -0.1535201829 | -0.49286569 | -0.493717489 | -0.062418433 | -0.49286569 |  0.105545635 |  0.624400137 | -0.979660281 |\n",
       "| 26009 | -0.28997347 |  0.125021499 | -0.02921499 |  0.201748892 | -0.239514994 | -0.19190377 |  1.00008741 | -0.84401986 |  0.08612588 | -0.25613537 | â‹¯ |  0.888723568 |  0.49895492 |  0.2160336185 |  0.14336281 | -0.041202772 |  0.022793456 | -0.31798122 | -0.365189237 | -0.229886863 | -0.328878046 |\n",
       "\n"
      ],
      "text/plain": [
       "          9           3            35          18           7           \n",
       "1         -1.58231886  0.41362108  -1.22017300  0.075095675  0.05888384 \n",
       "503538     0.22612657  0.02686424  -0.46544478 -0.176204605 -0.70208641 \n",
       "2          1.66568079 -0.63666687  -0.17419729 -0.326858659  0.47458381 \n",
       "144571     0.41620526 -0.52085278  -0.15142775 -0.301583681  0.11572232 \n",
       "144568    -0.81472165  3.15369407   2.88161537 -1.017703568 -1.01770357 \n",
       "53947      0.75217226 -0.35293797  -0.39829659 -0.457284541 -0.81206319 \n",
       "8086       0.48742979  0.21737047   0.11733274  0.244340206 -0.52053759 \n",
       "65985     -0.11137395  0.94451945   0.86124177  0.374050600 -0.83866229 \n",
       "13         2.28027252  1.21879050  -0.15999967 -0.387926308 -0.15818095 \n",
       "51166      0.07411433  0.40828556  -0.42778929  0.498749883  0.25237782 \n",
       "195827    -0.15622431 -0.78312785  -0.59006520  0.551936365  0.67649007 \n",
       "79719     -0.16976131 -0.22447172  -0.22749895  0.534682617  0.12373455 \n",
       "22848     -0.46017301 -0.29121717   0.21594748  0.326251447  0.25445216 \n",
       "28971     -0.48638879 -0.21824053  -1.17608636 -0.231041671  0.09737793 \n",
       "14        -0.65785204  0.71096814  -0.33834631  0.854973969  0.16286874 \n",
       "25980     -0.78707497 -0.32964982  -0.95395678  0.045168229 -0.40703090 \n",
       "441376     0.17069129 -0.39929260  -0.39929260 -0.275296321 -0.04612832 \n",
       "16        -0.29852934 -0.25603742  -0.32059161  0.794134979 -0.05356968 \n",
       "57505     -0.96633877  0.05055959  -0.27581646 -1.116953635 -0.11914141 \n",
       "80755      0.48769170  0.03067254  -0.75952377 -0.108241457 -0.55017112 \n",
       "132949     0.86332423 -0.06173112   0.44876646 -0.946300713 -0.33610057 \n",
       "60496     -0.52066005 -0.83259409  -0.90452187  0.007721265  0.34966399 \n",
       "10157     -0.28107565 -0.11313725  -0.19382979  0.138589209 -1.27446539 \n",
       "26574     -0.36949241  0.09586981  -0.08007427  0.305067084  0.31037075 \n",
       "9625       1.33596224 -0.64153963  -0.76434337  2.813354136  0.36940161 \n",
       "18        -1.34884806 -1.22335298   0.19324014  0.749346603  0.05016278 \n",
       "19         0.57062632 -0.62202917   0.06079913  0.053167363  0.84822211 \n",
       "10349      0.76894096 -0.28041801   0.18591823 -1.140640744 -0.57503604 \n",
       "79963     -0.09047424  0.07728631   0.31389312 -0.736425825  0.45394367 \n",
       "26154     -1.16538393  3.15509099   4.98314606 -1.353532409 -1.37951032 \n",
       "â‹®         â‹®           â‹®            â‹®           â‹®            â‹®           \n",
       "342945    -0.39294577  0.096308836 -0.26777865 -0.003399216 -0.041148565\n",
       "222696    -0.07896764  0.256559940  0.53548393 -1.077633334 -0.347763031\n",
       "221785    -0.07410275  0.310468830 -0.52020067  0.147978885 -0.249543264\n",
       "7741       0.16242310 -0.208648160 -0.86760850 -0.326618305 -0.049824697\n",
       "146050    -0.27147497 -0.302664855  0.06591467 -0.152672835 -0.160049443\n",
       "100101467  0.12910724 -0.166620561  0.28927637  0.073944360 -0.490339352\n",
       "64288     -1.02840200  0.359290820  1.85331112  0.818719068 -1.023331801\n",
       "54925     -0.83947128 -0.004984449  0.04287005  0.170293562 -0.144611436\n",
       "79149     -0.36451498 -0.282897107  0.22024346  0.240838354 -0.022385447\n",
       "7746      -0.00206872 -0.520789273 -0.56790558 -0.164572233 -0.252870332\n",
       "90204     -1.14964320 -0.147744435 -0.09304375 -0.369502811 -0.215164625\n",
       "140831    -0.00666463 -0.162000037 -0.34872188 -0.038364962  0.031084124\n",
       "65249     -0.38720323 -0.093166377 -0.23694355  0.100231654  0.165662988\n",
       "57643     -0.01064160 -0.465813717  0.20079688 -0.085240817 -0.002401227\n",
       "57688      0.19444757 -0.277799290 -0.18015048  0.667250124  0.548716996\n",
       "125150     0.95979664  0.097384370 -0.25316554 -0.238988700  0.304486775\n",
       "23053     -0.13607023  0.171724976  0.04046160 -0.194183921 -0.207473320\n",
       "100507331 -0.24203460 -0.124494934 -0.24203460 -0.242034603 -0.242034603\n",
       "221302     0.69326584 -0.071362313 -0.19068943 -0.427521968  0.550458540\n",
       "9183      -0.50392570 -0.258998258  0.11535521 -0.185181954  0.396080431\n",
       "55055     -0.51800739 -0.777894079 -0.32027729  0.565210576  0.334335123\n",
       "11130     -0.62215237  0.478047773 -0.86643923  0.374102143  0.873875033\n",
       "7789       0.22747089  0.323184074  0.15631043 -0.117003751  0.359357971\n",
       "158586    -0.22274651  0.077719635 -0.18119199  0.323917763  0.612691509\n",
       "79364     -0.31517698 -0.135534837  0.11321388 -0.140344557 -0.445200566\n",
       "440590     0.02419371 -0.149946066  0.25268109 -0.189932683 -0.125614127\n",
       "79699     -0.35364727  0.251256278 -0.40650049  0.402207088  0.150676605\n",
       "7791       0.91660440  0.468444252 -0.12853882  0.768776526  0.563966735\n",
       "23140     -0.36565228  0.202778225  0.79860248 -0.193560502  0.006282023\n",
       "26009     -0.28997347  0.125021499 -0.02921499  0.201748892 -0.239514994\n",
       "          48           30          14          13          46           â‹¯\n",
       "1         -0.662010151  0.42966948 -0.11535008  0.67577556  0.513876358 â‹¯\n",
       "503538    -0.458452942 -0.84484596 -0.18471088 -0.48203131  0.005365473 â‹¯\n",
       "2         -1.241568243 -0.98130509 -0.45533603 -1.63309646 -0.610543313 â‹¯\n",
       "144571     0.546215021 -0.55657029  0.11802313  0.49090024  0.145104377 â‹¯\n",
       "144568    -0.988625504 -1.01770357  3.30190882  2.39125358  0.024950337 â‹¯\n",
       "53947     -0.235179430  0.20997399 -0.45430870 -0.79193292 -0.032976780 â‹¯\n",
       "8086      -0.209526830 -1.27586077  0.24283611 -0.07076524  0.042689150 â‹¯\n",
       "65985      0.739460281 -0.63456805  0.10825169  0.60201350  0.292313400 â‹¯\n",
       "13        -0.387926308 -0.38792631 -0.38792631  0.49829857  0.279778470 â‹¯\n",
       "51166      0.483951204 -0.36446250 -0.77588290  0.51513916 -0.567818972 â‹¯\n",
       "195827     0.002704479  2.07968485 -0.98986906  0.23131085  0.234997541 â‹¯\n",
       "79719     -0.110848158 -0.23184604 -0.01083574  0.27340130  0.243176297 â‹¯\n",
       "22848     -0.026024129  0.30164170 -0.05457508 -0.85703852 -0.327565362 â‹¯\n",
       "28971     -0.208717060 -0.03902958 -1.54787646 -0.26017828 -0.081992985 â‹¯\n",
       "14         0.252956602 -0.70442039 -0.11893037  0.19064217  0.504712351 â‹¯\n",
       "25980      0.743494230 -0.97246165  0.08247697 -0.13492104  0.155322460 â‹¯\n",
       "441376    -0.399292598  0.32547599 -0.39929260  0.08184085 -0.302149654 â‹¯\n",
       "16        -0.090494599  1.13564450  0.68170751 -0.40844636  0.250835705 â‹¯\n",
       "57505      0.339404995 -0.58047375  0.73854765 -0.19135946  0.190814401 â‹¯\n",
       "80755      0.027737771 -0.27220937 -0.04731449  0.03021470  0.245068451 â‹¯\n",
       "132949     0.350492560 -1.67205617 -0.15645411  0.14392756 -0.468626608 â‹¯\n",
       "60496      0.072953185  1.08434100  0.49852088 -0.47817360  0.035106906 â‹¯\n",
       "10157      0.040623811 -0.90281200  1.08500532  0.54223586  0.373594229 â‹¯\n",
       "26574      0.219291256 -0.38057925  0.21194798 -0.02866318  0.340586441 â‹¯\n",
       "9625      -0.359284895 -0.61628550 -0.22869959 -0.11397219  0.024823023 â‹¯\n",
       "18        -0.081464081 -1.46347567  1.15016654  1.44516632 -0.394611391 â‹¯\n",
       "19         0.109128273  0.28281056 -0.62430545 -1.30694301 -0.179727567 â‹¯\n",
       "10349     -1.121317065 -1.25531169 -1.07364413 -0.98652452 -0.059129827 â‹¯\n",
       "79963     -0.177660722 -0.23023263 -0.39486568  0.17138151  0.300319076 â‹¯\n",
       "26154     -1.170400887  0.15566811  0.44696954  1.74485005  1.937359390 â‹¯\n",
       "â‹®         â‹®            â‹®           â‹®           â‹®           â‹®            â‹±\n",
       "342945     0.08257988   0.08671578 -0.22094886 -0.22588735 -0.28616068  â‹¯\n",
       "222696     0.06051791  -0.08824179  0.96799885 -1.20323474 -0.78240965  â‹¯\n",
       "221785     0.27914555  -0.15915279  0.44407197 -0.32460787  0.67977028  â‹¯\n",
       "7741      -0.56721658   0.46012375 -0.53993221 -0.03964494 -0.73673124  â‹¯\n",
       "146050    -0.10847992  -0.04025381  0.46024624 -0.20124888  0.07894973  â‹¯\n",
       "100101467 -0.60852126   1.33012799  0.12608064  0.38993901 -0.27890109  â‹¯\n",
       "64288     -0.67226726   0.54029218  0.59971663 -0.12614354 -0.48486218  â‹¯\n",
       "54925      0.05666641   0.02912597  0.77800716 -0.15610934 -0.29030552  â‹¯\n",
       "79149     -0.03440686   0.02211164  0.76406537 -0.75989309 -0.06453149  â‹¯\n",
       "7746      -0.53017798  -0.02311678 -0.67609253  0.12835082 -0.40101131  â‹¯\n",
       "90204      0.42634586   0.43448683 -0.23477435  0.01957181 -0.51313923  â‹¯\n",
       "140831    -0.03009380   0.53934447  0.03553720 -0.10423836 -0.34545282  â‹¯\n",
       "65249     -0.06423251   0.97493166  0.03873013 -0.20637817 -0.21953342  â‹¯\n",
       "57643     -0.39307241  -0.27559524 -0.57942548  0.53107017 -0.20389400  â‹¯\n",
       "57688     -0.29490229  -0.11153040 -0.20611479 -0.40036983 -0.57255898  â‹¯\n",
       "125150     0.03438547  -2.04427608 -0.71663732  0.50273247  0.45390129  â‹¯\n",
       "23053      0.25460964  -0.44015119  0.61839382  0.12357510 -0.28101915  â‹¯\n",
       "100507331  0.11690554  -0.24203460  0.28866537  0.21692086 -0.24203460  â‹¯\n",
       "221302     0.37559772  -0.07026790 -0.03371417 -0.23804433 -0.05715200  â‹¯\n",
       "9183      -0.09233644  -0.19261525  0.02280537 -0.39436320 -0.29743124  â‹¯\n",
       "55055     -0.23997050   1.41658928  0.33614144 -0.43369412  0.63079954  â‹¯\n",
       "11130      0.20676718   0.06242660 -0.17613154  1.13091160  1.03166565  â‹¯\n",
       "7789      -0.17908868  -1.42470143 -0.36559417 -0.27771088  0.01034329  â‹¯\n",
       "158586    -0.14261207  -0.24798209 -0.75921926 -0.12975976  0.13307078  â‹¯\n",
       "79364     -0.10593877  -0.11521950  0.41185003 -0.06003260 -0.06398976  â‹¯\n",
       "440590    -0.10368129   1.03268700 -0.11559656 -0.12662805 -0.11879850  â‹¯\n",
       "79699     -0.42023214   0.46235717 -0.05134074 -0.13856663  0.13974445  â‹¯\n",
       "7791       0.48732913   0.57172041 -0.26650284 -1.21787913  0.05403603  â‹¯\n",
       "23140      0.18718332  -0.68741730 -0.30519406 -0.20991515 -0.10143972  â‹¯\n",
       "26009     -0.19190377   1.00008741 -0.84401986  0.08612588 -0.25613537  â‹¯\n",
       "          50           4           40            25           52          \n",
       "1         -0.92372234  -0.91234682 -0.19708134    0.718437503  0.25690495 \n",
       "503538    -0.02059807  -1.08931032  0.28315354   -0.047598322  0.19613082 \n",
       "2         -1.26427983   0.23970161  1.18647523    0.737057442 -1.81640023 \n",
       "144571    -0.11756944   0.20399209  0.39210061    0.253308910 -0.43541291 \n",
       "144568    -0.96750137   0.53103697 -1.01770357    0.481178167 -1.01770357 \n",
       "53947      1.09366423   0.76756632  0.17559646   -0.011900328 -0.59484600 \n",
       "8086      -0.36088541  -0.15312547 -0.28569714    0.121104364  0.55932299 \n",
       "65985     -1.32322790  -0.21753685 -0.05100234    0.273182689 -0.45761784 \n",
       "13         1.36663079   0.38520734 -0.38792631   -0.082744787 -0.17048984 \n",
       "51166      0.22049161  -0.64948469 -0.02668299   -0.063968115 -1.37391267 \n",
       "195827     0.23435838   0.61337288  0.07559452   -0.041484582 -1.08635043 \n",
       "79719      0.56435072  -0.12728530  0.01733162   -0.251213399  0.53918913 \n",
       "22848      0.41537062   0.20026864  0.39486466   -0.064217165 -0.14424554 \n",
       "28971     -0.31408441   0.02798369 -0.96179339   -0.002690759 -0.07200012 \n",
       "14         0.12815124  -0.48746042 -0.33896029    0.555516426  0.45480429 \n",
       "25980      0.39814979  -1.12073787 -0.77615949    0.287138265  0.28906247 \n",
       "441376     0.25473658  -0.28207724 -0.39929260   -0.197240187 -0.15507086 \n",
       "16         0.59019100  -0.86965064  0.56005477   -0.288958537  0.98258352 \n",
       "57505     -0.38099883  -0.31885272 -0.35588020    0.117412713  0.42701335 \n",
       "80755      0.66515244  -0.99256546  0.06394071    0.322414374  0.78806025 \n",
       "132949    -0.60969240  -0.77181384  0.76987189   -0.125153194 -0.04695216 \n",
       "60496     -0.26016705   0.94000318 -0.59660687    0.239252511  0.66599271 \n",
       "10157     -0.43716549  -0.56186282 -0.40903938    0.694874411  0.48684804 \n",
       "26574      1.05987638  -0.95376429 -0.07585459    0.367789073  0.08194599 \n",
       "9625       2.36858681  -0.93226101 -0.02532996   -0.552781114  0.02734172 \n",
       "18         0.23292362  -0.34922853  1.15692495    0.338521821  0.25730823 \n",
       "19        -0.10482467   0.90796692  1.04065385   -0.275747047  0.18227452 \n",
       "10349     -0.05785176   1.25167870  0.34050201   -1.098587752 -0.65226049 \n",
       "79963     -0.27733364   0.54842656  0.14685390   -0.320077364 -0.15694583 \n",
       "26154     -1.36386728   1.51554187 -1.18750135    0.911097223 -0.71180554 \n",
       "â‹®         â‹®            â‹®           â‹®             â‹®            â‹®           \n",
       "342945    -0.178795354 -0.20914143 -0.1646908853 -0.01495588  -0.029144403\n",
       "222696     0.187451703 -0.20500992 -0.3409709978  0.56968717  -0.262422582\n",
       "221785     0.039696162 -0.38818506 -0.3768563963 -0.02315919   0.388894491\n",
       "7741      -0.174276131  0.26534046 -1.2589476332 -0.01356772   0.165900039\n",
       "146050    -0.095310917 -0.43302860 -0.6724953769  0.17577914  -0.417197835\n",
       "100101467  0.265599008  0.49555501 -0.6722087756 -0.26699014  -0.123679235\n",
       "64288     -0.007849682 -1.22117992 -0.8857645827  0.09952779  -0.068071370\n",
       "54925      0.083809267  0.21760002 -0.8257328974 -0.08204672   0.004640902\n",
       "79149      0.294939368  0.27671880 -0.1937818421 -0.35622686   0.481398402\n",
       "7746      -0.384008553 -0.35158415 -0.5736452159 -0.52383119   0.153667005\n",
       "90204     -0.343985279  0.04973041 -0.3105190487  0.04228306  -0.111616776\n",
       "140831    -0.242998865 -0.07201809 -0.0007784702  0.32665021   0.169246474\n",
       "65249      0.583283002 -0.83624952  0.0492035308 -0.16030035  -0.761126445\n",
       "57643      0.463350109 -0.37742257 -0.0131313227  0.15980244  -0.330078675\n",
       "57688      0.329921606 -0.96986065  0.3099456389 -0.21927048  -0.016714678\n",
       "125150    -0.958073429 -0.27029898  0.1194006800 -0.06238310  -0.683516498\n",
       "23053     -0.861787937 -0.34138932 -0.2637888566  0.07440251  -0.392845775\n",
       "100507331 -0.242034603 -0.24203460  0.2670646726 -0.24203460   0.014790405\n",
       "221302     0.462491077 -0.07180390 -0.1259258508 -0.24241293   0.430207997\n",
       "9183       0.467873073 -0.50126227  0.1511000508 -0.12861326   0.301007503\n",
       "55055      0.492820836  0.45022427 -0.3112274005  0.21330995  -0.513242871\n",
       "11130      0.097252152 -0.65085397  0.3316220752  0.53110123  -0.118791410\n",
       "7789      -0.091538589  0.04578399 -0.6211025988 -0.64730355  -0.589203198\n",
       "158586    -0.234891836 -0.24236341 -0.0978002512 -0.54270486  -0.171341938\n",
       "79364     -0.386671757  0.44765703 -0.2266679192  0.10962948  -0.082831527\n",
       "440590    -0.174289645 -0.18958255  0.2600903669 -0.16842562  -0.111939726\n",
       "79699      0.101051639 -0.28079830 -0.0513407417  0.34721238  -0.863812255\n",
       "7791       0.216502940 -0.26692534  0.5937474997  0.10479040   0.167516338\n",
       "23140     -0.434137380  0.41458369 -0.1535201829 -0.49286569  -0.493717489\n",
       "26009      0.888723568  0.49895492  0.2160336185  0.14336281  -0.041202772\n",
       "          19           41          34           23           54          \n",
       "1          0.83904346  -0.40860109  1.44645031   0.04754928   0.473103225\n",
       "503538     0.40829813  -0.04866972  0.32854358  -0.66091660  -0.195425198\n",
       "2         -0.25034316   2.96944712  0.32667241   2.03186221  -0.355766075\n",
       "144571    -0.58517654  -0.89701142 -0.30074905  -0.50093196  -0.515324225\n",
       "144568     1.40950498  -1.01770357 -1.01770357  -1.01770357  -1.017703568\n",
       "53947     -0.81832864  -0.70901232 -0.77721338   0.29027153  -1.092249883\n",
       "8086       0.28172048  -0.66782403 -0.76282357   0.12643972  -0.171057793\n",
       "65985     -0.03626696   0.41864303  0.19990466   0.75946942  -0.252467977\n",
       "13        -0.29837480  -0.38792631 -0.36056831  -0.33097686  -0.204260693\n",
       "51166      0.22347496   0.04092749 -0.14311666  -0.05786118  -0.416186634\n",
       "195827     0.45579427  -0.53358223 -0.01506003  -0.25253726  -0.197310382\n",
       "79719      0.28851319  -0.22284338 -0.03750106   0.45867577   0.200807668\n",
       "22848     -0.79530881   0.05579869  0.28014132   0.09369848  -0.301176142\n",
       "28971      0.03923363   0.58644076 -0.86111829   0.24225485   1.931549639\n",
       "14         0.32689198   0.33728202 -0.31787005   0.66394344   0.488121780\n",
       "25980      0.44357998   0.03860262  0.79306882   0.24078442   0.018539172\n",
       "441376     1.22369793  -0.39929260 -0.39929260   0.79279905  -0.366114299\n",
       "16        -0.03887593   0.22293528  0.31553218  -0.65155946  -0.009516557\n",
       "57505      0.66773792  -0.11955801  0.01002852  -0.38868035   0.460412600\n",
       "80755      0.32029527  -0.35662562 -0.59348610  -0.05527100   0.382764203\n",
       "132949    -0.50405529   0.24828407  0.32803017  -0.46622640  -0.150818256\n",
       "60496      0.31312698   0.61389364 -0.02754601   0.07727379   0.050452719\n",
       "10157      0.28716461  -0.25439021 -0.79120250   0.08412152  -0.151727888\n",
       "26574      0.70871374   0.31888482 -0.63148827  -0.69475016   0.637940467\n",
       "9625      -1.16950265  -1.04696869 -0.36775984  -0.17492891   1.134896901\n",
       "18        -1.01733786  -0.81613792 -0.77483279  -0.16228471  -0.616790030\n",
       "19        -0.99483322  -0.34180255  0.02461895   0.13689279  -0.486670325\n",
       "10349     -1.79959384  -0.79578118 -1.39103008  -1.00275071   1.047646825\n",
       "79963      0.13253828  -0.90280482 -0.54179962  -0.51918678  -0.870386578\n",
       "26154      0.88865516  -1.26938294 -1.24849157  -1.29689731  -1.057288203\n",
       "â‹®         â‹®            â‹®           â‹®            â‹®            â‹®           \n",
       "342945     0.690412486  0.09128651  0.013489043 -0.134634221  0.119221310\n",
       "222696    -1.157966151  0.92961187 -0.175632238  0.592542651 -1.305869998\n",
       "221785     0.057598233 -0.22957282 -0.555731094 -0.160710100 -0.427696151\n",
       "7741      -0.191272435  0.07697543  0.077322733 -0.523910072  0.351234287\n",
       "146050     0.048865450 -0.42079745  0.180282284 -0.193613714 -1.044585072\n",
       "100101467 -0.475728154 -0.19272112 -1.073103044  0.242644181 -0.794825133\n",
       "64288      0.217354160  0.05392430  0.079637817 -0.204035242 -0.009157544\n",
       "54925      0.126605086  0.03212684 -0.429831001 -0.010845006 -0.434026241\n",
       "79149      0.599227666  0.27045953  0.309293515 -0.132427098 -0.222590252\n",
       "7746       0.603364808 -0.03279160  0.228336635 -0.243975627  0.469857667\n",
       "90204      0.379118126  0.14163935  0.384902809 -0.087591757 -0.044880902\n",
       "140831    -0.026439721  0.12896315  0.145807970 -0.119736675 -0.054596189\n",
       "65249      0.098385831  0.23489732 -0.560842467  0.421292358  0.561837969\n",
       "57643     -0.721802712 -0.61027707 -0.433239676  0.297839050 -0.253985786\n",
       "57688     -0.027766105  0.40985529 -0.006746855  0.041948886  0.091440517\n",
       "125150     1.016254289  0.35361223 -0.088079050  0.691974840 -0.638923716\n",
       "23053     -0.420510190 -0.38840345  0.194476008 -0.633980586 -0.661179112\n",
       "100507331 -0.002485746 -0.07627356  0.196455240 -0.242034603  0.010426021\n",
       "221302    -0.084899135  0.38791226 -0.519062960  0.002186549  0.306981441\n",
       "9183       0.042471843  0.42301333  0.069997069 -0.208229171 -0.155087675\n",
       "55055      0.466551049 -0.13648162 -0.338087624  0.249057137  0.867817473\n",
       "11130      0.548726697  0.38776064  0.164356651  0.069003376  1.328808019\n",
       "7789      -0.340982084 -0.77864076 -0.394253124 -0.403180937  0.228809433\n",
       "158586     0.132527627 -0.07954015  0.011956714  0.088811412  0.189385304\n",
       "79364     -0.530266017 -0.27904401 -0.173219621  0.504679141 -0.040919069\n",
       "440590    -0.189932683 -0.18993268 -0.136040572 -0.186795252  0.705853569\n",
       "79699     -0.088285115  0.35310596 -0.363313462  0.279728853  0.197300128\n",
       "7791      -0.150368204  0.09664086 -0.469149675  1.324224649 -0.433947225\n",
       "23140     -0.062418433 -0.49286569  0.105545635  0.624400137 -0.979660281\n",
       "26009      0.022793456 -0.31798122 -0.365189237 -0.229886863 -0.328878046"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "pn_self_subtract"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "ff1bde57",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table>\n",
       "<caption>A data.frame: 41 Ã— 18570</caption>\n",
       "<thead>\n",
       "\t<tr><th></th><th scope=col>1</th><th scope=col>503538</th><th scope=col>2</th><th scope=col>144571</th><th scope=col>144568</th><th scope=col>53947</th><th scope=col>8086</th><th scope=col>65985</th><th scope=col>13</th><th scope=col>51166</th><th scope=col>â‹¯</th><th scope=col>55055</th><th scope=col>11130</th><th scope=col>7789</th><th scope=col>158586</th><th scope=col>79364</th><th scope=col>440590</th><th scope=col>79699</th><th scope=col>7791</th><th scope=col>23140</th><th scope=col>26009</th></tr>\n",
       "\t<tr><th></th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>â‹¯</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><th scope=row>9</th><td>-1.58231886</td><td> 0.226126567</td><td> 1.66568079</td><td> 0.416205261</td><td>-0.81472165</td><td> 0.752172262</td><td> 0.487429786</td><td>-0.11137395</td><td> 2.28027252</td><td> 0.074114330</td><td>â‹¯</td><td>-0.51800739</td><td>-0.62215237</td><td> 0.2274708862</td><td>-0.22274651</td><td>-0.31517698</td><td> 0.02419371</td><td>-0.35364727</td><td> 0.91660440</td><td>-0.365652282</td><td>-0.28997347</td></tr>\n",
       "\t<tr><th scope=row>3</th><td> 0.41362108</td><td> 0.026864237</td><td>-0.63666687</td><td>-0.520852783</td><td> 3.15369407</td><td>-0.352937973</td><td> 0.217370469</td><td> 0.94451945</td><td> 1.21879050</td><td> 0.408285561</td><td>â‹¯</td><td>-0.77789408</td><td> 0.47804777</td><td> 0.3231840744</td><td> 0.07771963</td><td>-0.13553484</td><td>-0.14994607</td><td> 0.25125628</td><td> 0.46844425</td><td> 0.202778225</td><td> 0.12502150</td></tr>\n",
       "\t<tr><th scope=row>35</th><td>-1.22017300</td><td>-0.465444781</td><td>-0.17419729</td><td>-0.151427753</td><td> 2.88161537</td><td>-0.398296587</td><td> 0.117332737</td><td> 0.86124177</td><td>-0.15999967</td><td>-0.427789287</td><td>â‹¯</td><td>-0.32027729</td><td>-0.86643923</td><td> 0.1563104344</td><td>-0.18119199</td><td> 0.11321388</td><td> 0.25268109</td><td>-0.40650049</td><td>-0.12853882</td><td> 0.798602483</td><td>-0.02921499</td></tr>\n",
       "\t<tr><th scope=row>18</th><td> 0.07509568</td><td>-0.176204605</td><td>-0.32685866</td><td>-0.301583681</td><td>-1.01770357</td><td>-0.457284541</td><td> 0.244340206</td><td> 0.37405060</td><td>-0.38792631</td><td> 0.498749883</td><td>â‹¯</td><td> 0.56521058</td><td> 0.37410214</td><td>-0.1170037510</td><td> 0.32391776</td><td>-0.14034456</td><td>-0.18993268</td><td> 0.40220709</td><td> 0.76877653</td><td>-0.193560502</td><td> 0.20174889</td></tr>\n",
       "\t<tr><th scope=row>7</th><td> 0.05888384</td><td>-0.702086411</td><td> 0.47458381</td><td> 0.115722317</td><td>-1.01770357</td><td>-0.812063186</td><td>-0.520537587</td><td>-0.83866229</td><td>-0.15818095</td><td> 0.252377818</td><td>â‹¯</td><td> 0.33433512</td><td> 0.87387503</td><td> 0.3593579706</td><td> 0.61269151</td><td>-0.44520057</td><td>-0.12561413</td><td> 0.15067660</td><td> 0.56396673</td><td> 0.006282023</td><td>-0.23951499</td></tr>\n",
       "\t<tr><th scope=row>48</th><td>-0.66201015</td><td>-0.458452942</td><td>-1.24156824</td><td> 0.546215021</td><td>-0.98862550</td><td>-0.235179430</td><td>-0.209526830</td><td> 0.73946028</td><td>-0.38792631</td><td> 0.483951204</td><td>â‹¯</td><td>-0.23997050</td><td> 0.20676718</td><td>-0.1790886828</td><td>-0.14261207</td><td>-0.10593877</td><td>-0.10368129</td><td>-0.42023214</td><td> 0.48732913</td><td> 0.187183322</td><td>-0.19190377</td></tr>\n",
       "\t<tr><th scope=row>30</th><td> 0.42966948</td><td>-0.844845961</td><td>-0.98130509</td><td>-0.556570291</td><td>-1.01770357</td><td> 0.209973995</td><td>-1.275860765</td><td>-0.63456805</td><td>-0.38792631</td><td>-0.364462502</td><td>â‹¯</td><td> 1.41658928</td><td> 0.06242660</td><td>-1.4247014274</td><td>-0.24798209</td><td>-0.11521950</td><td> 1.03268700</td><td> 0.46235717</td><td> 0.57172041</td><td>-0.687417296</td><td> 1.00008741</td></tr>\n",
       "\t<tr><th scope=row>14</th><td>-0.11535008</td><td>-0.184710883</td><td>-0.45533603</td><td> 0.118023126</td><td> 3.30190882</td><td>-0.454308700</td><td> 0.242836107</td><td> 0.10825169</td><td>-0.38792631</td><td>-0.775882897</td><td>â‹¯</td><td> 0.33614144</td><td>-0.17613154</td><td>-0.3655941746</td><td>-0.75921926</td><td> 0.41185003</td><td>-0.11559656</td><td>-0.05134074</td><td>-0.26650284</td><td>-0.305194059</td><td>-0.84401986</td></tr>\n",
       "\t<tr><th scope=row>13</th><td> 0.67577556</td><td>-0.482031312</td><td>-1.63309646</td><td> 0.490900241</td><td> 2.39125358</td><td>-0.791932925</td><td>-0.070765240</td><td> 0.60201350</td><td> 0.49829857</td><td> 0.515139163</td><td>â‹¯</td><td>-0.43369412</td><td> 1.13091160</td><td>-0.2777108820</td><td>-0.12975976</td><td>-0.06003260</td><td>-0.12662805</td><td>-0.13856663</td><td>-1.21787913</td><td>-0.209915150</td><td> 0.08612588</td></tr>\n",
       "\t<tr><th scope=row>46</th><td> 0.51387636</td><td> 0.005365473</td><td>-0.61054331</td><td> 0.145104377</td><td> 0.02495034</td><td>-0.032976780</td><td> 0.042689150</td><td> 0.29231340</td><td> 0.27977847</td><td>-0.567818972</td><td>â‹¯</td><td> 0.63079954</td><td> 1.03166565</td><td> 0.0103432872</td><td> 0.13307078</td><td>-0.06398976</td><td>-0.11879850</td><td> 0.13974445</td><td> 0.05403603</td><td>-0.101439718</td><td>-0.25613537</td></tr>\n",
       "\t<tr><th scope=row>45</th><td>-0.40772895</td><td> 1.033369372</td><td> 0.22458031</td><td> 1.535996269</td><td>-0.38789368</td><td>-0.080393783</td><td> 0.175954760</td><td>-0.65267896</td><td>-0.38792631</td><td>-0.887038183</td><td>â‹¯</td><td>-1.07644884</td><td>-0.45707750</td><td> 0.6808349316</td><td> 0.03664372</td><td> 0.34213037</td><td>-0.12595742</td><td> 0.27241290</td><td>-0.16797709</td><td> 0.400421450</td><td> 0.32499011</td></tr>\n",
       "\t<tr><th scope=row>11</th><td>-1.16982847</td><td>-0.682889907</td><td>-0.82723364</td><td>-0.446609752</td><td> 4.97014346</td><td> 1.267812028</td><td>-0.159704812</td><td> 2.30227398</td><td> 1.17731337</td><td>-0.784427694</td><td>â‹¯</td><td>-0.77856996</td><td>-1.01200334</td><td> 0.0005757279</td><td>-0.41480345</td><td> 0.05113678</td><td> 0.09727642</td><td>-0.16385787</td><td>-0.24692816</td><td> 0.117103894</td><td>-0.74993078</td></tr>\n",
       "\t<tr><th scope=row>17</th><td>-0.09359233</td><td>-0.259966422</td><td> 1.05863219</td><td>-0.454279206</td><td>-0.33880691</td><td> 0.577770083</td><td>-0.153125468</td><td>-0.98818177</td><td> 0.15765864</td><td>-0.001514237</td><td>â‹¯</td><td>-0.17379026</td><td> 0.74040639</td><td>-0.4681554262</td><td> 0.15447363</td><td>-0.20567601</td><td>-0.17463977</td><td> 0.21129616</td><td> 0.49320065</td><td>-0.153231356</td><td>-1.04327463</td></tr>\n",
       "\t<tr><th scope=row>2</th><td>-0.31468182</td><td>-0.279128699</td><td> 1.24142519</td><td> 0.535478896</td><td>-1.01770357</td><td> 1.055935983</td><td> 0.003660287</td><td>-0.14663585</td><td>-0.29233936</td><td>-0.219415612</td><td>â‹¯</td><td>-0.97348238</td><td>-0.76822450</td><td> 0.1028616068</td><td> 0.17016027</td><td>-0.06737654</td><td>-0.17636986</td><td> 0.34607368</td><td> 0.79620927</td><td> 0.417834906</td><td>-0.49855148</td></tr>\n",
       "\t<tr><th scope=row>12</th><td>-0.04601746</td><td> 1.502867859</td><td>-0.84960551</td><td>-0.702546587</td><td> 0.63181953</td><td> 1.418936265</td><td> 0.740208243</td><td> 0.69348873</td><td>-0.25497068</td><td> 0.575712444</td><td>â‹¯</td><td>-1.51889892</td><td>-0.62973116</td><td> 0.1098136507</td><td>-0.40977490</td><td>-0.18345745</td><td> 0.16842307</td><td>-0.19196153</td><td> 0.65804952</td><td> 0.978488181</td><td>-0.27105096</td></tr>\n",
       "\t<tr><th scope=row>8</th><td> 0.53285684</td><td>-0.514309629</td><td>-1.61717860</td><td>-0.707315341</td><td>-0.28577065</td><td>-1.050975264</td><td>-0.089809072</td><td>-0.12191303</td><td>-0.04747715</td><td> 0.814098058</td><td>â‹¯</td><td> 2.13134004</td><td> 0.79354018</td><td>-0.6054473351</td><td>-0.47590384</td><td> 0.38923947</td><td>-0.16430145</td><td>-0.15559126</td><td>-0.58664907</td><td>-0.535177362</td><td> 0.71530710</td></tr>\n",
       "\t<tr><th scope=row>49</th><td> 0.75573663</td><td> 0.422839465</td><td> 0.03443464</td><td>-0.044468476</td><td> 1.70789812</td><td> 0.103708933</td><td>-0.729380070</td><td> 0.22491213</td><td>-0.13340538</td><td>-0.257816120</td><td>â‹¯</td><td>-0.09931866</td><td> 0.50448279</td><td>-0.1173463375</td><td> 0.03523810</td><td> 0.08782326</td><td>-0.06818400</td><td>-0.03400262</td><td>-0.19159567</td><td>-0.330417090</td><td> 0.26656644</td></tr>\n",
       "\t<tr><th scope=row>10</th><td> 0.44967917</td><td>-0.125606335</td><td>-0.94284212</td><td>-0.613896552</td><td> 0.30014311</td><td>-0.800701408</td><td>-0.200123140</td><td> 0.60505725</td><td>-0.04817242</td><td>-1.070957859</td><td>â‹¯</td><td> 0.58714486</td><td> 1.51680290</td><td> 0.2051403085</td><td> 0.24970065</td><td> 0.50803986</td><td> 0.70851142</td><td> 0.45721398</td><td>-0.79611580</td><td> 0.242960585</td><td> 1.18213316</td></tr>\n",
       "\t<tr><th scope=row>16</th><td>-0.81082941</td><td> 0.810534942</td><td> 1.08458350</td><td>-0.574747402</td><td>-0.30170805</td><td> 0.238897740</td><td> 0.160629353</td><td>-0.84858354</td><td>-0.27134032</td><td> 2.080058576</td><td>â‹¯</td><td>-0.49731657</td><td>-0.93868918</td><td>-0.1095925899</td><td>-0.14107495</td><td> 0.02426093</td><td>-0.12426673</td><td>-0.01197064</td><td> 0.57544109</td><td>-0.009577050</td><td>-0.11839787</td></tr>\n",
       "\t<tr><th scope=row>38</th><td> 0.02073447</td><td> 0.430901224</td><td>-0.32990049</td><td>-0.332346436</td><td>-1.01770357</td><td>-0.048997533</td><td>-0.497132266</td><td>-0.55377487</td><td>-0.31726972</td><td> 0.037785343</td><td>â‹¯</td><td> 0.49836945</td><td>-0.05559454</td><td> 0.2066692551</td><td>-0.02215850</td><td> 0.23403080</td><td>-0.10698927</td><td> 0.04638785</td><td> 0.51787047</td><td> 0.004726486</td><td>-0.42979683</td></tr>\n",
       "\t<tr><th scope=row>6</th><td>-1.94961413</td><td>-1.593940748</td><td> 0.66314089</td><td> 2.034846587</td><td>-1.01770357</td><td> 0.723463802</td><td>-0.249486829</td><td>-0.37863586</td><td>-0.21435513</td><td>-0.275970621</td><td>â‹¯</td><td>-0.33982929</td><td> 0.02291629</td><td> 0.8663042318</td><td> 0.15111765</td><td>-0.57423345</td><td> 0.16435045</td><td>-0.79441902</td><td>-0.59637515</td><td>-0.241079994</td><td> 0.25761504</td></tr>\n",
       "\t<tr><th scope=row>5</th><td> 0.49017147</td><td>-0.257899257</td><td>-0.67680949</td><td> 0.030618037</td><td>-0.80238739</td><td> 0.138944720</td><td>-0.244429040</td><td>-0.70008815</td><td>-0.38792631</td><td> 0.093197491</td><td>â‹¯</td><td> 0.35049009</td><td> 0.41415905</td><td>-0.2752258429</td><td>-0.36741795</td><td>-0.39423587</td><td>-0.16876892</td><td> 0.12387581</td><td>-1.27476366</td><td> 0.168245743</td><td> 0.52170269</td></tr>\n",
       "\t<tr><th scope=row>36</th><td>-0.06181345</td><td>-0.002624338</td><td> 0.98195378</td><td> 0.756623465</td><td>-1.01770357</td><td>-0.453767465</td><td>-0.124112189</td><td>-0.01417041</td><td>-0.18193651</td><td> 0.173815168</td><td>â‹¯</td><td> 0.57650194</td><td> 0.37556121</td><td> 0.5342987385</td><td> 0.49915050</td><td> 0.15513046</td><td>-0.15267010</td><td> 0.09423050</td><td>-0.30689387</td><td>-0.028634074</td><td> 0.53526920</td></tr>\n",
       "\t<tr><th scope=row>29</th><td> 1.00053127</td><td> 1.315579836</td><td>-2.21891174</td><td>-0.517299386</td><td>-1.01770357</td><td>-0.663916034</td><td> 0.482680155</td><td> 1.00165017</td><td>-0.31958176</td><td> 0.101726654</td><td>â‹¯</td><td>-0.39822385</td><td>-0.31194865</td><td> 0.1895656253</td><td> 0.35678046</td><td>-0.24796229</td><td>-0.18993268</td><td> 0.38993575</td><td> 0.29388544</td><td> 0.273667791</td><td> 0.37929006</td></tr>\n",
       "\t<tr><th scope=row>47</th><td>-0.66116004</td><td>-0.550493332</td><td> 1.78785641</td><td> 0.764998907</td><td>-0.75935204</td><td> 1.152244151</td><td>-0.411004017</td><td>-0.99325010</td><td>-0.38792631</td><td>-0.288527050</td><td>â‹¯</td><td>-0.59926198</td><td>-0.26291383</td><td> 0.1458335064</td><td>-0.04796896</td><td>-0.47627302</td><td>-0.08631475</td><td> 0.25056648</td><td> 0.16522926</td><td> 0.611609680</td><td> 0.48758918</td></tr>\n",
       "\t<tr><th scope=row>44</th><td>-0.08459075</td><td> 0.135498930</td><td> 1.22513370</td><td> 1.905702575</td><td>-0.93344747</td><td> 0.380112324</td><td> 0.263603810</td><td>-0.17956652</td><td>-0.38792631</td><td>-0.562585964</td><td>â‹¯</td><td>-0.23502392</td><td>-1.19925542</td><td>-0.1301835397</td><td> 0.18490747</td><td> 0.29163788</td><td>-0.11693721</td><td>-0.19036457</td><td> 0.22075631</td><td> 0.517488704</td><td> 0.04570634</td></tr>\n",
       "\t<tr><th scope=row>15</th><td>-0.14481244</td><td> 1.302958389</td><td>-1.15111164</td><td>-0.005086172</td><td> 2.90104151</td><td> 1.133922145</td><td> 0.768757253</td><td> 0.91087530</td><td> 1.36327072</td><td> 0.256455283</td><td>â‹¯</td><td>-0.52527974</td><td>-1.40244281</td><td> 0.9012394246</td><td> 0.16067435</td><td> 0.67071102</td><td>-0.18993268</td><td>-0.11826441</td><td>-1.18621327</td><td> 0.026281237</td><td> 0.27000323</td></tr>\n",
       "\t<tr><th scope=row>42</th><td>-0.22502479</td><td> 0.341151245</td><td> 0.31639849</td><td>-0.358777357</td><td>-0.95003610</td><td> 0.828118034</td><td> 0.560142212</td><td>-0.62435000</td><td>-0.29013759</td><td>-0.472140399</td><td>â‹¯</td><td>-0.34399706</td><td>-1.08187780</td><td> 0.5367482772</td><td> 0.23679852</td><td> 0.16702184</td><td>-0.18993268</td><td> 0.07377460</td><td> 0.03571408</td><td> 0.022790961</td><td>-0.96885980</td></tr>\n",
       "\t<tr><th scope=row>53</th><td> 0.90689509</td><td>-0.327227288</td><td>-0.54435844</td><td> 0.011554165</td><td>-1.01770357</td><td> 0.002676076</td><td> 0.824120295</td><td>-0.26244684</td><td> 0.01225975</td><td> 0.394336735</td><td>â‹¯</td><td>-0.19119768</td><td>-1.23898244</td><td> 0.7186973882</td><td>-0.03140992</td><td> 0.58762230</td><td> 0.36310638</td><td>-0.65733209</td><td>-0.25724207</td><td> 0.560198223</td><td>-0.54578385</td></tr>\n",
       "\t<tr><th scope=row>27</th><td> 0.95860854</td><td> 0.848242647</td><td> 0.31639849</td><td>-0.181995218</td><td>-0.87268012</td><td>-0.793651120</td><td> 1.739264334</td><td>-0.12491037</td><td>-0.33570934</td><td> 0.454335213</td><td>â‹¯</td><td> 1.00413156</td><td>-0.03714418</td><td> 1.0552302173</td><td> 1.09627171</td><td>-0.05623189</td><td> 0.70739258</td><td> 0.10076517</td><td>-1.33815381</td><td> 0.210307940</td><td>-0.79727101</td></tr>\n",
       "\t<tr><th scope=row>21</th><td> 0.92767353</td><td> 0.351954821</td><td> 0.33829470</td><td>-0.435412909</td><td>-1.01770357</td><td>-0.880853812</td><td>-0.823195988</td><td>-0.79939760</td><td>-0.38792631</td><td> 1.988527342</td><td>â‹¯</td><td> 0.16868742</td><td>-0.15404176</td><td> 0.3311818672</td><td> 0.06066882</td><td> 0.21068949</td><td>-0.17223253</td><td> 0.28442772</td><td>-0.20843742</td><td>-0.621020206</td><td> 0.38779320</td></tr>\n",
       "\t<tr><th scope=row>50</th><td>-0.92372234</td><td>-0.020598068</td><td>-1.26427983</td><td>-0.117569443</td><td>-0.96750137</td><td> 1.093664232</td><td>-0.360885411</td><td>-1.32322790</td><td> 1.36663079</td><td> 0.220491607</td><td>â‹¯</td><td> 0.49282084</td><td> 0.09725215</td><td>-0.0915385889</td><td>-0.23489184</td><td>-0.38667176</td><td>-0.17428964</td><td> 0.10105164</td><td> 0.21650294</td><td>-0.434137380</td><td> 0.88872357</td></tr>\n",
       "\t<tr><th scope=row>4</th><td>-0.91234682</td><td>-1.089310316</td><td> 0.23970161</td><td> 0.203992089</td><td> 0.53103697</td><td> 0.767566324</td><td>-0.153125468</td><td>-0.21753685</td><td> 0.38520734</td><td>-0.649484686</td><td>â‹¯</td><td> 0.45022427</td><td>-0.65085397</td><td> 0.0457839900</td><td>-0.24236341</td><td> 0.44765703</td><td>-0.18958255</td><td>-0.28079830</td><td>-0.26692534</td><td> 0.414583686</td><td> 0.49895492</td></tr>\n",
       "\t<tr><th scope=row>40</th><td>-0.19708134</td><td> 0.283153541</td><td> 1.18647523</td><td> 0.392100608</td><td>-1.01770357</td><td> 0.175596457</td><td>-0.285697135</td><td>-0.05100234</td><td>-0.38792631</td><td>-0.026682987</td><td>â‹¯</td><td>-0.31122740</td><td> 0.33162208</td><td>-0.6211025988</td><td>-0.09780025</td><td>-0.22666792</td><td> 0.26009037</td><td>-0.05134074</td><td> 0.59374750</td><td>-0.153520183</td><td> 0.21603362</td></tr>\n",
       "\t<tr><th scope=row>25</th><td> 0.71843750</td><td>-0.047598322</td><td> 0.73705744</td><td> 0.253308910</td><td> 0.48117817</td><td>-0.011900328</td><td> 0.121104364</td><td> 0.27318269</td><td>-0.08274479</td><td>-0.063968115</td><td>â‹¯</td><td> 0.21330995</td><td> 0.53110123</td><td>-0.6473035526</td><td>-0.54270486</td><td> 0.10962948</td><td>-0.16842562</td><td> 0.34721238</td><td> 0.10479040</td><td>-0.492865694</td><td> 0.14336281</td></tr>\n",
       "\t<tr><th scope=row>52</th><td> 0.25690495</td><td> 0.196130822</td><td>-1.81640023</td><td>-0.435412909</td><td>-1.01770357</td><td>-0.594845995</td><td> 0.559322988</td><td>-0.45761784</td><td>-0.17048984</td><td>-1.373912670</td><td>â‹¯</td><td>-0.51324287</td><td>-0.11879141</td><td>-0.5892031981</td><td>-0.17134194</td><td>-0.08283153</td><td>-0.11193973</td><td>-0.86381226</td><td> 0.16751634</td><td>-0.493717489</td><td>-0.04120277</td></tr>\n",
       "\t<tr><th scope=row>19</th><td> 0.83904346</td><td> 0.408298127</td><td>-0.25034316</td><td>-0.585176536</td><td> 1.40950498</td><td>-0.818328637</td><td> 0.281720483</td><td>-0.03626696</td><td>-0.29837480</td><td> 0.223474960</td><td>â‹¯</td><td> 0.46655105</td><td> 0.54872670</td><td>-0.3409820845</td><td> 0.13252763</td><td>-0.53026602</td><td>-0.18993268</td><td>-0.08828512</td><td>-0.15036820</td><td>-0.062418433</td><td> 0.02279346</td></tr>\n",
       "\t<tr><th scope=row>41</th><td>-0.40860109</td><td>-0.048669723</td><td> 2.96944712</td><td>-0.897011424</td><td>-1.01770357</td><td>-0.709012316</td><td>-0.667824029</td><td> 0.41864303</td><td>-0.38792631</td><td> 0.040927493</td><td>â‹¯</td><td>-0.13648162</td><td> 0.38776064</td><td>-0.7786407607</td><td>-0.07954015</td><td>-0.27904401</td><td>-0.18993268</td><td> 0.35310596</td><td> 0.09664086</td><td>-0.492865694</td><td>-0.31798122</td></tr>\n",
       "\t<tr><th scope=row>34</th><td> 1.44645031</td><td> 0.328543578</td><td> 0.32667241</td><td>-0.300749054</td><td>-1.01770357</td><td>-0.777213376</td><td>-0.762823567</td><td> 0.19990466</td><td>-0.36056831</td><td>-0.143116658</td><td>â‹¯</td><td>-0.33808762</td><td> 0.16435665</td><td>-0.3942531236</td><td> 0.01195671</td><td>-0.17321962</td><td>-0.13604057</td><td>-0.36331346</td><td>-0.46914968</td><td> 0.105545635</td><td>-0.36518924</td></tr>\n",
       "\t<tr><th scope=row>23</th><td> 0.04754928</td><td>-0.660916598</td><td> 2.03186221</td><td>-0.500931958</td><td>-1.01770357</td><td> 0.290271525</td><td> 0.126439723</td><td> 0.75946942</td><td>-0.33097686</td><td>-0.057861180</td><td>â‹¯</td><td> 0.24905714</td><td> 0.06900338</td><td>-0.4031809368</td><td> 0.08881141</td><td> 0.50467914</td><td>-0.18679525</td><td> 0.27972885</td><td> 1.32422465</td><td> 0.624400137</td><td>-0.22988686</td></tr>\n",
       "\t<tr><th scope=row>54</th><td> 0.47310322</td><td>-0.195425198</td><td>-0.35576607</td><td>-0.515324225</td><td>-1.01770357</td><td>-1.092249883</td><td>-0.171057793</td><td>-0.25246798</td><td>-0.20426069</td><td>-0.416186634</td><td>â‹¯</td><td> 0.86781747</td><td> 1.32880802</td><td> 0.2288094333</td><td> 0.18938530</td><td>-0.04091907</td><td> 0.70585357</td><td> 0.19730013</td><td>-0.43394722</td><td>-0.979660281</td><td>-0.32887805</td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A data.frame: 41 Ã— 18570\n",
       "\\begin{tabular}{r|lllllllllllllllllllll}\n",
       "  & 1 & 503538 & 2 & 144571 & 144568 & 53947 & 8086 & 65985 & 13 & 51166 & â‹¯ & 55055 & 11130 & 7789 & 158586 & 79364 & 440590 & 79699 & 7791 & 23140 & 26009\\\\\n",
       "  & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & â‹¯ & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl>\\\\\n",
       "\\hline\n",
       "\t9 & -1.58231886 &  0.226126567 &  1.66568079 &  0.416205261 & -0.81472165 &  0.752172262 &  0.487429786 & -0.11137395 &  2.28027252 &  0.074114330 & â‹¯ & -0.51800739 & -0.62215237 &  0.2274708862 & -0.22274651 & -0.31517698 &  0.02419371 & -0.35364727 &  0.91660440 & -0.365652282 & -0.28997347\\\\\n",
       "\t3 &  0.41362108 &  0.026864237 & -0.63666687 & -0.520852783 &  3.15369407 & -0.352937973 &  0.217370469 &  0.94451945 &  1.21879050 &  0.408285561 & â‹¯ & -0.77789408 &  0.47804777 &  0.3231840744 &  0.07771963 & -0.13553484 & -0.14994607 &  0.25125628 &  0.46844425 &  0.202778225 &  0.12502150\\\\\n",
       "\t35 & -1.22017300 & -0.465444781 & -0.17419729 & -0.151427753 &  2.88161537 & -0.398296587 &  0.117332737 &  0.86124177 & -0.15999967 & -0.427789287 & â‹¯ & -0.32027729 & -0.86643923 &  0.1563104344 & -0.18119199 &  0.11321388 &  0.25268109 & -0.40650049 & -0.12853882 &  0.798602483 & -0.02921499\\\\\n",
       "\t18 &  0.07509568 & -0.176204605 & -0.32685866 & -0.301583681 & -1.01770357 & -0.457284541 &  0.244340206 &  0.37405060 & -0.38792631 &  0.498749883 & â‹¯ &  0.56521058 &  0.37410214 & -0.1170037510 &  0.32391776 & -0.14034456 & -0.18993268 &  0.40220709 &  0.76877653 & -0.193560502 &  0.20174889\\\\\n",
       "\t7 &  0.05888384 & -0.702086411 &  0.47458381 &  0.115722317 & -1.01770357 & -0.812063186 & -0.520537587 & -0.83866229 & -0.15818095 &  0.252377818 & â‹¯ &  0.33433512 &  0.87387503 &  0.3593579706 &  0.61269151 & -0.44520057 & -0.12561413 &  0.15067660 &  0.56396673 &  0.006282023 & -0.23951499\\\\\n",
       "\t48 & -0.66201015 & -0.458452942 & -1.24156824 &  0.546215021 & -0.98862550 & -0.235179430 & -0.209526830 &  0.73946028 & -0.38792631 &  0.483951204 & â‹¯ & -0.23997050 &  0.20676718 & -0.1790886828 & -0.14261207 & -0.10593877 & -0.10368129 & -0.42023214 &  0.48732913 &  0.187183322 & -0.19190377\\\\\n",
       "\t30 &  0.42966948 & -0.844845961 & -0.98130509 & -0.556570291 & -1.01770357 &  0.209973995 & -1.275860765 & -0.63456805 & -0.38792631 & -0.364462502 & â‹¯ &  1.41658928 &  0.06242660 & -1.4247014274 & -0.24798209 & -0.11521950 &  1.03268700 &  0.46235717 &  0.57172041 & -0.687417296 &  1.00008741\\\\\n",
       "\t14 & -0.11535008 & -0.184710883 & -0.45533603 &  0.118023126 &  3.30190882 & -0.454308700 &  0.242836107 &  0.10825169 & -0.38792631 & -0.775882897 & â‹¯ &  0.33614144 & -0.17613154 & -0.3655941746 & -0.75921926 &  0.41185003 & -0.11559656 & -0.05134074 & -0.26650284 & -0.305194059 & -0.84401986\\\\\n",
       "\t13 &  0.67577556 & -0.482031312 & -1.63309646 &  0.490900241 &  2.39125358 & -0.791932925 & -0.070765240 &  0.60201350 &  0.49829857 &  0.515139163 & â‹¯ & -0.43369412 &  1.13091160 & -0.2777108820 & -0.12975976 & -0.06003260 & -0.12662805 & -0.13856663 & -1.21787913 & -0.209915150 &  0.08612588\\\\\n",
       "\t46 &  0.51387636 &  0.005365473 & -0.61054331 &  0.145104377 &  0.02495034 & -0.032976780 &  0.042689150 &  0.29231340 &  0.27977847 & -0.567818972 & â‹¯ &  0.63079954 &  1.03166565 &  0.0103432872 &  0.13307078 & -0.06398976 & -0.11879850 &  0.13974445 &  0.05403603 & -0.101439718 & -0.25613537\\\\\n",
       "\t45 & -0.40772895 &  1.033369372 &  0.22458031 &  1.535996269 & -0.38789368 & -0.080393783 &  0.175954760 & -0.65267896 & -0.38792631 & -0.887038183 & â‹¯ & -1.07644884 & -0.45707750 &  0.6808349316 &  0.03664372 &  0.34213037 & -0.12595742 &  0.27241290 & -0.16797709 &  0.400421450 &  0.32499011\\\\\n",
       "\t11 & -1.16982847 & -0.682889907 & -0.82723364 & -0.446609752 &  4.97014346 &  1.267812028 & -0.159704812 &  2.30227398 &  1.17731337 & -0.784427694 & â‹¯ & -0.77856996 & -1.01200334 &  0.0005757279 & -0.41480345 &  0.05113678 &  0.09727642 & -0.16385787 & -0.24692816 &  0.117103894 & -0.74993078\\\\\n",
       "\t17 & -0.09359233 & -0.259966422 &  1.05863219 & -0.454279206 & -0.33880691 &  0.577770083 & -0.153125468 & -0.98818177 &  0.15765864 & -0.001514237 & â‹¯ & -0.17379026 &  0.74040639 & -0.4681554262 &  0.15447363 & -0.20567601 & -0.17463977 &  0.21129616 &  0.49320065 & -0.153231356 & -1.04327463\\\\\n",
       "\t2 & -0.31468182 & -0.279128699 &  1.24142519 &  0.535478896 & -1.01770357 &  1.055935983 &  0.003660287 & -0.14663585 & -0.29233936 & -0.219415612 & â‹¯ & -0.97348238 & -0.76822450 &  0.1028616068 &  0.17016027 & -0.06737654 & -0.17636986 &  0.34607368 &  0.79620927 &  0.417834906 & -0.49855148\\\\\n",
       "\t12 & -0.04601746 &  1.502867859 & -0.84960551 & -0.702546587 &  0.63181953 &  1.418936265 &  0.740208243 &  0.69348873 & -0.25497068 &  0.575712444 & â‹¯ & -1.51889892 & -0.62973116 &  0.1098136507 & -0.40977490 & -0.18345745 &  0.16842307 & -0.19196153 &  0.65804952 &  0.978488181 & -0.27105096\\\\\n",
       "\t8 &  0.53285684 & -0.514309629 & -1.61717860 & -0.707315341 & -0.28577065 & -1.050975264 & -0.089809072 & -0.12191303 & -0.04747715 &  0.814098058 & â‹¯ &  2.13134004 &  0.79354018 & -0.6054473351 & -0.47590384 &  0.38923947 & -0.16430145 & -0.15559126 & -0.58664907 & -0.535177362 &  0.71530710\\\\\n",
       "\t49 &  0.75573663 &  0.422839465 &  0.03443464 & -0.044468476 &  1.70789812 &  0.103708933 & -0.729380070 &  0.22491213 & -0.13340538 & -0.257816120 & â‹¯ & -0.09931866 &  0.50448279 & -0.1173463375 &  0.03523810 &  0.08782326 & -0.06818400 & -0.03400262 & -0.19159567 & -0.330417090 &  0.26656644\\\\\n",
       "\t10 &  0.44967917 & -0.125606335 & -0.94284212 & -0.613896552 &  0.30014311 & -0.800701408 & -0.200123140 &  0.60505725 & -0.04817242 & -1.070957859 & â‹¯ &  0.58714486 &  1.51680290 &  0.2051403085 &  0.24970065 &  0.50803986 &  0.70851142 &  0.45721398 & -0.79611580 &  0.242960585 &  1.18213316\\\\\n",
       "\t16 & -0.81082941 &  0.810534942 &  1.08458350 & -0.574747402 & -0.30170805 &  0.238897740 &  0.160629353 & -0.84858354 & -0.27134032 &  2.080058576 & â‹¯ & -0.49731657 & -0.93868918 & -0.1095925899 & -0.14107495 &  0.02426093 & -0.12426673 & -0.01197064 &  0.57544109 & -0.009577050 & -0.11839787\\\\\n",
       "\t38 &  0.02073447 &  0.430901224 & -0.32990049 & -0.332346436 & -1.01770357 & -0.048997533 & -0.497132266 & -0.55377487 & -0.31726972 &  0.037785343 & â‹¯ &  0.49836945 & -0.05559454 &  0.2066692551 & -0.02215850 &  0.23403080 & -0.10698927 &  0.04638785 &  0.51787047 &  0.004726486 & -0.42979683\\\\\n",
       "\t6 & -1.94961413 & -1.593940748 &  0.66314089 &  2.034846587 & -1.01770357 &  0.723463802 & -0.249486829 & -0.37863586 & -0.21435513 & -0.275970621 & â‹¯ & -0.33982929 &  0.02291629 &  0.8663042318 &  0.15111765 & -0.57423345 &  0.16435045 & -0.79441902 & -0.59637515 & -0.241079994 &  0.25761504\\\\\n",
       "\t5 &  0.49017147 & -0.257899257 & -0.67680949 &  0.030618037 & -0.80238739 &  0.138944720 & -0.244429040 & -0.70008815 & -0.38792631 &  0.093197491 & â‹¯ &  0.35049009 &  0.41415905 & -0.2752258429 & -0.36741795 & -0.39423587 & -0.16876892 &  0.12387581 & -1.27476366 &  0.168245743 &  0.52170269\\\\\n",
       "\t36 & -0.06181345 & -0.002624338 &  0.98195378 &  0.756623465 & -1.01770357 & -0.453767465 & -0.124112189 & -0.01417041 & -0.18193651 &  0.173815168 & â‹¯ &  0.57650194 &  0.37556121 &  0.5342987385 &  0.49915050 &  0.15513046 & -0.15267010 &  0.09423050 & -0.30689387 & -0.028634074 &  0.53526920\\\\\n",
       "\t29 &  1.00053127 &  1.315579836 & -2.21891174 & -0.517299386 & -1.01770357 & -0.663916034 &  0.482680155 &  1.00165017 & -0.31958176 &  0.101726654 & â‹¯ & -0.39822385 & -0.31194865 &  0.1895656253 &  0.35678046 & -0.24796229 & -0.18993268 &  0.38993575 &  0.29388544 &  0.273667791 &  0.37929006\\\\\n",
       "\t47 & -0.66116004 & -0.550493332 &  1.78785641 &  0.764998907 & -0.75935204 &  1.152244151 & -0.411004017 & -0.99325010 & -0.38792631 & -0.288527050 & â‹¯ & -0.59926198 & -0.26291383 &  0.1458335064 & -0.04796896 & -0.47627302 & -0.08631475 &  0.25056648 &  0.16522926 &  0.611609680 &  0.48758918\\\\\n",
       "\t44 & -0.08459075 &  0.135498930 &  1.22513370 &  1.905702575 & -0.93344747 &  0.380112324 &  0.263603810 & -0.17956652 & -0.38792631 & -0.562585964 & â‹¯ & -0.23502392 & -1.19925542 & -0.1301835397 &  0.18490747 &  0.29163788 & -0.11693721 & -0.19036457 &  0.22075631 &  0.517488704 &  0.04570634\\\\\n",
       "\t15 & -0.14481244 &  1.302958389 & -1.15111164 & -0.005086172 &  2.90104151 &  1.133922145 &  0.768757253 &  0.91087530 &  1.36327072 &  0.256455283 & â‹¯ & -0.52527974 & -1.40244281 &  0.9012394246 &  0.16067435 &  0.67071102 & -0.18993268 & -0.11826441 & -1.18621327 &  0.026281237 &  0.27000323\\\\\n",
       "\t42 & -0.22502479 &  0.341151245 &  0.31639849 & -0.358777357 & -0.95003610 &  0.828118034 &  0.560142212 & -0.62435000 & -0.29013759 & -0.472140399 & â‹¯ & -0.34399706 & -1.08187780 &  0.5367482772 &  0.23679852 &  0.16702184 & -0.18993268 &  0.07377460 &  0.03571408 &  0.022790961 & -0.96885980\\\\\n",
       "\t53 &  0.90689509 & -0.327227288 & -0.54435844 &  0.011554165 & -1.01770357 &  0.002676076 &  0.824120295 & -0.26244684 &  0.01225975 &  0.394336735 & â‹¯ & -0.19119768 & -1.23898244 &  0.7186973882 & -0.03140992 &  0.58762230 &  0.36310638 & -0.65733209 & -0.25724207 &  0.560198223 & -0.54578385\\\\\n",
       "\t27 &  0.95860854 &  0.848242647 &  0.31639849 & -0.181995218 & -0.87268012 & -0.793651120 &  1.739264334 & -0.12491037 & -0.33570934 &  0.454335213 & â‹¯ &  1.00413156 & -0.03714418 &  1.0552302173 &  1.09627171 & -0.05623189 &  0.70739258 &  0.10076517 & -1.33815381 &  0.210307940 & -0.79727101\\\\\n",
       "\t21 &  0.92767353 &  0.351954821 &  0.33829470 & -0.435412909 & -1.01770357 & -0.880853812 & -0.823195988 & -0.79939760 & -0.38792631 &  1.988527342 & â‹¯ &  0.16868742 & -0.15404176 &  0.3311818672 &  0.06066882 &  0.21068949 & -0.17223253 &  0.28442772 & -0.20843742 & -0.621020206 &  0.38779320\\\\\n",
       "\t50 & -0.92372234 & -0.020598068 & -1.26427983 & -0.117569443 & -0.96750137 &  1.093664232 & -0.360885411 & -1.32322790 &  1.36663079 &  0.220491607 & â‹¯ &  0.49282084 &  0.09725215 & -0.0915385889 & -0.23489184 & -0.38667176 & -0.17428964 &  0.10105164 &  0.21650294 & -0.434137380 &  0.88872357\\\\\n",
       "\t4 & -0.91234682 & -1.089310316 &  0.23970161 &  0.203992089 &  0.53103697 &  0.767566324 & -0.153125468 & -0.21753685 &  0.38520734 & -0.649484686 & â‹¯ &  0.45022427 & -0.65085397 &  0.0457839900 & -0.24236341 &  0.44765703 & -0.18958255 & -0.28079830 & -0.26692534 &  0.414583686 &  0.49895492\\\\\n",
       "\t40 & -0.19708134 &  0.283153541 &  1.18647523 &  0.392100608 & -1.01770357 &  0.175596457 & -0.285697135 & -0.05100234 & -0.38792631 & -0.026682987 & â‹¯ & -0.31122740 &  0.33162208 & -0.6211025988 & -0.09780025 & -0.22666792 &  0.26009037 & -0.05134074 &  0.59374750 & -0.153520183 &  0.21603362\\\\\n",
       "\t25 &  0.71843750 & -0.047598322 &  0.73705744 &  0.253308910 &  0.48117817 & -0.011900328 &  0.121104364 &  0.27318269 & -0.08274479 & -0.063968115 & â‹¯ &  0.21330995 &  0.53110123 & -0.6473035526 & -0.54270486 &  0.10962948 & -0.16842562 &  0.34721238 &  0.10479040 & -0.492865694 &  0.14336281\\\\\n",
       "\t52 &  0.25690495 &  0.196130822 & -1.81640023 & -0.435412909 & -1.01770357 & -0.594845995 &  0.559322988 & -0.45761784 & -0.17048984 & -1.373912670 & â‹¯ & -0.51324287 & -0.11879141 & -0.5892031981 & -0.17134194 & -0.08283153 & -0.11193973 & -0.86381226 &  0.16751634 & -0.493717489 & -0.04120277\\\\\n",
       "\t19 &  0.83904346 &  0.408298127 & -0.25034316 & -0.585176536 &  1.40950498 & -0.818328637 &  0.281720483 & -0.03626696 & -0.29837480 &  0.223474960 & â‹¯ &  0.46655105 &  0.54872670 & -0.3409820845 &  0.13252763 & -0.53026602 & -0.18993268 & -0.08828512 & -0.15036820 & -0.062418433 &  0.02279346\\\\\n",
       "\t41 & -0.40860109 & -0.048669723 &  2.96944712 & -0.897011424 & -1.01770357 & -0.709012316 & -0.667824029 &  0.41864303 & -0.38792631 &  0.040927493 & â‹¯ & -0.13648162 &  0.38776064 & -0.7786407607 & -0.07954015 & -0.27904401 & -0.18993268 &  0.35310596 &  0.09664086 & -0.492865694 & -0.31798122\\\\\n",
       "\t34 &  1.44645031 &  0.328543578 &  0.32667241 & -0.300749054 & -1.01770357 & -0.777213376 & -0.762823567 &  0.19990466 & -0.36056831 & -0.143116658 & â‹¯ & -0.33808762 &  0.16435665 & -0.3942531236 &  0.01195671 & -0.17321962 & -0.13604057 & -0.36331346 & -0.46914968 &  0.105545635 & -0.36518924\\\\\n",
       "\t23 &  0.04754928 & -0.660916598 &  2.03186221 & -0.500931958 & -1.01770357 &  0.290271525 &  0.126439723 &  0.75946942 & -0.33097686 & -0.057861180 & â‹¯ &  0.24905714 &  0.06900338 & -0.4031809368 &  0.08881141 &  0.50467914 & -0.18679525 &  0.27972885 &  1.32422465 &  0.624400137 & -0.22988686\\\\\n",
       "\t54 &  0.47310322 & -0.195425198 & -0.35576607 & -0.515324225 & -1.01770357 & -1.092249883 & -0.171057793 & -0.25246798 & -0.20426069 & -0.416186634 & â‹¯ &  0.86781747 &  1.32880802 &  0.2288094333 &  0.18938530 & -0.04091907 &  0.70585357 &  0.19730013 & -0.43394722 & -0.979660281 & -0.32887805\\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A data.frame: 41 Ã— 18570\n",
       "\n",
       "| <!--/--> | 1 &lt;dbl&gt; | 503538 &lt;dbl&gt; | 2 &lt;dbl&gt; | 144571 &lt;dbl&gt; | 144568 &lt;dbl&gt; | 53947 &lt;dbl&gt; | 8086 &lt;dbl&gt; | 65985 &lt;dbl&gt; | 13 &lt;dbl&gt; | 51166 &lt;dbl&gt; | â‹¯ â‹¯ | 55055 &lt;dbl&gt; | 11130 &lt;dbl&gt; | 7789 &lt;dbl&gt; | 158586 &lt;dbl&gt; | 79364 &lt;dbl&gt; | 440590 &lt;dbl&gt; | 79699 &lt;dbl&gt; | 7791 &lt;dbl&gt; | 23140 &lt;dbl&gt; | 26009 &lt;dbl&gt; |\n",
       "|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|\n",
       "| 9 | -1.58231886 |  0.226126567 |  1.66568079 |  0.416205261 | -0.81472165 |  0.752172262 |  0.487429786 | -0.11137395 |  2.28027252 |  0.074114330 | â‹¯ | -0.51800739 | -0.62215237 |  0.2274708862 | -0.22274651 | -0.31517698 |  0.02419371 | -0.35364727 |  0.91660440 | -0.365652282 | -0.28997347 |\n",
       "| 3 |  0.41362108 |  0.026864237 | -0.63666687 | -0.520852783 |  3.15369407 | -0.352937973 |  0.217370469 |  0.94451945 |  1.21879050 |  0.408285561 | â‹¯ | -0.77789408 |  0.47804777 |  0.3231840744 |  0.07771963 | -0.13553484 | -0.14994607 |  0.25125628 |  0.46844425 |  0.202778225 |  0.12502150 |\n",
       "| 35 | -1.22017300 | -0.465444781 | -0.17419729 | -0.151427753 |  2.88161537 | -0.398296587 |  0.117332737 |  0.86124177 | -0.15999967 | -0.427789287 | â‹¯ | -0.32027729 | -0.86643923 |  0.1563104344 | -0.18119199 |  0.11321388 |  0.25268109 | -0.40650049 | -0.12853882 |  0.798602483 | -0.02921499 |\n",
       "| 18 |  0.07509568 | -0.176204605 | -0.32685866 | -0.301583681 | -1.01770357 | -0.457284541 |  0.244340206 |  0.37405060 | -0.38792631 |  0.498749883 | â‹¯ |  0.56521058 |  0.37410214 | -0.1170037510 |  0.32391776 | -0.14034456 | -0.18993268 |  0.40220709 |  0.76877653 | -0.193560502 |  0.20174889 |\n",
       "| 7 |  0.05888384 | -0.702086411 |  0.47458381 |  0.115722317 | -1.01770357 | -0.812063186 | -0.520537587 | -0.83866229 | -0.15818095 |  0.252377818 | â‹¯ |  0.33433512 |  0.87387503 |  0.3593579706 |  0.61269151 | -0.44520057 | -0.12561413 |  0.15067660 |  0.56396673 |  0.006282023 | -0.23951499 |\n",
       "| 48 | -0.66201015 | -0.458452942 | -1.24156824 |  0.546215021 | -0.98862550 | -0.235179430 | -0.209526830 |  0.73946028 | -0.38792631 |  0.483951204 | â‹¯ | -0.23997050 |  0.20676718 | -0.1790886828 | -0.14261207 | -0.10593877 | -0.10368129 | -0.42023214 |  0.48732913 |  0.187183322 | -0.19190377 |\n",
       "| 30 |  0.42966948 | -0.844845961 | -0.98130509 | -0.556570291 | -1.01770357 |  0.209973995 | -1.275860765 | -0.63456805 | -0.38792631 | -0.364462502 | â‹¯ |  1.41658928 |  0.06242660 | -1.4247014274 | -0.24798209 | -0.11521950 |  1.03268700 |  0.46235717 |  0.57172041 | -0.687417296 |  1.00008741 |\n",
       "| 14 | -0.11535008 | -0.184710883 | -0.45533603 |  0.118023126 |  3.30190882 | -0.454308700 |  0.242836107 |  0.10825169 | -0.38792631 | -0.775882897 | â‹¯ |  0.33614144 | -0.17613154 | -0.3655941746 | -0.75921926 |  0.41185003 | -0.11559656 | -0.05134074 | -0.26650284 | -0.305194059 | -0.84401986 |\n",
       "| 13 |  0.67577556 | -0.482031312 | -1.63309646 |  0.490900241 |  2.39125358 | -0.791932925 | -0.070765240 |  0.60201350 |  0.49829857 |  0.515139163 | â‹¯ | -0.43369412 |  1.13091160 | -0.2777108820 | -0.12975976 | -0.06003260 | -0.12662805 | -0.13856663 | -1.21787913 | -0.209915150 |  0.08612588 |\n",
       "| 46 |  0.51387636 |  0.005365473 | -0.61054331 |  0.145104377 |  0.02495034 | -0.032976780 |  0.042689150 |  0.29231340 |  0.27977847 | -0.567818972 | â‹¯ |  0.63079954 |  1.03166565 |  0.0103432872 |  0.13307078 | -0.06398976 | -0.11879850 |  0.13974445 |  0.05403603 | -0.101439718 | -0.25613537 |\n",
       "| 45 | -0.40772895 |  1.033369372 |  0.22458031 |  1.535996269 | -0.38789368 | -0.080393783 |  0.175954760 | -0.65267896 | -0.38792631 | -0.887038183 | â‹¯ | -1.07644884 | -0.45707750 |  0.6808349316 |  0.03664372 |  0.34213037 | -0.12595742 |  0.27241290 | -0.16797709 |  0.400421450 |  0.32499011 |\n",
       "| 11 | -1.16982847 | -0.682889907 | -0.82723364 | -0.446609752 |  4.97014346 |  1.267812028 | -0.159704812 |  2.30227398 |  1.17731337 | -0.784427694 | â‹¯ | -0.77856996 | -1.01200334 |  0.0005757279 | -0.41480345 |  0.05113678 |  0.09727642 | -0.16385787 | -0.24692816 |  0.117103894 | -0.74993078 |\n",
       "| 17 | -0.09359233 | -0.259966422 |  1.05863219 | -0.454279206 | -0.33880691 |  0.577770083 | -0.153125468 | -0.98818177 |  0.15765864 | -0.001514237 | â‹¯ | -0.17379026 |  0.74040639 | -0.4681554262 |  0.15447363 | -0.20567601 | -0.17463977 |  0.21129616 |  0.49320065 | -0.153231356 | -1.04327463 |\n",
       "| 2 | -0.31468182 | -0.279128699 |  1.24142519 |  0.535478896 | -1.01770357 |  1.055935983 |  0.003660287 | -0.14663585 | -0.29233936 | -0.219415612 | â‹¯ | -0.97348238 | -0.76822450 |  0.1028616068 |  0.17016027 | -0.06737654 | -0.17636986 |  0.34607368 |  0.79620927 |  0.417834906 | -0.49855148 |\n",
       "| 12 | -0.04601746 |  1.502867859 | -0.84960551 | -0.702546587 |  0.63181953 |  1.418936265 |  0.740208243 |  0.69348873 | -0.25497068 |  0.575712444 | â‹¯ | -1.51889892 | -0.62973116 |  0.1098136507 | -0.40977490 | -0.18345745 |  0.16842307 | -0.19196153 |  0.65804952 |  0.978488181 | -0.27105096 |\n",
       "| 8 |  0.53285684 | -0.514309629 | -1.61717860 | -0.707315341 | -0.28577065 | -1.050975264 | -0.089809072 | -0.12191303 | -0.04747715 |  0.814098058 | â‹¯ |  2.13134004 |  0.79354018 | -0.6054473351 | -0.47590384 |  0.38923947 | -0.16430145 | -0.15559126 | -0.58664907 | -0.535177362 |  0.71530710 |\n",
       "| 49 |  0.75573663 |  0.422839465 |  0.03443464 | -0.044468476 |  1.70789812 |  0.103708933 | -0.729380070 |  0.22491213 | -0.13340538 | -0.257816120 | â‹¯ | -0.09931866 |  0.50448279 | -0.1173463375 |  0.03523810 |  0.08782326 | -0.06818400 | -0.03400262 | -0.19159567 | -0.330417090 |  0.26656644 |\n",
       "| 10 |  0.44967917 | -0.125606335 | -0.94284212 | -0.613896552 |  0.30014311 | -0.800701408 | -0.200123140 |  0.60505725 | -0.04817242 | -1.070957859 | â‹¯ |  0.58714486 |  1.51680290 |  0.2051403085 |  0.24970065 |  0.50803986 |  0.70851142 |  0.45721398 | -0.79611580 |  0.242960585 |  1.18213316 |\n",
       "| 16 | -0.81082941 |  0.810534942 |  1.08458350 | -0.574747402 | -0.30170805 |  0.238897740 |  0.160629353 | -0.84858354 | -0.27134032 |  2.080058576 | â‹¯ | -0.49731657 | -0.93868918 | -0.1095925899 | -0.14107495 |  0.02426093 | -0.12426673 | -0.01197064 |  0.57544109 | -0.009577050 | -0.11839787 |\n",
       "| 38 |  0.02073447 |  0.430901224 | -0.32990049 | -0.332346436 | -1.01770357 | -0.048997533 | -0.497132266 | -0.55377487 | -0.31726972 |  0.037785343 | â‹¯ |  0.49836945 | -0.05559454 |  0.2066692551 | -0.02215850 |  0.23403080 | -0.10698927 |  0.04638785 |  0.51787047 |  0.004726486 | -0.42979683 |\n",
       "| 6 | -1.94961413 | -1.593940748 |  0.66314089 |  2.034846587 | -1.01770357 |  0.723463802 | -0.249486829 | -0.37863586 | -0.21435513 | -0.275970621 | â‹¯ | -0.33982929 |  0.02291629 |  0.8663042318 |  0.15111765 | -0.57423345 |  0.16435045 | -0.79441902 | -0.59637515 | -0.241079994 |  0.25761504 |\n",
       "| 5 |  0.49017147 | -0.257899257 | -0.67680949 |  0.030618037 | -0.80238739 |  0.138944720 | -0.244429040 | -0.70008815 | -0.38792631 |  0.093197491 | â‹¯ |  0.35049009 |  0.41415905 | -0.2752258429 | -0.36741795 | -0.39423587 | -0.16876892 |  0.12387581 | -1.27476366 |  0.168245743 |  0.52170269 |\n",
       "| 36 | -0.06181345 | -0.002624338 |  0.98195378 |  0.756623465 | -1.01770357 | -0.453767465 | -0.124112189 | -0.01417041 | -0.18193651 |  0.173815168 | â‹¯ |  0.57650194 |  0.37556121 |  0.5342987385 |  0.49915050 |  0.15513046 | -0.15267010 |  0.09423050 | -0.30689387 | -0.028634074 |  0.53526920 |\n",
       "| 29 |  1.00053127 |  1.315579836 | -2.21891174 | -0.517299386 | -1.01770357 | -0.663916034 |  0.482680155 |  1.00165017 | -0.31958176 |  0.101726654 | â‹¯ | -0.39822385 | -0.31194865 |  0.1895656253 |  0.35678046 | -0.24796229 | -0.18993268 |  0.38993575 |  0.29388544 |  0.273667791 |  0.37929006 |\n",
       "| 47 | -0.66116004 | -0.550493332 |  1.78785641 |  0.764998907 | -0.75935204 |  1.152244151 | -0.411004017 | -0.99325010 | -0.38792631 | -0.288527050 | â‹¯ | -0.59926198 | -0.26291383 |  0.1458335064 | -0.04796896 | -0.47627302 | -0.08631475 |  0.25056648 |  0.16522926 |  0.611609680 |  0.48758918 |\n",
       "| 44 | -0.08459075 |  0.135498930 |  1.22513370 |  1.905702575 | -0.93344747 |  0.380112324 |  0.263603810 | -0.17956652 | -0.38792631 | -0.562585964 | â‹¯ | -0.23502392 | -1.19925542 | -0.1301835397 |  0.18490747 |  0.29163788 | -0.11693721 | -0.19036457 |  0.22075631 |  0.517488704 |  0.04570634 |\n",
       "| 15 | -0.14481244 |  1.302958389 | -1.15111164 | -0.005086172 |  2.90104151 |  1.133922145 |  0.768757253 |  0.91087530 |  1.36327072 |  0.256455283 | â‹¯ | -0.52527974 | -1.40244281 |  0.9012394246 |  0.16067435 |  0.67071102 | -0.18993268 | -0.11826441 | -1.18621327 |  0.026281237 |  0.27000323 |\n",
       "| 42 | -0.22502479 |  0.341151245 |  0.31639849 | -0.358777357 | -0.95003610 |  0.828118034 |  0.560142212 | -0.62435000 | -0.29013759 | -0.472140399 | â‹¯ | -0.34399706 | -1.08187780 |  0.5367482772 |  0.23679852 |  0.16702184 | -0.18993268 |  0.07377460 |  0.03571408 |  0.022790961 | -0.96885980 |\n",
       "| 53 |  0.90689509 | -0.327227288 | -0.54435844 |  0.011554165 | -1.01770357 |  0.002676076 |  0.824120295 | -0.26244684 |  0.01225975 |  0.394336735 | â‹¯ | -0.19119768 | -1.23898244 |  0.7186973882 | -0.03140992 |  0.58762230 |  0.36310638 | -0.65733209 | -0.25724207 |  0.560198223 | -0.54578385 |\n",
       "| 27 |  0.95860854 |  0.848242647 |  0.31639849 | -0.181995218 | -0.87268012 | -0.793651120 |  1.739264334 | -0.12491037 | -0.33570934 |  0.454335213 | â‹¯ |  1.00413156 | -0.03714418 |  1.0552302173 |  1.09627171 | -0.05623189 |  0.70739258 |  0.10076517 | -1.33815381 |  0.210307940 | -0.79727101 |\n",
       "| 21 |  0.92767353 |  0.351954821 |  0.33829470 | -0.435412909 | -1.01770357 | -0.880853812 | -0.823195988 | -0.79939760 | -0.38792631 |  1.988527342 | â‹¯ |  0.16868742 | -0.15404176 |  0.3311818672 |  0.06066882 |  0.21068949 | -0.17223253 |  0.28442772 | -0.20843742 | -0.621020206 |  0.38779320 |\n",
       "| 50 | -0.92372234 | -0.020598068 | -1.26427983 | -0.117569443 | -0.96750137 |  1.093664232 | -0.360885411 | -1.32322790 |  1.36663079 |  0.220491607 | â‹¯ |  0.49282084 |  0.09725215 | -0.0915385889 | -0.23489184 | -0.38667176 | -0.17428964 |  0.10105164 |  0.21650294 | -0.434137380 |  0.88872357 |\n",
       "| 4 | -0.91234682 | -1.089310316 |  0.23970161 |  0.203992089 |  0.53103697 |  0.767566324 | -0.153125468 | -0.21753685 |  0.38520734 | -0.649484686 | â‹¯ |  0.45022427 | -0.65085397 |  0.0457839900 | -0.24236341 |  0.44765703 | -0.18958255 | -0.28079830 | -0.26692534 |  0.414583686 |  0.49895492 |\n",
       "| 40 | -0.19708134 |  0.283153541 |  1.18647523 |  0.392100608 | -1.01770357 |  0.175596457 | -0.285697135 | -0.05100234 | -0.38792631 | -0.026682987 | â‹¯ | -0.31122740 |  0.33162208 | -0.6211025988 | -0.09780025 | -0.22666792 |  0.26009037 | -0.05134074 |  0.59374750 | -0.153520183 |  0.21603362 |\n",
       "| 25 |  0.71843750 | -0.047598322 |  0.73705744 |  0.253308910 |  0.48117817 | -0.011900328 |  0.121104364 |  0.27318269 | -0.08274479 | -0.063968115 | â‹¯ |  0.21330995 |  0.53110123 | -0.6473035526 | -0.54270486 |  0.10962948 | -0.16842562 |  0.34721238 |  0.10479040 | -0.492865694 |  0.14336281 |\n",
       "| 52 |  0.25690495 |  0.196130822 | -1.81640023 | -0.435412909 | -1.01770357 | -0.594845995 |  0.559322988 | -0.45761784 | -0.17048984 | -1.373912670 | â‹¯ | -0.51324287 | -0.11879141 | -0.5892031981 | -0.17134194 | -0.08283153 | -0.11193973 | -0.86381226 |  0.16751634 | -0.493717489 | -0.04120277 |\n",
       "| 19 |  0.83904346 |  0.408298127 | -0.25034316 | -0.585176536 |  1.40950498 | -0.818328637 |  0.281720483 | -0.03626696 | -0.29837480 |  0.223474960 | â‹¯ |  0.46655105 |  0.54872670 | -0.3409820845 |  0.13252763 | -0.53026602 | -0.18993268 | -0.08828512 | -0.15036820 | -0.062418433 |  0.02279346 |\n",
       "| 41 | -0.40860109 | -0.048669723 |  2.96944712 | -0.897011424 | -1.01770357 | -0.709012316 | -0.667824029 |  0.41864303 | -0.38792631 |  0.040927493 | â‹¯ | -0.13648162 |  0.38776064 | -0.7786407607 | -0.07954015 | -0.27904401 | -0.18993268 |  0.35310596 |  0.09664086 | -0.492865694 | -0.31798122 |\n",
       "| 34 |  1.44645031 |  0.328543578 |  0.32667241 | -0.300749054 | -1.01770357 | -0.777213376 | -0.762823567 |  0.19990466 | -0.36056831 | -0.143116658 | â‹¯ | -0.33808762 |  0.16435665 | -0.3942531236 |  0.01195671 | -0.17321962 | -0.13604057 | -0.36331346 | -0.46914968 |  0.105545635 | -0.36518924 |\n",
       "| 23 |  0.04754928 | -0.660916598 |  2.03186221 | -0.500931958 | -1.01770357 |  0.290271525 |  0.126439723 |  0.75946942 | -0.33097686 | -0.057861180 | â‹¯ |  0.24905714 |  0.06900338 | -0.4031809368 |  0.08881141 |  0.50467914 | -0.18679525 |  0.27972885 |  1.32422465 |  0.624400137 | -0.22988686 |\n",
       "| 54 |  0.47310322 | -0.195425198 | -0.35576607 | -0.515324225 | -1.01770357 | -1.092249883 | -0.171057793 | -0.25246798 | -0.20426069 | -0.416186634 | â‹¯ |  0.86781747 |  1.32880802 |  0.2288094333 |  0.18938530 | -0.04091907 |  0.70585357 |  0.19730013 | -0.43394722 | -0.979660281 | -0.32887805 |\n",
       "\n"
      ],
      "text/plain": [
       "   1           503538       2           144571       144568      53947       \n",
       "9  -1.58231886  0.226126567  1.66568079  0.416205261 -0.81472165  0.752172262\n",
       "3   0.41362108  0.026864237 -0.63666687 -0.520852783  3.15369407 -0.352937973\n",
       "35 -1.22017300 -0.465444781 -0.17419729 -0.151427753  2.88161537 -0.398296587\n",
       "18  0.07509568 -0.176204605 -0.32685866 -0.301583681 -1.01770357 -0.457284541\n",
       "7   0.05888384 -0.702086411  0.47458381  0.115722317 -1.01770357 -0.812063186\n",
       "48 -0.66201015 -0.458452942 -1.24156824  0.546215021 -0.98862550 -0.235179430\n",
       "30  0.42966948 -0.844845961 -0.98130509 -0.556570291 -1.01770357  0.209973995\n",
       "14 -0.11535008 -0.184710883 -0.45533603  0.118023126  3.30190882 -0.454308700\n",
       "13  0.67577556 -0.482031312 -1.63309646  0.490900241  2.39125358 -0.791932925\n",
       "46  0.51387636  0.005365473 -0.61054331  0.145104377  0.02495034 -0.032976780\n",
       "45 -0.40772895  1.033369372  0.22458031  1.535996269 -0.38789368 -0.080393783\n",
       "11 -1.16982847 -0.682889907 -0.82723364 -0.446609752  4.97014346  1.267812028\n",
       "17 -0.09359233 -0.259966422  1.05863219 -0.454279206 -0.33880691  0.577770083\n",
       "2  -0.31468182 -0.279128699  1.24142519  0.535478896 -1.01770357  1.055935983\n",
       "12 -0.04601746  1.502867859 -0.84960551 -0.702546587  0.63181953  1.418936265\n",
       "8   0.53285684 -0.514309629 -1.61717860 -0.707315341 -0.28577065 -1.050975264\n",
       "49  0.75573663  0.422839465  0.03443464 -0.044468476  1.70789812  0.103708933\n",
       "10  0.44967917 -0.125606335 -0.94284212 -0.613896552  0.30014311 -0.800701408\n",
       "16 -0.81082941  0.810534942  1.08458350 -0.574747402 -0.30170805  0.238897740\n",
       "38  0.02073447  0.430901224 -0.32990049 -0.332346436 -1.01770357 -0.048997533\n",
       "6  -1.94961413 -1.593940748  0.66314089  2.034846587 -1.01770357  0.723463802\n",
       "5   0.49017147 -0.257899257 -0.67680949  0.030618037 -0.80238739  0.138944720\n",
       "36 -0.06181345 -0.002624338  0.98195378  0.756623465 -1.01770357 -0.453767465\n",
       "29  1.00053127  1.315579836 -2.21891174 -0.517299386 -1.01770357 -0.663916034\n",
       "47 -0.66116004 -0.550493332  1.78785641  0.764998907 -0.75935204  1.152244151\n",
       "44 -0.08459075  0.135498930  1.22513370  1.905702575 -0.93344747  0.380112324\n",
       "15 -0.14481244  1.302958389 -1.15111164 -0.005086172  2.90104151  1.133922145\n",
       "42 -0.22502479  0.341151245  0.31639849 -0.358777357 -0.95003610  0.828118034\n",
       "53  0.90689509 -0.327227288 -0.54435844  0.011554165 -1.01770357  0.002676076\n",
       "27  0.95860854  0.848242647  0.31639849 -0.181995218 -0.87268012 -0.793651120\n",
       "21  0.92767353  0.351954821  0.33829470 -0.435412909 -1.01770357 -0.880853812\n",
       "50 -0.92372234 -0.020598068 -1.26427983 -0.117569443 -0.96750137  1.093664232\n",
       "4  -0.91234682 -1.089310316  0.23970161  0.203992089  0.53103697  0.767566324\n",
       "40 -0.19708134  0.283153541  1.18647523  0.392100608 -1.01770357  0.175596457\n",
       "25  0.71843750 -0.047598322  0.73705744  0.253308910  0.48117817 -0.011900328\n",
       "52  0.25690495  0.196130822 -1.81640023 -0.435412909 -1.01770357 -0.594845995\n",
       "19  0.83904346  0.408298127 -0.25034316 -0.585176536  1.40950498 -0.818328637\n",
       "41 -0.40860109 -0.048669723  2.96944712 -0.897011424 -1.01770357 -0.709012316\n",
       "34  1.44645031  0.328543578  0.32667241 -0.300749054 -1.01770357 -0.777213376\n",
       "23  0.04754928 -0.660916598  2.03186221 -0.500931958 -1.01770357  0.290271525\n",
       "54  0.47310322 -0.195425198 -0.35576607 -0.515324225 -1.01770357 -1.092249883\n",
       "   8086         65985       13          51166        â‹¯ 55055       11130      \n",
       "9   0.487429786 -0.11137395  2.28027252  0.074114330 â‹¯ -0.51800739 -0.62215237\n",
       "3   0.217370469  0.94451945  1.21879050  0.408285561 â‹¯ -0.77789408  0.47804777\n",
       "35  0.117332737  0.86124177 -0.15999967 -0.427789287 â‹¯ -0.32027729 -0.86643923\n",
       "18  0.244340206  0.37405060 -0.38792631  0.498749883 â‹¯  0.56521058  0.37410214\n",
       "7  -0.520537587 -0.83866229 -0.15818095  0.252377818 â‹¯  0.33433512  0.87387503\n",
       "48 -0.209526830  0.73946028 -0.38792631  0.483951204 â‹¯ -0.23997050  0.20676718\n",
       "30 -1.275860765 -0.63456805 -0.38792631 -0.364462502 â‹¯  1.41658928  0.06242660\n",
       "14  0.242836107  0.10825169 -0.38792631 -0.775882897 â‹¯  0.33614144 -0.17613154\n",
       "13 -0.070765240  0.60201350  0.49829857  0.515139163 â‹¯ -0.43369412  1.13091160\n",
       "46  0.042689150  0.29231340  0.27977847 -0.567818972 â‹¯  0.63079954  1.03166565\n",
       "45  0.175954760 -0.65267896 -0.38792631 -0.887038183 â‹¯ -1.07644884 -0.45707750\n",
       "11 -0.159704812  2.30227398  1.17731337 -0.784427694 â‹¯ -0.77856996 -1.01200334\n",
       "17 -0.153125468 -0.98818177  0.15765864 -0.001514237 â‹¯ -0.17379026  0.74040639\n",
       "2   0.003660287 -0.14663585 -0.29233936 -0.219415612 â‹¯ -0.97348238 -0.76822450\n",
       "12  0.740208243  0.69348873 -0.25497068  0.575712444 â‹¯ -1.51889892 -0.62973116\n",
       "8  -0.089809072 -0.12191303 -0.04747715  0.814098058 â‹¯  2.13134004  0.79354018\n",
       "49 -0.729380070  0.22491213 -0.13340538 -0.257816120 â‹¯ -0.09931866  0.50448279\n",
       "10 -0.200123140  0.60505725 -0.04817242 -1.070957859 â‹¯  0.58714486  1.51680290\n",
       "16  0.160629353 -0.84858354 -0.27134032  2.080058576 â‹¯ -0.49731657 -0.93868918\n",
       "38 -0.497132266 -0.55377487 -0.31726972  0.037785343 â‹¯  0.49836945 -0.05559454\n",
       "6  -0.249486829 -0.37863586 -0.21435513 -0.275970621 â‹¯ -0.33982929  0.02291629\n",
       "5  -0.244429040 -0.70008815 -0.38792631  0.093197491 â‹¯  0.35049009  0.41415905\n",
       "36 -0.124112189 -0.01417041 -0.18193651  0.173815168 â‹¯  0.57650194  0.37556121\n",
       "29  0.482680155  1.00165017 -0.31958176  0.101726654 â‹¯ -0.39822385 -0.31194865\n",
       "47 -0.411004017 -0.99325010 -0.38792631 -0.288527050 â‹¯ -0.59926198 -0.26291383\n",
       "44  0.263603810 -0.17956652 -0.38792631 -0.562585964 â‹¯ -0.23502392 -1.19925542\n",
       "15  0.768757253  0.91087530  1.36327072  0.256455283 â‹¯ -0.52527974 -1.40244281\n",
       "42  0.560142212 -0.62435000 -0.29013759 -0.472140399 â‹¯ -0.34399706 -1.08187780\n",
       "53  0.824120295 -0.26244684  0.01225975  0.394336735 â‹¯ -0.19119768 -1.23898244\n",
       "27  1.739264334 -0.12491037 -0.33570934  0.454335213 â‹¯  1.00413156 -0.03714418\n",
       "21 -0.823195988 -0.79939760 -0.38792631  1.988527342 â‹¯  0.16868742 -0.15404176\n",
       "50 -0.360885411 -1.32322790  1.36663079  0.220491607 â‹¯  0.49282084  0.09725215\n",
       "4  -0.153125468 -0.21753685  0.38520734 -0.649484686 â‹¯  0.45022427 -0.65085397\n",
       "40 -0.285697135 -0.05100234 -0.38792631 -0.026682987 â‹¯ -0.31122740  0.33162208\n",
       "25  0.121104364  0.27318269 -0.08274479 -0.063968115 â‹¯  0.21330995  0.53110123\n",
       "52  0.559322988 -0.45761784 -0.17048984 -1.373912670 â‹¯ -0.51324287 -0.11879141\n",
       "19  0.281720483 -0.03626696 -0.29837480  0.223474960 â‹¯  0.46655105  0.54872670\n",
       "41 -0.667824029  0.41864303 -0.38792631  0.040927493 â‹¯ -0.13648162  0.38776064\n",
       "34 -0.762823567  0.19990466 -0.36056831 -0.143116658 â‹¯ -0.33808762  0.16435665\n",
       "23  0.126439723  0.75946942 -0.33097686 -0.057861180 â‹¯  0.24905714  0.06900338\n",
       "54 -0.171057793 -0.25246798 -0.20426069 -0.416186634 â‹¯  0.86781747  1.32880802\n",
       "   7789          158586      79364       440590      79699       7791       \n",
       "9   0.2274708862 -0.22274651 -0.31517698  0.02419371 -0.35364727  0.91660440\n",
       "3   0.3231840744  0.07771963 -0.13553484 -0.14994607  0.25125628  0.46844425\n",
       "35  0.1563104344 -0.18119199  0.11321388  0.25268109 -0.40650049 -0.12853882\n",
       "18 -0.1170037510  0.32391776 -0.14034456 -0.18993268  0.40220709  0.76877653\n",
       "7   0.3593579706  0.61269151 -0.44520057 -0.12561413  0.15067660  0.56396673\n",
       "48 -0.1790886828 -0.14261207 -0.10593877 -0.10368129 -0.42023214  0.48732913\n",
       "30 -1.4247014274 -0.24798209 -0.11521950  1.03268700  0.46235717  0.57172041\n",
       "14 -0.3655941746 -0.75921926  0.41185003 -0.11559656 -0.05134074 -0.26650284\n",
       "13 -0.2777108820 -0.12975976 -0.06003260 -0.12662805 -0.13856663 -1.21787913\n",
       "46  0.0103432872  0.13307078 -0.06398976 -0.11879850  0.13974445  0.05403603\n",
       "45  0.6808349316  0.03664372  0.34213037 -0.12595742  0.27241290 -0.16797709\n",
       "11  0.0005757279 -0.41480345  0.05113678  0.09727642 -0.16385787 -0.24692816\n",
       "17 -0.4681554262  0.15447363 -0.20567601 -0.17463977  0.21129616  0.49320065\n",
       "2   0.1028616068  0.17016027 -0.06737654 -0.17636986  0.34607368  0.79620927\n",
       "12  0.1098136507 -0.40977490 -0.18345745  0.16842307 -0.19196153  0.65804952\n",
       "8  -0.6054473351 -0.47590384  0.38923947 -0.16430145 -0.15559126 -0.58664907\n",
       "49 -0.1173463375  0.03523810  0.08782326 -0.06818400 -0.03400262 -0.19159567\n",
       "10  0.2051403085  0.24970065  0.50803986  0.70851142  0.45721398 -0.79611580\n",
       "16 -0.1095925899 -0.14107495  0.02426093 -0.12426673 -0.01197064  0.57544109\n",
       "38  0.2066692551 -0.02215850  0.23403080 -0.10698927  0.04638785  0.51787047\n",
       "6   0.8663042318  0.15111765 -0.57423345  0.16435045 -0.79441902 -0.59637515\n",
       "5  -0.2752258429 -0.36741795 -0.39423587 -0.16876892  0.12387581 -1.27476366\n",
       "36  0.5342987385  0.49915050  0.15513046 -0.15267010  0.09423050 -0.30689387\n",
       "29  0.1895656253  0.35678046 -0.24796229 -0.18993268  0.38993575  0.29388544\n",
       "47  0.1458335064 -0.04796896 -0.47627302 -0.08631475  0.25056648  0.16522926\n",
       "44 -0.1301835397  0.18490747  0.29163788 -0.11693721 -0.19036457  0.22075631\n",
       "15  0.9012394246  0.16067435  0.67071102 -0.18993268 -0.11826441 -1.18621327\n",
       "42  0.5367482772  0.23679852  0.16702184 -0.18993268  0.07377460  0.03571408\n",
       "53  0.7186973882 -0.03140992  0.58762230  0.36310638 -0.65733209 -0.25724207\n",
       "27  1.0552302173  1.09627171 -0.05623189  0.70739258  0.10076517 -1.33815381\n",
       "21  0.3311818672  0.06066882  0.21068949 -0.17223253  0.28442772 -0.20843742\n",
       "50 -0.0915385889 -0.23489184 -0.38667176 -0.17428964  0.10105164  0.21650294\n",
       "4   0.0457839900 -0.24236341  0.44765703 -0.18958255 -0.28079830 -0.26692534\n",
       "40 -0.6211025988 -0.09780025 -0.22666792  0.26009037 -0.05134074  0.59374750\n",
       "25 -0.6473035526 -0.54270486  0.10962948 -0.16842562  0.34721238  0.10479040\n",
       "52 -0.5892031981 -0.17134194 -0.08283153 -0.11193973 -0.86381226  0.16751634\n",
       "19 -0.3409820845  0.13252763 -0.53026602 -0.18993268 -0.08828512 -0.15036820\n",
       "41 -0.7786407607 -0.07954015 -0.27904401 -0.18993268  0.35310596  0.09664086\n",
       "34 -0.3942531236  0.01195671 -0.17321962 -0.13604057 -0.36331346 -0.46914968\n",
       "23 -0.4031809368  0.08881141  0.50467914 -0.18679525  0.27972885  1.32422465\n",
       "54  0.2288094333  0.18938530 -0.04091907  0.70585357  0.19730013 -0.43394722\n",
       "   23140        26009      \n",
       "9  -0.365652282 -0.28997347\n",
       "3   0.202778225  0.12502150\n",
       "35  0.798602483 -0.02921499\n",
       "18 -0.193560502  0.20174889\n",
       "7   0.006282023 -0.23951499\n",
       "48  0.187183322 -0.19190377\n",
       "30 -0.687417296  1.00008741\n",
       "14 -0.305194059 -0.84401986\n",
       "13 -0.209915150  0.08612588\n",
       "46 -0.101439718 -0.25613537\n",
       "45  0.400421450  0.32499011\n",
       "11  0.117103894 -0.74993078\n",
       "17 -0.153231356 -1.04327463\n",
       "2   0.417834906 -0.49855148\n",
       "12  0.978488181 -0.27105096\n",
       "8  -0.535177362  0.71530710\n",
       "49 -0.330417090  0.26656644\n",
       "10  0.242960585  1.18213316\n",
       "16 -0.009577050 -0.11839787\n",
       "38  0.004726486 -0.42979683\n",
       "6  -0.241079994  0.25761504\n",
       "5   0.168245743  0.52170269\n",
       "36 -0.028634074  0.53526920\n",
       "29  0.273667791  0.37929006\n",
       "47  0.611609680  0.48758918\n",
       "44  0.517488704  0.04570634\n",
       "15  0.026281237  0.27000323\n",
       "42  0.022790961 -0.96885980\n",
       "53  0.560198223 -0.54578385\n",
       "27  0.210307940 -0.79727101\n",
       "21 -0.621020206  0.38779320\n",
       "50 -0.434137380  0.88872357\n",
       "4   0.414583686  0.49895492\n",
       "40 -0.153520183  0.21603362\n",
       "25 -0.492865694  0.14336281\n",
       "52 -0.493717489 -0.04120277\n",
       "19 -0.062418433  0.02279346\n",
       "41 -0.492865694 -0.31798122\n",
       "34  0.105545635 -0.36518924\n",
       "23  0.624400137 -0.22988686\n",
       "54 -0.979660281 -0.32887805"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "pn_self_subtract <- as.data.frame(t(pn_self_subtract))  # transpose\n",
    "pn_self_subtract"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "0b8173ef",
   "metadata": {},
   "source": [
    "### Merge"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "5c8aee5d",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table>\n",
       "<caption>A data.frame: 54 Ã— 18582</caption>\n",
       "<thead>\n",
       "\t<tr><th scope=col>Patient</th><th scope=col>OS</th><th scope=col>OS.Event</th><th scope=col>PFS</th><th scope=col>PFS.Event</th><th scope=col>RECIST</th><th scope=col>Age</th><th scope=col>Gender</th><th scope=col>Treatment</th><th scope=col>Site</th><th scope=col>â‹¯</th><th scope=col>55055</th><th scope=col>11130</th><th scope=col>7789</th><th scope=col>158586</th><th scope=col>79364</th><th scope=col>440590</th><th scope=col>79699</th><th scope=col>7791</th><th scope=col>23140</th><th scope=col>26009</th></tr>\n",
       "\t<tr><th scope=col>&lt;I&lt;chr&gt;&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>â‹¯</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><td>1 </td><td> 147</td><td>1</td><td>   9</td><td>1</td><td>0</td><td>48</td><td>1</td><td>Nivolumab    </td><td>LN    </td><td>â‹¯</td><td>         NA</td><td>         NA</td><td>           NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>          NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>10</td><td> 551</td><td>0</td><td>  76</td><td>1</td><td>0</td><td>90</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td> 0.58714486</td><td> 1.51680290</td><td> 0.2051403085</td><td> 0.24970065</td><td> 0.50803986</td><td> 0.70851142</td><td> 0.45721398</td><td>-0.79611580</td><td> 0.242960585</td><td> 1.18213316</td></tr>\n",
       "\t<tr><td>11</td><td> 166</td><td>1</td><td>  78</td><td>1</td><td>0</td><td>66</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-0.77856996</td><td>-1.01200334</td><td> 0.0005757279</td><td>-0.41480345</td><td> 0.05113678</td><td> 0.09727642</td><td>-0.16385787</td><td>-0.24692816</td><td> 0.117103894</td><td>-0.74993078</td></tr>\n",
       "\t<tr><td>12</td><td> 199</td><td>1</td><td>  80</td><td>1</td><td>1</td><td>52</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-1.51889892</td><td>-0.62973116</td><td> 0.1098136507</td><td>-0.40977490</td><td>-0.18345745</td><td> 0.16842307</td><td>-0.19196153</td><td> 0.65804952</td><td> 0.978488181</td><td>-0.27105096</td></tr>\n",
       "\t<tr><td>13</td><td>  96</td><td>1</td><td>  82</td><td>1</td><td>0</td><td>69</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-0.43369412</td><td> 1.13091160</td><td>-0.2777108820</td><td>-0.12975976</td><td>-0.06003260</td><td>-0.12662805</td><td>-0.13856663</td><td>-1.21787913</td><td>-0.209915150</td><td> 0.08612588</td></tr>\n",
       "\t<tr><td>14</td><td> 993</td><td>1</td><td>  83</td><td>1</td><td>0</td><td>58</td><td>0</td><td>Pembrolizumab</td><td>Mucosa</td><td>â‹¯</td><td> 0.33614144</td><td>-0.17613154</td><td>-0.3655941746</td><td>-0.75921926</td><td> 0.41185003</td><td>-0.11559656</td><td>-0.05134074</td><td>-0.26650284</td><td>-0.305194059</td><td>-0.84401986</td></tr>\n",
       "\t<tr><td>15</td><td> 300</td><td>0</td><td>  84</td><td>1</td><td>0</td><td>76</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-0.52527974</td><td>-1.40244281</td><td> 0.9012394246</td><td> 0.16067435</td><td> 0.67071102</td><td>-0.18993268</td><td>-0.11826441</td><td>-1.18621327</td><td> 0.026281237</td><td> 0.27000323</td></tr>\n",
       "\t<tr><td>16</td><td> 169</td><td>1</td><td>  84</td><td>1</td><td>0</td><td>55</td><td>0</td><td>Pembrolizumab</td><td>LN    </td><td>â‹¯</td><td>-0.49731657</td><td>-0.93868918</td><td>-0.1095925899</td><td>-0.14107495</td><td> 0.02426093</td><td>-0.12426673</td><td>-0.01197064</td><td> 0.57544109</td><td>-0.009577050</td><td>-0.11839787</td></tr>\n",
       "\t<tr><td>17</td><td> 258</td><td>1</td><td>  96</td><td>1</td><td>0</td><td>37</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-0.17379026</td><td> 0.74040639</td><td>-0.4681554262</td><td> 0.15447363</td><td>-0.20567601</td><td>-0.17463977</td><td> 0.21129616</td><td> 0.49320065</td><td>-0.153231356</td><td>-1.04327463</td></tr>\n",
       "\t<tr><td>18</td><td> 228</td><td>1</td><td> 100</td><td>1</td><td>0</td><td>62</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td> 0.56521058</td><td> 0.37410214</td><td>-0.1170037510</td><td> 0.32391776</td><td>-0.14034456</td><td>-0.18993268</td><td> 0.40220709</td><td> 0.76877653</td><td>-0.193560502</td><td> 0.20174889</td></tr>\n",
       "\t<tr><td>19</td><td> 385</td><td>1</td><td> 125</td><td>1</td><td>1</td><td>54</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td> 0.46655105</td><td> 0.54872670</td><td>-0.3409820845</td><td> 0.13252763</td><td>-0.53026602</td><td>-0.18993268</td><td>-0.08828512</td><td>-0.15036820</td><td>-0.062418433</td><td> 0.02279346</td></tr>\n",
       "\t<tr><td>2 </td><td>  65</td><td>1</td><td>  13</td><td>1</td><td>0</td><td>61</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-0.97348238</td><td>-0.76822450</td><td> 0.1028616068</td><td> 0.17016027</td><td>-0.06737654</td><td>-0.17636986</td><td> 0.34607368</td><td> 0.79620927</td><td> 0.417834906</td><td>-0.49855148</td></tr>\n",
       "\t<tr><td>20</td><td> 553</td><td>1</td><td> 156</td><td>1</td><td>2</td><td>45</td><td>1</td><td>Pembrolizumab</td><td>Brain </td><td>â‹¯</td><td>         NA</td><td>         NA</td><td>           NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>          NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>21</td><td> 551</td><td>1</td><td> 166</td><td>1</td><td>1</td><td>67</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td> 0.16868742</td><td>-0.15404176</td><td> 0.3311818672</td><td> 0.06066882</td><td> 0.21068949</td><td>-0.17223253</td><td> 0.28442772</td><td>-0.20843742</td><td>-0.621020206</td><td> 0.38779320</td></tr>\n",
       "\t<tr><td>22</td><td> 379</td><td>0</td><td> 176</td><td>1</td><td>1</td><td>69</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>         NA</td><td>         NA</td><td>           NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>          NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>23</td><td> 191</td><td>1</td><td> 191</td><td>1</td><td>1</td><td>40</td><td>0</td><td>Nivolumab    </td><td>SQ    </td><td>â‹¯</td><td> 0.24905714</td><td> 0.06900338</td><td>-0.4031809368</td><td> 0.08881141</td><td> 0.50467914</td><td>-0.18679525</td><td> 0.27972885</td><td> 1.32422465</td><td> 0.624400137</td><td>-0.22988686</td></tr>\n",
       "\t<tr><td>24</td><td> 407</td><td>1</td><td> 197</td><td>1</td><td>1</td><td>54</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>         NA</td><td>         NA</td><td>           NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>          NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>25</td><td> 897</td><td>1</td><td> 271</td><td>1</td><td>2</td><td>49</td><td>0</td><td>Nivolumab    </td><td>SQ    </td><td>â‹¯</td><td> 0.21330995</td><td> 0.53110123</td><td>-0.6473035526</td><td>-0.54270486</td><td> 0.10962948</td><td>-0.16842562</td><td> 0.34721238</td><td> 0.10479040</td><td>-0.492865694</td><td> 0.14336281</td></tr>\n",
       "\t<tr><td>26</td><td> 275</td><td>0</td><td> 275</td><td>0</td><td>3</td><td>89</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>         NA</td><td>         NA</td><td>           NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>          NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>27</td><td>1067</td><td>1</td><td> 314</td><td>1</td><td>2</td><td>76</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td> 1.00413156</td><td>-0.03714418</td><td> 1.0552302173</td><td> 1.09627171</td><td>-0.05623189</td><td> 0.70739258</td><td> 0.10076517</td><td>-1.33815381</td><td> 0.210307940</td><td>-0.79727101</td></tr>\n",
       "\t<tr><td>28</td><td> 324</td><td>0</td><td> 324</td><td>0</td><td>2</td><td>81</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>         NA</td><td>         NA</td><td>           NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>          NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>29</td><td> 825</td><td>1</td><td> 335</td><td>1</td><td>1</td><td>55</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-0.39822385</td><td>-0.31194865</td><td> 0.1895656253</td><td> 0.35678046</td><td>-0.24796229</td><td>-0.18993268</td><td> 0.38993575</td><td> 0.29388544</td><td> 0.273667791</td><td> 0.37929006</td></tr>\n",
       "\t<tr><td>3 </td><td>  59</td><td>1</td><td>  23</td><td>1</td><td>0</td><td>50</td><td>0</td><td>Nivolumab    </td><td>SQ    </td><td>â‹¯</td><td>-0.77789408</td><td> 0.47804777</td><td> 0.3231840744</td><td> 0.07771963</td><td>-0.13553484</td><td>-0.14994607</td><td> 0.25125628</td><td> 0.46844425</td><td> 0.202778225</td><td> 0.12502150</td></tr>\n",
       "\t<tr><td>30</td><td> 581</td><td>0</td><td> 358</td><td>1</td><td>1</td><td>86</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td> 1.41658928</td><td> 0.06242660</td><td>-1.4247014274</td><td>-0.24798209</td><td>-0.11521950</td><td> 1.03268700</td><td> 0.46235717</td><td> 0.57172041</td><td>-0.687417296</td><td> 1.00008741</td></tr>\n",
       "\t<tr><td>31</td><td> 365</td><td>0</td><td> 365</td><td>0</td><td>2</td><td>74</td><td>1</td><td>Nivolumab    </td><td>SQ    </td><td>â‹¯</td><td>         NA</td><td>         NA</td><td>           NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>          NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>32</td><td> 460</td><td>0</td><td> 460</td><td>0</td><td>3</td><td>69</td><td>1</td><td>Pembrolizumab</td><td>Brain </td><td>â‹¯</td><td>         NA</td><td>         NA</td><td>           NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>          NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>33</td><td> 477</td><td>0</td><td> 477</td><td>0</td><td>3</td><td>76</td><td>0</td><td>Pembrolizumab</td><td>LN    </td><td>â‹¯</td><td>         NA</td><td>         NA</td><td>           NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>          NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>34</td><td> 878</td><td>1</td><td> 544</td><td>1</td><td>2</td><td>78</td><td>0</td><td>Pembrolizumab</td><td>LN    </td><td>â‹¯</td><td>-0.33808762</td><td> 0.16435665</td><td>-0.3942531236</td><td> 0.01195671</td><td>-0.17321962</td><td>-0.13604057</td><td>-0.36331346</td><td>-0.46914968</td><td> 0.105545635</td><td>-0.36518924</td></tr>\n",
       "\t<tr><td>35</td><td>1091</td><td>0</td><td> 586</td><td>1</td><td>2</td><td>55</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-0.32027729</td><td>-0.86643923</td><td> 0.1563104344</td><td>-0.18119199</td><td> 0.11321388</td><td> 0.25268109</td><td>-0.40650049</td><td>-0.12853882</td><td> 0.798602483</td><td>-0.02921499</td></tr>\n",
       "\t<tr><td>36</td><td> 607</td><td>1</td><td> 590</td><td>1</td><td>2</td><td>76</td><td>0</td><td>Nivolumab    </td><td>SQ    </td><td>â‹¯</td><td> 0.57650194</td><td> 0.37556121</td><td> 0.5342987385</td><td> 0.49915050</td><td> 0.15513046</td><td>-0.15267010</td><td> 0.09423050</td><td>-0.30689387</td><td>-0.028634074</td><td> 0.53526920</td></tr>\n",
       "\t<tr><td>37</td><td> 910</td><td>0</td><td> 647</td><td>1</td><td>3</td><td>66</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>         NA</td><td>         NA</td><td>           NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>          NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>38</td><td>1547</td><td>0</td><td> 755</td><td>1</td><td>2</td><td>69</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td> 0.49836945</td><td>-0.05559454</td><td> 0.2066692551</td><td>-0.02215850</td><td> 0.23403080</td><td>-0.10698927</td><td> 0.04638785</td><td> 0.51787047</td><td> 0.004726486</td><td>-0.42979683</td></tr>\n",
       "\t<tr><td>39</td><td> 815</td><td>0</td><td> 815</td><td>0</td><td>1</td><td>72</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>         NA</td><td>         NA</td><td>           NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>          NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>4 </td><td>  22</td><td>1</td><td>  23</td><td>1</td><td>0</td><td>84</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td> 0.45022427</td><td>-0.65085397</td><td> 0.0457839900</td><td>-0.24236341</td><td> 0.44765703</td><td>-0.18958255</td><td>-0.28079830</td><td>-0.26692534</td><td> 0.414583686</td><td> 0.49895492</td></tr>\n",
       "\t<tr><td>40</td><td> 845</td><td>0</td><td> 845</td><td>0</td><td>2</td><td>78</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-0.31122740</td><td> 0.33162208</td><td>-0.6211025988</td><td>-0.09780025</td><td>-0.22666792</td><td> 0.26009037</td><td>-0.05134074</td><td> 0.59374750</td><td>-0.153520183</td><td> 0.21603362</td></tr>\n",
       "\t<tr><td>41</td><td> 886</td><td>0</td><td> 870</td><td>1</td><td>2</td><td>61</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-0.13648162</td><td> 0.38776064</td><td>-0.7786407607</td><td>-0.07954015</td><td>-0.27904401</td><td>-0.18993268</td><td> 0.35310596</td><td> 0.09664086</td><td>-0.492865694</td><td>-0.31798122</td></tr>\n",
       "\t<tr><td>42</td><td> 891</td><td>0</td><td> 891</td><td>0</td><td>3</td><td>59</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-0.34399706</td><td>-1.08187780</td><td> 0.5367482772</td><td> 0.23679852</td><td> 0.16702184</td><td>-0.18993268</td><td> 0.07377460</td><td> 0.03571408</td><td> 0.022790961</td><td>-0.96885980</td></tr>\n",
       "\t<tr><td>43</td><td> 905</td><td>0</td><td> 905</td><td>0</td><td>3</td><td>63</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>         NA</td><td>         NA</td><td>           NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>          NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>44</td><td>1075</td><td>0</td><td>1075</td><td>0</td><td>2</td><td>45</td><td>1</td><td>Pembrolizumab</td><td>LN    </td><td>â‹¯</td><td>-0.23502392</td><td>-1.19925542</td><td>-0.1301835397</td><td> 0.18490747</td><td> 0.29163788</td><td>-0.11693721</td><td>-0.19036457</td><td> 0.22075631</td><td> 0.517488704</td><td> 0.04570634</td></tr>\n",
       "\t<tr><td>45</td><td>1085</td><td>0</td><td>1085</td><td>0</td><td>2</td><td>82</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-1.07644884</td><td>-0.45707750</td><td> 0.6808349316</td><td> 0.03664372</td><td> 0.34213037</td><td>-0.12595742</td><td> 0.27241290</td><td>-0.16797709</td><td> 0.400421450</td><td> 0.32499011</td></tr>\n",
       "\t<tr><td>46</td><td>1098</td><td>0</td><td>1098</td><td>0</td><td>2</td><td>71</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td> 0.63079954</td><td> 1.03166565</td><td> 0.0103432872</td><td> 0.13307078</td><td>-0.06398976</td><td>-0.11879850</td><td> 0.13974445</td><td> 0.05403603</td><td>-0.101439718</td><td>-0.25613537</td></tr>\n",
       "\t<tr><td>47</td><td>1174</td><td>0</td><td>1174</td><td>0</td><td>2</td><td>62</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-0.59926198</td><td>-0.26291383</td><td> 0.1458335064</td><td>-0.04796896</td><td>-0.47627302</td><td>-0.08631475</td><td> 0.25056648</td><td> 0.16522926</td><td> 0.611609680</td><td> 0.48758918</td></tr>\n",
       "\t<tr><td>48</td><td>1189</td><td>0</td><td>1189</td><td>0</td><td>2</td><td>40</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-0.23997050</td><td> 0.20676718</td><td>-0.1790886828</td><td>-0.14261207</td><td>-0.10593877</td><td>-0.10368129</td><td>-0.42023214</td><td> 0.48732913</td><td> 0.187183322</td><td>-0.19190377</td></tr>\n",
       "\t<tr><td>49</td><td>1328</td><td>0</td><td>1328</td><td>0</td><td>3</td><td>72</td><td>1</td><td>Nivolumab    </td><td>SQ    </td><td>â‹¯</td><td>-0.09931866</td><td> 0.50448279</td><td>-0.1173463375</td><td> 0.03523810</td><td> 0.08782326</td><td>-0.06818400</td><td>-0.03400262</td><td>-0.19159567</td><td>-0.330417090</td><td> 0.26656644</td></tr>\n",
       "\t<tr><td>5 </td><td> 155</td><td>1</td><td>  39</td><td>1</td><td>0</td><td>67</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td> 0.35049009</td><td> 0.41415905</td><td>-0.2752258429</td><td>-0.36741795</td><td>-0.39423587</td><td>-0.16876892</td><td> 0.12387581</td><td>-1.27476366</td><td> 0.168245743</td><td> 0.52170269</td></tr>\n",
       "\t<tr><td>50</td><td>1342</td><td>0</td><td>1342</td><td>0</td><td>3</td><td>86</td><td>0</td><td>Nivolumab    </td><td>SQ    </td><td>â‹¯</td><td> 0.49282084</td><td> 0.09725215</td><td>-0.0915385889</td><td>-0.23489184</td><td>-0.38667176</td><td>-0.17428964</td><td> 0.10105164</td><td> 0.21650294</td><td>-0.434137380</td><td> 0.88872357</td></tr>\n",
       "\t<tr><td>51</td><td>1397</td><td>0</td><td>1397</td><td>0</td><td>3</td><td>64</td><td>0</td><td>Nivolumab    </td><td>SQ    </td><td>â‹¯</td><td>         NA</td><td>         NA</td><td>           NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>          NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>52</td><td>1553</td><td>0</td><td>1553</td><td>0</td><td>2</td><td>63</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-0.51324287</td><td>-0.11879141</td><td>-0.5892031981</td><td>-0.17134194</td><td>-0.08283153</td><td>-0.11193973</td><td>-0.86381226</td><td> 0.16751634</td><td>-0.493717489</td><td>-0.04120277</td></tr>\n",
       "\t<tr><td>53</td><td>1589</td><td>0</td><td>1589</td><td>0</td><td>3</td><td>71</td><td>1</td><td>Pembrolizumab</td><td>LN    </td><td>â‹¯</td><td>-0.19119768</td><td>-1.23898244</td><td> 0.7186973882</td><td>-0.03140992</td><td> 0.58762230</td><td> 0.36310638</td><td>-0.65733209</td><td>-0.25724207</td><td> 0.560198223</td><td>-0.54578385</td></tr>\n",
       "\t<tr><td>54</td><td>1603</td><td>0</td><td>1603</td><td>0</td><td>2</td><td>52</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td> 0.86781747</td><td> 1.32880802</td><td> 0.2288094333</td><td> 0.18938530</td><td>-0.04091907</td><td> 0.70585357</td><td> 0.19730013</td><td>-0.43394722</td><td>-0.979660281</td><td>-0.32887805</td></tr>\n",
       "\t<tr><td>6 </td><td>  94</td><td>1</td><td>  42</td><td>1</td><td>0</td><td>68</td><td>0</td><td>Nivolumab    </td><td>LN    </td><td>â‹¯</td><td>-0.33982929</td><td> 0.02291629</td><td> 0.8663042318</td><td> 0.15111765</td><td>-0.57423345</td><td> 0.16435045</td><td>-0.79441902</td><td>-0.59637515</td><td>-0.241079994</td><td> 0.25761504</td></tr>\n",
       "\t<tr><td>7 </td><td>  80</td><td>1</td><td>  47</td><td>1</td><td>0</td><td>57</td><td>1</td><td>Nivolumab    </td><td>LN    </td><td>â‹¯</td><td> 0.33433512</td><td> 0.87387503</td><td> 0.3593579706</td><td> 0.61269151</td><td>-0.44520057</td><td>-0.12561413</td><td> 0.15067660</td><td> 0.56396673</td><td> 0.006282023</td><td>-0.23951499</td></tr>\n",
       "\t<tr><td>8 </td><td>  58</td><td>1</td><td>  58</td><td>1</td><td>0</td><td>85</td><td>1</td><td>Nivolumab    </td><td>SQ    </td><td>â‹¯</td><td> 2.13134004</td><td> 0.79354018</td><td>-0.6054473351</td><td>-0.47590384</td><td> 0.38923947</td><td>-0.16430145</td><td>-0.15559126</td><td>-0.58664907</td><td>-0.535177362</td><td> 0.71530710</td></tr>\n",
       "\t<tr><td>9 </td><td>  99</td><td>1</td><td>  71</td><td>1</td><td>0</td><td>70</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-0.51800739</td><td>-0.62215237</td><td> 0.2274708862</td><td>-0.22274651</td><td>-0.31517698</td><td> 0.02419371</td><td>-0.35364727</td><td> 0.91660440</td><td>-0.365652282</td><td>-0.28997347</td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A data.frame: 54 Ã— 18582\n",
       "\\begin{tabular}{lllllllllllllllllllll}\n",
       " Patient & OS & OS.Event & PFS & PFS.Event & RECIST & Age & Gender & Treatment & Site & â‹¯ & 55055 & 11130 & 7789 & 158586 & 79364 & 440590 & 79699 & 7791 & 23140 & 26009\\\\\n",
       " <I<chr>> & <int> & <int> & <int> & <int> & <int> & <int> & <int> & <fct> & <fct> & â‹¯ & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl>\\\\\n",
       "\\hline\n",
       "\t 1  &  147 & 1 &    9 & 1 & 0 & 48 & 1 & Nivolumab     & LN     & â‹¯ &          NA &          NA &            NA &          NA &          NA &          NA &          NA &          NA &           NA &          NA\\\\\n",
       "\t 10 &  551 & 0 &   76 & 1 & 0 & 90 & 0 & Pembrolizumab & SQ     & â‹¯ &  0.58714486 &  1.51680290 &  0.2051403085 &  0.24970065 &  0.50803986 &  0.70851142 &  0.45721398 & -0.79611580 &  0.242960585 &  1.18213316\\\\\n",
       "\t 11 &  166 & 1 &   78 & 1 & 0 & 66 & 0 & Pembrolizumab & SQ     & â‹¯ & -0.77856996 & -1.01200334 &  0.0005757279 & -0.41480345 &  0.05113678 &  0.09727642 & -0.16385787 & -0.24692816 &  0.117103894 & -0.74993078\\\\\n",
       "\t 12 &  199 & 1 &   80 & 1 & 1 & 52 & 0 & Pembrolizumab & SQ     & â‹¯ & -1.51889892 & -0.62973116 &  0.1098136507 & -0.40977490 & -0.18345745 &  0.16842307 & -0.19196153 &  0.65804952 &  0.978488181 & -0.27105096\\\\\n",
       "\t 13 &   96 & 1 &   82 & 1 & 0 & 69 & 0 & Pembrolizumab & SQ     & â‹¯ & -0.43369412 &  1.13091160 & -0.2777108820 & -0.12975976 & -0.06003260 & -0.12662805 & -0.13856663 & -1.21787913 & -0.209915150 &  0.08612588\\\\\n",
       "\t 14 &  993 & 1 &   83 & 1 & 0 & 58 & 0 & Pembrolizumab & Mucosa & â‹¯ &  0.33614144 & -0.17613154 & -0.3655941746 & -0.75921926 &  0.41185003 & -0.11559656 & -0.05134074 & -0.26650284 & -0.305194059 & -0.84401986\\\\\n",
       "\t 15 &  300 & 0 &   84 & 1 & 0 & 76 & 1 & Pembrolizumab & SQ     & â‹¯ & -0.52527974 & -1.40244281 &  0.9012394246 &  0.16067435 &  0.67071102 & -0.18993268 & -0.11826441 & -1.18621327 &  0.026281237 &  0.27000323\\\\\n",
       "\t 16 &  169 & 1 &   84 & 1 & 0 & 55 & 0 & Pembrolizumab & LN     & â‹¯ & -0.49731657 & -0.93868918 & -0.1095925899 & -0.14107495 &  0.02426093 & -0.12426673 & -0.01197064 &  0.57544109 & -0.009577050 & -0.11839787\\\\\n",
       "\t 17 &  258 & 1 &   96 & 1 & 0 & 37 & 0 & Pembrolizumab & SQ     & â‹¯ & -0.17379026 &  0.74040639 & -0.4681554262 &  0.15447363 & -0.20567601 & -0.17463977 &  0.21129616 &  0.49320065 & -0.153231356 & -1.04327463\\\\\n",
       "\t 18 &  228 & 1 &  100 & 1 & 0 & 62 & 0 & Pembrolizumab & SQ     & â‹¯ &  0.56521058 &  0.37410214 & -0.1170037510 &  0.32391776 & -0.14034456 & -0.18993268 &  0.40220709 &  0.76877653 & -0.193560502 &  0.20174889\\\\\n",
       "\t 19 &  385 & 1 &  125 & 1 & 1 & 54 & 0 & Pembrolizumab & SQ     & â‹¯ &  0.46655105 &  0.54872670 & -0.3409820845 &  0.13252763 & -0.53026602 & -0.18993268 & -0.08828512 & -0.15036820 & -0.062418433 &  0.02279346\\\\\n",
       "\t 2  &   65 & 1 &   13 & 1 & 0 & 61 & 1 & Pembrolizumab & SQ     & â‹¯ & -0.97348238 & -0.76822450 &  0.1028616068 &  0.17016027 & -0.06737654 & -0.17636986 &  0.34607368 &  0.79620927 &  0.417834906 & -0.49855148\\\\\n",
       "\t 20 &  553 & 1 &  156 & 1 & 2 & 45 & 1 & Pembrolizumab & Brain  & â‹¯ &          NA &          NA &            NA &          NA &          NA &          NA &          NA &          NA &           NA &          NA\\\\\n",
       "\t 21 &  551 & 1 &  166 & 1 & 1 & 67 & 0 & Pembrolizumab & SQ     & â‹¯ &  0.16868742 & -0.15404176 &  0.3311818672 &  0.06066882 &  0.21068949 & -0.17223253 &  0.28442772 & -0.20843742 & -0.621020206 &  0.38779320\\\\\n",
       "\t 22 &  379 & 0 &  176 & 1 & 1 & 69 & 1 & Pembrolizumab & SQ     & â‹¯ &          NA &          NA &            NA &          NA &          NA &          NA &          NA &          NA &           NA &          NA\\\\\n",
       "\t 23 &  191 & 1 &  191 & 1 & 1 & 40 & 0 & Nivolumab     & SQ     & â‹¯ &  0.24905714 &  0.06900338 & -0.4031809368 &  0.08881141 &  0.50467914 & -0.18679525 &  0.27972885 &  1.32422465 &  0.624400137 & -0.22988686\\\\\n",
       "\t 24 &  407 & 1 &  197 & 1 & 1 & 54 & 1 & Pembrolizumab & SQ     & â‹¯ &          NA &          NA &            NA &          NA &          NA &          NA &          NA &          NA &           NA &          NA\\\\\n",
       "\t 25 &  897 & 1 &  271 & 1 & 2 & 49 & 0 & Nivolumab     & SQ     & â‹¯ &  0.21330995 &  0.53110123 & -0.6473035526 & -0.54270486 &  0.10962948 & -0.16842562 &  0.34721238 &  0.10479040 & -0.492865694 &  0.14336281\\\\\n",
       "\t 26 &  275 & 0 &  275 & 0 & 3 & 89 & 1 & Pembrolizumab & SQ     & â‹¯ &          NA &          NA &            NA &          NA &          NA &          NA &          NA &          NA &           NA &          NA\\\\\n",
       "\t 27 & 1067 & 1 &  314 & 1 & 2 & 76 & 0 & Pembrolizumab & SQ     & â‹¯ &  1.00413156 & -0.03714418 &  1.0552302173 &  1.09627171 & -0.05623189 &  0.70739258 &  0.10076517 & -1.33815381 &  0.210307940 & -0.79727101\\\\\n",
       "\t 28 &  324 & 0 &  324 & 0 & 2 & 81 & 0 & Pembrolizumab & SQ     & â‹¯ &          NA &          NA &            NA &          NA &          NA &          NA &          NA &          NA &           NA &          NA\\\\\n",
       "\t 29 &  825 & 1 &  335 & 1 & 1 & 55 & 0 & Pembrolizumab & SQ     & â‹¯ & -0.39822385 & -0.31194865 &  0.1895656253 &  0.35678046 & -0.24796229 & -0.18993268 &  0.38993575 &  0.29388544 &  0.273667791 &  0.37929006\\\\\n",
       "\t 3  &   59 & 1 &   23 & 1 & 0 & 50 & 0 & Nivolumab     & SQ     & â‹¯ & -0.77789408 &  0.47804777 &  0.3231840744 &  0.07771963 & -0.13553484 & -0.14994607 &  0.25125628 &  0.46844425 &  0.202778225 &  0.12502150\\\\\n",
       "\t 30 &  581 & 0 &  358 & 1 & 1 & 86 & 1 & Pembrolizumab & SQ     & â‹¯ &  1.41658928 &  0.06242660 & -1.4247014274 & -0.24798209 & -0.11521950 &  1.03268700 &  0.46235717 &  0.57172041 & -0.687417296 &  1.00008741\\\\\n",
       "\t 31 &  365 & 0 &  365 & 0 & 2 & 74 & 1 & Nivolumab     & SQ     & â‹¯ &          NA &          NA &            NA &          NA &          NA &          NA &          NA &          NA &           NA &          NA\\\\\n",
       "\t 32 &  460 & 0 &  460 & 0 & 3 & 69 & 1 & Pembrolizumab & Brain  & â‹¯ &          NA &          NA &            NA &          NA &          NA &          NA &          NA &          NA &           NA &          NA\\\\\n",
       "\t 33 &  477 & 0 &  477 & 0 & 3 & 76 & 0 & Pembrolizumab & LN     & â‹¯ &          NA &          NA &            NA &          NA &          NA &          NA &          NA &          NA &           NA &          NA\\\\\n",
       "\t 34 &  878 & 1 &  544 & 1 & 2 & 78 & 0 & Pembrolizumab & LN     & â‹¯ & -0.33808762 &  0.16435665 & -0.3942531236 &  0.01195671 & -0.17321962 & -0.13604057 & -0.36331346 & -0.46914968 &  0.105545635 & -0.36518924\\\\\n",
       "\t 35 & 1091 & 0 &  586 & 1 & 2 & 55 & 1 & Pembrolizumab & SQ     & â‹¯ & -0.32027729 & -0.86643923 &  0.1563104344 & -0.18119199 &  0.11321388 &  0.25268109 & -0.40650049 & -0.12853882 &  0.798602483 & -0.02921499\\\\\n",
       "\t 36 &  607 & 1 &  590 & 1 & 2 & 76 & 0 & Nivolumab     & SQ     & â‹¯ &  0.57650194 &  0.37556121 &  0.5342987385 &  0.49915050 &  0.15513046 & -0.15267010 &  0.09423050 & -0.30689387 & -0.028634074 &  0.53526920\\\\\n",
       "\t 37 &  910 & 0 &  647 & 1 & 3 & 66 & 0 & Pembrolizumab & SQ     & â‹¯ &          NA &          NA &            NA &          NA &          NA &          NA &          NA &          NA &           NA &          NA\\\\\n",
       "\t 38 & 1547 & 0 &  755 & 1 & 2 & 69 & 1 & Pembrolizumab & SQ     & â‹¯ &  0.49836945 & -0.05559454 &  0.2066692551 & -0.02215850 &  0.23403080 & -0.10698927 &  0.04638785 &  0.51787047 &  0.004726486 & -0.42979683\\\\\n",
       "\t 39 &  815 & 0 &  815 & 0 & 1 & 72 & 0 & Pembrolizumab & SQ     & â‹¯ &          NA &          NA &            NA &          NA &          NA &          NA &          NA &          NA &           NA &          NA\\\\\n",
       "\t 4  &   22 & 1 &   23 & 1 & 0 & 84 & 0 & Pembrolizumab & SQ     & â‹¯ &  0.45022427 & -0.65085397 &  0.0457839900 & -0.24236341 &  0.44765703 & -0.18958255 & -0.28079830 & -0.26692534 &  0.414583686 &  0.49895492\\\\\n",
       "\t 40 &  845 & 0 &  845 & 0 & 2 & 78 & 0 & Pembrolizumab & SQ     & â‹¯ & -0.31122740 &  0.33162208 & -0.6211025988 & -0.09780025 & -0.22666792 &  0.26009037 & -0.05134074 &  0.59374750 & -0.153520183 &  0.21603362\\\\\n",
       "\t 41 &  886 & 0 &  870 & 1 & 2 & 61 & 1 & Pembrolizumab & SQ     & â‹¯ & -0.13648162 &  0.38776064 & -0.7786407607 & -0.07954015 & -0.27904401 & -0.18993268 &  0.35310596 &  0.09664086 & -0.492865694 & -0.31798122\\\\\n",
       "\t 42 &  891 & 0 &  891 & 0 & 3 & 59 & 1 & Pembrolizumab & SQ     & â‹¯ & -0.34399706 & -1.08187780 &  0.5367482772 &  0.23679852 &  0.16702184 & -0.18993268 &  0.07377460 &  0.03571408 &  0.022790961 & -0.96885980\\\\\n",
       "\t 43 &  905 & 0 &  905 & 0 & 3 & 63 & 0 & Pembrolizumab & SQ     & â‹¯ &          NA &          NA &            NA &          NA &          NA &          NA &          NA &          NA &           NA &          NA\\\\\n",
       "\t 44 & 1075 & 0 & 1075 & 0 & 2 & 45 & 1 & Pembrolizumab & LN     & â‹¯ & -0.23502392 & -1.19925542 & -0.1301835397 &  0.18490747 &  0.29163788 & -0.11693721 & -0.19036457 &  0.22075631 &  0.517488704 &  0.04570634\\\\\n",
       "\t 45 & 1085 & 0 & 1085 & 0 & 2 & 82 & 0 & Pembrolizumab & SQ     & â‹¯ & -1.07644884 & -0.45707750 &  0.6808349316 &  0.03664372 &  0.34213037 & -0.12595742 &  0.27241290 & -0.16797709 &  0.400421450 &  0.32499011\\\\\n",
       "\t 46 & 1098 & 0 & 1098 & 0 & 2 & 71 & 0 & Pembrolizumab & SQ     & â‹¯ &  0.63079954 &  1.03166565 &  0.0103432872 &  0.13307078 & -0.06398976 & -0.11879850 &  0.13974445 &  0.05403603 & -0.101439718 & -0.25613537\\\\\n",
       "\t 47 & 1174 & 0 & 1174 & 0 & 2 & 62 & 0 & Pembrolizumab & SQ     & â‹¯ & -0.59926198 & -0.26291383 &  0.1458335064 & -0.04796896 & -0.47627302 & -0.08631475 &  0.25056648 &  0.16522926 &  0.611609680 &  0.48758918\\\\\n",
       "\t 48 & 1189 & 0 & 1189 & 0 & 2 & 40 & 0 & Pembrolizumab & SQ     & â‹¯ & -0.23997050 &  0.20676718 & -0.1790886828 & -0.14261207 & -0.10593877 & -0.10368129 & -0.42023214 &  0.48732913 &  0.187183322 & -0.19190377\\\\\n",
       "\t 49 & 1328 & 0 & 1328 & 0 & 3 & 72 & 1 & Nivolumab     & SQ     & â‹¯ & -0.09931866 &  0.50448279 & -0.1173463375 &  0.03523810 &  0.08782326 & -0.06818400 & -0.03400262 & -0.19159567 & -0.330417090 &  0.26656644\\\\\n",
       "\t 5  &  155 & 1 &   39 & 1 & 0 & 67 & 0 & Pembrolizumab & SQ     & â‹¯ &  0.35049009 &  0.41415905 & -0.2752258429 & -0.36741795 & -0.39423587 & -0.16876892 &  0.12387581 & -1.27476366 &  0.168245743 &  0.52170269\\\\\n",
       "\t 50 & 1342 & 0 & 1342 & 0 & 3 & 86 & 0 & Nivolumab     & SQ     & â‹¯ &  0.49282084 &  0.09725215 & -0.0915385889 & -0.23489184 & -0.38667176 & -0.17428964 &  0.10105164 &  0.21650294 & -0.434137380 &  0.88872357\\\\\n",
       "\t 51 & 1397 & 0 & 1397 & 0 & 3 & 64 & 0 & Nivolumab     & SQ     & â‹¯ &          NA &          NA &            NA &          NA &          NA &          NA &          NA &          NA &           NA &          NA\\\\\n",
       "\t 52 & 1553 & 0 & 1553 & 0 & 2 & 63 & 1 & Pembrolizumab & SQ     & â‹¯ & -0.51324287 & -0.11879141 & -0.5892031981 & -0.17134194 & -0.08283153 & -0.11193973 & -0.86381226 &  0.16751634 & -0.493717489 & -0.04120277\\\\\n",
       "\t 53 & 1589 & 0 & 1589 & 0 & 3 & 71 & 1 & Pembrolizumab & LN     & â‹¯ & -0.19119768 & -1.23898244 &  0.7186973882 & -0.03140992 &  0.58762230 &  0.36310638 & -0.65733209 & -0.25724207 &  0.560198223 & -0.54578385\\\\\n",
       "\t 54 & 1603 & 0 & 1603 & 0 & 2 & 52 & 1 & Pembrolizumab & SQ     & â‹¯ &  0.86781747 &  1.32880802 &  0.2288094333 &  0.18938530 & -0.04091907 &  0.70585357 &  0.19730013 & -0.43394722 & -0.979660281 & -0.32887805\\\\\n",
       "\t 6  &   94 & 1 &   42 & 1 & 0 & 68 & 0 & Nivolumab     & LN     & â‹¯ & -0.33982929 &  0.02291629 &  0.8663042318 &  0.15111765 & -0.57423345 &  0.16435045 & -0.79441902 & -0.59637515 & -0.241079994 &  0.25761504\\\\\n",
       "\t 7  &   80 & 1 &   47 & 1 & 0 & 57 & 1 & Nivolumab     & LN     & â‹¯ &  0.33433512 &  0.87387503 &  0.3593579706 &  0.61269151 & -0.44520057 & -0.12561413 &  0.15067660 &  0.56396673 &  0.006282023 & -0.23951499\\\\\n",
       "\t 8  &   58 & 1 &   58 & 1 & 0 & 85 & 1 & Nivolumab     & SQ     & â‹¯ &  2.13134004 &  0.79354018 & -0.6054473351 & -0.47590384 &  0.38923947 & -0.16430145 & -0.15559126 & -0.58664907 & -0.535177362 &  0.71530710\\\\\n",
       "\t 9  &   99 & 1 &   71 & 1 & 0 & 70 & 1 & Pembrolizumab & SQ     & â‹¯ & -0.51800739 & -0.62215237 &  0.2274708862 & -0.22274651 & -0.31517698 &  0.02419371 & -0.35364727 &  0.91660440 & -0.365652282 & -0.28997347\\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A data.frame: 54 Ã— 18582\n",
       "\n",
       "| Patient &lt;I&lt;chr&gt;&gt; | OS &lt;int&gt; | OS.Event &lt;int&gt; | PFS &lt;int&gt; | PFS.Event &lt;int&gt; | RECIST &lt;int&gt; | Age &lt;int&gt; | Gender &lt;int&gt; | Treatment &lt;fct&gt; | Site &lt;fct&gt; | â‹¯ â‹¯ | 55055 &lt;dbl&gt; | 11130 &lt;dbl&gt; | 7789 &lt;dbl&gt; | 158586 &lt;dbl&gt; | 79364 &lt;dbl&gt; | 440590 &lt;dbl&gt; | 79699 &lt;dbl&gt; | 7791 &lt;dbl&gt; | 23140 &lt;dbl&gt; | 26009 &lt;dbl&gt; |\n",
       "|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|\n",
       "| 1  |  147 | 1 |    9 | 1 | 0 | 48 | 1 | Nivolumab     | LN     | â‹¯ |          NA |          NA |            NA |          NA |          NA |          NA |          NA |          NA |           NA |          NA |\n",
       "| 10 |  551 | 0 |   76 | 1 | 0 | 90 | 0 | Pembrolizumab | SQ     | â‹¯ |  0.58714486 |  1.51680290 |  0.2051403085 |  0.24970065 |  0.50803986 |  0.70851142 |  0.45721398 | -0.79611580 |  0.242960585 |  1.18213316 |\n",
       "| 11 |  166 | 1 |   78 | 1 | 0 | 66 | 0 | Pembrolizumab | SQ     | â‹¯ | -0.77856996 | -1.01200334 |  0.0005757279 | -0.41480345 |  0.05113678 |  0.09727642 | -0.16385787 | -0.24692816 |  0.117103894 | -0.74993078 |\n",
       "| 12 |  199 | 1 |   80 | 1 | 1 | 52 | 0 | Pembrolizumab | SQ     | â‹¯ | -1.51889892 | -0.62973116 |  0.1098136507 | -0.40977490 | -0.18345745 |  0.16842307 | -0.19196153 |  0.65804952 |  0.978488181 | -0.27105096 |\n",
       "| 13 |   96 | 1 |   82 | 1 | 0 | 69 | 0 | Pembrolizumab | SQ     | â‹¯ | -0.43369412 |  1.13091160 | -0.2777108820 | -0.12975976 | -0.06003260 | -0.12662805 | -0.13856663 | -1.21787913 | -0.209915150 |  0.08612588 |\n",
       "| 14 |  993 | 1 |   83 | 1 | 0 | 58 | 0 | Pembrolizumab | Mucosa | â‹¯ |  0.33614144 | -0.17613154 | -0.3655941746 | -0.75921926 |  0.41185003 | -0.11559656 | -0.05134074 | -0.26650284 | -0.305194059 | -0.84401986 |\n",
       "| 15 |  300 | 0 |   84 | 1 | 0 | 76 | 1 | Pembrolizumab | SQ     | â‹¯ | -0.52527974 | -1.40244281 |  0.9012394246 |  0.16067435 |  0.67071102 | -0.18993268 | -0.11826441 | -1.18621327 |  0.026281237 |  0.27000323 |\n",
       "| 16 |  169 | 1 |   84 | 1 | 0 | 55 | 0 | Pembrolizumab | LN     | â‹¯ | -0.49731657 | -0.93868918 | -0.1095925899 | -0.14107495 |  0.02426093 | -0.12426673 | -0.01197064 |  0.57544109 | -0.009577050 | -0.11839787 |\n",
       "| 17 |  258 | 1 |   96 | 1 | 0 | 37 | 0 | Pembrolizumab | SQ     | â‹¯ | -0.17379026 |  0.74040639 | -0.4681554262 |  0.15447363 | -0.20567601 | -0.17463977 |  0.21129616 |  0.49320065 | -0.153231356 | -1.04327463 |\n",
       "| 18 |  228 | 1 |  100 | 1 | 0 | 62 | 0 | Pembrolizumab | SQ     | â‹¯ |  0.56521058 |  0.37410214 | -0.1170037510 |  0.32391776 | -0.14034456 | -0.18993268 |  0.40220709 |  0.76877653 | -0.193560502 |  0.20174889 |\n",
       "| 19 |  385 | 1 |  125 | 1 | 1 | 54 | 0 | Pembrolizumab | SQ     | â‹¯ |  0.46655105 |  0.54872670 | -0.3409820845 |  0.13252763 | -0.53026602 | -0.18993268 | -0.08828512 | -0.15036820 | -0.062418433 |  0.02279346 |\n",
       "| 2  |   65 | 1 |   13 | 1 | 0 | 61 | 1 | Pembrolizumab | SQ     | â‹¯ | -0.97348238 | -0.76822450 |  0.1028616068 |  0.17016027 | -0.06737654 | -0.17636986 |  0.34607368 |  0.79620927 |  0.417834906 | -0.49855148 |\n",
       "| 20 |  553 | 1 |  156 | 1 | 2 | 45 | 1 | Pembrolizumab | Brain  | â‹¯ |          NA |          NA |            NA |          NA |          NA |          NA |          NA |          NA |           NA |          NA |\n",
       "| 21 |  551 | 1 |  166 | 1 | 1 | 67 | 0 | Pembrolizumab | SQ     | â‹¯ |  0.16868742 | -0.15404176 |  0.3311818672 |  0.06066882 |  0.21068949 | -0.17223253 |  0.28442772 | -0.20843742 | -0.621020206 |  0.38779320 |\n",
       "| 22 |  379 | 0 |  176 | 1 | 1 | 69 | 1 | Pembrolizumab | SQ     | â‹¯ |          NA |          NA |            NA |          NA |          NA |          NA |          NA |          NA |           NA |          NA |\n",
       "| 23 |  191 | 1 |  191 | 1 | 1 | 40 | 0 | Nivolumab     | SQ     | â‹¯ |  0.24905714 |  0.06900338 | -0.4031809368 |  0.08881141 |  0.50467914 | -0.18679525 |  0.27972885 |  1.32422465 |  0.624400137 | -0.22988686 |\n",
       "| 24 |  407 | 1 |  197 | 1 | 1 | 54 | 1 | Pembrolizumab | SQ     | â‹¯ |          NA |          NA |            NA |          NA |          NA |          NA |          NA |          NA |           NA |          NA |\n",
       "| 25 |  897 | 1 |  271 | 1 | 2 | 49 | 0 | Nivolumab     | SQ     | â‹¯ |  0.21330995 |  0.53110123 | -0.6473035526 | -0.54270486 |  0.10962948 | -0.16842562 |  0.34721238 |  0.10479040 | -0.492865694 |  0.14336281 |\n",
       "| 26 |  275 | 0 |  275 | 0 | 3 | 89 | 1 | Pembrolizumab | SQ     | â‹¯ |          NA |          NA |            NA |          NA |          NA |          NA |          NA |          NA |           NA |          NA |\n",
       "| 27 | 1067 | 1 |  314 | 1 | 2 | 76 | 0 | Pembrolizumab | SQ     | â‹¯ |  1.00413156 | -0.03714418 |  1.0552302173 |  1.09627171 | -0.05623189 |  0.70739258 |  0.10076517 | -1.33815381 |  0.210307940 | -0.79727101 |\n",
       "| 28 |  324 | 0 |  324 | 0 | 2 | 81 | 0 | Pembrolizumab | SQ     | â‹¯ |          NA |          NA |            NA |          NA |          NA |          NA |          NA |          NA |           NA |          NA |\n",
       "| 29 |  825 | 1 |  335 | 1 | 1 | 55 | 0 | Pembrolizumab | SQ     | â‹¯ | -0.39822385 | -0.31194865 |  0.1895656253 |  0.35678046 | -0.24796229 | -0.18993268 |  0.38993575 |  0.29388544 |  0.273667791 |  0.37929006 |\n",
       "| 3  |   59 | 1 |   23 | 1 | 0 | 50 | 0 | Nivolumab     | SQ     | â‹¯ | -0.77789408 |  0.47804777 |  0.3231840744 |  0.07771963 | -0.13553484 | -0.14994607 |  0.25125628 |  0.46844425 |  0.202778225 |  0.12502150 |\n",
       "| 30 |  581 | 0 |  358 | 1 | 1 | 86 | 1 | Pembrolizumab | SQ     | â‹¯ |  1.41658928 |  0.06242660 | -1.4247014274 | -0.24798209 | -0.11521950 |  1.03268700 |  0.46235717 |  0.57172041 | -0.687417296 |  1.00008741 |\n",
       "| 31 |  365 | 0 |  365 | 0 | 2 | 74 | 1 | Nivolumab     | SQ     | â‹¯ |          NA |          NA |            NA |          NA |          NA |          NA |          NA |          NA |           NA |          NA |\n",
       "| 32 |  460 | 0 |  460 | 0 | 3 | 69 | 1 | Pembrolizumab | Brain  | â‹¯ |          NA |          NA |            NA |          NA |          NA |          NA |          NA |          NA |           NA |          NA |\n",
       "| 33 |  477 | 0 |  477 | 0 | 3 | 76 | 0 | Pembrolizumab | LN     | â‹¯ |          NA |          NA |            NA |          NA |          NA |          NA |          NA |          NA |           NA |          NA |\n",
       "| 34 |  878 | 1 |  544 | 1 | 2 | 78 | 0 | Pembrolizumab | LN     | â‹¯ | -0.33808762 |  0.16435665 | -0.3942531236 |  0.01195671 | -0.17321962 | -0.13604057 | -0.36331346 | -0.46914968 |  0.105545635 | -0.36518924 |\n",
       "| 35 | 1091 | 0 |  586 | 1 | 2 | 55 | 1 | Pembrolizumab | SQ     | â‹¯ | -0.32027729 | -0.86643923 |  0.1563104344 | -0.18119199 |  0.11321388 |  0.25268109 | -0.40650049 | -0.12853882 |  0.798602483 | -0.02921499 |\n",
       "| 36 |  607 | 1 |  590 | 1 | 2 | 76 | 0 | Nivolumab     | SQ     | â‹¯ |  0.57650194 |  0.37556121 |  0.5342987385 |  0.49915050 |  0.15513046 | -0.15267010 |  0.09423050 | -0.30689387 | -0.028634074 |  0.53526920 |\n",
       "| 37 |  910 | 0 |  647 | 1 | 3 | 66 | 0 | Pembrolizumab | SQ     | â‹¯ |          NA |          NA |            NA |          NA |          NA |          NA |          NA |          NA |           NA |          NA |\n",
       "| 38 | 1547 | 0 |  755 | 1 | 2 | 69 | 1 | Pembrolizumab | SQ     | â‹¯ |  0.49836945 | -0.05559454 |  0.2066692551 | -0.02215850 |  0.23403080 | -0.10698927 |  0.04638785 |  0.51787047 |  0.004726486 | -0.42979683 |\n",
       "| 39 |  815 | 0 |  815 | 0 | 1 | 72 | 0 | Pembrolizumab | SQ     | â‹¯ |          NA |          NA |            NA |          NA |          NA |          NA |          NA |          NA |           NA |          NA |\n",
       "| 4  |   22 | 1 |   23 | 1 | 0 | 84 | 0 | Pembrolizumab | SQ     | â‹¯ |  0.45022427 | -0.65085397 |  0.0457839900 | -0.24236341 |  0.44765703 | -0.18958255 | -0.28079830 | -0.26692534 |  0.414583686 |  0.49895492 |\n",
       "| 40 |  845 | 0 |  845 | 0 | 2 | 78 | 0 | Pembrolizumab | SQ     | â‹¯ | -0.31122740 |  0.33162208 | -0.6211025988 | -0.09780025 | -0.22666792 |  0.26009037 | -0.05134074 |  0.59374750 | -0.153520183 |  0.21603362 |\n",
       "| 41 |  886 | 0 |  870 | 1 | 2 | 61 | 1 | Pembrolizumab | SQ     | â‹¯ | -0.13648162 |  0.38776064 | -0.7786407607 | -0.07954015 | -0.27904401 | -0.18993268 |  0.35310596 |  0.09664086 | -0.492865694 | -0.31798122 |\n",
       "| 42 |  891 | 0 |  891 | 0 | 3 | 59 | 1 | Pembrolizumab | SQ     | â‹¯ | -0.34399706 | -1.08187780 |  0.5367482772 |  0.23679852 |  0.16702184 | -0.18993268 |  0.07377460 |  0.03571408 |  0.022790961 | -0.96885980 |\n",
       "| 43 |  905 | 0 |  905 | 0 | 3 | 63 | 0 | Pembrolizumab | SQ     | â‹¯ |          NA |          NA |            NA |          NA |          NA |          NA |          NA |          NA |           NA |          NA |\n",
       "| 44 | 1075 | 0 | 1075 | 0 | 2 | 45 | 1 | Pembrolizumab | LN     | â‹¯ | -0.23502392 | -1.19925542 | -0.1301835397 |  0.18490747 |  0.29163788 | -0.11693721 | -0.19036457 |  0.22075631 |  0.517488704 |  0.04570634 |\n",
       "| 45 | 1085 | 0 | 1085 | 0 | 2 | 82 | 0 | Pembrolizumab | SQ     | â‹¯ | -1.07644884 | -0.45707750 |  0.6808349316 |  0.03664372 |  0.34213037 | -0.12595742 |  0.27241290 | -0.16797709 |  0.400421450 |  0.32499011 |\n",
       "| 46 | 1098 | 0 | 1098 | 0 | 2 | 71 | 0 | Pembrolizumab | SQ     | â‹¯ |  0.63079954 |  1.03166565 |  0.0103432872 |  0.13307078 | -0.06398976 | -0.11879850 |  0.13974445 |  0.05403603 | -0.101439718 | -0.25613537 |\n",
       "| 47 | 1174 | 0 | 1174 | 0 | 2 | 62 | 0 | Pembrolizumab | SQ     | â‹¯ | -0.59926198 | -0.26291383 |  0.1458335064 | -0.04796896 | -0.47627302 | -0.08631475 |  0.25056648 |  0.16522926 |  0.611609680 |  0.48758918 |\n",
       "| 48 | 1189 | 0 | 1189 | 0 | 2 | 40 | 0 | Pembrolizumab | SQ     | â‹¯ | -0.23997050 |  0.20676718 | -0.1790886828 | -0.14261207 | -0.10593877 | -0.10368129 | -0.42023214 |  0.48732913 |  0.187183322 | -0.19190377 |\n",
       "| 49 | 1328 | 0 | 1328 | 0 | 3 | 72 | 1 | Nivolumab     | SQ     | â‹¯ | -0.09931866 |  0.50448279 | -0.1173463375 |  0.03523810 |  0.08782326 | -0.06818400 | -0.03400262 | -0.19159567 | -0.330417090 |  0.26656644 |\n",
       "| 5  |  155 | 1 |   39 | 1 | 0 | 67 | 0 | Pembrolizumab | SQ     | â‹¯ |  0.35049009 |  0.41415905 | -0.2752258429 | -0.36741795 | -0.39423587 | -0.16876892 |  0.12387581 | -1.27476366 |  0.168245743 |  0.52170269 |\n",
       "| 50 | 1342 | 0 | 1342 | 0 | 3 | 86 | 0 | Nivolumab     | SQ     | â‹¯ |  0.49282084 |  0.09725215 | -0.0915385889 | -0.23489184 | -0.38667176 | -0.17428964 |  0.10105164 |  0.21650294 | -0.434137380 |  0.88872357 |\n",
       "| 51 | 1397 | 0 | 1397 | 0 | 3 | 64 | 0 | Nivolumab     | SQ     | â‹¯ |          NA |          NA |            NA |          NA |          NA |          NA |          NA |          NA |           NA |          NA |\n",
       "| 52 | 1553 | 0 | 1553 | 0 | 2 | 63 | 1 | Pembrolizumab | SQ     | â‹¯ | -0.51324287 | -0.11879141 | -0.5892031981 | -0.17134194 | -0.08283153 | -0.11193973 | -0.86381226 |  0.16751634 | -0.493717489 | -0.04120277 |\n",
       "| 53 | 1589 | 0 | 1589 | 0 | 3 | 71 | 1 | Pembrolizumab | LN     | â‹¯ | -0.19119768 | -1.23898244 |  0.7186973882 | -0.03140992 |  0.58762230 |  0.36310638 | -0.65733209 | -0.25724207 |  0.560198223 | -0.54578385 |\n",
       "| 54 | 1603 | 0 | 1603 | 0 | 2 | 52 | 1 | Pembrolizumab | SQ     | â‹¯ |  0.86781747 |  1.32880802 |  0.2288094333 |  0.18938530 | -0.04091907 |  0.70585357 |  0.19730013 | -0.43394722 | -0.979660281 | -0.32887805 |\n",
       "| 6  |   94 | 1 |   42 | 1 | 0 | 68 | 0 | Nivolumab     | LN     | â‹¯ | -0.33982929 |  0.02291629 |  0.8663042318 |  0.15111765 | -0.57423345 |  0.16435045 | -0.79441902 | -0.59637515 | -0.241079994 |  0.25761504 |\n",
       "| 7  |   80 | 1 |   47 | 1 | 0 | 57 | 1 | Nivolumab     | LN     | â‹¯ |  0.33433512 |  0.87387503 |  0.3593579706 |  0.61269151 | -0.44520057 | -0.12561413 |  0.15067660 |  0.56396673 |  0.006282023 | -0.23951499 |\n",
       "| 8  |   58 | 1 |   58 | 1 | 0 | 85 | 1 | Nivolumab     | SQ     | â‹¯ |  2.13134004 |  0.79354018 | -0.6054473351 | -0.47590384 |  0.38923947 | -0.16430145 | -0.15559126 | -0.58664907 | -0.535177362 |  0.71530710 |\n",
       "| 9  |   99 | 1 |   71 | 1 | 0 | 70 | 1 | Pembrolizumab | SQ     | â‹¯ | -0.51800739 | -0.62215237 |  0.2274708862 | -0.22274651 | -0.31517698 |  0.02419371 | -0.35364727 |  0.91660440 | -0.365652282 | -0.28997347 |\n",
       "\n"
      ],
      "text/plain": [
       "   Patient OS   OS.Event PFS  PFS.Event RECIST Age Gender Treatment     Site  \n",
       "1  1        147 1           9 1         0      48  1      Nivolumab     LN    \n",
       "2  10       551 0          76 1         0      90  0      Pembrolizumab SQ    \n",
       "3  11       166 1          78 1         0      66  0      Pembrolizumab SQ    \n",
       "4  12       199 1          80 1         1      52  0      Pembrolizumab SQ    \n",
       "5  13        96 1          82 1         0      69  0      Pembrolizumab SQ    \n",
       "6  14       993 1          83 1         0      58  0      Pembrolizumab Mucosa\n",
       "7  15       300 0          84 1         0      76  1      Pembrolizumab SQ    \n",
       "8  16       169 1          84 1         0      55  0      Pembrolizumab LN    \n",
       "9  17       258 1          96 1         0      37  0      Pembrolizumab SQ    \n",
       "10 18       228 1         100 1         0      62  0      Pembrolizumab SQ    \n",
       "11 19       385 1         125 1         1      54  0      Pembrolizumab SQ    \n",
       "12 2         65 1          13 1         0      61  1      Pembrolizumab SQ    \n",
       "13 20       553 1         156 1         2      45  1      Pembrolizumab Brain \n",
       "14 21       551 1         166 1         1      67  0      Pembrolizumab SQ    \n",
       "15 22       379 0         176 1         1      69  1      Pembrolizumab SQ    \n",
       "16 23       191 1         191 1         1      40  0      Nivolumab     SQ    \n",
       "17 24       407 1         197 1         1      54  1      Pembrolizumab SQ    \n",
       "18 25       897 1         271 1         2      49  0      Nivolumab     SQ    \n",
       "19 26       275 0         275 0         3      89  1      Pembrolizumab SQ    \n",
       "20 27      1067 1         314 1         2      76  0      Pembrolizumab SQ    \n",
       "21 28       324 0         324 0         2      81  0      Pembrolizumab SQ    \n",
       "22 29       825 1         335 1         1      55  0      Pembrolizumab SQ    \n",
       "23 3         59 1          23 1         0      50  0      Nivolumab     SQ    \n",
       "24 30       581 0         358 1         1      86  1      Pembrolizumab SQ    \n",
       "25 31       365 0         365 0         2      74  1      Nivolumab     SQ    \n",
       "26 32       460 0         460 0         3      69  1      Pembrolizumab Brain \n",
       "27 33       477 0         477 0         3      76  0      Pembrolizumab LN    \n",
       "28 34       878 1         544 1         2      78  0      Pembrolizumab LN    \n",
       "29 35      1091 0         586 1         2      55  1      Pembrolizumab SQ    \n",
       "30 36       607 1         590 1         2      76  0      Nivolumab     SQ    \n",
       "31 37       910 0         647 1         3      66  0      Pembrolizumab SQ    \n",
       "32 38      1547 0         755 1         2      69  1      Pembrolizumab SQ    \n",
       "33 39       815 0         815 0         1      72  0      Pembrolizumab SQ    \n",
       "34 4         22 1          23 1         0      84  0      Pembrolizumab SQ    \n",
       "35 40       845 0         845 0         2      78  0      Pembrolizumab SQ    \n",
       "36 41       886 0         870 1         2      61  1      Pembrolizumab SQ    \n",
       "37 42       891 0         891 0         3      59  1      Pembrolizumab SQ    \n",
       "38 43       905 0         905 0         3      63  0      Pembrolizumab SQ    \n",
       "39 44      1075 0        1075 0         2      45  1      Pembrolizumab LN    \n",
       "40 45      1085 0        1085 0         2      82  0      Pembrolizumab SQ    \n",
       "41 46      1098 0        1098 0         2      71  0      Pembrolizumab SQ    \n",
       "42 47      1174 0        1174 0         2      62  0      Pembrolizumab SQ    \n",
       "43 48      1189 0        1189 0         2      40  0      Pembrolizumab SQ    \n",
       "44 49      1328 0        1328 0         3      72  1      Nivolumab     SQ    \n",
       "45 5        155 1          39 1         0      67  0      Pembrolizumab SQ    \n",
       "46 50      1342 0        1342 0         3      86  0      Nivolumab     SQ    \n",
       "47 51      1397 0        1397 0         3      64  0      Nivolumab     SQ    \n",
       "48 52      1553 0        1553 0         2      63  1      Pembrolizumab SQ    \n",
       "49 53      1589 0        1589 0         3      71  1      Pembrolizumab LN    \n",
       "50 54      1603 0        1603 0         2      52  1      Pembrolizumab SQ    \n",
       "51 6         94 1          42 1         0      68  0      Nivolumab     LN    \n",
       "52 7         80 1          47 1         0      57  1      Nivolumab     LN    \n",
       "53 8         58 1          58 1         0      85  1      Nivolumab     SQ    \n",
       "54 9         99 1          71 1         0      70  1      Pembrolizumab SQ    \n",
       "   â‹¯ 55055       11130       7789          158586      79364       440590     \n",
       "1  â‹¯          NA          NA            NA          NA          NA          NA\n",
       "2  â‹¯  0.58714486  1.51680290  0.2051403085  0.24970065  0.50803986  0.70851142\n",
       "3  â‹¯ -0.77856996 -1.01200334  0.0005757279 -0.41480345  0.05113678  0.09727642\n",
       "4  â‹¯ -1.51889892 -0.62973116  0.1098136507 -0.40977490 -0.18345745  0.16842307\n",
       "5  â‹¯ -0.43369412  1.13091160 -0.2777108820 -0.12975976 -0.06003260 -0.12662805\n",
       "6  â‹¯  0.33614144 -0.17613154 -0.3655941746 -0.75921926  0.41185003 -0.11559656\n",
       "7  â‹¯ -0.52527974 -1.40244281  0.9012394246  0.16067435  0.67071102 -0.18993268\n",
       "8  â‹¯ -0.49731657 -0.93868918 -0.1095925899 -0.14107495  0.02426093 -0.12426673\n",
       "9  â‹¯ -0.17379026  0.74040639 -0.4681554262  0.15447363 -0.20567601 -0.17463977\n",
       "10 â‹¯  0.56521058  0.37410214 -0.1170037510  0.32391776 -0.14034456 -0.18993268\n",
       "11 â‹¯  0.46655105  0.54872670 -0.3409820845  0.13252763 -0.53026602 -0.18993268\n",
       "12 â‹¯ -0.97348238 -0.76822450  0.1028616068  0.17016027 -0.06737654 -0.17636986\n",
       "13 â‹¯          NA          NA            NA          NA          NA          NA\n",
       "14 â‹¯  0.16868742 -0.15404176  0.3311818672  0.06066882  0.21068949 -0.17223253\n",
       "15 â‹¯          NA          NA            NA          NA          NA          NA\n",
       "16 â‹¯  0.24905714  0.06900338 -0.4031809368  0.08881141  0.50467914 -0.18679525\n",
       "17 â‹¯          NA          NA            NA          NA          NA          NA\n",
       "18 â‹¯  0.21330995  0.53110123 -0.6473035526 -0.54270486  0.10962948 -0.16842562\n",
       "19 â‹¯          NA          NA            NA          NA          NA          NA\n",
       "20 â‹¯  1.00413156 -0.03714418  1.0552302173  1.09627171 -0.05623189  0.70739258\n",
       "21 â‹¯          NA          NA            NA          NA          NA          NA\n",
       "22 â‹¯ -0.39822385 -0.31194865  0.1895656253  0.35678046 -0.24796229 -0.18993268\n",
       "23 â‹¯ -0.77789408  0.47804777  0.3231840744  0.07771963 -0.13553484 -0.14994607\n",
       "24 â‹¯  1.41658928  0.06242660 -1.4247014274 -0.24798209 -0.11521950  1.03268700\n",
       "25 â‹¯          NA          NA            NA          NA          NA          NA\n",
       "26 â‹¯          NA          NA            NA          NA          NA          NA\n",
       "27 â‹¯          NA          NA            NA          NA          NA          NA\n",
       "28 â‹¯ -0.33808762  0.16435665 -0.3942531236  0.01195671 -0.17321962 -0.13604057\n",
       "29 â‹¯ -0.32027729 -0.86643923  0.1563104344 -0.18119199  0.11321388  0.25268109\n",
       "30 â‹¯  0.57650194  0.37556121  0.5342987385  0.49915050  0.15513046 -0.15267010\n",
       "31 â‹¯          NA          NA            NA          NA          NA          NA\n",
       "32 â‹¯  0.49836945 -0.05559454  0.2066692551 -0.02215850  0.23403080 -0.10698927\n",
       "33 â‹¯          NA          NA            NA          NA          NA          NA\n",
       "34 â‹¯  0.45022427 -0.65085397  0.0457839900 -0.24236341  0.44765703 -0.18958255\n",
       "35 â‹¯ -0.31122740  0.33162208 -0.6211025988 -0.09780025 -0.22666792  0.26009037\n",
       "36 â‹¯ -0.13648162  0.38776064 -0.7786407607 -0.07954015 -0.27904401 -0.18993268\n",
       "37 â‹¯ -0.34399706 -1.08187780  0.5367482772  0.23679852  0.16702184 -0.18993268\n",
       "38 â‹¯          NA          NA            NA          NA          NA          NA\n",
       "39 â‹¯ -0.23502392 -1.19925542 -0.1301835397  0.18490747  0.29163788 -0.11693721\n",
       "40 â‹¯ -1.07644884 -0.45707750  0.6808349316  0.03664372  0.34213037 -0.12595742\n",
       "41 â‹¯  0.63079954  1.03166565  0.0103432872  0.13307078 -0.06398976 -0.11879850\n",
       "42 â‹¯ -0.59926198 -0.26291383  0.1458335064 -0.04796896 -0.47627302 -0.08631475\n",
       "43 â‹¯ -0.23997050  0.20676718 -0.1790886828 -0.14261207 -0.10593877 -0.10368129\n",
       "44 â‹¯ -0.09931866  0.50448279 -0.1173463375  0.03523810  0.08782326 -0.06818400\n",
       "45 â‹¯  0.35049009  0.41415905 -0.2752258429 -0.36741795 -0.39423587 -0.16876892\n",
       "46 â‹¯  0.49282084  0.09725215 -0.0915385889 -0.23489184 -0.38667176 -0.17428964\n",
       "47 â‹¯          NA          NA            NA          NA          NA          NA\n",
       "48 â‹¯ -0.51324287 -0.11879141 -0.5892031981 -0.17134194 -0.08283153 -0.11193973\n",
       "49 â‹¯ -0.19119768 -1.23898244  0.7186973882 -0.03140992  0.58762230  0.36310638\n",
       "50 â‹¯  0.86781747  1.32880802  0.2288094333  0.18938530 -0.04091907  0.70585357\n",
       "51 â‹¯ -0.33982929  0.02291629  0.8663042318  0.15111765 -0.57423345  0.16435045\n",
       "52 â‹¯  0.33433512  0.87387503  0.3593579706  0.61269151 -0.44520057 -0.12561413\n",
       "53 â‹¯  2.13134004  0.79354018 -0.6054473351 -0.47590384  0.38923947 -0.16430145\n",
       "54 â‹¯ -0.51800739 -0.62215237  0.2274708862 -0.22274651 -0.31517698  0.02419371\n",
       "   79699       7791        23140        26009      \n",
       "1           NA          NA           NA          NA\n",
       "2   0.45721398 -0.79611580  0.242960585  1.18213316\n",
       "3  -0.16385787 -0.24692816  0.117103894 -0.74993078\n",
       "4  -0.19196153  0.65804952  0.978488181 -0.27105096\n",
       "5  -0.13856663 -1.21787913 -0.209915150  0.08612588\n",
       "6  -0.05134074 -0.26650284 -0.305194059 -0.84401986\n",
       "7  -0.11826441 -1.18621327  0.026281237  0.27000323\n",
       "8  -0.01197064  0.57544109 -0.009577050 -0.11839787\n",
       "9   0.21129616  0.49320065 -0.153231356 -1.04327463\n",
       "10  0.40220709  0.76877653 -0.193560502  0.20174889\n",
       "11 -0.08828512 -0.15036820 -0.062418433  0.02279346\n",
       "12  0.34607368  0.79620927  0.417834906 -0.49855148\n",
       "13          NA          NA           NA          NA\n",
       "14  0.28442772 -0.20843742 -0.621020206  0.38779320\n",
       "15          NA          NA           NA          NA\n",
       "16  0.27972885  1.32422465  0.624400137 -0.22988686\n",
       "17          NA          NA           NA          NA\n",
       "18  0.34721238  0.10479040 -0.492865694  0.14336281\n",
       "19          NA          NA           NA          NA\n",
       "20  0.10076517 -1.33815381  0.210307940 -0.79727101\n",
       "21          NA          NA           NA          NA\n",
       "22  0.38993575  0.29388544  0.273667791  0.37929006\n",
       "23  0.25125628  0.46844425  0.202778225  0.12502150\n",
       "24  0.46235717  0.57172041 -0.687417296  1.00008741\n",
       "25          NA          NA           NA          NA\n",
       "26          NA          NA           NA          NA\n",
       "27          NA          NA           NA          NA\n",
       "28 -0.36331346 -0.46914968  0.105545635 -0.36518924\n",
       "29 -0.40650049 -0.12853882  0.798602483 -0.02921499\n",
       "30  0.09423050 -0.30689387 -0.028634074  0.53526920\n",
       "31          NA          NA           NA          NA\n",
       "32  0.04638785  0.51787047  0.004726486 -0.42979683\n",
       "33          NA          NA           NA          NA\n",
       "34 -0.28079830 -0.26692534  0.414583686  0.49895492\n",
       "35 -0.05134074  0.59374750 -0.153520183  0.21603362\n",
       "36  0.35310596  0.09664086 -0.492865694 -0.31798122\n",
       "37  0.07377460  0.03571408  0.022790961 -0.96885980\n",
       "38          NA          NA           NA          NA\n",
       "39 -0.19036457  0.22075631  0.517488704  0.04570634\n",
       "40  0.27241290 -0.16797709  0.400421450  0.32499011\n",
       "41  0.13974445  0.05403603 -0.101439718 -0.25613537\n",
       "42  0.25056648  0.16522926  0.611609680  0.48758918\n",
       "43 -0.42023214  0.48732913  0.187183322 -0.19190377\n",
       "44 -0.03400262 -0.19159567 -0.330417090  0.26656644\n",
       "45  0.12387581 -1.27476366  0.168245743  0.52170269\n",
       "46  0.10105164  0.21650294 -0.434137380  0.88872357\n",
       "47          NA          NA           NA          NA\n",
       "48 -0.86381226  0.16751634 -0.493717489 -0.04120277\n",
       "49 -0.65733209 -0.25724207  0.560198223 -0.54578385\n",
       "50  0.19730013 -0.43394722 -0.979660281 -0.32887805\n",
       "51 -0.79441902 -0.59637515 -0.241079994  0.25761504\n",
       "52  0.15067660  0.56396673  0.006282023 -0.23951499\n",
       "53 -0.15559126 -0.58664907 -0.535177362  0.71530710\n",
       "54 -0.35364727  0.91660440 -0.365652282 -0.28997347"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "pn_combined <- merge(pn_clinical,pn_self_subtract,by='row.names',all=TRUE)\n",
    "colnames(pn_combined)[colnames(pn_combined) == \"Row.names\"] <- \"Patient\"\n",
    "pn_combined"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "e73f6b25",
   "metadata": {},
   "source": [
    "# Writing final tables in file "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "id": "7cb67a30",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "'/home/jp/ICP_Responders/FinalTables'"
      ],
      "text/latex": [
       "'/home/jp/ICP\\_Responders/FinalTables'"
      ],
      "text/markdown": [
       "'/home/jp/ICP_Responders/FinalTables'"
      ],
      "text/plain": [
       "[1] \"/home/jp/ICP_Responders/FinalTables\""
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "setwd(\"/home/jp/ICP_Responders/FinalTables\")\n",
    "getwd()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "bc0b661c",
   "metadata": {},
   "outputs": [],
   "source": [
    "write.csv(pni_combined, \"Gide_pni.csv\", row.names = FALSE)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "ba2d52d0",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table>\n",
       "<caption>A data.frame: 51 Ã— 18792</caption>\n",
       "<thead>\n",
       "\t<tr><th scope=col>Patient</th><th scope=col>OS</th><th scope=col>OS.Event</th><th scope=col>PFS</th><th scope=col>PFS.Event</th><th scope=col>RECIST</th><th scope=col>Age</th><th scope=col>Gender</th><th scope=col>Treatment</th><th scope=col>Site</th><th scope=col>â‹¯</th><th scope=col>X55055</th><th scope=col>X11130</th><th scope=col>X7789</th><th scope=col>X158586</th><th scope=col>X79364</th><th scope=col>X440590</th><th scope=col>X79699</th><th scope=col>X7791</th><th scope=col>X23140</th><th scope=col>X26009</th></tr>\n",
       "\t<tr><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>â‹¯</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><td> 1</td><td> 689</td><td>0</td><td>  15</td><td>1</td><td>0</td><td>42</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>â‹¯</td><td> 0.814559991</td><td> 0.09616738</td><td>-0.27965633</td><td> 0.31559451</td><td>-0.0626374123</td><td> 0.055108447</td><td>-0.56911380</td><td>-0.380607347</td><td>-0.52103880</td><td>-0.46877980</td></tr>\n",
       "\t<tr><td>10</td><td> 176</td><td>1</td><td>  81</td><td>1</td><td>0</td><td>51</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td> 0.464824631</td><td> 0.30872910</td><td>-0.66759771</td><td> 0.56592965</td><td>-0.4606691302</td><td> 0.554262011</td><td> 0.69282995</td><td> 0.539471466</td><td>-0.33190657</td><td> 0.11705793</td></tr>\n",
       "\t<tr><td>11</td><td> 221</td><td>0</td><td>  82</td><td>1</td><td>0</td><td>62</td><td>0</td><td>Ipilimumab + Nivolumab    </td><td>LN             </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>12</td><td> 293</td><td>0</td><td>  82</td><td>1</td><td>0</td><td>55</td><td>1</td><td>Ipilimumab + Nivolumab    </td><td>Lung           </td><td>â‹¯</td><td>-1.115560810</td><td>-2.62608070</td><td> 0.33662516</td><td>-0.09917793</td><td> 0.5652990871</td><td>-0.061318728</td><td> 0.01378568</td><td> 0.632443208</td><td> 0.78257787</td><td>-0.20470475</td></tr>\n",
       "\t<tr><td>13</td><td> 357</td><td>1</td><td> 108</td><td>1</td><td>2</td><td>68</td><td>1</td><td>Ipilimumab + Nivolumab    </td><td>SQ             </td><td>â‹¯</td><td>-0.209928304</td><td> 0.81250891</td><td> 0.04422525</td><td> 0.06929868</td><td>-0.3294996664</td><td>-0.095807574</td><td>-0.01927152</td><td> 0.254432485</td><td>-0.03632622</td><td> 0.10893968</td></tr>\n",
       "\t<tr><td>14</td><td> 691</td><td>0</td><td> 123</td><td>1</td><td>1</td><td>47</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>â‹¯</td><td>-0.229523423</td><td> 1.34753221</td><td> 0.49996400</td><td> 0.10629174</td><td>-0.0166411617</td><td>-0.023002256</td><td> 0.46454270</td><td>-0.437119044</td><td>-0.41935743</td><td>-0.15979738</td></tr>\n",
       "\t<tr><td>15</td><td> 660</td><td>1</td><td> 152</td><td>1</td><td>1</td><td>57</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>â‹¯</td><td>-0.033292657</td><td> 1.11436707</td><td> 0.13554354</td><td> 0.25877652</td><td>-0.2631522968</td><td>-0.054781348</td><td> 0.14859193</td><td>-0.330010210</td><td>-0.70105036</td><td> 1.23636907</td></tr>\n",
       "\t<tr><td>16</td><td> 558</td><td>0</td><td> 168</td><td>1</td><td>2</td><td>39</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>17</td><td> 196</td><td>0</td><td> 196</td><td>0</td><td>2</td><td>48</td><td>1</td><td>Ipilimumab + Nivolumab    </td><td>LN             </td><td>â‹¯</td><td> 0.397248856</td><td>-0.54785782</td><td>-0.22319036</td><td>-0.51547930</td><td> 0.1365183514</td><td>-0.025940561</td><td> 0.18921212</td><td> 0.424191448</td><td> 0.10411358</td><td>-0.16324147</td></tr>\n",
       "\t<tr><td>18</td><td> 278</td><td>0</td><td> 278</td><td>0</td><td>2</td><td>58</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Lung           </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>19</td><td> 635</td><td>0</td><td> 301</td><td>1</td><td>1</td><td>56</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>â‹¯</td><td>-0.990153661</td><td>-0.66884995</td><td> 0.75507446</td><td> 0.45702034</td><td>-0.0978608256</td><td>-0.037910521</td><td>-0.19641500</td><td>-0.002663966</td><td> 0.14242927</td><td>-0.53603414</td></tr>\n",
       "\t<tr><td> 2</td><td> 530</td><td>0</td><td>  34</td><td>1</td><td>0</td><td>41</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td> 1.079653224</td><td> 0.62934788</td><td>-1.23471534</td><td>-0.96470192</td><td> 0.5255918237</td><td>-0.095807574</td><td>-0.52099920</td><td> 0.825633802</td><td> 0.08874634</td><td> 0.01569202</td></tr>\n",
       "\t<tr><td>20</td><td> 538</td><td>0</td><td> 386</td><td>1</td><td>1</td><td>57</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td>-0.399369346</td><td>-1.27744820</td><td> 1.16563917</td><td> 0.44796852</td><td> 0.9177473835</td><td>-0.044360443</td><td>-0.21307855</td><td>-0.099479074</td><td> 1.54256398</td><td> 0.60783149</td></tr>\n",
       "\t<tr><td>21</td><td> 410</td><td>0</td><td> 410</td><td>0</td><td>2</td><td>63</td><td>0</td><td>Ipilimumab + Nivolumab    </td><td>SQ             </td><td>â‹¯</td><td> 0.262799951</td><td> 0.64011166</td><td> 0.24011332</td><td>-0.11178293</td><td> 0.1601318153</td><td> 0.001045315</td><td>-0.02779061</td><td>-0.079428025</td><td> 0.24134531</td><td> 0.22767313</td></tr>\n",
       "\t<tr><td>22</td><td> 706</td><td>0</td><td> 487</td><td>1</td><td>2</td><td>59</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>23</td><td> 506</td><td>0</td><td> 506</td><td>0</td><td>2</td><td>51</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>Brain          </td><td>â‹¯</td><td> 0.410802324</td><td>-0.35400995</td><td>-0.38289902</td><td> 0.26529255</td><td> 0.0681192357</td><td>-0.046954071</td><td>-0.03533289</td><td>-0.555163096</td><td>-0.54986056</td><td> 1.10751447</td></tr>\n",
       "\t<tr><td>24</td><td>1203</td><td>0</td><td> 509</td><td>1</td><td>2</td><td>34</td><td>0</td><td>Ipilimumab + Nivolumab    </td><td>LN             </td><td>â‹¯</td><td>-0.772687949</td><td>-0.17954929</td><td> 0.15757350</td><td>-0.04612901</td><td> 0.1787330668</td><td>-0.049971772</td><td> 0.06365311</td><td>-0.651993693</td><td> 0.41805088</td><td>-0.40544793</td></tr>\n",
       "\t<tr><td>25</td><td> 518</td><td>1</td><td> 518</td><td>0</td><td>1</td><td>67</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td> 0.323958497</td><td>-0.28877420</td><td>-0.34308412</td><td>-0.42472156</td><td> 0.7366265926</td><td>-0.095807574</td><td> 0.41074512</td><td>-0.507792891</td><td> 0.20384346</td><td> 0.47588991</td></tr>\n",
       "\t<tr><td>26</td><td> 544</td><td>0</td><td> 544</td><td>0</td><td>3</td><td>75</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td> 0.462127921</td><td> 0.57497284</td><td>-0.59890304</td><td>-0.44415190</td><td> 0.7441192974</td><td> 0.069465219</td><td>-0.38604727</td><td>-0.899311870</td><td> 0.37238568</td><td>-0.43646272</td></tr>\n",
       "\t<tr><td>27</td><td> 546</td><td>0</td><td> 546</td><td>0</td><td>3</td><td>49</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Abdomen        </td><td>â‹¯</td><td>-0.605366439</td><td> 0.35143929</td><td> 0.32851067</td><td> 0.35746238</td><td>-0.1407782292</td><td>-0.077796562</td><td> 0.07142574</td><td> 0.107125170</td><td>-0.01490806</td><td>-0.75544253</td></tr>\n",
       "\t<tr><td>28</td><td> 553</td><td>0</td><td> 553</td><td>0</td><td>3</td><td>33</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>29</td><td> 567</td><td>0</td><td> 567</td><td>0</td><td>3</td><td>66</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td> 3</td><td> 300</td><td>0</td><td>  37</td><td>1</td><td>0</td><td>58</td><td>1</td><td>Ipilimumab + Nivolumab    </td><td>Lung           </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>30</td><td> 573</td><td>0</td><td> 573</td><td>0</td><td>2</td><td>56</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Small intestine</td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>31</td><td> 588</td><td>0</td><td> 588</td><td>0</td><td>3</td><td>45</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Lung           </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>32</td><td> 597</td><td>0</td><td> 597</td><td>0</td><td>3</td><td>71</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td> 0.008691614</td><td>-0.39469549</td><td>-0.73498518</td><td>-0.43149567</td><td> 0.5530308342</td><td> 0.567570255</td><td>-0.17093020</td><td>-0.578044742</td><td> 1.00302316</td><td> 0.72587330</td></tr>\n",
       "\t<tr><td>33</td><td> 609</td><td>0</td><td> 609</td><td>0</td><td>2</td><td>73</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>â‹¯</td><td> 0.543191258</td><td> 0.96220905</td><td> 0.08654803</td><td> 0.29531747</td><td>-0.0733442796</td><td>-0.071404280</td><td> 0.04744246</td><td> 0.311459770</td><td>-0.45692695</td><td>-0.22853974</td></tr>\n",
       "\t<tr><td>34</td><td> 623</td><td>0</td><td> 623</td><td>0</td><td>3</td><td>51</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Lung           </td><td>â‹¯</td><td>-0.766047908</td><td>-1.69531674</td><td>-0.14342511</td><td>-0.17124200</td><td> 0.5643143914</td><td>-0.068337272</td><td>-0.19164100</td><td> 0.736564406</td><td> 0.06647244</td><td>-0.16604761</td></tr>\n",
       "\t<tr><td>35</td><td> 627</td><td>0</td><td> 627</td><td>0</td><td>3</td><td>72</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>â‹¯</td><td>-0.468675161</td><td> 0.38191325</td><td>-0.13353630</td><td> 0.44677454</td><td>-0.1907897938</td><td>-0.014894504</td><td>-0.06091901</td><td>-0.292491200</td><td> 0.06483150</td><td> 0.36725970</td></tr>\n",
       "\t<tr><td>36</td><td> 637</td><td>0</td><td> 637</td><td>0</td><td>3</td><td>74</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>â‹¯</td><td>-0.231554875</td><td> 0.42826173</td><td> 0.17136963</td><td> 0.43681965</td><td>-0.0434933523</td><td>-0.070101252</td><td>-0.77012086</td><td> 0.026242002</td><td>-0.29389081</td><td>-1.04418568</td></tr>\n",
       "\t<tr><td>37</td><td> 637</td><td>0</td><td> 637</td><td>0</td><td>2</td><td>76</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td> 0.255039312</td><td> 0.97348718</td><td> 0.37727755</td><td> 0.11511414</td><td>-0.5009587486</td><td>-0.059131734</td><td> 0.17357627</td><td> 0.336104507</td><td>-0.43932309</td><td>-0.15576478</td></tr>\n",
       "\t<tr><td>38</td><td> 650</td><td>0</td><td> 650</td><td>0</td><td>3</td><td>59</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>â‹¯</td><td>-0.253086816</td><td>-1.03622267</td><td> 0.74340903</td><td>-0.44263081</td><td>-0.7088331041</td><td> 0.021772744</td><td> 0.30909709</td><td> 0.001373924</td><td> 0.42681432</td><td>-0.13050942</td></tr>\n",
       "\t<tr><td>39</td><td> 657</td><td>0</td><td> 657</td><td>0</td><td>3</td><td>33</td><td>0</td><td>Ipilimumab + Nivolumab    </td><td>LN             </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td> 4</td><td> 129</td><td>0</td><td>  39</td><td>1</td><td>0</td><td>48</td><td>0</td><td>Ipilimumab + Nivolumab    </td><td>SQ             </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>40</td><td> 671</td><td>0</td><td> 671</td><td>0</td><td>2</td><td>81</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>41</td><td> 672</td><td>0</td><td> 672</td><td>0</td><td>2</td><td>57</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>42</td><td> 692</td><td>0</td><td> 692</td><td>0</td><td>2</td><td>71</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Lung           </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>43</td><td> 693</td><td>0</td><td> 693</td><td>0</td><td>3</td><td>53</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>44</td><td> 695</td><td>0</td><td> 695</td><td>0</td><td>2</td><td>68</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>â‹¯</td><td> 0.206773696</td><td>-0.42747899</td><td>-0.06521667</td><td>-0.31779465</td><td>-0.6308434283</td><td>-0.012797742</td><td> 0.16718252</td><td> 1.344192060</td><td>-0.03809493</td><td>-0.45864802</td></tr>\n",
       "\t<tr><td>45</td><td> 721</td><td>0</td><td> 721</td><td>0</td><td>3</td><td>70</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Mucosa         </td><td>â‹¯</td><td>-0.441284649</td><td>-0.90003180</td><td>-0.55994432</td><td>-0.56467426</td><td>-0.0005595549</td><td>-0.095807574</td><td>-0.42775717</td><td> 0.073520455</td><td> 0.32066835</td><td>-0.20276745</td></tr>\n",
       "\t<tr><td>46</td><td> 721</td><td>0</td><td> 721</td><td>0</td><td>3</td><td>54</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>Lung           </td><td>â‹¯</td><td>-0.235865821</td><td>-0.80103916</td><td> 0.22053955</td><td>-0.19983454</td><td> 0.2138286755</td><td>-0.086896878</td><td>-0.09116498</td><td> 0.038010253</td><td> 0.27755322</td><td> 0.04282373</td></tr>\n",
       "\t<tr><td>47</td><td> 732</td><td>0</td><td> 732</td><td>0</td><td>2</td><td>24</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>â‹¯</td><td>-0.570139294</td><td>-0.38900084</td><td> 0.20432131</td><td> 0.13540615</td><td>-0.4530921630</td><td>-0.018278153</td><td> 0.07228018</td><td> 0.273916435</td><td>-0.32552466</td><td>-0.16369490</td></tr>\n",
       "\t<tr><td>48</td><td> 737</td><td>0</td><td> 737</td><td>0</td><td>2</td><td>72</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>SQ             </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>49</td><td> 775</td><td>0</td><td> 775</td><td>0</td><td>3</td><td>36</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td> 0.387066334</td><td> 0.80556102</td><td>-0.04602627</td><td> 0.15027246</td><td>-0.6784978765</td><td> 0.038183825</td><td> 0.16128751</td><td>-0.238370565</td><td>-0.13963415</td><td>-0.21243155</td></tr>\n",
       "\t<tr><td> 5</td><td>  93</td><td>1</td><td>  40</td><td>1</td><td>0</td><td>49</td><td>1</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>50</td><td> 904</td><td>0</td><td> 904</td><td>0</td><td>2</td><td>68</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td> 0.314961134</td><td> 1.37143617</td><td> 0.08818719</td><td> 0.27088915</td><td>-0.2879368575</td><td> 0.045436179</td><td> 0.33126353</td><td> 0.210137373</td><td>-0.54818555</td><td>-0.23738481</td></tr>\n",
       "\t<tr><td>51</td><td>1379</td><td>0</td><td>1379</td><td>0</td><td>2</td><td>64</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>Liver          </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "\t<tr><td> 6</td><td> 108</td><td>1</td><td>  41</td><td>1</td><td>0</td><td>75</td><td>0</td><td>Ipilimumab + Nivolumab    </td><td>LN             </td><td>â‹¯</td><td> 0.230476038</td><td>-0.34597308</td><td>-0.02931501</td><td> 0.33392762</td><td> 0.1422300068</td><td>-0.006887237</td><td>-0.09623038</td><td>-1.180614170</td><td> 0.44382387</td><td> 0.03539586</td></tr>\n",
       "\t<tr><td> 7</td><td> 169</td><td>0</td><td>  81</td><td>1</td><td>2</td><td>59</td><td>0</td><td>Ipilimumab + Nivolumab    </td><td>SQ             </td><td>â‹¯</td><td> 0.715314720</td><td> 0.32665483</td><td> 0.27464873</td><td>-0.37869573</td><td>-0.2000784318</td><td>-0.095807574</td><td> 0.13778226</td><td> 0.704947921</td><td>-0.55133851</td><td> 0.40732392</td></tr>\n",
       "\t<tr><td> 8</td><td> 637</td><td>0</td><td>  81</td><td>1</td><td>0</td><td>55</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td> 0.445047608</td><td> 0.80762933</td><td>-0.38707532</td><td> 0.08435613</td><td>-0.3666242486</td><td>-0.043040810</td><td> 0.32211429</td><td>-0.606676792</td><td>-1.13187658</td><td> 0.65424050</td></tr>\n",
       "\t<tr><td> 9</td><td> 156</td><td>1</td><td>  81</td><td>1</td><td>0</td><td>56</td><td>0</td><td>Ipilimumab + Pembrolizumab</td><td>LN             </td><td>â‹¯</td><td>          NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>           NA</td><td>          NA</td><td>         NA</td><td>          NA</td><td>         NA</td><td>         NA</td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A data.frame: 51 Ã— 18792\n",
       "\\begin{tabular}{lllllllllllllllllllll}\n",
       " Patient & OS & OS.Event & PFS & PFS.Event & RECIST & Age & Gender & Treatment & Site & â‹¯ & X55055 & X11130 & X7789 & X158586 & X79364 & X440590 & X79699 & X7791 & X23140 & X26009\\\\\n",
       " <int> & <int> & <int> & <int> & <int> & <int> & <int> & <int> & <fct> & <fct> & â‹¯ & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl>\\\\\n",
       "\\hline\n",
       "\t  1 &  689 & 0 &   15 & 1 & 0 & 42 & 1 & Ipilimumab + Pembrolizumab & SQ              & â‹¯ &  0.814559991 &  0.09616738 & -0.27965633 &  0.31559451 & -0.0626374123 &  0.055108447 & -0.56911380 & -0.380607347 & -0.52103880 & -0.46877980\\\\\n",
       "\t 10 &  176 & 1 &   81 & 1 & 0 & 51 & 0 & Ipilimumab + Pembrolizumab & LN              & â‹¯ &  0.464824631 &  0.30872910 & -0.66759771 &  0.56592965 & -0.4606691302 &  0.554262011 &  0.69282995 &  0.539471466 & -0.33190657 &  0.11705793\\\\\n",
       "\t 11 &  221 & 0 &   82 & 1 & 0 & 62 & 0 & Ipilimumab + Nivolumab     & LN              & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 12 &  293 & 0 &   82 & 1 & 0 & 55 & 1 & Ipilimumab + Nivolumab     & Lung            & â‹¯ & -1.115560810 & -2.62608070 &  0.33662516 & -0.09917793 &  0.5652990871 & -0.061318728 &  0.01378568 &  0.632443208 &  0.78257787 & -0.20470475\\\\\n",
       "\t 13 &  357 & 1 &  108 & 1 & 2 & 68 & 1 & Ipilimumab + Nivolumab     & SQ              & â‹¯ & -0.209928304 &  0.81250891 &  0.04422525 &  0.06929868 & -0.3294996664 & -0.095807574 & -0.01927152 &  0.254432485 & -0.03632622 &  0.10893968\\\\\n",
       "\t 14 &  691 & 0 &  123 & 1 & 1 & 47 & 1 & Ipilimumab + Pembrolizumab & SQ              & â‹¯ & -0.229523423 &  1.34753221 &  0.49996400 &  0.10629174 & -0.0166411617 & -0.023002256 &  0.46454270 & -0.437119044 & -0.41935743 & -0.15979738\\\\\n",
       "\t 15 &  660 & 1 &  152 & 1 & 1 & 57 & 0 & Ipilimumab + Pembrolizumab & SQ              & â‹¯ & -0.033292657 &  1.11436707 &  0.13554354 &  0.25877652 & -0.2631522968 & -0.054781348 &  0.14859193 & -0.330010210 & -0.70105036 &  1.23636907\\\\\n",
       "\t 16 &  558 & 0 &  168 & 1 & 2 & 39 & 1 & Ipilimumab + Pembrolizumab & LN              & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 17 &  196 & 0 &  196 & 0 & 2 & 48 & 1 & Ipilimumab + Nivolumab     & LN              & â‹¯ &  0.397248856 & -0.54785782 & -0.22319036 & -0.51547930 &  0.1365183514 & -0.025940561 &  0.18921212 &  0.424191448 &  0.10411358 & -0.16324147\\\\\n",
       "\t 18 &  278 & 0 &  278 & 0 & 2 & 58 & 0 & Ipilimumab + Pembrolizumab & Lung            & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 19 &  635 & 0 &  301 & 1 & 1 & 56 & 0 & Ipilimumab + Pembrolizumab & SQ              & â‹¯ & -0.990153661 & -0.66884995 &  0.75507446 &  0.45702034 & -0.0978608256 & -0.037910521 & -0.19641500 & -0.002663966 &  0.14242927 & -0.53603414\\\\\n",
       "\t  2 &  530 & 0 &   34 & 1 & 0 & 41 & 0 & Ipilimumab + Pembrolizumab & LN              & â‹¯ &  1.079653224 &  0.62934788 & -1.23471534 & -0.96470192 &  0.5255918237 & -0.095807574 & -0.52099920 &  0.825633802 &  0.08874634 &  0.01569202\\\\\n",
       "\t 20 &  538 & 0 &  386 & 1 & 1 & 57 & 0 & Ipilimumab + Pembrolizumab & LN              & â‹¯ & -0.399369346 & -1.27744820 &  1.16563917 &  0.44796852 &  0.9177473835 & -0.044360443 & -0.21307855 & -0.099479074 &  1.54256398 &  0.60783149\\\\\n",
       "\t 21 &  410 & 0 &  410 & 0 & 2 & 63 & 0 & Ipilimumab + Nivolumab     & SQ              & â‹¯ &  0.262799951 &  0.64011166 &  0.24011332 & -0.11178293 &  0.1601318153 &  0.001045315 & -0.02779061 & -0.079428025 &  0.24134531 &  0.22767313\\\\\n",
       "\t 22 &  706 & 0 &  487 & 1 & 2 & 59 & 1 & Ipilimumab + Pembrolizumab & LN              & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 23 &  506 & 0 &  506 & 0 & 2 & 51 & 1 & Ipilimumab + Pembrolizumab & Brain           & â‹¯ &  0.410802324 & -0.35400995 & -0.38289902 &  0.26529255 &  0.0681192357 & -0.046954071 & -0.03533289 & -0.555163096 & -0.54986056 &  1.10751447\\\\\n",
       "\t 24 & 1203 & 0 &  509 & 1 & 2 & 34 & 0 & Ipilimumab + Nivolumab     & LN              & â‹¯ & -0.772687949 & -0.17954929 &  0.15757350 & -0.04612901 &  0.1787330668 & -0.049971772 &  0.06365311 & -0.651993693 &  0.41805088 & -0.40544793\\\\\n",
       "\t 25 &  518 & 1 &  518 & 0 & 1 & 67 & 1 & Ipilimumab + Pembrolizumab & LN              & â‹¯ &  0.323958497 & -0.28877420 & -0.34308412 & -0.42472156 &  0.7366265926 & -0.095807574 &  0.41074512 & -0.507792891 &  0.20384346 &  0.47588991\\\\\n",
       "\t 26 &  544 & 0 &  544 & 0 & 3 & 75 & 0 & Ipilimumab + Pembrolizumab & LN              & â‹¯ &  0.462127921 &  0.57497284 & -0.59890304 & -0.44415190 &  0.7441192974 &  0.069465219 & -0.38604727 & -0.899311870 &  0.37238568 & -0.43646272\\\\\n",
       "\t 27 &  546 & 0 &  546 & 0 & 3 & 49 & 0 & Ipilimumab + Pembrolizumab & Abdomen         & â‹¯ & -0.605366439 &  0.35143929 &  0.32851067 &  0.35746238 & -0.1407782292 & -0.077796562 &  0.07142574 &  0.107125170 & -0.01490806 & -0.75544253\\\\\n",
       "\t 28 &  553 & 0 &  553 & 0 & 3 & 33 & 0 & Ipilimumab + Pembrolizumab & LN              & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 29 &  567 & 0 &  567 & 0 & 3 & 66 & 1 & Ipilimumab + Pembrolizumab & LN              & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t  3 &  300 & 0 &   37 & 1 & 0 & 58 & 1 & Ipilimumab + Nivolumab     & Lung            & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 30 &  573 & 0 &  573 & 0 & 2 & 56 & 0 & Ipilimumab + Pembrolizumab & Small intestine & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 31 &  588 & 0 &  588 & 0 & 3 & 45 & 0 & Ipilimumab + Pembrolizumab & Lung            & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 32 &  597 & 0 &  597 & 0 & 3 & 71 & 0 & Ipilimumab + Pembrolizumab & LN              & â‹¯ &  0.008691614 & -0.39469549 & -0.73498518 & -0.43149567 &  0.5530308342 &  0.567570255 & -0.17093020 & -0.578044742 &  1.00302316 &  0.72587330\\\\\n",
       "\t 33 &  609 & 0 &  609 & 0 & 2 & 73 & 0 & Ipilimumab + Pembrolizumab & SQ              & â‹¯ &  0.543191258 &  0.96220905 &  0.08654803 &  0.29531747 & -0.0733442796 & -0.071404280 &  0.04744246 &  0.311459770 & -0.45692695 & -0.22853974\\\\\n",
       "\t 34 &  623 & 0 &  623 & 0 & 3 & 51 & 0 & Ipilimumab + Pembrolizumab & Lung            & â‹¯ & -0.766047908 & -1.69531674 & -0.14342511 & -0.17124200 &  0.5643143914 & -0.068337272 & -0.19164100 &  0.736564406 &  0.06647244 & -0.16604761\\\\\n",
       "\t 35 &  627 & 0 &  627 & 0 & 3 & 72 & 0 & Ipilimumab + Pembrolizumab & SQ              & â‹¯ & -0.468675161 &  0.38191325 & -0.13353630 &  0.44677454 & -0.1907897938 & -0.014894504 & -0.06091901 & -0.292491200 &  0.06483150 &  0.36725970\\\\\n",
       "\t 36 &  637 & 0 &  637 & 0 & 3 & 74 & 1 & Ipilimumab + Pembrolizumab & SQ              & â‹¯ & -0.231554875 &  0.42826173 &  0.17136963 &  0.43681965 & -0.0434933523 & -0.070101252 & -0.77012086 &  0.026242002 & -0.29389081 & -1.04418568\\\\\n",
       "\t 37 &  637 & 0 &  637 & 0 & 2 & 76 & 0 & Ipilimumab + Pembrolizumab & LN              & â‹¯ &  0.255039312 &  0.97348718 &  0.37727755 &  0.11511414 & -0.5009587486 & -0.059131734 &  0.17357627 &  0.336104507 & -0.43932309 & -0.15576478\\\\\n",
       "\t 38 &  650 & 0 &  650 & 0 & 3 & 59 & 1 & Ipilimumab + Pembrolizumab & SQ              & â‹¯ & -0.253086816 & -1.03622267 &  0.74340903 & -0.44263081 & -0.7088331041 &  0.021772744 &  0.30909709 &  0.001373924 &  0.42681432 & -0.13050942\\\\\n",
       "\t 39 &  657 & 0 &  657 & 0 & 3 & 33 & 0 & Ipilimumab + Nivolumab     & LN              & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t  4 &  129 & 0 &   39 & 1 & 0 & 48 & 0 & Ipilimumab + Nivolumab     & SQ              & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 40 &  671 & 0 &  671 & 0 & 2 & 81 & 0 & Ipilimumab + Pembrolizumab & SQ              & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 41 &  672 & 0 &  672 & 0 & 2 & 57 & 1 & Ipilimumab + Pembrolizumab & SQ              & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 42 &  692 & 0 &  692 & 0 & 2 & 71 & 0 & Ipilimumab + Pembrolizumab & Lung            & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 43 &  693 & 0 &  693 & 0 & 3 & 53 & 1 & Ipilimumab + Pembrolizumab & SQ              & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 44 &  695 & 0 &  695 & 0 & 2 & 68 & 0 & Ipilimumab + Pembrolizumab & SQ              & â‹¯ &  0.206773696 & -0.42747899 & -0.06521667 & -0.31779465 & -0.6308434283 & -0.012797742 &  0.16718252 &  1.344192060 & -0.03809493 & -0.45864802\\\\\n",
       "\t 45 &  721 & 0 &  721 & 0 & 3 & 70 & 0 & Ipilimumab + Pembrolizumab & Mucosa          & â‹¯ & -0.441284649 & -0.90003180 & -0.55994432 & -0.56467426 & -0.0005595549 & -0.095807574 & -0.42775717 &  0.073520455 &  0.32066835 & -0.20276745\\\\\n",
       "\t 46 &  721 & 0 &  721 & 0 & 3 & 54 & 1 & Ipilimumab + Pembrolizumab & Lung            & â‹¯ & -0.235865821 & -0.80103916 &  0.22053955 & -0.19983454 &  0.2138286755 & -0.086896878 & -0.09116498 &  0.038010253 &  0.27755322 &  0.04282373\\\\\n",
       "\t 47 &  732 & 0 &  732 & 0 & 2 & 24 & 1 & Ipilimumab + Pembrolizumab & SQ              & â‹¯ & -0.570139294 & -0.38900084 &  0.20432131 &  0.13540615 & -0.4530921630 & -0.018278153 &  0.07228018 &  0.273916435 & -0.32552466 & -0.16369490\\\\\n",
       "\t 48 &  737 & 0 &  737 & 0 & 2 & 72 & 0 & Ipilimumab + Pembrolizumab & SQ              & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 49 &  775 & 0 &  775 & 0 & 3 & 36 & 0 & Ipilimumab + Pembrolizumab & LN              & â‹¯ &  0.387066334 &  0.80556102 & -0.04602627 &  0.15027246 & -0.6784978765 &  0.038183825 &  0.16128751 & -0.238370565 & -0.13963415 & -0.21243155\\\\\n",
       "\t  5 &   93 & 1 &   40 & 1 & 0 & 49 & 1 & Ipilimumab + Pembrolizumab & LN              & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t 50 &  904 & 0 &  904 & 0 & 2 & 68 & 0 & Ipilimumab + Pembrolizumab & LN              & â‹¯ &  0.314961134 &  1.37143617 &  0.08818719 &  0.27088915 & -0.2879368575 &  0.045436179 &  0.33126353 &  0.210137373 & -0.54818555 & -0.23738481\\\\\n",
       "\t 51 & 1379 & 0 & 1379 & 0 & 2 & 64 & 0 & Ipilimumab + Pembrolizumab & Liver           & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\t  6 &  108 & 1 &   41 & 1 & 0 & 75 & 0 & Ipilimumab + Nivolumab     & LN              & â‹¯ &  0.230476038 & -0.34597308 & -0.02931501 &  0.33392762 &  0.1422300068 & -0.006887237 & -0.09623038 & -1.180614170 &  0.44382387 &  0.03539586\\\\\n",
       "\t  7 &  169 & 0 &   81 & 1 & 2 & 59 & 0 & Ipilimumab + Nivolumab     & SQ              & â‹¯ &  0.715314720 &  0.32665483 &  0.27464873 & -0.37869573 & -0.2000784318 & -0.095807574 &  0.13778226 &  0.704947921 & -0.55133851 &  0.40732392\\\\\n",
       "\t  8 &  637 & 0 &   81 & 1 & 0 & 55 & 0 & Ipilimumab + Pembrolizumab & LN              & â‹¯ &  0.445047608 &  0.80762933 & -0.38707532 &  0.08435613 & -0.3666242486 & -0.043040810 &  0.32211429 & -0.606676792 & -1.13187658 &  0.65424050\\\\\n",
       "\t  9 &  156 & 1 &   81 & 1 & 0 & 56 & 0 & Ipilimumab + Pembrolizumab & LN              & â‹¯ &           NA &          NA &          NA &          NA &            NA &           NA &          NA &           NA &          NA &          NA\\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A data.frame: 51 Ã— 18792\n",
       "\n",
       "| Patient &lt;int&gt; | OS &lt;int&gt; | OS.Event &lt;int&gt; | PFS &lt;int&gt; | PFS.Event &lt;int&gt; | RECIST &lt;int&gt; | Age &lt;int&gt; | Gender &lt;int&gt; | Treatment &lt;fct&gt; | Site &lt;fct&gt; | â‹¯ â‹¯ | X55055 &lt;dbl&gt; | X11130 &lt;dbl&gt; | X7789 &lt;dbl&gt; | X158586 &lt;dbl&gt; | X79364 &lt;dbl&gt; | X440590 &lt;dbl&gt; | X79699 &lt;dbl&gt; | X7791 &lt;dbl&gt; | X23140 &lt;dbl&gt; | X26009 &lt;dbl&gt; |\n",
       "|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|\n",
       "|  1 |  689 | 0 |   15 | 1 | 0 | 42 | 1 | Ipilimumab + Pembrolizumab | SQ              | â‹¯ |  0.814559991 |  0.09616738 | -0.27965633 |  0.31559451 | -0.0626374123 |  0.055108447 | -0.56911380 | -0.380607347 | -0.52103880 | -0.46877980 |\n",
       "| 10 |  176 | 1 |   81 | 1 | 0 | 51 | 0 | Ipilimumab + Pembrolizumab | LN              | â‹¯ |  0.464824631 |  0.30872910 | -0.66759771 |  0.56592965 | -0.4606691302 |  0.554262011 |  0.69282995 |  0.539471466 | -0.33190657 |  0.11705793 |\n",
       "| 11 |  221 | 0 |   82 | 1 | 0 | 62 | 0 | Ipilimumab + Nivolumab     | LN              | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 12 |  293 | 0 |   82 | 1 | 0 | 55 | 1 | Ipilimumab + Nivolumab     | Lung            | â‹¯ | -1.115560810 | -2.62608070 |  0.33662516 | -0.09917793 |  0.5652990871 | -0.061318728 |  0.01378568 |  0.632443208 |  0.78257787 | -0.20470475 |\n",
       "| 13 |  357 | 1 |  108 | 1 | 2 | 68 | 1 | Ipilimumab + Nivolumab     | SQ              | â‹¯ | -0.209928304 |  0.81250891 |  0.04422525 |  0.06929868 | -0.3294996664 | -0.095807574 | -0.01927152 |  0.254432485 | -0.03632622 |  0.10893968 |\n",
       "| 14 |  691 | 0 |  123 | 1 | 1 | 47 | 1 | Ipilimumab + Pembrolizumab | SQ              | â‹¯ | -0.229523423 |  1.34753221 |  0.49996400 |  0.10629174 | -0.0166411617 | -0.023002256 |  0.46454270 | -0.437119044 | -0.41935743 | -0.15979738 |\n",
       "| 15 |  660 | 1 |  152 | 1 | 1 | 57 | 0 | Ipilimumab + Pembrolizumab | SQ              | â‹¯ | -0.033292657 |  1.11436707 |  0.13554354 |  0.25877652 | -0.2631522968 | -0.054781348 |  0.14859193 | -0.330010210 | -0.70105036 |  1.23636907 |\n",
       "| 16 |  558 | 0 |  168 | 1 | 2 | 39 | 1 | Ipilimumab + Pembrolizumab | LN              | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 17 |  196 | 0 |  196 | 0 | 2 | 48 | 1 | Ipilimumab + Nivolumab     | LN              | â‹¯ |  0.397248856 | -0.54785782 | -0.22319036 | -0.51547930 |  0.1365183514 | -0.025940561 |  0.18921212 |  0.424191448 |  0.10411358 | -0.16324147 |\n",
       "| 18 |  278 | 0 |  278 | 0 | 2 | 58 | 0 | Ipilimumab + Pembrolizumab | Lung            | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 19 |  635 | 0 |  301 | 1 | 1 | 56 | 0 | Ipilimumab + Pembrolizumab | SQ              | â‹¯ | -0.990153661 | -0.66884995 |  0.75507446 |  0.45702034 | -0.0978608256 | -0.037910521 | -0.19641500 | -0.002663966 |  0.14242927 | -0.53603414 |\n",
       "|  2 |  530 | 0 |   34 | 1 | 0 | 41 | 0 | Ipilimumab + Pembrolizumab | LN              | â‹¯ |  1.079653224 |  0.62934788 | -1.23471534 | -0.96470192 |  0.5255918237 | -0.095807574 | -0.52099920 |  0.825633802 |  0.08874634 |  0.01569202 |\n",
       "| 20 |  538 | 0 |  386 | 1 | 1 | 57 | 0 | Ipilimumab + Pembrolizumab | LN              | â‹¯ | -0.399369346 | -1.27744820 |  1.16563917 |  0.44796852 |  0.9177473835 | -0.044360443 | -0.21307855 | -0.099479074 |  1.54256398 |  0.60783149 |\n",
       "| 21 |  410 | 0 |  410 | 0 | 2 | 63 | 0 | Ipilimumab + Nivolumab     | SQ              | â‹¯ |  0.262799951 |  0.64011166 |  0.24011332 | -0.11178293 |  0.1601318153 |  0.001045315 | -0.02779061 | -0.079428025 |  0.24134531 |  0.22767313 |\n",
       "| 22 |  706 | 0 |  487 | 1 | 2 | 59 | 1 | Ipilimumab + Pembrolizumab | LN              | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 23 |  506 | 0 |  506 | 0 | 2 | 51 | 1 | Ipilimumab + Pembrolizumab | Brain           | â‹¯ |  0.410802324 | -0.35400995 | -0.38289902 |  0.26529255 |  0.0681192357 | -0.046954071 | -0.03533289 | -0.555163096 | -0.54986056 |  1.10751447 |\n",
       "| 24 | 1203 | 0 |  509 | 1 | 2 | 34 | 0 | Ipilimumab + Nivolumab     | LN              | â‹¯ | -0.772687949 | -0.17954929 |  0.15757350 | -0.04612901 |  0.1787330668 | -0.049971772 |  0.06365311 | -0.651993693 |  0.41805088 | -0.40544793 |\n",
       "| 25 |  518 | 1 |  518 | 0 | 1 | 67 | 1 | Ipilimumab + Pembrolizumab | LN              | â‹¯ |  0.323958497 | -0.28877420 | -0.34308412 | -0.42472156 |  0.7366265926 | -0.095807574 |  0.41074512 | -0.507792891 |  0.20384346 |  0.47588991 |\n",
       "| 26 |  544 | 0 |  544 | 0 | 3 | 75 | 0 | Ipilimumab + Pembrolizumab | LN              | â‹¯ |  0.462127921 |  0.57497284 | -0.59890304 | -0.44415190 |  0.7441192974 |  0.069465219 | -0.38604727 | -0.899311870 |  0.37238568 | -0.43646272 |\n",
       "| 27 |  546 | 0 |  546 | 0 | 3 | 49 | 0 | Ipilimumab + Pembrolizumab | Abdomen         | â‹¯ | -0.605366439 |  0.35143929 |  0.32851067 |  0.35746238 | -0.1407782292 | -0.077796562 |  0.07142574 |  0.107125170 | -0.01490806 | -0.75544253 |\n",
       "| 28 |  553 | 0 |  553 | 0 | 3 | 33 | 0 | Ipilimumab + Pembrolizumab | LN              | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 29 |  567 | 0 |  567 | 0 | 3 | 66 | 1 | Ipilimumab + Pembrolizumab | LN              | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "|  3 |  300 | 0 |   37 | 1 | 0 | 58 | 1 | Ipilimumab + Nivolumab     | Lung            | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 30 |  573 | 0 |  573 | 0 | 2 | 56 | 0 | Ipilimumab + Pembrolizumab | Small intestine | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 31 |  588 | 0 |  588 | 0 | 3 | 45 | 0 | Ipilimumab + Pembrolizumab | Lung            | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 32 |  597 | 0 |  597 | 0 | 3 | 71 | 0 | Ipilimumab + Pembrolizumab | LN              | â‹¯ |  0.008691614 | -0.39469549 | -0.73498518 | -0.43149567 |  0.5530308342 |  0.567570255 | -0.17093020 | -0.578044742 |  1.00302316 |  0.72587330 |\n",
       "| 33 |  609 | 0 |  609 | 0 | 2 | 73 | 0 | Ipilimumab + Pembrolizumab | SQ              | â‹¯ |  0.543191258 |  0.96220905 |  0.08654803 |  0.29531747 | -0.0733442796 | -0.071404280 |  0.04744246 |  0.311459770 | -0.45692695 | -0.22853974 |\n",
       "| 34 |  623 | 0 |  623 | 0 | 3 | 51 | 0 | Ipilimumab + Pembrolizumab | Lung            | â‹¯ | -0.766047908 | -1.69531674 | -0.14342511 | -0.17124200 |  0.5643143914 | -0.068337272 | -0.19164100 |  0.736564406 |  0.06647244 | -0.16604761 |\n",
       "| 35 |  627 | 0 |  627 | 0 | 3 | 72 | 0 | Ipilimumab + Pembrolizumab | SQ              | â‹¯ | -0.468675161 |  0.38191325 | -0.13353630 |  0.44677454 | -0.1907897938 | -0.014894504 | -0.06091901 | -0.292491200 |  0.06483150 |  0.36725970 |\n",
       "| 36 |  637 | 0 |  637 | 0 | 3 | 74 | 1 | Ipilimumab + Pembrolizumab | SQ              | â‹¯ | -0.231554875 |  0.42826173 |  0.17136963 |  0.43681965 | -0.0434933523 | -0.070101252 | -0.77012086 |  0.026242002 | -0.29389081 | -1.04418568 |\n",
       "| 37 |  637 | 0 |  637 | 0 | 2 | 76 | 0 | Ipilimumab + Pembrolizumab | LN              | â‹¯ |  0.255039312 |  0.97348718 |  0.37727755 |  0.11511414 | -0.5009587486 | -0.059131734 |  0.17357627 |  0.336104507 | -0.43932309 | -0.15576478 |\n",
       "| 38 |  650 | 0 |  650 | 0 | 3 | 59 | 1 | Ipilimumab + Pembrolizumab | SQ              | â‹¯ | -0.253086816 | -1.03622267 |  0.74340903 | -0.44263081 | -0.7088331041 |  0.021772744 |  0.30909709 |  0.001373924 |  0.42681432 | -0.13050942 |\n",
       "| 39 |  657 | 0 |  657 | 0 | 3 | 33 | 0 | Ipilimumab + Nivolumab     | LN              | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "|  4 |  129 | 0 |   39 | 1 | 0 | 48 | 0 | Ipilimumab + Nivolumab     | SQ              | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 40 |  671 | 0 |  671 | 0 | 2 | 81 | 0 | Ipilimumab + Pembrolizumab | SQ              | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 41 |  672 | 0 |  672 | 0 | 2 | 57 | 1 | Ipilimumab + Pembrolizumab | SQ              | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 42 |  692 | 0 |  692 | 0 | 2 | 71 | 0 | Ipilimumab + Pembrolizumab | Lung            | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 43 |  693 | 0 |  693 | 0 | 3 | 53 | 1 | Ipilimumab + Pembrolizumab | SQ              | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 44 |  695 | 0 |  695 | 0 | 2 | 68 | 0 | Ipilimumab + Pembrolizumab | SQ              | â‹¯ |  0.206773696 | -0.42747899 | -0.06521667 | -0.31779465 | -0.6308434283 | -0.012797742 |  0.16718252 |  1.344192060 | -0.03809493 | -0.45864802 |\n",
       "| 45 |  721 | 0 |  721 | 0 | 3 | 70 | 0 | Ipilimumab + Pembrolizumab | Mucosa          | â‹¯ | -0.441284649 | -0.90003180 | -0.55994432 | -0.56467426 | -0.0005595549 | -0.095807574 | -0.42775717 |  0.073520455 |  0.32066835 | -0.20276745 |\n",
       "| 46 |  721 | 0 |  721 | 0 | 3 | 54 | 1 | Ipilimumab + Pembrolizumab | Lung            | â‹¯ | -0.235865821 | -0.80103916 |  0.22053955 | -0.19983454 |  0.2138286755 | -0.086896878 | -0.09116498 |  0.038010253 |  0.27755322 |  0.04282373 |\n",
       "| 47 |  732 | 0 |  732 | 0 | 2 | 24 | 1 | Ipilimumab + Pembrolizumab | SQ              | â‹¯ | -0.570139294 | -0.38900084 |  0.20432131 |  0.13540615 | -0.4530921630 | -0.018278153 |  0.07228018 |  0.273916435 | -0.32552466 | -0.16369490 |\n",
       "| 48 |  737 | 0 |  737 | 0 | 2 | 72 | 0 | Ipilimumab + Pembrolizumab | SQ              | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 49 |  775 | 0 |  775 | 0 | 3 | 36 | 0 | Ipilimumab + Pembrolizumab | LN              | â‹¯ |  0.387066334 |  0.80556102 | -0.04602627 |  0.15027246 | -0.6784978765 |  0.038183825 |  0.16128751 | -0.238370565 | -0.13963415 | -0.21243155 |\n",
       "|  5 |   93 | 1 |   40 | 1 | 0 | 49 | 1 | Ipilimumab + Pembrolizumab | LN              | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "| 50 |  904 | 0 |  904 | 0 | 2 | 68 | 0 | Ipilimumab + Pembrolizumab | LN              | â‹¯ |  0.314961134 |  1.37143617 |  0.08818719 |  0.27088915 | -0.2879368575 |  0.045436179 |  0.33126353 |  0.210137373 | -0.54818555 | -0.23738481 |\n",
       "| 51 | 1379 | 0 | 1379 | 0 | 2 | 64 | 0 | Ipilimumab + Pembrolizumab | Liver           | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "|  6 |  108 | 1 |   41 | 1 | 0 | 75 | 0 | Ipilimumab + Nivolumab     | LN              | â‹¯ |  0.230476038 | -0.34597308 | -0.02931501 |  0.33392762 |  0.1422300068 | -0.006887237 | -0.09623038 | -1.180614170 |  0.44382387 |  0.03539586 |\n",
       "|  7 |  169 | 0 |   81 | 1 | 2 | 59 | 0 | Ipilimumab + Nivolumab     | SQ              | â‹¯ |  0.715314720 |  0.32665483 |  0.27464873 | -0.37869573 | -0.2000784318 | -0.095807574 |  0.13778226 |  0.704947921 | -0.55133851 |  0.40732392 |\n",
       "|  8 |  637 | 0 |   81 | 1 | 0 | 55 | 0 | Ipilimumab + Pembrolizumab | LN              | â‹¯ |  0.445047608 |  0.80762933 | -0.38707532 |  0.08435613 | -0.3666242486 | -0.043040810 |  0.32211429 | -0.606676792 | -1.13187658 |  0.65424050 |\n",
       "|  9 |  156 | 1 |   81 | 1 | 0 | 56 | 0 | Ipilimumab + Pembrolizumab | LN              | â‹¯ |           NA |          NA |          NA |          NA |            NA |           NA |          NA |           NA |          NA |          NA |\n",
       "\n"
      ],
      "text/plain": [
       "   Patient OS   OS.Event PFS  PFS.Event RECIST Age Gender\n",
       "1   1       689 0          15 1         0      42  1     \n",
       "2  10       176 1          81 1         0      51  0     \n",
       "3  11       221 0          82 1         0      62  0     \n",
       "4  12       293 0          82 1         0      55  1     \n",
       "5  13       357 1         108 1         2      68  1     \n",
       "6  14       691 0         123 1         1      47  1     \n",
       "7  15       660 1         152 1         1      57  0     \n",
       "8  16       558 0         168 1         2      39  1     \n",
       "9  17       196 0         196 0         2      48  1     \n",
       "10 18       278 0         278 0         2      58  0     \n",
       "11 19       635 0         301 1         1      56  0     \n",
       "12  2       530 0          34 1         0      41  0     \n",
       "13 20       538 0         386 1         1      57  0     \n",
       "14 21       410 0         410 0         2      63  0     \n",
       "15 22       706 0         487 1         2      59  1     \n",
       "16 23       506 0         506 0         2      51  1     \n",
       "17 24      1203 0         509 1         2      34  0     \n",
       "18 25       518 1         518 0         1      67  1     \n",
       "19 26       544 0         544 0         3      75  0     \n",
       "20 27       546 0         546 0         3      49  0     \n",
       "21 28       553 0         553 0         3      33  0     \n",
       "22 29       567 0         567 0         3      66  1     \n",
       "23  3       300 0          37 1         0      58  1     \n",
       "24 30       573 0         573 0         2      56  0     \n",
       "25 31       588 0         588 0         3      45  0     \n",
       "26 32       597 0         597 0         3      71  0     \n",
       "27 33       609 0         609 0         2      73  0     \n",
       "28 34       623 0         623 0         3      51  0     \n",
       "29 35       627 0         627 0         3      72  0     \n",
       "30 36       637 0         637 0         3      74  1     \n",
       "31 37       637 0         637 0         2      76  0     \n",
       "32 38       650 0         650 0         3      59  1     \n",
       "33 39       657 0         657 0         3      33  0     \n",
       "34  4       129 0          39 1         0      48  0     \n",
       "35 40       671 0         671 0         2      81  0     \n",
       "36 41       672 0         672 0         2      57  1     \n",
       "37 42       692 0         692 0         2      71  0     \n",
       "38 43       693 0         693 0         3      53  1     \n",
       "39 44       695 0         695 0         2      68  0     \n",
       "40 45       721 0         721 0         3      70  0     \n",
       "41 46       721 0         721 0         3      54  1     \n",
       "42 47       732 0         732 0         2      24  1     \n",
       "43 48       737 0         737 0         2      72  0     \n",
       "44 49       775 0         775 0         3      36  0     \n",
       "45  5        93 1          40 1         0      49  1     \n",
       "46 50       904 0         904 0         2      68  0     \n",
       "47 51      1379 0        1379 0         2      64  0     \n",
       "48  6       108 1          41 1         0      75  0     \n",
       "49  7       169 0          81 1         2      59  0     \n",
       "50  8       637 0          81 1         0      55  0     \n",
       "51  9       156 1          81 1         0      56  0     \n",
       "   Treatment                  Site            â‹¯ X55055       X11130     \n",
       "1  Ipilimumab + Pembrolizumab SQ              â‹¯  0.814559991  0.09616738\n",
       "2  Ipilimumab + Pembrolizumab LN              â‹¯  0.464824631  0.30872910\n",
       "3  Ipilimumab + Nivolumab     LN              â‹¯           NA          NA\n",
       "4  Ipilimumab + Nivolumab     Lung            â‹¯ -1.115560810 -2.62608070\n",
       "5  Ipilimumab + Nivolumab     SQ              â‹¯ -0.209928304  0.81250891\n",
       "6  Ipilimumab + Pembrolizumab SQ              â‹¯ -0.229523423  1.34753221\n",
       "7  Ipilimumab + Pembrolizumab SQ              â‹¯ -0.033292657  1.11436707\n",
       "8  Ipilimumab + Pembrolizumab LN              â‹¯           NA          NA\n",
       "9  Ipilimumab + Nivolumab     LN              â‹¯  0.397248856 -0.54785782\n",
       "10 Ipilimumab + Pembrolizumab Lung            â‹¯           NA          NA\n",
       "11 Ipilimumab + Pembrolizumab SQ              â‹¯ -0.990153661 -0.66884995\n",
       "12 Ipilimumab + Pembrolizumab LN              â‹¯  1.079653224  0.62934788\n",
       "13 Ipilimumab + Pembrolizumab LN              â‹¯ -0.399369346 -1.27744820\n",
       "14 Ipilimumab + Nivolumab     SQ              â‹¯  0.262799951  0.64011166\n",
       "15 Ipilimumab + Pembrolizumab LN              â‹¯           NA          NA\n",
       "16 Ipilimumab + Pembrolizumab Brain           â‹¯  0.410802324 -0.35400995\n",
       "17 Ipilimumab + Nivolumab     LN              â‹¯ -0.772687949 -0.17954929\n",
       "18 Ipilimumab + Pembrolizumab LN              â‹¯  0.323958497 -0.28877420\n",
       "19 Ipilimumab + Pembrolizumab LN              â‹¯  0.462127921  0.57497284\n",
       "20 Ipilimumab + Pembrolizumab Abdomen         â‹¯ -0.605366439  0.35143929\n",
       "21 Ipilimumab + Pembrolizumab LN              â‹¯           NA          NA\n",
       "22 Ipilimumab + Pembrolizumab LN              â‹¯           NA          NA\n",
       "23 Ipilimumab + Nivolumab     Lung            â‹¯           NA          NA\n",
       "24 Ipilimumab + Pembrolizumab Small intestine â‹¯           NA          NA\n",
       "25 Ipilimumab + Pembrolizumab Lung            â‹¯           NA          NA\n",
       "26 Ipilimumab + Pembrolizumab LN              â‹¯  0.008691614 -0.39469549\n",
       "27 Ipilimumab + Pembrolizumab SQ              â‹¯  0.543191258  0.96220905\n",
       "28 Ipilimumab + Pembrolizumab Lung            â‹¯ -0.766047908 -1.69531674\n",
       "29 Ipilimumab + Pembrolizumab SQ              â‹¯ -0.468675161  0.38191325\n",
       "30 Ipilimumab + Pembrolizumab SQ              â‹¯ -0.231554875  0.42826173\n",
       "31 Ipilimumab + Pembrolizumab LN              â‹¯  0.255039312  0.97348718\n",
       "32 Ipilimumab + Pembrolizumab SQ              â‹¯ -0.253086816 -1.03622267\n",
       "33 Ipilimumab + Nivolumab     LN              â‹¯           NA          NA\n",
       "34 Ipilimumab + Nivolumab     SQ              â‹¯           NA          NA\n",
       "35 Ipilimumab + Pembrolizumab SQ              â‹¯           NA          NA\n",
       "36 Ipilimumab + Pembrolizumab SQ              â‹¯           NA          NA\n",
       "37 Ipilimumab + Pembrolizumab Lung            â‹¯           NA          NA\n",
       "38 Ipilimumab + Pembrolizumab SQ              â‹¯           NA          NA\n",
       "39 Ipilimumab + Pembrolizumab SQ              â‹¯  0.206773696 -0.42747899\n",
       "40 Ipilimumab + Pembrolizumab Mucosa          â‹¯ -0.441284649 -0.90003180\n",
       "41 Ipilimumab + Pembrolizumab Lung            â‹¯ -0.235865821 -0.80103916\n",
       "42 Ipilimumab + Pembrolizumab SQ              â‹¯ -0.570139294 -0.38900084\n",
       "43 Ipilimumab + Pembrolizumab SQ              â‹¯           NA          NA\n",
       "44 Ipilimumab + Pembrolizumab LN              â‹¯  0.387066334  0.80556102\n",
       "45 Ipilimumab + Pembrolizumab LN              â‹¯           NA          NA\n",
       "46 Ipilimumab + Pembrolizumab LN              â‹¯  0.314961134  1.37143617\n",
       "47 Ipilimumab + Pembrolizumab Liver           â‹¯           NA          NA\n",
       "48 Ipilimumab + Nivolumab     LN              â‹¯  0.230476038 -0.34597308\n",
       "49 Ipilimumab + Nivolumab     SQ              â‹¯  0.715314720  0.32665483\n",
       "50 Ipilimumab + Pembrolizumab LN              â‹¯  0.445047608  0.80762933\n",
       "51 Ipilimumab + Pembrolizumab LN              â‹¯           NA          NA\n",
       "   X7789       X158586     X79364        X440590      X79699      X7791       \n",
       "1  -0.27965633  0.31559451 -0.0626374123  0.055108447 -0.56911380 -0.380607347\n",
       "2  -0.66759771  0.56592965 -0.4606691302  0.554262011  0.69282995  0.539471466\n",
       "3           NA          NA            NA           NA          NA           NA\n",
       "4   0.33662516 -0.09917793  0.5652990871 -0.061318728  0.01378568  0.632443208\n",
       "5   0.04422525  0.06929868 -0.3294996664 -0.095807574 -0.01927152  0.254432485\n",
       "6   0.49996400  0.10629174 -0.0166411617 -0.023002256  0.46454270 -0.437119044\n",
       "7   0.13554354  0.25877652 -0.2631522968 -0.054781348  0.14859193 -0.330010210\n",
       "8           NA          NA            NA           NA          NA           NA\n",
       "9  -0.22319036 -0.51547930  0.1365183514 -0.025940561  0.18921212  0.424191448\n",
       "10          NA          NA            NA           NA          NA           NA\n",
       "11  0.75507446  0.45702034 -0.0978608256 -0.037910521 -0.19641500 -0.002663966\n",
       "12 -1.23471534 -0.96470192  0.5255918237 -0.095807574 -0.52099920  0.825633802\n",
       "13  1.16563917  0.44796852  0.9177473835 -0.044360443 -0.21307855 -0.099479074\n",
       "14  0.24011332 -0.11178293  0.1601318153  0.001045315 -0.02779061 -0.079428025\n",
       "15          NA          NA            NA           NA          NA           NA\n",
       "16 -0.38289902  0.26529255  0.0681192357 -0.046954071 -0.03533289 -0.555163096\n",
       "17  0.15757350 -0.04612901  0.1787330668 -0.049971772  0.06365311 -0.651993693\n",
       "18 -0.34308412 -0.42472156  0.7366265926 -0.095807574  0.41074512 -0.507792891\n",
       "19 -0.59890304 -0.44415190  0.7441192974  0.069465219 -0.38604727 -0.899311870\n",
       "20  0.32851067  0.35746238 -0.1407782292 -0.077796562  0.07142574  0.107125170\n",
       "21          NA          NA            NA           NA          NA           NA\n",
       "22          NA          NA            NA           NA          NA           NA\n",
       "23          NA          NA            NA           NA          NA           NA\n",
       "24          NA          NA            NA           NA          NA           NA\n",
       "25          NA          NA            NA           NA          NA           NA\n",
       "26 -0.73498518 -0.43149567  0.5530308342  0.567570255 -0.17093020 -0.578044742\n",
       "27  0.08654803  0.29531747 -0.0733442796 -0.071404280  0.04744246  0.311459770\n",
       "28 -0.14342511 -0.17124200  0.5643143914 -0.068337272 -0.19164100  0.736564406\n",
       "29 -0.13353630  0.44677454 -0.1907897938 -0.014894504 -0.06091901 -0.292491200\n",
       "30  0.17136963  0.43681965 -0.0434933523 -0.070101252 -0.77012086  0.026242002\n",
       "31  0.37727755  0.11511414 -0.5009587486 -0.059131734  0.17357627  0.336104507\n",
       "32  0.74340903 -0.44263081 -0.7088331041  0.021772744  0.30909709  0.001373924\n",
       "33          NA          NA            NA           NA          NA           NA\n",
       "34          NA          NA            NA           NA          NA           NA\n",
       "35          NA          NA            NA           NA          NA           NA\n",
       "36          NA          NA            NA           NA          NA           NA\n",
       "37          NA          NA            NA           NA          NA           NA\n",
       "38          NA          NA            NA           NA          NA           NA\n",
       "39 -0.06521667 -0.31779465 -0.6308434283 -0.012797742  0.16718252  1.344192060\n",
       "40 -0.55994432 -0.56467426 -0.0005595549 -0.095807574 -0.42775717  0.073520455\n",
       "41  0.22053955 -0.19983454  0.2138286755 -0.086896878 -0.09116498  0.038010253\n",
       "42  0.20432131  0.13540615 -0.4530921630 -0.018278153  0.07228018  0.273916435\n",
       "43          NA          NA            NA           NA          NA           NA\n",
       "44 -0.04602627  0.15027246 -0.6784978765  0.038183825  0.16128751 -0.238370565\n",
       "45          NA          NA            NA           NA          NA           NA\n",
       "46  0.08818719  0.27088915 -0.2879368575  0.045436179  0.33126353  0.210137373\n",
       "47          NA          NA            NA           NA          NA           NA\n",
       "48 -0.02931501  0.33392762  0.1422300068 -0.006887237 -0.09623038 -1.180614170\n",
       "49  0.27464873 -0.37869573 -0.2000784318 -0.095807574  0.13778226  0.704947921\n",
       "50 -0.38707532  0.08435613 -0.3666242486 -0.043040810  0.32211429 -0.606676792\n",
       "51          NA          NA            NA           NA          NA           NA\n",
       "   X23140      X26009     \n",
       "1  -0.52103880 -0.46877980\n",
       "2  -0.33190657  0.11705793\n",
       "3           NA          NA\n",
       "4   0.78257787 -0.20470475\n",
       "5  -0.03632622  0.10893968\n",
       "6  -0.41935743 -0.15979738\n",
       "7  -0.70105036  1.23636907\n",
       "8           NA          NA\n",
       "9   0.10411358 -0.16324147\n",
       "10          NA          NA\n",
       "11  0.14242927 -0.53603414\n",
       "12  0.08874634  0.01569202\n",
       "13  1.54256398  0.60783149\n",
       "14  0.24134531  0.22767313\n",
       "15          NA          NA\n",
       "16 -0.54986056  1.10751447\n",
       "17  0.41805088 -0.40544793\n",
       "18  0.20384346  0.47588991\n",
       "19  0.37238568 -0.43646272\n",
       "20 -0.01490806 -0.75544253\n",
       "21          NA          NA\n",
       "22          NA          NA\n",
       "23          NA          NA\n",
       "24          NA          NA\n",
       "25          NA          NA\n",
       "26  1.00302316  0.72587330\n",
       "27 -0.45692695 -0.22853974\n",
       "28  0.06647244 -0.16604761\n",
       "29  0.06483150  0.36725970\n",
       "30 -0.29389081 -1.04418568\n",
       "31 -0.43932309 -0.15576478\n",
       "32  0.42681432 -0.13050942\n",
       "33          NA          NA\n",
       "34          NA          NA\n",
       "35          NA          NA\n",
       "36          NA          NA\n",
       "37          NA          NA\n",
       "38          NA          NA\n",
       "39 -0.03809493 -0.45864802\n",
       "40  0.32066835 -0.20276745\n",
       "41  0.27755322  0.04282373\n",
       "42 -0.32552466 -0.16369490\n",
       "43          NA          NA\n",
       "44 -0.13963415 -0.21243155\n",
       "45          NA          NA\n",
       "46 -0.54818555 -0.23738481\n",
       "47          NA          NA\n",
       "48  0.44382387  0.03539586\n",
       "49 -0.55133851  0.40732392\n",
       "50 -1.13187658  0.65424050\n",
       "51          NA          NA"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "df <- read.csv(\"Gide_pni.csv\")\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "7aa8ddcf",
   "metadata": {},
   "outputs": [],
   "source": [
    "write.csv(pn_combined, \"Gide_pn.csv\", row.names = FALSE)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "id": "fb849273",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table>\n",
       "<caption>A data.frame: 54 Ã— 18582</caption>\n",
       "<thead>\n",
       "\t<tr><th scope=col>Patient</th><th scope=col>OS</th><th scope=col>OS.Event</th><th scope=col>PFS</th><th scope=col>PFS.Event</th><th scope=col>RECIST</th><th scope=col>Age</th><th scope=col>Gender</th><th scope=col>Treatment</th><th scope=col>Site</th><th scope=col>â‹¯</th><th scope=col>X55055</th><th scope=col>X11130</th><th scope=col>X7789</th><th scope=col>X158586</th><th scope=col>X79364</th><th scope=col>X440590</th><th scope=col>X79699</th><th scope=col>X7791</th><th scope=col>X23140</th><th scope=col>X26009</th></tr>\n",
       "\t<tr><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>&lt;fct&gt;</th><th scope=col>â‹¯</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th><th scope=col>&lt;dbl&gt;</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><td> 1</td><td> 147</td><td>1</td><td>   9</td><td>1</td><td>0</td><td>48</td><td>1</td><td>Nivolumab    </td><td>LN    </td><td>â‹¯</td><td>         NA</td><td>         NA</td><td>           NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>          NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>10</td><td> 551</td><td>0</td><td>  76</td><td>1</td><td>0</td><td>90</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td> 0.58714486</td><td> 1.51680290</td><td> 0.2051403085</td><td> 0.24970065</td><td> 0.50803986</td><td> 0.70851142</td><td> 0.45721398</td><td>-0.79611580</td><td> 0.242960585</td><td> 1.18213316</td></tr>\n",
       "\t<tr><td>11</td><td> 166</td><td>1</td><td>  78</td><td>1</td><td>0</td><td>66</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-0.77856996</td><td>-1.01200334</td><td> 0.0005757279</td><td>-0.41480345</td><td> 0.05113678</td><td> 0.09727642</td><td>-0.16385787</td><td>-0.24692816</td><td> 0.117103894</td><td>-0.74993078</td></tr>\n",
       "\t<tr><td>12</td><td> 199</td><td>1</td><td>  80</td><td>1</td><td>1</td><td>52</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-1.51889892</td><td>-0.62973116</td><td> 0.1098136507</td><td>-0.40977490</td><td>-0.18345745</td><td> 0.16842307</td><td>-0.19196153</td><td> 0.65804952</td><td> 0.978488181</td><td>-0.27105096</td></tr>\n",
       "\t<tr><td>13</td><td>  96</td><td>1</td><td>  82</td><td>1</td><td>0</td><td>69</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-0.43369412</td><td> 1.13091160</td><td>-0.2777108820</td><td>-0.12975976</td><td>-0.06003260</td><td>-0.12662805</td><td>-0.13856663</td><td>-1.21787913</td><td>-0.209915150</td><td> 0.08612588</td></tr>\n",
       "\t<tr><td>14</td><td> 993</td><td>1</td><td>  83</td><td>1</td><td>0</td><td>58</td><td>0</td><td>Pembrolizumab</td><td>Mucosa</td><td>â‹¯</td><td> 0.33614144</td><td>-0.17613154</td><td>-0.3655941746</td><td>-0.75921926</td><td> 0.41185003</td><td>-0.11559656</td><td>-0.05134074</td><td>-0.26650284</td><td>-0.305194059</td><td>-0.84401986</td></tr>\n",
       "\t<tr><td>15</td><td> 300</td><td>0</td><td>  84</td><td>1</td><td>0</td><td>76</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-0.52527974</td><td>-1.40244281</td><td> 0.9012394246</td><td> 0.16067435</td><td> 0.67071102</td><td>-0.18993268</td><td>-0.11826441</td><td>-1.18621327</td><td> 0.026281237</td><td> 0.27000323</td></tr>\n",
       "\t<tr><td>16</td><td> 169</td><td>1</td><td>  84</td><td>1</td><td>0</td><td>55</td><td>0</td><td>Pembrolizumab</td><td>LN    </td><td>â‹¯</td><td>-0.49731657</td><td>-0.93868918</td><td>-0.1095925899</td><td>-0.14107495</td><td> 0.02426093</td><td>-0.12426673</td><td>-0.01197064</td><td> 0.57544109</td><td>-0.009577050</td><td>-0.11839787</td></tr>\n",
       "\t<tr><td>17</td><td> 258</td><td>1</td><td>  96</td><td>1</td><td>0</td><td>37</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-0.17379026</td><td> 0.74040639</td><td>-0.4681554262</td><td> 0.15447363</td><td>-0.20567601</td><td>-0.17463977</td><td> 0.21129616</td><td> 0.49320065</td><td>-0.153231356</td><td>-1.04327463</td></tr>\n",
       "\t<tr><td>18</td><td> 228</td><td>1</td><td> 100</td><td>1</td><td>0</td><td>62</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td> 0.56521058</td><td> 0.37410214</td><td>-0.1170037510</td><td> 0.32391776</td><td>-0.14034456</td><td>-0.18993268</td><td> 0.40220709</td><td> 0.76877653</td><td>-0.193560502</td><td> 0.20174889</td></tr>\n",
       "\t<tr><td>19</td><td> 385</td><td>1</td><td> 125</td><td>1</td><td>1</td><td>54</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td> 0.46655105</td><td> 0.54872670</td><td>-0.3409820845</td><td> 0.13252763</td><td>-0.53026602</td><td>-0.18993268</td><td>-0.08828512</td><td>-0.15036820</td><td>-0.062418433</td><td> 0.02279346</td></tr>\n",
       "\t<tr><td> 2</td><td>  65</td><td>1</td><td>  13</td><td>1</td><td>0</td><td>61</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-0.97348238</td><td>-0.76822450</td><td> 0.1028616068</td><td> 0.17016027</td><td>-0.06737654</td><td>-0.17636986</td><td> 0.34607368</td><td> 0.79620927</td><td> 0.417834906</td><td>-0.49855148</td></tr>\n",
       "\t<tr><td>20</td><td> 553</td><td>1</td><td> 156</td><td>1</td><td>2</td><td>45</td><td>1</td><td>Pembrolizumab</td><td>Brain </td><td>â‹¯</td><td>         NA</td><td>         NA</td><td>           NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>          NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>21</td><td> 551</td><td>1</td><td> 166</td><td>1</td><td>1</td><td>67</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td> 0.16868742</td><td>-0.15404176</td><td> 0.3311818672</td><td> 0.06066882</td><td> 0.21068949</td><td>-0.17223253</td><td> 0.28442772</td><td>-0.20843742</td><td>-0.621020206</td><td> 0.38779320</td></tr>\n",
       "\t<tr><td>22</td><td> 379</td><td>0</td><td> 176</td><td>1</td><td>1</td><td>69</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>         NA</td><td>         NA</td><td>           NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>          NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>23</td><td> 191</td><td>1</td><td> 191</td><td>1</td><td>1</td><td>40</td><td>0</td><td>Nivolumab    </td><td>SQ    </td><td>â‹¯</td><td> 0.24905714</td><td> 0.06900338</td><td>-0.4031809368</td><td> 0.08881141</td><td> 0.50467914</td><td>-0.18679525</td><td> 0.27972885</td><td> 1.32422465</td><td> 0.624400137</td><td>-0.22988686</td></tr>\n",
       "\t<tr><td>24</td><td> 407</td><td>1</td><td> 197</td><td>1</td><td>1</td><td>54</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>         NA</td><td>         NA</td><td>           NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>          NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>25</td><td> 897</td><td>1</td><td> 271</td><td>1</td><td>2</td><td>49</td><td>0</td><td>Nivolumab    </td><td>SQ    </td><td>â‹¯</td><td> 0.21330995</td><td> 0.53110123</td><td>-0.6473035526</td><td>-0.54270486</td><td> 0.10962948</td><td>-0.16842562</td><td> 0.34721238</td><td> 0.10479040</td><td>-0.492865694</td><td> 0.14336281</td></tr>\n",
       "\t<tr><td>26</td><td> 275</td><td>0</td><td> 275</td><td>0</td><td>3</td><td>89</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>         NA</td><td>         NA</td><td>           NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>          NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>27</td><td>1067</td><td>1</td><td> 314</td><td>1</td><td>2</td><td>76</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td> 1.00413156</td><td>-0.03714418</td><td> 1.0552302173</td><td> 1.09627171</td><td>-0.05623189</td><td> 0.70739258</td><td> 0.10076517</td><td>-1.33815381</td><td> 0.210307940</td><td>-0.79727101</td></tr>\n",
       "\t<tr><td>28</td><td> 324</td><td>0</td><td> 324</td><td>0</td><td>2</td><td>81</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>         NA</td><td>         NA</td><td>           NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>          NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>29</td><td> 825</td><td>1</td><td> 335</td><td>1</td><td>1</td><td>55</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-0.39822385</td><td>-0.31194865</td><td> 0.1895656253</td><td> 0.35678046</td><td>-0.24796229</td><td>-0.18993268</td><td> 0.38993575</td><td> 0.29388544</td><td> 0.273667791</td><td> 0.37929006</td></tr>\n",
       "\t<tr><td> 3</td><td>  59</td><td>1</td><td>  23</td><td>1</td><td>0</td><td>50</td><td>0</td><td>Nivolumab    </td><td>SQ    </td><td>â‹¯</td><td>-0.77789408</td><td> 0.47804777</td><td> 0.3231840744</td><td> 0.07771963</td><td>-0.13553484</td><td>-0.14994607</td><td> 0.25125628</td><td> 0.46844425</td><td> 0.202778225</td><td> 0.12502150</td></tr>\n",
       "\t<tr><td>30</td><td> 581</td><td>0</td><td> 358</td><td>1</td><td>1</td><td>86</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td> 1.41658928</td><td> 0.06242660</td><td>-1.4247014274</td><td>-0.24798209</td><td>-0.11521950</td><td> 1.03268700</td><td> 0.46235717</td><td> 0.57172041</td><td>-0.687417296</td><td> 1.00008741</td></tr>\n",
       "\t<tr><td>31</td><td> 365</td><td>0</td><td> 365</td><td>0</td><td>2</td><td>74</td><td>1</td><td>Nivolumab    </td><td>SQ    </td><td>â‹¯</td><td>         NA</td><td>         NA</td><td>           NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>          NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>32</td><td> 460</td><td>0</td><td> 460</td><td>0</td><td>3</td><td>69</td><td>1</td><td>Pembrolizumab</td><td>Brain </td><td>â‹¯</td><td>         NA</td><td>         NA</td><td>           NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>          NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>33</td><td> 477</td><td>0</td><td> 477</td><td>0</td><td>3</td><td>76</td><td>0</td><td>Pembrolizumab</td><td>LN    </td><td>â‹¯</td><td>         NA</td><td>         NA</td><td>           NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>          NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>34</td><td> 878</td><td>1</td><td> 544</td><td>1</td><td>2</td><td>78</td><td>0</td><td>Pembrolizumab</td><td>LN    </td><td>â‹¯</td><td>-0.33808762</td><td> 0.16435665</td><td>-0.3942531236</td><td> 0.01195671</td><td>-0.17321962</td><td>-0.13604057</td><td>-0.36331346</td><td>-0.46914968</td><td> 0.105545635</td><td>-0.36518924</td></tr>\n",
       "\t<tr><td>35</td><td>1091</td><td>0</td><td> 586</td><td>1</td><td>2</td><td>55</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-0.32027729</td><td>-0.86643923</td><td> 0.1563104344</td><td>-0.18119199</td><td> 0.11321388</td><td> 0.25268109</td><td>-0.40650049</td><td>-0.12853882</td><td> 0.798602483</td><td>-0.02921499</td></tr>\n",
       "\t<tr><td>36</td><td> 607</td><td>1</td><td> 590</td><td>1</td><td>2</td><td>76</td><td>0</td><td>Nivolumab    </td><td>SQ    </td><td>â‹¯</td><td> 0.57650194</td><td> 0.37556121</td><td> 0.5342987385</td><td> 0.49915050</td><td> 0.15513046</td><td>-0.15267010</td><td> 0.09423050</td><td>-0.30689387</td><td>-0.028634074</td><td> 0.53526920</td></tr>\n",
       "\t<tr><td>37</td><td> 910</td><td>0</td><td> 647</td><td>1</td><td>3</td><td>66</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>         NA</td><td>         NA</td><td>           NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>          NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>38</td><td>1547</td><td>0</td><td> 755</td><td>1</td><td>2</td><td>69</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td> 0.49836945</td><td>-0.05559454</td><td> 0.2066692551</td><td>-0.02215850</td><td> 0.23403080</td><td>-0.10698927</td><td> 0.04638785</td><td> 0.51787047</td><td> 0.004726486</td><td>-0.42979683</td></tr>\n",
       "\t<tr><td>39</td><td> 815</td><td>0</td><td> 815</td><td>0</td><td>1</td><td>72</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>         NA</td><td>         NA</td><td>           NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>          NA</td><td>         NA</td></tr>\n",
       "\t<tr><td> 4</td><td>  22</td><td>1</td><td>  23</td><td>1</td><td>0</td><td>84</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td> 0.45022427</td><td>-0.65085397</td><td> 0.0457839900</td><td>-0.24236341</td><td> 0.44765703</td><td>-0.18958255</td><td>-0.28079830</td><td>-0.26692534</td><td> 0.414583686</td><td> 0.49895492</td></tr>\n",
       "\t<tr><td>40</td><td> 845</td><td>0</td><td> 845</td><td>0</td><td>2</td><td>78</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-0.31122740</td><td> 0.33162208</td><td>-0.6211025988</td><td>-0.09780025</td><td>-0.22666792</td><td> 0.26009037</td><td>-0.05134074</td><td> 0.59374750</td><td>-0.153520183</td><td> 0.21603362</td></tr>\n",
       "\t<tr><td>41</td><td> 886</td><td>0</td><td> 870</td><td>1</td><td>2</td><td>61</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-0.13648162</td><td> 0.38776064</td><td>-0.7786407607</td><td>-0.07954015</td><td>-0.27904401</td><td>-0.18993268</td><td> 0.35310596</td><td> 0.09664086</td><td>-0.492865694</td><td>-0.31798122</td></tr>\n",
       "\t<tr><td>42</td><td> 891</td><td>0</td><td> 891</td><td>0</td><td>3</td><td>59</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-0.34399706</td><td>-1.08187780</td><td> 0.5367482772</td><td> 0.23679852</td><td> 0.16702184</td><td>-0.18993268</td><td> 0.07377460</td><td> 0.03571408</td><td> 0.022790961</td><td>-0.96885980</td></tr>\n",
       "\t<tr><td>43</td><td> 905</td><td>0</td><td> 905</td><td>0</td><td>3</td><td>63</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>         NA</td><td>         NA</td><td>           NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>          NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>44</td><td>1075</td><td>0</td><td>1075</td><td>0</td><td>2</td><td>45</td><td>1</td><td>Pembrolizumab</td><td>LN    </td><td>â‹¯</td><td>-0.23502392</td><td>-1.19925542</td><td>-0.1301835397</td><td> 0.18490747</td><td> 0.29163788</td><td>-0.11693721</td><td>-0.19036457</td><td> 0.22075631</td><td> 0.517488704</td><td> 0.04570634</td></tr>\n",
       "\t<tr><td>45</td><td>1085</td><td>0</td><td>1085</td><td>0</td><td>2</td><td>82</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-1.07644884</td><td>-0.45707750</td><td> 0.6808349316</td><td> 0.03664372</td><td> 0.34213037</td><td>-0.12595742</td><td> 0.27241290</td><td>-0.16797709</td><td> 0.400421450</td><td> 0.32499011</td></tr>\n",
       "\t<tr><td>46</td><td>1098</td><td>0</td><td>1098</td><td>0</td><td>2</td><td>71</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td> 0.63079954</td><td> 1.03166565</td><td> 0.0103432872</td><td> 0.13307078</td><td>-0.06398976</td><td>-0.11879850</td><td> 0.13974445</td><td> 0.05403603</td><td>-0.101439718</td><td>-0.25613537</td></tr>\n",
       "\t<tr><td>47</td><td>1174</td><td>0</td><td>1174</td><td>0</td><td>2</td><td>62</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-0.59926198</td><td>-0.26291383</td><td> 0.1458335064</td><td>-0.04796896</td><td>-0.47627302</td><td>-0.08631475</td><td> 0.25056648</td><td> 0.16522926</td><td> 0.611609680</td><td> 0.48758918</td></tr>\n",
       "\t<tr><td>48</td><td>1189</td><td>0</td><td>1189</td><td>0</td><td>2</td><td>40</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-0.23997050</td><td> 0.20676718</td><td>-0.1790886828</td><td>-0.14261207</td><td>-0.10593877</td><td>-0.10368129</td><td>-0.42023214</td><td> 0.48732913</td><td> 0.187183322</td><td>-0.19190377</td></tr>\n",
       "\t<tr><td>49</td><td>1328</td><td>0</td><td>1328</td><td>0</td><td>3</td><td>72</td><td>1</td><td>Nivolumab    </td><td>SQ    </td><td>â‹¯</td><td>-0.09931866</td><td> 0.50448279</td><td>-0.1173463375</td><td> 0.03523810</td><td> 0.08782326</td><td>-0.06818400</td><td>-0.03400262</td><td>-0.19159567</td><td>-0.330417090</td><td> 0.26656644</td></tr>\n",
       "\t<tr><td> 5</td><td> 155</td><td>1</td><td>  39</td><td>1</td><td>0</td><td>67</td><td>0</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td> 0.35049009</td><td> 0.41415905</td><td>-0.2752258429</td><td>-0.36741795</td><td>-0.39423587</td><td>-0.16876892</td><td> 0.12387581</td><td>-1.27476366</td><td> 0.168245743</td><td> 0.52170269</td></tr>\n",
       "\t<tr><td>50</td><td>1342</td><td>0</td><td>1342</td><td>0</td><td>3</td><td>86</td><td>0</td><td>Nivolumab    </td><td>SQ    </td><td>â‹¯</td><td> 0.49282084</td><td> 0.09725215</td><td>-0.0915385889</td><td>-0.23489184</td><td>-0.38667176</td><td>-0.17428964</td><td> 0.10105164</td><td> 0.21650294</td><td>-0.434137380</td><td> 0.88872357</td></tr>\n",
       "\t<tr><td>51</td><td>1397</td><td>0</td><td>1397</td><td>0</td><td>3</td><td>64</td><td>0</td><td>Nivolumab    </td><td>SQ    </td><td>â‹¯</td><td>         NA</td><td>         NA</td><td>           NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>         NA</td><td>          NA</td><td>         NA</td></tr>\n",
       "\t<tr><td>52</td><td>1553</td><td>0</td><td>1553</td><td>0</td><td>2</td><td>63</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-0.51324287</td><td>-0.11879141</td><td>-0.5892031981</td><td>-0.17134194</td><td>-0.08283153</td><td>-0.11193973</td><td>-0.86381226</td><td> 0.16751634</td><td>-0.493717489</td><td>-0.04120277</td></tr>\n",
       "\t<tr><td>53</td><td>1589</td><td>0</td><td>1589</td><td>0</td><td>3</td><td>71</td><td>1</td><td>Pembrolizumab</td><td>LN    </td><td>â‹¯</td><td>-0.19119768</td><td>-1.23898244</td><td> 0.7186973882</td><td>-0.03140992</td><td> 0.58762230</td><td> 0.36310638</td><td>-0.65733209</td><td>-0.25724207</td><td> 0.560198223</td><td>-0.54578385</td></tr>\n",
       "\t<tr><td>54</td><td>1603</td><td>0</td><td>1603</td><td>0</td><td>2</td><td>52</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td> 0.86781747</td><td> 1.32880802</td><td> 0.2288094333</td><td> 0.18938530</td><td>-0.04091907</td><td> 0.70585357</td><td> 0.19730013</td><td>-0.43394722</td><td>-0.979660281</td><td>-0.32887805</td></tr>\n",
       "\t<tr><td> 6</td><td>  94</td><td>1</td><td>  42</td><td>1</td><td>0</td><td>68</td><td>0</td><td>Nivolumab    </td><td>LN    </td><td>â‹¯</td><td>-0.33982929</td><td> 0.02291629</td><td> 0.8663042318</td><td> 0.15111765</td><td>-0.57423345</td><td> 0.16435045</td><td>-0.79441902</td><td>-0.59637515</td><td>-0.241079994</td><td> 0.25761504</td></tr>\n",
       "\t<tr><td> 7</td><td>  80</td><td>1</td><td>  47</td><td>1</td><td>0</td><td>57</td><td>1</td><td>Nivolumab    </td><td>LN    </td><td>â‹¯</td><td> 0.33433512</td><td> 0.87387503</td><td> 0.3593579706</td><td> 0.61269151</td><td>-0.44520057</td><td>-0.12561413</td><td> 0.15067660</td><td> 0.56396673</td><td> 0.006282023</td><td>-0.23951499</td></tr>\n",
       "\t<tr><td> 8</td><td>  58</td><td>1</td><td>  58</td><td>1</td><td>0</td><td>85</td><td>1</td><td>Nivolumab    </td><td>SQ    </td><td>â‹¯</td><td> 2.13134004</td><td> 0.79354018</td><td>-0.6054473351</td><td>-0.47590384</td><td> 0.38923947</td><td>-0.16430145</td><td>-0.15559126</td><td>-0.58664907</td><td>-0.535177362</td><td> 0.71530710</td></tr>\n",
       "\t<tr><td> 9</td><td>  99</td><td>1</td><td>  71</td><td>1</td><td>0</td><td>70</td><td>1</td><td>Pembrolizumab</td><td>SQ    </td><td>â‹¯</td><td>-0.51800739</td><td>-0.62215237</td><td> 0.2274708862</td><td>-0.22274651</td><td>-0.31517698</td><td> 0.02419371</td><td>-0.35364727</td><td> 0.91660440</td><td>-0.365652282</td><td>-0.28997347</td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A data.frame: 54 Ã— 18582\n",
       "\\begin{tabular}{lllllllllllllllllllll}\n",
       " Patient & OS & OS.Event & PFS & PFS.Event & RECIST & Age & Gender & Treatment & Site & â‹¯ & X55055 & X11130 & X7789 & X158586 & X79364 & X440590 & X79699 & X7791 & X23140 & X26009\\\\\n",
       " <int> & <int> & <int> & <int> & <int> & <int> & <int> & <int> & <fct> & <fct> & â‹¯ & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl> & <dbl>\\\\\n",
       "\\hline\n",
       "\t  1 &  147 & 1 &    9 & 1 & 0 & 48 & 1 & Nivolumab     & LN     & â‹¯ &          NA &          NA &            NA &          NA &          NA &          NA &          NA &          NA &           NA &          NA\\\\\n",
       "\t 10 &  551 & 0 &   76 & 1 & 0 & 90 & 0 & Pembrolizumab & SQ     & â‹¯ &  0.58714486 &  1.51680290 &  0.2051403085 &  0.24970065 &  0.50803986 &  0.70851142 &  0.45721398 & -0.79611580 &  0.242960585 &  1.18213316\\\\\n",
       "\t 11 &  166 & 1 &   78 & 1 & 0 & 66 & 0 & Pembrolizumab & SQ     & â‹¯ & -0.77856996 & -1.01200334 &  0.0005757279 & -0.41480345 &  0.05113678 &  0.09727642 & -0.16385787 & -0.24692816 &  0.117103894 & -0.74993078\\\\\n",
       "\t 12 &  199 & 1 &   80 & 1 & 1 & 52 & 0 & Pembrolizumab & SQ     & â‹¯ & -1.51889892 & -0.62973116 &  0.1098136507 & -0.40977490 & -0.18345745 &  0.16842307 & -0.19196153 &  0.65804952 &  0.978488181 & -0.27105096\\\\\n",
       "\t 13 &   96 & 1 &   82 & 1 & 0 & 69 & 0 & Pembrolizumab & SQ     & â‹¯ & -0.43369412 &  1.13091160 & -0.2777108820 & -0.12975976 & -0.06003260 & -0.12662805 & -0.13856663 & -1.21787913 & -0.209915150 &  0.08612588\\\\\n",
       "\t 14 &  993 & 1 &   83 & 1 & 0 & 58 & 0 & Pembrolizumab & Mucosa & â‹¯ &  0.33614144 & -0.17613154 & -0.3655941746 & -0.75921926 &  0.41185003 & -0.11559656 & -0.05134074 & -0.26650284 & -0.305194059 & -0.84401986\\\\\n",
       "\t 15 &  300 & 0 &   84 & 1 & 0 & 76 & 1 & Pembrolizumab & SQ     & â‹¯ & -0.52527974 & -1.40244281 &  0.9012394246 &  0.16067435 &  0.67071102 & -0.18993268 & -0.11826441 & -1.18621327 &  0.026281237 &  0.27000323\\\\\n",
       "\t 16 &  169 & 1 &   84 & 1 & 0 & 55 & 0 & Pembrolizumab & LN     & â‹¯ & -0.49731657 & -0.93868918 & -0.1095925899 & -0.14107495 &  0.02426093 & -0.12426673 & -0.01197064 &  0.57544109 & -0.009577050 & -0.11839787\\\\\n",
       "\t 17 &  258 & 1 &   96 & 1 & 0 & 37 & 0 & Pembrolizumab & SQ     & â‹¯ & -0.17379026 &  0.74040639 & -0.4681554262 &  0.15447363 & -0.20567601 & -0.17463977 &  0.21129616 &  0.49320065 & -0.153231356 & -1.04327463\\\\\n",
       "\t 18 &  228 & 1 &  100 & 1 & 0 & 62 & 0 & Pembrolizumab & SQ     & â‹¯ &  0.56521058 &  0.37410214 & -0.1170037510 &  0.32391776 & -0.14034456 & -0.18993268 &  0.40220709 &  0.76877653 & -0.193560502 &  0.20174889\\\\\n",
       "\t 19 &  385 & 1 &  125 & 1 & 1 & 54 & 0 & Pembrolizumab & SQ     & â‹¯ &  0.46655105 &  0.54872670 & -0.3409820845 &  0.13252763 & -0.53026602 & -0.18993268 & -0.08828512 & -0.15036820 & -0.062418433 &  0.02279346\\\\\n",
       "\t  2 &   65 & 1 &   13 & 1 & 0 & 61 & 1 & Pembrolizumab & SQ     & â‹¯ & -0.97348238 & -0.76822450 &  0.1028616068 &  0.17016027 & -0.06737654 & -0.17636986 &  0.34607368 &  0.79620927 &  0.417834906 & -0.49855148\\\\\n",
       "\t 20 &  553 & 1 &  156 & 1 & 2 & 45 & 1 & Pembrolizumab & Brain  & â‹¯ &          NA &          NA &            NA &          NA &          NA &          NA &          NA &          NA &           NA &          NA\\\\\n",
       "\t 21 &  551 & 1 &  166 & 1 & 1 & 67 & 0 & Pembrolizumab & SQ     & â‹¯ &  0.16868742 & -0.15404176 &  0.3311818672 &  0.06066882 &  0.21068949 & -0.17223253 &  0.28442772 & -0.20843742 & -0.621020206 &  0.38779320\\\\\n",
       "\t 22 &  379 & 0 &  176 & 1 & 1 & 69 & 1 & Pembrolizumab & SQ     & â‹¯ &          NA &          NA &            NA &          NA &          NA &          NA &          NA &          NA &           NA &          NA\\\\\n",
       "\t 23 &  191 & 1 &  191 & 1 & 1 & 40 & 0 & Nivolumab     & SQ     & â‹¯ &  0.24905714 &  0.06900338 & -0.4031809368 &  0.08881141 &  0.50467914 & -0.18679525 &  0.27972885 &  1.32422465 &  0.624400137 & -0.22988686\\\\\n",
       "\t 24 &  407 & 1 &  197 & 1 & 1 & 54 & 1 & Pembrolizumab & SQ     & â‹¯ &          NA &          NA &            NA &          NA &          NA &          NA &          NA &          NA &           NA &          NA\\\\\n",
       "\t 25 &  897 & 1 &  271 & 1 & 2 & 49 & 0 & Nivolumab     & SQ     & â‹¯ &  0.21330995 &  0.53110123 & -0.6473035526 & -0.54270486 &  0.10962948 & -0.16842562 &  0.34721238 &  0.10479040 & -0.492865694 &  0.14336281\\\\\n",
       "\t 26 &  275 & 0 &  275 & 0 & 3 & 89 & 1 & Pembrolizumab & SQ     & â‹¯ &          NA &          NA &            NA &          NA &          NA &          NA &          NA &          NA &           NA &          NA\\\\\n",
       "\t 27 & 1067 & 1 &  314 & 1 & 2 & 76 & 0 & Pembrolizumab & SQ     & â‹¯ &  1.00413156 & -0.03714418 &  1.0552302173 &  1.09627171 & -0.05623189 &  0.70739258 &  0.10076517 & -1.33815381 &  0.210307940 & -0.79727101\\\\\n",
       "\t 28 &  324 & 0 &  324 & 0 & 2 & 81 & 0 & Pembrolizumab & SQ     & â‹¯ &          NA &          NA &            NA &          NA &          NA &          NA &          NA &          NA &           NA &          NA\\\\\n",
       "\t 29 &  825 & 1 &  335 & 1 & 1 & 55 & 0 & Pembrolizumab & SQ     & â‹¯ & -0.39822385 & -0.31194865 &  0.1895656253 &  0.35678046 & -0.24796229 & -0.18993268 &  0.38993575 &  0.29388544 &  0.273667791 &  0.37929006\\\\\n",
       "\t  3 &   59 & 1 &   23 & 1 & 0 & 50 & 0 & Nivolumab     & SQ     & â‹¯ & -0.77789408 &  0.47804777 &  0.3231840744 &  0.07771963 & -0.13553484 & -0.14994607 &  0.25125628 &  0.46844425 &  0.202778225 &  0.12502150\\\\\n",
       "\t 30 &  581 & 0 &  358 & 1 & 1 & 86 & 1 & Pembrolizumab & SQ     & â‹¯ &  1.41658928 &  0.06242660 & -1.4247014274 & -0.24798209 & -0.11521950 &  1.03268700 &  0.46235717 &  0.57172041 & -0.687417296 &  1.00008741\\\\\n",
       "\t 31 &  365 & 0 &  365 & 0 & 2 & 74 & 1 & Nivolumab     & SQ     & â‹¯ &          NA &          NA &            NA &          NA &          NA &          NA &          NA &          NA &           NA &          NA\\\\\n",
       "\t 32 &  460 & 0 &  460 & 0 & 3 & 69 & 1 & Pembrolizumab & Brain  & â‹¯ &          NA &          NA &            NA &          NA &          NA &          NA &          NA &          NA &           NA &          NA\\\\\n",
       "\t 33 &  477 & 0 &  477 & 0 & 3 & 76 & 0 & Pembrolizumab & LN     & â‹¯ &          NA &          NA &            NA &          NA &          NA &          NA &          NA &          NA &           NA &          NA\\\\\n",
       "\t 34 &  878 & 1 &  544 & 1 & 2 & 78 & 0 & Pembrolizumab & LN     & â‹¯ & -0.33808762 &  0.16435665 & -0.3942531236 &  0.01195671 & -0.17321962 & -0.13604057 & -0.36331346 & -0.46914968 &  0.105545635 & -0.36518924\\\\\n",
       "\t 35 & 1091 & 0 &  586 & 1 & 2 & 55 & 1 & Pembrolizumab & SQ     & â‹¯ & -0.32027729 & -0.86643923 &  0.1563104344 & -0.18119199 &  0.11321388 &  0.25268109 & -0.40650049 & -0.12853882 &  0.798602483 & -0.02921499\\\\\n",
       "\t 36 &  607 & 1 &  590 & 1 & 2 & 76 & 0 & Nivolumab     & SQ     & â‹¯ &  0.57650194 &  0.37556121 &  0.5342987385 &  0.49915050 &  0.15513046 & -0.15267010 &  0.09423050 & -0.30689387 & -0.028634074 &  0.53526920\\\\\n",
       "\t 37 &  910 & 0 &  647 & 1 & 3 & 66 & 0 & Pembrolizumab & SQ     & â‹¯ &          NA &          NA &            NA &          NA &          NA &          NA &          NA &          NA &           NA &          NA\\\\\n",
       "\t 38 & 1547 & 0 &  755 & 1 & 2 & 69 & 1 & Pembrolizumab & SQ     & â‹¯ &  0.49836945 & -0.05559454 &  0.2066692551 & -0.02215850 &  0.23403080 & -0.10698927 &  0.04638785 &  0.51787047 &  0.004726486 & -0.42979683\\\\\n",
       "\t 39 &  815 & 0 &  815 & 0 & 1 & 72 & 0 & Pembrolizumab & SQ     & â‹¯ &          NA &          NA &            NA &          NA &          NA &          NA &          NA &          NA &           NA &          NA\\\\\n",
       "\t  4 &   22 & 1 &   23 & 1 & 0 & 84 & 0 & Pembrolizumab & SQ     & â‹¯ &  0.45022427 & -0.65085397 &  0.0457839900 & -0.24236341 &  0.44765703 & -0.18958255 & -0.28079830 & -0.26692534 &  0.414583686 &  0.49895492\\\\\n",
       "\t 40 &  845 & 0 &  845 & 0 & 2 & 78 & 0 & Pembrolizumab & SQ     & â‹¯ & -0.31122740 &  0.33162208 & -0.6211025988 & -0.09780025 & -0.22666792 &  0.26009037 & -0.05134074 &  0.59374750 & -0.153520183 &  0.21603362\\\\\n",
       "\t 41 &  886 & 0 &  870 & 1 & 2 & 61 & 1 & Pembrolizumab & SQ     & â‹¯ & -0.13648162 &  0.38776064 & -0.7786407607 & -0.07954015 & -0.27904401 & -0.18993268 &  0.35310596 &  0.09664086 & -0.492865694 & -0.31798122\\\\\n",
       "\t 42 &  891 & 0 &  891 & 0 & 3 & 59 & 1 & Pembrolizumab & SQ     & â‹¯ & -0.34399706 & -1.08187780 &  0.5367482772 &  0.23679852 &  0.16702184 & -0.18993268 &  0.07377460 &  0.03571408 &  0.022790961 & -0.96885980\\\\\n",
       "\t 43 &  905 & 0 &  905 & 0 & 3 & 63 & 0 & Pembrolizumab & SQ     & â‹¯ &          NA &          NA &            NA &          NA &          NA &          NA &          NA &          NA &           NA &          NA\\\\\n",
       "\t 44 & 1075 & 0 & 1075 & 0 & 2 & 45 & 1 & Pembrolizumab & LN     & â‹¯ & -0.23502392 & -1.19925542 & -0.1301835397 &  0.18490747 &  0.29163788 & -0.11693721 & -0.19036457 &  0.22075631 &  0.517488704 &  0.04570634\\\\\n",
       "\t 45 & 1085 & 0 & 1085 & 0 & 2 & 82 & 0 & Pembrolizumab & SQ     & â‹¯ & -1.07644884 & -0.45707750 &  0.6808349316 &  0.03664372 &  0.34213037 & -0.12595742 &  0.27241290 & -0.16797709 &  0.400421450 &  0.32499011\\\\\n",
       "\t 46 & 1098 & 0 & 1098 & 0 & 2 & 71 & 0 & Pembrolizumab & SQ     & â‹¯ &  0.63079954 &  1.03166565 &  0.0103432872 &  0.13307078 & -0.06398976 & -0.11879850 &  0.13974445 &  0.05403603 & -0.101439718 & -0.25613537\\\\\n",
       "\t 47 & 1174 & 0 & 1174 & 0 & 2 & 62 & 0 & Pembrolizumab & SQ     & â‹¯ & -0.59926198 & -0.26291383 &  0.1458335064 & -0.04796896 & -0.47627302 & -0.08631475 &  0.25056648 &  0.16522926 &  0.611609680 &  0.48758918\\\\\n",
       "\t 48 & 1189 & 0 & 1189 & 0 & 2 & 40 & 0 & Pembrolizumab & SQ     & â‹¯ & -0.23997050 &  0.20676718 & -0.1790886828 & -0.14261207 & -0.10593877 & -0.10368129 & -0.42023214 &  0.48732913 &  0.187183322 & -0.19190377\\\\\n",
       "\t 49 & 1328 & 0 & 1328 & 0 & 3 & 72 & 1 & Nivolumab     & SQ     & â‹¯ & -0.09931866 &  0.50448279 & -0.1173463375 &  0.03523810 &  0.08782326 & -0.06818400 & -0.03400262 & -0.19159567 & -0.330417090 &  0.26656644\\\\\n",
       "\t  5 &  155 & 1 &   39 & 1 & 0 & 67 & 0 & Pembrolizumab & SQ     & â‹¯ &  0.35049009 &  0.41415905 & -0.2752258429 & -0.36741795 & -0.39423587 & -0.16876892 &  0.12387581 & -1.27476366 &  0.168245743 &  0.52170269\\\\\n",
       "\t 50 & 1342 & 0 & 1342 & 0 & 3 & 86 & 0 & Nivolumab     & SQ     & â‹¯ &  0.49282084 &  0.09725215 & -0.0915385889 & -0.23489184 & -0.38667176 & -0.17428964 &  0.10105164 &  0.21650294 & -0.434137380 &  0.88872357\\\\\n",
       "\t 51 & 1397 & 0 & 1397 & 0 & 3 & 64 & 0 & Nivolumab     & SQ     & â‹¯ &          NA &          NA &            NA &          NA &          NA &          NA &          NA &          NA &           NA &          NA\\\\\n",
       "\t 52 & 1553 & 0 & 1553 & 0 & 2 & 63 & 1 & Pembrolizumab & SQ     & â‹¯ & -0.51324287 & -0.11879141 & -0.5892031981 & -0.17134194 & -0.08283153 & -0.11193973 & -0.86381226 &  0.16751634 & -0.493717489 & -0.04120277\\\\\n",
       "\t 53 & 1589 & 0 & 1589 & 0 & 3 & 71 & 1 & Pembrolizumab & LN     & â‹¯ & -0.19119768 & -1.23898244 &  0.7186973882 & -0.03140992 &  0.58762230 &  0.36310638 & -0.65733209 & -0.25724207 &  0.560198223 & -0.54578385\\\\\n",
       "\t 54 & 1603 & 0 & 1603 & 0 & 2 & 52 & 1 & Pembrolizumab & SQ     & â‹¯ &  0.86781747 &  1.32880802 &  0.2288094333 &  0.18938530 & -0.04091907 &  0.70585357 &  0.19730013 & -0.43394722 & -0.979660281 & -0.32887805\\\\\n",
       "\t  6 &   94 & 1 &   42 & 1 & 0 & 68 & 0 & Nivolumab     & LN     & â‹¯ & -0.33982929 &  0.02291629 &  0.8663042318 &  0.15111765 & -0.57423345 &  0.16435045 & -0.79441902 & -0.59637515 & -0.241079994 &  0.25761504\\\\\n",
       "\t  7 &   80 & 1 &   47 & 1 & 0 & 57 & 1 & Nivolumab     & LN     & â‹¯ &  0.33433512 &  0.87387503 &  0.3593579706 &  0.61269151 & -0.44520057 & -0.12561413 &  0.15067660 &  0.56396673 &  0.006282023 & -0.23951499\\\\\n",
       "\t  8 &   58 & 1 &   58 & 1 & 0 & 85 & 1 & Nivolumab     & SQ     & â‹¯ &  2.13134004 &  0.79354018 & -0.6054473351 & -0.47590384 &  0.38923947 & -0.16430145 & -0.15559126 & -0.58664907 & -0.535177362 &  0.71530710\\\\\n",
       "\t  9 &   99 & 1 &   71 & 1 & 0 & 70 & 1 & Pembrolizumab & SQ     & â‹¯ & -0.51800739 & -0.62215237 &  0.2274708862 & -0.22274651 & -0.31517698 &  0.02419371 & -0.35364727 &  0.91660440 & -0.365652282 & -0.28997347\\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A data.frame: 54 Ã— 18582\n",
       "\n",
       "| Patient &lt;int&gt; | OS &lt;int&gt; | OS.Event &lt;int&gt; | PFS &lt;int&gt; | PFS.Event &lt;int&gt; | RECIST &lt;int&gt; | Age &lt;int&gt; | Gender &lt;int&gt; | Treatment &lt;fct&gt; | Site &lt;fct&gt; | â‹¯ â‹¯ | X55055 &lt;dbl&gt; | X11130 &lt;dbl&gt; | X7789 &lt;dbl&gt; | X158586 &lt;dbl&gt; | X79364 &lt;dbl&gt; | X440590 &lt;dbl&gt; | X79699 &lt;dbl&gt; | X7791 &lt;dbl&gt; | X23140 &lt;dbl&gt; | X26009 &lt;dbl&gt; |\n",
       "|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|\n",
       "|  1 |  147 | 1 |    9 | 1 | 0 | 48 | 1 | Nivolumab     | LN     | â‹¯ |          NA |          NA |            NA |          NA |          NA |          NA |          NA |          NA |           NA |          NA |\n",
       "| 10 |  551 | 0 |   76 | 1 | 0 | 90 | 0 | Pembrolizumab | SQ     | â‹¯ |  0.58714486 |  1.51680290 |  0.2051403085 |  0.24970065 |  0.50803986 |  0.70851142 |  0.45721398 | -0.79611580 |  0.242960585 |  1.18213316 |\n",
       "| 11 |  166 | 1 |   78 | 1 | 0 | 66 | 0 | Pembrolizumab | SQ     | â‹¯ | -0.77856996 | -1.01200334 |  0.0005757279 | -0.41480345 |  0.05113678 |  0.09727642 | -0.16385787 | -0.24692816 |  0.117103894 | -0.74993078 |\n",
       "| 12 |  199 | 1 |   80 | 1 | 1 | 52 | 0 | Pembrolizumab | SQ     | â‹¯ | -1.51889892 | -0.62973116 |  0.1098136507 | -0.40977490 | -0.18345745 |  0.16842307 | -0.19196153 |  0.65804952 |  0.978488181 | -0.27105096 |\n",
       "| 13 |   96 | 1 |   82 | 1 | 0 | 69 | 0 | Pembrolizumab | SQ     | â‹¯ | -0.43369412 |  1.13091160 | -0.2777108820 | -0.12975976 | -0.06003260 | -0.12662805 | -0.13856663 | -1.21787913 | -0.209915150 |  0.08612588 |\n",
       "| 14 |  993 | 1 |   83 | 1 | 0 | 58 | 0 | Pembrolizumab | Mucosa | â‹¯ |  0.33614144 | -0.17613154 | -0.3655941746 | -0.75921926 |  0.41185003 | -0.11559656 | -0.05134074 | -0.26650284 | -0.305194059 | -0.84401986 |\n",
       "| 15 |  300 | 0 |   84 | 1 | 0 | 76 | 1 | Pembrolizumab | SQ     | â‹¯ | -0.52527974 | -1.40244281 |  0.9012394246 |  0.16067435 |  0.67071102 | -0.18993268 | -0.11826441 | -1.18621327 |  0.026281237 |  0.27000323 |\n",
       "| 16 |  169 | 1 |   84 | 1 | 0 | 55 | 0 | Pembrolizumab | LN     | â‹¯ | -0.49731657 | -0.93868918 | -0.1095925899 | -0.14107495 |  0.02426093 | -0.12426673 | -0.01197064 |  0.57544109 | -0.009577050 | -0.11839787 |\n",
       "| 17 |  258 | 1 |   96 | 1 | 0 | 37 | 0 | Pembrolizumab | SQ     | â‹¯ | -0.17379026 |  0.74040639 | -0.4681554262 |  0.15447363 | -0.20567601 | -0.17463977 |  0.21129616 |  0.49320065 | -0.153231356 | -1.04327463 |\n",
       "| 18 |  228 | 1 |  100 | 1 | 0 | 62 | 0 | Pembrolizumab | SQ     | â‹¯ |  0.56521058 |  0.37410214 | -0.1170037510 |  0.32391776 | -0.14034456 | -0.18993268 |  0.40220709 |  0.76877653 | -0.193560502 |  0.20174889 |\n",
       "| 19 |  385 | 1 |  125 | 1 | 1 | 54 | 0 | Pembrolizumab | SQ     | â‹¯ |  0.46655105 |  0.54872670 | -0.3409820845 |  0.13252763 | -0.53026602 | -0.18993268 | -0.08828512 | -0.15036820 | -0.062418433 |  0.02279346 |\n",
       "|  2 |   65 | 1 |   13 | 1 | 0 | 61 | 1 | Pembrolizumab | SQ     | â‹¯ | -0.97348238 | -0.76822450 |  0.1028616068 |  0.17016027 | -0.06737654 | -0.17636986 |  0.34607368 |  0.79620927 |  0.417834906 | -0.49855148 |\n",
       "| 20 |  553 | 1 |  156 | 1 | 2 | 45 | 1 | Pembrolizumab | Brain  | â‹¯ |          NA |          NA |            NA |          NA |          NA |          NA |          NA |          NA |           NA |          NA |\n",
       "| 21 |  551 | 1 |  166 | 1 | 1 | 67 | 0 | Pembrolizumab | SQ     | â‹¯ |  0.16868742 | -0.15404176 |  0.3311818672 |  0.06066882 |  0.21068949 | -0.17223253 |  0.28442772 | -0.20843742 | -0.621020206 |  0.38779320 |\n",
       "| 22 |  379 | 0 |  176 | 1 | 1 | 69 | 1 | Pembrolizumab | SQ     | â‹¯ |          NA |          NA |            NA |          NA |          NA |          NA |          NA |          NA |           NA |          NA |\n",
       "| 23 |  191 | 1 |  191 | 1 | 1 | 40 | 0 | Nivolumab     | SQ     | â‹¯ |  0.24905714 |  0.06900338 | -0.4031809368 |  0.08881141 |  0.50467914 | -0.18679525 |  0.27972885 |  1.32422465 |  0.624400137 | -0.22988686 |\n",
       "| 24 |  407 | 1 |  197 | 1 | 1 | 54 | 1 | Pembrolizumab | SQ     | â‹¯ |          NA |          NA |            NA |          NA |          NA |          NA |          NA |          NA |           NA |          NA |\n",
       "| 25 |  897 | 1 |  271 | 1 | 2 | 49 | 0 | Nivolumab     | SQ     | â‹¯ |  0.21330995 |  0.53110123 | -0.6473035526 | -0.54270486 |  0.10962948 | -0.16842562 |  0.34721238 |  0.10479040 | -0.492865694 |  0.14336281 |\n",
       "| 26 |  275 | 0 |  275 | 0 | 3 | 89 | 1 | Pembrolizumab | SQ     | â‹¯ |          NA |          NA |            NA |          NA |          NA |          NA |          NA |          NA |           NA |          NA |\n",
       "| 27 | 1067 | 1 |  314 | 1 | 2 | 76 | 0 | Pembrolizumab | SQ     | â‹¯ |  1.00413156 | -0.03714418 |  1.0552302173 |  1.09627171 | -0.05623189 |  0.70739258 |  0.10076517 | -1.33815381 |  0.210307940 | -0.79727101 |\n",
       "| 28 |  324 | 0 |  324 | 0 | 2 | 81 | 0 | Pembrolizumab | SQ     | â‹¯ |          NA |          NA |            NA |          NA |          NA |          NA |          NA |          NA |           NA |          NA |\n",
       "| 29 |  825 | 1 |  335 | 1 | 1 | 55 | 0 | Pembrolizumab | SQ     | â‹¯ | -0.39822385 | -0.31194865 |  0.1895656253 |  0.35678046 | -0.24796229 | -0.18993268 |  0.38993575 |  0.29388544 |  0.273667791 |  0.37929006 |\n",
       "|  3 |   59 | 1 |   23 | 1 | 0 | 50 | 0 | Nivolumab     | SQ     | â‹¯ | -0.77789408 |  0.47804777 |  0.3231840744 |  0.07771963 | -0.13553484 | -0.14994607 |  0.25125628 |  0.46844425 |  0.202778225 |  0.12502150 |\n",
       "| 30 |  581 | 0 |  358 | 1 | 1 | 86 | 1 | Pembrolizumab | SQ     | â‹¯ |  1.41658928 |  0.06242660 | -1.4247014274 | -0.24798209 | -0.11521950 |  1.03268700 |  0.46235717 |  0.57172041 | -0.687417296 |  1.00008741 |\n",
       "| 31 |  365 | 0 |  365 | 0 | 2 | 74 | 1 | Nivolumab     | SQ     | â‹¯ |          NA |          NA |            NA |          NA |          NA |          NA |          NA |          NA |           NA |          NA |\n",
       "| 32 |  460 | 0 |  460 | 0 | 3 | 69 | 1 | Pembrolizumab | Brain  | â‹¯ |          NA |          NA |            NA |          NA |          NA |          NA |          NA |          NA |           NA |          NA |\n",
       "| 33 |  477 | 0 |  477 | 0 | 3 | 76 | 0 | Pembrolizumab | LN     | â‹¯ |          NA |          NA |            NA |          NA |          NA |          NA |          NA |          NA |           NA |          NA |\n",
       "| 34 |  878 | 1 |  544 | 1 | 2 | 78 | 0 | Pembrolizumab | LN     | â‹¯ | -0.33808762 |  0.16435665 | -0.3942531236 |  0.01195671 | -0.17321962 | -0.13604057 | -0.36331346 | -0.46914968 |  0.105545635 | -0.36518924 |\n",
       "| 35 | 1091 | 0 |  586 | 1 | 2 | 55 | 1 | Pembrolizumab | SQ     | â‹¯ | -0.32027729 | -0.86643923 |  0.1563104344 | -0.18119199 |  0.11321388 |  0.25268109 | -0.40650049 | -0.12853882 |  0.798602483 | -0.02921499 |\n",
       "| 36 |  607 | 1 |  590 | 1 | 2 | 76 | 0 | Nivolumab     | SQ     | â‹¯ |  0.57650194 |  0.37556121 |  0.5342987385 |  0.49915050 |  0.15513046 | -0.15267010 |  0.09423050 | -0.30689387 | -0.028634074 |  0.53526920 |\n",
       "| 37 |  910 | 0 |  647 | 1 | 3 | 66 | 0 | Pembrolizumab | SQ     | â‹¯ |          NA |          NA |            NA |          NA |          NA |          NA |          NA |          NA |           NA |          NA |\n",
       "| 38 | 1547 | 0 |  755 | 1 | 2 | 69 | 1 | Pembrolizumab | SQ     | â‹¯ |  0.49836945 | -0.05559454 |  0.2066692551 | -0.02215850 |  0.23403080 | -0.10698927 |  0.04638785 |  0.51787047 |  0.004726486 | -0.42979683 |\n",
       "| 39 |  815 | 0 |  815 | 0 | 1 | 72 | 0 | Pembrolizumab | SQ     | â‹¯ |          NA |          NA |            NA |          NA |          NA |          NA |          NA |          NA |           NA |          NA |\n",
       "|  4 |   22 | 1 |   23 | 1 | 0 | 84 | 0 | Pembrolizumab | SQ     | â‹¯ |  0.45022427 | -0.65085397 |  0.0457839900 | -0.24236341 |  0.44765703 | -0.18958255 | -0.28079830 | -0.26692534 |  0.414583686 |  0.49895492 |\n",
       "| 40 |  845 | 0 |  845 | 0 | 2 | 78 | 0 | Pembrolizumab | SQ     | â‹¯ | -0.31122740 |  0.33162208 | -0.6211025988 | -0.09780025 | -0.22666792 |  0.26009037 | -0.05134074 |  0.59374750 | -0.153520183 |  0.21603362 |\n",
       "| 41 |  886 | 0 |  870 | 1 | 2 | 61 | 1 | Pembrolizumab | SQ     | â‹¯ | -0.13648162 |  0.38776064 | -0.7786407607 | -0.07954015 | -0.27904401 | -0.18993268 |  0.35310596 |  0.09664086 | -0.492865694 | -0.31798122 |\n",
       "| 42 |  891 | 0 |  891 | 0 | 3 | 59 | 1 | Pembrolizumab | SQ     | â‹¯ | -0.34399706 | -1.08187780 |  0.5367482772 |  0.23679852 |  0.16702184 | -0.18993268 |  0.07377460 |  0.03571408 |  0.022790961 | -0.96885980 |\n",
       "| 43 |  905 | 0 |  905 | 0 | 3 | 63 | 0 | Pembrolizumab | SQ     | â‹¯ |          NA |          NA |            NA |          NA |          NA |          NA |          NA |          NA |           NA |          NA |\n",
       "| 44 | 1075 | 0 | 1075 | 0 | 2 | 45 | 1 | Pembrolizumab | LN     | â‹¯ | -0.23502392 | -1.19925542 | -0.1301835397 |  0.18490747 |  0.29163788 | -0.11693721 | -0.19036457 |  0.22075631 |  0.517488704 |  0.04570634 |\n",
       "| 45 | 1085 | 0 | 1085 | 0 | 2 | 82 | 0 | Pembrolizumab | SQ     | â‹¯ | -1.07644884 | -0.45707750 |  0.6808349316 |  0.03664372 |  0.34213037 | -0.12595742 |  0.27241290 | -0.16797709 |  0.400421450 |  0.32499011 |\n",
       "| 46 | 1098 | 0 | 1098 | 0 | 2 | 71 | 0 | Pembrolizumab | SQ     | â‹¯ |  0.63079954 |  1.03166565 |  0.0103432872 |  0.13307078 | -0.06398976 | -0.11879850 |  0.13974445 |  0.05403603 | -0.101439718 | -0.25613537 |\n",
       "| 47 | 1174 | 0 | 1174 | 0 | 2 | 62 | 0 | Pembrolizumab | SQ     | â‹¯ | -0.59926198 | -0.26291383 |  0.1458335064 | -0.04796896 | -0.47627302 | -0.08631475 |  0.25056648 |  0.16522926 |  0.611609680 |  0.48758918 |\n",
       "| 48 | 1189 | 0 | 1189 | 0 | 2 | 40 | 0 | Pembrolizumab | SQ     | â‹¯ | -0.23997050 |  0.20676718 | -0.1790886828 | -0.14261207 | -0.10593877 | -0.10368129 | -0.42023214 |  0.48732913 |  0.187183322 | -0.19190377 |\n",
       "| 49 | 1328 | 0 | 1328 | 0 | 3 | 72 | 1 | Nivolumab     | SQ     | â‹¯ | -0.09931866 |  0.50448279 | -0.1173463375 |  0.03523810 |  0.08782326 | -0.06818400 | -0.03400262 | -0.19159567 | -0.330417090 |  0.26656644 |\n",
       "|  5 |  155 | 1 |   39 | 1 | 0 | 67 | 0 | Pembrolizumab | SQ     | â‹¯ |  0.35049009 |  0.41415905 | -0.2752258429 | -0.36741795 | -0.39423587 | -0.16876892 |  0.12387581 | -1.27476366 |  0.168245743 |  0.52170269 |\n",
       "| 50 | 1342 | 0 | 1342 | 0 | 3 | 86 | 0 | Nivolumab     | SQ     | â‹¯ |  0.49282084 |  0.09725215 | -0.0915385889 | -0.23489184 | -0.38667176 | -0.17428964 |  0.10105164 |  0.21650294 | -0.434137380 |  0.88872357 |\n",
       "| 51 | 1397 | 0 | 1397 | 0 | 3 | 64 | 0 | Nivolumab     | SQ     | â‹¯ |          NA |          NA |            NA |          NA |          NA |          NA |          NA |          NA |           NA |          NA |\n",
       "| 52 | 1553 | 0 | 1553 | 0 | 2 | 63 | 1 | Pembrolizumab | SQ     | â‹¯ | -0.51324287 | -0.11879141 | -0.5892031981 | -0.17134194 | -0.08283153 | -0.11193973 | -0.86381226 |  0.16751634 | -0.493717489 | -0.04120277 |\n",
       "| 53 | 1589 | 0 | 1589 | 0 | 3 | 71 | 1 | Pembrolizumab | LN     | â‹¯ | -0.19119768 | -1.23898244 |  0.7186973882 | -0.03140992 |  0.58762230 |  0.36310638 | -0.65733209 | -0.25724207 |  0.560198223 | -0.54578385 |\n",
       "| 54 | 1603 | 0 | 1603 | 0 | 2 | 52 | 1 | Pembrolizumab | SQ     | â‹¯ |  0.86781747 |  1.32880802 |  0.2288094333 |  0.18938530 | -0.04091907 |  0.70585357 |  0.19730013 | -0.43394722 | -0.979660281 | -0.32887805 |\n",
       "|  6 |   94 | 1 |   42 | 1 | 0 | 68 | 0 | Nivolumab     | LN     | â‹¯ | -0.33982929 |  0.02291629 |  0.8663042318 |  0.15111765 | -0.57423345 |  0.16435045 | -0.79441902 | -0.59637515 | -0.241079994 |  0.25761504 |\n",
       "|  7 |   80 | 1 |   47 | 1 | 0 | 57 | 1 | Nivolumab     | LN     | â‹¯ |  0.33433512 |  0.87387503 |  0.3593579706 |  0.61269151 | -0.44520057 | -0.12561413 |  0.15067660 |  0.56396673 |  0.006282023 | -0.23951499 |\n",
       "|  8 |   58 | 1 |   58 | 1 | 0 | 85 | 1 | Nivolumab     | SQ     | â‹¯ |  2.13134004 |  0.79354018 | -0.6054473351 | -0.47590384 |  0.38923947 | -0.16430145 | -0.15559126 | -0.58664907 | -0.535177362 |  0.71530710 |\n",
       "|  9 |   99 | 1 |   71 | 1 | 0 | 70 | 1 | Pembrolizumab | SQ     | â‹¯ | -0.51800739 | -0.62215237 |  0.2274708862 | -0.22274651 | -0.31517698 |  0.02419371 | -0.35364727 |  0.91660440 | -0.365652282 | -0.28997347 |\n",
       "\n"
      ],
      "text/plain": [
       "   Patient OS   OS.Event PFS  PFS.Event RECIST Age Gender Treatment     Site  \n",
       "1   1       147 1           9 1         0      48  1      Nivolumab     LN    \n",
       "2  10       551 0          76 1         0      90  0      Pembrolizumab SQ    \n",
       "3  11       166 1          78 1         0      66  0      Pembrolizumab SQ    \n",
       "4  12       199 1          80 1         1      52  0      Pembrolizumab SQ    \n",
       "5  13        96 1          82 1         0      69  0      Pembrolizumab SQ    \n",
       "6  14       993 1          83 1         0      58  0      Pembrolizumab Mucosa\n",
       "7  15       300 0          84 1         0      76  1      Pembrolizumab SQ    \n",
       "8  16       169 1          84 1         0      55  0      Pembrolizumab LN    \n",
       "9  17       258 1          96 1         0      37  0      Pembrolizumab SQ    \n",
       "10 18       228 1         100 1         0      62  0      Pembrolizumab SQ    \n",
       "11 19       385 1         125 1         1      54  0      Pembrolizumab SQ    \n",
       "12  2        65 1          13 1         0      61  1      Pembrolizumab SQ    \n",
       "13 20       553 1         156 1         2      45  1      Pembrolizumab Brain \n",
       "14 21       551 1         166 1         1      67  0      Pembrolizumab SQ    \n",
       "15 22       379 0         176 1         1      69  1      Pembrolizumab SQ    \n",
       "16 23       191 1         191 1         1      40  0      Nivolumab     SQ    \n",
       "17 24       407 1         197 1         1      54  1      Pembrolizumab SQ    \n",
       "18 25       897 1         271 1         2      49  0      Nivolumab     SQ    \n",
       "19 26       275 0         275 0         3      89  1      Pembrolizumab SQ    \n",
       "20 27      1067 1         314 1         2      76  0      Pembrolizumab SQ    \n",
       "21 28       324 0         324 0         2      81  0      Pembrolizumab SQ    \n",
       "22 29       825 1         335 1         1      55  0      Pembrolizumab SQ    \n",
       "23  3        59 1          23 1         0      50  0      Nivolumab     SQ    \n",
       "24 30       581 0         358 1         1      86  1      Pembrolizumab SQ    \n",
       "25 31       365 0         365 0         2      74  1      Nivolumab     SQ    \n",
       "26 32       460 0         460 0         3      69  1      Pembrolizumab Brain \n",
       "27 33       477 0         477 0         3      76  0      Pembrolizumab LN    \n",
       "28 34       878 1         544 1         2      78  0      Pembrolizumab LN    \n",
       "29 35      1091 0         586 1         2      55  1      Pembrolizumab SQ    \n",
       "30 36       607 1         590 1         2      76  0      Nivolumab     SQ    \n",
       "31 37       910 0         647 1         3      66  0      Pembrolizumab SQ    \n",
       "32 38      1547 0         755 1         2      69  1      Pembrolizumab SQ    \n",
       "33 39       815 0         815 0         1      72  0      Pembrolizumab SQ    \n",
       "34  4        22 1          23 1         0      84  0      Pembrolizumab SQ    \n",
       "35 40       845 0         845 0         2      78  0      Pembrolizumab SQ    \n",
       "36 41       886 0         870 1         2      61  1      Pembrolizumab SQ    \n",
       "37 42       891 0         891 0         3      59  1      Pembrolizumab SQ    \n",
       "38 43       905 0         905 0         3      63  0      Pembrolizumab SQ    \n",
       "39 44      1075 0        1075 0         2      45  1      Pembrolizumab LN    \n",
       "40 45      1085 0        1085 0         2      82  0      Pembrolizumab SQ    \n",
       "41 46      1098 0        1098 0         2      71  0      Pembrolizumab SQ    \n",
       "42 47      1174 0        1174 0         2      62  0      Pembrolizumab SQ    \n",
       "43 48      1189 0        1189 0         2      40  0      Pembrolizumab SQ    \n",
       "44 49      1328 0        1328 0         3      72  1      Nivolumab     SQ    \n",
       "45  5       155 1          39 1         0      67  0      Pembrolizumab SQ    \n",
       "46 50      1342 0        1342 0         3      86  0      Nivolumab     SQ    \n",
       "47 51      1397 0        1397 0         3      64  0      Nivolumab     SQ    \n",
       "48 52      1553 0        1553 0         2      63  1      Pembrolizumab SQ    \n",
       "49 53      1589 0        1589 0         3      71  1      Pembrolizumab LN    \n",
       "50 54      1603 0        1603 0         2      52  1      Pembrolizumab SQ    \n",
       "51  6        94 1          42 1         0      68  0      Nivolumab     LN    \n",
       "52  7        80 1          47 1         0      57  1      Nivolumab     LN    \n",
       "53  8        58 1          58 1         0      85  1      Nivolumab     SQ    \n",
       "54  9        99 1          71 1         0      70  1      Pembrolizumab SQ    \n",
       "   â‹¯ X55055      X11130      X7789         X158586     X79364      X440590    \n",
       "1  â‹¯          NA          NA            NA          NA          NA          NA\n",
       "2  â‹¯  0.58714486  1.51680290  0.2051403085  0.24970065  0.50803986  0.70851142\n",
       "3  â‹¯ -0.77856996 -1.01200334  0.0005757279 -0.41480345  0.05113678  0.09727642\n",
       "4  â‹¯ -1.51889892 -0.62973116  0.1098136507 -0.40977490 -0.18345745  0.16842307\n",
       "5  â‹¯ -0.43369412  1.13091160 -0.2777108820 -0.12975976 -0.06003260 -0.12662805\n",
       "6  â‹¯  0.33614144 -0.17613154 -0.3655941746 -0.75921926  0.41185003 -0.11559656\n",
       "7  â‹¯ -0.52527974 -1.40244281  0.9012394246  0.16067435  0.67071102 -0.18993268\n",
       "8  â‹¯ -0.49731657 -0.93868918 -0.1095925899 -0.14107495  0.02426093 -0.12426673\n",
       "9  â‹¯ -0.17379026  0.74040639 -0.4681554262  0.15447363 -0.20567601 -0.17463977\n",
       "10 â‹¯  0.56521058  0.37410214 -0.1170037510  0.32391776 -0.14034456 -0.18993268\n",
       "11 â‹¯  0.46655105  0.54872670 -0.3409820845  0.13252763 -0.53026602 -0.18993268\n",
       "12 â‹¯ -0.97348238 -0.76822450  0.1028616068  0.17016027 -0.06737654 -0.17636986\n",
       "13 â‹¯          NA          NA            NA          NA          NA          NA\n",
       "14 â‹¯  0.16868742 -0.15404176  0.3311818672  0.06066882  0.21068949 -0.17223253\n",
       "15 â‹¯          NA          NA            NA          NA          NA          NA\n",
       "16 â‹¯  0.24905714  0.06900338 -0.4031809368  0.08881141  0.50467914 -0.18679525\n",
       "17 â‹¯          NA          NA            NA          NA          NA          NA\n",
       "18 â‹¯  0.21330995  0.53110123 -0.6473035526 -0.54270486  0.10962948 -0.16842562\n",
       "19 â‹¯          NA          NA            NA          NA          NA          NA\n",
       "20 â‹¯  1.00413156 -0.03714418  1.0552302173  1.09627171 -0.05623189  0.70739258\n",
       "21 â‹¯          NA          NA            NA          NA          NA          NA\n",
       "22 â‹¯ -0.39822385 -0.31194865  0.1895656253  0.35678046 -0.24796229 -0.18993268\n",
       "23 â‹¯ -0.77789408  0.47804777  0.3231840744  0.07771963 -0.13553484 -0.14994607\n",
       "24 â‹¯  1.41658928  0.06242660 -1.4247014274 -0.24798209 -0.11521950  1.03268700\n",
       "25 â‹¯          NA          NA            NA          NA          NA          NA\n",
       "26 â‹¯          NA          NA            NA          NA          NA          NA\n",
       "27 â‹¯          NA          NA            NA          NA          NA          NA\n",
       "28 â‹¯ -0.33808762  0.16435665 -0.3942531236  0.01195671 -0.17321962 -0.13604057\n",
       "29 â‹¯ -0.32027729 -0.86643923  0.1563104344 -0.18119199  0.11321388  0.25268109\n",
       "30 â‹¯  0.57650194  0.37556121  0.5342987385  0.49915050  0.15513046 -0.15267010\n",
       "31 â‹¯          NA          NA            NA          NA          NA          NA\n",
       "32 â‹¯  0.49836945 -0.05559454  0.2066692551 -0.02215850  0.23403080 -0.10698927\n",
       "33 â‹¯          NA          NA            NA          NA          NA          NA\n",
       "34 â‹¯  0.45022427 -0.65085397  0.0457839900 -0.24236341  0.44765703 -0.18958255\n",
       "35 â‹¯ -0.31122740  0.33162208 -0.6211025988 -0.09780025 -0.22666792  0.26009037\n",
       "36 â‹¯ -0.13648162  0.38776064 -0.7786407607 -0.07954015 -0.27904401 -0.18993268\n",
       "37 â‹¯ -0.34399706 -1.08187780  0.5367482772  0.23679852  0.16702184 -0.18993268\n",
       "38 â‹¯          NA          NA            NA          NA          NA          NA\n",
       "39 â‹¯ -0.23502392 -1.19925542 -0.1301835397  0.18490747  0.29163788 -0.11693721\n",
       "40 â‹¯ -1.07644884 -0.45707750  0.6808349316  0.03664372  0.34213037 -0.12595742\n",
       "41 â‹¯  0.63079954  1.03166565  0.0103432872  0.13307078 -0.06398976 -0.11879850\n",
       "42 â‹¯ -0.59926198 -0.26291383  0.1458335064 -0.04796896 -0.47627302 -0.08631475\n",
       "43 â‹¯ -0.23997050  0.20676718 -0.1790886828 -0.14261207 -0.10593877 -0.10368129\n",
       "44 â‹¯ -0.09931866  0.50448279 -0.1173463375  0.03523810  0.08782326 -0.06818400\n",
       "45 â‹¯  0.35049009  0.41415905 -0.2752258429 -0.36741795 -0.39423587 -0.16876892\n",
       "46 â‹¯  0.49282084  0.09725215 -0.0915385889 -0.23489184 -0.38667176 -0.17428964\n",
       "47 â‹¯          NA          NA            NA          NA          NA          NA\n",
       "48 â‹¯ -0.51324287 -0.11879141 -0.5892031981 -0.17134194 -0.08283153 -0.11193973\n",
       "49 â‹¯ -0.19119768 -1.23898244  0.7186973882 -0.03140992  0.58762230  0.36310638\n",
       "50 â‹¯  0.86781747  1.32880802  0.2288094333  0.18938530 -0.04091907  0.70585357\n",
       "51 â‹¯ -0.33982929  0.02291629  0.8663042318  0.15111765 -0.57423345  0.16435045\n",
       "52 â‹¯  0.33433512  0.87387503  0.3593579706  0.61269151 -0.44520057 -0.12561413\n",
       "53 â‹¯  2.13134004  0.79354018 -0.6054473351 -0.47590384  0.38923947 -0.16430145\n",
       "54 â‹¯ -0.51800739 -0.62215237  0.2274708862 -0.22274651 -0.31517698  0.02419371\n",
       "   X79699      X7791       X23140       X26009     \n",
       "1           NA          NA           NA          NA\n",
       "2   0.45721398 -0.79611580  0.242960585  1.18213316\n",
       "3  -0.16385787 -0.24692816  0.117103894 -0.74993078\n",
       "4  -0.19196153  0.65804952  0.978488181 -0.27105096\n",
       "5  -0.13856663 -1.21787913 -0.209915150  0.08612588\n",
       "6  -0.05134074 -0.26650284 -0.305194059 -0.84401986\n",
       "7  -0.11826441 -1.18621327  0.026281237  0.27000323\n",
       "8  -0.01197064  0.57544109 -0.009577050 -0.11839787\n",
       "9   0.21129616  0.49320065 -0.153231356 -1.04327463\n",
       "10  0.40220709  0.76877653 -0.193560502  0.20174889\n",
       "11 -0.08828512 -0.15036820 -0.062418433  0.02279346\n",
       "12  0.34607368  0.79620927  0.417834906 -0.49855148\n",
       "13          NA          NA           NA          NA\n",
       "14  0.28442772 -0.20843742 -0.621020206  0.38779320\n",
       "15          NA          NA           NA          NA\n",
       "16  0.27972885  1.32422465  0.624400137 -0.22988686\n",
       "17          NA          NA           NA          NA\n",
       "18  0.34721238  0.10479040 -0.492865694  0.14336281\n",
       "19          NA          NA           NA          NA\n",
       "20  0.10076517 -1.33815381  0.210307940 -0.79727101\n",
       "21          NA          NA           NA          NA\n",
       "22  0.38993575  0.29388544  0.273667791  0.37929006\n",
       "23  0.25125628  0.46844425  0.202778225  0.12502150\n",
       "24  0.46235717  0.57172041 -0.687417296  1.00008741\n",
       "25          NA          NA           NA          NA\n",
       "26          NA          NA           NA          NA\n",
       "27          NA          NA           NA          NA\n",
       "28 -0.36331346 -0.46914968  0.105545635 -0.36518924\n",
       "29 -0.40650049 -0.12853882  0.798602483 -0.02921499\n",
       "30  0.09423050 -0.30689387 -0.028634074  0.53526920\n",
       "31          NA          NA           NA          NA\n",
       "32  0.04638785  0.51787047  0.004726486 -0.42979683\n",
       "33          NA          NA           NA          NA\n",
       "34 -0.28079830 -0.26692534  0.414583686  0.49895492\n",
       "35 -0.05134074  0.59374750 -0.153520183  0.21603362\n",
       "36  0.35310596  0.09664086 -0.492865694 -0.31798122\n",
       "37  0.07377460  0.03571408  0.022790961 -0.96885980\n",
       "38          NA          NA           NA          NA\n",
       "39 -0.19036457  0.22075631  0.517488704  0.04570634\n",
       "40  0.27241290 -0.16797709  0.400421450  0.32499011\n",
       "41  0.13974445  0.05403603 -0.101439718 -0.25613537\n",
       "42  0.25056648  0.16522926  0.611609680  0.48758918\n",
       "43 -0.42023214  0.48732913  0.187183322 -0.19190377\n",
       "44 -0.03400262 -0.19159567 -0.330417090  0.26656644\n",
       "45  0.12387581 -1.27476366  0.168245743  0.52170269\n",
       "46  0.10105164  0.21650294 -0.434137380  0.88872357\n",
       "47          NA          NA           NA          NA\n",
       "48 -0.86381226  0.16751634 -0.493717489 -0.04120277\n",
       "49 -0.65733209 -0.25724207  0.560198223 -0.54578385\n",
       "50  0.19730013 -0.43394722 -0.979660281 -0.32887805\n",
       "51 -0.79441902 -0.59637515 -0.241079994  0.25761504\n",
       "52  0.15067660  0.56396673  0.006282023 -0.23951499\n",
       "53 -0.15559126 -0.58664907 -0.535177362  0.71530710\n",
       "54 -0.35364727  0.91660440 -0.365652282 -0.28997347"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "df <- read.csv(\"Gide_pn.csv\")\n",
    "df"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "R [conda env:jpEnv] *",
   "language": "R",
   "name": "conda-env-jpEnv-r"
  },
  "language_info": {
   "codemirror_mode": "r",
   "file_extension": ".r",
   "mimetype": "text/x-r-source",
   "name": "R",
   "pygments_lexer": "r",
   "version": "3.5.1"
  },
  "toc": {
   "base_numbering": 1,
   "nav_menu": {},
   "number_sections": true,
   "sideBar": true,
   "skip_h1_title": false,
   "title_cell": "Table of Contents",
   "title_sidebar": "Contents",
   "toc_cell": false,
   "toc_position": {
    "height": "calc(100% - 180px)",
    "left": "10px",
    "top": "150px",
    "width": "167.188px"
   },
   "toc_section_display": true,
   "toc_window_display": true
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
